Cystic Fibrosis (Lung Biology in Health and Disease)

Cystic Fibrosis

LUNG BIOLOGY IN HEALTH AND DISEASE

Executive Editor Claude Lenfant Former Director, National Heart, Lung, and Blood Institute National Institutes of Health Bethesda, Maryland

1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24.

Immunologic and Infectious Reactions in the Lung, edited by C. H. Kirkpatrick and H. Y. Reynolds The Biochemical Basis of Pulmonary Function, edited by R. G. Crystal Bioengineering Aspects of the Lung, edited by J. B. West Metabolic Functions of the Lung, edited by Y. S. Bakhle and J. R. Vane Respiratory Defense Mechanisms (in two parts), edited by J. D. Brain, D. F. Proctor, and L. M. Reid Development of the Lung, edited by W. A. Hodson Lung Water and Solute Exchange, edited by N. C. Staub Extrapulmonary Manifestations of Respiratory Disease, edited by E. D. Robin Chronic Obstructive Pulmonary Disease, edited by T. L. Petty Pathogenesis and Therapy of Lung Cancer, edited by C. C. Harris Genetic Determinants of Pulmonary Disease, edited by S. D. Litwin The Lung in the Transition Between Health and Disease, edited by P. T. Macklem and S. Permutt Evolution of Respiratory Processes: A Comparative Approach, edited by S. C. Wood and C. Lenfant Pulmonary Vascular Diseases, edited by K. M. Moser Physiology and Pharmacology of the Airways, edited by J. A. Nadel Diagnostic Techniques in Pulmonary Disease (in two parts), edited by M. A. Sackner Regulation of Breathing (in two parts), edited by T. F. Hornbein Occupational Lung Diseases: Research Approaches and Methods, edited by H. Weill and M. Turner-Warwick Immunopharmacology of the Lung, edited by H. H. Newball Sarcoidosis and Other Granulomatous Diseases of the Lung, edited by B. L. Fanburg Sleep and Breathing, edited by N. A. Saunders and C. E. Sullivan Pneumocystis carinii Pneumonia: Pathogenesis, Diagnosis, and Treatment, edited by L. S. Young Pulmonary Nuclear Medicine: Techniques in Diagnosis of Lung Disease, edited by H. L. Atkins Acute Respiratory Failure, edited by W. M. Zapol and K. J. FaIke

For information on volumes 25–188 in the Lung Biology in Health and Disease series, please visit www.informahealthcare.com 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217.

Interventional Pulmonary Medicine, edited by J. F. Beamis, Jr., P. N. Mathur, and A. C. Mehta Lung Development and Regeneration, edited by D. J. Massaro, G. Massaro, and P. Chambon Long-Term Intervention in Chronic Obstructive Pulmonary Disease, edited by R. Pauwels, D. S. Postma, and S. T. Weiss Sleep Deprivation: Basic Science, Physiology, and Behavior, edited by Clete A. Kushida Sleep Deprivation: Clinical Issues, Pharmacology, and Sleep Loss Effects, edited by Clete A. Kushida Pneumocystis Pneumonia: Third Edition, Revised and Expanded, edited by P. D. Walzer and M. Cushion Asthma Prevention, edited by William W. Busse and Robert F. Lemanske, Jr. Lung Injury: Mechanisms, Pathophysiology, and Therapy, edited by Robert H. Notter, Jacob Finkelstein, and Bruce Holm Ion Channels in the Pulmonary Vasculature, edited by Jason X.-J. Yuan Chronic Obstructive Pulmonary Disease: Cellular and Molecular Mechanisms, edited by Peter J. Barnes Pediatric Nasal and Sinus Disorders, edited by Tania Sih and Peter A. R. Clement Functional Lung Imaging, edited by David Lipson and Edwin van Beek Lung Surfactant Function and Disorder, edited by Kaushik Nag Pharmacology and Pathophysiology of the Control of Breathing, edited by Denham S. Ward, Albert Dahan, and Luc J. Teppema Molecular Imaging of the Lungs, edited by Daniel Schuster and Timothy Blackwell Air Pollutants and the Respiratory Tract: Second Edition, edited by W. Michael Foster and Daniel L. Costa Acute and Chronic Cough, edited by Anthony E. Redington and Alyn H. Morice Severe Pneumonia, edited by Michael S. Niederman Monitoring Asthma, edited by Peter G. Gibson Dyspnea: Mechanisms, Measurement, and Management, Second Edition, edited by Donald A. Mahler and Denis E. O’Donnell Childhood Asthma, edited by Stanley J. Szefler and Sfren Pedersen Sarcoidosis, edited by Robert Baughman Tropical Lung Disease, Second Edition, edited by Om Sharma Pharmacotherapy of Asthma, edited by James T. Li Practical Pulmonary and Critical Care Medicine: Respiratory Failure, edited by Zab Mosenifar and Guy W. Soo Hoo Practical Pulmonary and Critical Care Medicine: Disease Management, edited by Zab Mosenifar and Guy W. Soo Hoo Ventilator-Induced Lung Injury, edited by Didier Dreyfuss, Georges Saumon, and Rolf D. Hubmayr Bronchial Vascular Remodeling in Asthma and COPD, edited by Aili Lazaar Lung and Heart–Lung Transplantation, edited by Joseph P. Lynch III and David J. Ross

218. 219. 220. 221. 222.

223.

224.

225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242.

Genetics of Asthma and Chronic Obstructive Pulmonary Disease, edited by Dirkje S. Postma and Scott T. Weiss Reichman and Hershfield’s Tuberculosis: A Comprehensive, International Approach, Third Edition (in two parts), edited by Mario C. Raviglione Narcolepsy and Hypersomnia, edited by Claudio Bassetti, Michel Billiard, and Emmanuel Mignot Inhalation Aerosols: Physical and Biological Basis for Therapy, Second Edition, edited by Anthony J. Hickey Clinical Management of Chronic Obstructive Pulmonary Disease, Second Edition, edited by Stephen I. Rennard, Roberto Rodriguez-Roisin, Ge´rard Huchon, and Nicolas Roche Sleep in Children, Second Edition: Developmental Changes in Sleep Patterns, edited by Carole L. Marcus, John L. Carroll, David F. Donnelly, and Gerald M. Loughlin Sleep and Breathing in Children, Second Edition: Developmental Changes in Breathing During Sleep, edited by Carole L. Marcus, John L. Carroll, David F. Donnelly, and Gerald M. Loughlin Ventilatory Support for Chronic Respiratory Failure, edited by Nicolino Ambrosino and Roger S. Goldstein Diagnostic Pulmonary Pathology, Second Edition, edited by Philip T. Cagle, Timothy C. Allen, and Mary Beth Beasley Interstitial Pulmonary and Bronchiolar Disorders, edited by Joseph P. Lynch III Chronic Obstructive Pulmonary Disease Exacerbations, edited by Jadwiga A. Wedzicha and Fernando J. Martinez Pleural Disease, Second Edition, edited by Demosthenes Bouros Interventional Pulmonary Medicine, Second Edition, edited by John F. Beamis, Jr., Praveen Mathur, and Atul C. Mehta Sleep Apnea: Implications in Cardiovascular and Cerebrovascular Disease, Second Edition, edited by Douglas T. Bradley and John Floras Respiratory Infections, edited by Sanjay Sethi Acute Respiratory Distress Syndrome, edited by Augustine M. K. Choi Pharmacology and Therapeutics of Airway Disease, Second Edition, edited by Kian Fan Chung and Peter J. Barnes Sleep Apnea: Pathogenesis, Diagnosis, and Treatment, Second Edition, edited by Allan I. Pack Pulmonary Hypertension, edited by Marc Humbert and Joseph P. Lynch III Tuberculosis: The Essentials, edited by Mario C. Raviglione Asthma Infections, edited by Richard Martin and Rand E. Sutherland Chronic Obstructive Pulmonary Disease: Outcomes and Biomarkers, edited by Mario Cazzola, Fernando J. Martinez, and Clive P. Page Bronchopulmonary Dysplasia, edited by Steven H. Abman Particle-Lung Interactions, Second Edition, edited by Peter Gehr, Christian Mu¨hlfeld, Barbara Rothen-Rutishauser, and Fabian Blank Cystic Fibrosis, edited by Julian L. Allen, Howard B. Panitch, and Ronald C. Rubenstein

The opinions expressed in these volumes do not necessarily represent the views of the National Institutes of Health.

Cystic Fibrosis Edited by Julian L. Allen University of Pennsylvania School of Medicine The Children’s Hospital of Philadelphia Philadelphia, Pennsylvania, U.S.A. Howard B. Panitch University of Pennsylvania School of Medicine The Children’s Hospital of Philadelphia Philadelphia, Pennsylvania, U.S.A. Ronald C. Rubenstein University of Pennsylvania School of Medicine The Children’s Hospital of Philadelphia Philadelphia, Pennsylvania, U.S.A.

Informa Healthcare USA, Inc. 52 Vanderbilt Avenue New York, NY 10017 # 2010 by Informa Healthcare USA, Inc. Informa Healthcare is an Informa business Cover illustration courtesy Marlene Galzin No claim to original U.S. Government works Printed in the United States of America on acid-free paper 10 9 8 7 6 5 4 3 2 1 International Standard Book Number-10: 1-4398-0181-9 (Hardcover) International Standard Book Number-13: 978-1-4398-0181-9 (Hardcover) Thisbookcontainsinformationobtainedfromauthenticandhighlyregardedsources.Reprintedmaterial is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequence of their use. No part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers. For permission to photocopy or use material electronically from this work, please access www.copyright.com (http://www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC) 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged. Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe. Library of Congress Cataloging-in-Publication Data Cystic fibrosis / edited by Julian L. Allen, Howard B. Panitch, and Ronald C. Rubenstein. p. ; cm. — (Lung biology in health and disease ; 242) Includes bibliographical references and index. ISBN-13: 978-1-4398-0181-9 (hb : alk. paper) ISBN-10: 1-4398-0181-9 (hb : alk. paper) 1. Cystic fibrosis. I. Allen, Julian Lewis. II. Panitch, Howard B. III Rubenstein, Ronald. IV. Series: Lung biology in health and disease ; v. 242. [DNLM: 1. Cystic Fibrosis. W1 LU62 v.242 2010 / WI 820 C99685 2010] RC858.C95C9332 2010 616.30 72—dc22 2009051589 For Corporate Sales and Reprint Permissions call 212-520-2700 or write to: Sales Department, 52 Vanderbilt Avenue, 7th floor, New York, NY 10017. Visit the Informa Web site at www.informa.com and the Informa Healthcare Web site at www.informahealthcare.com

To Debby, Eli and Jeremy, whose love, understanding and humor have enabled me to complete this book; to my parents, Beatrice and Emmanuel, who taught me to love music and science... JLA To Mary, Oren and Becky, for your encouragement and understanding; to my parents for demonstrating their love of learning... HBP To Andrea, Gavriel, Adina and Watson, for sharing this journey; to my parents, Honora and Murray for helping the journey start... RCR ...and to our patients and their families, who have taught us so much.

Preface

Improvement in the outcome of people with cystic fibrosis (CF) over the past 50 years is truly remarkable. What was once an almost universally fatal childhood genetic disorder has, through advances in research and clinical care, become a chronic illness whereby presently almost half of the people living with CF are adults. The known disease-causing mutations of the cystic fibrosis transmembrane regulator (CFTR) protein gene, which was cloned in 1989, have expanded from just over 150 in 1993 to over 1400 in 2009. Many of the physiologic processes influenced by abnormal CFTR function, from alterations in electrolyte transport to abnormalities of innate airways defense, are now recognized. Nevertheless, CF remains a disease that shortens and alters the quality of the lives of most affected individuals, and much progress remains to be made. In addition to new insights into the basic mechanisms that cause the CF phenotype, our understanding of the pathogenesis of both pulmonary and extrapulmonary manifestations of the disease have advanced. Concurrently, new techniques have been developed to detect CF lung disease at its earliest stages, well before it is clinically apparent. The confluence of these discoveries has led to the development of new therapeutic agents and approaches for the care of people with CF. This book attempts to detail recent insights and knowledge of CF pathogenesis, treatment, and health care systems approaches. We hope to make accessible to caregivers an increased understanding of both the molecular basis of CF and its expanding clinical features. We also hope to provide a common knowledge base that will allow the generation of testable hypotheses for future basic, clinical and translational research. We have sought to highlight new challenges for improving care and outcomes; new approaches for diagnosing, assessing, and treating CF; and the “new” clinical manifestations that have resulted from greater longevity of people with CF. We have also endeavored to relate the underlying cellular and molecular pathophysiologies to their relevant clinical phenotypes, and thereby provide the rationale for novel interventions. In this way, we hope this volume gives the reader an idea of how far we have come in the care of people living with CF, how far we still have to go, and some ideas about how we might get there.

ix

x

Preface

A book such as this is not possible without the contributions of many. We would like to thank the editorial staff at Informa Healthcare, especially Joseph Stubenrauch and Aimee Laussen, for their efficiency and especially their willingness to accommodate numerous last-minute changes. And, of course, we would like to thank the authors, whose knowledge and expertise are extraordinary. Julian L. Allen Howard B. Panitch Ronald C. Rubenstein

Contributors

Julian L. Allen University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A. David Barker University of Miami, Coral Gables, Florida, U.S.A. Suzanne E. Beck University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A. Alan S. Brody Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, U.S.A. A. Whitney Brown University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A. Andrew Bush Imperial School of Medicine at National Heart and Lung Institute and Royal Brompton Hospital, London, U.K. Andrew C. Calabria University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A. James F. Chmiel Case Western Reserve University School of Medicine, Rainbow Babies and Children’s Hospital, Cleveland, Ohio, U.S.A. John P. Clancy University of Alabama at Birmingham and Children’s Hospital of Alabama, Birmingham, Alabama, U.S.A. Susan Coffin University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A. Stephanie D. Davis University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A. Linda A. DiMeglio Indiana University School of Medicine and Riley Hospital for Children, Indianapolis, Indiana, U.S.A.

xi

xii

Contributors

Scott H. Donaldson University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A. Kelly Dougherty University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A. Mitchell Drumm Case Western Reserve University, Cleveland, Ohio, U.S.A. Peter R. Durie University of Toronto and the Hospital for Sick Children, Toronto, Ontario, Canada Andrew P. Feranchak University of Texas Southwestern Medical Center, Dallas, Texas, U.S.A. Terence R. Flotte University of Massachusetts Medical Center, Worcester, Massachusetts, U.S.A. J. Kevin Foskett University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, U.S.A. Ioanna K. Gisone The Children’s Hospital of Philadelphia, Craig-Dalsimer Division of Adolescent Medicine, Philadelphia, Pennsylvania, U.S.A. Samuel Goldfarb University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A. Nadine G. Haddad Indiana University School of Medicine and Riley Hospital for Children, Indianapolis, Indiana, U.S.A. Wynton Hoover University of Alabama at Birmingham and Children’s Hospital of Alabama, Birmingham, Alabama, U.S.A. Andrea Kelly University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A. Jeffrey C. Klick University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A. Michael W. Konstan Case Western Reserve University School of Medicine, Rainbow Babies and Children’s Hospital, Cleveland, Ohio, U.S.A.

Contributors

xiii

James L. Kreindler University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A. Craig Lapin Connecticut Children’s Medical Center, University of Connecticut, Hartford, Connecticut, U.S.A. Asim Maqbool University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A. Maria Mascarenhas University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A. Oscar H. Mayer University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A. Susanna A. McColley Northwestern University Feinberg School of Medicine, Chicago, Illinois, U.S.A. Suzanne H. Michel University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A. Christian Mueller University of Massachusetts Medical Center, Worcester, Massachusetts, U.S.A. Joshua P. Needleman Weill Cornell Medical College, New York, New York, U.S.A. Brian P. O’Sullivan University of Massachusetts Medical School and UMass Memorial Health Care, Worcester, Massachusetts, U.S.A. Chee Y. Ooi (Keith) The Hospital for Sick Children, Toronto, Ontario, Canada Howard B. Panitch University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A. Jessica E. Pittman University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A. Paul J. Planet Columbia University, New York, New York, U.S.A. Alexandra L. Quittner University of Miami, Coral Gables, Florida, U.S.A.

xiv

Contributors

Molly Raske Seattle Children’s Hospital, Seattle, Washington, U.S.A. Felix Ratjen Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada Clement L. Ren University of Rochester, Rochester, New York, U.S.A. Susan Rettig The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A. Fariba Rezaee University of Rochester, Rochester, New York, U.S.A. Walter M. Robinson Vanderbilt Children’s Hospital, Center for Biomedical Ethics and Society, Vanderbilt University, Nashville, Tennessee, U.S.A. Margaret Rosenfeld Seattle Children’s Hospital, Seattle, Washington, U.S.A. Alisha J. Rovner Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland, U.S.A. Ronald C. Rubenstein University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A. Lisa Saiman Columbia University, New York, New York, U.S.A. Don B. Sanders University of Wisconsin, Madison, Wisconsin, U.S.A. Meghana N. Sathe University of Texas Southwestern Medical Center, Dallas, Texas, U.S.A. Michael S. Schechter Emory University and Children’s Healthcare of Atlanta, Atlanta, Georgia, U.S.A. Virginia A. Stallings University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A. Laurence Suaud University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A. Sherstin G. Truitt University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A.

Contributors

xv

Lisa K. Tuchman Children’s National Medical Center, Division of Adolescent and Young Adult Medicine, Children’s Research Institute, Center for Clinical and Community Research, Washington, D.C., U.S.A. Elizabeth Tullis University of Toronto and St. Michael’s Hospital, Toronto, Ontario, Canada James R. Yankaskas University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A.

Contents

Preface . . . . ix Contributors . . . . .

xi

Part I Pathophysiology 1. The Genetics of Cystic Fibrosis . . . . . . . . . . . . . . . . . . . . . . Laurence Suaud and Ronald C. Rubenstein

1

2. Ion Transport . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . James L. Kreindler and J. Kevin Foskett

11

3. Mucus Abnormalities and Ciliary Dysfunction . . . . . . . . . . A. Whitney Brown and Scott H. Donaldson

24

4. Microbiology in Cystic Fibrosis . . . . . . . . . . . . . . . . . . . . . Paul J. Planet and Lisa Saiman

36

5. Inflammation in the Cystic Fibrosis Lung . . . . . . . . . . . . . James F. Chmiel and Michael W. Konstan

57

6. Modifier Genes of Cystic Fibrosis . . . . . . . . . . . . . . . . . . . Mitchell Drumm

78

Part II Diagnostics 7. Cystic Fibrosis: Diagnosis, Sweat Testing, and Newborn Screening . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Brian P. O’Sullivan

xvii

90

xviii

Contents

8. Diagnostic Approach to Diseases Associated with Cystic Fibrosis Transmembrane Conductance Regulator Gene Mutations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Chee Y. Ooi (Keith), Elizabeth Tullis, and Peter R. Durie 9. Lung Function Testing in Infants . . . . . . . . . . . . . . . . . . . . Jessica E. Pittman and Stephanie D. Davis

103

123

10. Assessment of Lung Function in Young Children with Cystic Fibrosis . . . . . . . . . . . . . . . . . Fariba Rezaee and Clement L. Ren

148

11. Lung Function Testing in School-Age Children with Cystic Fibrosis . . . . . . . . . . . . . . Oscar H. Mayer and Julian L. Allen

161

12. Thoracic Imaging in Cystic Fibrosis Pulmonary Disease . . . Molly Raske and Alan S. Brody

182

Part III Clinical Manifestations and Treatment 13. Pulmonary Manifestations . . . . . . . . . . . . . . . . . . . . . . . . . Andrew Bush 14. Treatment Strategies for Maintaining Pulmonary Health in Cystic Fibrosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Susanna A. McColley

198

224

15. Mucolytic Therapy and Airway Clearance Techniques . . . . Felix Ratjen and Craig Lapin

236

16. Pulmonary Exacerbations . . . . . . . . . . . . . . . . . . . . . . . . . Don B. Sanders and Margaret Rosenfeld

251

17. Gastrointestinal Complications of Cystic Fibrosis . . . . . . . . Maria Mascarenhas and Asim Maqbool

266

18. Liver Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Meghana N. Sathe and Andrew P. Feranchak

285

Contents

xix

19. Nutrition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Asim Maqbool, Kelly Dougherty, Alisha J. Rovner, Suzanne H. Michel, and Virginia A. Stallings

308

20. Bone Health and Treatment . . . . . . . . . . . . . . . . . . . . . . . . Nadine G. Haddad and Linda A. DiMeglio

328

21. Cystic Fibrosis–Related Diabetes and Management . . . . . . . Andrea Kelly and Andrew C. Calabria

341

22. Other Extrapulmonary Complications and Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Joshua P. Needleman and Suzanne E. Beck 23. Chronic Respiratory Failure and the Roles of Noninvasive Ventilation and Lung Transplantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Samuel Goldfarb and Howard B. Panitch 24. Gene Repair: Past, Present, and Future . . . . . . . . . . . . . . . Christian Mueller and Terence R. Flotte 25. Restoration of CFTR Function with Small-Molecule Modulators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Wynton Hoover and John P. Clancy

356

372

390

406

Part IV Psychosocial Considerations and Care Systems 26. Quality Improvement in Cystic Fibrosis Care . . . . . . . . . . . Michael S. Schechter

424

27. Cystic Fibrosis and Infection Control . . . . . . . . . . . . . . . . . Susan Rettig and Susan Coffin

440

28. Transition to Adult Care . . . . . . . . . . . . . . . . . . . . . . . . . . Sherstin G. Truitt and James R. Yankaskas

451

29. Reproduction, Sexuality, and Fertility . . . . . . . . . . . . . . . . Lisa K. Tuchman and Ioanna K. Gisone

457

xx

Contents

30. A Biopsychosocial Model of Cystic Fibrosis: Social and Emotional Functioning, Adherence, and Quality of Life . . . David Barker and Alexandra L. Quittner 31. Palliative and End-of-Life Care in Cystic Fibrosis . . . . . . . Walter M. Robinson and Jeffrey C. Klick Index . . . . 497

468

482

1 The Genetics of Cystic Fibrosis LAURENCE SUAUD and RONALD C. RUBENSTEIN University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A.

I.

The CF Gene

Over recent years there has been a dramatic increase in our understanding of the genetics of cystic fibrosis (CF). In 1949, Lowe et al. postulated that CF must be caused by a defect in a single gene on the basis of the autosomal recessive pattern of inheritance of the disease (1). The identification of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in 1989 by Collins et al. (2–4) created new hope for curative treatment. The CFTR gene is localized on the long arm of chromosome 7 (7q21-34), spanning approximately 190 kb of genomic DNA (5). The gene consists of 27 exons and encodes a mature mRNA transcript of 6.5 kb that is translated into a 1480–amino acid protein. CFTR is found in various epithelial cell types at the apical surface, including respiratory epithelia and submucosal glands, exocrine pancreas, liver, sweat ducts, and the reproductive tract. In these locations, its main function is to act as a cAMP-mediated chloride channel that regulates the ion and water balance across epithelia (6,7). It has also been reported to be present and to have function in the brain (8), neonatal murine cardiac myocytes (9), erythrocytes (10,11), and macrophages (12), among other cell types. CFTR is a member of the ATP-binding cassette (ABC) membrane transporter superfamily that includes proteins such as the multiple drug resistance protein (MDR) and bacterial periplasmic permeases. Like other ABC transporters, the CFTR protein contains two homologous halves comprising two membrane-spanning domains, each with six helices, and two nucleotide-binding domains (NBDs) (3). However, unlike other ABC transporters, CFTR has a unique regulatory (R) domain that separates the homologous halves and contains many charged amino acids and consensus sites for phosphorylation by protein kinases (Fig. 1). The two membrane-spanning domains form a low-conductance chloride channel pore (Fig. 1). CFTR is activated by protein kinase A (PKA), and is probably also regulated by protein kinase C (PKC), with phosphorylation occurring at multiple sites located in the R domain. As phosphorylation by PKA is mandatory for channel activity, CFTR channel is considered a “cAMP-activated channel.”

II.

Incidence

CF remains one of the commonest life-threatening autosomal recessive conditions affecting Caucasians. There are approximately 30,000 affected individuals in the United States, and about 1000 new cases are diagnosed each year. The incidence is 1/2500 to

1

2

Suaud and Rubenstein

Figure 1 Proposed domain structure of the CFTR protein within the cell membrane. Abbreviations: CFTR, cystic fibrosis transmembrane conductance regulator; MSD, membrane-spanning domain; NBD, nucleotide-binding domain; R, regulatory domain.

Table 1 CF Incidence Across the Globe

Country Finland Mexico Sweden Poland North Ireland Russia Denmark Norway The Netherlands Spain Greece Germany United States Czech republic United Kingdom Australia Italy France Switzerland Ireland Abbreviation: CF, cystic fibrosis. Source: From Ref. 13.

Incidence (1 case per x birth) 25000 8500 7300 6000 5350 4900 4700 4500 3650 3500 3500 3300 2835 2833 2600 2500 2438 2350 2000 1800

The Genetics of Cystic Fibrosis

3

1/90,000, and varies between populations of different ethnicity (Table 1): in Caucasians the incidence is estimated to be 1/3200; in African-Americans 1/15,000; and in AsianAmericans 1/31,000. Even among northern European Caucasian populations, the incidence varies significantly; the incidences in Ireland and Sweden are 1/1800 and 1/7300 live births, respectively (14). The geographical distribution of CFTR mutations also varies worldwide. These variations are likely to be due to founder effects and subsequent patterns of migration and settlement. The high prevalence of the CF gene in certain populations has led to speculations that there may be some selective advantage for heterozygotic carriers (15,16). For example, mutations in the CFTR gene are hypothesized to provide increased resistance to infectious diseases, thereby maintaining the mutant alleles at high frequency in selected populations. Pier and colleagues hypothesized that heterozygote carriers of CFTR mutations had increased resistance to infection with intracellular organisms such as Salmonella (17), while others hypothesized that carriers have a selective advantage because of resistance to diarrhea-causing enterotoxins elaborated by Vibrio cholera and Escherichia coli (18). Cholera toxin (CT) and the heat-labile toxin elaborated by enterotoxic E. coli cause irreversible activation of the stimulatory guanine nucleotide–binding protein, Gs, which in turn activates membrane-bound adenylyl cyclase. This greatly elevates cellular cAMP levels and causes subsequent activation of PKA, phosphorylation of R domain of CFTR, and opening of the CFTR channel, which is the predominant cAMP-regulated Cl
channel in the intestinal and colonic epithelia. The end result of this signaling cascade is massive Cl
secretion into the intestinal lumen and potentially lethal secretory diarrhea characterized by, in the case of cholera, “rice water stools.” The data of Gabriel and colleagues from cftr null and heterozygote carrier mice support this selective advantage hypothesis, as well as a central role of CFTR in the Cl
secretory response of the intestinal epithelia to CT. In response to intraluminal injection of CT, heterozygous CF-carrier mice secreted 50% less volume of fluid into their intestines than wild-type mice under the same conditions. The cftr
/
knockout mice had no fluid-secretory response to intraluminal injection of CT. However, this hypothesis was disputed by Hogenauer et al., who measured the in vivo basal (unstimulated) and prostaglandin-stimulated jejunal chloride secretion in normal human subjects, CF heterozygote carriers, and subjects with CF (19); prostaglandins similarly act to increase cellular cAMP. These data indicated that while subjects with CF had essentially no active chloride secretion in response to the prostaglandin secretagogue, individuals who were heterozygous carriers of a CF mutation secreted chloride at the same rate as people without a CF mutation. These data thus contradicted the earlier mouse model data. Furthermore, it is not clear how such resistance to cholera as the selective advantage for heterozygote carriers would have been significantly beneficial in the populations with the highest CFTR mutation carrier frequencies, as cholera is not endemic in those geographic regions.

III.

Classes of CFTR Mutations

More than 1500 CF mutations have been reported. Many of these mutations are rare in the population, with only a few affected individuals reported. There are also a number of silent and nonsilent changes in the coding sequence that are not clearly demonstrated to

4

Suaud and Rubenstein

Table 2 Most Common Mutations Found in the Total U.S. Population

Mutation

Prevalence (%)

DeltaF508 G542X G551D W1282X N1303K

68.6 2.4 2.1 1.4 1.3

Source: From Ref. 13.

induce CFTR dysfunction; such changes are therefore considered CFTR polymorphisms. Thus, the number of true disease-causing mutations is likely fewer [see the CFTR mutations database (20)]. The disease-causing mutations are situated throughout the entire coding region of the gene, and also the promoter and intronic regions, although there are “hot spot” regions where mutations are more common, such as the NBDs, the cytoplasmic loops of the transmembrane domains that are hypothesized to interact with the NBDs (21), and the regulatory (R) domain. The most common disease-causing CFTR mutation worldwide is DF508, which occurs on approximately 70% of mutant CFTR alleles. This absence of phenylalanine at position 508 of the CFTR protein results from an in-frame deletion of three base pairs from exon 10. The DF508 mutation results in an abnormal protein that is defective with regards to intracellular processing. This leads to absence of CFTR channels from the membrane and, as a result, absent CFTR function. This is discussed further below. The majority of the other mutations have significantly lower allele frequencies of less than 2% to 3% (Table 2), although this can clearly vary greatly within populations or ethnic groups suggesting founder effects. For example, the W1282X mutation has an allele frequency of 1% to 2% in the North American Population, but is the predominant allele in Israel and in those of Ashkenazi Jewish descent (22). Many of other mutations are unique to a particular individual or family or have been found in only a handful of cases across the world. Given the large and complicated makeup of the CFTR gene and promoter, as well as the large number of described rare mutations found by sequencing the CFTR coding region and targeted areas of intronic and promoter DNA, it is not surprising that such gene sequencing does not always identify two CFTR mutations in people with CF. Using present commercial techniques, up to 1% of people with a clinical diagnosis of CF may not have two identifiable CFTR mutations. It has become convenient to classify the large number of described CFTR mutations into six different groups according to the mechanism by which they disrupt CFTR Cl
transport function (Fig. 2) (23). However, for the vast majority of CFTR mutations, especially rarer mutations, mechanistic data on which to properly classify such mutations according to this scheme is lacking. Furthermore, there are a number of mutations that either have mechanistic defects that overlap two classes or frankly defy classification according to this scheme. Nevertheless, we briefly discuss this classification scheme here, as it has been clearly useful in assisting clinicians and investigators in thinking about genotype-phenotype correlation in people with CF- or CFTR-related disorders, and in guiding the development of novel, mutation-directed therapies for CF (discussed in Chapter 25 by Hoover and Clancy).

The Genetics of Cystic Fibrosis

5

Figure 2 Classes of mutant CFTR. Abbreviation: CFTR, cystic fibrosis transmembrane conductance regulator.

Class I mutations abolish protein production and result in complete loss of CFTR protein, and therefore CFTR function. About half of all mutations in CFTR (encompassing gene deletions, exon skipping due to aberrant mRNA splicing, and single nucleotide or smaller deletions leading to reading frame shifts) are thought to fall into this class. Class I also includes mutations that generate premature stop codons, including G542X and W1282X, that lead to early termination of protein translation and rapid mRNA degradation (24). Combined, these “X” mutations have an overall allele frequency of approximately 10%, and, as described in Chapter 25, may be targets for therapies that allow the ribosome to “read through” or suppress these premature termination codons. Class II CFTR mutations are characterized by aberrant intracellular trafficking of the CFTR protein, and therefore the absence of the functional protein from the apical membrane of epithelia. Mutations of this class include the common DF508, and N1303K. In the case of DF508, the mutant CFTR is recognized by the cell quality control mechanism and subsequently degraded. Interestingly, DF508 retains the ability to transport Cl
across intracellular membranes (25), and a number of physical and chemical maneuvers (26), including reduced temperature incubation (27), allow it to reach the apical membrane. However, both DF508 (28) and N1303K (29) appear to have abnormal functions even when at the plasma membrane. This suggests that these mutations make CFTR dysfunctional by multiple mechanisms, and that these mutations may, in fact, have characteristics of more than one CFTR mutation class. Class III mutations disrupt activation and regulation of mutant CFTRs, which are appropriately localized at the plasma membrane. Thus, biosynthesis, trafficking, and

6

Suaud and Rubenstein

processing are undisturbed, but the channel may be defective with respect to phosphorylation by PKA or the subsequent regulation of channel opening. This class of dysfunction tends to result from missense mutations in key areas of the protein that are important for regulation of CFTR function (30). The most common mutation of this class is G551D, which has an allele frequency of approximately 2%. G551D is a mutation in CFTR’s first nucleotide-binding fold (NBD-1), which results in a very low channel open probability. This leads to essentially absent CFTR function despite G551D-CFTR’s appropriate localization at the apical membrane of epithelia. Class IV CFTR mutants are defined by aberrant or reduced chloride conduction. These mutants tend to result from more conservative missense mutations of CFTR, and retain normal intracellular location of the mutant protein at the apical epithelial membrane (31). The most common of these class IV mutations is R117H, which is the substitution of a slightly less strongly positively charged histidine for a strongly positively charged arginine residue. Class V mutations reduce the amount of normal CFTR protein in the cell and at the apical membrane by decreasing, but not eliminating, protein production. However, in general, the CFTR protein that is produced by mutations of this class functions normally. Such effects may result from mutations in the promoter or by inefficient mRNA splicing. One example of a class V mutation is the 3849 þ 10 kb C?T mutation found in intron 19, which reduces the splicing efficiency of the CFTR mRNA to approximately 8% of normal (32). Another intronic mutation, 2789 þ 5 kb G?A reduces mRNA splicing efficiency to approximately 4% by altering the splice donor site of exon 14b (33). Class VI mutations, like class V mutations, reduce the amount of functional CFTR protein at the apical membrane. However, in contrast to class V mutations that decrease CFTR production, class VI mutations cause an increased rate of CFTR’s removal from the apical plasma membrane. Mutations leading to this type of CFTR defect are uncommon and include N287Y (34) as well as mutations that delete the carboxyl terminus of the CFTR protein.

IV.

Genotype/Phenotype Correlation

In general, mutations of classes I, II, and III are associated with absent CFTR function. Thus, any person with CF who is homozygous for a mutation of one of these classes, or who is compound heterozygous for any combination of class I, II, or III mutations, is expected to have an overall absence of CFTR function. This typically results in a “severe” or “classic” CF phenotype including exocrine pancreatic insufficiency. This phenotype is present in 85% to 90% of people with CF. Further attempts to delineate genotype/phenotype correlations in this group of people with CF have been less successful, perhaps because almost 50% of people with CF are DF508-homozygotes, and additional approximately one-third are DF508 compound heterozygotes. On the other hand, even among the people with CF who are DF508-homozygous, there is tremendous variability in phenotype and clinical course. This has led to the hypothesis and recent demonstration that polymorphisms in other genes, such as transforming growth factor b (TGF-b), are associated with significantly different clinical CF phenotypes (35). The topic of genes that modify the CF phenotype is discussed in more depth elsewhere in Chapter 6 by Drumm.

The Genetics of Cystic Fibrosis

7

The presence of class IV and V CFTR mutations are associated with significant residual CFTR function, even when present with a second allele where function is absent (i.e., a class I, II, or III mutation). This residual CFTR function of the class IV or V allele usually manifests clinically as phenotypically milder CF, often with exocrine pancreatic sufficiency and less sinopulmonary symptomatology. This milder phenotype occurs in the remaining 10% to 15% of people with CF. Interestingly, the amount of residual function of a class IV or V mutant CFTR, such as R117H, and subsequently clinical phenotype can be significantly modified by polymorphisms that influence how much mRNA encoding R117H, and therefore how much R117H protein is made. One well-studied example of this is exon 8-9 splicing. Failure to correctly splice exon 8 to exon 9 results in a nonfunctional CFTR, and the efficiency and fidelity of this reaction is influenced by a polythymidine sequence within intron 8 preceding the exon 9 splice acceptor site (36). This polythymidine tract is polymorphic with sequences of 5, 7, or 9 thymidines (5T, 7T, or 9T, respectively), and the efficiency of exon 8-9 splicing is directly proportional to the length of the thymidine sequences. The 9T variant allows the greatest proportion of normal exon 8-9 splicing and functional CFTR production, while the 5T variant is associated with the highest level of mRNA missplicing and nonfunctional CFTR protein production (36). The commonest polymorphism is the 7T variant, which has a splicing efficiency intermediate to that of 5T and 9T. The DF508 mutation occurs exclusively associated with the 9T variant, while other class I, II, or III mutations are more often found in cis with 9T than is wild-type CFTR (37). These data suggest that evolution has either sensed that more CFTR function is needed when CFTR is mutant, or that CFTR, when present, should have limited expression. In the case of R117H, this intron 8 polymorphism can clearly modulate phenotype. For a person with one R117H allele and a second nonfunctional allele of class I, II, or III, such as W1282X, DF508, or G551D, those with 5T in cis with R117H typically have more clinical symptoms of CF, including sweat chloride elevation, than do people with 7T in cis with R117H, who may even have normal or borderline abnormal sweat tests. Those with 9T in cis with R117H can, in fact, have minimal, if any, outward symptoms of classical or even pancreatic sufficient CF (36,38,39). Interestingly, the penetrance of the 5T polymorphism in men with congenital bilateral absence of the vas deferens (CBAVD) can be significantly influenced by a number of TG repeats directly adjacent to and upstream of 5T tract. In men with CBAVD who had a severe CFTR mutation (class I, II, or III) on one allele and a normal CFTR in cis with 5T on the other allele, a greater number of TG repeats, 12 or 13, adjacent to 5T were associated with a higher likelihood of CBAVD than if 11 TG repeats were present (40). This is the likely result of a greater number of TG repeats in cis with 5T, causing a further increase in exon 9 skipping during mRNA splicing (41). This would further decrease production of functional CFTR protein. This TG repeat polymorphism may also influence the penetrance of the R117H mutation. These issues are discussed further in Chapter 8 by Ooi, Tullis and Durie. The phenotypic implications of class VI mutations are less well defined. N287Y (34) is associated with a pancreatic sufficient phenotype according to the CFTR mutation database (20). In contrast, mutations that delete the carboxyl terminus of CFTR may be associated with a greater impairment of CFTR function and pancreatic insufficiency.

8

Suaud and Rubenstein

V. Heterozygote Carriers of CFTR Mutations It has been generally accepted that heterozygote carriers of CFTR mutations were “healthy” and essentially unaffected by having one dysfunctional CFTR allele. Recent data have challenged this belief and have suggested that there is an increased risk of clinically apparent disease in heterozygous carriers of CFTR mutations in tissues where CFTR has important epithelial function. For example, people with chronic rhinosinusitis have an increased frequency of being heterozygous carriers of CFTR mutations than does the general population (42). Similarly, heterozygote carriers of the DF508 mutation have an increased prevalence of asthma compared with the general population (43), and there is a higher prevalence of CFTR missense mutations in those with asthma than in the general population (44). Nonrespiratory epithelia also appear at risk in heterozygote CFTR mutation carriers. There are increased incidences of CFTR mutations found in people with chronic idiopathic pancreatitis (45), primary sclerosing cholangitis (46), and CAVBD (47). These recently recognized CFTR-related disorders will be explored in more depth in Chapter 8.

VI.

Summary

CF is a monogenic, autosomal recessive condition that results from the absence of the CFTR. Its classic presentation is associated with essentially absent CFTR function. NonCFTR genetic loci can significantly modulate the clinical manifestations of CF. Recent data also suggest that relatively small modulations of CFTR function may significantly alter the CF phenotype. Our understanding of a potential selective advantage for heterozygote carriers that has allowed persistence of CFTR mutations in the population is limited. This is especially apparent since heterozygote carriers of CFTR mutations also appear at an increased risk for clinical manifestations related to dysfunction of their CFTR-expressing epithelia.

Acknowledgment This work is supported by grants from the NIH/NIDDK, the American Heart Association, and the Cystic Fibrosis Foundation.

References 1. Lowe CU, May CD, Reed SC. Fibrosis of the pancreas in infants and children; a statistical study of clinical and hereditary features. Am J Dis Child 1949; 78(3):349–374. 2. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245(4922):1073–1080. 3. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245(4922):1066–1073. 4. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245(4922):1059–1065. 5. Ellsworth RE, Jamison DC, Touchman JW, et al. Comparative genomic sequence analysis of the human and mouse cystic fibrosis transmembrane conductance regulator genes. Proc Natl Acad Sci U S A 2000; 97(3):1172–1177.

The Genetics of Cystic Fibrosis

9

6. McIntosh I, Cutting GR. Cystic fibrosis transmembrane conductance regulator and the etiology and pathogenesis of cystic fibrosis. FASEB J 1992; 6(10):2775–2782. 7. Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiol Rev 1999; 79(1 suppl):S23–S45. 8. Mulberg AE, Wiedner EB, Bao X, et al. Cystic fibrosis transmembrane conductance regulator protein expression in brain. Neuroreport 1994; 5(13):1684–1688. 9. Lader AS, Wang Y, Jackson GR Jr., et al. cAMP-activated anion conductance is associated with expression of CFTR in neonatal mouse cardiac myocytes. Am J Physiol Cell Physiol 2000; 278(2):C436–C450. 10. Sprague RS, Ellsworth ML, Stephenson AH, et al. Deformation-induced ATP release from red blood cells requires CFTR activity. Am J Physiol 1998; 275(5 pt 2):H1726–H1732. 11. Lange T, Jungmann P, Haberle J, et al. Reduced number of CFTR molecules in erythrocyte plasma membrane of cystic fibrosis patients. Mol Membr Biol 2006; 23(4):317–323. 12. Di A, Brown ME, Deriy LV, et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol 2006; 8(9):933–944. 13. Bobadilla JL, Macek M, Fine JP, et al. Cystic fibrosis: a worldwide analysis of CFTR mutations—Correlation with incidence data and application to screening. Hum Mutat 2002; 19:575–606. 14. Tsui LC. The spectrum of cystic fibrosis mutations. Trends Genet 1992; 8(11):392–398. 15. Jorde LB, Lathrop GM. A test of the heterozygote-advantage hypothesis in cystic fibrosis carriers. Am J Hum Genet 1988; 42(6):808–815. 16. Pritchard DJ. Cystic fibrosis allele frequency, sex ratio anomalies and fertility: a new theory for the dissemination of mutant alleles. Hum Genet 1991; 87(6):671–676. 17. Pier GB, Grout M, Zaidi T, et al. Salmonella typhi uses CFTR to enter intestinal epithelial cells. Nature 1998; 393(6680):79–82. 18. Gabriel SE, Brigman KN, Koller BH, et al. Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science 1994; 266(5182):107–109. 19. Hogenauer C, Santa Ana CA, Porter JL, et al. Active intestinal chloride secretion in human carriers of cystic fibrosis mutations: an evaluation of the hypothesis that heterozygotes have subnormal active intestinal chloride secretion. Am J Hum Genet 2000; 67(6):1422–1427. 20. Cystic Fibrosis Mutation Database. Available at: http://www.genet.sickkids.on.ca/cftr/app. 21. Riordan JR. CFTR function and prospects for therapy. Annu Rev Biochem 2008; 77:701–726. 22. Kerem E, Kalman YM, Yahav Y, et al. Highly variable incidence of cystic fibrosis and different mutation distribution among different Jewish ethnic groups in Israel. Hum Genet 1995; 96(2):193–197. 23. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993; 73:1251–1254. 24. Hamosh A, Rosenstein BJ, Cutting GR. CFTR nonsense mutations G542X and W1282X associated with severe reduction of CFTR mRNA in nasal epithelial cells. Hum Mol Genet 1992; 1:542–544. 25. Pasyk EA, Foskett JK. Mutant (delta F508) cystic fibrosis transmembrane conductance regulator Cl- channel is functional when retained in endoplasmic reticulum of mammalian cells. J Biol Chem 1995; 270:12347–12350. 26. Rubenstein RC. Targeted therapy for cystic fibrosis: cystic fibrosis transmembrane conductance regulator mutation-specific pharmacologic strategies. Mol Diagn Ther 2006; 10(5):293–301. 27. Denning GM, Anderson MP, Amara JF, et al. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992; 358(6389):761–764. 28. Dalemans W, Barbry P, Champigny G, et al. Altered chloride channel kinetics associated with the deltaF508 cystic fibrosis mutation. Nature 1991; 354:526–528. 29. Randak C, Welsh MJ. An intrinsic adenylate kinase activity regulates gating of the ABC transporter CFTR. Cell 2003; 115(7):837–850.

10

Suaud and Rubenstein

30. Logan J, Hiestand D, Daram P, et al. Cystic fibrosis transmembrane conductance regulator mutations that disrupt nucleotide binding. J Clin Invest 1994; 94:228–236. 31. Sheppard DN, Rich DR, Ostergaard LS, et al. Mutations in CFTR associated with milddisease-form Cl
channels with altered pore properties. Nature 1993; 362:160–164. 32. Highsmith WE, Burch LH, Zhou Z, et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 1994; 331(15):974–980. 33. Highsmith WE Jr., Burch LH, Zhou Z, et al. Identification of a splice site mutation (2789 þ5 G > A) associated with small amounts of normal CFTR mRNA and mild cystic fibrosis. Hum Mutat 1997; 9(4):332–338. 34. Silvis MR, Picciano JA, Bertrand C, et al. A mutation in the cystic fibrosis transmembrane conductance regulator generates a novel internalization sequence and enhances endocytic rates. J Biol Chem 2003; 278(13):11554–11560. 35. Drumm ML, Konstan MW, Schluchter MD, et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 2005; 353(14):1443–1453. 36. Massie RJ, Poplawski N, Wilcken B, et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. Eur Respir J 2001; 17(6):1195–1200. 37. Chu CS, Trapnell BC, Curristin S, et al. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet 1993; 3(2):151–156. 38. Rave-Harel N, Kerem E, Nissim-Rafinia M, et al. The molecular basis of partial penetrance of splicing mutations in cystic fibrosis. Am J Hum Genet 1997; 60(1):87–94. 39. Kiesewetter S, Macek M Jr., Davis C, et al. A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat Genet 1993; 5(3):274–278. 40. Groman JD, Hefferon TW, Casals T, et al. Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet 2004; 74(1):176–179. 41. Cuppens H, Lin W, Jaspers M, et al. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest 1998; 101(2):487–496. 42. Wang X, Moylan B, Leopold DA, et al. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA 2000; 284(14): 1814–1819. 43. Dahl M, Tybjaerg-Hansen A, Lange P, et al. DeltaF508 heterozygosity in cystic fibrosis and susceptibility to asthma. Lancet 1998; 351(9120):1911–1913. 44. Lazaro C, de Cid R, Sunyer J, et al. Missense mutations in the cystic fibrosis gene in adult patients with asthma. Hum Mutat 1999; 14(6):510–519. 45. Cohn JA, Friedman KJ, Noone PG, et al. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 1998; 339(10):653–658. 46. Sheth S, Shea JC, Bishop MD, et al. Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. Hum Genet 2003; 113(3): 286–292. 47. Dumur V, Gervais R, Rigot JM, et al. Congenital bilateral absence of the vas deferens (CBAVD) and cystic fibrosis transmembrane regulator (CFTR): correlation between genotype and phenotype. Hum Genet 1996; 97(1):7–10.

2 Ion Transport JAMES L. KREINDLER University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A.

J. KEVIN FOSKETT University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, U.S.A.

I.

Introduction

Cystic fibrosis (CF) is a disease of abnormal ion transport. Specifically, abnormalities in the expression and function of the cystic fibrosis transmembrane conductance regulator (CFTR) result in abnormal salt and water transport across epithelial surfaces in the gastrointestinal and hepatobiliary systems, respiratory tract, reproductive system, and sweat glands. With the exception of the sweat glands, abnormal salt and water transport eventuate in end-organ damage causing significant morbidity and severely shortening life span. The connection between abnormally high salt concentration in sweat and fatal disease has been recognized since the Middle Ages. If a child tasted salty when kissed on the forehead, the child was “bewitched or fascinated and was feared to die soon” (1). This saying is assumed to reflect the existence and recognition of CF (2). We now know much more about the child who tastes salty as well as the genetic and molecular mechanisms underlying CF. Through this understanding and with advances in nutritional and pulmonary therapies, mean predicted survival in CF is now more than 37 years. In this chapter, we review the evolution of our knowledge of ion transport defects in CF, describe the ion channel properties of normal CFTR, discuss how changes in the amino acid sequence of CFTR result in channel dysfunction, and review how loss of CFTR function results in end-organ damage, especially in the lungs.

II.

Establishing A Role for Ion Transport in CF

The first description of CF as a pathological, genetic entity in the United States was published in 1938 by Dorothy Andersen, MD, a pathologist at The Babies’ and Children’s Hospital of Columbia University in New York City. This paper entitled “Cystic fibrosis of the pancreas and its relation to celiac disease (3)” firmly established CF of the pancreas as a diagnosis separate and apart from celiac disease. It was not until more than a decade later, however, that the connection was made between salt transport and CF of the pancreas. In 1951, Kessler and Andersen reported on 12 children admitted to Babies’ Hospital with heat prostration who were in relatively good health before a heat wave, and who presented acutely with vomiting and signs of shock without evidence of infection. All of these children, except for one who died, responded quickly to rehydration (4). In patients for whom laboratory data were available, serum electrolyte analyses showed low Cl
and high HCO3
concentrations that were reversed with 11

12

Kreindler and Foskett

therapy. These findings supported an etiological hypothesis that “fibrocystic disease is associated with widespread abnormality of epithelial glands (4).” Following these observations, Paul di Sant‘Agnese, MD, also at Columbia University, prospectively studied sweat electrolyte levels in 43 patients and 50 controls. His results demonstrated that Naþ, Kþ, and Cl
all were elevated in the sweat of CF patients, with sweat Naþ and Cl
levels being markedly elevated (5). The authors also demonstrated that the elevated sweat Naþ and Cl
levels were not the secondary result of pancreatic dysfunction, pulmonary disease, adrenal dysfunction, or renal disease, and concluded that the increased susceptibility to dehydration in CF was due to increased salt loss from sweat glands. These findings led directly to the development of the sweat test as a diagnostic test for CF (6).

III.

Finding The Gene

The paper by di Sant‘Agnese and colleagues included a statement that CF was a disease of altered ion transport, as opposed to one of abnormal mucus composition or secretion, because, although sweat glands had normal morphology, their abnormal function distinguished patients with CF from others (5). Nonetheless, there remained the clinical observations that end-organ damage in the pancreas and lung was characterized by thick, sticky mucus. The question therefore arose of how to rectify these two apparently disparate observations. Over the last five decades, this question has inspired more than 30,000 papers indexed in PubMed. By the early 1980s, observations in the sweat gland, pancreas, and respiratory tract began to suggest that CF was, at its essence, a disease of altered anion transport. Multiple studies confirmed the findings of di Sant‘Agnese that sweat electrolyte concentrations were abnormal in CF. In separate studies using different techniques, Quinton (7) and later Fromter (8) concluded that CF sweat glands had decreased ductal Cl
permeability and reduced secretion in response to adrenergic stimulation. Similarly, studies of pancreatic HCO3
secretion in CF patients concluded that abnormal pancreatic secretion in CF could be attributed at least in part to altered Cl
secretion (9). Knowles and colleagues at the University of North Carolina reported that the electrical potential across the nasal epithelia of CF patients was more electronegative than controls and did not respond appropriately to adrenergic stimulation (10). It seemed, then, that the basic defect in three different organ systems could be attributed to altered Cl
permeability. Armed with this knowledge, CF researchers began to search for the affected gene. In 1985, two laboratories using different markers for linkage analysis localized the gene to the long arm of chromosome 7 (11,12). In 1989, Tsui and colleagues discovered the gene responsible for CF (13) and found that in the majority of patients the gene was missing three nucleotides that resulted in the in-frame deletion of a phenylalanine residue at position 508 of the polypeptide chain (DF508) (14). They designated the protein as the CFTR (14). In doing so, the group recognized that if CFTR was not itself a Cl
channel, then the protein would almost certainly function as a regulator of Cl
channel activity.

IV.

Normal CFTR

Even before the CFTR gene was cloned, it was known that cAMP-stimulated Cl
secretion was defective in CF epithelial cells (15). Shortly after the CFTR gene was identified, data emerged that this defective cAMP-mediated Cl
secretion could be corrected by expression of normal CFTR, but not by expression of DF508 CFTR. These data supported the hypothesis that CFTR was a Cl
channel, but still left open the

Ion Transport

13

possibility that it was functioning as a positive regulator of another Cl
channel (16,17). In 1991, Anderson and colleagues at the University of Iowa expressed recombinant CFTR in three different cell lines, and conferred on those cells a cAMP-activated Cl
conductance that was not found in cells expressing DF508 CFTR (18). These results were independently confirmed in other cell lines (19,20). Demonstration that mutating specific amino acids in CFTR altered the anion selectivity of the ion permeation pathway conferred on cells in which CFTR was heterologously expressed also strongly suggested that CFTR was a Cl
channel (21). Finally, Bear and colleagues purified the CFTR protein, expressed it in isolated planar lipid bilayers, and demonstrated that it had ion permeation and gating (opening and closing activity) properties identical to those of CFTR heterologously expressed in cell culture (22). When studied by standard electrophysiological techniques in either native or heterologous systems, CFTR has a characteristic biophysical profile. It is an anionselective channel with a single channel Cl
conductance of 6 to 10 picosiemens (pS) in approximately 120 mM Cl
and a permeability selectivity sequence Br
 Cl
> I
> F
(23,24). CFTR can also conduct HCO3
(25,26). When studied by patch clamp electrophysiology in symmetrical Cl
-containing solutions, CFTR channels demonstrate a linear current-voltage relationship (Fig. 1) (18). The opening of the anion permeation pathway in CFTR requires phosphorylation of the channel, particularly by cAMPdependent protein kinase A (27), as well as the presence of ATP (28). CFTR is a unique member of the ATP-binding cassette family of transporters (ABC transporters), which ordinarily use energy from ATP hydrolysis to pump substrates actively through the protein and across the membrane (29). CFTR has seven domains: cytoplasmic amino and carboxyl termini, two membrane-spanning domains

Figure 1 Current-voltage (I-V) curve from an excised, inside-out patch containing a single wild-

type CFTR channel bathed in symmetrical Cl
solutions at 358C. Note the linear relationship between current and voltage. The calculated single channel conductance is 6 to 10 pS. Source: From Ref. 24.

14

Kreindler and Foskett

Figure 2 (A) Commonly accepted model of CFTR structure based on its amino acid sequence. (B) Recently published three-dimensional structure of CFTR based on homology modeling. Source: Part A adapted from Ref. 14 and part B from Ref. 30.

that each contain six membrane-spanning segments, two nucleotide binding domains (NBD1 and NBD2) and an R, or regulatory, domain (14). A high-resolution structure of full-length CFTR has not yet been determined, but homology modeling based on crystal structures of bacterial ABC transporters has provided clues about CFTR’s possible three-dimensional architecture in cell membranes (Fig. 2) (30). In addition, functional

Ion Transport

15

studies have revealed how each domain plays a role in the function or regulation of the channel. The putative 12 transmembrane helices provide the anion permeation pathway and contain the gate that controls transmembrane anion flux. The two NBDs of CFTR bind and/or hydrolyze ATP to modulate channel activity in a manner that is not yet completely determined, but likely involves dimerization of the two NBDs (31). Nucleotide binding and/or hydrolysis induces conformational changes of the NBDs that are somehow communicated to the channel gate in the transmembrane domain that result in its opening and closing. This communication may be mediated by extensions of the transmembrane helices that interact with the NBDs. The R-domain of CFTR, unique among ABC transporter family members, is rich in consensus phosphorylation sites, mainly for protein kinases A and C (32). However, other kinases can also phosphorylate CFTR (33). Phosphorylation of CFTR is necessary for CFTR activation (28), and CFTR channels are deactivated upon dephosphorylation carried out by protein phosphatases (34,35). The amino and carboxyl terminal regions have specific amino acid residues that allow CFTR to bind to intracellular proteins (36). For example, the carboxyl terminus interacts with the scaffolding protein NHERF-1 (37), which modulates channel gating (38) and enables CFTR to interact with other proteins (39). In addition to CFTR channel activity regulation by nucleotide binding, phosphorylation, and protein interactions, the amount of CFTR in the plasma membrane is also regulated by its trafficking and recycling in and out of the apical membrane of epithelial cells (40,41).

V. Abnormal CFTR and Tissue-Specific Ion Transport Abnormalities As discussed elsewhere in this volume, CF is an autosomal recessive disorder, meaning that a person must have two abnormal CFTR genes to manifest the abnormal epithelial ion transport characteristic of the disease. A patient’s clinical phenotype will usually reflect full loss of CFTR ion transport function, or if there is residual ion transport function afforded by one of the mutant alleles. For example, patients who have a single R117H CFTR allele have less severe reduction of plasma membrane anion permeability (42,43) and generally have milder disease than patients where CFTR function is absent. The pathophysiology of end-organ damage in CF patients differs from one organ system to the next; however, the basic defect—a lack of apical plasma membrane Cl
and HCO3
permeability in epithelial cells—remains the same. Although CF pancreatic and pulmonary disease are characterized by luminal obstruction and fibrotic parenchyma, the sweat gland is unique in that it does not demonstrate any macroscopic pathological defects such as luminal obstruction or scarring. This may be because the sweat gland does not secrete significant amounts of protein or mucus that need to be flushed from its lumen, as is the case in other tissues affected in CF. That the physiology of the sweat gland is abnormal in CF despite its not being a mucus-secreting epithelium strongly supports the notion that the basic defect in CF is confined to abnormal ion transport rather than extending to basic abnormalities in mucus production or secretion. A. The Sweat Gland

The human sweat gland comprises a coiled secretory acinus connected to an absorptive duct that empties at the surface of the skin. In the secretory acinus, fluid isotonic to plasma is derived primarily by cholinergic-stimulated, CFTR-independent salt secretion.

16

Kreindler and Foskett

As isotonic fluid moves up the sweat duct, NaCl is absorbed in a CFTR-dependent manner so that in normal individuals sweat becomes hypotonic to plasma at the skin surface; this allows sweat to easily evaporate from the skin and effect cooling. The sweat gland is unique among epithelia in that CFTR is detected at both apical and basolateral membranes of cells lining the absorptive duct (reviewed in Ref. 2). In CF, lack of Cl
permeability in the sweat duct impairs NaCl reabsorption, causing excretion of sweat with high salt content (5). This salty sweat evaporates less readily and leaves small salt crystal deposits on the skin. In addition to cholinergically mediated secretion, sweat secretion can be stimulated through adrenergic pathways (44). The rate at which sweat is produced after b-adrenergic stimulation is related to the amount of functional CFTR present in the sweat duct. Therefore, in response to b-adrenergic stimulation, patients without CFTR mutations have higher sweat rates, carriers of one CFTR mutation have intermediate rates of sweat production, and CF patients have virtually no sweat production (45,46). This has led some investigators to propose the use of sweat rates as an end point for clinical trials of pharmaceutical agents aimed at correcting the underlying molecular defect in CF, the lack of functional CFTR (47). B. The Pancreas

The pancreas consists of exocrine and endocrine cellular components. Although both can be affected in CF, this section will focus only on the exocrine pancreas because it is primarily affected by the ion transport defect in CF, whereas the endocrine dysfunction is, at least in part, secondary to pancreatic tissue damage. The exocrine pancreas is similar to the sweat duct in that it consists of secretory acini connected to ducts where the ionic composition of acinar secretions is modified. In response to stimuli that elevate intracellular Ca2þ, pancreatic acinar cells release zymogen granules to secrete a digestive enzyme-rich fluid into the lumen of the acinus. This protein-rich fluid is hydrated and alkalinized in the duct lumen by CFTR-dependent Cl
, HCO3
, and fluid secretion that flushes the contents into the intestinal lumen. In CF, the ability of the pancreatic ducts to secrete fluid is severely impaired because of absence of a functional interaction between CFTR and an apical Cl
/HCO3
exchanger (48–50). In this model, CFTR serves at the apical membrane of pancreatic duct cells both as a conductive pathway for Cl
and as a critical regulator of Cl
/HCO3
exchanger activity. As a result of absent ductal HCO3
and fluid secretion, acinar secretions become dehydrated and trapped in pancreatic ducts. This blocks secretion of both fluid and digestive enzymes into the intestine, and allows the digestive enzymes to act on pancreatic parenchyma causing inflammation and scarring that eventuate in destruction and fibrosis of the exocrine pancreas. C. The Intestine

The intestinal epithelium is histologically divided into villi and crypts and glands. CFTR is primarily expressed in intestinal crypts (51) where it promotes Cl
and fluid secretion that hydrates intestinal mucins produced in the glands. The primary mode of fluid secretion in the small intestine is the activation of CFTR at the apical membrane of intestinal epithelial cells and movement of Cl
down its electrochemical gradient into the lumen of the intestine. The opening of CFTR at the apical membrane and subsequent secretion of Cl
into the lumen of the intestine is accompanied by activation of the loop-diuretic (e.g., furosemide)

Ion Transport

17

sensitive Naþ-Kþ-2Cl
cotransporter on the basolateral membrane that provides a mechanism for Cl
entry into the cell (52). Naþ moves across the epithelium through paracellular pathways to maintain electroneutrality, and water follows osmotically. In CF, the absence of functional CFTR results in lack of Cl
secretion and associated fluid secretion so that intestinal mucus and stool are poorly hydrated. Histologically, retained mucins in intestinal crypts seen in pathology specimens are virtually pathognomonic for CF (53). Poorly hydrated intestinal mucus and stool can become trapped in the intestine causing partial or complete luminal obstruction. In the newborn, this process manifests as failure to pass meconium, known as meconium ileus. In the infant and older child, this manifests as inspissations of mucus and stool in the distal small intestine known as distal intestinal obstructive syndrome or DIOS. D. The Liver

Severe liver disease is the most common nonpulmonary cause of mortality in CF. Ion transport abnormalities in the liver result in abnormal salt and water transport resulting in blockage of biliary ducts, and in most patients, cirrhosis of the liver (54). Obstruction of biliary ducts causes periportal inflammation and fibrosis, which occurs in approximately 30% of CF patients (55). In a subset of these patients, liver damage progresses to become multilobular cirrhosis and may result in portal hypertension. This topic is discussed in detail in chapter 18. E.

The Reproductive Tract

More than 90% of males with CF have congenital bilateral absence of the vas deferens (CBAVD). Furthermore, 1% to 2% of non-CF male infertility is due to CBAVD, and these patients have a higher incidence of CFTR mutations than do patients without CBAVD (56). Therefore, the link between CFTR and CBAVD is firmly established. The role of abnormal ion transport in the pathophysiology of CBAVD is less clear. It may be that absence of normal salt and water transport in the vas deferens leads to blockage of the lumen during development of the vas deferens causing subsequent involution. F.

The Lungs

The mean age of predicted survival in CF has increased from less than a year in the 1950s to almost 40 years today. When CF patients died in infancy, it was largely the result of malnutrition or heat prostration, though most showed signs of lung disease at autopsy (3). As patients have survived longer, lung disease has emerged as by far the most common cause of morbidity and mortality in CF. The end result of CFTR dysfunction in the lung is often described as a vicious cycle of infection, inflammation, and tissue damage resulting from obstruction of the airways by thick, sticky mucus. What is the entry point into the vicious cycle? There are a number of hypotheses that try to answer this question. One well-accepted hypothesis states that lack of CFTR function in the apical membrane of airway surface epithelial cells results in hyperabsorption of NaCl from the airway surface liquid (ASL) and subsequent dehydration of airway lining fluid and mucus. This allows airway mucus to appose airway epithelial cells, which in turn flattens cilia and renders them unable to beat. Accordingly, airway mucus becomes trapped and inhaled bacteria are not cleared appropriately.

18

Kreindler and Foskett

This hypothesis encompasses two, not mutually distinct, hypotheses. The first of these hypotheses is that the lack of CFTR results in overactivation of the cellular Naþ absorption pathway via the epithelial sodium channel (ENaC). This overactive Naþ absorption drives Cl
absorption through the paracellular pathway to maintain electroneutrality. The second hypothesis includes a normal role for CFTR as a secretory pathway for Cl
; this Cl
secretion drives fluid secretion as is described earlier for the intestine. Both of these hypotheses have substantial in vitro and in vivo scientific support. In vivo evidence includes the elevated sensitivity to the ENaC-blocker amiloride in nasal potential difference measurements in CF epithelia compared to control epithelia (10,57) and the finding that overexpression of ENaC in mice caused CF-like airway disease (58). To study the effect of CFTR dysfunction on airways ion transport physiology in vitro, researchers have relied on airway epithelial cells grown and differentiated on permeable supports and exposed to air on their mucosal surface. First described using guinea pig cells (59) and later adapted for human cells (60), this model system recapitulates many of the normal functions of the airway epithelium (Fig. 3). In vitro measurements of ASL height in these well-differentiated, polarized cells strongly suggest that ASL height is reduced in cells from CF donors compared with normals (61). This model system has also been used in attempts to dissect the mechanisms by which Naþ absorption is increased in CF epithelial cells. One hypothesis is that absence of CFTR leads to elevated concentrations of proteases in the ASL that activate ENaC (62,63). Another hypothesis suggests there is a reciprocal relationship between CFTR

Figure 3 Simplified model of epithelial sodium and chloride transport. For Naþ absorption, Naþ

enters from the lumen through the epithelial sodium channel (ENaC, #1) and is pumped out of the cell by the Naþ/Kþ-ATPase (#5), which maintains ionic gradients at the expense of ATP hydrolysis. For Cl
secretion, Cl
enters the cell from the blood on the Naþ-Kþ-2Cl
cotransporter (NKCC-1, #6) and can exit the cell to the lumen through two separate channels. cAMPmediated secretion occurs via CFTR (#2), which is the predominant Cl
conductance in most epithelia. Ca2þ-activated Cl
secretion occurs via the Ca2þ-activated Cl
channel (TMEM16A, #3). Both Naþ absorption and Cl
secretion are dependent on apical membrane hyperpolarization by basolateral Kþ channels (#4), which serve as a shunt pathway for Kþ that enters the cell on the Naþ/Kþ-ATPase. Electroneutrality is maintained by paracellular movements of Naþ and Cl
.

Ion Transport

19

and ENaC at the plasma membrane (64). On the other hand, activation of an alternative apical membrane Cl
channel in the absence of CFTR can stabilize ASL volume (65). These data suggest that CFTR may normally play a role in counteracting Naþ-driven fluid absorption by providing a mechanism for Cl
-mediated fluid secretion. Lack of this counterbalance results in excessive salt and water absorption. The salt hyper-absorption hypotheses address the function of surface epithelial cells in removal of salt and water from the airway surface, but they do not address the possible roles of submucosal glands in the pathophysiology of CF. Anatomically, submucosal glands are found in highest density in the trachea and bronchi, but they can be found throughout the conducting airways, including small bronchi. Submucosal glands may secrete the majority of mucus and fluid that make up the ASL. CFTR is highly expressed in the serous cells of submucosal gland acini, even more highly than in the airway epithelia (66), where it plays a role in Cl
, HCO3
, and fluid secretion (67). Some evidence suggests that hyposecretion from submucosal glands in CF is a proximal cause of lung disease, and that this lack of secretion is due to absence of Cl
and HCO3
secretion (68). Hyposecretion from submucosal glands could also contribute to an imbalance of proteases and antiproteases in the CF airway (68), which could impinge on the activity of ENaC, as discussed earlier. A role for altered HCO3
secretion by airways epithelial cells and submucosal glands has been hypothesized in the pathophysiology of CF lung disease. In vitro, lack of CFTR-mediated HCO3
secretion by cultured bronchial epithelial cells results in defective alkalinization after acid challenge (69). In airway submucosal glands ex vivo, inhibition of HCO3
transport results in decreased fluid secretion (67). Furthermore, submucosal glands from CF patients secrete a more acidic fluid (70). Both pH and concentration may affect the manner in which macromolecules such as mucins and proteases behave. Taken together, these data suggest that altered HCO3
secretion may play a significant role in the pathogenesis of airways disease in CF.

VI.

Summary

In summary, our understanding of CF pathophysiology has progressed from folklore to scientifically based understanding of organ and tissue pathophysiology to subcellular and molecular identification of the basic cellular defects. CF is a disease of altered ion transport resulting from abnormal expression and function of CFTR, an anion channel found in apical membrane of many epithelia. In each affected organ, absence of CFTR is the proximate cause of disease. In some cases, such as the sweat gland, we understand completely how absence of CFTR causes altered organ function. In other cases, such as the lungs, there are multiple effects of CFTR absence that may impact on the disease, and questions remain regarding the underlying molecular mechanisms. Despite these questions, our understanding of how basic defects in CFTR lead to end-organ damage is much greater, and patients have benefited directly.

References 1. Busch R. On the history of cystic fibrosis. Acta Univ Carol [Med] (Praha) 1990; 36:13–15. 2. Quinton PM. Cystic fibrosis: lessons from the sweat gland. Physiology 2007; 22:212–225. 3. Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study. Am J Dis Child 1938; 56:344–399.

20

Kreindler and Foskett

4. Kessler WR, Andersen DH. Heat prostration in fibrocystic disease of the pancreas and other conditions. Pediatrics 1951; 8:648–656. 5. di Sant’Agnese PA, Darling RC, Perera GA, et al. Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas: clinical significance and relationship to the disease. Pediatrics 1953; 12:549–563. 6. Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959; 23:545–549. 7. Quinton PM, Bijman J. Higher bioelectric potentials due to decreased chloride absorption in the sweat glands of patients with cystic fibrosis. N Engl J Med 1983; 308:1185–1189. 8. Bijman J, Fromter E. Direct demonstration of high transepithelial chloride-conductance in normal human sweat duct which is absent in cystic fibrosis. Pflugers Arch 1986; 407(suppl 2): S123–S127. 9. Kopelman H, Corey M, Gaskin K, et al. Impaired chloride secretion, as well as bicarbonate secretion, underlies the fluid secretory defect in the cystic fibrosis pancreas. Gastroenterology 1988; 95:349–355. 10. Knowles M, Gatzy J, Boucher R. Relative ion permeability of normal and cystic fibrosis nasal epithelium. J Clin Invest 1983; 71:1410–1417. 11. Knowlton RG, Cohen-Haguenauer O, Van Cong N, et al. A polymorphic DNA marker linked to cystic fibrosis is located on chromosome 7. Nature 1985; 318:380–382. 12. Wainwright BJ, Scambler PJ, Schmidtke J, et al. Localization of cystic fibrosis locus to human chromosome 7cen-q22. Nature 1985; 318:384–385. 13. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245:1073–1080. 14. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245:1066–1073. 15. Frizzell RA, Rechkemmer G, Shoemaker RL. Altered regulation of airway epithelial cell chloride channels in cystic fibrosis. Science 1986; 233:558–560. 16. Rich DP, Anderson MP, Gregory RJ, et al. Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature 1990; 347:358–363. 17. Drumm ML, Pope HA, Cliff WH, et al. Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell 1990; 62:1227–1233. 18. Anderson MP, Rich DP, Gregory RJ, et al. Generation of cAMP-activated chloride currents by expression of CFTR. Science 1991; 251:679–682. 19. Rommens JM, Dho S, Bear CE, et al. cAMP-inducible chloride conductance in mouse fibroblast lines stably expressing the human cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci 1991; 88:7500–7504. 20. Kartner N, Hanrahan JW, Jensen TJ, et al. Expression of the cystic fibrosis gene in nonepithelial invertebrate cells produces a regulated anion conductance. Cell 1991; 64:681–691. 21. Anderson MP, Gregory RJ, Thompson S, et al. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 1991; 253:202–205. 22. Bear CE, Li CH, Kartner N, et al. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 1992; 68:809–818. 23. Quinton PM. Physiological basis of cystic fibrosis: a historical perspective. Physiol Rev 1999; 79:S3–S22. 24. Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiol Rev 1999; 79:23–45. 25. Poulsen JH, Fischer H, Illek B, et al. Bicarbonate conductance and pH regulatory capability of cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci U S A 1994; 91:5340–5344.

Ion Transport

21

26. Smith JJ, Welsh MJ. cAMP stimulates bicarbonate secretion across normal, but not cystic fibrosis airway epithelia. J Clin Invest 1992; 89:1148–1153. 27. Cheng SH, Rich DP, Marshall J, et al. Phosphorylation of the R domain by cAMPdependent protein kinase regulates the CFTR chloride channel. Cell 1991; 66:1027–1036. 28. Anderson MP, Berger HA, Rich DP, et al. Nucleoside triphosphates are required to open the CFTR chloride channel. Cell 1991; 67:775–784. 29. Gadsby DC, Vergani P, Csanady L. The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 2006; 440:477–483. 30. Serohijos AW, Hegedus T, Aleksandrov AA, et al. Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. Proc Natl Acad Sci U S A 2008; 105:3256–3261. 31. Vergani P, Lockless SW, Nairn AC, et al. CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. Nature 2005; 433:876–880. 32. Gadsby DC, Nairn AC. Control of CFTR channel gating by phosphorylation and nucleotide hydrolysis. Physiol Rev 1999; 79:S77–S107. 33. Picciotto MR, Cohn JA, Bertuzzi G, et al. Phosphorylation of the cystic fibrosis transmembrane conductance regulator. J Biol Chem 1992; 267:12742–12752. 34. Berger HA, Travis SM, Welsh MJ. Regulation of the cystic fibrosis transmembrane conductance regulator Cl- channel by specific protein kinases and protein phosphatases. J Biol Chem 1993; 268:2037–2047. 35. Reddy MM, Quinton PM. Deactivation of CFTR-Cl conductance by endogenous phosphatases in the native sweat duct. Am J Physiol Cell Physiol 1996; 270:C474–C480. 36. Guggino WB, Banks-Schlegel SP. Macromolecular interactions and ion transport in cystic fibrosis. Am J Respir Crit Care Med 2004; 170:815–820. 37. Hall RA, Ostedgaard LS, Premont RT, et al. A C-terminal motif found in the beta2-adrenergic receptor, P2Y1 receptor and cystic fibrosis transmembrane conductance regulator determines binding to the Naþ/Hþ exchanger regulatory factor family of PDZ proteins. Proc Natl Acad Sci U S A 1998; 95:8496–8501. 38. Raghuram V, Mak DO, Foskett JK. Regulation of cystic fibrosis transmembrane conductance regulator single-channel gating by bivalent PDZ-domain-mediated interaction. Proc Natl Acad Sci U S A 2001; 98:1300–1305. 39. Sun F, Hug MJ, Lewarchik CM, et al. E3KARP mediates the association of ezrin and protein kinase A with the cystic fibrosis transmembrane conductance regulator in airway cells. J Biol Chem 2000; 275:29539–29546. 40. Bradbury NA, Cohn JA, Venglarik CJ, et al. Biochemical and biophysical identification of cystic fibrosis transmembrane conductance regulator chloride channels as components of endocytic clathrin-coated vesicles. J Biol Chem 1994; 269:8296–8302. 41. Prince LS, Workman RB Jr., Marchase RB. Rapid endocytosis of the cystic fibrosis transmembrane conductance regulator chloride channel. Proc Natl Acad Sci U S A 1994; 91:5192–5196. 42. Reddy MM, Quinton PM. Control of dynamic CFTR selectivity by glutamate and ATP in epithelial cells. Nature 2003; 423:756–760. 43. Sheppard DN, Rich DP, Ostedgaard LS, et al. Mutations in CFTR associated with milddisease-form CI- channels with altered pore properties. Nature 1993; 362:160–164. 44. Emrich HM, Stoll E, Friolet B, et al. Sweat composition in relation to rate of sweating in patients with cystic fibrosis of the pancreas. Pediatr Res 1968; 2:464–478. 45. Behm JK, Hagiwara G, Lewiston NJ, et al. Hyposecretion of beta-adrenergically induced sweating in cystic fibrosis heterozygotes. Pediatr Res 1987; 22:271–276. 46. Sato K, Sato F. Defective beta adrenergic response of cystic fibrosis sweat glands in vivo and in vitro. J Clin Invest 1984; 73:1763–1771.

22

Kreindler and Foskett

47. Callen A, Diener-West M, Zeitlin PL, et al. A simplified cyclic adenosine monophosphatemediated sweat rate test for quantitative measure of cystic fibrosis transmembrane regulator (CFTR) function. J Pediatr 2000; 137:849–855. 48. Ko SB, Shcheynikov N, Choi JY, et al. A molecular mechanism for aberrant CFTRdependent HCO(3)(-) transport in cystic fibrosis. EMBO J 2002; 21:5662–5672. 49. Ko SB, Zeng W, Dorwart MR, et al. Gating of CFTR by the STAS domain of SLC26 transporters. Nat Cell Biol 2004; 6:343–350. 50. Wang Y, Soyombo AA, Shcheynikov N, et al. Slc26a6 regulates CFTR activity in vivo to determine pancreatic duct HCO3- secretion: relevance to cystic fibrosis. EMBO J 2006; 25:5049–5057. 51. Strong TV, Boehm K, Collins FS. Localization of cystic fibrosis transmembrane conductance regulator mRNA in the human gastrointestinal tract by in situ hybridization. J Clin Invest 1994; 93:347–354. 52. Weymer A, Huott P, Liu W, et al. Chloride secretory mechanism induced by prostaglandin E1 in a colonic epithelial cell line. J Clin Invest 1985; 76:1828–1836. 53. Orenstein DM, Rosenstein BJ, Stern RC. Cystic Fibrosis: Medical Care. Philadelphia: Lippincott Williams & Wilkins, 2000. 54. Maurage C, Lenaerts C, Weber A, et al. Meconium ileus and its equivalent as a risk factor for the development of cirrhosis: an autopsy study in cystic fibrosis. J Pediatr Gastroenterol Nutr 1989; 9:17–20. 55. Colombo C. Liver disease in cystic fibrosis. Curr Opin Pulm Med 2007; 13:529–536. 56. Dork T, Dworniczak B, Aulehla-Scholz C, et al. Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens. Hum Genet 1997; 100:365–377. 57. Knowles MR, Stutts MJ, Spock A, et al. Abnormal ion permeation through cystic fibrosis respiratory epithelium. Science 1983; 221:1067–1070. 58. Mall M, Grubb BR, Harkema JR, et al. Increased airway epithelial Naþ absorption produces cystic fibrosis-like lung disease in mice. Nat Med 2004; 10:487–493. 59. Whitcutt MJ, Adler KB, Wu R. A biphasic chamber system for maintaining polarity of differentiation of cultured respiratory tract epithelial cells. In Vitro Cell Dev Biol 1988; 24:420–428. 60. Gray TE, Guzman K, Davis CW, et al. Mucociliary differentiation of serially passaged normal human tracheobronchial epithelial cells. Am J Respir Cell Mol Biol 1996; 14:104–112. 61. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998; 95:1005–1015. 62. Bridges RJ, Newton BB, Pilewski JM, et al. Naþ transport in normal and CF human bronchial epithelial cells is inhibited by BAY 39-9437. Am J Physiol Lung Cell Mol Physiol 2001; 281:L16–L23. 63. Myerburg MM, Butterworth MB, McKenna EE, et al. Airway surface liquid volume regulates ENaC by altering the serine protease-protease inhibitor balance: a mechanism for sodium hyperabsorption in cystic fibrosis. J Biol Chem 2006; 281:27942–27949. 64. Yan W, Samaha FF, Ramkumar M, et al. Cystic fibrosis transmembrane conductance regulator differentially regulates human and mouse epithelial sodium channels in xenopus oocytes. J Biol Chem 2004; 279:23183–23192. 65. Tarran R, Button B, Picher M, et al. Normal and cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral infections. J Biol Chem 2005; 280:35751–35759. 66. Engelhardt JF, Zepeda M, Cohn JA, et al. Expression of the cystic fibrosis gene in adult human lung. J Clin Invest 1994; 93:737–749. 67. Ballard ST, Trout L, Bebok Z, et al. CFTR involvement in chloride, bicarbonate, and liquid secretion by airway submucosal glands. Am J Physiol 1999; 277:L694–L699.

Ion Transport

23

68. Joo NS, Irokawa T, Robbins RC, et al. Hyposecretion, not hyperabsorption, is the basic defect of cystic fibrosis airway glands. J Biol Chem 2006; 281:7392–7398. 69. Coakley RD, Grubb BR, Paradiso AM, et al. Abnormal surface liquid pH regulation by cultured cystic fibrosis bronchial epithelium. Proc Natl Acad Sci U S A 2003; 100:16083– 16088. 70. Song Y, Salinas D, Nielson DW, et al. Hyperacidity of secreted fluid from submucosal glands in early cystic fibrosis. Am J Physiol Cell Physiol 2006; 290:C741–C749.

3 Mucus Abnormalities and Ciliary Dysfunction A. WHITNEY BROWN and SCOTT H. DONALDSON University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A.

I.

Introduction to Mucus and Mucociliary Clearance

The unavoidable development of chronic bacterial lung infections in cystic fibrosis (CF) results from a significant defect in lung host defenses. Because adaptive defenses appear to be intact in patients with CF, a search for mechanisms to explain impaired innate defense of the lung has been vigorously pursued. The mucus clearance apparatus plays a key role in lung defense, thus it is not surprising that it has become a prime focus of study and therapeutic development for CF. Effective mucus clearance depends on coordinated ciliary motion and the formation of an airway surface liquid (ASL) layer that is capable of supporting mucus transport via cilia-driven and cough clearance. Traditionally, the ASL has been depicted as the aggregate of two distinct phases: a superficial mucus layer and an aqueous periciliary layer (PCL) that approximates the height of extended cilia. In this paradigm, mucus serves to entrap foreign particles and pathogens, and dissolve noxious gases. The PCL, in turn, supports the transport of mucus out of the lung by providing a lowviscosity environment for cilia beating (1) (Fig. 1). In this chapter, we will review our current understanding of the structure and function of the ASL, with particular attention to changes that may result in impaired host defense in CF.

II.

The Mucus Layer

Secreted mucus is a nonhomogeneous, adhesive, viscoelastic gel composed of water, carbohydrates, proteins, and lipids. Respiratory mucus also contains a host of antimicrobial factors (2). The mucus layer is most pronounced in the intermediate to large airways and is approximately 2 to 10 mm thick in the trachea (2). The major constituents of mucus are gigantic peptidoglycan biopolymers known as mucins. These mucins provide the structural framework of the mucus barrier and are largely responsible for the rheologic properties of mucus. They prevent barrier dehydration, sequester pathogens, and act as a reservoir for host-protective proteins and peptides (1). With molecular weights ranging from 3 to 7 million Da, these enormous hydrophilic molecules consist of a core polypeptide chain plus numerous sugar side chains. In fact, 70% of their mass is composed of carbohydrates (1). Mucin macromolecules are well suited for trapping inhaled particles, at least in part, due to diversity of their carbohydrate side chains, which essentially provide a library of ligands for pathogen binding (3). Intramolecular and intermolecular bonds, including disulfide linkages, and ionic and sugar-sugar

24

Mucus Abnormalities and Ciliary Dysfunction

25

Figure 1 Traditional and revised model of the ASL. The ASL is composed of the mucus layer and the PCL. The mucus layer is viscoelastic, heterogeneous gel layer primarily composed of gelforming mucins that serve to trap inhaled particles for clearance. Traditionally, the PCL was thought to be an aqueous solution that facilitated cilia beating (left image). A more contemporary “two-gel” view depicts the PCL more accurately as a grafted-gel structure of cell surface (tethered) mucins and glycolipids that coat the cilia and microvilli (right image). The gel-like PCL not only serves as a lubricating layer for cilia, but also as a barrier between inhaled particles and the cell surface through the protection provided by close approximation of the long-branched mucins. Abbreviations: ASL, airway surface liquid; PCL, periciliary layer.

interactions produce a complex, tangled structure that translates into tangible viscoelastic properties (4). MUC5B and MUC5AC are the major gel-forming, secreted mucins produced in the lung and together comprise approximately 90% of the mucin content of sputum (5), both in pathologic and normal states. Only small amounts of MUC2, another secreted mucin, have been detected in the lung (5). MUC5B is typically thought to originate from submucosal glands, whereas MUC5AC is produced and released by goblet cells of the surface epithelium. These cell types are normally restricted to large, conducting airways. The concentration of mucus-secreting cells in the larger airways brings into question the source and necessity of mucus for the defense of small airways, and the possibility that other cell types (e.g., Clara cells) could be an additional source of mucus in these critical lung regions. Mucin secretion from submucosal glands and superficial epithelia appears to be prompted by distinct stimuli (6,7), suggesting that the mucin composition of mucus may be influenced by the relative contribution from each source (1). It has been speculated that MUC5AC may be an acute-response mucin that is produced in response to insults to the upper and central airways (1). In fact, MUC5AC mRNA and protein expression are upregulated by neutrophil elastase, a protease secreted by neutrophils during inflammation (8). MUC5B, on the other hand, has been postulated to play a larger role in the setting of chronic inflammation and persistent infection (1). Confirming these speculations, both MUC5AC and MUC5B are found in the mucus plugs that obstruct CF airways, and both molecules are variably increased in induced sputum from patients with CF and COPD. Further, a low-charge glycoform of MUC5B is also elevated in these disease states and might impact the physical properties of the mucus gel (9,10). After synthesis, MUC5B and MUC5AC are stored in intracellular membranebound granules and await secretion via either constitutive or stimulated mechanisms. This allows the epithelium to respond rapidly to environmental challenges, with no requirement for de novo mucin production (1). Secretion of glycoproteins from submucosal glands is predominately under cholinergic control, although adrenergic agonists and multiple inflammatory mediators can also contribute to release. Mucin secretion

26

Brown and Donaldson

from goblet cells, on the other hand, is triggered by increased intracellular calcium levels and therefore responds to stimulation of luminal P2Y2 nucleotide receptors. Certain physiologic conditions can also increase mucus gland secretion, including (i) hypoxia, (ii) stimulation of mechanoreceptors in the stomach, (iii) stimulation of cough receptors in the trachea and bronchi with chemical agents, and (iv) inhalation of a wide variety of irritants (cigarette smoke, ammonia, etc). Many of the stimuli that increase mucus secretion also elicit cough, suggesting that the two mechanisms are linked. Under normal conditions, mucus efficiently protects the airways. However, there are situations in which mucin secretory cell hyperplasia occurs as an adaptive response to chronic inflammation. In chronic airway diseases such as CF, considerable hyperplasia of mucus secreting elements can lead to a pathologic increase in mucus production. In the extreme state, such as status asthmaticus, massive mucin hypersecretion coupled with airway smooth muscle contraction can lead to complete airway obstruction and death (11,12). Although the importance of mucins should not be underestimated, there is more to the airway mucus than mucins alone. This is evidenced by the fact that concentrated solutions of mucins, in isolation, do not reproduce all the physical properties of the mucus gel (13). Instead, mucus is a complex mixture of ions, mucins, glycoproteins, proteins, and lipids. In disease states, this biologic mixture becomes even more complex. It is estimated that there are more than 100 nonmucin proteins present in the mucus layer, with larger numbers expected in the setting of airways disease (14). Although a full characterization of the nonmucin components in the mucus layer has been slow to emerge, it is likely that the number of globular proteins and their associated functions have been greatly underappreciated and are worthy of further investigation. Another critical constituent of mucus lining airways is water. Normal mucus is approximately 98% water (2% solids), and even relatively small changes in water content (e.g., from 98% to 94%) can dramatically alter the physical properties of a mucus gel. After secretion, tightly packaged mucin molecules rapidly expand and form a hydrated gel. The characteristics of this gel are in part determined by the ionic composition and pH of the milieu it encounters upon secretion. Aberrant mucin hydration is of particular interest in patients with CF. Specifically, the water imbalance in epithelial fluid may negatively impact mucin unpackaging and hydration, which may help explain the abnormal properties of CF mucus (15).

III.

The Periciliary Layer

Traditionally, the PCL has been conceptualized as a simple aqueous solution that provides a low viscosity environment conducive to ciliary beating (16). More recently, the PCL has been envisioned as a highly ordered polyelectrolyte gel. The molecules comprising this gel in the periciliary space include tethered mucins, particularly MUC1, MUC4, and MUC16 (17), which possess transmembrane domains that fix them to epithelial cell membranes that cover microvilli and cilia. These tethered mucins are polyanionic, and repulsive forces cause them to take an extended, brush-like configuration around the cilia (Fig. 2). This PCL model is extremely attractive for several reasons. First, the polyelectrolyte brush configuration is expected to dramatically lower frictional forces between beating cilia (16,18) while also providing a means to mechanically couple their movements. Second, a gel-like PCL provides a mechanism

Mucus Abnormalities and Ciliary Dysfunction

27

Figure 2 Mucins on the respiratory epithelium. Tethered mucins (MUC1, MUC4, and MUC16) are found primarily along the cell surface in the PCL, but also comprise about 10% of the overlying mucin raft (layer). MUC5AC (from goblet cells) and MUC5B (from submucosal mucus glands) account for the large majority of the mucus raft. Source: From Ref. 17.

that prevents penetration of the mucus layer into the PCL environment and subsequent adhesion to cell surfaces. Third, the PCL gel serves a barrier function against inhaled pathogens with particles larger in diameter than the space between tethered mucin molecules being excluded (i.e., >20–30 nm). Finally, this configuration better explains the observation that excess fluid on airway surfaces does not cause separation of the PCL and mucus layers (i.e., mucus floating off cilia tips) and the consequent predicted decline in cilia-driven clearance (19). Rather, the mucus and PCL layers remain in proximity to each other and mucus transport is increased. The same phenomenon is observed in vivo in the case of patients with pseudohypoaldosteronism (PHA), in whom inherited defects in the epithelium sodium channel (ENaC) cause increased amounts of airway lining fluid and dramatically accelerated rates of mucociliary clearance (MCC) (20). Therefore, current data suggests that once the PCL is fully hydrated, additional water is absorbed by the sponge-like mucus layer, making it more easily transportable. In contrast, when moderate airway dehydration occurs, the mucus layer is able to donate water to the PCL to support its functions. This two-gel system is likely stable until extreme dehydration occurs and the osmotic pressure of the mucus layer exceeds that of

28

Brown and Donaldson

Figure 3 (A) ASL response to different states of hydration. When there is excess fluid on the

airway surface, the mucus layer absorbs it which makes it more transportable. With dehydration, the mucus layer is concentrated and encroaches into the PCL. (B) Electron micrograph of normal versus cystic fibrosis respiratory epithelia. The normal PCL is adequately hydrated, allowing full extension of cilia. The CF PCL is dehydrated and collapsed, altering cilia configuration and impairing motility. A concentrated mucus layer is seen above the PCL in the CF micrograph. Abbreviations: ASL, airway surface liquid; MCC, mucociliary clearance; CF, cystic fibrosis; PCL, periciliary layer.

the PCL, causing subsequent collapse of the PCL and encroachment of mucin into this space (Fig. 3).

IV.

Mucociliary Clearance

Inhaled particulates and pathogens routinely reach the lower airways, but are typically trapped within the mucus layer and transported out of the lung via mucus clearance mechanisms without the need to mount a potentially deleterious inflammatory response. Mucus clearance, therefore, is widely considered to be the primary innate airway defense mechanism (3). Perhaps the clearest example of the direct relationship between defective MCC and disease is provided by patients with primary ciliary dyskinesia (PCD), who have defective or absent ciliary activity. Over time, these patients develop chronic lower airway infections and bronchiectasis, as well as significant sinus and middle ear infections. Other examples of diseases in which defective mucus transport is felt to play a role in pathogenesis are chronic bronchitis, ventilator-associated pneumonia, and CF. Clearly, the failure to clear mucus renders the airways vulnerable to

Mucus Abnormalities and Ciliary Dysfunction

29

infection, as the antimicrobial substances present in mucus alone are incapable of chronically suppressing bacterial growth in the lung (3). Mucus is transported over airway surfaces via cilia and airflow-driven mechanisms. Cilia-mediated mucus clearance requires an intact PCL and is related to both ciliary beat frequency and mucus rheologic properties needed for optimal mucus transportability. An abnormality in either ciliary beating or mucus rheology can result in defective mucus transport. Cough clearance is independent of ciliary function, but instead requires the generation of adequate airflow velocity as the propulsive force. Cough, therefore, is most effective in the central airways, where airflow velocity is greatest. Like cilia-mediated clearance, cough clearance also is dependent on ASL properties. Cough clearance increases as the hydration of the ASL increases, but decreases with increased ASL viscosity (3). The preservation of cough clearance in PCD and COPD may explain why these diseases are less severe than CF, where both cilia and cough-mediated clearance are impacted by severe ASL dehydration. Given the importance of mucus clearance, it is not surprising that airway epithelial cells coordinate the relevant effector mechanisms (3). The basal rate of MCC is a function of cilia beat frequency and the properties of the overlying mucus, and there are autocrine and/or paracrine airway epithelial signals that help regulate these properties. For example, adenine nucleotides are released by airway epithelia in response to mechanical shear stresses created by tidal respiration and cough (3,21,22). After release, adenosine 50 -triphosphate (ATP) binds to P2Y2 receptors and, via calcium signaling pathways, increases cilia beat frequency and chloride/water secretion. The end result of these physiologic processes is accelerated mucus clearance. Metabolism of ATP by extracellular nucleotidases produces adenosine, which in turn stimulates chloride secretion via CFTR after binding to the A2B adenosine receptor and increasing intracellular cAMP. Likely, other extracellular signals influence MCC as well, perhaps working through distinct signaling pathways. Mucociliary clearance measurements have been performed for years using various methodologies. The inhalation of aerosolized, radiolabeled particles followed by imaging with g-scintigraphy is the most widely accepted method, although until recently there has been little standardization of the technique. This has limited the comparison of results published by different research groups (23). Even so, multiple studies have clearly demonstrated that patients with CF and COPD have defective mucociliary clearance (24). Interestingly, in COPD, the observed mucus clearance defect is most notable in study parameters that reflect large airway clearance (25). However, these patients appear to have intact small airway clearance and robust cough-induced clearance. In contrast, studies of patients with CF have revealed mucus clearance defects that are more pronounced in the small airways, along with markedly reduced cough clearance (26,27). These data, therefore, provide insights into the distinct pathophysiology of these diseases and suggest targets of tailored therapeutic interventions.

V. The Airway Surface Liquid in Cystic Fibrosis The abnormal properties of CF secretions are striking and give rise to duct obstruction in multiple organ systems. However, identifying the mechanisms that underlie this phenomenon in the lung has been problematic because separation of the primary pathophysiologic processes and secondary effects of infection and inflammation is often

30

Brown and Donaldson

difficult. In fact, most of the previously cited qualitative mucin abnormalities (elevated fucose content, decreased sialic acid content, increased sulfation) appear to reflect the presence of chronic infection and inflammation, rather than a CF-specific defect (28). The current prevailing hypothesis that links CFTR dysfunction to the development of lung disease proposes that dehydration of the PCL and mucus layer, because of altered ion transport, leads to mucus stasis in the lung and subsequent infection and inflammation. Ion transport abnormalities in CF have been thoroughly documented and include the absence of cAMP-mediated chloride secretion (via CFTR) and excessive sodium absorption through EnaC (22). The predicted net effect of altered CFTR and ENaC activity is reduced ASL volume. Support for this hypothesis comes in part from in vitro studies that demonstrate reduced PCL height in cultured CF airway epithelia using confocal microscopy (29). Additional support comes from the creation of transgenic mice that overexpress an ENaC subunit and has accelerated sodium absorption from across airway surfaces. These animals have a reduced ASL height, dehydration of airway secretions, slowed mucus transport, and mucus adhesion with plugging of airways. Interestingly, these mice also develop neutrophilic airways inflammation without overt bacterial infection, suggesting a potential direct link between mucus retention and the development of airway inflammation (30). Finally, data from patients with CF show that these patients do indeed have dehydrated airway secretions and abnormal mucus transport (27,31,32). The more refined view of the ASL as a “two-gel” system allows us to better understand the effect that ASL hydration has on airways function. Using in vitro airway models, studies have revealed that the volume depletion associated with CF occurs sequentially, first from the mucus layer and then from the PCL (19). With progressive dehydration, the osmotic pressure of the mucus layer eventually exceeds that of the PCL, forcing water movement from the PCL into the mucus layer, causing a reduction in PCL height/volume. Similarly, rehydration of airway surfaces, after ASL dehydration has occurred, first corrects the deficiency in PCL volume. Addition of volume thereafter preferentially swells the overlying mucus layer. The consequences of PCL dehydration in CF are likely twofold. First, and perhaps most importantly, once the PCL becomes volume depleted, the overlying mucus layer encroaches into the near-cell environment, and the secreted mucins, MUC5AC and MUC5B, begin to interact with the cell-attached mucins. Interaction between secreted and tethered mucins, and perhaps other cell surface molecules (e. g., glycocalyx), causes adhesion between the mucus layer and cell surfaces, resulting in the development of mucus plaques and plugs. Second, PCL volume contraction distorts the space in which cilia beat, thereby reducing or eliminating the propulsive force normally provided by beating cilia. Importantly, these phenomena are expected to interfere with both cilia and cough driven clearance. Exacerbating the problem, goblet cells and glands continue to secrete mucus in diseased airways, worsening the buildup of mucus. Static endobronchial mucus provides a fertile nidus for infection and, ultimately, motile Pseudomonas aeruginosa penetrates into mucus plaques and thrives in the privileged environment that they create. Pseudomonas quickly adapts to this unique environment, which includes regions characterized by significant hypoxia, by producing an alginate coating, significantly altering gene expression, and thereafter persisting as a bacterial biofilm. The ultimate result is a chronic, incurable bacterial infection.

Mucus Abnormalities and Ciliary Dysfunction

31

The effect of ASL dehydration on the mucus layer should also be considered. Once again, in vitro studies demonstrate that once airway secretions increase beyond approximately 6% solids (normal secretions are approximately 2% solids, 98% water), they become much less transportable. This degree of dehydration is in fact quite relevant, as airway secretions from stable adults with CF are often in the 5% to 10% solids range, with even higher levels observed in secretions harvested directly from airways at the time of lung transplantation. Dehydration of airway mucus also results in a reduction in the pore size of the mucin mesh network. When comparing normally hydrated and dehydrated airway mucus (i.e., 2.5% vs. 6.5% solids), neutrophil migration essentially ceased at the higher mucus concentrations, and bacterial capture and killing were significantly impaired (33). Concentrated airway mucus (8% solids) has also been shown to promote the development of Pseudomonas biofilms by limiting bacterial motility and the diffusion of small molecules, and to further the impairment of secondary immune defenses (e.g., lactoferrin) in the lung (34). These findings may also help to understand the accentuated inflammatory response that has been observed. If mucus is too concentrated to allow penetration and bacterial killing by neutrophils, the cells can remain in an activated state and continue to release cellular products (e.g., elastase) that ultimately damage airways and stimulate mucus secretion. Finally, as neutrophils degrade, they release DNA into the extracellular environment, which is a further impediment to the clearance of secretions because of its effects on mucus viscoelasticity. Although the number of mucus-secreting cells increases in CF, it is worth noting that there does not appear to be a major change in the cellular distribution of MUC5AC and MUC5B. It should also be mentioned that there are significant technical difficulties associated with mucin immunodetection. Not only are these molecules very large and highly glycosylated, but the generation of robust antibodies also has been difficult, and the CF airways environment itself is replete with proteases that degrade mucus proteins and reduce our ability to detect them using the antibodies that are available. As a result, some investigators have reported that CF is associated with a reduced quantity of mucins, leading them to the hypothesis that this could represent a host defense defect in and of itself (35,36). In contrast, others have shown that an abundance of mucins are present in CF secretions (9,10). Further experiments done in the presence of protease inhibitors and using methodologies that do not rely on antibody detection (i.e., mass spectroscopy) may shed light on this issue.

VI.

Cilia in Cystic Fibrosis

In one of the first examinations of the ultrastructural features of respiratory cilia in CF, cilia from patients with CF were noted to appropriately contain dynein arms and radial spokes (37). Minimal ciliary abnormalities were detected including compound cilia, cilia with excess cytoplasmic matrix, rippled cilia, and cilia with abnormal number or arrangement of microtubular doublets (37). Except for the slightly higher occurrence of rippled cilia in these patients, the abnormalities were similar in morphology and incidence to that of a control group of patients with chronic bronchitis (37). Unmistakably, patients with CF do not have ultrastructural ciliary defects like those seen in PCD. Nasal ciliary function and mucociliary clearance have been studied in patient cohorts with CF, sinusitis, non-CF bronchiectasis, and aged-matched controls. Ciliary beat frequency was slower in the patients with non-CF bronchiectasis (p < 0.05)

32

Brown and Donaldson

compared with patients with CF, sinusitis, and aged-matched controls (38). Nasal mucociliary clearance in CF and non-CF bronchiectasis was slower than that of controls (p < 0.001) and patients with sinusitis (p < 0.01) (38). The finding of a normal beat frequency in CF cilia studied in vitro in combination with abnormal nasal mucociliary clearance measured in vivo in the same patients suggests an abnormality of mucus, rather than of the cilia themselves. More recently, nasal mucociliary clearance in children with CF was studied and compared with that of children with PCD and with simple cardiac but no respiratory disease (considered negative controls). No difference was seen in nasal MCC times between children with CF and those without respiratory disease (39). However, those with PCD universally had delayed nasal MCC times. An adult CF cohort was also examined after being divided into those with and without chronic sinusitis (39). Those with sinusitis, which included 43% of CF adults, had longer nasal MCC times than those without chronic sinusitis (39). These data suggest that there does not appear to be a primary impairment in cilia-mediated mucus clearance in CF subjects. Instead, there is likely secondary impairment of cilia-mediated mucus clearance as a consequence of longstanding mucosal inflammation as evidenced by longer nasal MCC times in adults compared with children with CF, particularly in adults with chronic sinusitis. Therefore, virtually all studies agree that ciliary morphology and function in CF airway epithelia are intrinsically normal (37). This is in stark contrast to PCD in which congenital defects in ciliary structure and function lead to impaired mucociliary clearance and repeated respiratory tract infections (40). The lack of ciliamediated mucus clearance in PCD leads to heavy dependence on cough clearance alone. Patients with CF, in contrast, have impaired mucociliary clearance due to volume depletion of airway surfaces. With progressive dehydration, the PCL fails to support transport of the airway mucus layer, resulting in mucus adhesion. This is catastrophic, because not only are cilia unable to function in this configuration, but cough clearance fails as well.

VII.

Therapies for Defective Mucociliary Clearance in CF

A number of novel CF therapeutics are aimed at improving ASL hydration by either stimulating increased epithelial liquid secretion (e.g., hypertonic saline, dry powder mannitol, denufosol tetrasodium, and small molecules that restore mutant CFTR function), or slowing ASL absorption (e.g., amiloride, PS-552, and other ENaC inhibitors). Together, these novel therapeutics represent a substantial portion of the CF drug discovery pipeline, and signify that an improved understanding of disease pathogenesis is now being translated into interventions that target the underlying cause of disease. In the case of hyperosmotic hydrators, inhaled hypertonic saline and dry powder mannitol have both been shown to improve mucociliary clearance in proportion to the administered dose (41,42). The basis of this dose-response relationship likely reflects a direct relationship between the number of osmoles deposited on airway surfaces and the resulting magnitude and duration of the ASL volume response. Unfortunately, the tolerability of inhaled hyperosmotic solutions is also related (inversely) to the administered dose, with pharyngeal irritation, cough, and bronchospasm being the usual limiting symptoms. Importantly, hypertonic saline has been shown to improve lung function and significantly reduce disease exacerbations (43). Currently, studies are being performed

Mucus Abnormalities and Ciliary Dysfunction

33

that will test the impact of hypertonic saline in CF infants, where the greatest potential benefit may be realized. Sodium channel blockers (amiloride, PS-552) are antagonists of ENaC and work to slow absorption of sodium from the airway lumen. Although amiloride has not been shown to have clinical efficacy in CF (27,44,45), longer-acting, more potent ENaC blockers are now being tested (46). It is also intriguing to consider whether an ENaC inhibitor could act synergistically with a drug that stimulates ASL secretion by accentuating the size and/or duration of the resulting ASL volume response. Denufosol tetrasodium, a selective P2Y2 receptor agonist, bypasses the defective CFTR chloride channel by activating an alternative chloride channel (calcium-dependent chloride channels or CaCC). This is predicted to result in an increase in airway surface epithelial hydration. It appears to be therapeutically promising (47) and is currently in phase 3 clinical development. How it might interact with hyperosmotic agents is unknown and difficult to predict a priori, but will be an important issue if approved for clinical use. Recombinant human deoxyribonuclease I (rhDNase, or Pulmozyme), a cloned enzyme that cleaves the DNA residue left by degenerating neutrophils thus reducing sputum viscosity, is another means of altering mucus properties in CF (48). The enzyme was approved by the U.S. Food and Drug Administration in 1994 for use in CF patients. It has since accumulated a considerable history of safe administration and robust evidence for efficacy in CF patients across the disease spectrum. Other therapeutics that target mucus adhesion or other adverse rheologic properties in CF constitute another exciting prospect that is being explored. Perhaps most exciting is the possibility of restoring CFTR function, the most basic defect in CF pathophysiology. An enormous amount of work has gone into identifying orally available small molecules that have the capacity to correct mutant CFTR processing (i.e., DF508) and CFTR function (class III and IV mutations), or to promote readthrough of CFTR stop mutations. These new therapeutic classes, designed to address specific CFTR mutations and systemically restore CFTR function rather than ameliorating the sequelae CFTR dysfunction, hold great promise for revolutionizing the care of CF patients in the future. They are another prime example of how improved understanding of disease pathogenesis is driving the development of therapeutics in CF, particularly at the level of early disease pathogenesis.

References 1. Thornton DJ, Rousseau K, McGuckin MA. Structure and function of the polymeric mucins in airways mucus. Annu Rev Physiol 2008; 70:459–486. 2. Rubin BK. Physiology of airway mucus clearance. Respir Care 2002; 47(7):761–768. 3. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002; 109(5):571–577. 4. Fraser RS. Fraser and Pare´’s Diagnosis of Diseases of the Chest. 4th ed. Philadelphia: Saunder’s, 1999. 5. Hovenberg HW, Davies JR, Carlstedt I. Different mucins are produced by the surface epithelium and the submucosa in human trachea: identification of MUC5AC as a major mucin from the goblet cells. Biochem J 1996; 318(pt 1):319–324. 6. Fung DC, Rogers DF. Airway submucosal glands: physiology and pharmacology. In: Rogers D, Lethem MI, eds. Airway Mucus: Basic Mechanisms and Clinical Perspectives. Basel: Birkhauser, 1997, 179–210.

34

Brown and Donaldson

7. Davis CW. Goblet cells: physiology and pharmacology. In: Rogers D, Lethem MI, eds. Airway Mucus: Basic Mechanisms and Clinical Perspectives. Basel: Birkhauser, 1997:149–177. 8. Voynow JA, Young LR, Wang Y, et al. Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells. Am J Physiol 1999; 276(5 pt 1):L835–L843. 9. Kirkham S, Sheehan JK, Knight D, et al. Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B. Biochem J 2002; 361(pt 3):537–546. 10. Burgel PR, Montani D, Danel C, et al. A morphometric study of mucins and small airway plugging in cystic fibrosis. Thorax 2007; 62(2):153–161. 11. Sheehan JK, Richardson PS, Fung DC, et al. Analysis of respiratory mucus glycoproteins in asthma: a detailed study from a patient who died in status asthmaticus. Am J Respir Cell Mol Biol 1995; 13(6):748–756. 12. Rogers DF. Airway mucus hypersecretion in asthma: an undervalued pathology? Curr Opin Pharmacol 2004; 4(3):241–250. 13. Raynal BD, Hardingham TE, Thornton DJ, et al. Concentrated solutions of salivary MUC5B mucin do not replicate the gel-forming properties of saliva. Biochem J 2002; 362(pt 2):289– 296. 14. Sheehan JK, Kesimer M, Pickles R. Innate immunity and mucus structure and function. Novartis Found Symp 2006; 279:155–219. 15. Thornton DJ, Sheehan JK. From mucins to mucus: toward a more coherent understanding of this essential barrier. Proc Am Thorac Soc 2004; 1(1):54–61. 16. Randell SH, Boucher RC. Effective mucus clearance is essential for respiratory health. Am J Respir Cell Mol Biol 2006; 35(1):20–28. 17. Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol 2008; 70:431–457. 18. Raviv U, Giasson S, Kampf N, et al. Lubrication by charged polymers. Nature 2003; 425 (6954):163–165. 19. Tarran R, Grubb BR, Gatzy JT, et al. The relative roles of passive surface forces and active ion transport in the modulation of airway surface liquid volume and composition. J Gen Physiol 2001; 118(2):223–236. 20. Kerem E, Bistritzer T, Hanukoglu A, et al. Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism. N Engl J Med 1999; 341(3):156–162. 21. Lazarowski ER, Tarran R, Grubb BR, et al. Nucleotide release provides a mechanism for airway surface liquid homeostasis. J Biol Chem 2004; 279(35):36855–36864. 22. Tarran R, Button B, Picher M, et al. Normal and cystic fibrosis airway surface liquid homeostasis: the effects of phasic shear stress and viral infections. J Biol Chem 2005; 280 (42):35751–35759. 23. Donaldson SH, Corcoran TE, Laube BL, et al. Mucociliary clearance as an outcome measure for cystic fibrosis clinical research. Proc Am Thorac Soc 2007; 4(4):399–405. 24. Robinson M, Eberl S, Tomlinson C, et al. Regional mucociliary clearance in patients with cystic fibrosis. J Aerosol Med 2000; 13(2):73–86. 25. Smaldone GC, Foster WM, O’Riordan TG, et al. Regional impairment of mucociliary clearance in chronic obstructive pulmonary disease. Chest 1993; 103(5):1390–1396. 26. Bennett WD, Olivier KN, Zeman KL, et al. Effect of uridine 50 -triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am J Respir Crit Care Med 1996; 153(6 pt 1):1796–1801. 27. Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354(3):241–250. 28. Davril M, Degroote S, Humbert P, et al. The sialylation of bronchial mucins secreted by patients suffering from cystic fibrosis or from chronic bronchitis is related to the severity of airway infection. Glycobiology 1999; 9(3):311–321.

Mucus Abnormalities and Ciliary Dysfunction

35

29. Matsui H, Grubb B, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998; 95(7):1005–1015. 30. Mall M, Grubb BR, Harkema JR, et al. Increased airway epithelial Naþ absorption produces cystic fibrosis-like lung disease in mice. Nat Med 2004; 10(5):487–493. 31. Redding GJ, Kishioka C, Martinez P, et al. Physical and transport properties of sputum from children with idiopathic bronchiectasis. Chest 2008; 134(6):1129–1134. 32. Donaldson SH. Hydrator therapies for cystic fibrosis lung disease. Pediatr Pulmonol 2008; 43:S18–S23. 33. Matsui H, Verghese MW, Kesimer M, et al. Reduced three-dimensional motility in dehydrated airway mucus prevents neutrophil capture and killing bacteria on airway epithelial surfaces. J Immunol 2005; 175(2):1090–1099. 34. Matsui H, Wagner VE, Hill DB, et al. A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms. Proc Natl Acad Sci U S A 2006; 103(48):18131–18136. 35. Henke MO, Renner A, Huber RM, et al. MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions. Am J Respir Cell Mol Biol 2004; 31(1):86–91. 36. Henke MO, John G, Germann M, et al. MUC5AC and MUC5B mucins increase in cystic fibrosis airway secretions during pulmonary exacerbation. Am J Respir Crit Care Med 2007; 175(8):816–821. 37. Katz SM, Holsclaw DS Jr. Ultrastructural features of respiratory cilia in cystic fibrosis. Am J Clin Pathol 1980; 73(5):682–685. 38. Rutland J, Cole PJ. Nasal mucociliary clearance and ciliary beat frequency in cystic fibrosis compared with sinusitis and bronchiectasis. Thorax 1981; 36(9):654–658. 39. McShane D, Davies JC, Wodehouse T, et al. Normal nasal mucociliary clearance in CF children: evidence against a CFTR-related defect. Eur Respir J 2004; 24(1):95–100. 40. Noone PG, Leigh MW, Sannuti A, et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med 2004; 169(4):459–467. 41. Robinson M, Hemming AL, Regnis JA, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997; 52(10):900–903. 42. Daviskas E, Anderson SD, Eberl S, et al. Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur Respir J 2008; 31(4):765–772. 43. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354(3):229–240. 44. Knowles M, Church N, Waltner W, et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990; 322(17):1189–1194. 45. Graham A, Hasani A, Alton E, et al. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 1993; 6(9):1243–1248. 46. Hirsh AJ, Zhang J, Zamurs A, et al. Pharmacological properties of N-(3,5-diamino-6chloropyrazine-2-carbonyl)-N0 -4-[4-(2,3-dihydroxypropoxy) phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J Pharmacol Exp Ther 2008; 325(1):77–88. 47. Deterding RR, Lavange LM, Engels JM, et al. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am J Respir Crit Care Med 2007; 176 (4):362–369. 48. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group [see comments]. N Engl J Med 1994; 331(10): 637–642.

4 Microbiology in Cystic Fibrosis PAUL J. PLANET and LISA SAIMAN Columbia University, New York, New York, U.S.A.

I.

Introduction

The unique microbiology of cystic fibrosis (CF) lung disease has been appreciated for decades. Fulminant pneumonia with Staphylococcus aureus was described in infants with CF in the 1940s along with the initial descriptions of CF (1), and S. aureus was the most common pathogen isolated (2). Descriptions of the epidemiology of Pseudomonas aeruginosa were first provided in the 1960s, including the unique mucoid phenotype (3–5). Initial reports of the “cepacia syndrome” appeared in the late 1970s and early 1980s (6,7). Numerous improvements in diagnostic and therapeutic strategies for CF patients have been made over the past 20 years, which have been associated with decreased morbidity and increased life expectancy as well as changes in the microbiology of CF pathogens. These changing strategies have included improved nutrition (8); inhaled DNase (9,10); suppressive therapy for chronic infection with P. aeruginosa, that is, inhaled tobramycin (11) and oral azithromycin (12); implementation of standardized microbiology laboratory protocols to improve detection and identification of microorganisms from respiratory tract specimens (13,14); increased surveillance by quarterly cultures (13); improved infection control practices (13,14); and the increased acceptance early eradication therapy for P. aeruginosa (15–17). Changes in microbiology have included not only changes in the epidemiology of classic CF pathogens, but the emergence of several new pathogens (Table 1) and a recent interest in the potential role of noncultivatable organisms, anaerobes, and intracellular organisms in CF disease. This chapter will describe the critical importance of the clinical microbiology laboratory and the efforts needed to ensure appropriate processing of CF respiratory tract specimens. The epidemiology and clinical impact of both classic CF pathogens and emerging pathogens as well as our current understanding of virulence factors will be reviewed. In addition, the potential contribution of culture-independent to our understanding of CF lung disease will be discussed.

II.

Role of Clinical Microbiology Laboratory

A. Detection and Identification of Pathogens

Accurate detection and identification of the microorganisms from the respiratory tract of CF patients are critical to provide appropriate treatment, further the understanding of the epidemiology of CF pathogens, and promote effective infection control.

36

Microbiology in Cystic Fibrosis

37

Table 1 Classic and Emerging Pathogens in CF

Microorganism

Classic

Emerging

Bacteria

Staphylococcus aureus–methicillin susceptible Haemophilus influenzae Pseudomonas aeruginosa—nonmucoid and mucoid Burkholderia spp.

Staphylococcus aureus– methicillin resistant Stenotrophomonas maltophilia Achromobacter xylosoxidans Ralstonia spp. Streptococcus milleri Pandoraea apista Iniquilinus spp.

Molds

Aspergillus spp., A. fumigatus >> A. terreus, A. nidulans, A. flavus

Scedosporium apiospermum Scedosporium prolificans Exophiala dermatitidis Mucor spp. Penicillium spp.

Mycobacteria

Mycobacteria spp. Mycobacterium avium complex M. abscessus M. intracellulare M. chelonae M. fortuitum

Abbreviation: CF, cystic fibrosis.

Recommendations for appropriate collection and processing of CF specimens are presented in Table 2. The CF care team should be familiar with these recommendations and ensure they are instituted and monitored at the laboratories that process CF specimens. The use of selective media and more frequent culturing has most likely contributed to the increased prevalence of several CF pathogens due to detection bias. In the early 1980s, the use of selective media for Burkholderia spp. was critical to detect these pathogens and unravel patient-to-patient transmission (7). As will be described below, molecular identification methods have greatly facilitated identification of Burkholderia spp. and furthered our understanding of the complex epidemiology of these microorganisms. In the 1990s, it was shown that CF care sites that instituted complete microbiology protocols had a higher prevalence of S. aureus than sites that used incomplete protocols (18). Increased frequency of culturing has also increased “transient colonization” with Burkholderia, methicillin-resistant S. aureus (MRSA), and Stenotrophomonas maltophilia. Detection of nontuberculous mycobacteria (NTM) can be challenging; as many as three specimens may be needed for acid-fast bacilli (AFB) smear and culture. Proficiency studies for clinical laboratories participating in an NTM epidemiology study further elucidated the importance of a decontamination step to prevent overgrowth of NTM samples with P. aeruginosa (19). Cultures may require six to eight weeks to grow NTM, although the rapid growers, Mycobacteria abscessus, M. chelonae, and M. fortuitum can grow within one to two weeks. Molecular detection techniques can be

38

Planet and Saiman

Table 2 Appropriate Collection and Processing of CF Respiratory Tract Specimens

Step

Appropriate procedure

Comment

Collection

Specimens collected by experienced personnel Specimens labeled “CF Specimens” to ensure proper processing Cultures sent quarterly or during exacerbations Specimens brought to lab within 2 hr of collection.

Types of specimens include expectorated sputum, deep throat swabs, induced sputum, or bronchoalveolar lavage. Specimens from CF patients following lung transplantation should be processed as CF Specimens If specimens cannot be delivered within 2 hr, place specimens on ice but do not freeze. Specimens must be processed within 24 hr of collection Prolonged incubation may be required to detect more fastidious microorganisms, e.g., Burkholderia

Transport

Selective media

Biochemical identification

Selective media and/or culture conditions for isolation of S. aureus, H. influenzae, Burkholderia spp., and nontuberculous mycobacteria Commercial assays may misidentify or incompletely identify NLFGNR

Misidentification of l

l

l

Molecular identification

Antimicrobial susceptibility testing

Molecular typing

a

Use of reference laboratory to identify multidrug-resistant “NLFGNR” or Burkholderia cepacia complex Agar-based diffusion methods, e.g., Kirby-Bauer disks or Etest, preferred susceptibility testing assays for Pseudomonas aeruginosa Used for epidemiologic investigations to assess potential routes of transmission or success of early eradication strategies

Burkholderia spp. as other NLFGNRa Other NLFGNR as Burkholderia spp. Nonmucoid, nonpigmented P. aeruginosa as other NLFGNR

Molecular strategies can be used to delineate new taxonomy, e.g., emerging Burkholderia spp. Commercial microtiter assays have unacceptable rate of falsesusceptible results

Can be performed on bacterial and fungal species

Other NLFGNR include B. gladioli, Stenotrophomonas, Pseudomonas, Achromobacter, Ralstonia, Flavobacterium, or Chryseobacterium. Abbreviations: CF, cystic fibrosis; NLFGNR, nonlactose fermenting gram-negative rods

Microbiology in Cystic Fibrosis

39

used for AFB smear-positive specimens (direct amplification tests for ribosomal RNA) and for isolates growing in media (DNA probes for species identification). The interested reader is referred to the consensus document titled, “Infection control recommendations for patients with CF: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.” (13) and “Laboratory aspects of management of chronic pulmonary infections in patients with CF” (20) for detailed recommendations for processing CF respiratory cultures. B. Role of Susceptibility Testing

Current guidelines endorse the need for antimicrobial susceptibility testing to guide treatment, to promote appropriate infection control for multidrug-resistance pathogens, and to track the epidemiology of resistance (21). However, over the past several years, there has been growing concern that conventional susceptibility testing for patients with CF may lack clinical utility. This controversy has roots in clinical observations whereby patients having a pulmonary exacerbation clinically improve while being treated with antibiotics to which their pathogens are resistant in vitro and fail to improve while being treated with antibiotics to which their pathogens are susceptible in vitro. In addition, there has been concern that susceptibility testing assays use laboratory conditions that are irrelevant for the conditions within the CF lung. In the laboratory, bacteria are grown planktonically in aerobic conditions, and in enriched media, while in the CF lung, bacteria are thought to exist in biofilms, in stationary phase, and in a nutrient deficient millieu. Thus, there has been a great deal of interest in the usefulness of susceptibility testing performed on isolates grown in biofilms (22,23). However, the clinical utility of such assays has yet to be proven. Unfortunately, data obtained from clinical trials are lacking that support or refute the usefulness of susceptibility testing. Clinical trials assessing the efficacy of antibiotics during pulmonary exacerbations generally enrolled patients harboring pathogens that were susceptible to the agents tested (24), as such inclusion criteria are standard in antibiotic studies. In an attempt to shed light on this issue, a secondary analysis of the aerosolized tobramycin clinical trial data (25) was performed to assess the relationship between susceptibility to tobramycin and ceftazidime and clinical response (measured as change in lung function) (26). During the trial, 77 patients experienced a pulmonary exacerbation and were treated with these agents, 54 patients improved, 14 were unchanged, and 9 worsened. However, susceptibility to these agents did not correlate with clinical response; patients infected with resistant P. aeruginosa were as likely to respond as those with susceptible strains. Thus, while current in vitro susceptibility testing assays are imperfect, no suitable alternative exists at this time. C. Role of Synergy Testing

To date, the role of synergy testing has not been clearly defined. There is only one randomized, controlled trial assessing the clinical efficacy of synergy studies wherein patients were treated for a pulmonary exacerbation using antibiotic combinations guided by minimal bacteriocidal testing versus conventional susceptibility testing (27). There were no differences in the time until next pulmonary exacerbation or improvement in lung function. The pros and cons of synergy testing in CF were recently explored

40

Planet and Saiman

(28,29). These authors concluded that routine synergy testing was not justified based on the current evidence, but that synergy testing should be reserved for patients infected with multidrug-resistant P. aeruginosa who are failing conventional therapy, patients with substantial drug allergies, and/or patients with severely impaired lung function.

III.

Pathogens in CF

In CF patients, respiratory tract infections can begin in early infancy (Fig. 1). Heightened awareness of the diagnosis of CF among pediatric health care professionals and the implementation of newborn screening programs for CF around the world have lead to an earlier diagnosis of CF and a better understanding of the respiratory tract flora of young, often asymptomatic infants (30–32). Methicillin-susceptible S. aureus (MSSA), nontypeable Haemophilus influenzae, and P. aeruginosa are the most common organisms isolated during the first decade of life. Infections with P. aeruginosa, particularly infections with the mucoid phenotype, and Burkholderia cepacia complex are associated with a decline in lung function and predict morbidity and mortality in CF (33). A. Staphylococcus aureus

S. aureus is most often the earliest pathogen to be cultured from respiratory cultures of CF patients and can persist despite antibiotic treatment (median duration ~30 months) (34–36). The mechanism of long-term persistence is multifactorial and may include the ability to form biofilms (37,38), intracellular invasion (39,40), increased antibiotic resistance (41,42), decreased growth rate and metabolism, and/or increased rates of evolution (42). In some cases, persistence may also depend on the presence of other organisms (43). These factors are associated with a phenotypic switch that creates a subpopulation of cells identified by their colony morphology, that is, “small colony variants” (SCV) (44).

Figure 1 The age-specific prevalence per age group for each of the reported pathogens. Source:

Courtesy of Cystic Fibrosis Foundation, National Patient Registry 2007.

Microbiology in Cystic Fibrosis

41

Colonization of the upper respiratory tract seems to be an important risk factor for development of pulmonary infection in non-CF patients, but in CF patients the relevant site of colonization may be the oropharynx as opposed to the anterior nares (45). Documented transmission of S. aureus has been seen between CF patients (35). The introduction of effective antibiotic regimens appears to have greatly reduced mortality due to S. aureus, but the role of S. aureus in the progression of CF has not been fully explored (46,47). Some studies have suggested that early prophylaxis with flucloxacillin reduced colonization with S. aureus and reduced respiratory tract symptoms, although these studies have not shown clear long-term benefit (47). In other studies, prophylaxis with cephalexin has been associated with an increased risk of acquisition of P. aeruginosa (47,48). The differences in findings may be due to differences in the antimicrobial agent used or the age at initiation of prophylaxis. B. Haemophilus influenzae

H. influenzae (Hi) is also an early colonizer of young patients with CF. Most often, it is the nonencapsulated, nontypeable H. influenzae, strains that infect CF patients and, therefore, the Hib vaccine, which targets type B strains, does not protect against infection. Both in vivo and in vitro evidence suggests that H. influezae has the capability to form biofilms on airway epithelial cells (49), which may allow it to persist over longer periods of time. What might seem like chronic infection with H. influenzae may in fact represent reinfection over time with different strains thereby mimicking chronic infections (50). Although generally very susceptible to antimicrobial treatment, H. influenzae can acquire resistance to fluoroquinolones and other antibiotics used to treat other classic CF pathogens (50). This exposure and resultant phenotype may be related to increased mutation rates in certain clones, so-called hypermutability (51). It is unclear what role H. influenzae plays in the progression of lung disease in CF. C. Pseudomonas aeruginosa

P. aeruginosa is the pathogen most often cultured from sputum cultures of CF patients. It is also the pathogen for which the most evidence exists for a direct role in pathogenesis. Children and infants with CF who are colonized/infected with P. aeruginosa have reduced 10-year survival and increased pulmonary disease compared with CF controls who are not colonized/infected (52,53). P. aeruginosa strains are thought to persist for long periods, sometimes life-long, in the lungs of CF patients (54–57). Distinct clones can also coexist within the same patient (58,59). It seems likely that strains are acquired from the environment in many cases; P. aeruginosa can be easily cultured from environmental sources such as soil and tap water (60). However, there are documented cases in which P. aeruginosa seems to have been acquired through contact with other CF patients both in and out of the health care setting (58,59,61–65), emphasizing the potential for patient-to-patient transmission of classic CF pathogens. Much work has been done to understand the molecular basis of chronic lung infections with P. aeruginosa in CF. The long-term persistence of P. aeruginosa within the unique milieu of the CF lung provides this microorganism with the opportunity to evolve and adapt in situ (66–68). This evolution occurs both by mutation in existing genes (66) and

42

Planet and Saiman

through large-scale genomic rearrangements and acquisition of new genes (67,69). Observed phenotypic changes in persistent infections include development of antibiotic resistance (70,71) and loss of motility and other factors involved in acute infection (66). Increased mutation rate during long-term infection has been observed as well (72). One of the important phenotypic transitions that occurs in chronic P. aeruginosa infection in CF is the switch to the mucoid phenotype in which organisms overproduce the exopolysaccharide alginate and enter a nonmotile state (73,74). This switch is associated with clinical deterioration and a poor prognosis (75). The switch to mucoidy is thought to be important in formation of adherent biofilms, which can resist clearance, evade the defenses of the immune system, and are more resistant to antibiotic killing (73). Other phenotypes associated with biofilms, such as slow-growing, hyperadherent small colony variant, may also have an important role in colonization and persistence (76–79). Bacterial appendages such as pili and flagella aid in biofilm formation (80–82), while quorum-sensing systems (83) allow chemical communication between bacteria to regulate genes needed for virulence and life within a biofilm. In addition to the virulence factors that facilitate chronic infections, P. aeruginosa strains also express several other virulence factors including exotoxin A, exoenzyme S, leukocidin, alkaline protease, type III secretion systems, and pyocyanins (84,85). The precise role of these virulence factors in CF is not fully understood. D. Burkholderia spp.

Several research laboratories and referral centers around the world have been using molecular identification via 16S rRNA gene sequencing and sequence polymorphisms within the protein-coding gene, recA, as well as multilocus sequence typing (MLST) to provide accurate identification and explore the unique epidemiology of the genus Burkholderia and related genera, for example, Ralstonia and Pandoraea spp. (86–89). B. cepacia complex is now known to consist of phenotypically indistinguishable, genetically distinct species, also termed genomovars. To date more than 15 such species have been identified and isolated from patients with CF, but the two most common species detected in CF are B. cenocepacia and B. multivorans (Table 3). Other species are far less common although B. cepacia, B. stabilis, B. vietnamiensis, and B. dolosa are generally more frequently isolated than B. ambifaria, B. anthina, and B. pyrrocinia. Table 3 Burkholderia spp. Isolated from Patients with CF

Genomovar

Species

I II III IV V VI VII VIII IX X Indeterminate

Burkholderia cepacia B. multivorans B. cenocepacia B. stabilis B. vietnamiensis B. dolosa B. ambifaria B. anthina B. pyrrocinia B. ubonensis –

Estimated prevalence (%) 6 17–38 39–67 1 6 3 1 A 2184delA

I507del F508del G542X G551D R553X

R560T R1162X W1282X N1303K

2789 þ 5G > A 3120 þ 1G > A 3659delC 3849 þ 10kbC > T

Abbreviations: CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator.

Cystic Fibrosis: Diagnosis, Sweat Testing, and Newborn Screening

97

missed if the subject is affected by a mutation that is not included on the panel in use. For this reason, regional mutation panels are often modified to include particular mutations unique to the population being tested. Full sequence analysis will detect virtually all CFTR mutations; however, it raises the specter of discovering polymorphisms and novel mutations whose significance is not known. Furthermore, such sequencing only includes the exons and flanking intronic sequences, meaning that deep intronic mutations will be missed. A helpful tool in assessing subjects who may have CF but who do not meet classical diagnostic criteria is measurement of transepithelial NPD (7,8). NPD is performed by determining the electrical potential difference across the nasal epithelium compared with a subcutaneous reference. This potential difference is generated by the transport of ions across the respiratory epithelium and is abnormal in subjects lacking functional CFTR protein. Bathing the nasal mucosa in various solutions while recording potential differences allows for estimation of the change in current attributable to epithelial chloride and sodium channels. At baseline, CF patients have a more negative potential difference than non-CF controls owing to enhanced sodium reabsorption (22). Perfusion of the nose with the epithelial sodium channel blocking agent amiloride causes a greater change in potential difference (less negative) in CF patients than is seen in nonCF subjects. Application of a chloride-free solution causes a negative deflection of the potential difference in a subject without CF, but causes no such change in a CF patient. Finally, a CF patient will have little or no response to perfusion of the nose with isoproterenol, a drug that stimulates CFTR function, whereas a non-CF subject will have a large negative change in potential difference with this agent (22). NPD can be quite useful for confirming or negating the presence of a CFTR abnormality in a patient with uncertain symptoms and a borderline sweat test. Unfortunately, NPD is labor intensive, technically difficult, and is not available at all CF centers.

III.

Newborn Screening

In the early 1990s, only a handful of regions worldwide were performing newborn screening for CF. By the end of the first decade of this century, newborn screening has become commonplace, with almost all states in the United States and many EU countries performing this test. Children diagnosed via newborn screening have improved growth, reduced therapeutic burden, and reduced morbidity when compared with children diagnosed later in life due to clinical symptoms (23–25). Additionally, two U.K. CF Trust registry–based studies have shown both the clinical benefit and cost-effectiveness of newborn screening (23,26). Thus, the benefits of newborn screening for CF are no longer in doubt (27), and the Centers for Disease Control and Prevention has supported adoption of CF newborn screening throughout the United States (28). In regions performing CF newborn screening, it has become highly unusual to see patients present with symptoms of classical CF, like chronic or recurrent respiratory disease and emaciation. Similarly, problems related to electrolyte abnormalities or occult vitamin deficiency due to undiagnosed CF have become almost nonexistent. Since children identified by newborn screening are diagnosed when asymptomatic or with only mild growth retardation, it is possible to help them maintain or recover normal somatic growth. This is crucial because registry studies have shown an association between better preschool nutritional status and higher pulmonary function test results at

98

O’Sullivan

school age (29,30). Indeed, multiple studies have shown that newborn screening for CF leads to improved nutritional outcomes (31,32), and screened infants have better weight gain than do malnourished nonscreened infants with CF (33). Furthermore, recovery of weight z-scores within two years of diagnosis in both screened and nonscreened infants is associated with improved pulmonary status at six years of age (34). Therefore, it is presumed that the improved nutritional status in infancy as a result of newborn screening will lead to improved pulmonary function later in life and, in fact, there are data supporting this hypothesis (35,36). Implementation of CF newborn screening takes considerable foreplanning with cooperation being vital between the newborn screening laboratory, regional CF centers, geneticists, and parents (37,38). Newborn screening is performed by measuring immunoreactive trypsinogen (IRT) in blood spots taken from newborn infants. A very high IRT implies pancreatic injury consistent with (but not specific for) CF. This marker is elevated even in infants with CFTR mutations associated with pancreatic sufficiency. Those infants who have an elevated IRT on initial testing then have further evaluation via a repeat IRT one to three weeks later (IRT/IRT) or by analysis of the initial blood spot for a specified panel of CFTR mutations (IRT/DNA) (39,40). Most screening programs identify infants in the top 5% of values each day for further IRT or DNA analysis. Because of lot-to-lot and seasonal variation in IRT results, it is best to designate a percentage of IRT levels each day as being positive (for example, the top 5%) rather than using a static absolute cutoff value (41). Use of a higher cutoff value (e.g., 2–3% of the highest daily values) will decrease both the number of falsepositive screening tests and the number of unaffected carriers detected. This advantage must be weighed against a loss of sensitivity and an increased chance that an infant with CF will be missed. Of note, the positive predictive value for an elevated IRT is lower in African-American children than in European-American children (42). The reason for higher IRT values in non-CF affected African-American children is unclear, but must be taken into account when initiating newborn screening programs in areas with a high density of families of African origin. Low-birth-weight infants also have higher IRT values and retesting of premature infants who have an initially elevated IRT is appropriate. An advantage of the IRT/IRT method of screening is that it avoids the problems associated with detecting mutations of uncertain clinical significance and of having to counsel families in regard to carrier status or nonpaternity. Unfortunately, the IRT/IRT algorithm requires obtaining a second blood spot one to three weeks after the first one, which may be a major logistical problem in some populations. In contrast, the IRT/DNA method allows complete testing using the initial blood specimen only. Furthermore, IRT/IRT testing has a lower sensitivity (80.2%) than IRT/DNA screening (96.2%) (41) (keeping in mind that the sensitivity of the IRT/ DNA method depend on the number of mutations included in the DNA panel). For regions instituting DNA-based newborn screening, the mutations included on the DNA panel should reflect the frequency of specific CF mutations in the local population (21,40). Again, a balance must be struck between sensitivity and specificity; including too many mutations in the panel can result in identification of more carriers or of children with CFTR dysfunction of questionable clinical significance. Inclusion of only a few of the most common mutations can lead to missing children who truly have CF, especially those in minority populations.

Cystic Fibrosis: Diagnosis, Sweat Testing, and Newborn Screening

99

Not surprisingly, there is much controversy about which mutations should be included on newborn screening panels. Some advocate for only including mutations that cause known, serious dysfunction in the CFTR protein. Others recommend more complete screening with even full CFTR sequence analysis proposed for regions with extremely diverse populations. Perhaps most hotly debated is inclusion of the R117H mutation on screening panels. This mutation has variable expression, in part determined by its association with the polythymidine tract in intron 8. When found in association with a five polythymidine tract (5T), the R117H mutation can cause CF symptoms; when associated with the 7T tract, symptoms may be limited, not appear until adulthood, or be absent. Scotet et al. (43) reported nine infants with the R117H-7T variant in combination with a severe mutation on the other allele. None of these children had developed symptoms of CF by a mean age of seven years. Given the relatively high frequency of the R117H allele, the uncertainty that it is a disease-causing mutation and the difficulty of counseling families about what may occur in the future, the authors recommended against including it in newborn screening panels. In contrast, Lording et al. (44) and O’Sullivan et al. (45) have described compound heterozygote children with a severe CF mutation on one allele and the R117H-7T variant on the other who developed respiratory symptoms and became infected with PA early in life. On the basis of this information, it seems imprudent to ignore the R117H mutation; however, care should be taken when discussing its significance with parents, as the clinical outcome of a child with this mutation is uncertain (46). A positive newborn screening result by either IRT/IRT or IRT/DNA coupled with identification of only one known mutation indicates that a child is at increased risk for CF, not that the child has the disease. Unfortunately, many families and some primary care providers mistakenly believe that a report of a positive newborn screen indicates that the child has CF. A sweat test or expanded mutation analysis must be done to confirm the diagnosis. Identification of two mutations known to be CF disease-causing using the IRT/DNA method is tantamount to a diagnosis of CF; however, there is a minute chance that two different mutations might be inherited in cis from the same parent. Thus, even these children should have a sweat test performed to confirm the diagnosis. Genetic counseling is an integral part of a newborn screening program. Once a child is identified as having CF, the parents are automatically determined to be carriers and siblings and other relatives are at risk for being affected with CF or being carriers of one mutated allele. Although most CF care providers feel comfortable discussing the basics of CF genetics, it is best to involve a trained genetic counselor to advise the family as to their options for further testing (47). It is most appropriate to test young siblings with a sweat test rather than mutation analysis since the decision as to whether or not they want to know their carrier status is best left to them when they reach the age of majority. Siblings who have a borderline sweat test can have the test repeated or, provided the proband’s genetics are known, can have mutation analysis performed to definitively rule in or out the diagnosis of CF. Parents of a child who has a positive IRT and one CF mutation identified and who has a negative sweat test (i.e., a child who is a carrier) must be educated that they may each be carriers since 50% of infants born to two carriers will be unaffected carriers. The genetic counselor can help these parents arrange to get genetic testing if they so desire. Obviously, this is an area where the IRT/IRT newborn screening method provides less information but also creates fewer complications.

100

O’Sullivan

IV.

Conclusion

CF, once considered easy to diagnose—malabsorption, respiratory disease, and a positive sweat test sealed the diagnosis—is now recognized as a multifaceted metabolic problem with many permutations. Diagnosis involves multiple layers of testing with uncertainty possible at all levels including clinical symptoms, sweat chloride values, and genetic testing. Still, CF remains a clinical disease and diagnosis must be based on the presence of clinical symptoms with supporting laboratory values. These supporting tests (newborn screening, sweat testing, mutation analysis, and NPD) must be performed appropriately and interpreted cautiously. The sweat chloride test remains the gold standard for CF diagnosis but does not always give a clear answer. Algorithms are available to the clinician to help determine if a patient has classical CF, atypical (nonclassical) CF, or does not have CF at all.

References 1. O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009; 373:1891–1904. 2. Borowitz D, Baker SS, Duffy L, et al. Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis. J Pediatr 2004; 145:322–326. 3. Carlson D, McKeen E, Mitchell M, et al. Oropharyngeal flora in healthy infants: observations and implications for cystic fibrosis care. Pediatr Pulmonol 2009; 44:497–502. 4. El Solh AA, Akinnusi ME, Wiener-Kronish JP, et al. Persistent Infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. Am J Respir Crit Care Med 2008; 178:513–519. 5. di Sant’Agnese PA, Darling RC, Perera GA, et al. Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas. Pediatrics 1953; 12:549–563. 6. Bates CM, Baum M, Quigley R. Cystic fibrosis presenting with hypokalemia and metabolic alkalosis in a previously healthy adolescent. J Am Soc Nephrol 1997; 8:352–356. 7. Farrell PM, Rosenstein BJ, White TB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation Consensus Report. J Pediatr 2008; 153:S4–S14. 8. De Boeck K, Wilschanski M, Castellani C, et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006; 61:627–635. 9. Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat of cystic fibrosis of the pancreas utilizing pilocarpine iontophoresis. Pediatrics 1959; 23:545–549. 10. Green A, Kirk J. Guidelines for the performance of the sweat test for the diagnosis of cystic fibrosis. Ann Clin Biochem 2007; 44:25–34. 11. LeGrys VA, Yankaskas JR, Quittell LM, et al. Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. J Pediatr 2007; 151(1):85–89. 12. LeGrys VA. Sweat testing for the diagnosis of cystic fibrosis: practical considerations. J Pediatr 1996; 129:892–897. 13. Lezana JL, Vargas MH, Karam-Bechara J, et al. Sweat conductivity and chloride titration for cystic fibrosis diagnosis in 3834 subjects. J Cyst Fibros 2003; 2:1–7. 14. Eng W, LeGrys VA, Schechter MS, et al. Sweat-testing in preterm and full-term infants less than 6 weeks of age. Pediatr Pulmonol 2005; 40:64–67. 15. Mishra A, Greaves RF, Carlin J, et al. The diagnosis of cystic fibrosis by sweat test: age-specific reference intervals. J Pediatr 2008; 153:758–763. 16. Farrell PM, Koscik RE. Sweat chloride concentrations in infants homozygous or heterozygous for dF508 cystic fibrosis. Pediatrics 1996; 97:524–528. 17. Massie J, Gaskin K, Van Asperen P, et al. Sweat testing following newborn screening for cystic fibrosis. Pediatr Pulmonol 2000; 29:452–456.

Cystic Fibrosis: Diagnosis, Sweat Testing, and Newborn Screening

101

18. Parad RB, Comeau AM, Dorkin HL, et al. Sweat testing infants detected by cystic fibrosis newborn screening. J Pediatr 2005; 147:S69–S72. 19. Soultan ZN, Foster MM, Newman NB, et al. Sweat chloride testing in infants identified as heterozygote carriers by newborn screening. J Pediatr 2008; 153:857–859. 20. O’Sullivan BP, Zwerdling RG. By the sweat of our brows: how salty should a person be? J Pediatr 2008; 153:735–736. 21. Watson MS, Cutting GR, Desnick RJ, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med 2004; 6:387–391. 22. Wallis C. Diagnosis of cystic fibrosis. In: Hodson M, Geddes DM, Bush A, eds. Cystic Fibrosis. 3rd ed. London: Edward Arnold, Ltd, 2007:99–108. 23. Sims EJ, Mugford M, Clark A, et al. Economic implications of newborn screening for cystic fibrosis: a cost of illness retrospective cohort study. Lancet 2007; 369:1187–1195. 24. Siret D, Bretaudeau G, Branger B, et al. Comparing the clinical evolution of cystic fibrosis screened neonatally to that of cystic fibrosis diagnosed from clinical symptoms: a 10-year retrospective study in a French region (Brittany). Pediatr Pulmonol 2003; 35:342–349. 25. Accurso FJ, Sontag MK, Wagener JS. Complications associated with symptomatic diagnosis in infants with cystic fibrosis. J Pediatr 2005; 147:S37–S41. 26. Sims EJ, McCormick J, Mehta G, et al. Neonatal screening for cystic fibrosis is beneficial even in the context of modern treatment. J Pediatr 2005; 147(suppl 1):S42–S46. 27. Farrell PM. Cystic fibrosis newborn screening: shifting the key question from “should we screen?” to “how should we screen?” Pediatrics 2004; 113(6):1811–1812. 28. Grosse SD, Boyle CA, Botkin JR, et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep 2004; 53:1–36. 29. Konstan MW, Butler SM, Wohl MEB, et al. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr 2003; 142(6):624–630. 30. Padman R, McColley SA, Miller DP, et al. Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function. Pediatrics 2007; 119(3): E531–E537. 31. Farrell PM, Kosorok MR, Laxova A, et al. Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. N Engl J Med 1997; 337(14):963–969. 32. Farrell PM, Kosorok MR, Rock MJ, et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Pediatrics 2001; 107:1–13. 33. Shoff SM, Ahn H-Y, Davis L, et al. Temporal associations among energy intake, plasma linoleic acid, and growth improvement in response to treatment initiation after diagnosis of cystic fibrosis. Pediatrics 2006; 117:391–400. 34. Lai HJ, Shoff SM, Farrell PM. Recovery of birth weight z score within 2 years of diagnosis is positively associated with pulmonary status at 6 years of age in children with cystic fibrosis. Pediatrics 2009; 123:714–722. 35. McKay KO, Waters DL, Gaskin KJ. The influence of newborn screening for cystic fibrosis on pulmonary outcomes in New South Wales. J Pediatr 2005; 147:S47–S50. 36. Collins MS, Abbott M-A, Wakefield DB, et al. Improved pulmonary and growth outcomes in cystic fibrosis by newborn screening. Pediatr Pulmonol 2008; 43:648–655. 37. Comeau AM, Parad R, Gerstle R, et al. Challenges in implementing a successful newborn cystic fibrosis screening program. J Pediatr 2005; 147:S89–S93. 38. Comeau AM, Parad R, Gerstle R, et al. Communications systems and their models: Massachusetts parent compliance with recommended specialty care after positive cystic fibrosis newborn screening result. J Pediatr 2005; 147:S98–S100.

102

O’Sullivan

39. Therrell BL, Lloyd-Puryear MA, Mann MY. Understanding newborn screening system issues with emphasis on cystic fibrosis screening. J Pediatr 2005; 147(3 suppl 1):S6–S10. 40. Comeau AM, Accurso FJ, White TB, et al. Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. Pediatrics 2007; 119:e495–e518. 41. Kloosterboer M, Hoffman G, Rock M, et al. Clarification of laboratory and clinical variables that influence cystic fibrosis newborn screening with initial analysis of immunoreactive trypsinogen. Pediatrics 2009; 123:e338–e346. 42. Giusti R. Consortium NYSCFNS. Elevated IRT levels in African-American infants: implications for newborn screening in an ethnically diverse population. Pediatr Pulmonol 2008; 43:638–641. 43. Scotet V, Audrezet M-P, Roussey M, et al. Immunoreactive trypsin/DNA newborn screening for cystic fibrosis: should the R117H variant be included in CFTR mutation panels? Pediatrics 2006; 118:e1523–e1529. 44. Lording A, McGaw M, Dalton A, et al. Pulmonary infection in mild variant cystic fibrosis: implications for care. J Cyst Fibros 2006; 5:101–104. 45. O’Sullivan BP, Zwerdling RG, Dorkin H, et al. Early pulmonary manifestation of cystic fibrosis in children with the dF508/R117H-7T genotype. Pediatrics 2006; 118:1260–1265. 46. Curnow L, Savarirayan R, Massie J. Genetic counseling after carrier detection by newborn screening when one parent carries DeltaF508 and the other R117H. Arch Dis Child 2003; 88:886–888. 47. Moskowitz SM, Chmiel JF, Sternen DL, et al. Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. Genet Med 2008; 10:851–868.

8 Diagnostic Approach to Diseases Associated with Cystic Fibrosis Transmembrane Conductance Regulator Gene Mutations CHEE Y. OOI (KEITH) The Hospital for Sick Children, Toronto, Ontario, Canada

ELIZABETH TULLIS University of Toronto and St. Michael’s Hospital, Toronto, Ontario, Canada

PETER R. DURIE University of Toronto and the Hospital for Sick Children, Toronto, Ontario, Canada

I.

Introduction

The discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene led to a significant increase in our knowledge and understanding of the spectrum of disorders associated with functional alterations in the CFTR gene. Prior to this discovery, cystic fibrosis (CF) was thought to be a multisystem disease that manifests clinically either at birth (with intestinal obstruction) or in infancy/early childhood (with failure to thrive and recurrent pulmonary symptoms) (1). Great advances in molecular analysis techniques have led to not only the identification of more than 1550 CFTR mutations (2) but also the recognition of a wide spectrum of diseases associated with mutations in the CFTR gene. What was once considered a disease of infants and young childhood is no longer the case as individuals with symptoms manifesting in adolescence and adulthood are receiving a diagnosis of CF. This has been complicated by the fact that several diseases that resemble CF at an organ-specific level have also been found to be strongly associated with mutations in the CFTR gene. Consequently, the clinical diagnosis of CF disease is not always straightforward because progress in molecular genetics has not been matched by equal progress in our understanding of the clinical consequences of the majority of known CFTR mutations. A. Nomenclature

In effect, as knowledge of the range of phenotypes associated with CFTR gene mutations has expanded the demarcation line between patients with CF disease and those not classified as CF by current diagnostic criteria has blurred. This is further complicated by the introduction of various confusing terms to describe the range of severity of CF and CFTR-related conditions. These include terms such as typical CF, atypical CF, CF variant, pre-CF, and classic and nonclassic CF. Furthermore, these classifications are misleading, and are no longer relevant in the age of newborn screening and to the current state of knowledge of CF disease. CF is no longer considered an unambiguous disease

103

104

Ooi et al.

entity resulting in death in early childhood, and it is not possible to determine individual prognosis using currently available diagnostic tests. In fact, individuals who display few or no deleterious health effects earlier in life can later develop severe disease in one or more organ systems. Furthermore, there is emerging evidence to suggest that the pulmonary outcomes of individuals classified as having “mild” CF may be as severe as those with “severe” CF. The results of two recent consensus conferences with participants from Europe, North America, and Australasia (3,4) agreed that this classification should be limited to two terms: (i) CF disease, to describe patients who fulfill the current diagnostic criteria, and (ii) “CFTR-related disorder,” to describe individuals with a CF phenotype in at least one affected organ as well as evidence of CFTR dysfunction (CFTR mutations and/or evidence of CFTR ion channel dysfunction) that do not fulfill the diagnostic criteria for CF disease. Nonetheless, as we describe in detail below, individuals who carry mutations in the CFTR gene show an overlapping clinical spectrum, ranging from no clinical disease at one extreme through those with CFTR-related disorders to CF disease with and without sufficient pancreatic function at the other extreme. Similarly ion channel measurements (ICMs) in the sweat gland and nasal epithelium show a continuum of values, with no clear delineating point, ranging from those observed in healthy controls and obligate heterozygotes to values for pancreatic sufficient (PS) and insufficient (PI) CF. Consequently, our ability to establish or exclude CF disease has become increasingly problematic. B. CFTR Function and Disease

The CFTR protein is a cyclic AMP-dependent chloride channel, located in the apical membrane of secretory and absorptive epithelial cells of the airway, pancreas, intestine, liver, vas deferens, and sweat glands. The manifestations of CF predominantly arise from glandular or ductal plugging due to an inability to hydrate macromolecules within the lumen. There is a continuous spectrum of CFTR dysfunction that results in a complex and heterogeneous disease (Fig. 1). In addition, there is a clear relation between the number and functional severity of CFTR gene mutations with the range of CFTR-mediated ion channel abnormalities (5). This observation is providing insight into our understanding of the threshold of CFTR-mediated ion channel function that is required for disease pathogenesis and diagnosis. Different mutations in the CFTR gene have varying effects on CFTR function. A five class system was devised to predict how mutations influence CFTR-mediated ion channel function (6) (Fig. 2). Class I mutations include nonsense or frameshift mutations that cause defective protein biosynthesis while class II mutations (e.g., DF508) result in misfolded functional CFTR protein, which is largely degraded intracellularly. Class III mutations affect channel activation by preventing binding and hydrolysis of ATP at one of the two nucleotide-binding domains. Class IV mutations result in impaired protein function due to abnormal anion conductance. Class V mutations include abnormal splicing, promoter mutations, or inefficient trafficking that lead to a reduced number of normally functioning protein. In general, patients homozygous or compound heterozygous for mutations in classes I, II, and III (which confer loss of CFTR function) are more susceptible to severe clinical consequences.

Diagnostic Approach to Diseases Associated with CFTR Gene Mutations

105

Figure 1 Spectrum of disorders associated with level of CFTR function. Abbreviation: CFTR, cystic fibrosis transmembrane conductance regulator.

Figure 2 Classification of CFTR mutations according to the functional consequences of the gene product. Severe mutations (classes I–III and VI) confer little or no functional CFTR at the apical membrane, while mild mutations (classes IV and V) confer some partial CFTR function (see text for explanation). Abbreviation: CFTR, cystic fibrosis transmembrane conductance regulator. Source: Adapted from Ref. 7.

106

Ooi et al.

The exocrine pancreas is the most reliable phenotypic barometer of CFTR function, and most patients with the PI phenotype carry classes I, II, or III mutations on both alleles. Patients who are homozygous or compound heterozygous for severe mutations are also more likely to develop meconium ileus and severe liver disease (cirrhosis and portal hypertension). Class IV or V mutations confer some residual but highly variable CFTR function. Patients carrying a class IV or V mutation on at least one allele usually have sufficient pancreatic function and commonly do not experience significant intestinal and hepatic complications. These patients usually have the PS form of CF or a CFTR-related disorder. Nonetheless, it is important to note that genotype may not be closely associated with pancreatic phenotype in very young infants, particularly those identified by newborn screening. This is almost certainly due to the fact that some infants carrying severe mutations on both alleles have some residual exocrine pancreatic function. However, almost all of the patients who are homozygous or compound heterozygous for class I, II, or III mutations will develop PI before two years of life (8). While this classification system for CFTR mutations is useful as a conceptual framework, its limitations are acknowledged (e.g., class IV and V mutations can have overlapping consequences, and inferred properties of many mutations remain to be confirmed by functional studies). In addition, the heterogeneous CF disease spectrum in other organs, especially the airways, is poorly explained by CFTR genotype and is also influenced by environmental and other genetic modifying factors (9–11).

II.

Diagnosis of CF and CFTR-Related Disorders

According to the most recent United States Cystic Fibrosis Foundation (USCFF) consensus report (3), a diagnosis of CF can be made in individuals who present with a characteristic clinical phenotype or a history of CF in a sibling plus an abnormal sweat chloride value
60 mmol/L and/or two CF-causing mutations. It is important to note that the diagnosis of CF cannot be made on the basis of identification of CFTR mutations that are not designated as CF-causing. The confirmation or exclusion of CF is usually straightforward, particularly among individuals in the extreme ends of the CFTR function spectrum (i.e., normal healthy individuals and heterozygotes at one extreme and CF patients homozygous or compound heterozygous for severe mutations at the other). However, the diagnosis of CF disease may be less clear-cut among individuals who have residual function of the CFTR protein. A significant number of individuals who have diseases associated with CFTR mutations conferring partial function do not meet the current diagnostic criteria for CF disease. These individuals, who are considered to have a CFTR-related disorder, characteristically present with symptoms of CFTR dysfunction (e.g., chronic sinopulmonary disease; obstructive azoospermia; or acute, recurrent, or chronic pancreatitis) at an older age, and have either sweat chloride values in the intermediate range (40–59 mmol/L for individuals above six months of age) and/or one or two CFTR mutations that are not classified as CF-causing mutations (3). While discussion of excluding or establishing a diagnosis of CF in the era of newborn screening test is covered in a companion chapter by O’Sullivan, it is worthy to note that the diagnosis of CF will be uncertain in a subset of asymptomatic infants that screen positive for CF. Despite the fact that neonatal screening programs for CF have been in existence since the 1980s, the prevalence and natural history of infants with an

Diagnostic Approach to Diseases Associated with CFTR Gene Mutations

107

uncertain diagnosis of CF is not well defined. We are unaware of any careful, prospective longitudinal studies of screen-positive infants with an uncertain diagnosis of CF. A single retrospective study has been performed in screen-positive infants who carried one CFTR mutation and a normal or intermediate sweat chloride concentration (12). Extensive CFTR mutation analysis revealed that 20/32 (62.5%) of screen-positive newborns carried a change in the CFTR gene on the second allele (compound heterozygote), but none of these changes were established as CF-causing and may represent functional polymorphisms. Nine of 20 compound heterozygotes evaluated in follow-up at four years of age displayed at least one clinical feature of CF disease, which is not surprising since there are reports of an increased incidence of chronic rhinosinusitis, diffuse bronchiectasis, and idiopathic pancreatitis in individuals who carry at least one CFTR mutation (discussed in more detail below). Three of these patients had a sweat chloride test that was consistent with CF. This study was limited by incomplete ascertainment at follow-up. Only a subset of patients underwent extensive CFTR mutation analysis and an even smaller number of subjects were recalled for follow-up evaluation. Clearly, a carefully performed prospective longitudinal assessment of newborn screen-positive individuals is warranted to determine the true prevalence of CF-disease and CFTR-related disorders in this population.

III.

Diagnostic Challenges

There is considerable debate and difficulty on where to draw the diagnostic line between CF and CFTR-related disorder. Although the following discussion separates them into two entities, they form part of a continuous spectrum of diseases associated with CFTR dysfunction (Fig. 1). A. Cystic Fibrosis Diagnosed in Adolescence and Adulthood

CF may manifest at different ages, in different organs, with variable severity and includes chronic sinopulmonary disease, pancreatic exocrine insufficiency, intestinal diseases, pancreatitis, hepatobiliary disease, and obstructive azoospermia in men (1,5,7,13–22,24). In its traditionally recognized form, CF disease either presents with intestinal obstruction at birth or with failure to thrive and recurrent pulmonary symptoms in infancy/early childhood. However, a subset of patients is diagnosed with CF in adolescence and adulthood, with a wide spectrum of symptoms and severity of disease that does not resemble the typical clinical presentation in infancy or early childhood (1,13–15). In fact, they may first come to the attention of an urologist, otolaryngologist, or gastroenterologist, rather than a pulmonologist. With increasing awareness, the number of CF patients receiving a diagnosis in adolescence and adulthood continues to increase. Gilljam et al. prospectively examined all patients with a CF diagnosis made at the Toronto CF clinics (adult and pediatric) over a 41-year period and compared patients who received a diagnosis of CF in adulthood with those who were diagnosed in infancy or childhood (13). Among all patients who were diagnosed with CF between 1960 and 1989, only 3% were over 16 years of age. In contrast, in the subsequent decade (1990 and 2001), the proportion of subjects diagnosed in adulthood rose to 18% (Table 1) (13). Among patients older than 16 years of age at clinical presentation, the median age of CF diagnosis was 32  11 years (range, 16–58 years), with no age difference between

108

Ooi et al.

Table 1 Proportion of Patients with CF Diagnosed in Adulthood and Childhood at the Toronto

CF Clinics Between 1960 and 2001.

1960–1989: Number of diagnoses (%) 1990–2001: Number of diagnoses (%)

Childhood

Adulthood

767 (97) 211 (82)

27 (3) 46 (18)

Abbreviation: CF, cystic fibrosis. Source: Adapted from Ref. 2.

males (54%) and females (13). Patients who received a diagnosis of CF at an older age tended to have more subtle clinical features, present with single-organ manifestations, have lower sweat chloride levels, and were more likely to be PS (73%) (13). Among patients who were diagnosed in adulthood between 1990 and 2001, the majority (39%) presented with pulmonary symptoms, whereas obstructive azoospermia (men) and pancreatitis accounted for 26% and 4% of the population, respectively (13). Pulmonary symptoms at the time of diagnosis may include chronic productive or nonproductive cough, recurrent airway infections requiring antibiotics, dyspnea, hemoptysis, and wheezing (13). CF-associated pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus may be cultured from sputum in a large percentage of these individuals (13). Approximately 30% have normal chest radiographic findings and 50% had FEV1 >87% predicted (13). However, a number had well-established bronchopulmonary disease that progressed to pulmonary failure and premature death or a life-saving lung transplant (13,25). Gilljam et al. also observed that the smaller number of individuals diagnosed with PI-CF at an older age were likely to have concurrently severe pulmonary disease. Among adolescents and adults who have sufficient pancreatic function at presentation, pancreatitis may be the primary manifestation of CF disease (26). Severe CF-related liver disease, as defined by the development of cirrhosis with or without portal hypertension, is a very uncommon presentation in those diagnosed de novo in adolescence and adulthood (13,27), due largely to the fact that the most of CF patients with severe liver disease have established cirrhosis before the age of 15 (28).

B. CFTR-Related Diseases

Adolescents and adults with a CF phenotype in one or more CF-affected organs carry a much higher frequency of CFTR gene mutations than the general population (5,7,16). These include men with infertility due to obstructive azoospermia due to bilateral absence of the vas deferens (5,7,17), patients with idiopathic recurrent acute and chronic pancreatitis (13,18,19), and a variety of chronic sinopulmonary disorders including chronic rhinosinusitis and bronchiectasis (13,20–22). There is currently insufficient evidence to support a strong association between diseases such as asthma, allergic bronchopulmonary aspergillosis, and primary sclerosing cholangitis with mutation(s) in the CFTR gene, such that, if there is a link, loss of CFTR function is likely to play only a small role in the pathogenesis of these complex genetic diseases (7,22). Of all the organs that are affected by reduced CFTR function, the male reproductive tract appears to be the most sensitive to very minor defects in function (29–34). This is most likely due to several factors, including the narrow lumen, length, and

Diagnostic Approach to Diseases Associated with CFTR Gene Mutations

109

Table 2 Diagnosis of CF in Patients with CBAVD or Idiopathic Pancreatitis by Disease-Causing

Mutations, Sweat Chloride, and NPD Group

n

Two CF diseasecausing mutations, n (%)

Sweat chloride > 60 mmol/ L, n (%)

NPD DCl Any test, -free þ Iso n (%) < 7.65 mV, n (%)

All CBAVD CBAVD with no CFTR mutation CBAVD with 1 CFTR mutation CBAVD with 2 CFTR mutations All pancreatitis Pancreatitis with no CFTR mutation Pancreatitis with 1 CFTR mutation Pancreatitis with 2 CFTR mutations

60 6 18 36 56 32 18 6

2 0 0 2 2 0 0 2

17 (28) 0 (0) 6 (33) 11 (31) 5/54 (9) 0/30 (0) 3/18 (17) 2/6 (33)

26 (43) 0 (0) 7 (39) 19 (53) 9/42 (21) 2/23 (9) 4/14 (29) 3/5 (60)

(3) (0) (0) (6) (4) (0) (0) (33)

34 (57) 0 (0) 10 (56) 24 (67) 12 (21) 2/32 (6) 6/18 (33) 4/6 (66)

CF disease-causing mutations according to the 1998 consensus statement on the diagnosis of CF. Chloride-free and isoproterenol-stimulated chloride diffusion potential on the nasal epithelium (DCl -free þ Iso) 50 years) and compared them with a cohort of established CF patients with PI (aged 15–41 years) (51). In children aged 5 to 9 years, the upper limit (97.5th percentile) of the reference interval for sweat chloride concentration was 39.5 mmol/L, which is remarkably consistent with

Diagnostic Approach to Diseases Associated with CFTR Gene Mutations

111

those used to exclude CF (i.e., T 1717  1G > A 1898 þ 1G > A 2184delA

2789 þ 5G > A 3120 þ 1G > A 3659delC 3849 þ 10kbC > T

Abbreviation: CF, cystic fibrosis. Source: Adapted from Ref. 3.

intron splice sites (3,4). While a limited number of additional CFTR mutations may fulfill the strict criteria as accepted CF-causing mutations, the majority do not (4). Additional molecular factors contribute to difficulties in interpreting the clinical consequences of CFTR mutations. For example, variable penetrance of the R117H mutation in the CFTR gene is dependent on the length of the polythymidine tract in intron 8 (IVS8-5T, 7T, and 9T) which have a major effect on the splicing efficiency. The R117H-5T, which is associated with poor splicing efficiency, is common in CF patients with pancreatic sufficiency, but can also be seen in subjects with a CFTR-related disorder. The variable penetrance is partially explained by the influence of the number of TG repeat adjacent to the 5T tract (66). R117H in cis with 7T, which has intermediate levels of splicing efficiency, is more frequent among individuals with CFTR-related disorders such as CBAVD and pancreatitis. The 9T allele is most efficient and associated with normal levels of CFTR protein. Also, some mutations can exist as complex alleles. The missense mutation I148T was initially identified as a severe CF-causing allele based on genotype-phenotype associations. In vitro evidence suggests that, despite normal chloride transport function, I148T-CFTR has aberrant function with regards to regulation of bicarbonate transport (67) and regulation of the epithelial sodium channel (68). However, subsequently a disease-causing deletion 3199del6 in exon 20, which cosegregates in 1% of all I148T CFTR genes in the general Caucasian population, is now considered to be the underlying disease-causing mutation in most CF patients carrying the I148T CFTR mutation (69,70). Consequently, the recent ECFS consensus report currently considered I148T alone as a neutral mutation with no clinical consequence (4). Furthermore, the American College of Medical Genetics have recommended removing I148T from the list of mutations recommended for screening in CF carrier testing (71). The difficulties with interpreting and predicting the clinical consequences of IVS8 variants and complex alleles provide further evidence that mere identification of changes in the CFTR gene is insufficient to diagnose CF and that correlations with clinical phenotype and ICMs are necessary. In older patients with a suspected, but unproven diagnosis of CF, complete sequencing of the CFTR gene appears to be least sensitive and specific than carefully performed sweat chloride testing (5,16). CF mutation screening panels usually include only the more common disease-causing mutations associated with childhood onset of CF. Patients presenting in adolescence and adulthood and/or those who present with monosymptomatic diseases in CF-affected organs frequently carry one or more rare CFTR gene mutations, which are often not included in most screening panels. While many of these rare mutations may be detected by complete sequencing of the CFTR

116

Ooi et al.

gene, the diagnosis often still remains unclear because the gene changes found may not be proven CF-causing mutations (3,4). On the basis of the stringent criteria for designating CF-causing mutations, CFTR genotyping alone carried the lowest diagnostic sensitivity. In a cohort of CF patients diagnosed in adulthood, only 33% fulfilled the diagnostic criteria of CF based on genotyping alone (13). When combined with sweat testing, the diagnostic sensitivity improved to 67% (13).

V. Clinical Assessment In cases of diagnostic uncertainty, referral should be made to a CF care center that can provide comprehensive clinical testing to help establish or exclude the diagnosis of CF disease or CFTR-related disorder. The role of additional testing is to accurately define the phenotype and its severity, exclude other diseases, and identify ion channel abnormalities through alternative method(s). Depending on the nature of the clinical presentation, more detailed assessment of affected organ systems is necessary. For example, patients with pulmonary symptoms should be referred for pulmonary function testing, chest imaging (which may include computed tomography of the chest), and testing to exclude conditions such as immunodeficiency states and primary ciliary dyskinesia. It is valuable to clarify the presence of CF-associated pathogens in the respiratory tract from a clinical care perspective, although the presence of these pathogens is neither sensitive nor specific for the diagnosis of CF. It is similarly important to assess the exocrine pancreas through imaging and pancreatic function testing, and to assess males for evidence of obstructive azoospermia. The degree of exocrine pancreatic dysfunction is difficult to assess due to relative inaccessibility of its secretions. The exocrine pancreas also has a large reserve capacity and requires between 90% and 99% of enzyme secretory capacity to be lost before a subject develops clinical manifestations of PI. The direct pancreatic stimulation test is considered the gold standard of pancreatic function tests and allows assessment of both pancreatic acinar (enzyme) and ductular (electrolyte and fluid) status. However, there is no standardized methodology for direct pancreatic stimulation testing, and various techniques are used throughout the world. If not done accurately, measurements and diagnosis of exocrine pancreatic status based on pancreatic stimulation testing warrants careful interpretation and can be misleading. The quantitative pancreatic stimulation test technique that uses perfusion markers with multiple sampling periods is sensitive, highly specific, and capable of evaluating the entire range of pancreatic function (72). With the marker perfusion technique, a double lumen catheter is inserted under fluoroscopic guidance into the duodenum with a proximal lumen positioned at the ampulla of Vater and the other lumen positioned distally in proximity to the ligament of Treitz. Through the proximal opening, a nonabsorbable marker solution is infused into the duodenum throughout the test. Pancreatic juice mixed with infused marker solution is aspirated distally over a timed sampling period while continuously infusing secretin/cholecystokinin. A separate nasogastric tube is placed to aspirate gastric juice and prevent contamination of duodenal contents. The marker perfusion technique offers an ability to quantify recovery of pancreatic secretions and, therefore, allows accurate quantification of pancreatic acinar and ductular secretions. This technique is regarded as the true gold standard in direct pancreatic

Diagnostic Approach to Diseases Associated with CFTR Gene Mutations

117

stimulation testing. Nevertheless, this test is time consuming, technically complex to perform and not routinely available. Consequently, alternative and simpler direct pancreatic stimulation techniques (nonquantitative) are used at many clinical centers. These generally utilize a singlelumen duodenal tube or endoscope to aspirate duodenal pancreatic secretions as a spot sample and/or over a timed sampling period (73–76). Despite their popularity, we do not recommend the use of nonquantitative techniques, because they are predicted to have a high false-positive rate for misdiagnosing PI and have not been proven superior over noninvasive indirect pancreatic function tests. In fact, Schibli et al. demonstrated that among PS patients with a secretory capacity between the threshold of PI and the lower limit of normal, these techniques carry the greatest risk of misclassifying a PS patient as PI (77). Currently, noninvasive pancreatic function tests are routinely utilized for defining the CF pancreatic phenotype. The 72-hour fecal fat balance test, expressed as the coefficient of fat absorption (CFA), is considered as the gold standard as far as noninvasive tests are concerned. However, this test is inconvenient and not well accepted by patients or laboratory personnel. Fecal elastase is considered an ideal indirect stool marker of pancreatic function because elastase, an endogenous pancreatic secretion enzyme, is resistant to degradation within the gastrointestinal tract. Previous studies have found it to be a good measure of exocrine pancreatic function. Using a cutoff of 200 mg/g stool, the sensitivity was 63% for mild, 100% for moderate, 100% for severe, and 93% for all patients with exocrine pancreatic insufficiency, and specificity was 93% (78). In another study, which compared fecal elastase and 72-hour fecal fat balance studies in children with CF and non-CF pancreatic disease (PI and PS) as well as disease controls with documented steatorrhea due to nonpancreatic causes, it was found that fecal elastase values below 100 mg/g stool were highly indicative of pancreatic insufficiency, when compared with the 72-hour fecal fat (79). Serum trypsinogen have been used for newborn screening for more than two decades (80) and shown to help define pancreatic functional status (after the age of 7 years) and predict the progression of pancreatic status from PS to PI (81). Serum trypsinogen is also capable of identifying presence of pancreatic disease and pancreatic dysfunction (loss of pancreatic reserve or pancreatitis) in individuals with a CFTRrelated disorder. For example, serum trypsinogen levels may be elevated in patients with CF-like phenotype providing evidence of pancreatic disease, while levels will be low in patients with chronic pancreatitis due to a loss of pancreatic reserve. Despite exocrine pancreatic insufficiency being uncommon in this population of patients, imaging of the pancreas and testing of exocrine pancreatic function may be helpful for diagnostic and therapeutic purposes. However, the finding of PI alone is not diagnostic of CF even in patients who have intermediate sweat chloride values, considering the substantial test and biologic variability in sweat chloride values among normal healthy individuals (51). PI due to chronic pancreatitis unrelated to CF and inherited conditions such as Shwachman–Diamond syndrome, which may also be associated with recurrent respiratory infections, should still be considered (82). Individuals who are PS at presentation need to be assessed periodically or when new symptoms suggestive of PI develop, as some may progress to PI (13). All male patients should be assessed by semen analysis for evidence of obstructive azoospermia. Referral to an experienced urologist for full assessment and careful

118

Ooi et al.

physical examination of the genital tract and transrectal ultrasound may be warranted. Because of the high prevalence of CFTR mutations in men with obstructive azoospermia, affected men and their partners require comprehensive assessment and genetic counseling if assisted reproductive technology is being considered.

VI.

Recommended Approach to Management

There is clear evidence that, following comprehensive assessment, the diagnosis of CF disease will remain uncertain in a significant subset of patients who present with a CF phenotype. We strongly recommend that this uncertainty should be communicated to affected individuals, and the rationale and plan for appropriate follow-up discussed. The inability to confirm a diagnosis of CF in patients with CFTR-related disorders should not exclude them from periodic monitoring as they may be at risk of developing significant disease in CF-affected organs, and early treatment may improve quality of life and longterm outcome (especially in those with pulmonary disease). Over time, further evaluation may confirm a CF diagnosis in some of these individuals, especially infants with an uncertain diagnosis of CF following a positive newborn screening process. Ultimately, the decision to treat an individual should be based on clinical indication(s) rather than the diagnostic label used, assuming alternative diagnoses have been excluded. For instance, an individual with a CFTR-related disorder who has bronchiectasis and is chronically infected with P. aeruginosa would be more appropriately followed in a CF center and offered the same treatments that are available for CF patients with pulmonary disease.

VII.

Conclusion

The discovery of the CFTR gene has led to a significant expansion in knowledge of the wide range of phenotypes associated with CFTR dysfunction. A significant number of individuals who have diseases associated with CFTR mutations that confer partial loss of function typically present in adolescence and adulthood, usually with single-organ manifestations of CF. Many of these subjects do not meet the current diagnostic criteria for CF disease. There are limitations in the traditional diagnostic tests, and the diagnosis of CF cannot simply be made based on the presence of two CFTR mutations. CFTR genotyping alone functions poorly as a diagnostic test especially in the setting of an uncertain diagnosis of CF or CFTR-related disorder. Although sweat chloride testing effectively diagnoses CF patients with the severe PI phenotype, it has limited ability to establish or exclude a diagnosis of CF in PS patients and those with CFTR-related disorders. While NPD and possibly intestinal ICM testing appear to be superior to sweat testing as a diagnostic measure, they still lack the basic and fundamental requirements needed for proper use outside a research setting and remain to be adequately standardized and validated as diagnostic tools. Nevertheless, we expect that there would be ongoing challenges and diagnostic dilemmas related to diseases associated with CFTR mutations, even in the presence of a well-validated, highly sensitive and specific test, due to the continuous spectrum of disorders associated with CFTR mutations and the contributory effects of various modifier genes and environmental factors on the clinical phenotype. Consequently, it is important and reasonable for this uncertainty to be conveyed to affected individuals. Referral to a tertiary CF center for further assessment is

Diagnostic Approach to Diseases Associated with CFTR Gene Mutations

119

recommended, and periodic reassessment may be necessary. In selected cases, especially among those with pulmonary disease and pancreatic disease, follow-up and treatment may be best provided in the setting of a CF center, even if the diagnostic criteria for CF cannot be fulfilled.

References 1. Knowles MR, Durie PR. What is cystic fibrosis? N Engl J Med 2002; 347:439–442. 2. Cystic Fibrosis Mutation Database. Available at: http://www.genet.sickkids.on.ca/cftr. 3. Farrell PM, Rosenstein BJ, White TB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation Consensus Report. J Pediatr 2008; 153:S4–S14. 4. Castellani C, Cuppens H, Macek M Jr., et al. Consensus on the use and clinical interpretation of cystic fibrosis mutation analysis in clinical practice. J Cystic Fibrosis 2008; 7:179–196. 5. Wilschanski M, Dupuis A, Ellis L, et al. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med 2006; 174:787–794. 6. Tsui LC. The spectrum of cystic fibrosis mutations. Genet 1992; 8:392–398. 7. Wilschanski M, Durie PR. Patterns of gastrointestinal disease in adulthood associated with mutations in the CFTR gene. Gut 2007; 56:1153–1163. 8. Waters DL, Dorney SF, Gaskin KJ, et al. Pancreatic function in infants identified as having cystic fibrosis in a neonatal screening program. N Engl J Med 1990; 322(5):303–308. 9. Pall H, Zielenski J, Jonas MM, et al. Primary sclerosing cholangitis in childhood is associated with abnormalities in cystic fibrosis-mediated chloride channel function. J Pediatr 2007; 151:255–259. 10. Dorfman R, Sandford A, Taylor C, et al. Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest 2008; 118(3):1040–1049. 11. Drumm ML, Konstan MW, Schluchter MD, et al. Gene Modifier Study Group. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 2005; 353(14):1443–1453. 12. Narzi L, Ferraguti G, Stamato A, et al. Does cystic fibrosis neonatal screening detect atypical CF forms? Extended genetic characterization and 4-year clinical follow-up. Clin Genet 2007; 72:39–46. 13. Gilljam K, Ellis L, Corey M, et al. Clinical manifestations of cystic fibrosis among patients diagnosed in adulthood. Chest 2004; 126:1215–1224. 14. Welsh MJ, Ramsey BW, Accurso F, et al. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, et al. eds, The Metabolic and Molecular Basis of Inherited Disease. 8th ed. New York: McGraw-Hill, 2001:5121–5188. 15. Gaskin K, Gurwitz D, Durie PR, et al. Improved respiratory prognosis in cystic fibrosis patients with normal fat absorption. J Pediatr 1982; 100:857–862. 16. Bishop MD, Freedman SD, Zielenski J, et al. The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis. Hum Genet 2005; 118:372–381. 17. Jarvi K, Zielenski J, Wilschanski M, et al. Cystic fibrosis transmembrane regulator and obstructive azoospermia. Lancet 1995; 345:1578. 18. Cohn JA, Friedman KJ, Noone PG, et al. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 1998; 339:653–658. 19. Noone PG, Zhou Z, Silverman LM, et al. Cystic fibrosis gene mutations and pancreatitis risk: relation to epithelial ion transport and trypsin inhibitor gene mutations. Gastroenterol 2001; 121:1310–1319.

120

Ooi et al.

20. Wang X, Moylan B, Leopold DA, et al. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA 2000; 284:1814–1819. 21. Pignatti PF, Bombieri C, Marigo C, et al. Increased incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis. Hum Mol Genet 1995; 4:635–639. 22. Miller PW, Hamosh A, Macek M Jr., et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. Am J Hum Genet 1996; 59:45–51. 23. Shwachman H MA. Pilocarpine iontophoresis sweat testing results of seven years’ experience. In: Rossi E, Stoll E, eds. Modern Problems in Pediatrics. Basel/NY: S. Karger AG, 1967:158–182. 24. Carla C, Maria Chiara R, Laura Z, et al. Liver disease in cystic fibrosis. J Pediatr Gastroenterol Nutr 2006; 43:S49YS55. 25. Nick JA, Chacon C, Brayshaw S, et al. Diagnosis, patterns of care, and long-term survival in nonclassic cystic fibrosis. Pediatr Pulmonol 2008; 31(suppl):556 (abstr). 26. Durno C, Corey M, Zielenski J, et al. Genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis. Gastroenterology 2002; 123(6):1857–1864. 27. Greaves R, Patchett S, Empey D, et al. A 22-year old with jaundice and a bit of cough. Lancet 1997; 349:324. 28. Stonebraker JR, Friedman KJ, Ling SC, et al. Genetic modifiers of severe liver disease in cystic fibrosis: a replication study. Pediatr Pulmonol Suppl 2007; 30:381 (498). 29. Colin AA, Sawyer SM, Mickle JE, et al. Pulmonary function and clinical observations in men with congenital bilateral absence of the vas deferens. Chest 1996; 110(2):440–445. 30. Casals T, Bassas L, Egozcue S, et al. Heterogeneity for mutations in the CFTR gene and clinical correlations in patients with congenital absence of the vas deferens. Hum Reprod 2000; 15(7):1476–1483. 31. Attardo T, Vicari E, Mollica F, et al. Genetic, andrological and clinical characteristics of patients with congenital bilateral absence of the vas deferens. Int J Androl 2001; 24(2):73–79. 32. Mak V, Jarvi KA, Zielenski J, et al. Higher proportion of intact exon 9 CFTR mRNA in nasal epithelium compared with vas deferens. Hum Mol Genet 1997; 6(12):2099–2107. 33. Mak V, Zielenski J, Tsui LC, et al. Cystic fibrosis gene mutations and infertile men with primary testicular failure. Hum Reprod 2000; 15(2):436–439. 34. Gilljam M, Moltyaner Y, Downey GP, et al. Airway inflammation and infection in congenital bilateral absence of the vas deferens. Am J Respir Crit Care Med 2004; 169(2):174–179. 35. Carlin RW, Quesnell RR, Zheng L, et al. Functional and molecular evidence for Na(þ)-HCO cotransporter in porcine vas deferens epithelia. Am J Physiol Cell Physiol 2002; 283(4): C1033–C1044. 36. Anguiano A, Oates RD, Amos JA, et al. Congenital bilateral absence of the vas deferens. A primarily genital form of cystic fibrosis. JAMA 1992; 267(13):1794–1797. 37. Sharer N, Schwarz M, Malone G, et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 1998; 339(10):645–652. 38. Weiss FU, Simon P, Bogdanova N, et al. Complete cystic fibrosis transmembrane conductance regulator gene sequencing in patients with idiopathic chronic pancreatitis and controls. Gut 2005; 54(10):1456–1460. 39. Frulloni L, Scattolini C, Graziani R, et al. Clinical and radiological outcome of patients suffering from chronic pancreatitis associated with gene mutations. Pancreas 2008; 37(4):371–376. 40. Pignatti PF, Bombieri C, Benetazzo M, et al. CFTR gene variant IVS8-5T in disseminated bronchiectasis. Am J Hum Genet 1996; 58(4):889–892.

Diagnostic Approach to Diseases Associated with CFTR Gene Mutations

121

41. Girodon E, Cazeneuve C, Lebargy F, et al. CFTR gene mutations in adults with disseminated bronchiectasis. Eur J Hum Genet 1997; 5(3):149–155. 42. Bombieri C, Benetazzo M, Saccomani A, et al. Complete mutational screening of the CFTR gene in 120 patients with pulmonary disease. Hum Genet 1998; 103(6):718–722. 43. Ziedalski TM, Kao PN, Henig NR, et al. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. Chest 2006; 130(4):995–1002. 44. Divac A, Nikolic A, Mitic-Milikic M, et al. CFTR mutations and polymorphisms in adults with disseminated bronchiectasis: a controversial issue. Thorax 2005; 60(1):85. 45. De Boeck K, Wilschanski M, Castellani C, et al. Diagnostic Working Group. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006; 61(7):627–635. 46. Di Sant’Agnese PA, Darling RC, Perera GA, et al. Sweat electrolyte disturbances associated with childhood pancreatic disease. Am J Med 1953; 15:777–783. 47. Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959; 23:545–549. 48. Cystic Fibrosis Foundation. “GAP” Conference Reports. Problems in Sweat Testing. Atlanta, February 6–7, 1975. 49. Shwachman H, Mahmoodian A. Pilocarpine iontophoresis sweat testing results of seven years’ experience. In: Rossi E, Stoll E, eds. Modern Problems in Pediatrics. Basel/NY: S. Karger AG, 1967:158–182. 50. Mishra A, Greaves R, Massie J. The limitations of sweat electrolyte reference intervals for the diagnosis of cystic fibrosis: a systematic review. Clin Biochem Rev 2007; 28:60–76. 51. Mishra A, Greaves R, Smith K, et al. Diagnosis of cystic fibrosis by sweat testing: agespecific reference intervals. J Pediatr 2008; 153(6):758–763. 52. Ellis L, Tullis E, Corey M, et al. R117H (7T) can be associated with a CF diagnosis. Pediatr Pulmonol 2002; S24:228. 53. Highsmith WE, Burch LH, Zhou Z, et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 1994; 331:974–980. 54. Stewart B, Zabner J, Shuber AP, et al. Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis. Am J Respir Crit Care Med 1995; 151:899–903. 55. Desmarquest P, Feldmann D, Tamalat A, et al. Genotype analysis and phenotypic manifestations of children with intermediate sweat chloride test results. Chest 2000; 118:1591–1597. 56. Schu¨ler D, Sermet-Gaudelus I, Wilschanski M, et al. Basic protocol for transepithelial nasal potential difference measurements. J Cyst Fibros 2004; 3 (suppl 2):151–155. 57. Wilson DC, Ellis L, Zielenski J, et al. Uncertainty in the diagnosis of cystic fibrosis: possible role of in vivo nasal potential difference measurements. J Pediatr 1998; 132:596–599. 58. Cantin AM, Hanrahan JW, Bilodeau G, et al. Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med 2006; 173:1139–1144. 59. Hirtz S, Gonska T, Seydewitz HH, et al. CFTR Cl- channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. Gastroenterol 2004; 127(4):1085–1095. 60. Veeze HJ, Halley DJ, Bijman J, et al. Determinants of mild clinical symptoms in cystic fibrosis patients. Residual chloride secretion measured in rectal biopsies in relation to the genotype. J Clin Invest 1994; 93(2):461–466. 61. Veeze HJ, Sinaasappel M, Bijman J, et al. Ion transport abnormalities in rectal suction biopsies from children with cystic fibrosis. Gastroenterol 1991; 101(2):398–403. 62. Mall M, Hirtz S, Gonska T, et al. Assessment of CFTR function in rectal biopsies for the diagnosis of cystic fibrosis. J Cyst Fibros 2004; 3(suppl 2):165–169.

122

Ooi et al.

63. De Jonge HR, Ballmann M, Veeze H, et al. Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers. J Cyst Fibros 2004; 3(suppl 2):159–163. 64. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245:1066–1073. 65. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245:1059–1065. 66. Groman JD, Hefferon TW, Casals T, et al. Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet 2004; 74(1):176–179. 67. Choi JY, Muallem D, Kiselyov K, et al. Aberrant CFTR-dependent HCO3- transport in mutations associated with cystic fibrosis. Nature 2001; 410(6824):94–97. 68. Suaud L, Yan W, Rubenstein RC. Abnormal regulatory interactions of I148T-CFTR and the epithelial Naþ channel in Xenopus oocytes. Am J Physiol Cell Physiol 2007; 292(1): C603–C611. 69. Rohlfs EM, Zhou Z, Sugarman EA, et al. The I148T CFTR allele occurs on multiple haplotypes: a complex allele is associated with cystic fibrosis. Genet Med 2002; 4(5):319–323. 70. Monaghan KG, Highsmith WE, Amos J, et al. Genotype-phenotype correlation and frequency of the 3199del6 cystic fibrosis mutation among I148T carriers: results from a collaborative study. Genet Med 2004; 6(5):421–425. 71. GrodyWW, Cutting GR, KlingerKW, et al. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med 2001; 3:149–154. 72. Gaskin KJ, Durie PR, Lee L, et al. Colipase and lipase secretion in childhood-onset pancreatic insufficiency. Delineation of patients with steatorrhea secondary to relative colipase deficiency. Gastroenterology 1984; 86:1–7. 73. Madrazo-de la Garza JA, Gotthold M, Lu RB, et al. A new direct pancreatic function test in pediatrics. J Pediatr Gastroenterol Nutr 1991; 12(3):356–360. 74. Del Rosario MA, Fitzgerald JF, Gupta SK, et al. Direct measurement of pancreatic enzymes after stimulation with secretin versus secretin plus cholecystokinin. J Pediatr Gastroenterol Nutr 2000; 31(1):28–32. 75. Conwell DL, Zuccaro G, Morrow JB, et al. Cholecystokinin-stimulated peak lipase concentration in duodenal drainage fluid: a new pancreatic function test. Am J Gastroenterol 2002; 97(6):1392–1397. 76. Conwell DL, Zuccaro G Jr., Vargo JJ, et al. An endoscopic pancreatic function test with synthetic porcine secretin for the evaluation of chronic abdominal pain and suspected chronic pancreatitis. Gastrointest Endosc 2003; 57(1):37–40. 77. Schibli S, Corey M, Gaskin KJ, et al. Towards the ideal quantitative pancreatic function test: analysis of test variables that influence validity. Clin Gastroenterol Hepatol 2006; 4(1):90–97. 78. Loser C, Mollgaard A, Folsch UR. Faecal elastase 1: a novel, highly sensitive and specific tubeless pancreatic function test. Gut 1996; 39:580–586. 79. Beharry S, Ellis L, Corey M, et al. How useful is fecal pancreatic elastase 1 as a marker of exocrine pancreatic disease? J Pediatr 2002; 141:84–90. 80. Wilcken B, Wiley V, Sherry G, et al. Neonatal screening for cystic fibrosis: a comparison of two strategies for case detection in 1.2 million babies. J Pediatr 1995; 127:965–970. 81. Couper RTL, Corey M, Durie PR, et al. Longitudinal evaluation of serum trypsinogen measurement in pancreatic-insufficient and pancreatic sufficient patients with cystic fibrosis. J Pediatr 1995; 127:408–413. 82. Cipolli M, D’Orazio C, Delmarco A, et al. Shwachman’s syndrome: pathomorphosis and long-term outcome. J Pediatr Gastroenterol Nutr 1999; 29(3):265–272.

9 Lung Function Testing in Infants JESSICA E. PITTMAN and STEPHANIE D. DAVIS University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A.

I.

Introduction

Recent studies have confirmed that cystic fibrosis (CF) lung disease begins during infancy (1–3). Historically, a paucity of sensitive, repeatable physiologic techniques for evaluating early lung disease led to a lack of detection and recognition of the “silent” airway damage in CF (4,5). Considerable progress in infant pulmonary function testing (PFT) within the past 20 to 30 years has furthered the understanding of pulmonary physiology in infants and toddlers, thereby revealing previously hidden disease burden in the lungs of the youngest CF population (4–7). This chapter discusses the techniques currently available for measurement of lung function in infants, the particular challenges associated with these studies, and pertinent research findings utilizing physiologic measures in young children with CF.

II.

Challenges of Studying Infants

In infants with CF, evidence of airway inflammation, obstruction, and damage as severe as bronchiectasis has been found through bronchoscopic, physiologic, and radiologic studies (1–3), demonstrating that pulmonary disease begins at an early age. The widespread availability of newborn screening in the United States, Europe, and Australia has led to a decline in the age of CF diagnosis and may lead to an increased number of individuals diagnosed with CF prior to the presence of any respiratory symptoms (8). Several studies have shown evidence of airway disease in infants and young children with CF even in the absence of a history of respiratory symptoms (3,9,10). As a result, infancy is often a period of silent lung disease in children with CF, where an absence of clinical symptoms belies the underlying airway damage that is occurring (4). Measuring pulmonary function in infancy thus serves a vital role in the care of the CF patient. The ability to quantify pulmonary disease in infants with CF offers the potential for aggressive intervention before permanent airway damage has occurred, with possible improvement in CF morbidity and mortality. Obstacles faced when assessing lung function in infants are the following: (i) differences in respiratory physiology between infants and older children, (ii) the need for sedation secondary to infants’ inability to cooperate with study maneuvers, (iii) the considerable time and expertise required for study execution and interpretation, and (iv) limited reference data in healthy controls (4,7).

123

124

Pittman and Davis

Respiratory mechanics in infants are affected by preferential nasal breathing and increased chest wall compliance compared with older children and adults (7,11). Nasal resistance, which contributes up to 50% of the total airway resistance in infants, may effectively conceal subtle disease in the lower airways (7). The increased chest wall compliance of infants results in greater net inward-recoil forces of the respiratory system, which in turn leads to exhalation to a lower lung volume relative to total lung capacity (TLC) compared to older children. This subsequently contributes to collapse of peripheral airways and variability of functional residual capacity (FRC). In normal infants, this phenomenon is countered by dynamic elevation of the end-expiratory volume, which is accomplished by initiation of inspiration before reaching equilibration of outward elastic recoil of the chest wall and inward recoil of the lung (7,12). An increased respiratory rate in this age group promotes dynamic elevation of FRC. Another obstacle encountered when evaluating lung function in infants is the obvious lack of cooperation of these patients. Most of the testing performed in infants requires sedation, which adds an increased risk to any procedure, as well as increased personnel and monitoring demands (7). Sedation may also alter airway mechanics by impairing diaphragmatic tone, which is important to the normal, dynamic elevation of end-expiratory volumes in infants (7,13). PFT in infants requires significant expertise on the part of the physician, respiratory therapist, and/or lung function technician. These tests demand technical proficiency, specialized equipment, and a comprehensive understanding of infant pulmonary physiology (14–16). Dedicated personnel are necessary to ensure appropriate testing technique and accurate study interpretation. As such, infant PFT methods are predominantly limited to large tertiary care centers (4,5). Finally, the lack of comprehensive normal reference data for infant PFT, due to, in large part, the ethical issues raised by the prospect of sedating healthy infants (4), is a major challenge. The majority of reference equations available are from small, singlecenter trials, bringing into question the generalizability of reference ranges among different patient populations and between pulmonary function laboratories (4,17–19). Many single-center studies circumvent this issue by including healthy controls as a comparison group (20–22); however, lack of standardized reference equations and normal values is an obvious hindrance to multicenter studies and to the use of infant PFT in clinical practice. The dearth of normal values and of longitudinal data also raises the question of prognostic importance of infant PFT. While airway disease has clearly been demonstrated when comparing infants with CF to healthy controls, to date only one study has investigated how findings on infant PFTs translate into the preschool years (3), and it remains to be seen how these changes will progress and translate to adult-type spirometric measures in later childhood.

III.

Pulmonary Manifestations of Cystic Fibrosis in Infancy

CF begins as an obstructive process in the distal airways caused by mucus plugging due to poor mucociliary clearance, chronic inflammation, and chronic or recurrent infection. These processes eventually lead to bronchial wall thickening and bronchiectasis, as well as obstructive lung disease eventually complicated by restriction. Though many infants with CF diagnosed by newborn screening are asymptomatic at the time of diagnosis, there is evidence that airways disease may be present even in infants with no respiratory

Lung Function Testing in Infants

125

symptoms (3,23,24). In these asymptomatic infants, early disease is likely heterogeneous and confined to small, peripheral airways, making these abnormalities difficult to detect (25). Inhomogeneity in the distribution of CF lung disease presents a challenge for accurate measurement of pulmonary function. Minor changes in an already small disease burden may be masked by the predominance of relatively normal (particularly more central) airways in young infants (6,7). Mucus plugging resulting in peripheral airway obstruction can actually lead to exclusion of those airways from sampling by some methods of infant lung function testing (7). Certain measurements of lung function in infants (e.g., resistance and compliance) are thought to more closely measure proximal airway caliber than small, distal airways, and this can lead to underestimation of disease in infants with predominantly peripheral airways involvement (11).

IV.

Techniques for Infant Pulmonary Function Testing

A. Preparing the Infant and Devices

Infant lung function testing typically requires oral sedation, usually using chloral hydrate. Because sedation imparts increased risk to the patient, appropriate safety measures must be taken, including pulse oximetry and heart rate monitoring, as well as having oxygen and bag-mask ventilation materials on standby (16,26). A minimum of two dedicated and trained personnel need to be present throughout the procedure to assure adequate data acquisition and close monitoring of the sedated child (26). Institutional sedation policies should direct NPO rules, sedation administration, and monitoring policies. To maximize the likelihood of inducing a sleep state, procedures should be scheduled at the child’s naptime whenever possible, and the infant should be sleepdeprived prior to the study (26,27). All forms of infant PFT require specialized devices, with particular attention paid to minimizing dead space to improve accuracy (14–16,28–32). Face masks are required for infants, as they are obligatory nasal breathers, and putty is typically fitted to the face mask to prevent leaks during measurements. Dead space attributed to the face mask must be accounted for, and should not exceed a maximum of 1 to 1.5 mL/kg (14,33). Resistance of the measuring device must also be minimized (34). These measures require a pneumotachometer calibrated over the appropriate flow range, and computers for data acquisition and analysis (14). In addition, for plethysmographic measures an infant body box is needed to calculate pressure-volume changes (14). Forced expiratory maneuvers require a “squeeze jacket” or vest fitted with an appropriately sized bladder, as well as a pressure reservoir for rapid inflation (16,35). For multiple-breath washout (MBW), a study gas mixture and method of gas analysis (mass spectrometry, ultrasound, or photoacoustic spectroscopy) are necessary (Table 1) (12,36). B. Plethysmography

Plethysmography measures thoracic gas volume (TGV) or FRC (also known as FRCpleth). The infant is placed in an airtight plethysmograph and observed during tidal breathing. Using the principles of Dubois and colleagues (41), TGV is determined on the basis of changes in plethysmograph and mouth (approximating alveolar) pressures during respiratory efforts against an airway typically occluded at end-inspiration (7,32). FRC can be calculated by subtracting the tidal volume at the time of occlusion from the measured

Raw, Crs

Occlusion techniques

V0 maxFRC

FRC

Plethysmography

Partial flow-volume curves

Indices measured

Technique

. Assumes respiratory system functions as a single compartment . May not detect early peripheral airway disease . Assumption that airway opening pressure is equal to alveolar pressure not valid in severe obstruction . Unstable FRC may lead to variability in V0 maxFRC measurements . Inhalation prior to reaching RV . May not achieve flow limitation . Measuring flows over small lung volumes

459 (38)

MOT: 283 SOT: 54 (6)

. Overestimation of FRC in severe obstruction . Expensive equipment

. Commercially available equipment . Measures gas in communicating and noncommunicating airways . Commercially available equipment . Simple, noninvasive

. Commercially available equipment . Uses tidal breathing

311 (19,37)

Disadvantages

No. of healthy infants studied

Advantages

Table 1 Summary of Infant Pulmonary Function Testing Techniques

Yes (38)

No

Yes (19,37)

Reference equations available

126 Pittman and Davis

FVC, FEV0.4, FEV0.5, FEV0.75, FEF25–75, FEF50, FEF75

FRC

LCI

RV, TLC, FRC/ TLC, RV/TLC

RVRTC

Gas dilution

Multiple-breath washout

Fractional lung volumes

Yes

22 (19)

Yes (37,40)

No

. May not measure noncommunicating (completely obstructed) airways . May underestimate gas trapping . No FDA approved device in the United States for use in infants . Requires inert gases . Minimal reference data . Minimal reference data . Requires RVRTC technique and plethysmography . Expensive equipment

Yes (17)

none

469 (21,36,37, 39)

. Requires active inflation . Requires extensive expertise and personnel . Expensive equipment

. Commercially available equipment . Simulates adult-type flowvolume curves . Achieves flow limitation . Measuring flows from a consistent lung volume . Full exhalation to RV is achieved . Requires only tidal breathing . No specialized study gas requirement (N2 washout) . Commercial equipment

. Requires only tidal breathing . LCI may be sensitive marker for early peripheral airways disease . Provides information on air trapping . Detection of restrictive lung disease

433 (16)

Disadvantages

Advantages

Reference equations available

Abbreviations: FRC, functional residual capacity (by plethysmography or gas dilution); Raw, airways resistance; Crs, respiratory system compliance; FVC, forced vital capacity; FEV, forced expiratory volume; TLC, total lung capacity; LCI, lung clearance index; FEF, forced expiratory flow; V0 maxFRC, maximal flow at functional residual capacity.

Indices measured

Technique

No. of healthy infants studied

Lung Function Testing in Infants 127

128

Pittman and Davis

TGV (7,32,34). Specific airways resistance (sRaw) can also be calculated via plethysmography as the relationship between change in volume of the plethysmograph (Vpleth) and change in the flow (32,34). C. Occlusion Techniques

During the occlusion techniques, the Herring–Breuer reflex helps elicit relaxation of the respiratory system (11,29). Airflow, pressure, and volume changes are measured at the mouth, and changes noted at the mouth are assumed to be in equilibrium with airways during the induced respiratory pause (11). The single-breath occlusion technique (SOT) is used to evaluate the resistance, compliance, and time constant of the respiratory system (Rrs, Crs, Trs), which are determined by the characteristics of the chest wall, airways, and lung parenchyma (11,29). During this maneuver, the airway is occluded at end-inspiration during tidal breathing. This induces a respiratory pause through the Herring–Breuer reflex, at which point the occlusion is released. Compliance (Crs) is calculated as the change in volume divided by the change in pressure (7,11,29). Resistance (Rrs) is equal to the change in pressure divided by the change in flow. The time constant (Trs) (change in volume divided by change in flow) is defined as the product of Crs and Rrs. Use of the SOT in children with significant obstructive lung disease is challenging both because of their increased respiratory rate and drive, leading to an inability to invoke the Herring–Breuer reflex, and because a respiratory system with significant disease cannot be described by a single time constant, violating one of the assumptions necessary for SOT measurements (7,11,29). Crs is also measured through the multiple occlusion technique (MOT), which allows assessment at several lung volumes. During this technique, occlusions occur at 10 or more different lung volumes above FRC. Airway opening pressure and volume are assessed with each occlusion; the slope of the resultant pressure-volume measurements is the Crs (11,29). D. Forced Expiratory Flows: Partial and Raised Volume Rapid Thoracoabdominal Compression

Forced expiratory flow measures employ the rapid thoracoabdominal compression technique (compression of the thoracic cage by a squeeze jacket containing an inflatable bladder) to mimic the forced exhalations used in adult-type spirometric maneuvers (7,27). The partial flow-volume technique relies on tidal breathing and measures maximal flow at FRC (V0 maxFRC). During tidal breathing, the jacket is inflated, “squeezing” the chest at the end-inspiratory point of a tidal breath to produce a forced exhalation. Jacket pressure is increased until maximal flow no longer increases, and V0 maxFRC is reported from the curves that are presumed to be flow limited (7,27). This technique has several limitations, including (i) variability of FRC during tidal breathing, which may lead to an unstable reference for V0 maxFRC, (ii) the possibility that flow limitation may not be achieved, (iii) measurement of flows over small lung volume ranges (vs. larger ranges with the raised volume technique), and (iv) inhalation before reaching residual volume secondary to lack of adequate control over the respiratory drive (no induction of the Herring–Breuer reflex) (4–6,42). The raised volume rapid thoracoabdominal compression (RVRTC) technique avoids problems of a changing FRC by passively inflating the infant’s lungs to a

Lung Function Testing in Infants

129

standard pressure (typically 30 cm H2O) and initiating forced exhalation from this elevated volume. First, repeated cycles of inflation and passive exhalation are performed, followed by inflation and forced exhalation elicited through rapid inflation of the jacket bladder (43). The initial cycles of inflation with passive exhalation ensure an adequate respiratory pause (via the Herring–Breuer reflex and/or modest reduction in PaCO2) prior to the forced exhalation maneuver. The absence of an inspiratory effort during the maneuver is critical to achieve full exhalation to residual volume (RV) (16,27). This maneuver mimics adult-type flow-volume curves, is reproducible, and flow limitation has been demonstrated through transesophageal pressure catheter measurements (4,16,44). Moreover, by combining RVRTC with plethysmography, fractional lung volume measurements can be obtained (4). For the RVRTC technique, forced vital capacity (FVC) is defined as the difference between the inflation volume at 30 cmH2O and residual volume. Forced expiratory volume at 0.5 seconds (FEV0.5) (volume exhaled in the first 0.5 seconds) is measured instead of FEV1 secondary to shorter exhalation times in young children; occasionally forced expiratory volume in 0.4 seconds (FEV0.4) or 0.75 seconds (FEV0.75) are reported (16). Forced expiratory flow is measured between 25% and 75% of FVC (FEF25–75), and diminished FEF25–75 may serve as an early marker of airways obstruction. Forced expiratory flows at 25%, 50%, 75%, and 85% of FVC (FEF25, FEF50, FEF75, FEF85) are less frequently reported, but also serve as measures of obstructive airway disease. By combining the RVRTC technique with plethysmography, TLC, RV, and RV/TLC can also be determined (Fig. 1) (4,16,19). E.

Gas Dilution Techniques: FRC Measures and Multiple-Breath Washout

FRC can also be determined in infants by helium dilution or via N2 washout. Helium dilution employs a rebreathing system (with bleeding in of O2 and removal of CO2) in which the patient breathes a known concentration of marker gas (helium) until gas concentrations in the study apparatus and infant lung have equilibrated. FRC is calculated using the change in helium concentration and the known volume of the spirometer or study apparatus (12). Bias flow nitrogen washout is performed by measuring exhaled N2 concentration while having an infant breathe 100% oxygen until exhaled N2 reaches a specified concentration. FRC is calculated from the amount of N2 expired (12). Multiple-breath washout (MBW) measures ventilation inhomogeneity utilizing diffusion of inert (marker) gases [N2, He, or sulfur hexafluoride (SF6)]. The measures most often reported from MBW studies are FRC and lung clearance index (LCI); LCI is a measure of the number of lung volume turnovers necessary to clear the marker gas to a specified concentration (12,46). The degree of inhomogeneity determined by the LCI is considered to be a sensitive indicator of obstructive lung disease. To measure ventilation inhomogeneity using a bias flow system, the subject inhales a study gas mixture with known concentration of inert gas (often 4% SF6) until inhaled and exhaled marker gas levels are equal (the washin phase). At this point, study gas flow is terminated and the patient breathes room air until the exhaled marker gas concentration reaches 1/40 of the level at the end of the washin phase (washout phase) (Fig. 2). The cumulative expired volume divided by the FRC defines the LCI; a higher LCI equates to a larger number of lung volume turnovers necessary to clear the lungs of marker gas, implying ventilation inhomogeneity (12,46,47).

130

Pittman and Davis

Figure 1 The RVRTC technique: (A) Sedated infant undergoing pulmonary function testing via

the RVRTC technique. (B) Schematic diagram of equipment for the RVRTC technique. The lungs of the infant are inflated to 30 cm H2O using a pop-off valve that is part of the circuit. After several cycles of inflation and passive exhalation through the open expiratory valve, the jacket bladder wrapped around the infant’s thoracic cavity is rapidly inflated via the pressure reservoir at end-inspiration, leading to a forceful exhalation. Abbreviation: RVRTC, raised volume rapid thoracoabdominal compression. Source: Part A from Ref. 4 and part B from Ref. 4.

Other, less frequently reported measures include moment ratios and concentration-normalized phase III slope analysis, which are less intuitive for interpretation, and, in the case of moment ratios, appear to be no more sensitive than LCI for detection of early obstructive disease (12); discussion of these indices is beyond the scope of this chapter.

Lung Function Testing in Infants

131

Figure 2 The multiple-breath washout technique: (A) During the washin phase, the subject inhales a gas mixture with a known concentration of inert marker gas via a bias flow setup until the exhaled and inhaled concentrations (as measured by the gas analyzer) are in equilibrium. (B) During the washout phase, study gas flow is terminated, and the subject breathes room air until the marker gas concentration has decreased to a predetermined cutoff point

V. Research Studies Employing Infant Pulmonary Function Testing A. Observational Studies

Abnormal lung function in infants with CF has been demonstrated using a variety of lung function testing techniques. Kraemer and colleagues showed diminished specific airway conductance (sGaw) in 26% of their infant cohort with CF evaluated using

132

Pittman and Davis

plethysmography (48). Beardsmore et al. showed a strong correlation between sGaw and physicians’ clinical score in CF infants, with those with more prominent symptoms having decreased airway conductance (49). Assessing respiratory system compliance (Crs) using deflation pressure-volume curves from an inflation pressure of 30 cmH2O, Tepper and colleagues found no difference between CF infants and healthy controls (50). In an earlier study, the same group found that CF infants with pulmonary symptoms and failure to thrive at diagnosis had significantly lower Crs (measured via a weighted spirometer technique) than normal controls or CF infants presenting with meconium ileus or isolated failure to thrive (20). The conflicting results between these two studies may be due to differences in Crs measurement techniques, since the weighted spirometer measurement is performed over a smaller range of lung volumes. As this data demonstrates, the effect of CF on airway conductance and elastic properties of the respiratory system in early childhood has yet to be fully elucidated. FRC measured via plethysmography has been shown to be significantly elevated in infants with CF compared with healthy controls (51,52), and an elevated TGV has been correlated with worsening clinical scores (49). Hiatt et al. demonstrated a significant correlation between lower respiratory tract infection and elevated FRC measured via helium dilution in CF infants (21). In addition, a different set of investigators found a significant elevation in FRC values when comparing CF infants to healthy controls (20). Together, these findings suggest that hyperinflation plays an important role in the early pathogenesis of CF lung disease. Many studies in the late 1980s and early 1990s focused on measurements of V0 maxFRC using forced expiratory flow measured from the tidal breath. In a crosssectional study of CF infants designed to investigate associations between symptoms at clinical presentation and lung function, V0 maxFRC was noted to be diminished in CF infants with respiratory symptoms and failure to thrive at presentation as compared with both healthy controls and CF infants presenting with either meconium ileus or failure to thrive (20). Baseline V0 maxFRC has also been demonstrated to be significantly diminished in CF infants compared with healthy controls at a mean age of 10 months, and this difference persisted after the completion of the respiratory viral season despite an equal number of upper respiratory tract illnesses reported in the two groups (CF infants were also more likely to have lower respiratory tract illnesses) (21). Two longitudinal studies of V0 maxFRC in the first year of life showed that diminished V0 maxFRC correlated both with respiratory symptoms at initial CF clinical presentation (53) and with respiratory severity score assigned by a clinician (49). Thus, decreased V0 maxFRC has been shown to be present in the youngest population with CF. The RVRTC technique has superseded the partial flow-volume technique for obtaining forced expiratory flows in infants because of high intra- and intersubject variability of V0 maxFRC (42) compared with flows obtained via the RVRTC technique, as well as the potential increased sensitivity of raised volume measures over those obtained over only the tidal range of breathing. As an illustration, Turner demonstrated that FEV0.5 and FEV0.75 as measured by the RVRTC technique were both significantly diminished in CF infants compared with healthy controls, while there was no significant difference in V0 maxFRC between the two groups (54). More recently, FEV0.5 was noted to be more sensitive at detecting airway disease in CF infants when compared with V0 maxFRC measures, with 13 of 47 CF infants having significantly diminished FEV0.5 values, while only one CF infant had a decreased V0 maxFRC value (55).

Lung Function Testing in Infants

133

Over the past 10 years, the RVRTC technique has been employed to better characterize the pulmonary disease burden in infants with CF. In 2001, a significant reduction in forced expiratory volume in 0.4 seconds (FEV0.4) and forced expiratory flow at 75% of forced vital capacity (FEF75) was demonstrated in infants with CF compared with healthy controls (10). Interestingly, this difference persisted when comparing only those CF infants with no recognized history of a lower respiratory illness to healthy controls (10), suggesting that airway damage from CF lung disease occurs “silently” in early childhood. In a 2004 study employing RVRTC soon after CF diagnosis with measures repeated six months later, the same group found significant reduction in mean FVC, FEV0.5, and FEF75 z-scores in CF subjects at the time of the first study (mean age 28 weeks), which persisted at the return visit (56). Strikingly, 41% of CF subjects had an FEV0.5 below the fifth percentile (z score below 1.64) at both study visits (56). Linnane and colleagues recently showed diminished FEV0.5 and FEF75 in infants with CF diagnosed by newborn screen compared with healthy controls, with differences becoming significant at six months of age (23). These results stress the significant disease burden present in the youngest CF population and also highlight a potential therapeutic window where preventative efforts may have maximal effect. Kozlowska and colleagues recently completed the first longitudinal study of lung function in children with CF in which repeated RVRTC measures (for infants) and incentive spirometry measures (for preschoolers) were performed. Forty-eight children with CF and 33 healthy controls had at least two lung function studies performed before age six. Subjects with CF showed a significant decline in FEV 0.75 and FEF25–75 over time compared with controls. Growth of Pseudomonas aeruginosa on respiratory culture was associated with a further significant decline in FEV0.75 and FEV1, as well as in FEV0.5 and FVC. Wheeze and cough were also associated with a greater decline in FEV0.5 and FEF25–75 (3). This landmark study not only confirms previously found differences in forced expiratory values between CF subjects and healthy controls, but also highlights the variability in the rate of decline of these measurements in CF subjects that may be due, in part, to infectious status, though contributions from genetic modifiers, environmental exposures, and nutrition may also play a role. The MBW technique has recently been evaluated in infants with CF. A 2007 study demonstrated similar sensitivities in identifying CF infants versus healthy controls when comparing the LCI measured by MBW with FEV0.5 and FEF25–75 measured by RVRTC. Over 70% of infants with CF had an abnormal LCI and/or abnormal forced expiratory values (41% had abnormal LCI, 41% had abnormal forced expiratory values, with some overlap). Fifteen percent of infants with CF had an abnormal LCI with normal forced expiratory values, and 15% had abnormal forced expiratory values with normal LCI (24). On the basis of this one published study, the two techniques appear to have similar sensitivity in infants; however, LCI has been shown to be more sensitive than FEV0.5 or FEV1 for identification of small airway disease in CF preschoolers and older children, respectively (57,58). Furthermore, the lack of overlap between the two measures in 30% of infant subjects suggests they may, in part, be assessing different aspects of CF lung disease. These studies show the presence of early physiologic abnormalities in infants with CF, even those who are asymptomatic or have been diagnosed by newborn screening (Table 2). These results emphasize the importance of further study in our youngest

Year

1988

1988

1993

Author

Observational Beardsmore (49)

Tepper (20)

Tepper (53)

AIM: Longitudinal evaluation of partial flow-volume curves, plethysmographic measures, and clinical score in first year of life. FINDINGS: Correlation was seen between all parameters and clinical score at time of initial testing and between sGaw and V0 maxFRC. AIM: Evaluation of CF infants presenting with meconium ileus (mec), failure to thrive (ftt), and pulmonary and FTT (comb) symptoms compared with healthy controls, by partial flow-volume curves, compliance, and He dilution. FINDINGS: CF subjects presenting with pulmonary and FTT symptoms had lower Crs and V0 maxFRC than other CF subjects and controls. AIM: Longitudinal evaluation of CF infants at presentation and 1 yr later, comparing those with and without respiratory symptoms (RESP) at presentation by partial flow-volume curves and He dilution. FINDINGS: At presentation, subjects with respiratory symptoms had lower V0 maxFRC than those without. V0 maxFRC had improved at 1 yr follow-up, but remained lower in the RESP group.

AIM and findings

Table 2 Summary of Selected Studies Involving Infant Pulmonary Function Testing in CF

Healthy

32 (14 RESP) (5.4 mo)a

25 [1 mo (mec), 4 mo (ftt), 5 mo (comb)]a

28 (5–57 wk) repeated in 17

33 (6 mo)a

(Age at initial evaluation)a,b

CF

Number of subjects

. V0 maxFRC . FRC

. V0 maxFRC . FRC . Crs

. sGaw . V0 maxFRC . TGV

Parameters

134 Pittman and Davis

Year

1994

1999

2000

2001

2001

Author

Turner (54)

Hiatt (21)

Kraemer (48)

Davis (22)

Ranganathan (10)

AIM: Comparison of infants with CF with and without previous respiratory illness vs. healthy controls by RVRTC. FINDINGS: FEV0.4 and FEF75 were diminished in infants with CF, with similar reductions in those with and without previous respiratory symptoms.

AIM: Comparison of asymptomatic infants with CF vs. historic healthy controls by RVRTC vs. partial flowvolume curves. FINDINGS: FEV0.5 and FEV0.75 were diminished in the CF group compared with controls. V0 maxFRC did not distinguish between the two groups. AIM: Comparison of CF infants vs. healthy controls preand postrespiratory viral season by partial flow-volume curves and He dilution. FINDINGS: V0 maxFRC was diminished in CF infants vs. healthy controls at baseline; the difference persisted after viral illness. Lower respiratory tract infection resulted in further diminished V0 maxFRC in CF infants. AIM: Longitudinal evaluation by plethysmography in first 2 years of life; correlation of lung function with genotype. FINDINGS: Only 19% of CF infants had normal lung function in the first year of life. Decline in SGaw from 6 to 12 mo of age. AIM: Comparison of CF infants vs. healthy controls by RVRTC breathing room air and heliox. FINDINGS: CF infants had lower FEF50 than controls. Density dependence comparisons and flows measured with heliox did not distinguish between CF and controls.

AIM and findings

Healthy

33 (24.5 wk)a

10 (4–21 mo)

80 (4.6 mo)a repeated in 50

22 (10 mo)a

12 (10 mo)b

V0 maxFRC FEV0.5 FEV0.75 FEV1

. TGV . sGaw

. V0 maxFRC . FRC

. . . .

Parameters

(continued)

21 . FVC (2–24 mo) . FEV0.5 . FEF50 . FEF75 . FEF25–75 . DD50 . DD75 87 . FEV0.4 (8 wk)b . FEF75

27 (10 mo)a

26 (14 mo)b

(Age at initial evaluation)a,b

CF

Number of subjects

Lung Function Testing in Infants 135

Year

2002

2004

2004

2004

Author

Ranganathan (55)

Castile (51)

Ranganathan (56)

Tepper (50)

AIM: Comparison of CF infants vs. healthy controls by RVRTC and partial flow-volume curves. FINDINGS: FEV0.5 was more sensitive for CF than V0 maxFRC (diminished in 13 of 47 and 1 of 47, respectively). RVRTC measures were diminished in CF infants with and without prior lower respiratory tract illnesses. AIM: Comparison of CF infants and healthy controls by RVRTC, plethysmographic FRC, nitrogen washout FRC, and fractional lung volumes FINDINGS: FEF50, FEF75, and FEF25–75 were significantly lower in CF infants vs. controls. RV, FRCpleth, and FRCnitrogen were higher in CF infants. No difference in trapped gas measurements between CF and control subjects. AIM: Longitudinal comparison of CF infants vs. healthy controls by RVRTC. FINDINGS: FVC, FEV0.5, and FEF75 were all diminished both soon after birth and 6 mo later in CF infants compared with controls. AIM: Comparison of respiratory system compliance measured using passive deflation pressure-volume curves and RVRTC in infants with CF vs. controls. FINDINGS: Subjects with CF had lower FEF50, FEF75, FEF25–75. No difference in Crs measured using static deflation pressure-volume curves from an elevated lung volume between CF and controls.

AIM and findings

Healthy

Crs FVC FEF50 FEF75 FEF25–75

. . . . . 10 (68 wk)a

34 (28 wk)a

RV TLC FRCpleth V0 maxFRC FRCnitrogen FEF50 FEF75 FEF25–75 FVC FEV0.5 FEF75

. . . . . . . . . . . 29 (79 wk)a

34 (51 wk)a

32 (7 wk)a

30 (66 wk)a

187 . FVC (1–100 wk) . FEV0.5 . FEF75 . FEF25–75 . V0 maxFRC

Parameters

47 (6–93 wk)

(Age at initial evaluation)a,b

CF

Number of subjects

Table 2 Summary of Selected Studies Involving Infant Pulmonary Function Testing in CF (Continued )

136 Pittman and Davis

2007

2008

Lum (24)

Kozlowska (3)

AIM: Comparison of MBW and RVRTC for evaluation of lung disease in CF vs. healthy controls. FINDINGS: CF subjects had elevated LCI and FRC and lower FVC, FEV0.5, FEF75, and FEF25–75 compared with controls. 72% of CF subjects had abnormal lung function (41% by both techniques, 15% by MBW or RVRTC alone). AIM: Longitudinal evaluation of CF infants vs. healthy controls in the first 6 yrs of life by RVRTC and preschool spirometry. FINDINGS: Subjects with CF had greater decline in FEV0.75 and FEF25–75 than controls. Those who grew Pseudomonas aeruginosa had reduced FVC, FEV0.5, and FEV0.75. Wheeze was associated with diminished FEV0.5, FEV0.75, and FEF25–75. Cough was associated with diminished FEV0.5 and FEF25–75.

AIM and findings

Correlation with other measures of pulmonary disease Rosenfeld (59) 2001 AIM: Correlation of partial flow-volume curves and FRC with BAL findings. FINDINGS: FRC lower at age 2 in subjects with no pathogen growth vs. those with growth. FRC higher and V0 maxFRC lower in those with Pseudomonas aeruginosa on BAL culture. Dakin (60) 2002 AIM: Correlation of single-breath occlusion and nitrogen washout with BAL findings. FINDINGS: Subjects with higher (>105 cfu/mL) pathogen burden on BAL had lower sCrs and higher FRC/TLC. Martinez (61) 2005 AIM: Correlation of HRCT findings and RVRTC in infants with CF. FINDINGS: Higher airway wall area:lumen area ratio (increased wall thickness) was associated with lower FEV0.5, FEF50, and FEF75.

Year

Author

Healthy

33 (0.2 yr)a

48 (0.6 yr)a

11 (17 mo)a

22 (23.2 mo)a

40 (3.9 mo)a (at diagnosis)

21 (37 wk)a

39 (41 wk)a

(Age at initial evaluation)a,b

CF

Number of subjects

FVC FEV0.5 FEV0.75 FEV1 FEF25–75

. . . . .

. . . . . . .

(continued)

sCrs sRrs FRC TLC FEV0.5 FEF50 FEF75

. V0 maxFRC . FRC

LCI FRC FVC FEV0.5 FEF75 FEF25–75

. . . . . .

Parameters

Lung Function Testing in Infants 137

2005

2008

2009

Nixon (62)

Linnane (23)

PetersonCarmichael (63)

AIM: Correlation of RVRTC and BAL findings. FINDINGS: Respiratory pathogen growth in BAL and daily cough were independently, additively associated with reduction in FEV0.5. AIM: Correlation of RVRTC and BAL in CF infants diagnosed by newborn screening. FINDINGS: Subjects with CF demonstrated a decline in FVC, FEV0.5, and FEF75 beginning at 6 mo of age. No association of RVRTC measures with BAL markers or culture results. AIM: Determine correlation of RVRTC and plethysmography with BAL findings in infants with CF undergoing an exacerbation. FINDINGS: Direct correlation between neutrophil percentage on BAL and FRC, RV/TLC, and FRC/TLC. Indirect correlation between neutrophil percentage and FEF75 and FEF25–75. Correlation between increased pathogen density and FRC (increased) and FEF75 and FEF25–75 (decreased).

AIM and findings

Therapeutic/interventional Hiatt (64) 1988 AIM: Determine responsiveness to inhaled bronchodilator in CF infants vs. healthy controls by partial flowvolume curves. FINDINGS: Infants with CF had lower V0 maxFRC at baseline than healthy controls. After inhaled metaproterenol, V0 maxFRC in CF infants was equivalent to healthy controls.

Year

Author

. FEV0.5 . FEV0.75 . FEV1

36 (17.8 mo)a

. V0 maxFRC

FRC FVC FEV0.5 FEF75 FEF25–75 RV TLC

. . . . . . . 16 (86 wk)b

28 (16 mo)a

FVC FEV0.5 FEF75 FEF25–75

. . . .

68 (59 wk)a repeated in 16

22 (13 mo)a

Parameters

Healthy

(Age at initial evaluation)a,b

CF

Number of subjects

Table 2 Summary of Selected Studies Involving Infant Pulmonary Function Testing in CF (Continued )

138 Pittman and Davis

Year

1989

1994

1997

1998

2003

Author

Kraemer (52)

Beardsmore (65)

Tepper (66)

Clayton (67)

Berge (45)

AIM: Investigation of plethysmography and response to oral bronchodilator. FINDINGS: 15 subjects with TGV > 130% predicted, 13 subjects with Raw >130% predicted. Raw, sGaw, and TGV improved with oral salbutamol. AIM: Comparison of plethysmographic measures and partial flow-volume curves in CF infants receiving antistaphylococcal antibiotic prophylaxis vs. those receiving episodic antibiotics with exacerbations. FINDINGS: No difference in measurements between group receiving prophylactic treatment and the group receiving antibiotics only with exacerbations. AIM: Randomized control trial of effect of IV hydrocortisone during pulmonary exacerbation on partial flow-volume curves and FRC measured via nitrogen washout. FINDINGS: V0 maxFRC significantly increased 1–2 mo after hospitalization in treatment (Rx) group. FRC slightly decreased in the treatment group and slightly increased in placebo group. AIM: Characterization of airway disease before and after hospitalization and treatment for pulmonary CF exacerbation. FINDINGS: V0 maxFRC, GL, and CL significantly increased after treatment for CF exacerbation. AIM: Pilot study investigating effect of 2 wk of inhaled DNase vs. normal saline on partial flow-volume curves in CF infants. FINDINGS: Significant increase in V0 maxFRC after 2 wk of inhaled DNase.

AIM and findings

. TGV . sGaw . V0 maxFRC

. FRC . V0 maxFRC

42 (16.4 wk)a

20 [8.8 mo (Rx), 9.5 mo (placebo)]a

9 (1.4 yr)a

(continued)

. V0 maxFRC

. V0 maxFRC . GL . CL

. TGV . Raw . sGaw

24 (2.8 mo)a

17 (15.1 mo)a

Parameters

Healthy

(Age at initial evaluation)a,b

CF

Number of subjects

Lung Function Testing in Infants 139

2007

2008

Subbarao (68)

Dellon (69)

AIM: Investigate safety and tolerability of inhaled 7% hypertonic saline in infants using RVRTC. FINDINGS: No significant change in FVC, FEV0.5, or FEF25–75 after bronchodilator or inhaled hypertonic saline. AIM: Investigate safety and tolerability of 3% and 7% inhaled hypertonic saline using RVRTC. FINDINGS: No change in FVC, FEV0.5, or FEF25–75 following administration of 3% or 7% inhaled hypertonic saline.

AIM and findings

6 (3%), 8 (7%) (1.6 yr)a

13 (81)a

(Age at initial evaluation)a,b

Healthy

. FVC . FEV0.5 . FEF25—75

. FVC . FEV0.5 . FEF25–75

Parameters

b

Mean age reported. If repeated studies, age is at time of first lung function testing. Median age reported. If repeated studies, age is at time of first lung function testing. Abbreviations: FRC, functional residual capacity (by plethysmography or gas dilution); FVC, forced vital capacity; FEV, forced expiratory volume; MOT, multiple occlusion technique; SOT, single occlusion technique; RV, residual volume; FDA, Food and Drug Administration; TLC, total lung capacity; LCI, lung clearance index; CF, cystic fibrosis; FEF, forced expiratory flow; RVRTC, raised volume rapid thoracoabdominal compression technique; BAL, bronchoalveolar lavage; CL, lung compliance, Crs, respiratory system compliance; V0 maxFRC, maximal flow at functional residual capacity.

a

Year

Author

CF

Number of subjects

Table 2 Summary of Selected Studies Involving Infant Pulmonary Function Testing in CF (Continued )

140 Pittman and Davis

Lung Function Testing in Infants

141

patients with CF to better delineate pulmonary disease burden and progression, as well as the need for investigations that determine risk factors for CF airway damage. B. Correlation with Other Measures of Pulmonary Disease

Measures of infant lung function in CF subjects have been shown to correlate with both structural airway disease seen on high-resolution chest computed tomography (CT) and markers of airway inflammation and infection on bronchoalveolar lavage (BAL). Rosenfeld and colleagues demonstrated that lower FRC was associated with a lack of respiratory pathogen growth as assessed through BAL in two-year-old subjects with CF; FRC was significantly elevated and V0 maxFRC significantly diminished in subjects with a history of P. aeruginosa on BAL fluid culture (59). Diminished specific compliance of the respiratory system (sCrs, or Crs normalized for FRC) has been associated with greater infectious burden (>105 colony-forming units/mL) on BAL (60). Recently, Linnane et al. found no significant association between forced expiratory measures (RVRTC) and either inflammatory markers or culture results on BAL (23). This is in contrast to the findings of Peterson-Carmichael and colleagues, who demonstrated a direct correlation between neutrophil percentage on BAL and FRC, RV/TLC, and FRC/TLC, as well as an inverse correlation with FEF75 and FEF25–75 in subjects experiencing an acute pulmonary exacerbation (63). Though this group did not find a difference in lung function parameters between those with and without infection as determined by BAL, they did note an association between increased pathogen density on BAL and higher FRC, lower FEF75, and lower FEF25–75 (63). The variability of these results may be due to differences in disease burden between the two study populations (baseline vs. pulmonary exacerbation), but also implies that we have yet to definitively answer the question of association between lung function measures and infectious or inflammatory burden as determined by BAL (Table 2). High-resolution chest CT has been shown to correlate both with lung function testing (MBW and spirometry) in older children with CF (57) and with disease burden measured by BAL in CF infants (2); however, limited studies have been done comparing CT and lung function measures in CF infants. Martinez and colleagues compared forced expiratory flows (by RVRTC) and CT findings in 11 infants with CF aged 8 to 33 months. They found a significant negative correlation between the ratio of wall area to lumen area and FEV0.5, FEF50, and FEF75 (61). Thus, airway wall thickening appears to be associated with increased airway obstruction in infants with CF. C. Interventional Studies

There are relatively few interventional studies in infants employing lung function testing as an outcome measure. The lack of studies is likely due to the inherent institutional difficulties involved in studying infants, the technical expertise required for proper use of these techniques, the relatively new development of reliable commercial equipment to perform the techniques (such as RVRTC), and the large sample size requirement for such studies necessitating a multicenter collaboration. Tepper et al. performed a randomized control trial investigating the effect of 10 days of hydrocortisone versus placebo in 20 infants hospitalized with CF exacerbations. Results demonstrated that, while there was no difference between the two groups 10 days into treatment based on lung function measures, the steroid group had significantly increased V0 maxFRC at the one- to two-month follow-up compared with the

142

Pittman and Davis

placebo group (66). FRC was noted to have decreased slightly in the treatment group and increased slightly in the placebo group at follow-up, though this finding did not reach statistical significance. The authors suggested that intravenous steroid therapy during an acute exacerbation may diminish airway obstruction and air trapping. Clayton and colleagues assessed change in lung function following hospitalization and antibiotic therapy for CF exacerbation in a cohort of 17 infants and toddlers with CF. They demonstrated a significant improvement in V0 maxFRC following treatment, with those subjects with the most diminished lung function values at study initiation showing the greatest improvement in airway obstruction (67). Lung compliance (CL) and lung conductance (GL), as measured by esophageal balloon catheters, also improved following therapy (67). In a similar study employing RVRTC, investigators found statistically significant improvements in FEF25, FEF50, FEF75, FEF85, FEF25–75, V0 maxFRC, FVC, FRC, and RV/TLC in 44 CF infants compared before and after a mean of 13 days of antibiotic therapy for pulmonary exacerbation (70). Two groups have recently published tolerability studies of inhaled 3% and 7% hypertonic saline in a total of 25 children under three years of age with CF (68,69). Both centers performed RVRTC maneuvers postbronchodilator and repeated the measures post hypertonic saline. One of the groups also performed the RVRTC maneuvers prior to any inhaled therapies (68,69). Results from both studies showed no significant change in FEV0.5 or FEF25–75 post 3% or 7% hypertonic saline. The authors of both studies concluded that inhaled hypertonic saline was acutely well tolerated in infants with CF. These studies show that the RVRTC technique may be used to generate outcome measures both for short-term and long-term interventional trials in infants with CF (Table 2).

VI.

Clinical Uses

The role of PFT in the clinical management of infants with CF has yet to be determined. Many CF centers perform physiologic measures as a clinical tool in infants and toddlers with CF on an annual or semiannual basis, though this has not yet been adopted as standard of care. On the basis of our experience and recently published data (71), it appears that results of lung function testing may influence clinical decision making in the care of infants and toddlers with CF. There is no commercially available, FDA-approved device for performing multiple-breath washout maneuvers in infants in the United States. Though available in Europe, MBW is, much like RVRTC, limited to large tertiary care centers with active research in pediatric pulmonary disease. While a few experienced European physicians have begun using MBW in clinical practice, further study is necessary to determine its role in guiding clinical management.

VII.

Future Directions

Infant PFT shows significant promise in detecting burden of lung disease in infants with CF. However, further study is needed to determine the role these tests will assume in regular clinical practice. In particular, further correlation of RVRTC measures with preschool and adult-type spirometry findings later in life and longitudinal studies of the MBW technique in infants and preschoolers are necessary to determine the long-term

Lung Function Testing in Infants

143

clinical significance of early abnormalities in lung function measures. Correlation with inflammatory mediators, infectious status, pulmonary exacerbations, and findings on chest imaging will also help better define the importance of abnormal lung function measures in infants with CF. As newborn screening is now widely available in the United States, Europe, and Australia, this is an ideal time to undertake such studies. Questions that might be addressed include the impact of infant PFT on management of the CF infant (including antibiotic use and the use of chronic therapies), the effect of PFTs on nutritional status in infancy, and the impact of the clinical use of infant PFTs on pulmonary function in later childhood. There is a surprising paucity of therapeutic trials in CF utilizing infant PFT as an outcome measure. Because it is now recognized that CF pulmonary disease begins in infancy, it will become increasingly important to determine the efficacy and long-term benefits of therapeutic interventions in the infant population. This will require larger, multicenter trials to obtain adequate subject numbers, which raises questions of feasibility and quality assurance. Davis and colleagues have recently shown the feasibility of performing infant PFTs using the RVRTC technique coupled with plethysmography in a 10 site multicenter trial, with 72% to 88% of studies performed deemed to be of research quality (72). This was accomplished through rigorous attention to detailed standardized operating protocols, training, quality assurance, and overreading of studies by a central, lead site. A multicenter study of inhaled hypertonic saline in infants with CF using FEV0.5 as an exploratory outcome measure is currently enrolling. Infant PFT has tremendous research and clinical potential in the CF population. With proper training and personnel, these techniques will reveal unseen aspects of CF lung disease in our youngest, most vulnerable patients, where clinically silent damage to airways may be occurring during rapid lung growth (6). As a tool in longitudinal studies, therapeutic trials, and eventually clinical management, infant PFT may aid in further improvements in the morbidity associated with CF lung disease.

Abbreviations BAL CL Crs CT DD FEF25-75 FEF25 FEF50 FEF75 FEF85 FEV0.5 FEV0.75 FEV1 FRC FRCpleth FVC GL

bronchoalveolar lavage lung compliance respiratory system compliance computed tomography density dependence forced expiratory flow between 25 and 75% of FVC forced expiratory flow at 25% of FVC forced expiratory flow at 50% of FVC forced expiratory flow at 75% of FVC forced expiratory flow at 85% of FVC forced expiratory volume in 0.5 seconds forced expiratory volume in 0.75 seconds forced expiratory volume in 1 second functional residual capacity (by plethysmography or gas dilution) functional residual capacity measured by plethysmography forced vital capacity lung conductance

144

Pittman and Davis

LCI MBW MOT PFT Raw Rrs RVRTC sCrs sGaw sRrs SOT TGV TLC Trs V0 maxFRC

lung clearance index Multiple-breath washout multiple occlusion technique pulmonary function testing airways resistance resistance of the respiratory system raised volume rapid thoracoabdominal compression specific compliance of the respiratory system specific airways conductance specific resistance of the respiratory system single-breath occlusion technique thoracic gas volume total lung capacity time constant of the respiratory system maximal flow at functional residual capacity

References 1. Armstrong DS, Hook SM, Jamsen KM, et al. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol 2005; 40(6):500–510. 2. Davis SD, Fordham LA, Brody AS, et al. Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis. Am J Respir Crit Care Med 2007; 175(9):943–950. 3. Kozlowska WJ, Bush A, Wade A, et al. Lung function from infancy to the preschool years following clinical diagnosis of cystic fibrosis. Am J Respir Crit Care Med 2008; 178(1):42–49. 4. Davis SD, Brody AS, Emond MJ, et al. Endpoints for clinical trials in young children with cystic fibrosis. Proc Am Thorac Soc 2007; 4(4):418–430. 5. Ranganathan S, Linnane B, Nolan G, et al. Early detection of lung disease in children with cystic fibrosis using lung function. Paediatr Respir Rev 2008; 9(3):160–167. 6. Gappa M, Ranganathan SC, Stocks J. Lung function testing in infants with cystic fibrosis: lessons from the past and future directions. Pediatr Pulmonol 2001; 32(3):228–245. 7. Stocks J. Pulmonary function tests in infants and preschool children. In: Chernick VBT, Wilmott RW, Bush A, eds. Kendig’s Disorders of the Respiratory Tract in Children. 7th ed. Philadelphia: Saunders Elsevier, 2006:129–167. 8. Stick SM. Clinical trials in infants with cystic fibrosis detected following newborn screening. Paediatr Respir Rev 2008; 9(3):176–180. 9. Linnane B, Robinson P, Ranganathan S, et al. Role of high-resolution computed tomography in the detection of early cystic fibrosis lung disease. Paediatr Respir Rev 2008; 9(3):168–174; quiz 174–175. 10. Ranganathan SC, Dezateux C, Bush A, et al. Airway function in infants newly diagnosed with cystic fibrosis. Lancet 2001; 358(9297):1964–1965. 11. Davis S, Gappa M, Rosenfeld M. Respiratory mechanics. In: Hammer J, Eber E, eds. Pediatric Pulmonary Function Testing. New York: Karger, 2005:20–33. 12. Gustafsson P, Ljungberg H. Measurement of functional residual capacity and ventilation inhomogeneity by gas dilution techniques. In: Hammer J, Eber E, eds. Pediatric Pulmonary Function Testing. New York: Karger, 2005:54–65. 13. Hammer J, Eber E. The peculiarities of infant respiratory physiology. In: Hammer J, Eber E, eds. Pediatric Pulmonary Function Testing. Basel: Karger, 2005:2–7.

Lung Function Testing in Infants

145

14. Frey U, Stocks J, Coates A, et al. Specifications for equipment used for infant pulmonary function testing. ERS/ATS task force on standards for infant respiratory function testing. European respiratory society/American thoracic society. Eur Respir J 2000; 16(4):731–740. 15. Frey U, Stocks J, Sly P, et al. Specification for signal processing and data handling used for infant pulmonary function testing. ERS/ATS task force on standards for infant respiratory function testing. European respiratory society/American thoracic society. Eur Respir J 2000; 16(5):1016–1022. 16. ATS/ERS statement: raised volume forced expirations in infants: guidelines for current practice. Am J Respir Crit Care Med 2005; 172(11):1463–71. 17. Jones M, Castile R, Davis S, et al. Forced expiratory flows and volumes in infants. Normative data and lung growth. Am J Respir Crit Care Med 2000; 161(2 pt 1):353–359. 18. Ranganathan SC, Hoo AF, Lum SY, et al. Exploring the relationship between forced maximal flow at functional residual capacity and parameters of forced expiration from raised lung volume in healthy infants. Pediatr Pulmonol 2002; 33(6):419–428. 19. Castile R, Filbrun D, Flucke R, et al. Adult-type pulmonary function tests in infants without respiratory disease. Pediatr Pulmonol 2000; 30(3):215–227. 20. Tepper RS, Hiatt P, Eigen H, et al. Infants with cystic fibrosis: pulmonary function at diagnosis. Pediatr Pulmonol 1988; 5(1):15–8. 21. Hiatt PW, Grace SC, Kozinetz CA, et al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 1999; 103(3):619–626. 22. Davis S, Jones M, Kisling J, et al. Comparison of normal infants and infants with cystic fibrosis using forced expiratory flows breathing air and heliox. Pediatr Pulmonol 2001; 31(1):17–23. 23. Linnane BM, Hall GL, Nolan G, et al. Lung function in infants with cystic fibrosis diagnosed by newborn screening. Am J Respir Crit Care Med 2008; 178(12):1238–1244. 24. Lum S, Gustafsson P, Ljungberg H, et al. Early detection of cystic fibrosis lung disease: multiple-breath washout versus raised volume tests. Thorax 2007; 62(4):341–347. 25. Davis P. Pulmonary disease in cystic fibrosis. In: Chernick VBT, Wilmott RW, Bush A, eds. Kendig’s Diseases of the Respiratory Tract in Children. New York: Saunders Elsevier, 2006:873–886. 26. Gaultier CFM, Beardsmore C, Motoyama E, et al. Measurement conditions. In: Stocks JSP, Tepper RS, Morgan WJ, eds. Infant Respiratory Function Testing. New York: Wiley-Liss, 1996:29–44. 27. Modl M, Eber E. Forced expiratory flow-volume measurements. In: Hammer J, Eber E, eds. Pediatric Pulmonary Function Testing. New York: Karger, 2005:34–43. 28. Bates JH, Schmalisch G, Filbrun D, et al. Tidal breath analysis for infant pulmonary function testing. ERS/ATS task force on standards for infant respiratory function testing. European respiratory society/American thoracic society. Eur Respir J 2000; 16(6):1180–1192. 29. Gappa M, Colin AA, Goetz I, et al. Passive respiratory mechanics: the occlusion techniques. Eur Respir J 2001; 17(1):141–148. 30. Morris MG, Gustafsson P, Tepper R, et al. The bias flow nitrogen washout technique for measuring the functional residual capacity in infants. ERS/ATS task force on standards for infant respiratory function testing. Eur Respir J 2001; 17(3):529–536. 31. Sly PD, Tepper R, Henschen M, et al. Tidal forced expirations. ERS/ATS task force on standards for infant respiratory function testing. European respiratory society/American thoracic society. Eur Respir J 2000; 16(4):741–748. 32. Stocks J, Godfrey S, Beardsmore C, et al. Plethysmographic measurements of lung volume and airway resistance. ERS/ATS task force on standards for infant respiratory function testing. European respiratory society/American thoracic society. Eur Respir J 2001; 17(2):302–312. 33. Sly PD, Davis G. Equipment requirements for infant respiratory function testing. In: Stocks JSP, Tepper RS, Morgan WJ, eds. Infant Respiratory Function Testing. New York: Wiley-Liss, 1996:45–80.

146

Pittman and Davis

34. Gappa M, Hulskamp, G. Infant whole-body plethysmography. In: Hammer J, Eber E, eds. Pediatric Pulmonary Function Testing. New York: Karger, 2005:44–53. 35. LeSouef PN CR, Turner DJ, Motoyama E, et al. Forced expiratory maneuvers. In: Stocks J SP, Tepper RS, Morgan WJ, eds. Infant Respiratory Function Testing. New York: WileyLiss, 1996:379–409. 36. Pillow JJ, Ljungberg H, Hulskamp G, et al. Functional residual capacity measurements in healthy infants: ultrasonic flow meter versus a mass spectrometer. Eur Respir J 2004; 23(5):763–768. 37. Stocks J, Quanjer PH. Reference values for residual volume, functional residual capacity and total lung capacity. ATS workshop on lung volume measurements. Official statement of the European respiratory society. Eur Respir J 1995; 8(3):492–506. 38. Hoo AF, Dezateux C, Hanrahan JP, et al. Sex-specific prediction equations for Vmax(FRC) in infancy: a multicenter collaborative study. Am J Respir Crit Care Med 2002; 165(8): 1084–1092. 39. Latzin P, Sauteur L, Thamrin C, et al. Optimized temperature and deadspace correction improve analysis of multiple-breath washout measurements by ultrasonic flowmeter in infants. Pediatr Pulmonol 2007; 42(10):888–897. 40. Tepper RS, Reister T. Forced expiratory flows and lung volumes in normal infants. Pediatr Pulmonol 1993; 15(6):357–361. 41. Dubois AB, Botelho SY, Bedell GN, et al. A rapid plethysmographic method for measuring thoracic gas volume: a comparison with a nitrogen washout method for measuring functional residual capacity in normal subjects. J Clin Invest 1956; 35(3):322–326. 42. Henschen M, Stocks J. Assessment of airway function using partial expiratory flow-volume curves: how reliable are measurements of maximal expiratory flow at FRC during early infancy? Am J Respir Crit Care Med 1999; 159(2):480–486. 43. Davis SD JR, Flucke RL, Kisling JA, et al. AARC clinical practice guideline: infant/toddler pulmonary function tests—2008 Revision & Update. Respir Care 2008; 53(7):929–945. 44. Feher A, Castile R, Kisling J, et al. Flow limitation in normal infants: a new method for forced expiratory maneuvers from raised lung volumes. J Appl Physiol 1996; 80(6):2019–2025. 45. Berge MT, Wiel E, Tiddens HA, et al. DNase in stable cystic fibrosis infants: a pilot study. J Cyst Fibros 2003; 2(4):183–188. 46. Gustafsson PM, Kallman S, Ljungberg H, et al. Method for assessment of volume of trapped gas in infants during multiple-breath inert gas washout. Pediatr Pulmonol 2003; 35(1):42–49. 47. Aurora P, Gustafsson P, Bush A, et al. Multiple-breath inert gas washout as a measure of ventilation distribution in children with cystic fibrosis. Thorax 2004; 59(12):1068–1073. 48. Kraemer R, Aebi C, Casaulta Aebischer C, et al. Early detection of lung disease and its association with the nutritional status, genetic background and life events in patients with cystic fibrosis. Respiration 2000; 67(5):477–490. 49. Beardsmore CS, Bar-Yishay E, Maayan C, et al. Lung function in infants with cystic fibrosis. Thorax 1988; 43(7):545–551. 50. Tepper RS, Weist A, Williams-Nkomo T, et al. Elastic properties of the respiratory system in infants with cystic fibrosis. Am J Respir Crit Care Med 2004; 170(5):505–507. 51. Castile RG, Iram D, McCoy KS. Gas trapping in normal infants and in infants with cystic fibrosis. Pediatr Pulmonol 2004; 37(5):461–469. 52. Kraemer R. Early detection of lung function abnormalities in infants with cystic fibrosis. J R Soc Med 1989; 82(suppl 16):21–25. 53. Tepper RS, Montgomery GL, Ackerman V, et al. Longitudinal evaluation of pulmonary function in infants and very young children with cystic fibrosis. Pediatr Pulmonol 1993; 16(2): 96–100.

Lung Function Testing in Infants

147

54. Turner DJ, Lanteri CJ, LeSouef PN, et al. Improved detection of abnormal respiratory function using forced expiration from raised lung volume in infants with cystic fibrosis. Eur Respir J 1994; 7(11):1995–1999. 55. Ranganathan SC, Bush A, Dezateux C, et al. Relative ability of full and partial forced expiratory maneuvers to identify diminished airway function in infants with cystic fibrosis. Am J Respir Crit Care Med 2002; 166(10):1350–1357. 56. Ranganathan SC, Stocks J, Dezateux C, et al. The evolution of airway function in early childhood following clinical diagnosis of cystic fibrosis. Am J Respir Crit Care Med 2004; 169(8):928–933. 57. Gustafsson PM, De Jong PA, Tiddens HA, et al. Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. Thorax 2008; 63(2):129–134. 58. Aurora P, Bush A, Gustafsson P, et al. Multiple-breath washout as a marker of lung disease in preschool children with cystic fibrosis. Am J Respir Crit Care Med 2005; 171(3):249–256. 59. Rosenfeld M, Gibson RL, McNamara S, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001; 32(5):356–366. 60. Dakin CJ, Numa AH, Wang H, et al. Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 2002; 165(7):904–910. 61. Martinez TM, Llapur CJ, Williams TH, et al. High-resolution computed tomography imaging of airway disease in infants with cystic fibrosis. Am J Respir Crit Care Med 2005; 172(9):1133–1138. 62. Nixon GM, Armstrong DS, Carzino R, et al. Early airway infection, inflammation, and lung function in cystic fibrosis. Arch Dis Child 2002; 87(4):306–311. 63. Peterson-Carmichael SL, Harris WT, Goel R, et al. The association of lower airway inflammation with physiologic findings in young children with cystic fibrosis. Pediatr Pulmonol 2009; 44(5):503–511. 64. Hiatt P, Eigen H, Yu P, et al. Bronchodilator responsiveness in infants and young children with cystic fibrosis. Am Rev Respir Dis 1988; 137(1):119–122. 65. Beardsmore CS, Thompson JR, Williams A, et al. Pulmonary function in infants with cystic fibrosis: the effect of antibiotic treatment. Arch Dis Child 1994; 71(2):133–137. 66. Tepper RS, Eigen H, Stevens J, et al. Lower respiratory illness in infants and young children with cystic fibrosis: evaluation of treatment with intravenous hydrocortisone. Pediatr Pulmonol 1997; 24(1):48–51. 67. Clayton RG Sr., Diaz CE, Bashir NS, et al. Pulmonary function in hospitalized infants and toddlers with cystic fibrosis. J Pediatr 1998; 132(3 pt 1):405–408. 68. Subbarao P, Balkovec S, Solomon M, et al. Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis. Pediatr Pulmonol 2007; 42(5):471–476. 69. Dellon EP, Donaldson SH, Johnson R, et al. Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis. Pediatr Pulmonol 2008; 43(11):1100–1106. 70. Sheikh S, Flucke R, McCoy K, et al. Changes in lung function during treatment for pulmonary exacerbations in infants with cystic fibrosis. Pediatr Pulmonol 2000; S20(suppl):296 (abstr 429). 71. Binder A, Bordeaux KA, Ren CL. Do infant pulmonary function test (PFT) results affect treatment in cystic fibrosis (CF)? Am J Respir Crit Care Med 2009; 179(abstracts issue): A1780. 72. Davis S, Kerby G, Acton J, et al. Feasibility, sensitivity, and variability of adult-type pulmonary function tests in infants with CF in a multicenter, longitudinal trial. Pediatric Pulmonol 2006; (suppl 29):A360.

10 Assessment of Lung Function in Young Children with Cystic Fibrosis FARIBA REZAEE and CLEMENT L. REN University of Rochester, Rochester, New York, U.S.A.

I.

Introduction

Advances in our understanding of the pathophysiology of cystic fibrosis (CF) lung disease have resulted in the development of therapies to restore airway surface liquid (1), improve mucociliary clearance (2–4), reduce inflammation (5,6), and control infection (7,8). At the same time, CF newborn screening has been recommended in the United States and other countries (9) and is anticipated to be performed in almost every state in the United States by 2010 (P. M. Farrell, personal communication). These developments will result in a growing population of infants and young children with CF for whom methods to assess disease progression and to serve as outcome measures for clinical trials of new therapeutics will be critical. For older CF patients, measurement of the forced expiratory volume in one second (FEV1) by spirometry is widely accepted as a pulmonary function test (PFT) for both clinical practice and research (10). Techniques for PFTs in infants and toddlers less than three years old have been recently developed as well (see chap. 9). Young children between the ages of three to six years (preschool aged) pose special challenges to pulmonary function testing. They are too old for infant PFT techniques, but they are also not as capable of performing the maneuvers required for standard adult PFTs. However, in recent years, several techniques that require less active cooperation have been developed to assess lung function in this age group. A joint working group of the American Thoracic Society and European Respiratory Society (ATS/ERS) recently published recommendations for performing preschool PFTs and their application to clinical care and research (11). In this chapter, we will review the ATS/ERS recommendations with specific application to preschool CF patients.

II.

Modified Spirometry

Spirometry is the most frequently used method for measuring lung function. It is commonly performed in adults and children greater than six years old, and there are well-established criteria for its performance in this age group (10). Preschool children cannot consistently perform the maximal forced expiratory maneuvers required to meet the criteria for acceptable adult spirometry. However, more recent studies have shown

148

Assessment of Lung Function in Young Children with Cystic Fibrosis

149

that acceptable flow-volume curves can be generated by preschool children using modified criteria. Since spirometry equipment is present in most PFT laboratories, modified spirometry is an attractive option for preschool pulmonary function testing. Standard spirometry incorporates three key elements to obtain flow limitation and consistent flow-volume curves: inspiration to total lung capacity (TLC), expiration down to residual volume (RV), and continuous maximal forced expiration. A minimum of six seconds of expiratory effort is required to meet these criteria in adults. Reproducibility is established by generating a minimum of three flow-volume curves whose values are within 10% of each other. Modifications to these criteria in preschool children are based both on their inability to comply with all of these criteria and considerations of developmental pulmonary physiology. Several groups have conducted studies in preschool children using modified spirometry criteria (12–14). The criteria vary somewhat from site to site, but Table 1 summarizes some of the commonly used criteria for modified spirometry. In adults, a forced expiratory time of at least six seconds is usually required to ensure complete emptying of the lungs (10). Compared with adults, children have a higher specific conductance and empty their lungs much faster (15). Because of this physiologic difference and the difficulty that preschool children have in maintaining forced expiration, investigators have accepted a shorter forced expiratory time than six seconds. Some studies have utilized an expiratory time of 1 second (12), while others will accept times as short as 0.5 seconds as long as a plateau in the volume-time curve can be seen (16). Only two reproducible curves are required, and a single maneuver can be accepted provided it meets the other criteria for acceptable testing. A cessation of flow at >10% of peak flow is a sign of early termination, but a convex shape of the descending limb of the flow-volume curve should not be interpreted as early termination, since this is a common finding in many healthy preschool children (13,14,16). An objective measure of the start of test quality is the back-extrapolated volume (VBE) (Fig. 1). High values reflect a slow start of test, indicating suboptimal effort. The VBE is normally a larger proportion of the total forced vital capacity (FVC) in preschool children compared with adults, and this criterion should be adjusted accordingly. Reference values in normal, healthy preschool children have been generated using criteria outlined in Table 1 (12). Several investigators have applied modified spirometry to the study of young children with CF (17–20). The results of these studies are summarized in Table 2. A consistent finding in all of these studies is clear evidence that by preschool age, Table 1 Quality Control Criteria That Have Been Used for Modified Spirometry l l l l l l l

Volume of back extrapolation
80 mL or 12.5% of FVC Expiratory time 1 sec At least 2 reproducible maneuvers with values within 10% of each other Clearly defined PEF Cessation of flow occurs at
10% of PEF Flow-volume curve demonstrates a rapid rise to PEF and a smooth descending limb No evidence of cough or glottic closure

Abbreviations: FVC, forced vital capacity; PEF, peak expiratory flow. Source: Adapted from Refs. 12 and 16.

150

Rezaee and Ren

Table 2 Spirometric Findings in Young Children with CF

Study

Mayer et al. (20)

Marostica et al. (17)

Nielsen et al. (19)

Vilozni et al. (18)

Subjects Age(years) Success rate FVC FEV1 FEF25–75

49 3.1–6.9 79.5% 1.07  1.33 1.28  1.36 0.49  1.31

33 3.7–6.9 87.8% 0.75  1.63 1.23  1.97 0.74  1.36

30 4.9–7.5 100%a NRb 1.2  1.2 NRb

79 2.5–6.9 81.7% 0.36  0.58 0.36  0.72 NRb

Values for FVC, FEV1, and FEF25–75 are reported as mean Z score  SD for the study population compared with normal controls. The p value for all Z scores was 90 mg/mL, Immunocap) (134), but in this study, as with so many in this field, there was no second population to validate the findings in the discovery population. Others have used the pragmatic but minimalist criteria of new radiological shadowing that does not respond to intravenous antibiotics. A. fumigatus antigens may be secreted or cytoplasmic, and it is the latter that may be particularly elevated in ABPA patients. There is evidence that using targeted allergy testing to specific purified A. fumigatus antigens obtained from cDNA may be helpful, but the literature is unclear as to which antigens should be used. One study using intracutaneous testing suggested that Asp f4 and Asp f6 gave the optimal diagnostic results (135). Receiver operating curves in one study suggested that sensitivity to Asp f3 and Asp f4 gave the best sensitivity and specificity for ABPA in CF (136); unfortunately, this study lacked a second population in which to test this hypothesis. A further drawback is that the levels did not fall with remission of ABPA, making them not useful in following the effects of treatment (133). Another proposed marker, again needing validation in a second population, is serum thymus and activated regulated chemokine (TARC) levels, proposed to be better than IgE, Asp f4, or f6 levels (137). TARC is involved in the modulation of the T-cell response to fungal infection and is known to be elevated in ABPA. TARC levels may be useful in monitoring the response to treatment of ABPA; other cytokines were not useful. Screening

An annual measurement of total IgE is recommended, with further investigation if IgE >500, or 200 to 500 and the index of suspicion is high. Management

Avoidance of risk where practical is advisable, specifically playing or working in damp places such as stables where A. fumigatus spores are in high concentrations (138). There is no satisfactory evidence base on which to recommend the nature and duration of treatment of ABPA. If there is any doubt about the diagnosis, then intravenous antibiotics should be given first. The mainstay of treatment is oral prednisolone, which may need to be given in high dose for a prolonged period of time. A typical regime would be 2 mg/kg for two weeks (maximum 60 mg), then 1 mg/kg for two weeks, then 1 mg/kg on alternate days for two weeks, followed by a slow taper. My practice is to add an oral antifungal agent, usually itraconazole, for two reasons. Although there is no RCT in ABPA complicating CF, in ABPA complicating asthma there is clear evidence that this

Pulmonary Manifestations

211

is beneficial (139,140). There is also less strong, retrospective evidence of benefit in CF (141). However, it should be noted that oral absorption is poor and that serum levels should be measured if practical; there is also a drug interaction with inhaled budesonide, namely itraconazole inhibition of the cytochrome p450 enzyme CYP3A, which can lead to Cushing’s syndrome and iatrogenic adrenal suppression (142). Secondly, rare cases of invasive aspergillosis complicating CF have been described (143,144), and in the context of COPD, airway obstruction and prednisolone therapy are sufficient to trigger this complication (145), and at least in theory the addition of itraconazole may prevent this. If steroid side effects become intolerable, which is usually in the context of recurrent episodes of ABPA, anecdotally, other treatments used have included pulsed methyl prednisolone (146,147), nebulized amphotericin (which may be combined with nebulized budesonide) (148), oral voriconazole (149), a prolonged course of intravenous liposomal amphotericin, and the anti-IgE monoclonal antibody omalizumab (xolairTM) (150,151). Inhaled corticosteroids are commonly employed (124), but there is only the most limited evidence that they are beneficial. Prognosis

Some cases of ABPA may resolve spontaneously, but the majority have relapses after treatment. ABPA can be divided into five stages with different prognoses (Text Box) (120); it is arguable whether these are clinically useful. They are not a chronological progression in clinical practice. If not aggressively treated, ABPA may lead to severe proximal bronchiectasis. Rate of change of lung function during follow-up of ABPA was not affected by the diagnosis in the European Registry study (124); however, this was not the case in another study (152) so prognosis must be guarded.

Stages of ABPA Stage 1: Acute phase. There are acute infiltrates, which clear completely with prednisolone Stage 2: Remission. No prednisone therapy or infiltrates for six months Stage 3: Recurrent exacerbation similar in type to stage 1 Stage 4: Phase of steroid-dependent asthma Stage 5: Fibrotic disease, no longer completely responds to prednisolone therapy

D. Lung or Lobar Collapse

This should be relatively uncommon complication of CF if modern treatments are applied. The diagnosis should always lead to consideration of whether ABPA is the underlying cause. Lobar collapse may be due to proximal mucus plugging, or distal collapse and fibrosis, with the proximal airways patent; a CT scan can distinguish the two. Standard therapy includes the use of intensive physiotherapy, possibly augmented by positive airway pressure; either or both of rhDNase and hypertonic saline; and appropriate intravenous and nebulized antibiotics. If this fails, bronchoscopy should be considered. However, if the CT scan shows that the collapsed lobe contains a prominent

212

Bush

air bronchogram, it is unlikely that bronchoscopy will be effective. In the case of extensive proximal mucus plugging, there is evidence from case reports that directly instilling rhDNase endobronchially may be beneficial (153,154). If there are really tenacious plugs of sputum that cannot be removed using the fiberoptic bronchoscope, rigid bronchoscopy may be considered. Surgical removal of a chronically and irreversibly collapsed lobe is occasionally contemplated in the patient with otherwise mild disease elsewhere. However, in general a CT scan will reveal that the disease is not truly isolated, and there is widespread bronchiectasis. The occasional patient may get shortterm benefit from lobectomy (155), but only in the rare case of a destroyed nonfunctional lobe with otherwise well-preserved lung architecture. E.

Antibiotic Allergy and Desensitization

Aggressive use of antibiotics has brought many benefits to the CF patient, but inevitable problems including the selection of resistant organisms (156), subtle long-term toxic effects such as chronic renal failure (157), and antibiotic allergy (158–160). Antibiotic allergy is a frequent problem due to multiple exposures; there is no evidence that the CF patient is more likely to become sensitized than a normal person. Typically, it becomes a problem in teenagers and young adults, and multiple allergies are common. Most reactions occur within 24 hours of commencing treatment, pruritis and rash being the most common. Frequency increases with age, reaching up to 36% in adults, exposure and decrement in lung function. Piperacillin is particularly likely to lead to allergic reactions, including cross-allergy to other antibiotics (161). Allergic reactions are commonest for penicillins and cephalosporins, intermediate for carbapenems, and lowest for aztreonam. Aminoglycosides rarely cause allergic sensitization. Treatment is with desensitization, which is time-consuming and requires detailed monitoring, because there may be severe reactions in up to 20% of cases; detailed protocols have been published (160,162). However, in most, desensitization is successful, but in up to 25%, usually because allergy is non-IgE mediated, it fails (163). The use of corticosteroids and anti-histamines may increase the likelihood of successful desensitization.

VII.

The Lung Under Stress

A. Air Travel and Altitude

Issues for the CF patient contemplating a journey include (i) tolerance of the conditions of the journey itself, including hypoxemia in commercial jets, immobility, and potential lack of access to treatment for a prolonged period and (ii) the risks of the actual destination. The risks include whether there will be an access to CF care if needed, the risks of high altitude, and the risks of acquiring a new infection. It should be remembered that it is always easy to trigger an acute deterioration, but it may be much harder to regain lost ground; “holiday disasters” are well described (164) and should be preventable by careful planning. In particular during long flights, dehydration must be avoided by drinking liberal amounts of nonalcoholic fluids. Dehydration may predispose to bowel obstruction, and, combined with immobility, to pulmonary embolism. Salt supplements are recommended in hot climates. Commercial jet flights mean breathing the equivalent of 15% oxygen, so assessment of the need for supplemental oxygen is important (note that in nonpressurized cabins, the potential for hypoxemia is much greater. Unsurprisingly (165), the patients with the worst lung disease are more likely to need oxygen, but there is no one good predictive

Pulmonary Manifestations

213

clinical parameter. It is not known how best to assess this (164,166–168); predictive equations may be substantially overestimate the need for oxygen (169). A sea-level hypoxic challenge with 15% oxygen has been advocated (164,166), but this is not as sensitive or specific as one would wish; however, for all its imperfections, this remain our preferred test, and the level of oxygen supplementation can be titrated on the same visit. Furthermore, hypoxemia may be exacerbated if the patient falls asleep in the aeroplane (166). However, no one knows what level and duration of hypoxemia in an aeroplane is safe. Most commercial airlines will arrange in-flight oxygen if it is booked in advance, but the price charged varies considerably. It should be noted that the fiscal cost of diverting a commercial flight to make an emergency landing may exceed $50,000, quite apart from the inconvenience to other passengers, so the decision to sign a “fit to fly” letter is not a light one! If the CF patient is holidaying at altitude, hypoxemia becomes even more important. The ideal would be to do a hypoxic challenge during overnight sleep (169), but this is rarely feasible. If there is any suggestion of sleep desaturation on room air at sea level, prudence suggests that overnight oxygen might be wise at altitude; however, this is not evidence based advice. Pneumothorax is said to be a risk if the patient has cystic changes in the lung, because of fears of cyst rupture secondary to expansion of the cyst as cabin pressure drops. This fear is largely based on loose physiological thinking. By definition, the cystic areas must be in communication with the outside air, albeit with a long time constant, or else the air would be absorbed and the cyst would collapse. So during take-off and landing, when cabin pressures gradually change, there should be enough time for intracyst pressure to track. This is borne out by the extreme rarity of in-flight pneumothorax under any circumstances. Another important risk is acquisition of infection. Usual infections may be acquired in the cramped conditions of an aeroplane, but on arrival, new risks may become significant. There have been a number of reports of the acquisition of B. pseudomallei infection in, for example, Southeast Asia, northern Australia, and Brazil (170,171). Patients need to take an informed decision about these potential risks. Finally, an adequate supply of all medications needs to be taken on holiday. Patients should be warned about potential side effects, especially photosensitivity with ciprofloxacin and minocycline (172). It is important that they be equipped with a nebulizer that is compatible with local electricity supplies. Many units have devised a “holiday pack” of protocols, travel tips, and contact details, for the increasing number of CF patients who go abroad (173). B. During General Anesthesia

Surgery may need to be performed as a result of CF-related complications or for a coincidental, unrelated condition. In all cases, the anesthetic, surgical and CF teams need to work closely together; firstly to see if the surgery is truly necessary and secondly to ensure CF-related complications of anesthesia and surgery are detected early, and appropriate treatment is continued. It is easy for important CF-related issues to be forgotten in a nonspecialist CF surgical unit (174). Preoperative Planning and Assessment of the Patient

It is worth briefly considering whether other procedures should be performed opportunistically while the primary surgery is performed, particularly obtaining lower airway

214

Bush

secretions either by blind suction below the vocal cords performed by the anesthetist or by fiberoptic bronchoscopy. CF issues should not distract from the routine preoperative checks normally carried out by the anesthetist. Ideally, the anesthetist and the CF physician should jointly see the patient. If this is not possible, at least a discussion of the current CF issues should take place. In addition, there are a number of special CF-related issues that should be considered. Oxygen saturation and spirometry should be measured in all those over age five, unless pain or another severe illness precludes spirometry, and the results should be compared with the patient’s usual values. For elective procedures, the patient’s respiratory status should first be optimized with intensive physiotherapy and appropriate antibiotics. A sputum or cough swab culture should be obtained prior to surgery, if time permits. For all but minor procedures in well patients, a course of intravenous antibiotics should be considered, starting at least 48 hours prior to the procedure and continuing until the patient is pain free and has made a complete recovery. The need for per- and postoperative steroid treatment should be judged on standard criteria. A preoperative CXR should be obtained. Nutritional status should be assessed and optimized as the urgency of the surgical situation permits, and any electrolyte imbalance corrected. Any constipation should be treated vigorously to avoid postoperative distal intestinal obstruction syndrome (DIOS). The presence of GER should be noted. CFRD should be managed using standard protocols; the stress of surgery may precipitate hyperglycemia in the CF patient with borderline endocrine pancreatic function. Finally, the potential for drug interaction should be noted. Intraoperative Management

Suxamethonium should probably be avoided, because this agent may cause postoperative pain that will impede the performance of efficient physiotherapy. Standard intraoperative monitoring is performed as usual. The patient should be ventilated in such a way so as to prevent postoperative atelectasis as far as possible. The anesthetist should be aware of the possibility of the build up of secretions causing V:Q mismatch or even blocking the endotracheal tube. In general, preoperative chest physiotherapy while the patient is anesthetized has not been shown to be useful (175). Intra- and postoperatively, oxygen and other inhaled gases should be humidified. Drugs that might cause postoperative suppression of cough, or constipation, should be avoided. Regional blockade may reduce the need for opiate analgesia. Postoperative Care

Adequate pain relief without cough suppression is essential. Chest physiotherapy is crucial. Opiates and dehydration may predispose to constipation, which should be treated. If the postoperative phase is prolonged and nutrition is difficult, a nasogastric tube can be used for feeding using a predigested diet. If a prolonged period of ileus or other cause of failure of enteral nutrition is anticipated, then total parenteral nutrition should be instituted early. C. In the Intensive Care Unit

This section discusses the indications for intensive care in the CF patient, the details of the intensive care unit (ICU) course are discussed elsewhere. Admission to ICU is unequivocally indicated in the sick child in whom the diagnosis is in doubt and for

Pulmonary Manifestations

215

ventilation after surgical procedures. Infants and children aged four years and under with CF who need ventilation generally have a good outcome (176). ICU admission for invasive ventilation (intubation, tracheostomy) is in my view firmly contraindicated in CF patients who have deteriorated progressively and remorselessly despite optimal medical care, and are terminally ill. The position may be difficult if the patient is waitlisted for lung transplantation and is desperately hanging on and hoping for a donor organ, but the results of transplanting an invasively ventilated CF patient are significantly worse (177), and it is difficult to argue ethically that, in a situation of donor organ shortage, it is right to transplant a poor prognosis group. Having said that, prolonged survival after transplantation during the course of positive pressure ventilation has been described. The CF patient who has an acute severe deterioration on the background of relatively good health should be managed maximally without ventilation, but if ventilation is necessary, the results are reasonable. If deterioration is due to hematemesis, pneumothorax, or surgery, the results are good (178). Hemoptysis may carry a worse prognosis (114,176). Overall mortality has decreased in recent years, but the need for invasive ventilation is still a poor prognostic feature (a more than 16-fold increased risk of dying in this series, with a mortality of nearly 60%, which has not changed over time). Interestingly, ICU outcome is not predictable from standard prognostic markers of CF lung disease severity in at least some (179) but not all (114) series. Some have reported an adverse effect of malnutrition (174) and diabetes (180,181) Overall, ICU survival is similar in CF to a general ICU population (around 80%), although clearly the CF ICU population is highly selected. Prognosis for a pulmonary exacerbation severe enough to warrant ICU treatment is poor both during the ICU course and in the succeeding year in those who survive (182). Many ICU survivors (including those having been intubated) will go on to be transplanted in the following 12 months (183), with no apparent effect of previous ICU admission on at least short-term outcome. Use of non-invasive ventilation (NIV) after ICU care may anecdotally be beneficial in improving survival (114).

References 1. Hubeau C, Puchelle E, Gaillard D. Distinct pattern of immune cell population in the lung of human fetuses with cystic fibrosis. J Allergy Clin Immunol 2001; 108:524–529. 2. Sturgess J, Imrie J. Quantitative evaluation of the development of tracheal submucosal glands in infants with cystic fibrosis and control infants. Am J Pathol 1982; 106:303–311. 3. Sobonya RE, Taussig LM. Quantitative aspects of lung pathology in cystic fibrosis. Am Rev Respir Dis 1986; 134:290–295. 4. Esterley JR, Oppenheimer EH. Cystic fibrosis of the pancreas: structural changes in peripheral airways. Thorax 1968; 23:670–675. 5. Cantin A. Cystic fibrosis lung inflammation: early, sustained and severe. Am J Respir Crit Care Med 1995; 151:939–941. 6. Armstrong DS, Grimwood K, Carzino R, et al. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995; 310:1571–1572. 7. Armstrong DS, Grimwood K, Carlin JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997; 156:1197–1204. 8. Nixon GM, Armstrong DS, Carzino R, et al. Early airway infection, inflammation, and lung function in cystic fibrosis. Arch Dis Child 2002; 87:306–311. 9. Burns JL, Gibson RL, McNamara S, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001; 183:444–452.

216

Bush

10. Rosenfeld M, Gibson RL, McNamara S, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001; 32:356–366. 11. Armstrong DS, Hook SM, Jamsen KM, et al. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol 2005; 40:500–510. 12. Douglas TA, Brennan S, Gard S, et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J 2009; 33:305–311. 13. Kirchner KK, Wagener JS, Khan TZ, et al. Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis. Am J Respir Crit Care Med 1996; 154:1426–1429. 14. Konstan MW, Hilliard KA, Norvell TM, et al. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994; 150:448–454. 15. Linnane BM, Hall GL, Nolan G, et al. Lung function in infants with cystic fibrosis diagnosed by newborn screening. Am J Respir Crit Care Med 2008; 178:1238–1244. 16. Auerbach HS, Williams M, Kirkpatrick JA, et al. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985; 2:686–688. 17. Eigen H, Rosenstein BJ, FitzSimmons S, et al. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 1995; 126:515–523. 18. Berger M. Anti-inflammatory therapy for CF: mechanisms of action and adverse effects. Pediatr Pulmonol 2004; 38(suppl 27):170–172. 19. Tirouvanziam R, Khazaal I, Peault B. Primary inflammation in human cystic fibrosis small airways. Am J Physiol 2002; 283:L445–L451. 20. van Heeckeren AM, Schluchter MD, Drumm ML, et al. Role of Cftr genotype in the response to chronic Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol 2004; 287:L944–L952. 21. Downey DG, Bell SC, Elborn JS. Neutrophils in cystic fibrosis. Thorax 2009; 64:81–88. 22. Petit-Bertron AF, Tabary O, Corvol H, et al. Circulating and airway neutrophils in cystic fibrosis display different TLR expression and responsiveness to interleukin-10. Cytokine 2008; 41:54–60. 23. Witko-Sarsat V, Rieu P, Descamps-Latscha B, et al.. Neutrophils: molecules, functions and pathophysiological aspects. Lab Invest 2000; 80:617–653. 24. Gu Y, Harley IT, Henderson LB, et al. Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. Nature 2009; 458:1039–1042. 25. Bush A, Davies J. Non! to non-steroidal anti-inflammatory therapy for inflammatory lung disease in cystic fibrosis (at least at the moment). J Pediatr 2007; 151:228–230. 26. Saglani S, Malmstrom K, Pelkonen AS, et al. Airway remodeling and inflammation in symptomatic infants with reversible airflow obstruction. Am J Respir Crit Care Med 2005; 171:722–727. 27. Saglani S, Payne DN, Zhu J, et al. Early detection of airway wall remodelling and eosinophilic inflammation in preschool wheezers. Am J Respir Crit Care Med 2007; 176:858–864. 28. Payne D, Saglani S, Bush A. Are there different phenotypes of childhood asthma? Clin Pulm Med 2004;11:287–297. 29. Saglani S, Mathie SA, Gregory LG, et al. Pathophysiological features of asthma develop in parallel in house dust mite exposed neonatal mice. Am J Respir Cell Mol Biol 2009; 41(3):281–289 [Epub January 16, 2009]. 30. Ranganathan S, Dezateux C, Bush A, et al. Airway function in infants newly diagnosed with cystic fibrosis [research letter]. Lancet 2001; 358:1964–1965. 31. Ranganathan S, Bush A, Dezateux C, et al. Relative ability of full and partial forced expiratory manoeuvres to identify diminished airway function in infants with cystic fibrosis. Am J Respir Crit Care Med 2002; 166:1350–1357.

Pulmonary Manifestations

217

32. Ranganathan SC, Stocks J, Dezateux C, et al. The evolution of airway function in early childhood following clinical diagnosis of cystic fibrosis. Am J Respir Crit Care Med 2004; 169:928–933. 33. Kozlowska WJ, Bush A, Wade A, et al. Lung Function from Infancy to the preschool years following clinical diagnosis of cystic fibrosis. Am J Respir Crit Care Med 2008; 178:42–49. 34. Nielsen KG, Pressler T, Klug B, et al. Serial lung function and responsiveness in cystic fibrosis during early childhood. Am J Respir Crit Care Med 2004; 169:1209–1216. 35. Hilliard TN, Regamey N, Shute J, et al. Airway remodelling in children with cystic fibrosis. Thorax 2007; 62:1074–1080. 36. Regamey N, Ochs M, Hilliard TN, et al. Increased airway smooth muscle mass in children with asthma, cystic fibrosis and bronchiectasis. Am J Respir Crit Care Med 2008; 177: 837–843. 37. Hilliard TN, Zhu J, Farley R, et al. Nasal Abnormalities in cystic fibrosis mice independent of infection and inflammation. Am J Respir Cell Mol Biol 2008; 39:19–25. 38. Shalev J, Navon R, Urbach D, et al. Intestinal obstruction and cystic fibrosis: antenatal ultrasound appearance. J Med Genet 1983; 20:229–230. 39. Konje JC, de Chazal R, MacFadyen U, et al. Antenatal diagnosis and management of meconium peritonitis: a case report and review of the literature. Ultrasound Obstet Gynecol 1995; 6:66–69. 40. Ruiz MJ, Thatch KA, Fisher JC, et al. Neonatal outcomes associated with intestinal abnormalities diagnosed by fetal ultrasound. J Pediatr Surg 2009; 44:71–74. 41. Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med 2007; 261:5–16. 42. Mall M, Grubb BR, Harkema JR, et al. Increased airway epithelial Naþ absorption produces cystic fibrosis-like lung disease in mice. Nat Med 2004; 10:487–493. 43. Wilson SM, Olver RE, Walters DV. Developmental regulation of lumenal lung fluid and electrolyte transport. Respir Physiol Neurobiol 2007; 159:247–255. 44. Holzmann D, Felix H. Neonatal respiratory distress syndrome—a sign of primary ciliary dyskinesia? Eur J Pediatr 2000; 159:857–860. 45. Hossain T, Kappelman MD, Perez-Atayde AR, et al. Primary ciliary dyskinesia as a cause of neonatal respiratory distress: implications for the neonatologist. J Perinatol 2003; 23:684–687. 46. Soraisham AS, Tierney AJ, Amin HJ. Neonatal respiratory failure associated with mutation in the surfactant protein C gene. J Perinatol 2006; 26:67–70. 47. Saugstad OD, Hansen TW, Rønnestad A, et al. Novel mutations in the gene encoding ATP binding cassette protein member A3 (ABCA3) resulting in fatal neonatal lung disease. Acta Paediatr 2007; 96:185–190. 48. Wegner DJ, Hertzberg T, Heins HB, et al. A major deletion in the surfactant protein-B gene causing lethal respiratory distress. Acta Paediatr 2007; 96:516–520. 49. Abel R, Bush A, Chitty L, et al. Congenital lung disease. In: Chernick V, Boat T, Wilmott R, et al., eds. Kendig’s Disorders of the Respiratory Tract in Children. 7th ed. New York: Elsevier, 2006:280–316. 50. Chonmaitree T, Revai K, Grady JJ, et al. Viral upper respiratory tract infection and otitis media complication in young children. Clin Infect Dis 2008; 46:815–823. 51. Gru¨ber C, Riesberg A, Mansmann U, et al. The effect of hydrotherapy on the incidence of common cold episodes in children: a randomised clinical trial. Eur J Pediatr 2003; 162: 168–176. 52. Ball TM, Holberg CJ, Aldous MB, et al. Influence of attendance at day care on the common cold from birth through 13 years of age. Arch Pediatr Adolesc Med 2002; 156:121–126. 53. Lee GM, Friedman JF, Ross-Degnan D, et al. Misconceptions about colds and predictors of health service utilization. Pediatrics 2003; 111:231–236.

218

Bush

54. Shields MD, Bush A, Everard ML, et al. British thoracic society guidelines recommendations for the assessment and management of cough in children. Thorax 2008; 63:(suppl 3):iii1–iii15. 55. Chang AB, Gaffney JT, Eastburn MM, et al. Cough quality in children: a comparison of subjective vs. bronchoscopic findings. Respir Res 2005; 6:3. 56. Taussig LM, Belmonte MM, Beaudry PH. Staphylococcus aureus empyema in cystic fibrosis. J Pediatr 1974; 84:724–727. 57. Mestitz H, Bowes G. Pseudomonas aeruginosa empyema in an adult with cystic fibrosis. Chest 1990; 98:485–487. 58. Griffiths AL, Massie J. Pleural empyema in a 14-year-old adolescent with cystic fibrosis. J Paediatr Child Health 2006; 42:396–397. 59. Wexler ID, Knoll S, Picard E, et al. Clinical characteristics and outcome of complicated pneumococcal pneumonia in a pediatric population. Pediatr Pulmonol 2006; 41:726–734. 60. Sawicki GS, Lu FL, Valim C, et al. Necrotising pneumonia is an increasingly detected complication of pneumonia in children. Eur Respir J 2008; 31:1285–1291. 61. Martinez FD, Wright AL, Taussig LM, et al. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995; 332:133–138. 62. Cane RS, Ranganathan SC, McKenzie SA. What do parents of wheezy children understand by “wheeze”? Arch Dis Child 2000; 82:327–332. 63. Elphick HE, Ritson S, Rodgers H, et al. When a “wheeze” is not a wheeze: acoustic analysis of breath sounds in infants. Eur Respir J 2000; 16:593–597. 64. Cane RS, McKenzie SA. Parents’ interpretations of children’s respiratory symptoms on video. Arch Dis Child 2001; 84:31–34. 65. Saglani S, McKenzie SA, Bush A, et al. A video questionnaire identifies upper airway abnormalities in preschool children with reported wheeze. Arch Dis Child 2005; 90: 961–964. 66. Brand PL, Baraldi E, Bisgaard H, et al. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur Respir J 2008; 32: 1096–1110. 67. Balfour-Lynn IM, Elborn JS. “CF asthma”: what is it and what do we do about it? Thorax 2002; 57:742–748. 68. Sheppard MN, Nicholson AG. The pathology of cystic fibrosis. In: Hodson ME, Geddes DM, eds. Cystic Fibrosis. 2nd ed. London: Edward Arnold, 141—155, 2000. 69. Min YG, Shin JS, Choi SH, et al. Primary ciliary dyskinesia: ultrastructural defects and clinical features. Rhinology 1995; 33:189–193. 70. Rollin M, Seymour K, Hariri M, et al. Rhinosinusitis, symptomatology & absence of polyposis in children with primary ciliary dyskinesia. Rhinology 2009; 47:75–78. 71. Bush A, Chodhari R, Collins N, et al. Primary ciliary dyskinesia. Arch Dis Child 2007; 92:1136–1140. 72. Nick JA, Rodman DM. Manifestations of cystic fibrosis diagnosed in adulthood. Curr Opin Pulm Med 2005; 11:513–518. 73. Stern RC, Boat TF, Doershuk CF, et al. Cystic fibrosis diagnosed after age 13. Ann Intern Med 1977; 87:181–191. 74. Gilljam M, Ellis L, Corey M, et al. Clinical manifestations of cystic fibrosis among patients with diagnosis in adulthood. Chest 2004; 126:1215–1224. 75. McCloskey M, Redmond AO, Hill A, et al. Clinical features associated with a delayed diagnosis of cystic fibrosis. Respiration (Herrlisheim) 2000; 67:402–407. 76. Gan KH, Geus WP, Bakker W, et al. Genetic and clinical features of patients with cystic fibrosis diagnosed after the age of 16 years. Thorax 1995; 50:1301–1304. 77. Widerman E, Millner L, Sexauer W, et al. Health status and sociodemographic characteristics of adults receiving a CF diagnosis after age 18 years. Chest 2000; 118:427–433.

Pulmonary Manifestations

219

78. Modolell I, Alvarez A, Guarner L, et al. Gastrointestinal, liver, and pancreatic involvement in adult patients with cystic fibrosis. Pancreas 2001; 22:395–399. 79. McWilliams TJ, Wilsher ML, Kolbe J. Cystic fibrosis diagnosed in adult patients. N Z Med J 2000; 113:6–8. 80. Rodman DM, Polis JM, Heltshe SL, et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2005; 171:621–626. 81. Foundation C. CF Foundation: Patient Registry 2003 Annual Data Report. Bethesda, MD: CF Foundation, 2004. 82. Widerman E. Communicating a diagnosis of cystic fibrosis to an adult: what physicians need to know. Behav Med 2002; 28:45–52. 83. Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008; 178:1066–1074. 84. Coren ME, Meeks M, Buchdahl RM, et al. Primary ciliary dyskinesia (PCD) in children— age at diagnosis and symptom history. Acta Paediatr 2002; 91:667–669. 85. Kennedy MP, Omran H, Leigh MW, et al. Congenital heart disease and other heterotaxic defects in a large cohort of patients with primary ciliary dyskinesia. Circulation 2007; 115:2814–2821. 86. Garand SA, Kareti LR, Dumont TM, et al. Thoracoscopic repair of tracheoesophageal fistula in a septuagenarian. Ann Thorac Surg 2006; 81:1899–1901. 87. Gardella C, Toma` P, Sacco O, et al. Intermittent gaseous bowel distention: atypical sign of congenital tracheoesophageal fistula. Pediatr Pulmonol 2009; 44:244–248. 88. Zempsky WT, Rosenstein BJ. The cause of rectal prolapse in children. Am J Dis Child 1988; 142:338–339. 89. Kennedy JD, Dinwiddie R, Daman-Willems C, et al. Pseudo-Bartter’s syndrome in cystic fibrosis. Arch Dis Child 1990; 65:786–787. 90. O’Donnell AE. Bronchiectasis. Chest 2008; 134:815–823. 91. Redding GJ. Bronchiectasis in children. Pediatr Clin North Am 2009; 56:157–171. 92. Marchant JM, Masters IB, Taylor SM, et al. Evaluation and outcome of young children with chronic cough. Chest 2006; 129:1132–1141. 93. Donnelly D, Critchlow A, Everard ML. Outcomes in children treated for persistent bacterial bronchitis. Thorax 2007; 62:80–84. 94. Chang AB, Redding GJ, Everard ML. Chronic wet cough: protracted bronchitis, chronic suppurative lung disease and bronchiectasis. Pediatr Pulmonol 2008; 43:519–531. 95. Hafen GM, Ukoumunne OC, Robinson PJ. Pneumothorax in cystic fibrosis: a retrospective case series. Arch Dis Child 2006; 91:924–925. 96. Flume PA. Pneumothorax in cystic fibrosis. Chest 2003; 123:217–221. 97. Flume PA, Strange C, Ye X, et al. Pneumothorax in cystic fibrosis. Chest 2005; 128: 720–728. 98. Haworth CS, Dodd ME, Atkins M, et al. Pneumothorax in adults with cystic fibrosis dependent on nasal intermittent positive pressure ventilation (NIPPV): a management dilemma. Thorax 2000; 55:620–622. 99. Curtis HJ, Bourke SJ, Dark JH, et al. Lung transplantation outcome in cystic fibrosis patients with previous pneumothorax. J Heart Lung Transplant 2005; 24:865–869. 100. Ley S, Puderbach M, Fink C, et al. Assessment of hemodynamic changes in the systemic and pulmonary circulation in patients with cystic fibrosis using phase-contrast MRI. Eur Radiol 2005; 15:1575–1580. 101. Schidlow DV, Taussig LM, Knowles MR. Cystic fibrosis foundation consensus conference report on pulmonary complications of cystic fibrosis. Pediatr Pulmonol 1993; 15:187–198. 102. Barben JU, Ditchfield M, Carlin JB, et al. Major haemoptysis in children with cystic fibrosis: a 20-year retrospective study. J Cyst Fibros 2003; 2:105–111.

220

Bush

103. Flume PA, Yankaskas JR, Ebeling M, et al. Massive hemoptysis in cystic fibrosis. Chest 2005; 128:729–738. 104. Paredi P, Barnes PJ. The airway vasculature: recent advances and clinical implications. Thorax 2009; 64:444–450. 105. Verhaeghe C, Tabruyn SP, Oury C, et al. Intrinsic pro-angiogenic status of cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun 2007; 356:745–749. 106. McDonald DM. Angiogenesis and remodelling of airway vasculature in chronic inflammation. Am J Respir Crit Care Med 2001; 164:S39–S45. 107. Antonelli M, Midulla F, Tancredi G, et al. Bronchial artery embolization for the management of nonmassive hemoptysis in cystic fibrosis. Chest 2002; 121:796–801. 108. Barben J, Robertson D, Olinsky A, et al. Bronchial artery embolization for hemoptysis in young patients with cystic fibrosis. Radiology 2002; 224:124–130. 109. Brinson GM, Noone PG, Mauro MA, et al. Bronchial artery embolization for the treatment of hemoptysis in patients with cystic fibrosis. Am J Respir Crit Care Med 1998; 157:1951–1958. 110. Porter DK, Van Every MJ, Mack JW Jr. Emergency lobectomy for massive hemoptysis in cystic fibrosis. J Thorac Cardiovasc Surg 1983; 86:409–411. 111. Graff GR. Treatment of recurrent severe hemoptysis in cystic fibrosis with tranexamic acid. Respiration 2001; 68:91–94. 112. Chang AB, Ditchfield M, Robinson PJ, et al. Major hemoptysis in a child with cystic fibrosis from multiple aberrant bronchial arteries treated with tranexamic acid. Pediatr Pulmonol 1996; 22:416–420. 113. Wong LT, Lillquist YP, Culham G, et al. Treatment of recurrent hemoptysis in a child with cystic fibrosis by repeated bronchial artery embolizations and long-term tranexamic acid. Pediatr Pulmonol 1996; 22:275–279. 114. Vedam H, Moriarty C, Torzillo PJ, et al. Improved outcomes of patients with cystic fibrosis admitted to the intensive care unit. J Cyst Fibros 2004; 3:8–14. 115. Henig NR, Glenny RW, Aitken ML. A hypertrophied bronchial circulatory system may participate in gas exchange. Lancet 1998; 351:113. 116. Geller DE, Kaplowitz H, Light MJ, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. Chest 1999; 116:639–646. 117. Kanthan SK, Bush A, Kemp M, et al. Factors effecting impact of Aspergillus fumigatus sensitization in cystic fibrosis. Pediatr Pulmonol 2007; 42:785–793. 118. Shoseyov D, Brownlee KG, Conway SP, et al. Aspergillus bronchitis in cystic fibrosis. Chest 2006; 130:222–226. 119. Pihet M, Carrere J, Cimon B, et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis—a review. Med Mycol 2009; 47: 387–397. 120. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: cystic fibrosis foundation consensus conference. Clin Infect Dis 2003; 37(suppl 3):S225–S264. 121. Skov M, McKay K, Koch C, et al. Prevalence of allergic bronchopulmonary aspergillosis in cystic fibrosis in an area with a high frequency of atopy. Respir Med 2005; 99:887–893. 122. de Almeida MB, Bussamra MH, Rodrigues JC. Allergic bronchopulmonary aspergillosis in paediatric cystic fibrosis patients. Paediatr Respir Rev 2006; 7:67–72. 123. Blyth W, Forey A. The influence of respiratory bacteria and their biochemical function on Aspergillus fumigatus. Sabouradia 1971; 9:273–282. 124. Mastella G, Rainiso M, Harms HK, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis: a European epidemiological study. Epidemiological Registry of Cystic Fibrosis. Eur Respir J 2000; 16:464–471. 125. McKone EF, Emerson SS, Edwards KL, et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 2003; 361:1671–1676.

Pulmonary Manifestations

221

126. Mussaffi H, Rivlin J, Shalit I, et al. Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. Eur Respir J 2005; 25:324–328. 127. Chauhan B, Knutsen AP, Hutcheson PS, et al. T cell subsets, epitope mapping, and HLArestriction in patients with allergic bronchopulmonary aspergillosis. J Clin Invest 1996; 97:2324–2331. 128. Chauhan B, Santiago L, Kirschmann DA, et al. The association of HLA-DR alleles and T cell activation with allergic bronchopulmonary aspergillosis. J Immunol 1997; 159: 4072–4076. 129. Chauhan B, Santiago L, Hutcheson PS, et al. Evidence for the involvement of two different MHC class II regions in susceptibility or protection in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2000; 106:723–729. 130. Brouard J, Knauer N, Boelle P-Y, et al. Influence of interleukin-10 on Aspergillus fumigatus infection in patients with cystic fibrosis. J Infect Dis 2005; 199:1989–1991. 131. O’Connor TM, O’Donnell A, Hurley M, et al. Allergic bronchopulmonary aspergillosis: a rare cause of pleural effusion. Respirology 2001; 6:361–363. 132. Marchant JL, Warner JO, Bush A. Rise in total IgE as an indicator of allergic bronchopulmonary aspergillosis in cystic fibrosis. Thorax 1994; 49:1002–1005. 133. Casaulta C, Fluckiger S, Crameri R, et al. Time course of antibody response to recombinant Aspergillus fumigatus antigens in cystic fibrosis with and without ABPA. Pediatr Allergy Immunol 2005; 16:217–225. 134. Barton RC, Hobson RP, Denton M, et al. Serologic diagnosis of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis through the detection of immunoglobulin G to Aspergillus fumigatus. Diagn Microbiol Infect Dis 2008; 62:287–291. 135. Nikolaizik WH, Welchel M, Blaser K, et al. Intracutaneous tests with recombinant allergens in cystic fibrosis patients with allergic bronchopulmonary aspergillosis and Aspergillus allergy. Am J Respir Crit Care Med 2002; 165:916–921. 136. Knutsen AP, Hutcheson PS, Slavin RG, et al. IgE antibody to Aspergillus fumigatus recombinant allergens in cystic fibrosis patients with allergic bronchopulmonary aspergillosis. Allergy 2004; 59:198–203. 137. Hartl D, Latzin P, Zissel G, et al. Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Am J Respir Crit Care Med 2006; 173:1370–1376. 138. Simmonds EJ, Littlewood JM, Hopwood V, et al. Aspergillus fumigatus colonisation and population density of place of residence in cystic fibrosis. Arch Dis Child 1994; 70:139– 140. 139. Denning DW, Van Wye JE, Lewiston NJ, et al. Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. Chest 1991; 100:813–819. 140. Wark PA, Hensley MJ, Saltos N, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol 2003; 111:952–957. 141. Skov M, Hoiby N, Koch C. Itraconaziole treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Allergy 2002; 57:723–728. 142. De Wachter E, Malfroot A, De Schutter I, et al. Inhaled budesonide induced Cushing’s syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450. J Cyst Fibros 2003; 2:72–75. 143. Chung Y, Kraut JR, Stone AM, et al. Disseminated aspergillus in a patient with cystic fibrosis and allergic bronchopulmonary aspergillosis. Pediatr Pulmonol 1994; 17:131–134. 144. Brown K, Rosenthal M, Bush A. Fatal invasive aspergillosis in an adolescent with cystic fibrosis. Pediatr Pulmonol 1999; 27:130–133. 145. Palmer L, Greenberg H, Schiff MM. Corticosteroid treatment is a risk for invasive aspergillosis. Thorax 1991; 46:15–20.

222

Bush

146. Thomson JM, Wesley A, Byrnes CA, et al. Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary aspergillosis in cystic fibrosis. Pediatr Pulmonol 2006; 41:164–170. 147. Cohen-Cymberknoh M, Blau H, Shoseyov D, et al. Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis. J Cyst Fibros 2009; 8:253–257. 148. Laoudi Y, Paolini J-B, Grimfed A, et al. Nebulised corticosteroid and Amphotericin B: an alternative treatment for ABPA? Eur Respir J 2008; 31:908–909. 149. Hilliard T, Edwards S, Buchdahl R, et al. Voriconazole therapy in children with cystic fibrosis. J Cyst Fibros 2005; 4:215–220. 150. van der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007; 62:276–277. 151. Zirbes JM, Milla CE. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol 2008; 43:607–610. 152. Kraemer R, Delose´a N, Ballinari P, et al. Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis. Am J Respir Crit Care Med 2006; 174:1211–1220. 153. Shah PL, Scott S, Hodson ME. Lobar atelectasis in cystic fibrosis and treatment with recombinant human DNase 1. Respir Med 1994; 88:313–315. 154. Slattery DM, Waltz DA, Denham B, et al. Bronchoscopically administered human Dnase for lobar atelectasis in cystic fibrosis. Pediatr Pulmonol 2001; 31:383–388. 155. Lucas J, Connett GJ, Lea R, et al. Lung resection in cystic fibrosis patients with localised pulmonary disease. Arch Dis Child 1996; 74:449–451. 156. Valenza G, Tappe D, Turnwald D, et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros 2008; 7:123–127. 157. Al-Aloul M, Miller H, Alapati S, et al. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005; 39:15–20. 158. Pleasants RA, Walker TR, Samuelson WH. Allergic reactions to parental beta-lactam antibiotics in patients with cystic fibrosis. Chest 1994; 106:1124–1128. 159. Parmar JS, Nasser S. Antibiotic allergy in cystic fibrosis. Thorax 2005; 60:517–520. 160. Burrows JA, Nissen LM, Kirkpatrick CMJ, et al. Beta-lactam allergy in adults with cystic fibrosis. J Cyst Fibros 2007; 6:297–303. 161. Stead RJ, Kennedy HG, Hodson ME, et al. Adverse reactions to piperacillin in adults with cystic fibrosis. Thorax 1985; 40:184–186. 162. Burrows JA, Toon M, Bell SC. Antibiotic desensitization in adults with cystic fibrosis. Respirology 2003; 8:359–364. 163. Turvey SE, Cronin B, Arnold AD, et al. Antibiotic desensitization for the allergic patient: 5 years of experience and practice. Ann Allergy Asthma Immunol 2004; 92:426–432. 164. Oades PJ, Buchdahl RM, Bush A. Prediction of hypoxaemia at high altitude in children with cystic fibrosis. BMJ 1994; 308:15–18. 165. Peckham D, Watson A, Pollard K, et al. Predictors of desaturation during formal hypoxic challenge in adult patients with cystic fibrosis. J Cyst Fibros 2002; 1:281–286. 166. Buchdahl RM, Babiker A, Bush A, et al. Predicting hypoxaemia during flights in children with cystic fibrosis. Thorax 2001; 56:877–879. 167. Kamin W, Fleck B, Rose D-M, et al. Predicting hypoxia in cystic fibrosis patients during exposure to high altitudes. J Cyst Fibros 2006; 5:223–228. 168. Martin SE, Bradley JM, Buick JB, et al. Flight assessment in patients with respiratory disease: hypoxic challenge testing vs. predictive equations. QJM 2007; 100:361–367. 169. Parkins KJ, Poets CF, O’Brien LM, et al. Effect of exposure to 15% oxygen on breathing patterns and oxygen saturation in infants: interventional study. BMJ 1998; 316:887–891.

Pulmonary Manifestations

223

170. O’Carroll MR, Kidd TJ, Coulter C, et al. Burkholderia pseudomallei: another emerging pathogen in cystic fibrosis. Thorax 2003; 58:1087–1092. 171. Barth AL, de Abreu e Silva FA, Hoffman A, et al. Cystic fibrosis patient with Burkholderia pseudomallei infection acquired in Brazil. J Clin Microbiol 2007; 45:4077–4080. 172. Jaffe´ A, Bush A. If you can’t stand the rash, get out of the kitchen: an unusual adverse reaction to ciprofloxacin. Pediatr Pulmonol 1999; 28:449–450. 173. Verma A, Dodd ME, Haworth CS, et al. Holidays and cystic fibrosis. J R Soc Med 2000; 93(suppl 38):20–26. 174. Escobar MA, Grosfeld JL, Burdik JJ, et al. Surgical considerations in cystic fibrosis: a 32-year evaluation of outcomes. Surgery 2005; 138:560–572. 175. Tannenbaum E, Prasad SA, Main E, et al. The effect of chest physiotherapy on cystic fibrosis patients undergoing general anaesthesia for an elective surgical procedure. Pediatr Pulmonol 2001; 32(suppl 22):315. 176. Berlinski A, Fan LL, Kozinetz CA, et al. Invasive mechanical ventilation for acute respiratory failure in children with cystic fibrosis: outcome analysis and case-control study. Pediatr Pulmonol 2002; 34:297–303. 177. Elizur A, Sweet SC, Huddleston CB, et al. Pre-transplant mechanical ventilation increases short-term morbidity and mortality in pediatric patients with cystic fibrosis. J Heart Lung Transplant 2007; 26:127–131. 178. Texereau J, Jamal D, Choukroun G, et al. Determinants of mortality for adults with cystic fibrosis admitted in intensive care unit: a multicentre study. Respir Res 2006; 7:14. 179. Vedam H, Moriarty C, Torzillo PJ, et al. Improved outcomes of patients admitted to the intensive care unit. J Cyst Fibros 2004; 3:8–14. 180. Finkelstein SM, Wielinski CL, Elliot GR, et al. Diabetes mellitus associated with cystic fibrosis. J Pediatr 1988; 112:373–377. 181. Lanng S, Thorsteinsson B, Nerup J, et al. Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr 1992; 51:684–687. 182. Ellaffi M, Vlnsonneau C, Coste J, et al. One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis. Am J Respir Crit Care Med 2005; 171:158–164. 183. Sood N, Paradowski LJ, Yankaskas J. Outcomes of intensive care unit care in adults with cystic fibrosis. Am Rev Resp Crit Care Med 2001; 163:335–338.

14 Treatment Strategies for Maintaining Pulmonary Health in Cystic Fibrosis SUSANNA A. MCCOLLEY Northwestern University Feinberg School of Medicine, Chicago, Illinois, U.S.A.

I.

Introduction

Progressive lung disease causes most of the morbidity and mortality in cystic fibrosis (CF). To address this, significant effort has been put forth in understanding the pathophysiology of the disease and in developing therapies. In this chapter, a conceptual framework for maintenance treatment of CF pulmonary disease is presented. This framework includes both models of the progression of CF lung disease and strategies to maintain and improve lung health. Specific therapies are discussed, but the reader is encouraged to recognize that therapies for CF lung disease are constantly evolving.

II.

Principals of Maintenance Therapy for CF Lung Disease

A. Goals of Treatment to Maintain Pulmonary Health in CF

The specific goals of pulmonary therapies for CF will vary according to the stage of disease of the affected individual. All patients will benefit from therapies that maintain or improve pulmonary function, reduce the risk of pulmonary exacerbation, and reduce the rate of pulmonary function decline. It is important to recognize that many therapies for CF lung disease are expensive, time consuming, or otherwise burdensome. It is essential that clinicians, patients, and families communicate well about the risks and benefits of specific therapies and make decisions on treatment together. Suggested general goals are presented in Table 1. B. Approaches to Maintenance of Pulmonary Health in CF

Conceptually, it is useful to consider two different models of the progression of lung disease. Neither of these models alone leads to a single therapeutic approach to maintain pulmonary health in CF. Taken together, however, they allow the clinician or researcher to rationally consider interventions that may result in better clinical outcomes. The first, a pathophysiologic model, was first proposed by Dr Jeffrey Wine (1) and is presented in Figure 1. In this construct, the pathophysiologic cascade begins with the mutant cystic fibrosis transmembrane regulator (CFTR) gene, resulting in absent or abnormally functioning CFTR protein. The lack of a normally functioning protein results in abnormal mucociliary clearance, chronic bacterial infection, and intense airway inflammation. Destruction of the lung parenchyma and bronchiectasis result and worsen over time. Eventually, progression of lung disease leads to respiratory

224

Treatment Strategies for Maintaining Pulmonary Health in CF

225

Table 1 Goals for Pulmonary Maintenance Therapies in Cystic Fibrosis

Lung disease severity Asymptomatic

Mild

Moderate

Severe

Short-term goal

Long-term goal

Remain asymptomatic Avoid chronic infection Reduce the risk of exacerbation Reduce symptoms Avoid or reduce the burden of chronic infection Reduce the risk of exacerbation Reduce symptoms Maintain or improve quality of life Reduce the risk of complications, e.g., hemoptysis Reduce the risk of exacerbation Reduce the risk of respiratory failure Reduce symptoms Maintain or improve quality of life Reduce the risk of complications, e.g., hemoptysis Reduce the risk of exacerbation Reduce the risk of respiratory failure

Maintain normal lung function Reduce the rate of lung function decline Maintain or improve lung function Reduce the rate of lung function decline

Maintain or improve lung function Reduce the rate of lung function decline Reduce the risk of mortality

Reduce the risk of mortality Improve the outcome of lung transplantation, when applicable

insufficiency and failure, leading to death unless successful lung transplantation occurs. In this model, therapies are targeted toward specific abnormalities along the cascade. This model is extremely useful for understanding the development of therapeutic targets, including replacement of the mutant gene with a normal copy of CFTR, replacement or improvement in protein function, and treatments targeted toward improving mucociliary transport and reducing inflammation and infection, and, ultimately, replacement of lung through transplantation. A second model of CF lung disease is proposed in Table 2. This developmental model of onset and progression serves to summarize the stages of CF lung disease. The CF lung is essentially normal at birth; other than some hypertrophy of submucosal glands, there are no significant structural or functional abnormalities. Young infants with CF diagnosed by newborn screening show normal airways function, measured by forced expiratory volume in first 0.5 seconds (FEV0.5) until about six months of age, at which time lung function drops below age-matched infants without CF (2); this decline continues over subsequent years. During infancy and early childhood, there is significant airway inflammation, as measured by increased neutrophils and proinflammatory cytokines, notably IL-8, in bronchoalveolar lavage (BAL) fluid (3,4). Importantly, although infection clearly intensifies the inflammatory response, inflammation is seen even in the absence of infection detected by conventional techniques (5). Structural and

226

McColley

Table 2 Stages of CF Lung Disease

Approximate age or stage

Pulmonary pathophysiology

Newborn through early infancy (birth to 6 mo) Later infancy, preschool (6 mo–5 yr)

Nearly normal structure, normal function, intermittent infection Mildly abnormal pulmonary function, air trapping, early bronchiectasis, intermittent to chronic infection Variable pulmonary function, air trapping, early to moderate bronchiectasis, intermittent to chronic infection Variable, but often declining lung function, symptomatic bronchiectasis, often chronic infection Variable, but often abnormal lung function, symptomatic bronchiectasis, chronic infection Severe obstructive lung disease, bronchiectasis with chronic abscesses, abnormal gas exchange

Childhood (6–12 yr)

Adolescence (13–17 yr)

Adulthood (18 yr and older) End stage (childhood to elderly)

Figure 1 Pathophysiologic cascade of CF lung disease.

Treatment Strategies for Maintaining Pulmonary Health in CF

227

functional abnormalities are first seen in the smallest airways, with bronchiolar inflammation causing air trapping. The mucociliary clearance defect promotes airways infection, which ultimately becomes chronic. Bronchiectasis is evident early in life (6,7) and progresses with time. In this conceptual model, therapies are targeted toward reducing the progression of lung disease from an earlier to a later stage or toward maintaining health when disease is advanced.

III.

General Principles of Therapy

A. Frequent Health Care Supervision by a Multidisciplinary Care Team

CF is a complex, chronic, lifelong disorder. Positive family adjustment, support of family, and development of self-management strategies are essential to promote optimal health. The multidisciplinary care team, which includes physicians, nurses and/or nurse practitioners, physical and respiratory therapists, dieticians, social workers, and, often, clinical psychologists, is an essential resource to meet these goals. Family and patient education, emphasizing both knowledge of disease management and practical skills, and psychosocial support are ongoing activities for the CF team. Specific methods of disease education and self-management support in CF are varied, but must be sensitive and responsive to the family and patient’s belief systems, educational level, and primary language and culture. Team meetings to review patient status and plan outpatient sessions are helpful in assuring that patients and their families receive optimal care in a cohesive manner. Frequent monitoring allows for anticipatory guidance and also provides the clinician an opportunity to detect subtle changes in health status before overt symptoms occur. Frequent monitoring of respiratory tract cultures and pulmonary function tests are important strategies that are associated with better pulmonary outcomes in CF populations (8). Obviously, performing these measurements alone does not improve outcomes, but acting on these data allows the opportunity for additional diagnostic testing and earlier treatment of abnormalities. B. Rationale for “Aggressive” Care

There is significant variability in important health outcomes for CF patients treated at different CF clinical programs. Most of this variability is not readily explained by nonmodifiable differences in patient populations, such as genotype and socioeconomic status. The relationship between median pulmonary function (FEV1) in CF programs and care patterns, including frequency of outpatient visits and testing, prescription of various therapies, and utilization of intravenous antibiotics, was studied at 132 sites enrolled in the North American Epidemiologic Study of Cystic Fibrosis (8), a large, longitudinal observational study. Sites reporting median FEV1 in the highest quartile were compared with sites reporting median FEV1 in the lowest quartile. Those in the highest quartile saw patients more frequently, performed more spirometry and respiratory tract cultures, and had more frequent hospitalizations and courses of intravenous (IV) antibiotics than sites in the lowest quartile. Not surprisingly, sites with the highest FEV1 also reported more resistant bacteria on cultures. Utilization of other specific therapies did not vary significantly between sites. These data suggest that the general strategy of frequent monitoring and frequent use of IV antibiotics, which is probably a marker for diagnosis and treatment of pulmonary exacerbation, is more important than utilization of a given therapy.

228

McColley C. The Benefit and Challenge of “Additive” Therapies

The first therapy specifically developed for maintenance therapy in CF lung disease was dornase alfa (Pulmozyme1), which was approved for use by the U.S. Food and Drug Administration in 1993. Since that time, an increasing number of maintenance therapies have been developed or adopted for CF. In most cases, each therapy has been studied as additive to “usual care,” for example, patients enrolled in clinical trials have continued prior therapies such as dornase alfa. This leads to challenges both in the design and interpretation of clinical trials. Furthermore, in situations where a patient will only take a limited number of therapies due to financial or time constraints, it can be difficult to decide what an “optimal” therapeutic regimen contains. Nevertheless, the development of new therapies for CF has had a strong temporal association with increasing life expectancy for those affected. D. The Benefits and Limitations of Practice Guidelines

Consensus conferences and practice guidelines have been developed for a plethora of acute and chronic diseases, including CF. As of early 2009, 21 practice guidelines related to CF had been published; among these, 13 specifically address patient care. These publications are intended to guide clinicians, health systems, and third party payers. In some cases, lay summaries are created, intended to benefit patients and families. Consensus conferences are intended to provide guidance for care in circumstances when adequate literature does not yet provide a strong evidence basis. The process of developing evidence-based practice guidelines has evolved over the years and now generally includes a systematic review of the literature using specific and transparent strategies, and grading of evidence. While practice guidelines are useful to provide guidance on an approach to care, the utility of guidelines is limited in that recommendations can only be made when adequate research is available to review. Medications for maintenance of lung health were addressed in a consensus conference guideline of the Cystic Fibrosis Foundation in 2007 (9). These guidelines are limited to patients aged six and older because most randomized, controlled trials of CF pulmonary therapies have been designed to detect improvement in FEV1. Therefore, they include only patients who are able to perform this maneuver (generally, those aged 6 or older) and patients who have at least mildly impaired pulmonary function. As a result, there is little literature to suggest what therapies may benefit patients less than six years of age or patients who have normal FEV1. Furthermore, therapies only received a strong recommendation if a large cohort of patients in one or more clinical trials demonstrated a significant benefit. This means that a substantial research effort must have occurred before a strong recommendation can be made. To date, research has primarily focused on patients with measurably abnormal FEV1 so that improvement can be detected. Thus, a clinician must weigh guidelines in the context of current advances and use clinical judgment when decided whether, and when, to prescribe therapies that have less robust recommendations.

IV.

Preventive and Maintenance Treatment of Infection in CF Lung Disease The role of infection in CF is unique in human disease. The microenvironment of the CF respiratory tract allows chronic, high-level bacterial infection without a high rate of systemic dissemination. Pathogens are isolated from upper and lower airways early in

Treatment Strategies for Maintaining Pulmonary Health in CF

229

life. Staphylococcus aureus is the most common organism isolated from the CF respiratory tract in infancy and childhood. Pseudomonas aeruginosa can be isolated as early as the first year of life and becomes more prevalent over time; by early adulthood, it is the most commonly isolated pathogen. Further information about the microbiology of CF lung disease is found in chapter 4 by Planet and Saiman. The presence of chronic infection increases inflammation and is therefore an important target for intervention. One result of chronic infection is pulmonary exacerbation of CF; this is reviewed in chapter 16 by Sanders and Rosenfeld. Primary prevention of, or prophylaxis against, infections with specific pathogens is hypothesized to have the most potential impact. Treatment of initial infection, with the goal of eradication and prevention or delay of chronic infection, is another promising strategy. Chronic suppressive therapy has been widely studied and practiced, especially for patients with chronic P. aeruginosa infection. Preventive strategies have most often been employed for prevention of S. aureus infections in infants and young children with CF. A number of publications, using a variety of study designs and drugs, have shown various potential benefits of prophylactic anti-staphylococcal antibiotics. Weaver et al. (10) conducted a randomized study of daily flucloxacillin versus clinically indicated antibiotics alone in 38 CF infants diagnosed by newborn screening. Infants in the flucloxacillin group had a lower prevalence of positive cultures for S. aureus and lower hospital admission rates and lengths of stay than patients in the clinically indicated antibiotics group. A subsequent study of the same cohort revealed no difference in pulmonary function at three to four months and one year of age (11). Studies (12) that used microbiology as an outcome measure have consistently shown that anti-staphylococcal prophylaxis reduces the rate of isolation of S. aureus from respiratory tract cultures. One small study showed an improvement in weight gain, but no studies have shown an impact on pulmonary function. The largest study (13) of anti-staphylococcal prophylaxis was a double blind, placebo-controlled study of cephalexin. Among 209 children enrolled during the second year of life, 119 completed the study at six years of age. There were no differences in the clinical outcomes of the two groups, which included hospital days, other antibiotics, symptoms, signs, nutritional status, or pulmonary function. The treatment group, however, had an increased rate of respiratory tract cultures for P. aeruginosa. A retrospective study of pediatric CF patients without P. aeruginosa at baseline also showed an increased rate of P. aeruginosa infection in patients receiving various drugs for anti-staphylococcal prophylaxis (14). Other studies of prophylaxis have not shown this association. Some studies, such as Weaver et al. (10), have shown a reduction in symptoms and hospital days, though others have not. Interpretation of published literature is vexing due to methodological issues. Overall, there are insufficient data to formulate a strong conclusion regarding the effectiveness of anti-staphylococcal prophylaxis (12). Prevention of P. aeruginosa has also been explored using various techniques. Among the most promising strategies is vaccination. To date, while some vaccines have shown encouraging results (15), none has been adequately effective to develop for widespread clinical use. Primary prevention via routine inhalation of anti-pseudomonal antibiotics has also been suggested on the basis of clinical observations (16), but has not been adequately studied in randomized, prospective trials. Eradication strategies for CF infection have focused on treatment of patients with P. aeruginosa. This strategy was pioneered in Denmark, where treatment of initial

230

McColley

positive cultures for P. aeruginosa with a three-month course of ciprofloxacin and colistin was implemented on a widespread basis. Compared with historical controls, treated patients had a marked reduction in chronic infection with P. aeruginosa, improved pulmonary function, and a possible survival benefit (17); as controls were historical, the effects of eradication of P. aeruginosa could not be fully separated from other advances in care. Although this specific treatment strategy was not uniformly adopted across different countries, there is now broad consensus that it may be helpful to treat patients with new infections with P. aeruginosa with antibiotics, with a goal of eradication. Various antibiotics have been studied in this context, either as mono- or combination therapy. Gibson et al. (18) performed BAL in infants and young children with positive oropharyngeal cultures for P. aeruginosa. Those with P. aeruginosa isolated from BAL cultures were randomized to receive tobramycin inhalation solution (TIS) or placebo for 28 days. When BAL was repeated at the end of therapy, 8 of 8 subjects receiving TIS had cultures that were negative for P. aeruginosa, whereas only 1 of 13 subjects receiving placebo had a negative culture. In a subsequent study (19), subjects with positive BAL cultures for P. aeruginosa received either 28 or 56 days of TIS; BAL was repeated 4, 8 or 12 weeks following cessation of therapy. In this study, the majority of subjects had BAL cultures that were negative for P. aeruginosa up to 12 weeks after completing either 28 or 56 days of treatment. Thus, TIS appears to be an effective therapy for treatment of P. aeruginosa after initial infection or reinfection. Whether or not scheduled anti-pseudomonal antibiotic therapy after negative cultures are achieved has clinical benefit is under investigation. Chronic suppressive antibiotic therapy has been employed for many years in the treatment of CF lung disease. Studies on this strategy for S. aureus are limited, because most include both uninfected patients and infected patients; thus the prophylactic versus suppressive effects cannot be easily separated. Colistin via inhalation was the first antipseudomonal antibiotic employed for chronic suppression of P. aeruginosa, but no welldesigned double-blind, placebo-controlled clinical trials have been performed. Preclinical studies of inhaled tobramycin showed good potential for chronic suppression but predicted that very high doses would be required for adequate bacterial killing, because of biofilm formation and the properties of CF sputum. Ramsey et al. (20) reported improved pulmonary function after 28 days of high-dose tobramycin, 600 mg thrice daily via ultrasonic nebulizer, in a crossover study of patients with chronic P. aeruginosa infection. On the basis of these findings, TIS was developed. Two randomized, placebocontrolled clinical trials in patients with FEV1 25% to 75% predicted and chronic P. aeruginosa showed improvement in pulmonary function and reduction in exacerbation frequency in patients receiving TIS at a dose of 300 mg twice daily during alternating four-week periods compared with those receiving placebo (21). A subsequent randomized, open label study of subjects with mild lung disease was terminated early, after patients in the active treatment group showed a greater than twofold decrease in number of pulmonary exacerbations compared with a group receiving no treatment. Chronic therapy with TIS has become a common treatment strategy for patients with chronic P. aeruginosa infection; however, studies spanning several years are lacking. A number of other inhaled antibiotics are currently under development for chronic suppressive therapy of P. aeruginosa in CF. These include inhaled preparations of

Treatment Strategies for Maintaining Pulmonary Health in CF

231

aztreonam and fluoroquinolones as well as a liposomal preparation of amikacin. Some may have activity against other pathogens as well.

V. Other Specific Therapies for Maintenance of Pulmonary Health A. Airway Clearance and Mucoactive Therapies

Techniques to clear mucus from the airways via mechanical methods are among the oldest CF therapies in use. Therapies that improve mucociliary clearance, including dornase alfa and hypertonic saline, are widely used in CF care. Dornase alfa decreases sputum viscosity by degrading DNA that is released from dying neutrophils in the airway that were recruited to combat the airways infection. Hypertonic saline, in contrast, improves the defective mucociliary clearance of CF airways. These are discussed in more detail in chapter 15 by Ratjen and Lapin. B. Exercise

Exercise is an important adjunct to maintenance of pulmonary health in CF. Increased peak oxygen consumption (VO2 peak), a measure of aerobic fitness, is a significant and independent predictor of survival in CF (22). Long-term aerobic and anaerobic training are with improved measures of fitness, but variable results are seen in other measures such as weight, body composition, and pulmonary function, and it is unclear whether physical training is an adequate substitute for conventional airway clearance techniques (23). While benefits of exercise are clear, the best way to promote activity and adherence is not; individualized plans based on patient preferences and resources may be the optimal method, but have not been adequately studied (24). C. b-Agonists

Short-acting b-agonists, such as albuterol, have been used for many years for maintenance therapy of CF lung disease; long-acting b-agonists have been more recently introduced. The rationale for b-agonist therapy includes bronchodilation and enhanced mucociliary clearance through increasing ciliary beat frequency. Numerous studies have shown that administration of b-agonists improves FEV1; these have been reviewed in a Cochrane Collaborative report (25). While most of the randomized, clinical trials have been of short duration and are mixed in terms of inclusion of subjects with or without demonstrable bronchodilator responsiveness, both short- and longer-term studies have suggested better lung function in patients receiving short- or long-acting chronic b-agonist therapy. D. Anticholinergic Agents

Fewer studies of anticholinergics have been performed, all using short-acting anticholinergic drugs. These were included in the Cochrane Collaborative report mentioned above (25). Improvement in FEV1 has been seen in these studies; however, most are single-dose or very short-term studies, and other clinical outcomes have not been reported. There is ongoing interest in the use of anti-cholinergic agents, driven in part by their benefit in chronic obstructive pulmonary disease, and further clinical trials are anticipated.

232

McColley E.

Corticosteroid Therapy

Early studies of oral corticosteroid therapy of CF lung disease appeared promising, with improvement in both pulmonary function and nutritional indices (26). A subsequent large, multiyear clinical trial of alternate day prednisone (27) confirmed a small but significant benefit in pulmonary function; however, this was accompanied by a high rate of serious side effects, including abnormal glucose metabolism, linear growth retardation, cataracts, and an increased rate of cultures positive for P. aeruginosa. As a result, chronic therapy with oral corticosteroids is usually reserved for treatment of complicating conditions of CF, such as allergic bronchopulmonary aspergillosis. Inhaled corticosteroids (ICS), a mainstay of therapy for persistent asthma, are frequently prescribed to patients with CF (28). A number of studies have failed to show benefit on pulmonary function or on pulmonary exacerbation rate in CF. A withdrawal study that assessed the effect of discontinuing budesonide versus continuing therapy in 117 children with CF showed no difference in time to exacerbation, the primary endpoint, between the two groups. However, in the Epidemiologic Study of Cystic Fibrosis, addition of inhaled steroid therapy in children with CF was associated with a decreased rate of FEV1 decline compared with prior to initiation of ICS therapy (29) after controlling for use of other therapies, including intravenous antibiotics. Importantly, children starting ICS therapy had decreased linear growth and an increase in use of insulin and oral hypoglycemic agents. This suggests the possibility that some patients may benefit, but there are insufficient data to specifically identify which patients may be candidates for this therapy, and corticosteroid side effects are a risk of therapy. F.

Nonsteroidal Anti-inflammatory Therapy

Ibuprofen therapy for CF was first described in a four-year, double-blind, placebocontrolled study at a single CF center in the United States (30). The main outcome was a decrease in the rate of FEV1 decline in the patients randomized to ibuprofen. A subsequent, larger, multicenter trial in Canada showed similar positive benefits of ibuprofen (31). An analysis of U.S. Cystic Fibrosis Foundation Registry Data confirmed a reduction in the rate of pulmonary function decline in a cohort of patients taking high-dose ibuprofen therapy compared with patients in the same age range not taking ibuprofen (32). G. Macrolides

Several clinical trials have shown that chronic administration of low-dose azithromycin, a macrolide antibiotic, improves pulmonary function and reduces pulmonary exacerbation frequency compared with placebo (33–35), particularly in patients with chronic infection with P. aeruginosa. Some studies have included a substantial proportion of patients without P. aeruginosa (36), and a large study of chronic azithromycin therapy for patients with CF who are not colonized with P. aeruginosa is nearing completion. Chronic administration of azithromycin is associated with resistance to azithromycin in S. aureus strains (37). H. Ion Channel Therapies

Therapies that increase chloride transport or reduce sodium absorption across the airway epithelial surface are of great interest for pulmonary maintenance therapy. Clinical trials of several agents have been undertaken. One of these agents, denufosol tetrasodium, is a

Treatment Strategies for Maintaining Pulmonary Health in CF

233

P2Y2 receptor agonist that activates chloride transport via an alternate chloride channel. Phase 2 and 3 clinical trials showed a benefit in pulmonary function in patients with mild pulmonary disease by spirometric criteria (38,39). A phase 3 registration trial is in progress. I.

CFTR Mutation Directed Therapy and Gene Therapy

Improvement of function of mutant CFTR protein or incorporation of a normal copy of the CFTR gene into airway epithelial cells have been targets of drug development since the CFTR gene was first discovered. These are discussed in chapters 24 and 25 by Mueller and Flotte, and Hoover and Clancy, respectively.

VI.

Summary

CF lung disease has complex pathophysiology that remains incompletely understood 20 years after the discovery of the CFTR gene. Maintenance treatment is continually evolving. Prevention of pulmonary disease in CF remains an elusive goal; however, with an increasing number of therapies available, the opportunity to reduce the impact of lung disease is tremendous.

References 1. Wine JJ. Basic aspects of cystic fibrosis. Clin Rev Allergy 1991; 9:1–28. 2. Linnane BM, Hall GL, Nolan G, et al. Lung function in infants with cystic fibrosis diagnosed by newborn screening. Am J Respir Crit Care Med 2008; 178:1238–1244. 3. Khan TZ, Wagener J, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151:1075–1082. 4. Kirchner KK, Wagener JS, Khan TZ, et al. Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis. Am J Respir Crit Care Med 1996; 154: 1426–1429. 5. Armstrong DS, Grimwood K, Carlin JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997; 156:1197–1204. 6. Long FR, Williams RS, Castile RG. Structural abnormalities in infants and young children with cystic fibrosis. J Pediatr 2004; 144:154–161. 7. Tiddens HAWM. Detecting early structural lung damage in cystic fibrosis. Pediatr Pulmonol 2002; 34:228–213. 8. Johnson C, Butler SM, Konstan MW, et al. Factors influencing outcomes in cystic fibrosis: a center based analysis. Chest 2003; 123:20–27. 9. Flume PA, O’Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lug health. Am J Respir Crit Care Med 2007; 176:957–969. 10. Weaver LT, Green MR, Nicholson K, et al. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Arch Dis Child 1994; 70:84–89. 11. Beardsmore CS, Thompson JR, Williams A, et al. Pulmonary function in infants with cystic fibrosis: the effect of antibiotic treatment. Arch Dis Child 1994; 71:133–137. 12. McCaffery K, Olver RE, Franklin M, et al. Systematic review of antistaphylococcal antibiotic therapy in cystic fibrosis. Thorax 1999; 54:380–383. 13. Stutman HR, Lieberman JM, Nussbaum E, et al. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J Pediatr 2002; 140:299–305. 14. Ratjen F, Comes G, Paul K, et al. Effect of continuous anti-staphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis: a randomized controlled trial. Pediatr Pulmonol 2001; 31:13–16.

234

McColley

15. Zuercher AW, Horn MP, Que JU, et al. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. FEMS Immunol Med Microbiol 2006; 47:302–308. 16. Lebecque P, Leal T, Zylberberg K, et al. Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros 2006; 5:237–244. 17. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23:330–335. 18. Gibson RL, Emerson J, McNamara S, et al. Significant microbiologic effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003; 167:841–879. 19. Gibson RL, Emerson J, Mayer-Hamblett N, et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007; 42:610–623. 20. Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993; 328:1740–1746. 21. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic fibrosis inhaled tobramycin study group. N Engl J Med 1999; 340:23–30. 22. Nixon PA, Orenstein DM, Kelsey SF, et al. The prognostic value of exercise testing in patients with cystic fibrosis. N Engl J Med 1992; 327:1785–1788. 23. Bradley JM, Moran FM, Elborn JS. Evidence for physical therapies (airway clearance and physical training) in cystic fibrosis: an overview of five Cochrane systematic reviews. Respir Med 2006; 100:191–201. 24. Orenstein DM, Higgins LW. Update on the role of exercise in cystic fibrosis. Curr Opin Pulm Med 2005; 11:519–523. 25. Halfhide C, Evans HJ, Couriel J. Inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev 2005; 4:CD00348. Available at: http://www.cochrane.org/reviews/clibintro.htm. 26. Auerbach HS, Williams M, Kirkpatrick JA, et al. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985; 2:686–688. 27. Eigen H, Rosenstein BJ, FitzSimmons S, et al. Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995; 126:515–523. 28. Oermann CM, Sockrider MM, Konstan MW. The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes. Chest 1999; 115:1053–1058. 29. Ren CL, Pasta DJ, Rasouliyan L, et al. Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. J Pediatr 2008; 153:746–751. 30. Konstan MW, Byard PJ, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332:848–854. 31. Lands LC, Milner R, Cantin A, et al. High dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 2007; 149:249–254. 32. Konstan MW, Schulcter MD, Xue W, et al. Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007; 176:1084–1089. 33. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. J Am Med Assoc 2003; 290:1749–1756. 34. Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomized trial. Thorax 2002; 57:212–216. 35. Equi A, Balfour-Lynn JM, Bush A, et al. Long term azithromycin in children with cystic fibrosis: a randomized, placebo-controlled crossover trial. Lancet 2002; 360:978–984.

Treatment Strategies for Maintaining Pulmonary Health in CF

235

36. Clement A, Tamalet A, Leroux E, et al. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006; 61:895–902. 37. Tramper-Stranders GA, Wolfs TFW, Fleer A, et al. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis. Long term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J 2007; 26:8–12. 38. Deterding R, Retsch-Bogart G, Milgram L, et al. Cystic Fibrosis Foundation Therapeutics Development Network. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol 2005; 39:339–348. 39. Deterding RR, Lavange LM, Engels JM, et al. ; for the Cystic Fibrosis Therapeutics Development Network and the Inspire 08-103 Working Group. Phase 2 randomized safety and efficacy trial of denufosol tetrasodium in cystic fibrosis. Am J Respir Crit Care Med 2007; 176:362–369.

15 Mucolytic Therapy and Airway Clearance Techniques FELIX RATJEN Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada

CRAIG LAPIN Connecticut Children’s Medical Center, University of Connecticut, Hartford, Connecticut, U.S.A.

I.

Mucolytic Therapy

Airway mucus is a two compartment liquid consisting of both an aqueous layer that supports the epithelial cilia and a gel layer that mainly contains glycoproteins (mucins) (1). The term “mucus” is also used for secretions produced in respiratory diseases such as cystic fibrosis (CF), although this term may actually be inappropriate as the composition of airway secretions in CF differs greatly from normal physiological content. The goal of mucolytic therapy is to facilitate physiological clearance by optimizing the viscoelasticity of mucus. Optimizing viscoelasticity does not equal maximal reduction of both viscosity and elasticity: therapy that lowers mucus viscosity beyond the physiological state has the potential to negatively affect its transportability, as secretions with viscosity close to that of water cannot be cleared effectively by either mucociliary or cough clearance (2). Overall, mucociliary transportability of sputum can be improved by reducing sputum viscosity, given that elasticity is preserved, while cough clearability of secretions requires higher viscosity. Several agents, described below, have been used in an effort to enhance the removal of secretions from the CF airway. A. N-Acetylcysteine

Accumulation of mucopurulent secretions in the lower airways is a key feature of CF lung disease. Classic mucolytic drugs reduce the elasticity and viscosity of mucus by breaking down the gel structure of mucus. However, the major component of airway secretions in CF is not mucin derived from mucus-producing cells but rather it is pus derived from degraded neutrophils (3). While there is ongoing controversy as to whether mucins are reduced in CF airway secretions or not (4,5), there is little evidence that classic mucolytics have any efficacy in CF. The best studied compound is N-acetylcysteine (NAC), which lowers both the viscosity and elasticity of the mucus by substituting free sulfhydryl groups for the disulfide bonds connecting mucin proteins (6). Despite in vitro mucolytic activity in airways diseases including CF, there are no convincing data to support the use of inhaled NAC in CF lung disease (7). On the other hand, oral acetylcysteine has been shown to replete glutathione stores in CF patients and may potentially play a role as an antioxidant (8).

236

Mucolytic Therapy and Airway Clearance Techniques

237

B. Dornase alfa

CF sputum as well as bronchoalveolar lavage fluid have been shown to contain significant amounts of DNA (9,10). Extracellular DNA is mainly derived from neutrophils recruited into the airway lumen as part of the inflammatory response. Extracellular DNA polymerizes and contributes to the viscid airway secretions in CF patients (11). Dornase alfa is a recombinant form of the human DNase 1 enzyme and digests extracellular DNA. When mixed with purulent sputum from subjects with CF, dornase alfa has been shown to lower the viscosity and adhesivity of sputum in vitro (9). This effect has also been found in studies on sputum samples from patients inhaling dornase alfa, although variability in response exists. Reduction in viscosity is associated with fragmentation of DNA in the sputum that is seen in the majority, but not all cases (12). The change in sputum viscosity with the addition of dornase alfa is dose dependent, with greater reduction occurring at higher drug concentrations. Interestingly, while dornase alfa increased transportability of mucus in an in vitro model (the excised frog palate), in vivo studies in CF patients did not demonstrate any effect on mucociliary clearance (13,14). Initial studies with dornase alfa have demonstrated improvements in pulmonary function in patients during treatment, an effect that is lost once therapy is stopped (15). This resulted in the concept of designing dornase alfa as a long-term therapy for CF. The clinical response to dornase alfa treatment is well documented. In a large phase III trial, inhalation of dornase alfa was found to reduce the frequency of respiratory infections requiring parenteral antibiotics and to improve pulmonary function in CF patients with moderate disease severity (16). A subsequent study in patients with milder disease demonstrated similar effects on both pulmonary exacerbations and lung function (17). The safety and benefit of dornase alfa has also been demonstrated in patients with severe lung disease (18). On the basis of these positive study results dornase alfa is one of the compounds that has been recommended by the Cystic Fibrosis Foundation therapy guidelines committee (19). Dornase alfa treatment appears to have indirect effects on downstream aspects of CF lung disease such as infection and inflammation. A study using bronchoalveolar lavage to assess the evolution of airway inflammation in CF patients with normal lung function demonstrated a positive effect on inflammation in the treated patients (20). DNA burden was also reduced as were matrix proteinases (10,21). A recent study also suggested that treatment may lower the rate of Staphylococcus aureus infection in CF patients (22). Treatment with dornase alfa is well tolerated, and its side effects are rare. Adverse events occurring in higher frequency in treated patients include voice alterations, pharyngitis, or laryngitis; these are usually transient despite continuation of treatment (16). Because of its effect on mobilizing secretions, dornase alfa often induces cough during the initial phase of therapy and should not be given right before bedtime.

II.

Airway Surface Liquid Hydration Therapy

Effective mucociliary clearance depends on an adequate volume of airway surface liquid (ASL) as outlined in chapter 3. As CF is characterized by depletion of the ASL layer, osmotic agents that improve surface hydration by increasing the water content of the epithelial surface and therefore of the liquid phase of mucus can improve clearance of airway secretions (23). The osmotic effect is not limited to the ASL layer as treatment

238

Ratjen and Lapin

will also improve hydration of airway mucus thereby reducing its viscosity. However, the main function of these agents is thought to be the result of increasing ASL water content. Because of their mechanism of action, these agents are therefore considered to be hydrators rather than mucolytic agents.

A. Hypertonic Saline

Hypertonic saline has been shown to improve mucociliary clearance in CF patients when administered as a single dose (24). These positive effects were concentration dependent, and mucociliary clearance continued to increase up to a concentration of 7%. Higher concentrations did not further improve mucociliary clearance, but were associated with a higher rate of side effects; therefore, a 7% solution has been used in most clinical studies (25). A series of smaller studies using hypertonic saline showed promising short-term benefits on lung function in CF patients (26,27). Initially, the effect of hypertonic saline was thought to be rather short lived, since sodium applied to the epithelial surface was expected to be rapidly taken up through the epithelial sodium channel, whose activity is upregulated in CF. Surprisingly, a recent study demonstrated that hypertonic saline not only had a prolonged effect on ASL height of CF epithelium in vitro, but also resulted in a sustained improvement of mucociliary clearance in CF patients: improved mucociliary clearance was observed up to eight hours after the last dose (28). A large Australian trial with 7% hypertonic saline addressed the question of longterm benefit of this treatment (29). After 48 weeks of inhaled hypertonic saline, patients had a modest improvement in FEV1 compared with the isotonic saline control group. A more impressive effect was seen on pulmonary exacerbations, which were significantly reduced in patients receiving hypertonic saline. Notably, the beneficial effects seen in the study were independent of concurrent dornase alfa use. These studies did not clarify whether the improvement in mucociliary clearance arises from an increase in ASL, from improvements in airway clearance through induction of cough, or a combination of the two mechanisms. If hydration of the airways is the major effect, hypertonic saline could be an attractive early intervention strategy to be initiated before major airway disease is established. Two single-center studies recently showed that inhaled hypertonic saline can be used safely in infants and young children (30,31). A multicenter trial to assess the effect of inhaled hypertonic saline in infants is currently under way. Hypertonic saline can lead to bronchospasm and patients should be pretreated with bronchodilators. Testing of acute treatment response is recommended to assess tolerability in individual patients before initiating long-term treatment. Although salty taste, nausea, dyspnea, and chest pain have been reported, hypertonic saline has been found to be well tolerated in clinical studies. Similar to other medications administered via inhalation, deposition of an osmotic agent such as hypertonic saline will preferentially occur in areas not obstructed by mucous plugs. The most affected areas may therefore not benefit from this treatment approach. Moreover, hypertonic droplets exhibit hydroscopic growth in a water vapor saturated environment such as the lower airways, which will increase their particle size during inhalation and favor a more central deposition unless the nebulizer system is adjusted accordingly to produce a smaller particle size (32). This makes it less likely that adequate amounts of the osmotic agent enter the smaller airways, the area where CF lung disease is

Mucolytic Therapy and Airway Clearance Techniques

239

thought to originate. In addition, the small airways have a large overall surface area, by far exceeding the surface area of the central airways. It is currently not clear what quantity of an osmotic active agent is needed to restore ASL in CF patients. There is ongoing debate whether hypertonic saline should be used as an alternative or adjunct to other therapies addressing airway clearance. As outlined earlier, the only other medication with proven efficacy on airway clearance in CF patients is recombinant DNase (dornase alfa). Data for a head-to-head comparison of these two agents are rather limited. A crossover trial has found hypertonic saline to be inferior to dornase alfa with respect to lung function improvements. However, this study did not assess pulmonary exacerbations as an outcome parameter (33). In vitro studies have shown beneficial effects of combining hypertonic saline and dornase alfa, and the large Australian study found similar treatment effects of hypertonic saline in patients on dornase alfa therapy compared with those treated with hypertonic saline alone (14). B. Mannitol

Mannitol is a monosaccharide that is available as a dry powder for inhalation. Mannitol has primarily been developed as a simple alternative to histamine or methacholine to test for bronchial hyperresponsiveness, therefore its tolerability may be less favorable in patients with airway hyperreactivity (34). Similar to hypertonic saline, dry powder mannitol is hyperosmolar and can cause an influx of water into the CF airway thereby increasing ASL volume (35). Similar to hypertonic saline, mannitol has been shown to improve mucociliary clearance in CF patients (36). A recent phase II trial demonstrated improvements in lung function in treated patients, but the long-term benefit of inhaled mannitol are currently unknown (37). While tolerability was reported to be adequate in this trial, another study reported that one quarter of CF children showed a significant fall in FEV1 in response to a test dose of mannitol, which could potentially limit the broad applicability of this treatment (38). There is potential concern that chronic mannitol inhalation can contribute to the proliferation of bacteria in the lower airways, as mannitol can act as a carbon source for bacteria such as Pseudomonas. No evidence for this was seen in the recent phase II study, but further evidence is needed to clarify this in a trial of longer duration.

III.

Airway Clearance

Airway clearance therapy (ACT) is considered to be part of standard of care in CF, but this is not based on strong scientific data proving its efficacy. Many studies show no significant change between treated groups or the control, and it is unlikely that ACT will ever be completely evidence based in CF. Two excellent reviews have recently questioned the evidence supporting the use of any type of airway clearance (39,40). Most ACT studies were of short duration and/or included a small number of patients, thus decreasing their ability (power) to demonstrate a difference, but short-term benefits have been reported (41). The widespread acceptance of ACT in the CF community has reduced the possibility of performing trials that include an untreated control group, and most studies have therefore compared different modalities to each other. There is little consensus regarding which outcome measures should be used in trials evaluating ACTs. Pulmonary function tests generally are not sensitive enough for short-term studies to indicate superiority of one treatment over another, and few long-term studies have ever been attempted. Mucociliary clearance studies using

240

Ratjen and Lapin

nuclear medicine have shown differences between ACT modalities; unfortunately they are expensive, require expertise, and are not standardized. Secretion production, measured by wet or dry sputum weight, has been used in many studies; theoretically less mucus should mean less obstruction, less inflammation, and better preservation of health. The mixture of mucus with saliva during expectoration complicates the assessment of true clearance, and there is no clear correlation between sputum quantity and other clinically significant outcomes, making mucus production a difficult outcome to validate. Other outcome measures such as pulmonary exacerbation rates and quality of life have rarely been assessed in studies to date. Debate is ongoing as to whether airway clearance should be initiated in the asymptomatic infant, a discussion that has intensified with the wider utilization of newborn screening (42). There are several studies that document early signs of disease even in infants (43–45), but there are few studies that have considered airway clearance at this age (10,46,47).

A. Airway Clearance Physiology

Airway clearance is affected by a number of factors including the quantity and viscosity of mucus, size of bronchi and their apertures, ciliary beat frequency, as well as shear forces generated by airflow from ventilation. The greater the shear forces, the more the mucus movement. Airway clearance techniques cannot enhance secretion clearance without airflow (48). Factors that can affect airflow include airway resistance, expiratory pressures, bronchial wall stability, and elastic recoil. Airway clearance techniques employ maneuvers that can affect these factors. Many techniques utilize the concepts of asynchronous ventilation, collateral ventilation channels, and choke points (CP). CPs explain flow limitation in the wavespeed theory of pulmonary physiology (49). For this chapter, CP terminology will be used synonymously with the “equal pressure point” used in earlier studies. The CPs are the regions where the pressure within the airway has decreased to equal the pleural (extramural) pressure and hence the pressure difference across the airway wall is zero. With breathing at tidal volume to functional residual capacity (FRC), the CP lies in the trachea and main bronchi; as exhalation moves into lower lung volumes (expiratory reserve volume), the point at which dynamic compression takes place moves more peripherally (50,51). Coughing is the body’s natural mechanism for airway clearance. CPs play an extremely important part in the effectiveness of cough because a significant jump in airflow velocity occurs at these points of narrowing. High linear airflow velocity is associated with turbulent flow, high shearing forces at the airway walls, and high kinetic energies. Another means to produce supramaximal airflow and high linear velocities is a “huff.” This is a forced expiratory maneuver, usually initiated from mid-to-low lung volumes and is performed with an open glottis. The huff maneuver does not generate as high a transmural pressure as does cough, and so it may be more effective in helping to clear secretions when airway walls are unstable because of cartilage destruction, by causing less airway collapse. A huff can also be instituted at different lung volumes, thus allowing the shift of CPs to different areas. Mucus can be mobilized with expiratory airflow velocities of 1.0 to 2.5 m/sec for annular flow, or >2.5 m/sec for mist flow moving sputum droplets suspended as an

Mucolytic Therapy and Airway Clearance Techniques

241

Figure 1 Flow volume loops and flow transients with cough and huff.

aerosol (52). Airflow of sufficient magnitude to mobilize secretions and mucus transport itself can occur during forced exhalations (huffs) or even with tidal breathing in some circumstances (53). Bennett and Zeman determined that airway clearance with huff was faster than control and similar to that generated by voluntary cough (54) (Fig. 1). Asynchronous ventilation is related to different filling times for different regions of the lung—faster for healthier and unobstructed areas, slower for more diseased and obstructed regions. Alternate or collateral ventilation channels exist between bronchi and/or alveoli in older children and adults (55), but are not present in infants and toddlers. In healthy lungs, little gas movement occurs through these channels during regular breathing. Breath-holding maneuvers can improve aeration in obstructed, less healthy areas by maximizing filling time for slow-filling regions, promoting ventilation through collateral channels and interdependence (Pendelluft) (56). B. Airway Clearance Techniques Postural Drainage and Percussion

Postural drainage and percussion (PD&P) has been synonymous with chest physical therapy in CF for decades. There are 12 different positions in which a patient can be placed to optimize central movement of mucus from bronchopulmonary segments. Percussion, vibration, and shaking may be used as adjuncts. In each position, the chest is percussed between 2 to 10 minutes, usually followed by deep breathing exercises and huffing on exhalation in older patients. Studies have shown PD&P to be an effective technique for clearing excessive bronchial secretions in patients with CF (57–59). Potential problems associated with PD&P include time and energy used, discomfort and pain, hypoxemia (60), arrhythmias (61), and bronchospasm (62). The head-down position has become controversial because of concerns over gastroesophageal reflux and increased pulmonary disease (63,64). Modified PD&P excludes this position unless a specific focal lesion warrants it. It is now suggested that modified PD&P (omitting the

242

Ratjen and Lapin

head-down position) be performed in all patients, especially those with any symptoms of gastroesophageal reflux. Active cycle of breathing techniques

The active cycle of breathing technique (ACBT) is a cycle of breathing control (BC), thoracic expansion exercises (TEE), and the forced expiration technique (FET = huffing combined with BC) (65) (Fig. 2). The greatest strength of ACBT is its adaptability for different lung pathophysiology. TEE (with breath-hold) results in asynchronous ventilation; this component should be augmented in the cycle when atelectasis or emphysema is present. FET moves the secretions from different parts of the airways, and is used more often in patients with excess secretions. ACBT was initially known as the FET (65); however, this predisposed to a misinterpretation, with the BC and TEE components of the cycle sometimes being omitted entirely (66). ACBT trials have shown equivalence compared with directed coughing, PD&P, autogenic drainage (AD), positive expiratory pressure (PEP), or oscillating PEP/Flutter (oscPEP) with respect to pulmonary function, mucociliary clearance, and/or wet sputum weight (67–70).

Figure 2 Active cycle of breathing techniques—three cycles for differing lung pathology:

(A) mild disease; (B) increasing secretion; (C) complex disease with significant atelectasis, airway hyperreactivity, and secretions.

Mucolytic Therapy and Airway Clearance Techniques

243

Autogenic Drainage

The underlying concept of AD is to achieve high expiratory flow rates in different generations of bronchi by controlled breathing, but to avoid significant airway closure that may occur with coughing or forced exhalations (71–73). Performing regular tidal volume breaths at low to high lung volumes generates higher flow rates that start in the small peripheral airways and gradually move into larger central ones. These greater flow rates produce higher shear forces than might occur with cough or forced expiratory maneuvers. The incorporation of a breath-hold throughout the technique improves asynchronous ventilation by lengthening the time for alveolar filling and increasing collateral ventilation. The technique of AD requires feedback to the patient to facilitate mucociliary clearance. Preliminary evidence from a study comparing AD and PD&P demonstrated no difference in clinical status or pulmonary function (74); the study ended early after the first year because almost half the AD group refused to change over to PD&P as they felt AD was more effective. Studies comparing AD to PD&P (75), high pressure positive expiratory pressure (HiPEP) (76), or ACBT evaluating oxygenation, pulmonary functions, and mucociliary clearance (69) did not demonstrate significant differences in efficacy between techniques. Positive Expiratory Pressure

PEP is proposed to increase airflow via the collateral ventilatory channels (55). In the presence of lung disease, with breath-holds and when breathing out against a PEP, it is proposed that these channels open more. As a result, the resistance to airflow falls and air can flow along collateral channels, allowing air to build up behind secretions to assist in loosening and mobilizing them. More slowly ventilating lung units can also receive part of their inspired volume from the more rapidly ventilating units via the collateral channels. PEP also should reduce dynamic compression of unstable airways during expiration (77). PEP involves tidal breathing with a slightly active exhalation partially into the expiratory reserve volume through a mask or mouthpiece and one-way valve system. A resistor is attached to the expiratory limb, and this is adjusted to give pressures between 10 and 20 cmH2O in mid-exhalation. After several breaths to build up air behind mucus, the patient huffs or coughs to mobilize secretions. Effectiveness of PEP (78) as an airway clearance regimen was first demonstrated in a study from Denmark. A subsequent one year study (79) showed improved lung function with PEP, compared with a decline in lung function in the group using PD&P. High-pressure PEP is a modification (80) in which 8 to 10 breaths against a fixed resistor with pressures 10 to 20 cm, similar to regular PEP, is followed by 1 to 2 huffs or forced expirations through the resistor. Pressures generated usually are between 50 and 120 cmH2O, and the resistor selected is the one that maximizes forced vital capacity. The regimen of high-pressure PEP requires close and ongoing monitoring, using flow volume loops to select the resistor which optimizes the flow volume loop for highest vital capacity. This modality has been shown to be effective in airway clearance in CF, but superiority over conventional PEP has not been demonstrated (81). In spite of theoretical concern because of raised pressures, there has been no demonstration of increased complications of pneumothorax or hemoptysis using high-pressure PEP (82). Oscillating Positive Expiratory Pressure

This technique combines PEP with high-frequency oscillations (HFOs) generating intermittent acceleration of expiratory airflow. Oscillatory endobronchial pressure

244

Ratjen and Lapin

pulses cause flow transients, microsecond periods when flow exceeds the maximal expiratory flow able to be generated by a forced expiratory maneuver. Coughing and huffing also generate flow transients (Fig. 1). Endobronchial oscillating pressures are proposed to act as “microcoughs,” transiently increasing the airflow and shear forces over the mucus layer, thus promoting mucus clearance (83). The PEP generated may decrease dynamic collapse of unstable airways, and endobronchial vibrations help to dislodge secretions from the airway lumen (84). HFOs are capable of breaking mucus bonds, decreasing viscosity (61), and improving clearance. Finally, it is hypothesized that the oscillations enhance ciliary beat frequency as well as disrupt mucus adhesion to airway walls. The three main devices used in oscillating positive expiratory pressure (OscPEP) are the Flutter, RC Cornet1, and Acapella1; the latter also allows delivery of a fixed exogenous PEP beneath the endobronchial pressure pulses. In vitro comparative studies of the Flutter and Cornet show the Flutter generates higher peak pressures at higher frequencies, but lowers amplitudes of the endobronchial pulse (85). There is no convincing evidence that any of the devices is superior to the others (86), but the Acapella might be easier to use for some patients because its effectiveness is less dependent on technique. The Flutter has been used in several studies that have not demonstrated superiority to PD&P (87,88), ACBT (68), or PEP (89,90). High Frequency Chest Compression

High-frequency chest compression (HFCC) or high-frequency chest wall oscillation (HFCWO) has been shown to increase mucociliary clearance (91,92) theoretically by increasing an expiratory flow bias. This cephalad flow bias is purported to be the main mechanism of mucus clearance in smaller airways with bulk airflow (as opposed to convection) and is associated with a tendency toward shearing mucus and movement centrally (93,94). A comparison of a percussor (producing an unbiased sine wave) to an oscillator showed that the oscillator produced higher flow and a significantly increased mucus velocity (95). HFCC also enhances secretion clearance by decreasing the viscoelasticity of mucus (96). Multiple versions of HFCC vests exist; the waveform of the pressure pulse delivered varies by device (square wave for ThAIRpy, ABI, and Hill-Rom 101 and 102; sine wave for 103, 104, MedPulse, and SmartPulse; and triangle waveform for inCourage System). Because of this, review and evaluation of HFCC literature requires careful attention to the device used (97–99). Lower frequencies oscillate more volume for a given pressure setting, while higher frequencies cause higher oscillating flow rates and therefore more shear force. Increasing pressure settings increases both flows and volumes, but is usually associated with greater discomfort. Vests that generate a sine wave are used at the highest pressure setting that can be tolerated; lower frequencies are used to displace volume, while higher frequencies are used to increase flow rates. For vests generating triangular waveform pressure pulses both the largest airflows and air volumes reportedly occur over the same frequency range of 5 to 11 Hz (98). It is important for the patient to cough or huff during and at the end of treatment to perform the technique properly. Evidence for efficacy is limited and no studies have demonstrated clinically significant differences between the different devices. An observational retrospective analysis suggested that HFCC can increase sputum production (100). Decreased end-expiratory

Mucolytic Therapy and Airway Clearance Techniques

245

lung volumes have been documented with use of the vest (101), but atelectasis is not a reported complication of vest use in CF patients. Using positive end-expiratory pressure improves oscillatory flows with HFCC in CF (102,103). A recent small, short-term study showed better pulmonary function response in patients treated with ACBT compared with HFCC during an acute pulmonary exacerbation (104), but sufficiently powered studies have not been performed to compare HFCC with other treatment modalities. Intrapulmonary Percussive Ventilation

In theory, intrapulmonary percussive ventilation (IPV) improves airway clearance by several means. Mucus viscosity is decreased with exposure to high-HFO. During inspiration, high-frequency air pulses expand the lungs, enlarge the airways, vibrate, provide an increased mean airway pressure, and deliver gas into distal lung segments beyond accumulated mucus (105). It is further hypothesized that due to the percussive amplitude of shaking airways, mucus is dislodged. Similar to HFCWO, IPV should decrease asynchronous ventilation and improve gas exchange by oscillatory movement and migration of oxygen (room air). Use of IPV theoretically would be effective for patients who would benefit from airway distension (e.g., those with widespread bronchiolectasis) since it distends airways while oscillating them. Finally, IPV delivers continuous oral oscillating pressures during both inhalation and exhalation. Therefore, patients should experience flow transients (microcoughs during exhalation) similar to those found with OscPEP use. Studies on IPV in CF are not extensive and do not demonstrate significant differences to other modalities (106,107). No reports of its use in infants or younger children with CF exist. Exercise

Exercise has long been identified as an alternative or adjunct to airway clearance. A meta-analysis of PEP, FET, AD, exercise, and “standard physical therapy” (PD&P) examined outcomes of FEV1, sputum weight, or sputum clearance. PD&P significantly increased sputum expectoration above no treatment, and only exercise coupled with PD&P increased FEV1 above PD&P alone (59). There is little data to suggest precisely how it improves clearance. Recently, exercise was shown to inhibit epithelial sodium channels in patients with CF, causing a partial normalization of potential difference, and therefore improved ion and water movement into airway secretions (108). C. Selecting Airway Clearance Techniques

As outlined above, each technique is based on physiological principles by which it enhances mucociliary clearance; thus, one modality could potentially be more effective than another. There is, however, no specific research regarding which technique is best for a given patient. Given the lack of strong evidence for superiority of one technique versus others, techniques are often chosen to fit the individual patient’s age, life style, family situation, and culture. This increases the likelihood of adherence, which will then impact upon efficacy. Adherence with ACT in CF is notoriously poor, cited to be between 40% and 60% of patients performing ACT as described (109,110). Age plays a major role in the choice of ACT. Passive techniques are generally used in infants and young children. Techniques vary in complexity, with PEP, oscillating PEP, and HFCC being relatively easy to learn, and AD being the most difficult. For a

246

Ratjen and Lapin

working adult, the ability to perform ACT at any time without the need for adjunct devices may be important. Cost must be taken into consideration including financial and time investment. Ultimately, the ACT to which the patient adheres and performs will be more important than the best physiologically sound technique that the patient does not do (107).

References 1. Voynow JA, Rubin BK. Mucins, mucus, and sputum. Chest 2009; 135(2):505–512. 2. Gelman RA, Meyer FA. Mucociliary transference rate and mucus viscoelasticity dependence on dynamic storage and loss modulus. Am Rev Respir Dis 1979; 120:553–557. 3. Henke MO, Ratjen F. Mucolytics in cystic fibrosis. Paediatr Respir Rev 2007; 8(1):24–29. 4. Henke MO, Renner A, Huber RM, et al. MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions. Am J Respir Cell Mol Biol 2004; 31:86–89. 5. Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet 2008; 372(9636):415–417. 6. Sheffner AL, Medler EM, Jacobs LW, et al. The in vitro reduction in viscosity of human tracheobronchial secretions by acetylcysteine. Am Rev Respir Dis 1964; 90:721–729. 7. Nash EF, Stephenson A, Ratjen F, et al. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst Rev 2009; (1):CD007168. 8. Tirouvanziam R, Conrad CK, Bottiglieri T, et al. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A 2006; 103:4628–4633. 9. Shak S, Capon DJ, Hellmiss R, et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A 1990; 87:9188–9192. 10. Ratjen F, Paul K, van Koningsbruggen S, et al. DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha. Pediatr Pulmonol 2005; 39:1–4. 11. Picot R, Das I, Reid L. Pus, deoxyribonucleic acid, and sputum viscosity. Thorax 1978; 33(2):235–242. 12. Brandt T, Breitenstein S, von der Hardt H, et al. DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with recombinant human DNase. Thorax 1995; 50(8):880–882. 13. Robinson M, Hemming AL, Moriarty C, et al. Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis. Pediatr Pulmonol 2000; 30(1): 16–24. 14. Ramsey BW, Astley SJ, Aitken ML, et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993; 148(1):145–151. 15. King M, Dasgupta B, Tomkiewicz RP, et al. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am J Respir Crit Care Med 1997; 156:173–177. 16. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331:637–642. 17. Quan JM, Tiddens HA, Sy JP, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001; 139:813–820. 18. McCoy K, Hamilton S, Johnson C. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group. Chest 1996; 110:889–895.

Mucolytic Therapy and Airway Clearance Techniques

247

19. Flume PA, O’Sullivan BP, Robinson KA, et al.; for Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007; 176(10):957–969. 20. Paul K, Rietschel E, Ballmann M, et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004; 169:719–725. 21. Ratjen F, Hartog CM, Paul K, et al. Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha. Thorax 2002; 57 (11):930–934. 22. Frederiksen B, Pressler T, Hansen A, et al. Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatr 2006; 95(9):1070–1074. 23. Ratjen F. Restoring airway surface liquid in cystic fibrosis. N Engl J Med 2006; 354: 291–293. 24. Robinson M, Regnis JA, Bailey DL, et al. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med 1996; 153(5):1503–1509. 25. Robinson M, Hemming AL, Regnis JA, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997; 52(10):900–903. 26. Eng PA, Morton J, Douglass JA, et al. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 1996; 21(2):77–83. 27. Ballmann M, von der Hardt, H. Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. J Cyst Fibros 2002; 1(1):35–37. 28. Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354:241–250. 29. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354:229–240. 30. Subbarao P, Balkovec S, Solomon M, et al. Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis. Pediatr Pulmonol 2007; 42(5):471–476. 31. Dellon EP, Donaldson SH, Johnson R, et al. Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis. Pediatr Pulmonol 2008; 43(11):1100–1106. 32. Chan HK, Eberl S, Daviskas E, et al. Changes in lung deposition of aerosols due to hygroscopic growth: a fast SPECT study. J Aerosol Med 2002; 3:307–311. 33. Suri R, Metcalfe C, Lees B, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001; 358:1316–1321. 34. Anderson SD, Brannan J, Spring J, et al. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. Am J Respir Crit Care Med 1997; 156(3 pt 1):758–765. 35. Yankaskas JR, Gatzy JT, Boucher RC. Effects of raised osmolarity on canine tracheal epithelial ion transport function. J Appl Physiol 1987; 62(6):2241–2245. 36. Robinson M, Daviskas E, Eberl S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 1999; 14(3):678–685. 37. Jaques A, Daviskas E, Turton JA, et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008; 133(6):1388–1396. 38. Minasian C, Wallis C, Metcalfe C, et al. Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis. Pediatr Pulmonol 2008; 43(11):1078–1084. 39. Wallis C, Prasad A. Who needs chest physiotherapy? Moving from anecdote to evidence. Arch Dis Child 1999; 80:393–397. 40. Hess DR. The evidence for secretion clearance techniques. Respir Care 2001; 46: 1276–1292. 41. Van der Schans C, Prasad A, Main E. Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis. Cochrane Database of Syst Rev 2003; 1:1–36.

248

Ratjen and Lapin

42. Pryor JA, Main E, Agent P, et al. Physiotherapy. In: Bush A, Alton EWFW, Davies JC, et al., eds. Cystic Fibrosis. Basel: Karger, 2006. 43. Abman SH, Ogle JW, Harbeck RJ, et al. Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening. J Pediatr 1991; 119:211–217. 44. Frederick R, Long MD, Roger S, et al. Structural airway abnormalities in infants and young children with cystic fibrosis. J Pediatr 2004; 144:154–161. 45. Davis S, Jones M, Kisling J, et al. Comparison of normal infants and infants with cystic fibrosis using forced expiratory flow breathing air and heliox. Pediatr Pulmonol 2001; 31:17–23. 46. Hardy KA, Wolfson MR, Schidlow DV, et al. Mechanics and energetics of breathing in newly diagnosed infants with cystic fibrosis: effect of combined bronchodilator and chest physical therapy. Pediatr Pulmonol 1989; 6:103–108. 47. Maayan C, Bar-Yishay E, Yaacobi T, et al. Immediate effect of various treatments on lung function in infants with cystic fibrosis. Respiration 1989; 55:144–151. 48. Lapin CD. Airway physiology, autogenic drainage, and active cycle of breathing. Respir Care 2002; 47:778–785. 49. Dawson SV, Elliott EA. Wave-speed limitation on expiratory flow.- a unifying concept. J Appl Physiol 1977; 43:498–515. 50. Mead J, Turner JM, Macklem PT, et al. Significance of the relationship between lung recoil and maximum expiratory flow. J Appl Physiol 1967; 22:95–108. 51. Zach MS, Oberwaldner B. Chest physiotherapy. In: Taussig L, Landau L, eds. Textbook of Pediatric Respiratory Medicine. St Louis: Mosby, 1999:299–311. 52. Clarke SW, Jones JG, Oliver DR. Resistance to two-phase gas-liquid flow in airways. J Appl Physiol 1970; 29:464–471. 53. Sackner MA, Kim CS. Phasic flow mechanisms of mucus clearance. Eur J Respir Dis 1987; 153(suppl):159–164. 54. Bennett WD, Zeman KL. Effect of enhanced supramaximal flows on cough clearance. J Appl Physiol 1994; 77:1577–1583. 55. Menkes HA, Traystman RJ. Collateral ventilation. Am Rev Respir Dis 1977; 116:287–309. 56. Mead J, Takishima T, Leith D. Stress distribution in lungs: a model of pulmonary elasticity. J Appl Physiol 1970; 28:596–608. 57. Desmond KJ, Schwenk WF, Thomas E, et al. Immediate and long-term effects of chest physiotherapy in patients with cystic fibrosis. J Pediatr 1983; 103:538–542. 58. Reisman JJ, Rivington-Law B, Corey M, et al. Role of conventional physiotherapy in cystic fibrosis. J Pediatr 1988; 113:632–636. 59. Thomas J, Cook DJ, Brooks D. Chest physical therapy management with cystic fibrosis. A meta-analysis. Am J Respir Care Med 1995; 151:846–850. 60. McDonnell T, McNicholas WT, FitzGerald MX. Hypoxaemia during chest physiotherapy in patients with cystic fibrosis. Irish J Med Sci 1986; 155:345–348. 61. Laws AK, McIntyre RW. Chest physiotherapy, a physiological assessment during IPPV in respiratory failure. Can Anaesth Soc J 1969; 16:487–493. 62. Wollmer P, Ursing K, Midgren B, et al. Inefficiency of chest percussion in the physical therapy of chronic bronchitis. Eur J Respir Dis 1985; 66:233–239. 63. Button BM, Heine RG, Catto-Smith AG, et al. Chest physiotherapy in infants with cystic fibrosis: to tip or not? A five-year study. Pediatr Pulmonol 2003; 35:208–13. 64. Phillips GE, Pike SE, Rosenthal M et al. Holding the baby: head downwards positioning for physiotherapy does not cause gastro-oesophageal reflux. Eur Respir J 1998; 12:954–957. 65. Pryor JA, Webber BA, Hodson ME, et al. Evaluation of the forced expiration technique as an adjunct to postural drainage in treatment of cystic fibrosis. Br Med J 1979; 2:417–418. 66. Partridge C, Pryor J, Webber B. Characteristics of the forced expiration technique. Physiotherapy 1989; 75:193–194.

Mucolytic Therapy and Airway Clearance Techniques

249

67. Hofmeyr JL, Webber BA, Hodson ME. Evaluation of positive expiratory pressure as an adjunct to chest physiotherapy in cystic fibrosis. Thorax 1986; 41:951–954. 68. Pryor JA, Webber BA, Hodson ME, et al. The Flutter VRP1 as an adjunct to chest physiotherapy in cystic fibrosis. Respir Med 1994; 88:677–681. 69. Miller S, Hall DO, Clayton CB, et al. Chest physiotherapy in cystic fibrosis: a comparative study of autogenic drainage and the active cycle of breathing techniques with postural drainage. Thorax 1995; 50:165–169. 70. Sutton PP, Parker RA, Webber BA, et al. Assessment of the forced expiration technique, postural drainage and directed coughing in chest physiotherapy. Eur J Respir Dis 1983; 64:62–68. 71. Chevaillier J. Autogenic drainage (A.D.) In: Lawson D, ed. Cystic Fibrosis Horizons. Chichester: John Wiley, 1984:235. 72. Scho¨ni MH. Autogenic drainage—a modern approach to chest physiotherapy in cystic fibrosis. J Royal Soc Med 1989; 82(suppl 16):32–37. 73. Dab I, Alexander F. The mechanism of autogenic drainage studied with flow volume curves. Monogr Paediatr 1979; 10:50–53. 74. Davidson AGF, Wong LTK, Pirie GE, et al. Long-term comparative trial of conventional percussion and drainage physiotherapy to autogenic drainage in cystic fibrosis. Pediatr Pulmonol 1992; 14(suppl 8):A235. 75. Giles DR, Wagener J, Accurso F, et al. Short-term effects of postural drainage with clapping vs autogenic drainage on oxygen saturation and sputum recovery in patients with cystic fibrosis. Chest 1995; 108:952–954. 76. Pfleger A, Theissl B, Oberwalder B, et al. Self-administered chest physiotherapy in cystic fibrosis: a comparative study of high-pressure PEP and autogenic drainage. Lung 1992; 170:323–330. 77. Zach MS, Oberwaldner B, Forche G, et al. Bronchodilators increase airway instability in cystic fibrosis. Am Rev Respir Dis 1985; 131:537–543. 78. Falk M, Kelstrup M, Andersen JB, et al. Improving the ketchup bottle method with positive expiratory pressure, PEP, in cystic fibrosis. Eur J Respir Dis 1984; 65:423–432. 79. McIlwaine PM, Wong LT, Peacock D, et al. Long-term comparative trial of conventional postural drainage and percussion versus positive expiratory pressure physiotherapy in the treatment of cystic fibrosis. J Pediatr 1997; 131:570–574. 80. Oberwaldner B. High pressure PEP. In: Physiotherapy for people with Cystic Fibrosis: from infant to adult. 4th ed. 2009:15–17. Available at: http://www.cfww.org/ipg-cf/article/195/ Physiotherapy_in_the_Treatment_of_CF. 81. Oberwaldner B, Evans JC, Zach MS. Forced expirations against a variable resistance: a new chest physiotherapy method in cystic fibrosis. Pediatr Pulmonol 1986; 6:358–367. 82. Zach MS, Oberwaldner B. Effect of positive expiratory pressure breathing in patients with cystic fibrosis (comment). Thorax 1992; 47:66–67. 83. Schibler A, Casaulta C, Kraemer R. Rationale of oscillatory breathing as chest physiotherapy performed by the Flutter in patients with cystic fibrosis (CF). Pediatr Pulmonol 1992; 14(suppl 8):A301. 84. Lindeman H. The value of physical therapy with VRP1 destin (flutter). [German] Pneumologie 1992; 46:626–630. 85. Cegla UH. [Physiotherapy with oscillating PEP systems (RC-Cornet, VRP1)]. [German] Pneumologie 2000; 54:440–446. 86. Volsko TA, DiFiore JM, Chatburn RL. Performance comparison of two oscillating positive pressure devices: Acapella versus Flutter. Respir Care 2003; 48:124–130. 87. Konstan MW, Stern RC, Doershuk CF. Efficacy of the flutter device for airway mucus clearance in patients with cystic fibrosis. J Pediatr 1994; 124:689–693. 88. Gondor M, Nixon PA, Mutich R, et al. Comparison of the flutter device and chest physical therapy in the treatment of cystic fibrosis pulmonary exacerbation. Pediatr Pulmonol 1999; 28:255–260.

250

Ratjen and Lapin

89. van Winden CM, Visser A, Hop W, et al. Effects of flutter and PEP mask physiotherapy on symptoms and lung function in children with cystic fibrosis. Eur Respir J 1998; 12:143–147. 90. McIlwaine PM, Wong LT, Peacock D, et al. Long-term comparative trial of positive expiratory pressure versus oscillating positive expiratory pressure (flutter) physiotherapy in the treatment of cystic fibrosis. J Pediatr 2001; 138:845–850. 91. King M, Phillips DM, Gross D, et al. Enhanced tracheal mucus clearance with high frequency chest wall compression. Am Rev Respir Dis 1983; 128:511–515. 92. King M, Phillips DM, Zidulka A, et al. Tracheal mucus clearance in high frequency oscillation II: chest wall versus mouth oscillation. Am Rev Respir Dis 1984; 130:703–706. 93. Chang HK, Weber ME, King M. Mucus transport by high-frequency nonsymmetrical oscillatory airflow. J Appl Physiol 1988; 65:1203–1209. 94. Gross D, Zidulka A, O’Brien C, et al. Peripheral mucociliary clearance with high frequency chest wall compression. J Appl Physiol 1985; 58:1157–1163. 95. Rubin E, Scantlen GE, Chapman GA, et al. Effect of chest wall oscillation on mucus clearance: comparison of two vibrators. Pediatr Pulmonol 1989; 6:122–126. 96. Dasgupta B, Tomkiewicz RP, Boyd WA, et al. Effects of combined treatment with rhDNase and airflow oscillations on spinnability of cystic fibrosis sputum in vitro. Pediatr Pulmonol 1995; 20:78–82. 97. Milla CM, Hansen LG, Weber A, et al. High frequency chest compression: effect of the third generation compression waveform. Biomed Instrum Technol 2004; 38:322–328. 98. Warwick WJ. High frequency chest compression. In: Button B, McIlwaine M, ed. Airway Clearance Techniques Training Class. North American Cystic Fibrosis Conference, 2005. 99. Kempainen RR, Williams CB, Hazelwood A, et al. Comparison of high frequency chest wall oscillation with differing waveforms for airway clearance in cystic fibrosis. Chest 2007; 132:1227–1232. 100. Warwick WJ, Hansen LG. The long-term effect of high-frequency chest compression therapy on pulmonary complications of cystic fibrosis. Pediatr Pulmonol 1991; 11:265–271. 101. Jones RL, Lester RT, Brown NE. Effects of high frequency chest compression on respiratory system mechanics in normal and cystic fibrosis patients. Can Respir J 1995; 2:40–46. 102. Perry RJ, Man GCW, Jones RL. Effects of positive end-expiratory pressure on oscillated flow rate during high frequency chest compression. Chest 1998; 113:1028–1033. 103. Dosman CF, Zuberbuhler PC, Tabak JI, et al. Effects of positive end-expiratory pressure on oscillated flow rate during high frequency chest compression in children with cystic fibrosis. Can Respir J 2003; 10:94–98. 104. Phillips GE, Pike SE, Jaffe A, et al. Comparison of active cycle of breathing and highfrequency oscillation jacket in children with cystic fibrosis. Pediatr Pulmonol 2004; 37:71–75. 105. Langenderfer B. Alternatives to percussion and postural drainage, autogenic drainage, positive expiratory pressure, flutter valve, intrapulmonary percussive ventilation, and high frequency chest compression with the Thairpy vest. J Cardiopulm Rehabil 1998; 18: 283–289. 106. Newhouse PA, White F, Marks JH, et al. The intrapulmonary percussive ventilator and flutter device compared to standard chest physiotherapy in patients with cystic fibrosis. Clin Pediatr 1998; 37:427–432. 107. Homnick DN, White F, deCastro C. Comparison of the effects of an intrapulmonary percussive ventilator to standard aerosol and chest physiotherapy in cystic fibrosis. Pediatr Pulmonol 1995; 20:50–55. 108. Hebestreit A, Kerstin U, Basler B, et al. Exercise inhibits epithelial sodium channels in patients with cystic fibrosis. Am J Respir Crit Care Med 2001; 164:443–446. 109. Passero MA, Remor B, Salomon J. Patient-reported compliance with cystic fibrosis therapy. Clin Pediatr 1981; 20:264–268. 110. Modi AC, Lim CS, Yu N, et al. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 2006; 5:177–185.

16 Pulmonary Exacerbations DON B. SANDERS University of Wisconsin, Madison, Wisconsin, U.S.A.

MARGARET ROSENFELD Seattle Children’s Hospital, Seattle, Washington, U.S.A.

I.

Introduction

Cystic fibrosis (CF) lung disease is characterized by episodic increases in respiratory symptoms such as cough and sputum production, often accompanied by systemic symptoms such as anorexia and fatigue. These episodic changes in signs and symptoms from the patient’s baseline are termed pulmonary exacerbations (1,2). Pulmonary exacerbations have a significant impact on quality of life (3–6), mortality (7–10), and CF health care expenditures (11). Furthermore, they are amenable to therapies aimed both at prevention and treatment. The rate of pulmonary exacerbations has served as a key outcome measure in many clinical trials in CF over the past 15 years (12–18). This chapter reviews the pathophysiology, clinical characteristics, evaluation, treatment, and prevention of pulmonary exacerbations.

II.

Pathophysiology of Pulmonary Exacerbations

Given the importance of pulmonary exacerbations in CF, remarkably little is known about their underlying pathophysiology. A quasi-stable homeostasis exists in the CF lung between endobronchial pathogens and the associated host neutrophilic inflammatory response. Triggers such as viral respiratory infections, other infectious agents, pollutants (19), allergens, and respiratory tract irritants can disrupt this fragile homeostasis, resulting in an increase in endobronchial bacterial burden and airway inflammation, manifesting clinically as a pulmonary exacerbation (Fig. 1). Concentrations of bacteria and inflammatory markers are increased at the onset of an exacerbation and are reduced in respiratory secretions following aggressive antibiotic therapy (20–24). Recent studies suggest that Pseudomonas aeruginosa and other bacterial organisms exist in biofilms in chronic CF endobronchial infection (25). Biofilms are communities of microorganisms encased within an extracellular polysaccharide matrix that adhere to a surface. Bacteria within biofilms are slow growing and communicate by the process of quorum sensing. They demonstrate increased antibiotic resistance relative to planktonic bacteria, likely due to decreased penetration of antibiotics through the extracellular matrix and expression of biofilm-specific resistance mechanisms. In addition, the antibiotic susceptibility profiles of bacteria in biofilms differ markedly from that of the same bacteria growing planktonically.

251

252

Sanders and Rosenfeld

Figure 1 Pathophysiology of a pulmonary exacerbation.

Growth of bacteria in biofilms likely explains why chronic infections are rarely eradicated by current antibiotic therapy. However, the proven clinical efficacy of b-lactam antibiotics in treating exacerbations suggests that planktonic bacteria may play a role in pulmonary exacerbations. It has been proposed that bacteria growing in biofilms and in planktonic phase may play a role in chronic infection and exacerbations, respectively (26). Recent evidence that exacerbations in patients chronically infected with P. aeruginosa are generally due to the clonal expansion of strains of microorganisms present at the patient’s stable baseline rather than to the acquisition of new strains also supports this hypothesis (27).

III.

Definition of Pulmonary Exacerbations

Despite the central role that pulmonary exacerbations play in CF patient care and research, no standardized definition exists. Three groups have systematically evaluated which signs and symptoms best characterize a pulmonary exacerbation (28–30). The results of these three studies in different patient populations demonstrate fairly good concordance (Table 1). Some of the characteristics most strongly associated with a pulmonary exacerbation included increased cough, increased sputum production, decreased exercise tolerance, decline in weight-for-age percentile, reduced appetite, hemoptysis, and new adventitial sounds on examination of the chest. In all three studies, symptoms and signs were more predictive of an exacerbation than laboratory data. Pulmonary exacerbations are key clinical efficacy endpoints in many CF therapeutic trials (13–15,17,18,31,32). Participants in a 1992 Cystic Fibrosis Foundation, U.S. Food and Drug Administration (FDA) Consensus Conference on Outcome Measures in CF, recommended that a standardized definition of pulmonary exacerbations be established to strengthen individual trials and facilitate comparison between trials (33). The recommendation was for this definition to include clinical symptoms and not therapeutic interventions, in view of the rapid change in treatment modalities occurring in the field and the marked variability in treatment strategies between clinicians and CF centers (29,34). Yet, 15 years after the initial recommendations, no such universal definition has been established (35). Exacerbation definitions for clinical trials typically require antibiotic administration (most commonly intravenously) in association with a constellation of patient signs and symptoms and laboratory data. Empiric pulmonary exacerbation definitions have been developed for specific clinical trials (13,18,31), but their accuracy and precision have never been measured and there is no universally accepted definition. One limitation of all published definitions is that they are physician-derived interpretations of health outcomes, rather than patient-reported outcomes (PROs). In

– – 74 74 40 – 37 58

4.3 14.1 5.9 2.7i – –

70 62 35 95 30 58

– –

98 91 91 86 79 93

Well child

56 65 49 93 53 49

– –

93 98 88 98 91 91

Advanced diseased

– – 2.8h – 4.1 – –

7.8h – – – –

4.4 – 1.5 – 2.0 1.4g

6–12 yr

– –

3.9 – 2.2 – 3.2 2.2g

95%; 20,000 lipase units/kg/day (or 6000 units/meal). The recommended dose ranges are currently 5 to 10,000 lipase units/kg/day. Common practice is to provide 1000 to 3000 lipase units/kg/ meal (*1800 lipase units/g fat) and not to exceed 10,000 lipase units/kg/day (45,46). Other complications include oral ulcers and perianal rash in infants. Pancreatic transplantation is a newer modality that has recently been pioneered in combination with lung transplantation recently, and may be a modality to increase survival and outcomes in select eligible candidates (47–49).

IV.

Pancreatitis

Pancreatitis is the presenting symptom for an estimated one-third of subjects with CF and PS, with the actual percentage potentially being higher, when unexplained recurrent abdominal pain is the presenting symptom. No specific genotype predicts risk for pancreatitis (29). In fact, idiopathic pancreatitis may be the initial presentation of CF in, otherwise, asymptomatic adults. In one study of patients with idiopathic pancreatitis, CFTR gene mutational analysis revealed at least one CFTR allele mutation in all patients and both allele mutations in three subjects (50). CFTR mutations are one of three identified genetic defects associated with recurrent or chronic pancreatitis; the

270

Mascarenhas and Maqbool

other two are of the serine protease inhibitor Kazal 1 (SPINK1) and of cationic trypsinogen (PRSS1). In a study of 381 subjects with a primary diagnosis of recurrent or chronic pancreatitis, 49% of subjects had one or more mutations associated with hereditary pancreatitis; 32% of the subjects with pancreatitis had CFTR mutation– associated alleles, 6% had SPINK1 mutations, and 8.9% had PRSS1 mutations (51). Interestingly, 5.5% of subjects had mutations in both CFTR and SPINK1, and 1.8% with CFTR and PRSS1 mutations. In this study, 12 novel genes associated with CFTR mutations were identified. While these patients may not have the classical findings and clinical course of CF and may have a longer life expectancy than their PI counterparts, pancreatitis may have long-term consequences not traditionally ascribed to CF.

V. Meconium Ileus MI is neonatal intestinal obstruction due to meconium and is most often due to CF. Meconium from patients with CF has increased viscosity, reduced water content, and increased protein concentration. MI can be detected in utero by ultrasound and is the earliest manifestation of CF. It occurs in 15% of patients with CF. Gene modifiers probably influence the incidence of MI, independent of CFTR. MI also correlates with DIOS, but this is probably caused by nongenetic factors. Regions of suggestive linkage identified by genome-wide association analysis for modifier genes that cause MI are on chromosomes 4q35.1, 8p23.1, and 11q25, and regions that protect from MI are on chromosomes 20p11.22 and 21q22.3. DIOS in older patients is caused by nongenetic factors, but MI is associated with CFTR and two or more modifier genes (52). MI is caused by thick, inspissated, intestinal secretions, and can be associated with intestinal atresias, volvulus, perforation, peritonitis, calcification, and pseudocyst formation. Neonates typically present with symptoms and signs of intestinal obstruction, and the diagnosis of MI can be made by X rays (abdominal films and gastrograffin enema) and laparotomy. Surgery is indicated for neonates who do not clear the meconium obstruction with a gastrograffin enema, and for those with perforation and with persistent obstructive symptoms. In the early 1960s, the Bishop–Koop ileostomy was created because mortality was very high in infants with CF who needed intestinal surgery. Improved survival (37–90%) was noted in infants who had this type of surgery (53). Currently most neonates, who undergo surgery and need a resection, have a primary anastamosis; this has been found to be a safe option (54) and is associated with a reduced length of initial hospital stay (55). The long-term outcome of infants with MI is different (56) from infants without MI. Infants with MI who undergo surgery tend to have feeding difficulties and are at risk for parenteral nutrition–associated cholestasis when enteral feeds cannot be started soon after surgery. Aggressive postoperative nutritional care with use of parenteral nutrition is often required in these patients, and PERT is started when the rate of feeds is significant. Munck et al. (57) have not seen a difference between MI and non-MI patients in terms of genotype, nutritional status, and acquisition of pseudomonas. However, Li et al. (58) have shown more lung disease and more obstructive lung disease at age 8 to 10 years in a group of children with MI, who were diagnosed by newborn screening. This was seen in all infants with MI, including those who did and did not need surgery. In the past, patients with MI had high perinatal mortality, poor growth, and poor long-term survival; now with improvements in care, including surgical interventions, prognosis is improved.

Gastrointestinal Complications of Cystic Fibrosis

VI.

271

Distal Intestinal Obstruction Syndrome

DIOS, also called MI equivalent, is a recurrent variable intestinal obstruction starting in the ileocecal region and extending throughout the colon (59). DIOS can be seen in PI or PS patients (60). Abnormal water and electrolyte transport and intestinal mucus, dysmotility, inspissated secretions, increased protein content of mucus, and modifier genes are felt to be responsible for DIOS (61). Prolonged orocecal transit results in stasis in the colon, and stool builds up in the cecum and terminal ileum in a layered fashion. In CFTR knockout mice, MI and DIOS occur due to defective electroneutral sodium absorption, bicarbonate secretion, and defective chloride secretion. Precipitating factors for an episode of DIOS include dehydration, changes in diet, immobilization, respiratory infection, bacterial overgrowth, use of constipating medications, and fat malasorption. Patients with a history of previous GI surgery may be at increased risk during summer months because of intestinal dysmotility, dehydration, and bacterial overgrowth. Patients with lung transplantation are at increased risk for DIOS. Recognition of this complication and institution of preventative measures are important (62). Morton showed an incidence of DIOS of 10% in 121 patients with CF who underwent lung transplantation. Risk factors included a past history of MI or previous laparotomy. Initial treatment consisted of laxatives, stool softners, and bowel preparation formula that was successful in 14 out of 17 patients when the regimen was given for up to 14 days. However, 3 out of 17 patients needed enterotomy and fecal disimpaction. One patient died because of late diagnosis (63). Clinical symptoms of DIOS include chronic, recurrent, crampy abdominal pain frequently in the right lower quadrant, associated with a right lower quadrant palpable mass. No change in bowel movements is often noted. Management of DIOS consists of adequate hydration of fluid and electrolytes, medications (polyethylene glycol), optimization of PERT, and dietary measures. Adequate fluid and electrolyte intake is very important to hydrate intestinal secretions. Polyethylene glycol increases the volume of intestinal secretions and stimulates peristalsis. Prevention and treatment of fat malabsorption and bacterial overgrowth are important as well. For severe episodes of DIOS, including obstruction, patients need to be well hydrated and the obstruction is treated by using a gastrograffin enema. It is important to reflux the gastrograffin into the terminal ileum and to document clearance of stool by obtaining an abdominal X ray. Polyethylene glycol lavage solutions (orally or via nasogastric tube) can also be used to clear the obstruction from above, but several doses may be needed to clear the stool buildup. Passage of clear liquid stool is not an evidence of a good clean out, and an abdominal X ray must be done to document the absence of residual stool (64). Patients who have intestinal obstruction due to DIOS after abdominal surgery may benefit by having N-acetylcysteine instilled via J tube, as close to the obstruction as possible. It is also important in the postoperative period to avoid drugs that slow motility (such as narcotics) and keep patients well hydrated. In severe cases, recurrent DIOS may be treated with a modified antegrade continence enema procedure (65).

VII.

Gastroesophageal Reflux

GER is a normal physiological process. It is considered pathological, or as gastroesophageal reflux disease (GERD), when it results in esophagitis or is associated with dysphagia, odynophagia, failure to thrive, and extraesophageal manifestations, which

272

Mascarenhas and Maqbool

Figure 2 The normal anti-reflux barrier with factors contributing to reflux. Abbreviations: GER, gastroesophageal reflux; LES, lower esophageal sphincter.

may include the lungs (Fig. 2). GER is common in patients with CF, occurring in 25% to 55% of pediatric cases (66,67), in 19% of infants with CF (68), and 94% of adult patients (69). Duodenogastric bile reflux has also been recently observed in CF (70). GER occurs in response to transient relaxation of the lower esophageal sphincter (LES) mediated by vagal innervation, nitric oxide, and cholecystokinin A. Several factors may contribute to GER, including (i) posture and dietary composition; (ii) anatomical abnormalities (e.g., hiatal hernias); and (iii) gastric distention, volume, pressure, and motility (71). The gastric accommodation reflex and intrathoracic pressures influence GER (72). In adults, abnormal esophageal coordination and peristalsis, and decreased basal LES resting pressures on manometry have been seen in 60% of patients (69). Hiatal hernias may also increase the risk of GER, and have been documented in up to 30% of children and adolescents (73,74). Postural drainage techniques may also increase the frequency of GER episodes in infants (75), and similar effects due to supine positioning are noted in adults (69). Additionally, decreased intrathoracic pressure associated with hyperinflation (when present) and increased transdiaphragmatic pressure associated with coughing and wheezing can contribute to reflux. The role of altered gastric pressures, transit, and motility in subjects with CF has been summarized elsewhere (76). Esophagitis has been reported in at least 50% of pediatric cases (67,77). Barrett’s esophagitis, a precancerous condition, has also been reported in adolescent patients with

Gastrointestinal Complications of Cystic Fibrosis

273

CF (73). The relationship of GER with respect to lung disease in CF is complex, and most likely bidirectional. The traditional assessment tools for GER (contrast studies, scintigraphy, endoscopy, pH monitoring, and manometry) are limited and less informative in studying associations of GER with the airway. Recent research and clinical approaches include tracheal pH monitoring. Acidification of the airway and microaspiration as measured by tracheal breath condensate pH monitoring (to pH 8 yr: 200–400

Vitamin E (IU)c

2.5–5 mg/wk

100–400

300–500

Vitamin K (mg/day)

35–40% of calories

10,000

NIa

NIa

Consensus

USA CFF 2004 (4) Adult

PI or cholestasis 1 mg/day to 10 mg/wk

NIa

NIa

NIa Base calories on pattern of weight gain and fat stores NIa

Energy

Fat

Evidence and consensus NIa

Consensus

UK CF Trust) 2002 (3) All ages

Consensus

European CFS 2002 (2) All ages

Criteria

USA CFF 2002 (1) Pediatric

Table 1 International Consensus and Evidence-Based Recommendations for CF Care

400–1000

Unrestricted; 100 g/d if >5 yr 0–36 mo: 150–500 >4 yr: 300–500 0–12 mo: 40–80 1–3 yr: 50–150 4–7 yr: 150–300 >8 yr 150–500

120–150% Recommended dietary intake for non-CF

Evidence

Australasian 2006 (5) All ages

NIa b

b

b

NIa

NIa

NIa

(Continued )

Evidence and consensus Calorie dense feedings if wt loss or inadequate wt gain

USA CFF 2009 (7) Birth to 2 yr

NIa

Evidence and consensus 110–200% Recommended intake for non-CF

USA CFF 2008 (6) All ages

Nutrition 309

Supplement if dietary intake is inadequate

NIa

Infants: 1/8 tsp (12.6 mEq) Others: high salt diet

Watersoluble vitamins

Sodium, mEqd

NIa

10,000

1 yr: 4000– 10,000

NIa

USA CFF 2004 (4) Adult

UK CF Trust) 2002 (3) All ages

NIa Infants: 1–2 Infants: PRI: 23– mmol/kg/day 46 mg/kg (1–2 if urine Na < mEq/kg) daily 10 Breast-fed: supplement if fever or >2 yr: additional requirement in summer months warmer climates

PI 4000–10,000

0–12 mo 1500 1–3 yr 5000 4–8 yr 5000– 10,000 >8 yr 10,000

European CFS 2002 (2) All ages

Vitamin A (IU)

USA CFF 2002 (1) Pediatric

USA CFF 2008 (6) All ages

0–12 mo: 1500– NIa 2000 1–3 yr: 1500– 2500 >4 yr: 2500– 5000 NIa Supplement if intake is inadequate or evidence of B12 def or with terminal ileum resection Infants: 500– NIa 1000 mg Children: 4000 mg >12 yr: 6000 mg

Australasian 2006 (5) All ages

Table 1 International Consensus and Evidence-Based Recommendations for CF Care (Continued )

0–6mo: 1/8 tsp/day (12.6 mEq) > 6 mo: ¼ tsp/day (25.2 mEq) Up to 4 mEq/kg/ day

NIa

b

USA CFF 2009 (7) Birth to 2 yr

310 Maqbool et al.

Supplement if deficient

NIa

Consider for poor growth or refractory vitamin A deficiency. 6 mo zinc trial

Minimum:1997 IOM recommendations

NIa

Calcium

Pregnancy

Provides information

NIa

Provides information

NIa

As indicated

USA CFF 2004 (4) Adult NIa

USA CFF 2008 (6) All ages

Recommended NIa daily intake or 1500 mg/day with low bone density Provides NIa information

NIa

Australasian 2006 (5) All ages

NIa

Consider for inadequate growth despite PERT and sufficient calories 1 mg/kg/day, 6 month zinc supplementation trial. NIa

USA CFF 2009 (7) Birth to 2 yr

b

Not included in recommendations. Start CF-specific multivitamins shortly after diagnosis. c 1 IU of vitamin E ¼1 mg all-rac-a-tocopherol acetate ¼ 0.67 mg RRR-a tocopherol ¼ 0.74 mg RRR-a tocopherol acetate. The International Unit (IU) system is now outdated. Vitamin E intake as currently defined by the RDA is for a-tocopherol specifically. This includes RRR-a-tocopherol (the only natural form in foods and supplements) and the 2R-stereoisomeric forms of a-tocopherol (that are present in fortified foods and supplements). As per the Dietary Reference Intakes, 1 IU of all-rac-a-tocopherol or its esters = 0.45 mg 2R-a-tocopherol; 1 IU RRR-a-tocopherol or its esters = 0.67 mg 2R-a-tocopherol (8). Vitamin E in esterified form is protected from oxidization and normally has prolonged shelf life compared with unesterified forms. Esters are normally hydrolyzed in the intestine and then absorbed in the unesterified form; this process may be impaired in malabsorptive states, including CF. The DRI recommendations do not include g-tocopherol and other vitamin E compounds, secondary to a lack of evidence of health benefits in humans. d 1 mEq sodium ¼ 23 mg of sodium. Abbreviations: PI, pancreatic insufficient; PRI, Population Reference Intake; tsp, teaspoon; IOM, Institute of Medicine; DRI, Dietary Reference Intake.

a

UK CF Trust) 2002 (3) All ages

Consider with poor NIa growth or severe steatorrhea

European CFS 2002 (2) All ages

Zinc

USA CFF 2002 (1) Pediatric

Nutrition 311

SourceCF1a Drops, Chewables, Softgels

50 (1 mL) 100 (2 mL) 200/chewable

400/2 softgels

500 (1 mL) 1000 (2 mL) 1000/ chewable

2000/2 softgels

>9 years

Vitamin D (IU) 0–12 months 1–3 years 4–8 years

>9 years

32,000/2 softgels 88% BC

Vitamin E (IU)f 0–12 months 1–3 years 4–8 years

>9 years

Vitamin A (IU) retinol and b-carotene (BC) 0–12 months 4627 (1 mL) 75% BC 1–3 years 9254 (2 mL) 75% BC 4–8 years 16,000/chewable 88% BC

Age

800/2 chewables

– – 400/chewable

300/2 chewables

– – 150/chewable

18,000/2 chewables 60% BC

– – 9000/chewable 60% BC

ADEK Chewables1b

400 (1 mL) 800 (2 mL) Ages 4–10 yr: 800 / 1 softgel Ages 10 and up: 1600 / 2 softgels

50 (1 mL)g 100 (2 mL)g Ages 4–10 yr: 150/1 softgelg Ages 10 and up: 300/2 softgelsg

5751 (1 mL) 87% BC 11,502 ( 2 mL) 87% BC Ages 4–10 yr 18,167/1 softgel, 92% BC Ages 10 and up 36,334/ softgels, 92% BC

AquADEKs1c Drops, Softgels

Table 2 Comparison of CF-Specific Vitamin and Mineral Supplements in the United States

800/2 chewables

400 (1 mL) 800 (2 mL) 400/chewable

400/2 chewables

50 (1 mL) 100 (2 mL) 200/chewable

10,000/2 chewables 50% BC

3170 (1 mL) 0%BC 6,340 (2 mL) 0% BC 5000/chewable 50% BC

Vitamax1d Drops, Chewables

800/2 tablets

400 (1 mL) 800 (2 mL) 400/chewable

60/2 tablets

5 (1 mL) 10 (2 mL) 30/chewable

7000/2 tablets 29% BC

1500 (1 mL) 0% BC 3000 (2 mL) 0% BC 3500/chewable 29% BC

Poly-Vi-Sol Drops1e Centrum1 Chewable, Tablet

312 Maqbool et al.

1600/2 softgels

5 (1 mL) 10 (2 mL) 15/chewable 30/2 softgels

>9 years

Zinc (mg) 0–12 months 1–3 years 4–8 years >9 years – – 7.5/chewable 15/2 chewables

300/2 chewables

– – 150/chewable

ADEK Chewables1b

5 (1 mL) 10 (2 mL) For 4–10 yr: 10 / softgel For ages 10+: 20/2 softgels

400 (1 mL) 800 (2 mL) Ages 4–10 yr: 700/1 softgel Ages 10 and up: 1400 / 2 softgels

AquADEKs1c Drops, Softgels

7.5 (1 mL) 15 (2 mL) 7.5/chewable 15/2 chewables

400/2 chewables

300 (1 mL) 600 (2 mL) 200/chewable

Vitamax1d Drops, Chewables

0 0 15/chewable 22/2 tablets

50/2 tablets

0 0 10/chewable

Poly-Vi-Sol Drops1e Centrum1 Chewable, Tablet

The content of this table was confirmed December 2008. Products also contain a full range of water-soluble vitamins. a SourceCF1 Liquid, Chewables, and Softgels are registered trademarks of SourCF1 Inc., a subsidiary of Eurand Pharmaceuticals, Inc. b ADEK1 Chewables is a registered trademark of Axcan Pharma, Inc. c AquADEKs1 Liquid and Softgels are registered trademarks of Yasoo Health Inc. d Vitamax1 Drops and Chewables are registered trademarks of Shear/Kershman Labs. Inc. e Poly-vi-sol Drops1 is a registered trademark of Mead Johnson and Company. Centrum1 Chewables and Tablets are registered trademarks of Wyeth Consumer Care. f a-Tocopherol. g Contains mixed tocopherols. Source: Courtesy of SourceCF1 Inc., a subsidiary of Eurand Pharmaceuticals, Inc.

400 (1 mL) 800 (2 mL) 800/chewable

SourceCF1a Drops, Chewables, Softgels

Vitamin K (mg) 0–12 months 1–3 years 4 – 8 years

Age

Table 2 Comparison of CF-Specific Vitamin and Mineral Supplements in the United States (Continued )

Nutrition 313

314

Maqbool et al.

Table 3 Reported (Mean  SD) Energy and Fat Intake in Subjects with Cystic Fibrosis

Gordon et al., 2007 (10) Colombo et al., 2006 (12) Schall et al., 2006 (13) Olveira et al., 2006 (14) Powers et al., 2002 (15) Fung et al., 1999 (16) Collins et al., 1998 (17)

Sample

Age (yr)

% Energy intakea

% Intake as fat

USA

CF: 64

32  10

120–150

33  7

Italy

CF: 37 C: 68 CF: 75

CF: 8  3 C: 8  1 10  1

CF: 37 C: 37 CF: 35 C: 34 CF: 21

CF: 25  9 C: 26  6 CF: 19  8 C: 18  8 12  3

CF: 126  34 C: 101  21 CF: 115 range: 75–193 CF: 132  27 C: 108  24 CF: 103  26 C: 88  23 CF: 122  27

CF: 33  5 C: 30  4 CF: 37 range: 21–49 CF: 39  5 C: 40  5 CF: 34  6 C: 33  6 CF: 33  5

CF M: 12 CF F:17

M: 13  6 F: 11 5

CF M: 131  32 CF F: 107  16

CF M: 39  6 CF F: 37  6

USA Spain USA USA Australia

a

Energy intake as % country specific recommendations for healthy people. Abbrevaitions: CF, cystic fibrosis; C, control; M, males; F, females.

II.

Caloric and Fat Intake of People with CF

Long-term survival for people with CF is associated with numerous factors including nutritional status (25). To meet the goals of normal growth patterns for children and healthy weight for adults, nutrition recommendations for people with CF and PI include an energy intake of 20% to 50% above that for a healthy person of similar age and gender, and a fat intake of 35% to 40% of total calories (1). A review of studies prior to 1996 (9) indicated that these recommendations were seldom met. More recent studies are summarized in Table 3 and suggest higher energy but not higher fat intake in CF compared with healthy people. This summary demonstrates the variability in energy and fat intake and various international standards used to interpret the data. However, a recent report (18) suggested dietary intake reports from children, and their parents should be interpreted with caution and are often overestimated. Therefore, the accuracy of reported dietary intake of calories and fat may be unreliable and should be used to understand dietary patterns only.

III.

Nutrients Lost in Stool

Virtually all food presented to a healthy gastrointestinal tract is digested via pancreatic enzymes (lipase to digest fat, amylase for starch, and proteases for protein), absorbed by intestinal cells and enters the body for metabolic activities. Stool from healthy children and adults contain small amounts of carbohydrate and protein and < 7% kcal of ingested fat. In CF with PI pancreatic enzymes are not secreted into the duodenum and the loss of ~90% enzyme activity results in PI (19). Intestinal cells have some capacity to digest carbohydrates and proteins, but lack lipase. Lingual and gastric lipase is insufficient to support fat digestion, and CF and PI results in excess stool fat (steatorrhea). Since dietary fat provides approximately twice the energy as carbohydrate or protein per gram, fat malabsorption and steatorrhea lead to important clinical consequences including energy, fat-soluble vitamin and EFA malabsorption, and often to malnutrition and poor growth.

Nutrition

315

Table 4 Coefficient of Fat Absorption (Mean  SD) in Subjects with Cystic Fibrosis and

Pancreatic Insufficiency with and Without Pancreatic Enzyme Replacement Therapy

Existing product studies Patchell et al., 2002 (20)a Chen et al., 2005 (21) Schall et al., 2006 (13)c Cohen et al., 2005 (22)c New product studies Stern et al., 2000 (23)d Borowitz et al., 2006 (24)e

N

Age (yr)

59 53 75 75

10  4 9  1b 91 71

37 117

12–25  1–2 21–22  8–9

CFA (%) 91–95  5–8 86  1 85  13 81  14 PERT No PERT 84–87  2 51–52  6–7 67–70  18 52–56  18–20

a

Study investigating the subject preference between pancreatic enzyme formulations containing different sized spheres. b Standard error of the mean. c Same subjects at different ages: 6 to 9 years (13) and 8 to 11 years (22). d Novel PERT: minimocrospheres with enteric-coating, delayed release action. e Novel PERT: containing lipase, protease, and amylase. Abbreviations: CFA, coefficient of fat absorption; PERT, pancreatic enzyme replacement therapy.

Treatment for PI in patients with CF includes PERT, with the goal of sufficient active lipase for food in the duodenum. A 72-hour fecal fat balance study from which the coefficient of fat absorption (CFA) is derived is currently the most used objective measure of degree of PI and enzyme therapy effectiveness (1). Reported CFA range from 50% to 55% without PERT to 55% to 95% with PERT (Table 4) in people with CF and PI. Although studies have reported CFA for groups of patients in the desirable 85% range, it is evident that for many individual patients, PI is not corrected to this level.

IV.

Growth in Children with CF

The goal for children with CF is to achieve normal growth and optimal nutritional status, since better growth is associated with better health outcomes including reduced infections, improved lung function, and survival (Fig. 1) (6,11,25–27). The CF Foundation (CFF) recognizes that nutritional management is an integral part of CF care and have developed consensus reports that provide recommendations on how to monitor growth and nutritional status, strategies to prevent undernutrition, and interventions for those with nutritional failure. A pediatric nutrition care consensus report was published in 2002 (1) and was an update of the one published 10 years ago (28). More recently, the CFF Subcommittee on Growth and Nutrition conducted an evidenced-based review and performed new analyses using the CFF Patient Registry to update the recommendations for growth and weight-status monitoring for children and adults (6). For adults, broader nutrition screening and treatment recommendations are outlined in the 2004 CF Adult Care Consensus Report (4). The 2002 CFF nutrition guidelines recommend that patients be seen every three months with stature and weight assessed at every visit (1). Since these guidelines were published, the limitations of using percent ideal body weight (%IBW) in CF was

316

Maqbool et al.

Figure 1 (A) FEV1 percent predicted versus BMI percentile in children 6 to 20 years old. (B)

FEV1 percent predicted versus BMI percentile in adults 20 to 40 years old. Source: From Ref. 32. Reproduced with permission of the Cystic Fibrosis Foundation.

recognized (29) and %IBW should no longer be used (6). Instead the BMI (percentile or Z-score) method (30) should be used to assess stature and weight (31). In 2008, the CFF Subcommittee on Growth and Nutrition conducted new analyses from the CFF Patient Registry to examine the association of percent predicted FEV1 with weight-forstature status in individuals with CF and PI (6). BMI percentiles were used for children aged 6 to 20 years and BMI for those more than 20 years. The BMI percentile was shown to be sensitive to changes in percent predicted FEV1 and have a stronger association to percent predicted FEV1 than %IBW (29). On the basis of these, findings and the recommendations for growth monitoring in children and weight monitoring in adults were revised. The new recommendations are that children and adolescent 2 to 20 years of age maintain a BMI at or above the 50th percentile (6). For children

Nutrition

317

diagnosed before 2 years, a weight-for-length stature of 50th percentile by age 2 years is recommended. For adults, women should maintain a BMI at or above 22 and men should maintain a BMI at or above 23. Despite newborn screening and medical advances, undernutrition is common in people with CF. The most recent CFF Patient Registry reported the median BMI percentile for patients 2 to 20 years of age was 47 and BMI for patients 21 years of age the BMI was 21 (32). When poor growth is identified in children with CF, they should be evaluated more frequently. Children less than two years should be seen every two to four weeks, and children older than two years should be seen every four to six weeks (1). These visits include medical, behavioral, and nutrition assessment, with time to support family education and needed interventions. There are various CF-related medical conditions including active pulmonary or sinus disease, gastroesophageal reflux disease, CF-related diabetes, and liver disease that should be considered for patients who fail to gain weight at the expected velocity or those who have lost weight. PERT should be evaluated since ineffective doses or poor compliance are an easily treated cause of growth in CF. For patients with persistent poor pattern of growth, referral to a gastroenterologist should be considered. The nutrition evaluation in patients with poor growth or weight loss should include evaluation of feeding and eating behaviors and assessing dietary intake patterns. The Behavioral Pediatrics Feeding Assessment Scale is a caregiver self-reported measure of mealtime problems (33). Although estimating dietary intake is challenging, a 24hour diet recall provides a qualitative assessment of dietary patterns and is easily obtained in a clinic setting. To quantitatively assess energy and nutrient intake a three- to five-prospective-day diet record is required, although accuracy may be limited (18) as previously mentioned. Interventions for nutritional failure include behavioral and educational interventions to increase caloric intake, oral supplements, and enteral feedings. The first approach should be to encourage increased food and fat intake. Behavioral strategies that are proven to be effective in CF are increasing calories one meal at a time, teaching parents alternative ways to respond to children who eat slowly or negotiate what he/she eats, and identifying appropriate rewards for improved eating behavior (34). A metaanalysis of nutrition interventions demonstrated that behavioral interventions were as effective in improving weight gain in CF as other medical approaches (35). For those children who are unable to increase calories with food alone, enternal (oral, feeding tube) supplements are used. The goal is to increase intake with oral supplements and avoid the substitution of supplements for established food intake. Limited data exits to determine the superiority of one type of enteral access over another. The nutrition goal is to optimize weight-for-height proportions and to achieve genetic height potential. CFF nutrition guidelines on growth and nutritional monitoring, strategies to prevent undernutrition, and interventions for those with nutritional failure are designed to support optimal care.

V. EFAs and Choline Individuals with CF are prone to polyunsaturated fatty acid (PUFA) abnormalities, which include EFAs, linoleic acid (LA), and a-linolenic acid (ALA), as well as the longchain PUFAs. Humans cannot synthesize EFA, which must be supplied by food.

318

Maqbool et al.

Through a series of enzyme desaturation and elongation transformations, EFAs are rendered into longer chain PUFAs, which in turn have structural roles and confer fluidity to cellular membranes, as well as multiple cellular functional roles including cell signaling, gene expression via peroxisome proliferator–activated receptors (PPARs), and inflammatory activity modulation via the eicosanoid pathways. EFA deficiency (EFAD) was first described in CF in 1962 (36). The typical presentation of EFAD was in infancy or childhood at the time of diagnosis, with the classic clinical manifestations of alopecia, easy bruisability, desquamating skin rash, and suboptimal growth. While these classical manifestations still occur, biochemical evidence of EFAD is common in otherwise apparently adequately nourished individuals with CF (37). The etiology of PUFA abnormalities and EFAD in CF is multifactorial and associations with genotype (38) and pancreatic status in different tissue compartments have been described (39). Data suggest unique metabolic consequences of EFAD and PUFA abnormalities in CF; whereas EFAD was associated with a blunting of the inflammatory response in otherwise healthy individuals, a paradoxical, more pronounced inflammatory effect was observed in subjects with CF (40). Compared to healthy individuals, the most consistently described PUFA abnormalities in patients with CF are LA deficiency and decreased docasahexaenoic acid (DHA) (41,42). Serum LA status has been associated with clinically important CF outcomes of growth and pulmonary status (43–45) and such associations were not observed with the triene:tetraene ratio (45). This may indicate that LA status is a better clinical indicator of EFA status than the triene:tetraene ratio. Supplementation studies have demonstrated that improvement of LA status to concentrations observed in healthy individuals (serum level 26 mol% as the most common reference value) is possible (46). LA status and the triene:tetraene ratio are biochemically related, suggesting that in addition to or in lieu of the ratio, LA status may be a more informative biomarker of EFA status in CF (45). DHA is a long-chain omega 3 PUFA associated with retinal and brain development and with decreasing the inflammatory cascade via eicosanoids. DHA status is commonly suboptimal in CF patients compared with healthy subjects (41,42). Arachidonic acid (AA, a PUFA derived from LA) is considered pro-inflammatory; the AA: DHA ratio conveys information regarding inflammatory potential/status via eicosanoidmediated pathways. DHA supplementation studies resulted in improved DHA levels and decreased the AA:DHA ratio. A number of short-term supplementation trials have been performed, and were well tolerated without adverse health effects and associated with improvement of serum and tissue DHA status (47–49). Investigators have demonstrated improvement in anti-inflammatory eicosanoid and cytokine status with DHA supplementation with respect to leukotriene B4 (50,51). Studies have not, however, demonstrated an association of DHA status with clinically significant outcomes of pulmonary and growth status. Attainment of adequate status is the goal in the nutritional management of EFA and PUFA status in CF. An alternative goal is to promote serum PUFA profiles associated with optimal CF clinical outcomes (52), and associated with risk reduction of the general population chronic noncommunicable diseases (53). Choline is an essential nutrient and has a myriad of structural and functional roles including cell membrane functions, methyl donor in folate, homocysteine-methionine metabolism, and as such intersects with DNA repair; choline is additionally relevant to

Nutrition

319

hepatocyte and renal tubule function, a precursor to neurogenic compounds and has a role in apoptosis (54,55). Subjects with CF are prone to choline deficiency and to altered membrane phospholipid status (56,57). This may be related to increase in membrane turnover (56) and to dietary phospholipid malabsorption (21). Supplementation with choline or metabolites has increased serum choline approaching that of healthy subjects (58). A prospective supplementation trial employing a novel lipid matrix composed of lysophosphatidylcholine, monoglycerides, and fatty acids in subjects with CF showed improved weight, PUFA, and fat-soluble vitamin status in children with CF (59). Choline and thiol metabolism are associated with PUFA status and oxidative stress in CF (60), and may suggest a unifying hypothesis for the PUFA and membrane phospholipid abnormalities and increased oxidative stress observed in people with CF (61).

VI.

Vitamin D

Vitamin D is a fat-soluble vitamin that naturally occurs in very few commonly consumed foods, is added to others (fortification), and is available as a dietary supplement. Vitamin D is also produced in the skin from exposure to ultraviolet (UV) B radiation from sunlight (62). Various factors influence one’s ability to cutaneously synthesize vitamin D, including latitude, time of day, season, amount of skin exposed, age, skin pigmentation, and the use of a sunscreen (SPF > 8) (62). Supplemental vitamin D is available in two forms, ergocalciferol (D2) and cholecalciferol (D3). Ergocalciferol (D2) is manufactured by irradiation of ergosterol in yeast, and cholecalciferol (D3) by irradiation of 7-dehydrocholesterol from lanolin. Cholecalciferol (D3) is considered more clinically effective, although some uncertainty remains (63,64). Vitamin D from sun, food, and supplement undergoes CF in two hydroxylation steps for activation. The first occurs in the liver and converts vitamin D to 25-hydroxyvitamin D [25(OH)D], also known as calcidiol. The second occurs primarily in the kidney and converts 25(OH)D to 1,25-dihydroxyvitamin D [1,25(OH)2D], also known as calcitriol (65). Classic functions of vitamin D are to enhance calcium absorption and maintain blood levels of calcium and phosphorus. Rickets in children and osteomalacia in adults are the consequences of calcitrophic vitamin D deficiency, and are discussed in more detail in the chapter on bone health (chap. 20); however, vitamin D has additional important health roles. Secondary hyperparathyroidism from suboptimal vitamin D status results in the release of bone calcium to maintain serum concentrations (65), thus reducing bone mass. Health consequences related to vitamin D extend well beyond the skeletal system (66), and recent studies suggest that vitamin D is important for lung function and low concentrations may contribute to wheezing, asthma, and respiratory infections (67). In the third National Health and Nutrition Examination Survey, a doseresponse relationship was found between serum 25(OH)D and FEV1 (68). In addition, adequate concentration of 25(OH)D may reduce the risk of illness such as risk of type 1 diabetes mellitus (69), hypertension (70), and cancer (71). Serum 25(OH)D concentration is the best indicator of vitamin D status since it reflects both dietary intake (D2 and D3) and cutaneous synthesis (D3) (65). No consensus on optimal concentrations of serum 25(OH)D exists; however, a cutoff of 10 to 15 ng/ mL (25–37.5 nmol/L) is typically used to define deficiency when related only to skeletal health. In the 1997, Dietary Reference Intake (DRI), vitamin D deficiency was defined as a 25(OH)D concentration less than 11 ng/mL (27 nmol/L) (65), while others consider

320

Maqbool et al.

this too low. Studies in adults have demonstrated that serum parathyroid (PTH) concentrations are at ideal (suppressed) levels when 25(OH)D is more than 32 ng/mL (80 nmol/L)(72). Measuring 25(OH)D concentration is a challenge since variability exists among assays and standardization is needed (73). In a person without kidney disease, 1,25(OH)2D provides little additional insight because of its tight physiological control. Serum 1,25(OH)2D is usually normal in a vitamin D–deficient state since a physiological secondary hyperparathyroidism response increases renal production of 1,25(OH)2D. CFF guidelines recommend supplementation of at least 800 IU vitamin D per day for children older than one year of age (1,74), which is four times the intake recommended for healthy people, and guidelines remain silent on the vitamin D2 versus vitamin D3 issue. Higher supplements may be needed to achieve optimal 25(OH)D concentrations, which the CF defines as between 30 and 60 ng/mL (75–150 nmol/L). Standard of care includes checking 25(OH)D annually in the late autumn or winter when cutaneous synthesis is low. Studies demonstrated that many children with CF have suboptimal vitamin D status (75,76) and that high doses of ergocalciferol (D2) are ineffective for treating deficiency in adults (77). A recent study demonstrated the better effectiveness in CF with D3 supplementation (78). Vitamin D2 absorption was evaluated in 10 adults with CF and PI taking enzymes, and subjects absorbed less than half the D2 than the control subjects (79). Vitamin D3 increases serum 25(OH)D concentrations more efficiently than D2 in healthy people (64,80). To date, no study has examined the outcomes of vitamin D absorption in children with CF. A pilot study was conducted with five people with CF (81) and demonstrated that brief exposure to UV sunlamp light for eight weeks raised 25(OH)D concentrations. In summary, vitamin D is important both for skeletal and for extraskeletal functions. Evidence suggests that people with CF are not achieving 25(OH)D concentrations needed for optimizing bone, and lung and immune status.

VII.

Vitamin A

Vitamin A is a family of compounds important for cellular integrity, growth, immune function, and vision that is composed of preformed retinoid and pro-vitamin A carotenoids. Retinoids are fat-soluble, animal-derived compounds that include retinol, retinal, and retinoic acid. Ingested retinoids are solubilized and esterified into retinyl esters (REs) in the intestine, circulated as both bound RE and unbound retinol, and stored in the liver as retinol. While the serum retinol concentration is homeostatically maintained, hepatic stores accumulate indefinitely with increased ingestion. Conversely, pro-vitamin A carotenoids are water-soluble, plant-derived compounds that include carotene, lutein, and xanthophyll. They are less bioavailable than retinoids and excess amounts are excreted. The relative potency of the vitamin A compounds is expressed as retinol activity equivalents (RAEs); preformed retinol is 12 times as potent as b-carotene. Vitamin A deficiency is well described in CF. Preformed, water miscible vitamin A supplements have been available for about 25 years, and include preformed retinol preparations. Use of water miscible retinol supplements in the healthy population has raised concerns of potential liver toxicity as well as adverse impact to bone (82). Vitamin A status is assessed by serum retinol status, as well as serum retinol

Nutrition

321

binding protein, and by functional testing, such as modified relative dose response and dark adaptation tests. Serum retinol is depressed with acute inflammation, such as during pulmonary exacerbations and may be due to decreased release or increased turnover (83,84). There are no prospective randomized controlled trials of vitamin A supplementation on clinically relevant outcomes in (85). Investigators have demonstrated unexpectedly elevated serum retinol in children, adolescents, and young adults with CF (86,87) under current practices of supplementation with preformed, water-miscible vitamin A. Both of these studies documented excess vitamin A intake when compared to the Recommended Daily Allowance and Tolerable Upper Intake Level (82) and in excess of CFF Nutrition Consensus Committee recommendation (1,4). Hepatic vitamin A status of subjects with CF has been considered episodically, since the liver is the main storage. A 1972 study reported significantly higher hepatic and lower serum retinol concentrations in 12 subjects with CF (8–23 years old) compared with healthy controls (88). A 1997 study found normal hepatic retinol concentrations in 15 vitamin A–supplemented Swedish subjects with CF (8–34 years old) compared with healthy controls (89). While serum retinol and retinol binding protein are informative with respect to vitamin A deficiency, they do not reflect vitamin A excess. Measurement of serum REs as a function of serum retinol (normal is < 10%) provides information for risk of toxicity (90). Prospective studies of serum and tissue concentration employing newer, noninvasive techniques (including stable isotopes) are required to determine vitamin A status across compartments and across the clinical status ranges of deficiency to adequacy to toxicity (91). Newer formulations of CF supplements contain b-carotene as well as preformed retinol, and the benefits and risks of this supplement are not well studied in CF.

VIII.

Vitamin E

The vitamin E family of fat-soluble compounds is composed of tocopherols and tocotrienols, which are necessary for normal development, cell membrane stability, prevention of hemolysis, and in antioxidant status. Vitamin E plays a critical role in myelination and CNS development and is postulated to impact cognitive function (92). This increases the importance of preventing deficiency where possible and aggressive early correction when present in infants and children. The CF population is prone to vitamin E deficiency secondary to fat malabsorption and oxidative stress, and deficiency renders the cell membranes susceptible to damage (61). PUFA status has been linked to vitamin E status as well (48). Oxygen radical–scavenging capacity of a-tocopherol is well described, and recent data points to g-tocopherol functioning as a nitrogen radical– quenching entity (93). Defining clinical vitamin E status is not well established and complicates comparisons among studies. Vitamin E is reported as serum/plasma concentration, as a ratio to total cholesterol (decreased in CF), or as a ratio to total lipids (not commonly clinically available) (94). Serum or plasma reference values are available for a-tocopherol; reference values for g-tocopherol and other potentially important vitamin E compounds have not been established. The relationship of vitamin E status to functional and clinical outcomes in CF needs to be explored.

322

Maqbool et al.

IX.

Zinc

Zinc plays a critical role in over 300 cellular and metabolic functions including many related to pulmonary health and general immunity (95). Symptoms of zinc deficiency are nonspecific and include lack of appetite, alterations in taste, growth failure, and disturbed immune function (96–98). Zinc homeostasis is affected by nutrient content of the diet and fat malabsorption, therefore placing patients with CF at risk (99,100). The lack of a clinically informative laboratory method and reference values to identify zinc deficiency makes diagnosing deficiency challenging. Most zinc stores are intracellular (101), and investigators (101) suggest red blood cell zinc as a better indicator of zinc status. Reference values for zinc are dependent on the population and methods used (95,102). Prior to the initiation of PERT, infants are at risk of developing zinc deficiency because of their reduced ability to adequately absorb food zinc and endogenous recirculated zinc (103,104). Cases of acrodermatitis enteropathica-like rash due to zinc deficiency in infants and children prior to diagnosis with CF continue to be reported (105,106). Estimates of the prevalence of zinc deficiency in the CF population vary widely (95,102,107). In zinc supplementation trials, patients with lower zinc concentrations prior to intervention had greater benefit from supplementation (95,98,108). Empiric zinc supplementation for six months has been recommended for children with CF who exhibit growth failure, short stature, or have vitamin A deficiency, including night blindness, refractory to vitamin A therapy (1,109).

X. Summary Adequate nutrition is a key component of the standard of care for all patients with CF. Although advances in care have resulted in less undernutriton than in the past, the median BMI in children and adults with CF remains below recommendations. As the full impact of newborn screening (in USA) is realized, and infants and their families are quickly integrated into comprehensive CF care settings, the opportunity for nutritional care to contribute to better growth, lung health, immune and cognitive status, and quality of life will be even greater. As children and adolescents survive and thrive, research is key to discovering the evolving nutritional needs of patients with CF and PI to support optimal health into middle and older age. As further metabolic, cellular, and genomic roles of nutrients are discovered, there will be important roles for studies to determine the doses, nutritional or pharmacological, of vitamins, minerals, and fatty acids to support the well being of people with CF.

References 1. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002; 35(3):246–259. 2. Sinaasappel M, Stern M, Littlewood J, et al. Nutrition in patients with cystic fibrosis: a European Consensus. J Cyst Fibros 2002; 1(2):51–75. 3. UK Cystic Fibrosis Trust Nutrition Working Group. Nutritional Management of Cystic Fibrosis. Available at: www.cftrust.org.uk/aboutcf/publications/consensusdoc. Accessed April 24, 2009. 4. Yankaskas JR, Marshall BC, Sufian B, et al. Cystic fibrosis adult care: consensus conference report. Chest 2004; 125(1 suppl):1S–39S.

Nutrition

323

5. Stapleton DE. Australasian Clinical Practic Guidelines for Nutrition in Cystic Fibrosis. Available at: www.cysticfibrosis.org.au/books/nutritionbooks/PDF/CF nutritionguidelines. PDF. Accessed April 24, 2009. 6. Stallings VA, Stark LJ, Robinson KA, et al. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc 2008; 108(5):832–839. 7. Borowitz D, Robinson KA, Rosenfeld M, et al. Cystic Fibrosis Foundation Evidence-Based Guidelines for Management of Infants with Cystic Fibrosis. J Pediatr 2009; 155(6):S73–S93. 8. Institute of Medicine. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium and Carotenoids. Washington, DC: National Academy Press, 2002. 9. Kawchak DA, Zhao H, Scanlin TF, et al. Longitudinal, prospective analysis of dietary intake in children with cystic fibrosis. J Pediatr 1996; 129(1):119–129. 10. Gordon CM, Anderson EJ, Herlyn K, et al. Nutrient status of adults with cystic fibrosis. J Am Diet Assoc 2007; 107(12):2114–2119. 11. McPhail GL, Acton JD, Fenchel MC, et al. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase alfa use. J Pediatr 2008; 153(6):752–757. 12. Colombo C, Bennato V, Costantini D, et al. Dietary and circulating polyunsaturated fatty acids in cystic fibrosis: are they related to clinical outcomes? J Pediatr Gastroenterol Nutr 2006; 43(5):660–665. 13. Schall JI, Bentley T, Stallings VA. Meal patterns, dietary fat intake and pancreatic enzyme use in preadolescent children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2006; 43(5):651–659. 14. Olveira G, Dorado A, Olveira C, et al. Serum phospholipid fatty acid profile and dietary intake in an adult Mediterranean population with cystic fibrosis. Br J Nutr 2006; 96(2):343–349. 15. Powers SW, Patton SR, Byars KC, et al. Caloric intake and eating behavior in infants and toddlers with cystic fibrosis. Pediatrics 2002; 109(5):E75. 16. Fung EB, Barden EM, Wasserman D, et al. A six-month study of growth and energy expenditure in children with cystic fibrosis taking a pulmonary inhalation medication (rhDNase). J Am Coll Nutr 1999; 18(4):330–338. 17. Collins CE, O’Loughlin EV, Henry R. Discrepancies between males and females with cystic fibrosis in dietary intake and pancreatic enzyme use. J Pediatr Gastroenterol Nutr 1998; 26(3):258–262. 18. Trabulsi J, Schall JI, Ittenbach RF, et al. Energy balance and the accuracy of reported energy intake in preadolescent children with cystic fibrosis. Am J Clin Nutr 2006; 84(3):523–530. 19. DiMagno EP, Go VL, Summerskill WH. Relations between pancreatic enzyme ouputs and malabsorption in severe pancreatic insufficiency. N Engl J Med 1973; 288(16):813–815. 20. Patchell CJ, Desai M, Weller PH, et al. Creon 10,000 Minimicrospheres vs. Creon 8,000 microspheres—an open randomised crossover preference study. J Cyst Fibros 2002; 1(4):287–291. 21. Chen AH, Innis SM, Davidson AG, et al. Phosphatidylcholine and lysophosphatidylcholine excretion is increased in children with cystic fibrosis and is associated with plasma homocysteine, S-adenosylhomocysteine, and S-adenosylmethionine. Am J Clin Nutr 2005; 81(3):686–691. 22. Cohen JR, Schall JI, Ittenbach RF, et al. Fecal elastase: pancreatic status verification and influence on nutritional status in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2005; 40(4):438–444. 23. Stern RC, Eisenberg JD, Wagener JS, et al. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency. Am J Gastroenterol 2000; 95(8):1932–1938.

324

Maqbool et al.

24. Borowitz D, Goss CH, Limauro S, et al. Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis. J Pediatr 2006; 149(5): 658–662. 25. Zemel BS, Jawad AF, FitzSimmons S, et al. Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry. J Pediatr 2000; 137(3):374–380. 26. Milla CE. Association of nutritional status and pulmonary function in children with cystic fibrosis. Curr Opin Pulm Med 2004; 10(6):505–509. 27. Peterson ML, Jacobs DR Jr., Milla CE. Longitudinal changes in growth parameters are correlated with changes in pulmonary function in children with cystic fibrosis. Pediatrics 2003; 112(3 pt 1):588–592. 28. Ramsey BW, Farrell PM, Pencharz P. Nutritional assessment and management in cystic fibrosis: a consensus report. The Consensus Committee. Am J Clin Nutr 1992; 55(1): 108–116. 29. Zhang Z, Lai HJ. Comparison of the use of body mass index percentiles and percentage of ideal body weight to screen for malnutrition in children with cystic fibrosis. Am J Clin Nutr 2004; 80(4):982–991. 30. Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 2002; (246):1–190. 31. Centers for Disease Control and Prevention. Healthy Weight—it’s not a diet, it’s a lifestyle! Available at: http://www.cdc.gov/healthyweight/accessing/bmi/index.html. Accessed November 2009. 32. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation: Registry: 2006 Annual Data Report to the Center Directors. Bethesda, MD: Cystic Fibrosis Foundation, 2007. 33. Crist W, McDonnell P, Beck MP, et al. Behavior at Mealtimes and the Young Child with Cystic Fibrosis. J Dev Behav Pediatr 1994; 15(3):157–161. 34. Stark LJ, Mulvihill MM, Powers SW, et al. Behavioral intervention to improve calorie intake of children with cystic fibrosis: treatment versus wait list control. J Pediatr Gastroenterol Nutr 1996; 22(3):240–253. 35. Jelalian E, Stark LJ, Reynolds L, et al. Nutrition intervention for weight gain in cystic fibrosis: a meta analysis. J Pediatr 1998; 132(3 pt 1):486–492. 36. Kuo PT, Huang NN, Bassett DR. The fatty acid composition of the serum chylomicrons and adipose tissue of children with cystic fibrosis of the pancreas. J Pediatr 1962; 60:394–403. 37. Roulet M, Frascarolo P, Rappaz I, et al. Essential fatty acid deficiency in well nourished young cystic fibrosis patients. Eur J Pediatr 1997; 156(12):952–956. 38. Strandvik B, Gronowitz E, Enlund F, et al. Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis. J Pediatr 2001; 139(5):650–655. 39. Freedman SD, Blanco PG, Zaman MM, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004; 350(6):560–569. 40. Strandvik B, Svensson E, Seyberth HW. Prostanoid biosynthesis in patients with cystic fibrosis. Prostaglandins Leukot Essent Fatty Acids 1996; 55(6):419–425. 41. Coste TC, Armand M, Lebacq J, et al. An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis. Clin Biochem 2007; 40(8):511–520. 42. Cawood AL, Carroll MP, Wootton SA, et al. Is there a case for n-3 fatty acid supplementation in cystic fibrosis? Curr Opin Clin Nutr Metab Care 2005; 8(2):153–159. 43. Shoff SM, Ahn HY, Davis L, et al. Temporal associations among energy intake, plasma linoleic acid, and growth improvement in response to treatment initiation after diagnosis of cystic fibrosis. Pediatrics 2006; 117(2):391–400. 44. Walkowiak J, Lisowska A, Blaszczynski M, et al. Polyunsaturated fatty acids in cystic fibrosis are related to nutrition and clinical expression of the disease. J Pediatr Gastroenterol Nutr 2007; 45(4):488–489.

Nutrition

325

45. Maqbool A, Schall JI, Garcia-Espana JF, et al. Serum linoleic acid status as a clinical indicator of essential fatty acid status in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2008; 47(5):635–644. 46. Lloyd-Still JD, Johnson SB, Holman RT. Essential fatty acid status in cystic fibrosis and the effects of safflower oil supplementation. Am J Clin Nutr 1981; 34(1):1–7. 47. Lloyd-Still JD, Powers CA, Hoffman DR, et al. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study. Nutrition 2006; 22(1):36–46. 48. Van Biervliet S, Devos M, Delhaye T, et al. Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients. Prostaglandins Leukot Essent Fatty Acids 2008; 78(2):109–115. 49. McKarney C, Everard M, N’Diaye T. Omega-3 fatty acids (from fish oils) for cystic fibrosis. Cochrane Database Syst Rev 2007; (4):CD002201. 50. Kurlandsky LE, Bennink MR, Webb PM, et al. The absorption and effect of dietary supplementation with omega-3 fatty acids on serum leukotriene B4 in patients with cystic fibrosis. Pediatr Pulmonol 1994; 18(4):211–217. 51. Panchaud A, Sauty A, Kernen Y, et al. Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial. Clin Nutr 2006; 25(3):418–427. 52. Christophe A, Robberecht E. Directed modification instead of normalization of fatty acid patterns in cystic fibrosis: an emerging concept. Curr Opin Clin Nutr Metab Care 2001; 4(2):111–113. 53. Simopoulos AP. Essential fatty acids in health and chronic disease. Am J Clin Nutr 1999; 70(3 suppl):560S–569S. 54. Zeisel SH. Choline: an essential nutrient for humans. Nutrition 2000; 16(7-8):669–671. 55. Institute of Medicine. Vitamin B6. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington, DC: National Academy Press, 1998. 56. Ulane MM, Butler JD, Peri A, et al. Cystic fibrosis and phosphatidylcholine biosynthesis. Clin Chim Acta 1994; 230(2):109–116. 57. Innis SM, Davidson AG, Chen A, et al. Increased plasma homocysteine and Sadenosylhomocysteine and decreased methionine is associated with altered phosphatidylcholine and phosphatidylethanolamine in cystic fibrosis. J Pediatr 2003; 143(3):351–356. 58. Innis SM, Davidson AG, Melynk S, et al. Choline-related supplements improve abnormal plasma methionine-homocysteine metabolites and glutathione status in children with cystic fibrosis. Am J Clin Nutr 2007; 85(3):702–708. 59. Lepage G, Yesair DW, Ronco N, et al. Effect of an organized lipid matrix on lipid absorption and clinical outcomes in patients with cystic fibrosis. J Pediatr 2002; 141(2):178–185. 60. Innis SM, Davidson AG. Cystic fibrosis and nutrition: linking phospholipids and essential fatty acids with thiol metabolism. Annu Rev Nutr 2008; 28:55–72. 61. Wood LG, Fitzgerald DA, Lee AK, et al. Improved antioxidant and fatty acid status of patients with cystic fibrosis after antioxidant supplementation is linked to improved lung function. Am J Clin Nutr 2003; 77(1):150–159. 62. Holick MF, Vitamin D. In: Shils ME, Shike M, Ross AC, et al. eds. Modern Nutrition in Health and Disease. 10th ed. Philadelphia: Lippincott Williams & Wilkins, 2006:376–395. 63. Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008; 93(3):677–681. 64. Trang HM, Cole DE, Rubin LA, et al. Evidence that vitamin D3 increases serum 25hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr 1998; 68(4): 854–858.

326

Maqbool et al.

65. Institute of Medicine. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D and Fluoride. Washington, DC: National Academy Press, 1997. 66. Holick MF. The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanisms of action. Mol Aspects Med 2008; 29(6):361–368. 67. Ginde AA, Mansbach JM, Camargo CA Jr. Vitamin D, respiratory infections, and asthma. Curr Allergy Asthma Rep 2009; 9(1):81–87. 68. Black PN, Scragg R. Relationship between serum 25-hydroxyvitamin d and pulmonary function in the third national health and nutrition examination survey. Chest 2005; 128(6):3792–3798. 69. Hypponen E, Laara E, Reunanen A, et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001; 358(9292):1500–1503. 70. Krause R, Buhring M, Hopfenmuller W, et al. Ultraviolet B and blood pressure. Lancet 1998; 352(9129):709–710. 71. Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007; 85(6):1586–1591. 72. Heaney RP. Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr 2004; 80(6 suppl):1706S–1709S. 73. Hollis BW. Measuring 25-hydroxyvitamin D in a clinical environment: challenges and needs. Am J Clin Nutr 2008; 88(2):507S–510S. 74. Aris RM, Merkel PA, Bachrach LK, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005; 90(3):1888–1896. 75. Rovner AJ, Stallings VA, Schall JI, et al. Vitamin D insufficiency in children, adolescents, and young adults with cystic fibrosis despite routine oral supplementation. Am J Clin Nutr 2007; 86(6):1694–1699. 76. Green D, Carson K, Leonard A, et al. Current treatment recommendations for correcting vitamin D deficiency in pediatric patients with cystic fibrosis are inadequate. J Pediatr 2008; 153(4):554–559. 77. Boyle MP, Noschese ML, Watts SL, et al. Failure of high-dose ergocalciferol to correct vitamin D deficiency in adults with cystic fibrosis. Am J Respir Crit Care Med 2005; 172(2):212–217. 78. Stephenson A, Brotherwood M, Robert R, et al. Cholecalciferol significantly increases 25hydroxyvitamin D concentrations in adults with cystic fibrosis. Am J Clin Nutr 2007; 85(5):1307–1311. 79. Aris RM, Lester GE, Dingman S, et al. Altered calcium homeostasis in adults with cystic fibrosis. Osteoporos Int 1999; 10(2):102–108. 80. Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr 2006; 84(4):694–697. 81. Chandra P, Wolfenden LL, Ziegler TR, et al. Treatment of vitamin D deficiency with UV light in patients with malabsorption syndromes: a case series. Photodermatol Photoimmunol Photomed 2007; 23(5):179–185. 82. Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium and Zinc. Washington, DC: National Academy Press, 2001. 83. Hakim F, Kerem E, Rivlin J, et al. Vitamins A and E and pulmonary exacerbations in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2007; 45(3):347–353. 84. Duggan C, Colin AA, Agil A, et al. Vitamin A status in acute exacerbations of cystic fibrosis. Am J Clin Nutr 1996; 64(4):635–639. 85. O’Neil C, Shevill E, Chang AB. Vitamin A supplementation for cystic fibrosis. Cochrane Database Syst Rev 2008; (1):CD006751. 86. Graham-Maar RC, Schall JI, Stettler N, et al. Elevated vitamin A intake and serum retinol in preadolescent children with cystic fibrosis. Am J Clin Nutr 2006; 84(1):174–182. 87. Maqbool A, Graham-Maar RC, Schall JI, et al. Vitamin A intake and elevated serum retinol levels in children and young adults with cystic fibrosis. J Cyst Fibros 2008; 7(2):137–141.

Nutrition

327

88. Underwood BA, Denning CR. Blood and liver concentrations of vitamins A and E in children with cystic fibrosis of the pancreas. Pediatr Res 1972; 6(1):26–31. 89. Lindblad A, Diczfalusy U, Hultcrantz R, et al. Vitamin A concentration in the liver decreases with age in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 1997; 24(3):264–270. 90. James DR, Owen G, Campbell IA, et al. Vitamin A absorption in cystic fibrosis: risk of hypervitaminosis A. Gut 1992; 33(5):707–710. 91. Tanumihardjo SA. Assessing vitamin A status: past, present and future. J Nutr 2004; 134(1):290S–293S. 92. Koscik RL, Lai HJ, Laxova A, et al. Preventing early, prolonged vitamin E deficiency: an opportunity for better cognitive outcomes via early diagnosis through neonatal screening. J Pediatr 2005; 147(3 suppl):S51–S56. 93. Christen S, Woodall AA, Shigenaga MK, et al. Gamma-tocopherol traps mutagenic electrophiles such as NO(X) and complements alpha-tocopherol: physiological implications. Proc Natl Acad Sci U S A 1997; 94(7):3217–3222. 94. Huang SH, Schall JI, Zemel BS, et al. Vitamin E status in children with cystic fibrosis and pancreatic insufficiency. J Pediatr 2006; 148(4):556–559. 95. Abdulhamid I, Beck FW, Millard S, et al. Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatr Pulmonol 2008; 43(3):281–287. 96. Mocchegiani E, Provinciali M, Di Stefano G, et al. Role of the low zinc bioavailability on cellular immune effectiveness in cystic fibrosis. Clin Immunol Immunophathol 1995; 75(3):214–224. 97. Cantin AM. Potential for antioxidant therapy of cystic fibrosis. Curr Opin Pulm Med 2004; 10(6):531–536. 98. Van Biervliet S, Van Biervliet JP, Vande VS, et al. Serum zinc concentrations in cystic fibrosis patients aged above 4 years: a cross-sectional evaluation. Biol Trace Elem Res 2007; 119(1):19–26. 99. Krebs NF, Westcott JE, Arnold TD, et al. Abnormalities in zinc homeostasis in young infants with cystic fibrosis. Pediatr Res 2000; 48(2):256–261. 100. Easley D, Krebs N, Jefferson M, et al. Effect of pancreatic enzymes on zinc absorption in cystic fibrosis. J Pediatr Gastroenterol Nutr 1998; 26(2):136–139. 101. Akanli L, Lowenthal DB, Gjonaj S, et al. Plasma and red blood cell zinc in cystic fibrosis. Pediatr Pulmonol 2003; 35(1):2–7. 102. Maqbool A, Schall JI, Zemel BS, et al. Plasma zinc and growth status in preadolescent children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2006; 43(1):95–101. 103. Krebs NF, Sontag M, Accurso FJ, et al. Low plasma zinc concentrations in young infants with cystic fibrosis. J Pediatr 1998; 761–764. 104. Krebs NF. Overview of zinc absorption and excretion in the human gastrointestinal tract. J Nutr 2000; 130(5S suppl):1374S–1377S. 105. Bernstein ML, McCusker MM, Grant-Kels JM. Cutaneous manifestations of cystic fibrosis. Pediatr Dermatol 2008; 25(2):150–157. 106. Crone J, Huber WD, Eichler I, et al. Acrodermatitis enteropathica-like eruption as the presenting sign of cystic fibrosis—case report and review of the literature. Eur J Pediatr 2002; 161(9):475–478. 107. Van Biervliet S, Vanbillemont G, Van Biervliet JP, et al. Relation between fatty acid composition and clinical status or genotype in cystic fibrosis patients. Ann Nutr Metab 2007; 51(6):541–549. 108. Van Biervliet S, Vande VS, Van Biervliet JP, et al. The effect of zinc supplements in cystic fibrosis patients. Ann Nutr Metab 2008; 52(2):152–156. 109. Tinley CG, Withers NJ, Sheldon CD, et al. Zinc therapy for night blindness in cystic fibrosis. J Cyst Fibros 2008; 7(4):333–335.

20 Bone Health and Treatment NADINE G. HADDAD and LINDA A. DIMEGLIO Indiana University School of Medicine and Riley Hospital for Children, Indianapolis, Indiana, U.S.A.

I.

Introduction

As survival improves for persons with cystic fibrosis (CF), bone disease is increasingly recognized as a significant comorbidity. Manifestations of bone disease include low bone mineral density (BMD), bone pain, kyphosis, and fractures. The etiology is multifactorial, including overall malnutrition; deficiencies of vitamin D, vitamin K, and calcium; chronic infection and inflammation; steroid treatment; hypogonadism; low physical activity and reduced lean body mass (LBM); CF-related diabetes; and direct bone effects of cystic fibrosis transmembrane conductance regulator (CFTR) mutations. Prophylactic and therapeutic regimens should address each comorbidity if present, and may involve therapy with bisphosphonates in selected cases. Bone is a highly specialized tissue composed of bone cells (osteoblasts and osteoclasts) and a matrix (osteoid). Osteoblasts are responsible for bone matrix formation and its mineralization whereas osteoclasts resorb mineralized bone. Osteoid is comprised of type I collagen (~94%) and noncollagenous proteins. The hardness of bone results from mineral salts in the osteoid matrix, which is a crystalline complex of calcium and phosphate (hydroxyapatite). Poor bone mineralization in CF may be the result of decreased bone formation, increased resorption, or decreased mineralization.

II.

Clinical Manifestations

A. Bone Mineral Density

BMD is defined as the amount of mineral contained in a certain area or volume of bone. Bone mineralization status is most commonly assessed using dual energy X-ray absorptiometry (DXA). DXA measures bone mineral content (BMC, grams) and bone area (centimeters) at skeletal sites. It then provides a calculated value for areal BMD (g/cm2). In adults, measurements of the spine and proximal femur are the most common sites of assessment. In children, spine and total-body less head measurements are the most accurate and reproducible sites of assessment (1). A diagnosis of osteoporosis in adults is made when a t score (a standard deviation score comparing the BMD of the individual to the measurement in young adults of the same race and gender) is 2.5 or lower (2). Osteopenia is diagnosed when t scores are from 1 to 2.5. In children, the diagnosis of osteoporosis is not made solely by densitometry, but rather requires the presence of both a clinically significant fracture history and low BMC or BMD for age (3).

328

Bone Health and Treatment

329

Bone densitometry is used to identify individuals at risk for fracture and to monitor and guide therapy for those with compromised bone mass. Epidemiologic studies in healthy adults have demonstrated that risk of fracture increases proportionately to a decrease in BMD t score (4). There are few pediatric data on the relationship between fracture risk and BMD, particularly in children with chronic disease. However, there is increasing evidence for a relationship between DXA measurements and fracture risk in children and adolescents (1,5). BMD measurements are affected by several parameters including height, weight, bone size, LBM, skeletal age, and pubertal stage. For instance, an apparently low BMD in a short person may be due to smaller bones rather than aberrant mineral content for body size. These factors may be more pronounced in children with chronic illness, rendering interpretation of studies in such patients more difficult. Incorporating bone age assessment has been suggested as an approach to adjust for factors related to puberty and growth since bone age corresponds to pubertal maturation. However, bone age readings are subjective, and BMDs corrected for bone age can result in overestimations of z scores in children with delayed bone ages (1). Many adults with CF have either osteopenia or osteoporosis—estimates range from 40% to 70% (6). These rates increase with more severe pulmonary disease and poorer nutritional status and are particularly high in patients with end-stage lung disease and persons undergoing lung transplantation. Osteoporosis can also worsen after lung transplantation because of steroid and calcineurin inhibitor use (7). Studies of children with CF provide mixed results regarding the prevalence of low BMD for age. Some studies have shown normal BMD (8–11). In a study of children with CF and mild pulmonary disease, total-body BMC was similar between patients and a control group of healthy children matched for age, sex, LBM, and height (8). In a cross-sectional study of 20 prepubertal young children with CF, BMC was normal when compared with age- and sex-matched healthy sibling controls. However, patients had less LBM than controls at taller heights, suggesting that as children with CF grow, they fail to accrue bone mass normally (11). Other studies report BMD reductions (12–14). In a study of 136 young patients with CF aged 3 to 24 years, spine and total-body BMD z scores were low (z score < 1) in 66%, independent of sex and age (12). In this study, impaired pulmonary function and total steroid dose (both inhaled and enteral) had the greatest negative influences on bone mass. Similarly, 52% of 25 patients with CF less than six years of age who were well nourished and had mild pulmonary disease were found to have height-adjusted lumbar spine BMDs of < 1, suggesting that a primary, intrinsic bone factor may be partly responsible for low BMD in CF (14). Some of the variability in these results reflect factors involved in DXA interpretation such as height and bone volume (12). Since adolescents with CF commonly have delayed puberty and small stature, unadjusted DXA measurements underestimate BMD. Thus, adjustments for height, body mass index (BMI), and/or bone age are generally necessary to appropriately interpret studies (15). Some of the differences in reports also reflect difference in the ages, severity of lung disease, and nutrition of studied populations. Bone mineral accrual is a continuous process that starts prior to birth and continues through childhood and adolescence. A rapid gain in bone mass occurs during adolescence with up to 25% of peak bone mass being acquired around the period of peak

330

Haddad and DiMeglio

height velocity (16). Longitudinal studies suggest that bone disease results from decreased bone formation during childhood and adolescence, and increased bone turnover in adulthood (17). It has been postulated that failure to accrue bone mass during puberty may be the primary factor contributing to low BMD in persons with CF. In a study of 85 patients with CF, aged 5 to 18 years, followed for 2 years, gains in total-body and lumbar spine BMD were significantly lower than controls after adjusting for age, sex, and height z scores (18). In addition, studies in young adults with CF show progressive bone loss. A yearlong study of 55 patients aged 15 to 24 years showed an annualized bone loss rate of 2.5% in the femoral neck and 2.2% in the total hip (17). Thus, these young persons with CF not only fail to accrue bone mass, as would be expected at this young age, but also lose bone at a rate similar to postmenopausal women. Similarly, 59 people with CF aged 25 to 49 years experienced decreases of 1.9% per year at the femoral neck and 1.5% per year at the total hip (17). B. Fractures

A high fracture incidence has been reported in adults with CF (19). One study demonstrated a twofold higher fracture rate in persons aged 16 to 45 years compared with the general population (20). The most commonly reported fractures are vertebral and rib fractures, with rates 10 and 100 times higher, respectively, than in the general population. These fractures are clinically significant since they can alter chest wall structure and impair coughing and airway clearance, which in turn can cause a decline in lung function. In a longitudinal study of 49 adults with CF (mean age 25.2 years), the prevalence of at least one vertebral fracture was 16.3% at baseline and increased to 21.3% at 3-year follow-up (21). Studies of fractures in children are few and show variable results. A high prevalence of fractures and kyphosis were described in earlier studies of children and adolescents with CF (20,22). More recently, fracture risk adjusted for age and sex in a group of young patients with CF and mild-to-moderate pulmonary disease was not greater than that of controls (23). This latter study may reflect effects of improved management of lung disease and nutrition.

III.

Pathogenesis

The pathophysiology of bone disease in CF results from an interplay of factors, detailed below. A. Malnutrition

Adequate nutrient intake is important for achieving and maintaining both bone mass and LBM. A number of studies have shown a correlation between low BMD and low BMI in persons with CF (19,24,25), indicating that adequate nutritional support to maintain an adequate BMI is key for bone health, particularly during puberty when significant bone accrual occurs. B. Vitamin D Deficiency

Vitamin D is essential for calcium absorption and retention and normal bone mineralization. It can either be synthesized in the skin with ultraviolet B (UVB) light exposure or absorbed from dietary sources. The etiology of vitamin D deficiency in CF is

Bone Health and Treatment

331

postulated to result from inadequate absorption (26), decreased conversion of vitamin D to its active forms (27), and limited sun exposure. Current recommendations are for serum 25-hydroxy vitamin D (25-OHD) to be maintained above 75 nmol/L (30 ng/mL) (28). Levels less than 40 nmol/L (16 ng/mL) are considered “deficient” and 41 to 75 nmol/L (17–29 ng/mL) considered “insufficient.” However, despite wide acceptance of supplementation, vitamin D insufficiency and deficiency remain common regardless of latitude or season (28). In an observational study of 81 pediatric patients with CF, 95% had plasma 25-OHD levels below 75 nmol/L and 50% had values less than 40 nmol/L, despite these children being relatively well nourished and having only mildto-moderate lung disease (29). The majority of adults with CF also have vitamin D levels in the insufficient range (28,30). C. Vitamin K Deficiency

Vitamin K also plays a key role in maintaining bone formation through direct stimulatory effects on osteoblasts. It impacts osteocalcin activity by acting as a cofactor for posttranslational carboxylation of osteocalcin glutamic acid residues. Uncarboxylated osteocalcin has a reduced affinity for hydroxyapatite compared with carboxylated forms. Vitamin K insufficiency is common in CF. In a multicenter study of children and adolescents with CF, serum vitamin K levels were found to be low in 65% of patients, with 30% having undetectable levels (29). Similar results were found in a study of 93 children with CF, where 70% had suboptimal vitamin K levels (31). High uncarboxylated osteocalcin levels reflecting vitamin K deficiency have been reported in individuals with CF (32,33). High levels of uncarboxylated osteocalcin also predicted lower lumbar spine BMD in a study of 14, 8- to 12-year-old children with CF (32). D. Calcium Deficiency

Calcium is a critical component of bone mineral, yet it is often deficient in individuals with CF. Deficiency is the result of inadequate amounts of vitamin D or poor absorption of dietary calcium. E.

Chronic Infection and Inflammation

It is difficult to assess the role of chronic infection in isolation on bone health in people with CF, as those subjects with recurrent episodes of infection are also more likely to be more malnourished and have lower pulmonary function. Lung infection in CF increases cytokine release, particularly tumor necrosis factor (TNF)-a and interleukins (IL) 1 and 6. Cytokines affect bone metabolism by increasing bone resorption and decreasing bone formation (34,35). Several studies have shown an independent association between increased numbers of intravenous antibiotic courses and lower BMD in CF patients (19,36), reflecting the influence of chronic infection on BMD. F.

Glucocorticoids

Glucocorticoids worsen bone disease via a variety of complex and incompletely understood mechanisms. Primarily, they reduce bone formation by decreasing osteoblast number and activity and suppressing insulin-like growth factor 1 (IGF-1) secretion and action. They also decrease sex hormone production, inhibit calcium absorption, and decrease calcium renal tubular reabsorption (37). They tend to have the greatest effect

332

Haddad and DiMeglio

on sites with high amounts of trabecular bone (spine and ribs) rather than on those with more cortical bone (long bones). Steroid therapy, whether oral or inhaled, has been associated with low BMD in children and adults with CF (12,17,19). However, this association is confounded by disease severity, since sicker individuals are more likely to receive more courses of steroid therapy. G. Delayed Puberty and Hypogonadism

Delayed sexual maturation and early hypogonadism have been described in young adults with CF and are related to disease severity (19). Delayed puberty can result in a delay in attainment of peak bone mass. As management of CF has improved, delayed puberty has become less prevalent and severe (38), and by the time of young adulthood, most persons with CF have normal sex hormone levels (28). H. Physical Activity, Exercise, and LBM

In healthy individuals, weight-bearing exercise is important to increase BMD and maintain bone mass (39). LBM is one of the main determinants of bone development and BMD (40). Individuals with CF are often limited in exercise capacity by respiratory function. In children with CF, LBM is low and strongly correlates with bone mineral accrual and BMD (11,14,18). I.

CF-Related Diabetes

Type 1 diabetes is accompanied by low bone mass, primarily due to a failure of bone formation rather than bone loss (41). No studies have specifically addressed the role of CF-related diabetes (CFRD) in bone accrual or BMD. However, adverse effects on bone accrual from hyperglycemia, inflammation, and amylin (another b-cell hormone) deficiency may magnify other risk factors for osteoporosis. J.

CFTR in Bone

Accumulating in vitro and in vivo evidence suggests a direct role of the CFTR protein in CF-related bone disease. Other chloride channel mutations are implicated in disorders of bone metabolism, such as mutations in the chloride channel 7, which produce osteopetrosis through adverse effects on osteoclast function. The mechanism of action of CFTR in bone homeostasis remains largely unknown. Functional studies suggest that mutations in the CFTR protein can impair normal bone remodeling by adversely affecting parathyroid hormone (PTH) stimulation of osteoblasts (42). In mice, CFTR is expressed in osteoblasts but not osteoclasts (43). CFTR-null mice, despite having minimal pulmonary disease and malabsorption, have severe osteopenia with reduced cortical width and trabecular thinning (44,45). CFTR was recently found to be expressed in human bone osteoblasts, osteocytes, and osteoclasts (46). DF508 mutations, which are associated with worse pulmonary diseases, have been shown to be an independent risk factor for low BMD in persons with CF. In a study of 88 adults with CF, those who had at least one copy of DF508 exhibited significantly lower BMD than those with other mutations (47). Similarly, in a cross-sectional study of 20 prepubertal children with CF, patients homozygous for class I or II mutations, including DF508, had lower BMC and decreased markers of bone formation compared with other combinations (11).

Bone Health and Treatment

IV.

333

Biochemical Markers

Studies of bone markers in CFTR-null mice indicate a reduction of bone formation and concomitant increase in bone resorption (44,45). Studies of bone turnover markers in persons with CF also demonstrate increased turnover with high bone resorption (27,48). Markers of bone formation such as osteocalcin and bone alkaline phosphatase have been reported to be low in children and adults with CF (48,49). The rate of calcium deposition in bone in children with CF also appears to be low, contributing to low bone accretion. In a calcium kinetics analysis, calcium deposition in bone was found to be lower among a group of girls with CF compared with healthy children consuming comparable calcium intakes (50).

V. Bone Histopathology Iliac crest bone biopsies in adults with CF demonstrate lower cancellous bone area than controls, with a trend toward a decrease in the connections between bone trabeculae (higher length of trabeculae with greater marrow volume) (51). At the tissue level, bone formation indices are low with decreased mineralizing perimeter and mineral apposition rates and narrower wall widths. Autopsy bone samples demonstrate a decrease in osteoblast number and a decrease in biosynthetic potential of osteoblasts (52). These findings are consistent with the reductions in cortical bone width and trabecular thickness seen in CFTR-null mice (44,45).

VI.

Management

Prophylactic treatment of CF-related bone disease aims to prevent bone fracture, deformity, and bone pain. Early diagnosis is important for effective management. Diagnosis begins with DXA screening. Current guidelines recommend DXA for all adults with CF and for children over eight years of age if they have risk factors for low BMD, including low body weight, low FEV1 (forced expiratory volume in one second), high glucocorticoid use, delayed puberty, or fracture (Fig. 1). Prevention should begin in childhood and includes optimizing nutrition and management of lung disease, encouraging weight-bearing exercise, and adequate sun exposure. Approaches to management of various pathologies are outlined below. A. Vitamin D Replacement

Recommendations are based on serum concentrations of 25-OHD, whereas measurement of 1,25-OHD is not valuable. Vitamin D supplementation should be provided with the goal of achieving a target serum 25-OHD of 75 to 150 nmol/L (30–60 ng/mL) (28). Generally, current recommendations for vitamin D supplementation are achieved using either ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3), and include daily intake of 400 IU of ergocalciferol by infants and 800 IU by individuals older than one year. However, larger vitamin D doses may be needed to optimize serum 25-OHD levels (53). The best vitamin D preparation and dose required to achieve these levels needs further research. Studies on the effectiveness of vitamin D therapy in persons with CF are limited but promising. In one such study, 30 adults with CF who were already receiving a standard vitamin D supplement of 900 IU per day were randomized to receive an

334

Haddad and DiMeglio

Figure 1 Recommendation for screening of bone disease in CF. Abbreviations: CF, cystic fib-

rosis; DXA, dual energy X-ray absorptiometry; FEV1, forced expiratory volume in one second; BMI, body mass index; BMD, bone mineral density. Source: From Ref. 28.

Bone Health and Treatment

335

additional 800 IU of cholecalciferol plus 1 g of calcium daily or placebo for 12 months. The treatment group had decreased rates of both bone loss by DXA and bone turnover, although no values reached statistical significance (54). Interestingly, serum 25-OHD levels were not significantly changed by therapy, indicating that possibly larger vitamin D doses may be required to achieve clinically significant effects. Given concerns about decreased vitamin D absorption, small trials have assessed the efficacy of supplements with the hydroxylated forms calcifediol (25-OHD) and calcitriol (1–25 OHD). In a controlled study, 73 CF children and adults with BMD z scores of < 1.5 or < 2.0, respectively, were treated with calcifediol (0.7 mg/kg/ day) and 1 g of calcium. Sixty-seven percent of the calcifediol-treated patients experienced an increase in BMD compared to 32% of controls (55). The efficacy of calcitriol was also assessed in a short-term study of 10 adults with CF who were treated with oral calcitriol (0.5 mg twice daily) for 14 days (56). Calcitriol improved markers of calcium balance by significantly increasing fractional absorption of calcium, lowering PTH levels and suppressing bone resorption. UVB radiation, which converts 7-deoxycholesterol to previtamin D3 in the skin, may also be effective adjuvant therapy for persons with CF (57).

B. Vitamin K Supplementation

The current recommendation for individuals with CF is for a vitamin K supplement of 0.3 to 0.5 mg/day. Although literature on the appropriate dose to prevent vitamin K deficiency is limited, a study of 14 children with CF and pancreatic insufficiency supplemented with 1 mg or 5 mg of vitamin K daily showed that both doses restored normal serum vitamin K levels (58). The efficacy of vitamin K supplementation for improving bone formation rates in children and adolescents with CF has been studied (49). Twenty individuals aged 6 to 17 years were treated with a weekly 10-mg oral dose of vitamin K. Bone turnover markers were examined before and after therapy and compared with controls. Although BMD z scores did not improve with therapy, treated patients experienced an increase in serum levels of bone formation markers and a decrease in serum PTH levels, indicating a potential beneficial role.

C. Bisphosphonates

Bisphosphonates are chemical analogs of pyrophosphate in which the central oxygen has been replaced by a carbon (59). Bisphosphonates reduce bone resorption primarily through inhibitory effects on osteoclastic bone resorption. Side-chain substitutions determine their antiresorptive potency, with introduction of nitrogen atoms (pamidronate, alendronate), particularly within a ring structure (zoledronic acid, risedronate), further accentuating potency. Choice of bisphosphonate for a given clinical indication depends on these potency differences, the availability and expense of a particular compound, and prior experiences/labeling for that drug in a given patient population. Studies using bisphosphonates to improve BMD in adults with CF have yielded encouraging results. Intravenous pamidronate (30 mg every three months) was the first bisphosphonate used in adults with CF, since intravenous administration avoided both the potential for decreased intestinal bioavailability due to malabsorption as well as the risk of esophagitis from gastroesophageal reflux of oral preparations. In a trial of

336

Haddad and DiMeglio

30 persons with CF, six months of pamidronate therapy resulted in significant gains in lumbar spine and total hip BMD (mean difference between pamidronate-treated and untreated groups of 5.8% and 3.0% respectively, p < 0.05) (60). Unfortunately, 73% of pamidronate-treated individuals experienced significant bone pain, requiring shortening of the trial. Since patients on glucocorticoids did not experience bone pain, pretreatment with prednisone may be useful. Pamidronate was also shown to improve BMD in patients with CF after lung transplantation (61). Oral alendronate therapy has shown promising results in a few studies (62,63). In a randomized placebo-controlled study, 56 adults with CF (27 in treatment group and 29 controls) received 70 mg of oral alendronate weekly for 12 months in addition to 800 IU of vitamin D and 1 g of calcium daily. Treated patients had significant increases in lumbar spine and total hip BMDs (5.20% and 2.14%, respectively) compared with controls ( 0.08% and 0.3%). Alendronate therapy was well tolerated with no increase in the incidence of adverse events, including gastrointestinal-related events, in the treatment group (62). A retrospective study of eight children and adults with CF with lumbar spine z scores < 2 SD treated with cyclical etidronate for one year demonstrated significant increases in totalbody and lumbar spine BMD z scores without adverse effects (64). D. Growth Hormone Therapy

Growth hormone (GH) therapy has shown promising results on bone accrual in children with CF. In a multicenter, randomized, controlled crossover trial of 61 prepubertal children with CF, GH-treated patients demonstrated significant increases in height, weight, LBM, and BMC compared with the nontreated group (65). Although BMC, not BMD, was measured, improvements remained significant even with correction for height increases, suggesting that GH improves bone mineral accrual. E. Other Potential Therapies Calcium Supplementation

Although calcium intake is important for bone mineral accrual, there have been no randomized controlled studies of calcium supplements in CF to date. The current recommendation is for intake of 1300 to 1500 mg/day (28). Hormone Replacement Therapy

Therapy with testosterone and/or estrogen in adolescents with pubertal delay would be expected to improve bone mass, in addition to promoting growth and pubertal development. However, the effects of androgen and estrogen supplementation on bone mass in persons with CF with delayed puberty or early andro/menopause have not yet been studied. Therefore, such therapies cannot be recommended routinely for the primary purpose of amelioration of bone health in CF. Exercise

The efficacy of exercise interventions for bone health in CF has not been directly studied; however, they likely could play a significant role (66). Parathyroid Hormone

Recombinant intermittently administered PTH is a promising anabolic agent used for osteoporosis in adults. It is not used in children because of concerns about the development

Bone Health and Treatment

337

of osteosarcoma in the growing skeleton. Although no studies of PTH in adults with CF have been conducted to date, it may have promise in this population because of the pronounced anabolic effects of PTH on bone.

VII.

Conclusion

CF-related bone disease is multifactorial. Early screening and management of low bone density is important to prevent sequelae of osteopenia and osteoporosis. Adequate nutrition and supplementation with calcium and vitamin D and K are essential to maintain bone health. Many questions remain regarding optimal regimens for CF bone disease. More research is needed. For now, treatment of additional risk factors and use of bisphosphonates for severely affected individuals should be individualized.

References 1. Gordon CM, Bachrach LK, Carpenter TO, et al. Dual energy X-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD Pediatric Official Positions. J Clin Densitom 2008; 11:43–58. 2. Genant HK, Cooper C, Poor G, et al. Interim report and recommendations of the world health organization task-force for osteoporosis. Osteoporos Int 1999; 10:259–264. 3. Baim S, Leonard MB, Bianchi ML, et al. Official positions of the international society for clinical densitometry and executive summary of the 2007 ISCD pediatric position development conference. J Clin Densitom 2008; 11:6–21. 4. Raisz LG. Clinical practice. Screening for osteoporosis. N Engl J Med 2005; 353:164–171. 5. Rauch F, Plotkin H, DiMeglio L, et al. Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2007 pediatric official positions. J Clin Densitom 2008; 11:22–28. 6. Doring G, Conway SP. Osteoporosis in cystic fibrosis. J Pediatr 2008; 84:1–3. 7. Hadjiliadis D. Special considerations for patients with cystic fibrosis undergoing lung transplantation. Chest 2007; 131:1224–1231. 8. Hardin DS, Arumugam R, Seilheimer DK, et al. Normal bone mineral density in cystic fibrosis. Arch Dis Child 2001; 84:363–368. 9. Humphries IR, Allen JR, Waters DL, et al. Volumetric bone mineral density in children with cystic fibrosis. Appl Radiat Isot 1998; 49:593–595. 10. Laursen EM, Molgaard C, Michaelsen KF, et al. Bone mineral status in 134 patients with cystic fibrosis [see comment]. Arch Dis Child 1999; 81:235–240. 11. Haddad N, Howenstine M, Peacock M, et al. Bone Status Evaluation in Pre-Pubertal Children with Cystic Fibrosis (abstr). Montreal, Canada: American Society for Bone and Mineral Research, September 2008. 12. Bianchi ML, Romano G, Saraifoger S, et al. BMD and body composition in children and young patients affected by cystic fibrosis. J Bone Miner Res 2006; 21:388–396. 13. Gronowitz E, Garemo M, Lindblad A, et al. Decreased bone mineral density in normalgrowing patients with cystic fibrosis. Acta Paediatr 2003; 92:688–693. 14. Sermet-Gaudelus I, Souberbielle JC, Ruiz JC, et al. Low bone mineral density in young children with cystic fibrosis. Am J Respir Crit Care Med 2007; 175:951–957. 15. Kelly A, Schall JI, Stallings VA, et al. Deficits in bone mineral content in children and adolescents with cystic fibrosis are related to height deficits. J Clin Densitom 2008; 11:581–589. 16. Sabatier JP, Guaydier-Souquieres G, Laroche D, et al. Bone mineral acquisition during adolescence and early adulthood: a study in 574 healthy females 10–24 years of age. Osteoporos Int 1996; 6:141–148.

338

Haddad and DiMeglio

17. Haworth CS, Selby PL, Horrocks AW, et al. A prospective study of change in bone mineral density over one year in adults with cystic fibrosis. Thorax 2002; 57:719–723. 18. Buntain HM, Schluter PJ, Bell SC, et al. Controlled longitudinal study of bone mass accrual in children and adolescents with cystic fibrosis. Thorax 2006; 61:146–154. 19. Elkin SL, Fairney A, Burnett S, et al. Vertebral deformities and low bone mineral density in adults with cystic fibrosis: a cross-sectional study. Osteoporos Int 2001; 12: 366–372. 20. Aris RM, Renner JB, Winders AD, et al. Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann Intern Med 1998; 128: 186–193. 21. Papaioannou A, Kennedy CC, Freitag A, et al. Longitudinal analysis of vertebral fracture and BMD in a Canadian cohort of adult cystic fibrosis patients. BMC Musculoskelet Disord 2008; 9:125. 22. Henderson RC, Specter BB. Kyphosis and fractures in children and young adults with cystic fibrosis. J Pediatr 1994; 125:208–212. 23. Rovner AJ, Zemel BS, Leonard MB, et al. Mild to moderate cystic fibrosis is not associated with increased fracture risk in children and adolescents. J Pediatr 2005; 147:327–331. 24. Haworth CS, Selby PL, Webb AK, et al. Low bone mineral density in adults with cystic fibrosis. Thorax 1999; 54:961–967. 25. Gibbens DT, Gilsanz V, Boechat MI, et al. Osteoporosis in cystic fibrosis. J Pediatr 1988; 113:295–300. 26. Lark RK, Lester GE, Ontjes DA, et al. Diminished and erratic absorption of ergocalciferol in adult cystic fibrosis patients. Am J Clin Nutr 2001; 73:602–606. 27. Aris RM, Ontjes DA, Buell HE, et al. Abnormal bone turnover in cystic fibrosis adults. Osteoporos Int 2002; 13:151–157. 28. Aris RM, Merkel PA, Bachrach LK, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005; 90:1888–1896. 29. Grey V, Atkinson S, Drury D, et al. Prevalence of low bone mass and deficiencies of vitamins D and K in pediatric patients with cystic fibrosis from 3 Canadian centers. Pediatrics 2008; 122:1014–1020. 30. Donovan DS Jr., Papadopoulos A, Staron RB, et al. Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease. Am J Respir Crit Care Med 1998; 157:1892–1899. 31. Conway SP, Wolfe SP, Brownlee KG, et al. Vitamin K status among children with cystic fibrosis and its relationship to bone mineral density and bone turnover. Pediatrics 2005; 115:1325–1331. 32. Fewtrell MS, Benden C, Williams JE, et al. Undercarboxylated osteocalcin and bone mass in 8–12 year old children with cystic fibrosis. J Cyst Fibros 2008; 7:307–312. 33. Aris RM, Ontjes DA, Brown SA, et al. Carboxylated osteocalcin levels in cystic fibrosis. Am J Respir Crit Care Med 2003; 168:1129. 34. Norman D, Elborn J, Cordon S, et al. Plasma tumor necrosis factor alpha in cystic fibrosis. Thorax 1991; 46:91–95. 35. Manolagas SC. The role of IL-6 type cytokines and their receptors in bone. Ann N Y Acad Sci 1998; 840:194–204. 36. Aris RM, Stephens AR, Ontjes DA, et al. Adverse alterations in bone metabolism are associated with lung infection in adults with cystic fibrosis. Am J Respir Crit Care Med 2000; 162:1674–1678. 37. Ali NJ, Capewell S, Ward MJ. Bone turnover during high dose inhaled corticosteroid treatment. Thorax 1991; 46:160–164.

Bone Health and Treatment

339

38. Buntain HM, Greer RM, Wong JC, et al. Pubertal development and its influences on bone mineral density in Australian children and adolescents with cystic fibrosis. J Paediatr Child Health 2005; 41:317–322. 39. Hind K, Burrows M. Weight-bearing exercise and bone mineral accrual in children and adolescents: a review of controlled trials. Bone 2007; 40:14–27. 40. Young D, Hopper JL, Macinnis RJ, et al. Changes in body composition as determinants of longitudinal changes in bone mineral measures in 8 to 26-year-old female twins. Osteoporos Int 2001; 12:506–515. 41. McCabe LR. Understanding the pathology and mechanisms of type I diabetic bone loss. J Cell Biochem 2007; 102:1343–1357. 42. Kingsley L, McKibbin C, Clines K, et al. CFTR Regulates Osteoblast Bone Formation Independent of Chloride Conductance (abstr). Montreal, Canada: American Society for Bone and Mineral Research, September 2008. 43. Aris RM, Guise TA, Clines G. Murine calvarial osteoblasts express CFTR mRNA in an amount similar to the pancreas. Ped Pulmonol 2006; 29:393. 44. Haston CK, Li W, Li A, et al. Persistent osteopenia in adult cystic fibrosis transmembrane conductance regulator-deficient mice. Am J Respir Crit Care Med 2008; 177:309–315. 45. Dif F, Marty C, Baudoin C, et al. Severe osteopenia in CFTR-null mice. Bone 2004; 35: 595–603. 46. Shead EF, Haworth CS, Condliffe AM, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. Thorax 2007; 62:650–651. 47. King SJ, Topliss DJ, Kotsimbos T, et al. Reduced bone density in cystic fibrosis: deltaF508 mutation is an independent risk factor. Eur Respir J 2005; 25:54–61. 48. Greer RM, Buntain HM, Potter JM, et al. Abnormalities of the PTH-vitamin D axis and bone turnover markers in children, adolescents, and adults with cystic fibrosis: comparison with healthy controls. Osteoporos Int 2003; 14:404–411. 49. Nicolaidou P, Stavrinadis I, Loukou I, et al. The effect of vitamin K supplementation on biochemical markers of bone formation in children and adolescents with cystic fibrosis. Eur J Pediatr 2006; 165:540–545. 50. Schulze KJ, O’Brien KO, Germain-Lee EL, et al. Calcium kinetics are altered in clinically stable girls with cystic fibrosis. J Clin Endocrinol Metab 2004; 89:3385–3391. 51. Elkin SL, Vedi S, Bord S, et al. Histomorphometric analysis of bone biopsies from the iliac crest of adults with cystic fibrosis. Am J Respir Crit Care Med 2002; 166:1470–1474. 52. Haworth CS, Webb AK, Egan JJ, et al. Bone histomorphometry in adult patients with cystic fibrosis. Chest 2000; 118:434–439. 53. Boyle MP, Noschese M, Watts S, et al. Prevalence of 25-hydroxyvitamin D deficiency in adults with CF and effect of high dose ergocalciferol supplementation. Pediatr Pulmonol 2003; 25(suppl):350 (abstr). 54. Haworth CS, Jones AM, Adams JE, et al. Randomised double blind placebo controlled trial investigating the effect of calcium and vitamin D supplementation on bone mineral density and bone metabolism in adult patients with cystic fibrosis. J Cyst Fibros 2004; 3:233–236. 55. Enfissi L, Bianchi ML, Galbiati E, et al. Osteoporosis in CF: calcifediol therapy increases bone mineral density (BMD). Pediatr Pulmonol Suppl 2001; 22:334 (abstr 475). 56. Brown SA, Ontjes DA, Lester GE, et al. Short-term calcitriol administration improves calcium homeostasis in adults with cystic fibrosis. Osteoporos Int 2003; 14:442–449. 57. Gronowitz E, Larko O, Gilljam M, et al. Ultraviolet B radiation improves serum levels of vitamin D in patients with cystic fibrosis. Acta Paediatr 2005; 94:547–552. 58. Drury D, Grey VL, Ferland G, et al. Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. J Cyst Fibros 2008; 7:457–459. 59. Russell RG. Bisphophonates: mode of action and pharmacology. Pediatrics 2007; 119(suppl 2): S150–S162.

340

Haddad and DiMeglio

60. Haworth CS, Selby PL, Adams JE, et al. Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis. Thorax 2001; 56:314–316. 61. Aris RM, Lester GE, Renner JB, et al. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am J Respir Crit Care Med 2000; 162:941–946. 62. Papaioannou A, Kennedy CC, Freitag A, et al. Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial). Chest 2008; 134:794–800. 63. Aris RM, Lester GE, Caminiti M, et al. Efficacy of alendronate in adults with cystic fibrosis with low bone density. Am J Respir Crit Care Med 2004; 169:77–82. 64. Ringuier B, Leboucher B, Leblanc M, et al. Efficacite des biphosphonates oraux sur la demineralisation osseuse des patients atteints de mucoviscidose. Arch Pediatr 2004; 11: 1445–1449. 65. Hardin DS, Adams-Huet B, Brown D, et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. J Clin Endocrinol Metab 2006; 91:4925–4929. 66. Hind K, Truscott JG, Conway SP. Exercise during childhood and adolescence: a prophylaxis against cystic fibrosis-related low bone mineral density? Exercise for bone health in children with cystic fibrosis. J Cyst Fibros 2008; 7:270–276.

21 Cystic Fibrosis–Related Diabetes and Management ANDREA KELLY and ANDREW C. CALABRIA University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A.

I.

Introduction

With improved survival among individuals with cystic fibrosis (CF), diabetes mellitus has emerged as a significant comorbidity. While much of its pathophysiology overlaps that of both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), cystic fibrosis–related diabetes (CFRD) is considered a distinct form of diabetes. An important distinction clinically is the management approach, which is tailored to meet the unique medical needs of the individual with CF.

II.

Insulin Physiology

III.

Diabetes Classification/Clinical Features

Insulin is a peptide hormone secreted by b-cells. These glucose-responsive cells are housed with other hormone-secreting cells in pancreatic islets which are distributed throughout the exocrine pancreas. Integrated with the feeding and fasting cycle, insulin secretion is positioned to govern glucose, amino acid, and fat disposition. In an insulinreplete state, these fuels are targeted for storage (1): insulin stimulates glycogen synthesis and glucose uptake by fat and muscle while suppressing hepatic glycogenolysis and gluconeogenesis, lipolysis, and ketogenesis. In this way, insulin tightly regulates blood glucose concentrations and promotes anabolism. The ability of insulin to induce glucose uptake and suppress hepatic glucose production provides a measure of insulin sensitivity. Conversely, insulin resistance can be defined by a decrease in the ability of insulin to evoke such effects. Insulin sensitivity may be objectively quantified by hyperinsulinemic euglycemic clamp studies as well as other surrogate measures.

Diabetes arises from insulin deficiency, insulin resistance, or a combination of both. The American Diabetes Association (ADA) classifies diabetes mellitus on the basis of their etiology. T1DM arises from b-cell destruction. T2DM arises from insulin resistance coupled with compromised b-cell insulin secretion. Genetic defects of b-cell function, drug-induced diabetes, and exocrine pancreatic disorders, such as CFRD are grouped as “other” (2). A. Type 1 Diabetes Mellitus

T1DM, previously referred to as juvenile or insulin-dependent diabetes mellitus, generally presents in childhood and adolescence. It primarily arises from autoimmune-mediated

341

342

Kelly and Calabria

b-cell destruction. Insulin deficiency is severe. Affected individuals depend on exogenous insulin delivery for glucose homeostasis and prevention of ketoacidosis. Thus, insulin replacement is targeted to address both carbohydrate intake and basal requirements. B. Type 2 Diabetes Mellitus

T2DM, formerly referred to as non-insulin-dependent diabetes mellitus, is characterized by insulin resistance superimposed on an insulin secretory defect. Initially, increased insulin secretion compensates for insulin resistance, and euglycemia is maintained. As b-cells are “overtaxed,” insulin secretion defects progress, and b-cells can no longer meet the increased insulin requirements established by insulin resistance. Varying degrees of hyperglycemia ensue. T2DM is treated with weight loss, caloric restriction, and oral medications or insulin, depending on the severity of b-cell compromise. Ketoacidosis occurs only occasionally. C. Cystic Fibrosis–Related Diabetes

CFRD shares features with both T1DM and T2DM. Like T1DM, CFRD is characterized by insulin deficiency arising from b-cell destruction. Unlike T1DM, CFRD is not a b-cell-specific autoimmune process. A possible link has been found, though, between CFRD and T1DM genes associated with inflammation, such as tumor necrosis factor (3). Mouse models have suggested a role for CFTR (cystic fibrosis transmembrane regulator) in the susceptibility toward islet dysfunction in CFRD (4), but twin studies suggest that the risk of CFRD may closely correlate with certain genetic modifiers that are independent of CFTR as well as genes that may be associated with T2DM, such as TCF7L2 (5). Despite the insulin deficiency and frequent need for exogenous insulin in CFRD, ketoacidosis is uncommon. Patients with CF often develop insulin resistance, as occurs with T2DM. However, this insulin resistance rarely arises because of obesity but because of intercurrent illness or systemic glucocorticoid use. As with T2DM, insulin resistance can complicate reduced b-cell mass as well as the defective insulin secretion suspected to occur in CF.

IV.

Diagnosis

Diagnostic criteria for CFRD are similar to those for other forms of diabetes (Table 1). Relatively few patients with CFRD are identified by symptoms. Rather, oral glucose tolerance tests (OGTTs), although only occasionally used as a diagnostic tool for the Table 1 2009 CFRD Diagnostic Criteria

NGT IGT CFRDa Indeterminate a

Fasting plasma glucose (mg/dL)

Two-hour OGTT glucose (mg/dL)


126

200a Hemoglobin A1c
6.5%b Preliminary screening with home glucose monitoring acceptable in high risk situationscc: Continuous gastrostomy feedings Home intravenous antibiotics High-dose glucocorticoids Inpatient All pancreatic insufficient patients to have FPG and 2-hr values measured on multiple days FPG < 126 and 2-hr values < 200: no further action required, routine screening when well If FPG
126 and/or 2-hr values > 200—diagnostic if persists for > 48 hr a

Repeat testing on multiple days required for diagnosis. Hemoglobin A1c < 6.5% does not exclude diagnosis. c Hyperglycemia must be confirmed by laboratory glucose levels. Abbreviations: OGTT, oral glucose tolerance test; CFRD, cystic fibrosis–related diabetes; FPG, fasting plasma glucose. b

Resolution may occur between episodes, but the individual remains at risk for recurrent hyperglycemia. As such, once the diagnosis of CFRD is made this diagnosis persists even if the hyperglycemia resolves. For acutely hospitalized patients, CFRD is diagnosed when hyperglycemia persists for more than 48 hours. Screening strategies for inpatient and outpatient care are outlined in Table 2. A. Hemoglobin A1c

Hemoglobin A1c (HbA1c) has generally not been considered an appropriate screening test for CFRD. The relationship between HbA1c and mean plasma glucose levels is not established as in other forms of diabetes (34). The majority of studies find HbA1c underestimates overall glycemic control in nondiabetic CF patients compared with the non-CF population. In fact, HbA1c has poor sensitivity, being normal in about 70% of CFRD cases diagnosed by OGTT (28). Still, Yung et al. found that only 16% of patients with CFRD diagnosed by OGTT had normal HbA1c values (35). Some authors have speculated that HbA1c may be unreliable because of altered red blood cell turnover in CF patients, but this has never been proven. Nevertheless, the 2009 CFF Consensus adopted as part of its CFRD diagnostic criteria the ADA diagnostic criteria of HbA1C
6.5%. Because of its poor sensitivity in individuals with CF, however, a normal HbA1C cannot exclude the diagnosis of CFRD. Alternative measures of glycemic control, such as fructosamine and GlycoMark, have not been formally tested. B. Oral Glucose Tolerance Tests

The majority of patients with CFRD does not have FH and can only be detected by OGTT. A comprehensive evaluation of 285 patients with CFRD over a 15-year period showed that most patients with CFRD w/o FH progressed to CFRD with FH over time (36). Comparison of OGTT blood glucose in CF subjects and controls reveals similar fasting

Cystic Fibrosis–Related Diabetes and Management

347

and two-hour values, but marked differences at intermediate values. In CF subjects, 30-, 60-, and 90-minutes values are elevated and may provide a more sensitive method for detecting glucose intolerance than two-hour values (37). Currently, the CFF does not diagnose CFRD based upon these intermediate time points. These elevations fall under the category of indeterminate. C. Casual Blood Glucose

Casual blood glucose testing alone is generally not sufficient to make a diagnosis of diabetes, although hyperglycemia is generally diagnostic of diabetes. Many CF patients will have elevated casual blood sugars in the diabetic range, even with normal OGTTdefined glucose tolerance (38). While alarming to clinicians, this finding should prompt further investigations before a diagnosis of CFRD is made. However, in certain high risk situations, such as continuous gastrostomy feedings, home intravenous antibiotics, and high dose glucocorticoids, preliminary screening with home glucose monitoring can be used if the patient is not hospitalized with later laboratory confirmation of hyperglycemia. D. Continuous Glucose Monitoring

Evidence suggests that the OGTT criteria in CF patients may be missing episodes of hyperglycemia. Some authors report glucose values exceeding 200 mg/dL in CF patients with declining weight and lung function despite normal OGTTs (39). The continuous glucose monitoring system (CGMS) has been validated in non-CF patients and provides a clinically relevant means by which to investigate glucose trends that may previously have been undetected. Its extension to CF patients has identified mean glucose levels higher than age-matched controls (40). In a study of 49 CF patients, CGMS revealed postprandial peaks above 200 mg/dL in 36% of subjects with NGT, in 52% of IGT subjects, and in all patients with CFRD (41). Since CGMS may reveal elevated glucose values that were not previously documented with OGTT (Fig. 1), it may offer a potential tool for the earlier detection of hyperglycemia in CF. Because CGMS does not actually

Figure 1 CGMS in a seven-year-old with CF and normal OGTT (fasting plasma glucose ¼ 83 mg/dL, one hour glucose ¼ 134 mg/dL, and two hour glucose ¼ 83 mg/dL). Despite the normal OGTT, CGMS identified elevated glucose (>200 mg/dL) on two consecutive days. Abbreviations: CF, cystic fibrosis; OGTT, oral glucose tolerance test; CGMS, continuous glucose monitoring system.

348

Kelly and Calabria

measure plasma glucose and the agreement between interstitial glucose and plasma glucose is not perfect, the CFF does not recommend the use of CGMS for diagnostic purposes. For the patient with established CFRD, however, it may provide adjunct information for identifying blood glucose trends and tailoring diabetes management.

VIII.

Prevalence/Incidence

The prevalence of CFRD may be underestimated because of lack of universal screening at many CF centers. Still, as the median survival has doubled over the past 25 to 37 years as of 2007, CFRD has emerged as the most common comorbidity in CF (42). The 2006 Cystic Fibrosis Foundation Patient Registry Annual Report, which reflects data from 24,487 patients at U.S. accredited CF care centers, reported that 19.5% of CF patients in the United States
14 years of age had CFRD/glucose intolerance (42). In Denmark, where OGTTs are performed annually, 50% of CF patients aged 30 years or older are reported to have CFRD (3). Risk factors include female gender, pancreatic insufficiency, and the DF508 homozygous genotype (43–45). While CFRD is generally uncommon before the age of 10 years, the incidence and prevalence increase markedly with age. Data from the University of Minnesota (Fig. 2) where annual OGTT screening is recommended for all patients
6 years, reveal CFRD prevalences of 9% of 5- to 9-year-olds, 26% of 10- to 20-year-olds, and 43% in individuals 30 years of age and older (7). In a comprehensive 15-year-study of 775 patients
6 years, CFRD was diagnosed by OGTT in 285 patients, 64% of whom had FH (36). Sixty percent of patients with CFRD w/o FH progressed to CFRD with FH within a 10year period (36). Lanng et al. reported that the annual incidence of CFRD increased with age at 5.0% per year in patients >10 years and 9.3% per year in patients >20 years (28).

Figure 2 Glucose tolerance categories in CF, expressed as percent prevalence within age groups

(n ¼ total number of patients studied within that age group). Patients with CFRD with FH include those who chronically required insulin to prevent FH and those who intermittently required insulin during periods of stress. Abbreviations: CF, cystic fibrosis; CFRD, cystic fibrosis–related diabetes; FH, fasting hyperglycemia. Source: From Refs. 5 and 33.

Cystic Fibrosis–Related Diabetes and Management

349

Figure 3 Survival curves for male subjects with CF but without diabetes (A, median survival

49.5 years), male subjects with CF and diabetes (B, median 47.4 years), female subjects with CF but without diabetes (C, median 47.0 years), and female subjects with CF and diabetes (D, median survival 30.7 years). Abbreviation: CF, cystic fibrosis. Source: From Ref. 41.

The number of patients diagnosed with CFRD is rapidly increasing, possibly reflecting better surveillance and improved survival. Prior studies have suggested greater implications of CFRD for females compared to males, but this has become less apparent over time. A U.K. study, beginning 12 months after diagnosis, showed that female CFRD subjects had a 20% lower FEV1% compared with CF females with NGT (46). Likewise, a U.S. study found median survival of 49.5 years for males without CFRD, 47.4 years for males with CFRD, 47 years for females without CFRD, and 30.7 years for females with CFRD (43) (Fig. 3). However, after 15 years of follow up, this apparent gender difference has disappeared, possibly due to earlier surveillance and more intensive regimens (47). Other studies have similarly not identified a gender disparity (48). Still, the potential for a gender difference in some populations may represent an opportunity for more intensive interventions in high-risk populations.

IX.

Complications

A. Morbidity/Mortality

CFRD has been associated with increased morbidity and up to a sixfold greater mortality rate (49). In the 1980s, Finkelstein et al. found that 85% versus those with body weight 408) has been described in 22% to 77% of CF patients, depending on age and sex (36–38). Vertebral body fractures associated with osteopenia are presumed to contribute to this change in chest shape (37,38). The effects of thoracic kyphosis on chest wall compliance or lung function have not been studied directly in

374

Goldfarb and Panitch

patients with CF. In adult women with kyphosis from osteopenia, however, there is an associated reduction in lung volumes and lateral rib expansion (39). Thus, it has been speculated that kyphosis contributes to reduced chest wall compliance and inefficiency of the respiratory pump in CF patients, leading to increased work of breathing and a more rapid, shallow breathing pattern (40). B. Alterations in Respiratory Pump Function

The respiratory pump includes muscles of ventilation of the chest and anterior abdominal wall and the thoracic skeleton. While little investigation has been performed to determine how alterations in chest wall shape affect ventilatory function in CF, several studies on respiratory muscle function have been performed. Factors that could impact respiratory muscle function include the increased load against which the pump must work, nutritional status, lung hyperinflation, and the general effects of hypoxemia and hypercapnia on muscle function. Studies of respiratory muscle strength in CF patients have yielded conflicting results from decreased (41–46), to normal (26,47,48), to supranormal (49–51). The varied outcomes are in part explained by differences in the groups studied with respect to age and disease severity, methods of testing and measurement, and whether the presence of hyperinflation (and thus the lung volume at which the measurements were taken) was accounted for. Some studies related reduced respiratory muscle strength with poorer nutritional status (43,44), whereas others found no relationship between respiratory muscle strength and malnutrition (46,47,49). Those that found supranormal values for inspiratory muscle strength speculated that the constant work against an increased load acts as a training effect for the diaphragm, and so maintains inspiratory muscle function even when peripheral skeletal muscle function may be compromised (47,50). Strength, however, might not be the critical characteristic of respiratory muscle function that predisposes to respiratory failure. Rather, the tendency of the muscle to resist fatigue under conditions of increased work is likely to be a chief determinant of respiratory success or failure. The tension-time index of the respiratory muscles (TTmus) is a measure of the tendency for the respiratory muscles to become fatigued. Its components are described in chapter 11, but conceptually, if the respiratory muscles have to generate a greater percentage of their maximal force with each breath, or if they have to contract for longer periods of the total respiratory cycle, they will also be more likely to fatigue within a finite amount of time. Even in CF patients with only mild to moderate disease (FEV1 46–114% predicted), the ratio of mean inspiratory pressure to maximal inspiratory pressure was found to be higher than in healthy age-matched controls (52). Although no CF subject was close to the fatigue threshold, the group had a significantly higher mean TTmus value compared with the control group. Furthermore, TTmus was found to correlate with the percent predicted FRC and other measures of hyperinflation and air trapping, and negatively with lean body mass. It has been established that the inspiratory muscles of CF patients with advanced lung disease must do more work during quiet breathing than those of patients with less severe disease (33). In a recent study of 47 children and adults with CF, the TTmus correlated with severity of lung disease, and those who were hypercapnic had values just below the fatigue threshold (53). Similar to the results of Hayot et al. (52), the major difference between CF subjects and controls was in the mean inspiratory pressure/ maximal inspiratory pressure fraction. Furthermore, the P0.1, from which mean

Chronic Respiratory Failure, NIV, and Lung Transplantation

375

inspiratory pressure was calculated, correlated with parameters that reflected airway obstruction and hyperinflation. Thus, CF patients increase respiratory neural output in response to increasing loads. From studies of respiratory mechanics and pump function, it is clear that as CF lung disease progresses, the load against which the respiratory muscles function must increase. At the same time, alterations in the shape of the thoracic cage, including caudal depression of the diaphragm from hyperinflation, can impair respiratory muscle function. Respiratory work increases although efficiency of the respiratory muscles can become impaired. The increased energy demands can contribute to nutritional compromise, and further stresses to the respiratory system like acute exacerbations or ongoing progression of lung disease can tip the balance from respiratory adequacy to failure.

III.

Noninvasive Ventilation for Chronic Respiratory Failure

A role for assisted ventilation in hypercapnic respiratory failure was recognized in a CF Foundation Consensus Conference report for several groups of CF patients: infants, those patients with a reversible cause for their respiratory failure, those whose underlying disease had not been treated aggressively, and those patients accepted as lung transplant candidates (54). While the use of noninvasive methods of assisted ventilation was mentioned in the report for patients with chronic respiratory failure who were not considered as candidates for lung transplantation, the practice was felt unlikely to be of any benefit except in selected patients. Chronic respiratory failure in CF patients is often presaged by alterations of gas exchange during sleep, along with disruption of sleep architecture (55) (chap. 22). It is noteworthy that several studies have demonstrated improvement in hypoxemia and hypercapnia during sleep in CF patients with advanced lung disease who used nocturnal NIV compared with those with no intervention or low flow nasal cannula oxygen (17,18,27). In two of the studies, hypercapnia worsened when patients were treated with supplemental oxygen alone (18,27), whereas in the third there was no change in transcutaneous CO2 determinations (17). Other acute effects of NIV have been assessed during short-term or overnight studies. Within 20 minutes of application of NIV to stable adult CF patients with hypercapnic respiratory failure, improvement in blood gases occurred along with reductions in minute ventilation (suggesting better alveolar ventilation) and work of breathing (56). Other studies have also demonstrated improved ventilation (17,57,58), unloading of the respiratory muscles (57,58), and improved cough and sputum production during physiotherapy (59) associated with short-term NIV use. Extended use of nocturnal supplemental oxygen in CF patients with awake hypoxemia (PaO2 < 65 mmHg) did not alter mortality or morbidity as reflected in frequency of hospitalization, change in lung functions, or blood gas values (60). Patients who used supplemental oxygen, however, maintained school or work attendance whereas those who were untreated did not. Similarly, in a randomized controlled crossover study of six weeks of air, supplemental oxygen, or NIV administration in random sequence to eight CF adults with advanced disease and diurnal hypercapnia, there were no effects of either nocturnal supplemental oxygen or NIV on awake blood gases or pulmonary function (27). In contrast, during the six weeks of NIV patients had better CF-Quality of Life and Transitional Dyspnea Index scores, and exercise performance compared with their six weeks of breathing air.

376

Goldfarb and Panitch

Nonrandomized reports of long-term NIV use can lend some insight into why patients receiving nocturnal NIV feel better. Four CF adults with hypercapnic respiratory failure treated with NIV for up to 18 months all demonstrated an increase in respiratory muscle strength, which the authors speculated might have resulted from ameliorating the deleterious effects of hypoxia and hypercarbia on diaphragm function (8). In contrast to the crossover study above (27), an earlier nonrandomized trial reported improved forced vital capacity (FVC) and arterial blood gases, as well as fewer inpatient days at 3 and 6 months after starting NIV compared with the 1 to 2 months before among 10 subjects with hypercapnic respiratory failure treated for 1 to 15 months (61). More recently, 20 CF patients were treated with NIV for up to 26 months after they developed hypercapnic respiratory failure following treatment with supplemental oxygen for hypoxemia (62). Within one month of initiating nocturnal NIV, daytime PaCO2 levels fell significantly below pretreatment levels and remained lower for weeks to months. Why some studies show nocturnal NIV results in improvement in blood gases and others do not is unclear, but may relate to differences in study size or design, bias introduced by selection of certain patients for lung transplantation after a period of NIV, and study duration or nocturnal duration of NIV. The availability of lung transplantation as a life-saving modality has redefined the role of chronic NIV among patients with CF. NIV not only avoids the complications associated with endotracheal intubation, but it can also be accomplished outside of the intensive care unit or hospital. There have been several case series describing the use of NIV as a “bridge to transplantation” among CF children and adults (7,9,10,63,64). Others have used NIV to treat acute on chronic respiratory failure, not only in those awaiting transplant, but also in those not considered eligible for lung transplantation (11). Efrati and coworkers described improved nutrition and daily activity among the nine patients treated with NIV while awaiting transplantation (64). Given that pretransplant nutritional status and ability to train physically are important indicators of post-transplant successful outcome, it is intriguing to consider how the use of NIV might be expanded as a conditioning modality for patients awaiting lung transplantation. Clearly, carefully controlled studies of NIV must be conducted to answer these and other critical questions regarding its role in the care of CF lung disease.

IV.

Lung Transplantation

Bilateral lung transplantation is considered when all other therapies have been exhausted. Lung transplantation is an elective procedure and is not indicated for all patients with advanced lung disease. Patients with CF account for 55% of all those transplanted between the ages of 6 and 11 years and for 69% of lung transplants between the ages of 12 and 17 (65). A. Timing of Referral for Transplantation

The general indication for bilateral lung transplantation in CF is a trajectory of illness that, despite optimal medical therapy, puts the individual at risk of dying without a lung transplant. Prior to May 2005, a patient’s chance to be chosen for lung transplantation was based on time accrued on a list and patient/donor blood type; the likelihood of surviving to transplantation was not considered in determining the listing order. Recognizing that many patients died waiting for a suitable donor, investigators have tried to

Chronic Respiratory Failure, NIV, and Lung Transplantation

377

develop methods that predict when the topic of lung transplantation should be discussed with patients and when patients should be placed on the transplant list in the disease course. Kerem et al. recommended that CF patients with an FEV1 < 30% predicted be referred for lung transplant since this severity of illness was associated with a two-year mortality rate of 50%. Furthermore, for a given FEV1 in this cohort, females and children under the age of 18 years had a higher 2-year mortality rate than their counterparts (66). Milla et al. suggested that the principal predictor of mortality was not the absolute value of FEV1, but instead was the rate of decline below an FEV1 of 30% (67). Liou published a five-year survivorship model using multiple parameters derived from CF registry data (68). Survival after transplantation was decreased among adults with Burkholderia cepacia, arthropathy or a five-year predicted survival of more than 50%. Furthermore, survival of pediatric patients did not improve with lung transplantation. Thus, the model suggested that adult patients with a low five-year predicted survival and without B. cepacia infection should receive priority for lung transplantation. Another multidimensional model was no better at predicting short-term mortality than using the criterion of less than 30% FEV1 (69). Both methods demonstrated a positive predictive value for two-year mortality in the range of only 50% (i.e., half of the patients predicted to die within 2 years would actually survive) (69). Since May 2005, the process of prioritizing patients for lung transplantation has been based on a scoring system known as the Lung Allocation Score (LAS). The score is calculated from estimates of survival probability while on the lung transplant waiting list and following transplantation. It reflects a comprehensive evaluation that takes into account age and diagnosis as well as several indicators of disease severity such as FEV1, BMI, serum creatinine, presence of diabetes, six-minute walk test score, increases in supplemental oxygen need, serum carbon dioxide levels (PCO2), need for assisted ventilation, functional status, and presence of pulmonary hypertension (70–72). The referral process to a transplant center should be initiated when a patient’s FEV1 is less than 30% predicted or sooner if there has been a rapid decline in pulmonary function. This, however, does not imply that the patient will be immediately listed. Other considerations for referral include recurrent hemoptysis that is not controlled by embolization or other means, recurrent or refractory pneumothorax, and frequent respiratory exacerbations requiring antibiotic therapy (70,73). Education of potential candidates regarding bilateral lung transplantation as a future treatment modality can occur as a patient’s lung disease worsens. Any patient considered for transplantation must have an adequate social support system and must be able to follow the prescribed medical regimen after transplant. Bilateral lung transplant is an elective procedure; therefore, potential recipients and their families must demonstrate a willingness and an ability to adhere to the rigorous therapy, daily monitoring and reevaluation schedule after transplant (74). B. Contraindications to Lung Transplantation

There are several absolute contraindications for bilateral lung transplant for patients with CF, which are similar to the contraindications for lung transplantation for all causes. These include malignancy within the last two years (some centers recommend a fiveyear disease-free period), infections that include sepsis, active tuberculosis, acquired immunodeficiency syndrome, and hepatitis B or C with histological liver disease, multiple organ dysfunction, severe neuromuscular disease, and documented refractory nonadherence to a medical regimen (70,74).

378

Goldfarb and Panitch

Relative contraindications to bilateral lung transplant occur commonly in patients with CF and include renal insufficiency, markedly abnormal body mass index, osteoporosis, poorly controlled diabetes mellitus, and colonization with resistant organisms (74). Significant renal dysfunction pre-transplantation can disqualify a patient from the procedure because of the risk of worsening renal function post transplant. The use of aminoglycosides in patients with CF is associated with a decline in renal function (75). Following transplant there is an increased incidence of chronic renal insufficiency from use of immunosuppressive medications. One study demonstrated that in the first three months post-transplant patients had a 33% decline in glomerular filtration rate (76). These findings were in accord with International Society of Heart and Lung Transplantation (ISHLT) registry data that reported a prevalence of hypertension at one-year post transplant at 39% and renal dysfunction, as measured by changes in serum creatinine, during the same time frame at roughly 9% (77). Thus, judicious use of antibiotics in the pre-transplant period to spare renal function is very important. Nutritional status affects both pre- and post-transplant mortality. Wasting, defined as a weight of less than 85% ideal body weight, has been shown to be a predictor of mortality in the pre-transplant CF patient independent of lung function, arterial blood oxygen, or carbon dioxide levels (78). In addition, when evaluating all subjects awaiting transplantation including those with CF, lean body mass depletion has been associated with more severe hypoxemia, reduced six-minute walking distance and a higher mortality, even in the setting of a normal BMI (79). In contrast, in both CF and non-CF transplant candidates, severe obesity is a significant indicator of post-transplant mortality. A BMI exceeding 27 kg/m2 was the greatest indicator of mortality in the first 90 days post transplant, whereas in those with a BMI of less than 17 kg/m2, only a statistically nonsignificant trend was demonstrated toward increased mortality (80). The degree of preexisting bone demineralization represents a major risk factor for severe osteoporosis following lung transplantation (81). Corticosteroids, used as part of the immunosupression regimen following transplant, contribute to bone disease by hastening bone resorption and inhibiting bone formation. Ideally, steroid dosing is gradually reduced to minimize the complications of long-term use (82). The use of antiresoprtive therapy to improve bone mineral density has expanded to include lung transplant recipients. While the effects of biphosponates in adults with CF related bone disease shows promise, the long-term efficacy and safety of biphosphonate use in children and adolescents requires further investigation. Cystic fibrosis related diabetes (CFRD) is often associated with worsening lung disease (83,84), but improvements in recognition and control of CFRD have reduced its impact on overall mortality (85). In the post-transplant period, there is an increased association of drug-related new onset diabetes mellitus (DM) in the pediatric lung and heart/lung transplant population when compared to either pediatric heart transplant recipients or adult lung transplant recipients (86–88). Twenty-five percent of all transplanted patients develop DM within the first year post transplant (89). CF patients with CFRD prior to transplant have more complication-related admissions to hospital post transplant and a higher mortality rate than those without CFRD who undergo transplant (88). These findings underscore the importance of both pre- and post-transplant management of DM. Patients colonized with multi- or pan-resistant Pseudomonas aeruginosa have no survival disadvantage post transplant (90). However, patients with B. cepacia complex

Chronic Respiratory Failure, NIV, and Lung Transplantation

379

infection have poorer outcomes and represent the majority of those who die of sepsis. CF patients infected with genomovar III of the B. cepacia complex before transplantation have markedly increased B. cepacia complex–related early mortality after transplantation. In one center, post-transplant survival percentages were significantly lower in those infected with B. cepacia complex at 1, 3, and 5 years (91). Post-transplant mortality among CF patients infected with Burkholderia, however, varies by infecting species, and there are even differences within the B. cenocepacia strains: infection with either one of the two so-called epidemic strains common in the United States (strain PHDC and the Midwest clone) are associated with increased survival when compared to infection with nonepidemic strains (92). As host-organism interactions become better understood, more centers may consider lung transplantation a viable option in this patient population. C. Listing

As of May 2005 lung transplant candidates 12 years are all listed according to the new LAS scoring system. Patients less than 12 years receive organs based on time accrued on a waiting list. D. Transplant Surgery

Double lung bilateral sequential transplantation is the procedure of choice in the pediatric population. The survival rate of children undergoing single lung transplantation was significantly lower when compared to those receiving bilateral transplants and so the procedure has been abandoned in this population (65). Organs are matched by height, weight and blood type. HLA antibody screening is performed and specific antibodies can be avoided if the recipient has elevated levels. E.

Immunosuppressive Therapy

Most centers have adopted the immunosupression protocol set forth by the International Pediatric Lung Transplant Consortium. Triple therapy with or without induction therapy has become standard practice. Roughly 50% of the pediatric centers reporting to the ISHLT use induction therapy in the post-transplant period. The majority of patients are given tacrolimus along with either azathioprine or mycophenolate. All centers at 1 and 5 years report the use of oral steroids as part of immunosuppressive therapy (65). F.

Complications

Complications from lung transplantation are divided into early and late and are listed in Table 1. Several that bear special mention are discussed below: Acute Rejection

The risk of acute cellular rejection (ACR) is highest in the first few weeks following transplantation. The incidence of ACR is 18% to 50% among those who undergo induction therapy and 50% to 55% among those who do not (82,93,94). Acute rejection is an infrequent problem beyond one year post transplant and infants tend to have a lower frequency of acute rejection than do older children. Risk factors for ACR include HLA mismatching, community acquired viral infection, and the immunosuppressive regimen (95). Although acute rejection is often asymptomatic, fever, dyspnea, and

380

Goldfarb and Panitch

Table 1 Complications of Lung Transplantation

Early l Hyperacute rejection l Acute rejection l

Demyelinating disease (due to tacrolimus or cyclosporine)

l

Seizure disorder

l

Ectopic atrial tachycardia (EAT)

l

Infection

8 8 8 8 l

Bacterial (including atypical mycobacterium) Viral (CMV, adenovirus, RSV) Fungal (Aspergillus) Other (PCP)

Anastomosis dehiscence

Late l Acute rejection l Chronic rejection/bronchiolitis obliterans l

Bronchiolitis obliterans syndrome

l

Infection

8 EBV 8 CMV 8 HHV6 l

Diabetes

l

Hypertension

l

Renal insufficiency/failure

l

Post-transplant lymphoproliferative disease Osteoporosis

l

hypoxemia can be present. Common findings on chest radiograph include parenchymal densities and bilateral pleural effusions. The FEV1 and FVC can be diminished. Distinguishing between rejection and infection on clinical grounds alone is often difficult. Therefore, appropriate evaluation includes bronchoscopy with bronchoalveolar lavage and transbronchial biopsy. Acute rejection is graded A0 (none) to A4 (severe); grade A2 acute rejection and above is treated with augmented immunosupression. The initial therapy is usually pulsed steroids. The few cases in which acute rejection persists usually respond favorably to additional augmented immunosupression, usually with a mono- or poly-clonal T-cell antibody. Infection

Up to 60% to 90% of lung transplant recipients experience at least one episode of infection after undergoing the procedure (96,97). The risk for serious infection starts in

Chronic Respiratory Failure, NIV, and Lung Transplantation

381

the perioperative period, and infection is the major cause of morbidity and mortality during the first six months after transplant surgery. Prophylactic antimicrobials against bacteria, viruses, and fungi are used in most transplant programs. Antimicrobial treatments should be given perioperatively on the basis of donor cultures and most common hospital pathogens. In the CF population, antibiotic therapy is directed by bacterial sputum colonization and the antibiogram. Pneumocystis jiroveci prophylaxis is a routine in almost all postoperative lung transplant regimens. Respiratory viral infections can be relatively mild to life threatening in the transplant recipient. RSV, influenza, human herpes viruses (particularly HHV6), Epstein–Barr virus, and adenovirus cause significant morbidity and mortality. Cytomegalovirus (CMV) remains the most commonly encountered serious viral infection. Onset of CMV pneumonitis after lung transplant is reported to have a strong correlation with subsequent development of bronchiolitis obliterans (BO), which in turn leads to graft dysfunction and death (98). The highest risk for CMV pneumonia is in seronegative patients who receive lungs from seropositive donors. This increased risk persists even when these patients receive aggressive antiviral prophylaxis (98). In the pediatric population, respiratory viral infections are associated with an increased mortality at one year (99). In this population, etiology of underlying disease other than CF, younger age, and absence of induction therapy are independently associated with risk of respiratory viral infections (99). While colonization with Aspergillus can be as high as 50% in post-transplant patients, invasive disease occurs in only 3% and only in patients colonized with A. fumigatus within the first six months post transplant (100). Antifungal therapy both before and after transplant is therefore an important component of care. Risk factors for pulmonary fungal infections in children include A2 rejection, repeated acute rejection, a CMV-positive donor, a tacrolimus-based regimen and pre-transplant Aspergillus colonization (101). Bronchiolitis Obliterans

BO is the histopathological correlate of chronic organ dysfunction. It is the leading cause of morbidity and late mortality one year after lung or heart-lung transplantation. BO is an inflammatory process, leading ultimately to occlusion of small airways by fibromyxoid tissue (102). Both BO and bronchiolitis obliterans syndrome (BOS), the clinical correlate of BO, are manifestations of chronic lung allograft rejection. BOS describes the otherwise unexplained development of an obstructive decrease in pulmonary function. The cardinal clinical feature of BOS is a reduction in FEV1 and/or the mid-expiratory flow rate (FEF25–75), which does not respond to bronchodilators (103). Roughly half of lung transplant recipients are diagnosed with BO by five years after transplant. More than 40% of deaths occurring beyond a year post transplant are a direct or indirect result of BO (65). The etiology of BO remains elusive in spite of a growing body of basic science and clinical research. Gastroesophageal reflux (GER) has been shown to have an increased association with BO. Furthermore, surgical correction of GER has, in some patients, either stopped or improved the decline in lung function (104–106). There is no consistently effective treatment strategy for BO. Augmentation of immunosupression is usually the initial intervention. Options include anti-thymocyte preparations, cyclophosphamide, methotrexate, photopheresis, and total lymphoid irradiation. All have shown benefit in some patients but none has proven to be uniformly

382

Goldfarb and Panitch

beneficial (107). Aerosolized cyclosporine is an investigational agent with substantial promise that may provide a survival advantage to lung transplant recipients (108). The use of tacrolimus as a “rescue” therapy in patients originally treated with cyclosporine may stabilize the decline in FEV1 (109). Sirolimus has also been used as a rescue agent in BO with some success (110,111). Several studies involving azithromycin administration, for its anti-inflammatory effect, have shown either improvement or stabilization of lung function (112–114). A retrospective study of patients prescribed statins for hypercholesterolemia found a lower incidence of BO and a better long-term survival. Re-transplantation may be an option in select individuals. G. Life Expectancy

Outcomes for bilateral lung transplantation have improved since the early nineties when this procedure was first introduced. Survival is the chief indicator of success for this procedure. Survival of pediatric patients is similar to that of adults with a median survival of 4.3 years over the period of 1990–2006. The major cause of death continues to be BO. There is a survival advantage to children with lung disease of all causes transplanted from 1 to 10 years of age when compared to adolescents (115). There are several proposed hypotheses for this survival difference: younger patients have fewer episodes of acute rejection and a lower incidence of BO (116). Alternatively, the adolescent population is predominately composed of patients with CF. Studies have also raised concerns that this age group is more prone to decreased adherence to medical regimens and this in turn could affect long-term survival (117–119). As noted above, early death (within the first 30 days following transplant) attributed to infection was only elevated in patients colonized with B. cepacia complex, whereas no other organisms conferred a survival disadvantage (90). H. Other Considerations in the CF Population

In recent years, some groups have begun to question the practice of lung transplantation, particularly in the adolescent age group. Liou et al. concluded that lung transplantation does not prolong life in children with CF (120). These findings contradicted other studies that showed a positive benefit for bilateral lung transplant in CF patients (121). While many have refuted Liou’s conclusion, there are several issues that must be considered when performing lung transplantation in the adolescent CF patient (122). Risk factors for this patient group have not been specifically identified. Potential specific risk factors would include poor adherence to a medical regimen, mood and adjustment disorders, and transplantation in centers with limited resources to work with the CF adolescent patient population. Adherence to medical regimens for patients with any chronic disease can be difficult, especially among adolescents (123). While complications are similar between adults and children, medical nonadherence appears to be more common in pediatric lung transplant recipients (124). Adolescents with CF underestimate the severity of their illness when compared with assessments of their health care providers and parents (125). More adolescent females than males receive lung transplants (71), and adolescent girls have been shown to have more difficulty than boys with adherence to CF care regimens (126). This general pattern of suboptimal adherence does not necessarily change post transplant; adolescents who received other solid organs struggle with medical regimen adherence as well (127).

Chronic Respiratory Failure, NIV, and Lung Transplantation

383

Depression, anxiety, and adjustment disorders are all comorbidities associated with CF. The CF 2007 patient registry reports an incidence of these problems of 5% to 17% with increasing frequency in older teenagers (128). Furthermore, depression rates in general in patients pre-transplant can be as high as 20%. Treatment of depression is an important aspect of pre-transplant care, and mental health treatment should be provided. Transplantation is not curative for anxiety, adjustment, or depressive disorders, and there can be reoccurrence of these problems post transplant. Such disorders can still be present, but they generally improve post transplant (129). A poorly planned transition from a pediatric to an adult center or transitioning adolescents to adult centers poorly prepared to care for them comprehensively could significantly affect a patient’s short- and long-term health. The added stress of dealing with issues around organ transplantation highlight the need for carefully planned transition of adolescent patients to adult care, as inadequate patient preparation can exacerbate poor patient adherence (130,131) and lead to decreased graft or overall patient survival.

V. Conclusions Progressive lung disease is the cause of morbidity and mortality for the majority of patients with CF. NIV can provide palliation of symptoms and perhaps restore some physiologic functions to patients with advanced disease, and is increasingly being used to support patients while they await lung transplantation. Lung transplantation in CF patients is a growing field and allows a therapeutic option for patients with advanced lung disease. The goal of transplantation is to increase the life expectancy of the transplanted patient. Comprehensive studies are also under way to understand better how lung transplantation improves quality of life. The ability of lung transplantation to restore function and respiratory health to CF patients with advanced disease is occasionally perceived as a panacea, but the process has its own set of complications and demands. Patients, families, and caregivers must be made aware of the benefits, risks, and medical demands associated with lung transplantation to make their best-informed choices.

References 1. Robinson WM, Ravilly S, Berde C, et al. End-of-life care in cystic fibrosis. Pediatrics 1997; 100(2 pt 1):205–209. 2. Davis PB, di Sant’Agnese PA. Assisted ventilation for patients with cystic fibrosis. JAMA 1978; 239(18):1851–1854. 3. Lloyd-Still JD. Assisted ventilation in cystic fibrosis. JAMA 1978; 240(8):739. 4. Garland JS, Chan YM, Kelly KJ, et al. Outcome of infants with cystic fibrosis requiring mechanical ventilation for respiratory failure. Chest 1989; 96(1):136–138. 5. Berlinski A, Fan LL, Kozinetz CA, et al. Invasive mechanical ventilation for acute respiratory failure in children with cystic fibrosis: outcome analysis and case-control study. Pediatr Pulmonol 2002; 34(4):297–303. 6. Slieker MG, van Gestel JP, Heijerman HG, et al. Outcome of assisted ventilation for acute respiratory failure in cystic fibrosis. Intensive Care Med 2006; 32(5):754–758. 7. Hodson ME, Madden BP, Steven MH, et al. Non-invasive mechanical ventilation for cystic fibrosis patients–a potential bridge to transplantation. Eur Respir J 1991; 4(5):524–527. 8. Piper AJ, Parker S, Torzillo PJ, et al. Nocturnal nasal IPPV stabilizes patients with cystic fibrosis and hypercapnic respiratory failure. Chest 1992; 102(3):846–850.

384

Goldfarb and Panitch

9. Padman R, Lawless S, Von Nessen S. Use of BiPAP by nasal mask in the treatment of respiratory insufficiency in pediatric patients: preliminary investigation. Pediatr Pulmonol 1994; 17(2):119–123. 10. Caronia CG, Silver P, Nimkoff L, et al. Use of bilevel positive airway pressure (BIPAP) in end-stage patients with cystic fibrosis awaiting lung transplantation. Clin Pediatr (Phila) 1998; 37(9):555–559. 11. Madden BP, Kariyawasam H, Siddiqi AJ, et al. Noninvasive ventilation in cystic fibrosis patients with acute or chronic respiratory failure. Eur Respir J 2002;19(2):310–313. 12. Cadiergue V, Philit F, Langevin B, et al. [Outcome of adult patients with cystic fibrosis admitted to intensive care with respiratory failure: the role of non-invasive ventilation]. Rev Mal Respir 2002; 19(4):425–430. 13. Vedam H, Moriarty C, Torzillo PJ, et al. Improved outcomes of patients with cystic fibrosis admitted to the intensive care unit. J Cyst Fibros 2004; 3(1):8–14. 14. Stokes DC, McBride JT, Wall MA, et al. Sleep hypoxemia in young adults with cystic fibrosis. Am J Dis Child 1980; 134(8):741–743. 15. Francis PW, Muller NL, Gurwitz D, et al. Hemoglobin desaturation: its occurrence during sleep in patients with cystic fibrosis. Am J Dis Child 1980; 134(8):734–740. 16. Tepper RS, Skatrud JB, Dempsey JA. Ventilation and oxygenation changes during sleep in cystic fibrosis. Chest 1983; 84(4):388–393. 17. Milross MA, Piper AJ, Norman M, et al. Low-flow oxygen and bilevel ventilatory support: effects on ventilation during sleep in cystic fibrosis. Am J Respir Crit Care Med 2001; 163(1):129–134. 18. Gozal D. Nocturnal ventilatory support in patients with cystic fibrosis: comparison with supplemental oxygen. Eur Respir J 1997; 10(9):1999–2003. 19. Nixon PA, Orenstein DM, Curtis SE, et al. Oxygen supplementation during exercise in cystic fibrosis. Am Rev Respir Dis 1990; 142(4):807–811. 20. Marcus CL, Bader D, Stabile MW, et al. Supplemental oxygen and exercise performance in patients with cystic fibrosis with severe pulmonary disease. Chest 1992; 101(1):52–57. 21. Allen MB, Mellon AF, Simmonds EJ, et al. Changes in nocturnal oximetry after treatment of exacerbations in cystic fibrosis. Arch Dis Child 1993; 69(2):197–201. 22. Waterhouse DF, McLaughlin AM, Gallagher CG. Time course and recovery of arterial blood gases during exacerbations in adults with Cystic Fibrosis. J Cyst Fibros 2009; 8(1):9–13. 23. Elphick HE, Mallory G. Oxygen therapy for cystic fibrosis. Cochrane Database Syst Rev 2009; (1):CD003884. 24. Urquhart DS, Montgomery H, Jaffe A. Assessment of hypoxia in children with cystic fibrosis. Arch Dis Child 2005; 90(11):1138–1143. 25. Balfour-Lynn IM, Primhak RA, Shaw BN. Home oxygen for children: who, how and when? Thorax 2005; 60(1):76–81. 26. Bradley S, Solin P, Wilson J, et al. Hypoxemia and hypercapnia during exercise and sleep in patients with cystic fibrosis. Chest 1999; 116(3):647–654. 27. Young AC, Wilson JW, Kotsimbos TC, et al. Randomised placebo controlled trial of noninvasive ventilation for hypercapnia in cystic fibrosis. Thorax 2008; 63(1):72–77. 28. Cropp GJ, Pullano TP, Cerny FJ, et al. Exercise tolerance and cardiorespiratory adjustments at peak work capacity in cystic fibrosis. Am Rev Respir Dis 1982; 126(2):211–216. 29. Coates AL, Canny G, Zinman R, et al. The effects of chronic airflow limitation, increased dead space, and the pattern of ventilation on gas exchange during maximal exercise in advanced cystic fibrosis. Am Rev Respir Dis 1988; 138(6):1524–1531. 30. Eckles M, Anderson P. Cor pulmonale in cystic fibrosis. Semin Respir Crit Care Med 2003; 24(3):323–330. 31. Davis PB. Pathophysiology of pulmonary disease in cystic fibrosis. Semin Resp Med 1985; 6(4):261–270.

Chronic Respiratory Failure, NIV, and Lung Transplantation

385

32. Cerny F, Armitage L, Hirsch JA, et al. Respiratory and abdominal muscle responses to expiratory threshold loading in cystic fibrosis. J Appl Physiol 1992; 72(3):842–850. 33. Hart N, Polkey MI, Clement A, et al. Changes in pulmonary mechanics with increasing disease severity in children and young adults with cystic fibrosis. Am J Respir Crit Care Med 2002; 166(1):61–66. 34. Coates AL, Desmond KJ, Milic-Emili J, et al. Ventilation, respiratory center output, and contribution of the rib cage and abdominal components to ventilation during CO2 rebreathing in children with cystic fibrosis. Am Rev Respir Dis 1981; 124(5):526–530. 35. Bureau MA, Lupien L, Begin R. Neural drive and ventilatory strategy of breathing in normal children, and in patients with cystic fibrosis and asthma. Pediatrics 1981; 68(2):187–194. 36. Logvinoff MM, Fon GT, Taussig LM, et al. Kyphosis and pulmonary function in cystic fibrosis. Clin Pediatr (Phila) 1984; 23(7):389–392. 37. Henderson RC, Specter BB. Kyphosis and fractures in children and young adults with cystic fibrosis. J Pediatr 1994; 125(2):208–212. 38. Aris RM, Renner JB, Winders AD, et al. Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann Intern Med 1998; 128(3):186–193. 39. Culham EG, Jimenez HA, King CE. Thoracic kyphosis, rib mobility, and lung volumes in normal women and women with osteoporosis. Spine 1994; 19(11):1250–1255. 40. Taylor-Cousar JL. Hypoventilation in cystic fibrosis. Semin Respir Crit Care Med 2009; 30(3):293–302. 41. Szeinberg A, England S, Mindorff C, et al. Maximal inspiratory and expiratory pressures are reduced in hyperinflated, malnourished, young adult male patients with cystic fibrosis. Am Rev Respir Dis 1985; 132(4):766–769. 42. Mier A, Redington A, Brophy C, et al. Respiratory muscle function in cystic fibrosis. Thorax 1990; 45(10):750–752. 43. Pradal U, Polese G, Braggion C, et al. Determinants of maximal transdiaphragmatic pressure in adults with cystic fibrosis. Am J Respir Crit Care Med 1994; 150(1):167–173. 44. Ionescu AA, Chatham K, Davies CA, et al. Inspiratory muscle function and body composition in cystic fibrosis. Am J Respir Crit Care Med 1998; 158(4):1271–1276. 45. Pinet C, Cassart M, Scillia P, et al. Function and bulk of respiratory and limb muscles in patients with cystic fibrosis. Am J Respir Crit Care Med 2003; 168(8):989–994. 46. Ziegler B, Lukrafka JL, de Oliveira Abraao CL, et al. Relationship between nutritional status and maximum inspiratory and expiratory pressures in cystic fibrosis. Respir Care 2008; 53(4):442–449. 47. Lands LC, Heigenhauser GJ, Jones NL. Respiratory and peripheral muscle function in cystic fibrosis. Am Rev Respir Dis 1993; 147(4):865–869. 48. Lands L, Desmond KJ, Demizio D, et al. The effects of nutritional status and hyperinflation on respiratory muscle strength in children and young adults. Am Rev Respir Dis 1990; 141(6):1506–1509. 49. O’Neill S, Leahy F, Pasterkamp H, et al. The effects of chronic hyperinflation, nutritional status, and posture on respiratory muscle strength in cystic fibrosis. Am Rev Respir Dis 1983; 128(6):1051–1054. 50. Marks J, Pasterkamp H, Tal A, et al. Relationship between respiratory muscle strength, nutritional status, and lung volume in cystic fibrosis and asthma. Am Rev Respir Dis 1986; 133(3):414–417. 51. Dunnink MA, Doeleman WR, Trappenburg JC, et al. Respiratory muscle strength in stable adolescent and adult patients with cystic fibrosis. J Cyst Fibros 2009; 8(1):31–36. 52. Hayot M, Guillaumont S, Ramonatxo M, et al. Determinants of the tension-time index of inspiratory muscles in children with cystic fibrosis [see comments]. Pediatr Pulmonol 1997; 23(5):336–343.

386

Goldfarb and Panitch

53. Hahn A, Ankermann T, Claass A, et al. Non-invasive tension time index in relation to severity of disease in children with cystic fibrosis. Pediatr Pulmonol 2008; 43(10):973–981. 54. Schidlow DV, Taussig LM, Knowles MR. Cystic Fibrosis Foundation consensus conference report on pulmonary complications of cystic fibrosis. Pediatr Pulmonol 1993; 15(3):187–198. 55. Cooper DM, Piper AJ, Willson G, et al. Invasive and noninvasive ventilatory assistance in cystic fibrosis. Pediatr Pulmonol Suppl 1995; 11:72–73. 56. Granton JT, Kesten S. The acute effects of nasal positive pressure ventilation in patients with advanced cystic fibrosis. Chest 1998; 113(4):1013–1018. 57. Fauroux B, Pigeot J, Polkey MI, et al. In vivo physiologic comparison of two ventilators used for domiciliary ventilation in children with cystic fibrosis. Crit Care Med 2001; 29(11):2097–2105. 58. Serra A, Polese G, Braggion C, et al. Non-invasive proportional assist and pressure support ventilation in patients with cystic fibrosis and chronic respiratory failure. Thorax 2002; 57(1):50–54. 59. Fauroux B, Boule M, Lofaso F, et al. Chest physiotherapy in cystic fibrosis: improved tolerance with nasal pressure support ventilation. Pediatrics 1999; 103(3):E32. 60. Zinman R, Corey M, Coates AL, et al. Nocturnal home oxygen in the treatment of hypoxemic cystic fibrosis patients. J Pediatr 1989; 114(3):368–377. 61. Hill AT, Edenborough FP, Cayton RM, et al. Long-term nasal intermittent positive pressure ventilation in patients with cystic fibrosis and hypercapnic respiratory failure (1991–1996). Respir Med 1998; 92(3):523–526. 62. Dobbin CJ, Milross MA, Piper AJ, et al. Sequential use of oxygen and bi-level ventilation for respiratory failure in cystic fibrosis. J Cyst Fibros 2004; 3(4):237–242. 63. Sprague K, Graff G, Tobias DJ. Noninvasive ventilation in respiratory failure due to cystic fibrosis. South Med J 2000; 93(10):954–961. 64. Efrati O, Modan-Moses D, Barak A, et al. Long-term non-invasive positive pressure ventilation among cystic fibrosis patients awaiting lung transplantation. Isr Med Assoc J 2004; 6(9):527–530. 65. Aurora P, Edwards LB, Christie J, et al. Registry of the international society for heart and lung transplantation: eleventh official pediatric lung and heart/lung transplantation report— 2008. J Heart Lung Transplant 2008; 27(9):978–983. 66. Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326(18):1187–1191. 67. Milla CE, Warwick WJ. Risk of death in cystic fibrosis patients with severely compromised lung function. Chest 1998; 113(5):1230–1234. 68. Liou TG, Adler FR, Huang D. Use of lung transplantation survival models to refine patient selection in cystic fibrosis. Am J Respir Crit Care Med 2005; 171(9):1053–1059. 69. Mayer-Hamblett N, Rosenfeld M, Emerson J, et al. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002; 166(12 pt 1):1550–1555. 70. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the pulmonary scientific council of the international society for heart and lung transplantation. J Heart Lung Transplant 2006; 25(7):745–755. 71. UNOS. United Network for Organ Sharing. Available at: http://www.unos.org/. 72. Egan TM, Murray S, Bustami RT, et al. Development of the new lung allocation system in the United States. Am J Transplant 2006; 6(5 pt 2):1212–1227. 73. Kreider M, Kotloff RM. Selection of candidates for lung transplantation. Proc Am Thorac Soc 2009; 6(1):20–27. 74. Faro A, Mallory GB, Visner GA, et al. American Society of Transplantation executive summary on pediatric lung transplantation. Am J Transplant 2007; 7(2):285–292.

Chronic Respiratory Failure, NIV, and Lung Transplantation

387

75. Al-Aloul M, Miller H, Alapati S, et al. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005; 39(1):15–20. 76. Benden C, Kansra S, Ridout DA, et al. Chronic kidney disease in children following lung and heart-lung transplantation. Pediatr Transplant 2009; 13(1):104–110. 77. Boucek MM, Aurora P, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: tenth official pediatric heart transplantation report—2007. J Heart Lung Transplant 2007; 26(8):796–807. 78. Sharma R, Florea VG, Bolger AP, et al. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax 2001; 56(10):746–750. 79. Schwebel C, Pin I, Barnoud D, et al. Prevalence and consequences of nutritional depletion in lung transplant candidates. Eur Respir J 2000; 16(6):1050–1055. 80. Madill J, Gutierrez C, Grossman J, et al. Nutritional assessment of the lung transplant patient: body mass index as a predictor of 90-day mortality following transplantation. J Heart Lung Transplant 2001; 20(3):288–296. 81. Aris RM, Neuringer IP, Weiner MA, et al. Severe osteoporosis before and after lung transplantation. Chest 1996; 109(5):1176–1183. 82. Knoop C, Haverich A, Fischer S. Immunosuppressive therapy after human lung transplantation. Eur Respir J 2004; 23(1):159–171. 83. Finkelstein SM, Wielinski CL, Elliott GR, et al. Diabetes mellitus associated with cystic fibrosis. J Pediatr 1988; 112(3):373–377. 84. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 2000; 162(3 pt 1):891–895. 85. Moran A, Dunitz J, Nathan B, et al. Cystic fibrosis related diabetes: current trends in prevalence, incidence and mortality. Diabetes Care 2009; 32(9):1626–1631. 86. Wagner K, Webber SA, Kurland G, et al. New-onset diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. J Heart Lung Transplant 1997; 16(3):275–282. 87. Alvarez A, Algar FJ, Santos F, et al. Pediatric lung transplantation. Transplant Proc 2005; 37(3):1519–1522. 88. Bradbury RA, Shirkhedkar D, Glanville AR, et al. Prior diabetes mellitus is associated with increased morbidity in cystic fibrosis patients undergoing bilateral lung transplantation: an “orphan” area? Intern Med J 2009; 39(6):384–388. 89. Aurora P, Boucek MM, Christie J, et al. Registry of the International Society for Heart and Lung Transplantation: tenth official pediatric lung and heart/lung transplantation report— 2007. J Heart Lung Transplant 2007; 26(12):1223–1228. 90. Meachery G, De Soyza A, Nicholson A, et al. Outcomes of lung transplantation for cystic fibrosis in a large UK cohort. Thorax 2008; 63(8):725–731. 91. Aris RM, Routh JC, LiPuma JJ, et al. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med 2001; 164(11):2102–2106. 92. Murray S, Charbeneau J, Marshall BC, et al. Impact of burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med 2008; 178(4):363–371. 93. Palmer SM, Miralles AP, Lawrence CM, et al. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest 1999; 116(1):127–133. 94. Brock MV, Borja MC, Ferber L, et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant 2001; 20(12):1282–1290. 95. Martinu T, Chen DF, Palmer SM. Acute rejection and humoral sensitization in lung transplant recipients. Proc Am Thorac Soc 2009; 6(1):54–65.

388

Goldfarb and Panitch

96. Kramer MR, Marshall SE, Starnes VA, et al. Infectious complications in heart-lung transplantation. Analysis of 200 episodes. Arch Intern Med 1993; 153(17):2010–2016. 97. Kanj SS, Tapson V, Davis RD, et al. Infections in patients with cystic fibrosis following lung transplantation. Chest 1997; 112(4):924–930. 98. Metras D, Viard L, Kreitmann B, et al. Lung infections in pediatric lung transplantation: experience in 49 cases. Eur J Cardiothorac Surg 1999; 15(4):490–494; discussion 495. 99. Liu M, Worley S, Arrigain S, et al. Respiratory viral infections within one year after pediatric lung transplant. Transpl Infect Dis 2009; 11(4):304–312. 100. Cahill BC, Hibbs JR, Savik K, et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest 1997; 112(5):1160–1164. 101. Danziger-Isakov LA, Worley S, Arrigain S, et al. Increased mortality after pulmonary fungal infection within the first year after pediatric lung transplantation. J Heart Lung Transplant 2008; 27(6):655–661. 102. Boehler A, Estenne M. Post-transplant bronchiolitis obliterans. Eur Respir J 2003; 22(6): 1007–1018. 103. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21(3):297–310. 104. O’Halloran EK, Reynolds JD, Lau CL, et al. Laparoscopic Nissen fundoplication for treating reflux in lung transplant recipients. J Gastrointest Surg 2004; 8(1):132–137. 105. Davis RD Jr., Lau CL, Eubanks S, et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg 2003; 125(3):533–542. 106. Palmer SM, Miralles AP, Howell DN, et al. Gastroesophageal reflux as a reversible cause of allograft dysfunction after lung transplantation. Chest 2000; 118(4):1214–1217. 107. Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med 2002; 166(4):440–444. 108. Iacono AT, Corcoran TE, Griffith BP, et al. Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans. Eur Respir J 2004; 23(3):384–390. 109. Sarahrudi K, Estenne M, Corris P, et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection. J Thorac Cardiovasc Surg 2004; 127(4):1126–1132. 110. Hernandez RL, Gil PU, Gallo CG, et al. Rapamycin in lung transplantation. Transplant Proc 2005; 37(9):3999–4000. 111. Snell GI, Westall GP. Immunosuppression for lung transplantation: evidence to date. Drugs 2007; 67(11):1531–1539. 112. Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004; 77(9):1465–1467. 113. Shitrit D, Bendayan D, Gidon S, et al. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant 2005; 24(9):1440–1443. 114. Gottlieb J, Szangolies J, Koehnlein T, et al. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008; 85(1):36–41. 115. Magee JC, Krishnan SM, Benfield MR, et al. Pediatric transplantation in the United States, 1997–2006. Am J Transplant 2008; 8(4 pt 2):935–945. 116. Ibrahim JE, Sweet SC, Flippin M, et al. Rejection is reduced in thoracic organ recipients when transplanted in the first year of life. J Heart Lung Transplant 2002; 21(3):311–318. 117. White T, Miller J, Smith GL, et al. Adherence and psychopathology in children and adolescents with cystic fibrosis. Eur Child Adolesc Psychiatry 2009; 18(2):96–104. 118. Wray J, Waters S, Radley-Smith R, et al. Adherence in adolescents and young adults following heart or heart-lung transplantation. Pediatr Transplant 2006; 10(6):694–700.

Chronic Respiratory Failure, NIV, and Lung Transplantation

389

119. De Geest S, Dobbels F, Fluri C, et al. Adherence to the therapeutic regimen in heart, lung, and heart-lung transplant recipients. J Cardiovasc Nurs 2005; 20(5 suppl):S88–S98. 120. Liou TG, Adler FR, Cox DR, et al. Lung transplantation and survival in children with cystic fibrosis. N Engl J Med 2007; 357(21):2143–2152. 121. Aurora P, Whitehead B, Wade A, et al. Lung transplantation and life extension in children with cystic fibrosis. Lancet 1999; 354(9190):1591–1593. 122. Sweet SC, Aurora P, Benden C, et al. Lung transplantation and survival in children with cystic fibrosis: solid statistics—flawed interpretation. Pediatr Transplant 2008; 12(2):129–136. 123. Bender BG. Risk taking, depression, adherence, and symptom control in adolescents and young adults with asthma. Am J Respir Crit Care Med 2006; 173(9):953–957. 124. Wells A, Faro A. Special considerations in pediatric lung transplantation. Semin Respir Crit Care Med 2006; 27(5):552–560. 125. Britto MT, Kotagal UR, Chenier T, et al. Differences between adolescents’ and parents’ reports of health-related quality of life in cystic fibrosis. Pediatr Pulmonol 2004; 37(2):165–171. 126. Patterson JM, Wall M, Berge J, et al. Gender differences in treatment adherence among youth with cystic fibrosis: development of a new questionnaire. J Cyst Fibros 2008; 7(2): 154–164. 127. Wray J, Radley-Smith R. Longitudinal assessment of psychological functioning in children after heart or heart-lung transplantation. J Heart Lung Transplant 2006; 25(3):345–352. 128. Cystic Fibrosis Foundation Patient Registry: 2007 Annual Data Report Bethesda, Maryland, 2008:1–24. 129. Wray J, Radley-Smith R. Depression in pediatric patients before and 1 year after heart or heart-lung transplantation. J Heart Lung Transplant 2004; 23(9):1103–1110. 130. Annunziato RA, Emre S, Shneider B, et al. Adherence and medical outcomes in pediatric liver transplant recipients who transition to adult services. Pediatr Transplant 2007; 11(6): 608–614. 131. Watson AR. Non-compliance and transfer from paediatric to adult transplant unit. Pediatr Nephrol 2000; 14(6):469–472.

24 Gene Repair: Past, Present, and Future CHRISTIAN MUELLER and TERENCE R. FLOTTE University of Massachusetts Medical Center, Worcester, Massachusetts, U.S.A.

I.

Issues for the Success of CF Gene Therapy

While there are an array of functions and conflicting theories have been put forth to explain the pathophysiology of cystic fibrosis (CF) as a result of the absence of the cystic fibrosis transmembrane regulator (CFTR), it is widely accepted that a predilection to infection and an exaggerated and sustained inflammatory response to these bacterial, viral, and fungal agents in the lung leading to progressive tissue damage is a main feature of the CF phenotype. Since the majority of CF related mortality has been associated with the lung, this has made the disease a prime candidate for pulmonary gene therapy by gene augmentation. The concept of gene therapy is a comparatively simple one: isolate the gene of interest and use a gene transfer agent (GTA) to express it in the appropriate target cells to normalize cellular function with protein synthesis from the therapeutic gene. For these reasons, following the discovery of the CFTR gene in 1989, gene therapy for CF was a natural fit; CF is a single gene recessive trait that is characterized by a loss of function of the CFTR gene. As a target organ, the lungs also seemed to offer ideal access since the epithelial cells interface with the environment and therefore are easily accessible. Thus, CF was one of the first diseases targeted by human gene therapy trials, including the very first trials to utilize recombinant adenovirus (rAd) and recombinant adeno-associated virus (rAAV) vectors in humans. Unfortunately, despite the initial demonstrations of successful gene transfer to cultured epithelial cells and small animal models, to date no dramatic therapeutic benefits have been observed in humans. However, a wealth of information has been gained from the preclinical and clinical studies performed. These data have led to the optimization of vector technology, and an appreciation of immune and mechanical barriers that have to be overcome for the successful delivery of modified genes. Importantly, several key points were identified through these studies: (i) which type or types of cell have to be corrected, (ii) what degree of correction is required, and (iii) how can immune and mechanical barriers be circumvented? A. Target Cells for CF Gene Therapy

The success and clinical benefit of gene therapy clearly depends on the ability to target and transduce the appropriate cells in the airway epithelium. Historically, CF is considered to affect the conducting airways and not the alveolar space, and the surface epithelium may be responsible for the initial trigger of disease. The larger bronchial

390

Gene Repair: Past, Present, and Future

391

airways are lined by pseudostratified columnar superficial epithelium and have submucosal glands. The smaller bronchiolar regions are generally devoid of glands and contain simple columnar epithelium. The optimal time and target cell for gene replacement therapy are not clear and remain controversial. Clinically relevant observations addressing this question include infants with CF typically presenting with bronchiolitis (small airway obstruction) as their first pulmonary abnormality. This target tissue favors the relatively easier topical administration by inhalation for delivering gene transfer vectors. The downside to targeting the bronchial epithelia is that these cells are terminally differentiated and their eventual cell death may limit the benefits of the GTA. In contrast, the CFTR gene is expressed at the highest levels in submucosal gland serous cells, and cell culture experiments have shown that there are abnormalities in the gland volume composition and the regulation of HCO3
associated with CFTR dysfunction (1). For these reasons, there is renewed interest and focus on the identification of pulmonary stem cells; gene transfer to such cells may have the potential to affect long-term CFTR expression in progeny cells. B. How Much Gene Replacement Is Enough?

This leads to the second question; what degree of correction is required for therapeutic benefits? Initial experiments designed to answer this question used monolayers of immortalized CF epithelial cells mixed at varying ratios with CFTR “corrected” cells. From these experiments it was suggested that between 6% and 10% of the cells had to be CFTR corrected to restore the normal Cl
transport of the cell monolayer (2). The issue is actually more complex as correction of a higher percentage of cells is necessary to normalize airway epithelial sodium absorption. Unlike normalization of Cl
transport that may rely on the movement of Cl
ions from noncorrected cells to corrected cells via gap junctions, Naþ transport is thought to be more local and involves CFTR protein interactions at the single cell level (3). This is further exemplified by the epithelial Naþ channel (ENaC)-overexpressing mouse model. Unlike the Cftr
/
mice, the ENaC-overexpressing mice do develop substantial airway disease, characterized by airway surface liquid (ASL) volume depletion, mucus obstruction, neutrophil accumulation, and poor bacterial clearance even in the presence of functional murine CFTR (4). Other in vitro data further suggest that close to 100% of CF epithelial cells must be transduced with a normal copy of the CFTR gene to reduce sodium hyperabsorption (5). This implies the possibility that, if hyperabsorption of Naþ across the surface epithelia plays a major role in the pathogenesis of CF lung disease, amelioration of airway disease with a positive clinical course, but not a complete cure, may result if gene transfer to the airway epithelium corrects Cl
but not Naþ transport. Further complicating the correlation between epithelial cell correction and amelioration of CF lung disease is the more recent appreciation of CFTR expression in immune cells such as macrophages, neutrophils, and lymphocytes. This expression of CFTR, which may in turn affect pulmonary infection and inflammation (6–10), could further influence the choice of optimal target cell for gene replacement. C. Barriers to Gene Therapy

Both mechanical and immune barriers became apparent after early gene transfer attempts. One of the most obvious limitations to transduction of the epithelial lung

392

Mueller and Flotte

surface is the overlying mucus layer that, under normal circumstances, is designed to clear particles such as bacteria and viruses, and therefore also viral gene therapy vectors, from the airway. In the CF airway, while having decreased clearance, this layer is even thicker with a more complex mixture of abnormal, underhydrated mucus and products of inflammation (e.g., dead and dying neutrophils, actin, DNA). In addition, both viral and nonviral gene therapy approaches have revealed that the immune system poses a significant barrier to safe and effective gene transfer by either mounting cytotoxic T lymphocyte (CTL) responses clearing the transduced cells or creating neutralizing antibodies (NAbs) to viral vectors hampering the efforts of vector readministration. The innate arm of the immune system also orchestrates inflammatory responses via toll-like receptors (TLRs) to bacterially derived plasmid DNA delivered with nonviral vectors. These data have informed the design of new vectors to circumvent or evade some of the immune responses associated with pulmonary gene delivery, as is discussed in the following section.

II.

Past and Current Efforts in CF Gene Therapy

Delivery of CFTR is a daunting task; given the nature of the CFTR as an intrinsic membrane protein, direct transduction of a significant proportion of airway epithelial cells throughout both lungs is required. The past, present, and possible future efforts to treat CF lung disease with gene therapy are reviewed here. Because, in general, naked DNA-mediated gene transfer only achieved low levels of transfection, the field has focused on developing GTAs, such as viral and nonviral synthetic agents, to improve transduction and transfection rates. To date, more than 15 phase I/II clinical trials involving approximately 400 patients with CF have been carried out using a various viral and nonviral GTAs (Table 1). Most of the early trials were conducted on the nasal epithelium due to safety concerns, and once the agents were deemed safe and promising, direct lung administration was tested. A. Recombinant Adenoviral Vectors

Adenovirus (Ad) is an icosahedral nonenveloped DNA virus with a 36 to 40 kb genome that is trophic for the airway epithelia, and naturally causes upper respiratory illnesses. Ad capsids enter epithelial cells by interacting with the coxsackievirus adenovirus receptor (CAR) as an initial binding step followed by secondary engagement of the integrin coreceptors a5b1, anb3, anb5, and aMb2. After entering the cell, Ad escapes the endosome and enters the nucleus via microtubules using nuclear pore complexes to inject its genome. The pioneering Ad vectors were based on Ad serotypes 2 and 5, two closely related members of group C of human Ads. The most extensively tested “first-generation” vectors had a deletion in the E1 region of the virus. The E1 deletion served to create a replication deficient vector that had lower immunogenicity due to reduced viral protein production. E1 deletion also increased the vector’s available packaging capacity. Despite successful early indications in mouse models, the basolateral localization of the CAR proved to be a major limiting factor in the transduction of airways in large animals and humans (Table 1) (13,25,26). This severely limited the Ad vector’s entry into epithelia when applied to the apical surface. While several strategies have been devised to disrupt epithelial tight junctions and overcome this issue, including the use of

Bronchoscope instillation Phase I and aerosol/lung Instillation/nose or Phase I intrabronchial spray/lungs Aerosol/lung Phase I

Instillation/maxillary sinus

Instillation/nose or Phase I intrabronchial spray/lungs

Aerosol/lung

Aerosol/lung

Ad

AAV2

AAV2

AAV2

AAV2

AAV2

Phase II Phase I Phase II

Cationic liposome Aerosol/lung

Cationic polymer

12

10 Liposome 2 Placebo 8

Safe and dose-dependent gene DNA transfer; no mRNA detectable Safe; no change in sinusitis frequency or other endpoints Safe; humoral immune response observed. DNA detected, mRNA and ion channel correction detected in a follow ex vivo study. Safe; vector DNA detected. mRNA not detected; FEV1 at day 14 increase; IL-8 at day 14 decreased; no change in sputum bacterial cultures Safe and well tolerated; no significant improvement in FEV1 or IL-8. Safe; no mRNA or physiologic response detected Safely readministered three times; mRNA detected along with mild physiologic effects Acute innate response elicited. mRNA detected in 3/8 patients Safe: DNA detected in dose-dependent manner. Partial physiologic effect in 8/12 patients

Transient and inefficient expression; CTL responses detected in most subjects Transient and inefficient expression; systemic immune response Transient and inefficient expression; nonepithelial cell were also transduced Systemic responses at the high dose

Results

Konstan et al., 2004 (24)

Ruiz et al., 2001 (23)

Hyde et al., 2000 (22)

Noone et al., 2000 (21)

Moss et al., 2007 (20)

Moss et al., 2004 (19)

Wagner et al., 2002 (16) Flotte et al., 2003 and 2005 (17,18)

Perricone et al., 2001 (13) Harvey et al., 2002 (14) Aitken et al., 2001 (15)

Zuckerman et al., 1999 (11) Joseph et al., 2001 (12)

Reference

Abbreviations: Ad, adenovirus; CTL, cytotoxic T lymphocyte; AAV, adeno-associated virus; IL, interleukin; FEV1, forced expiratory volume in one second

Instillation/nose

20 AAV2 17 Placebo

25

23

12

34

14

36

11

Subjects

51 AAV2 51 Placebo Phase I-II 11

Phase II

Phase II

Phase II

Phase I

Cationic liposome Spray/nose

Cationic liposome Spray/nose

Ad

Ad

Phase I

Bronchoscope instillation/ lung Aerosol/lung

Ad

Phase

Route/target site

Vector

Table 1 Recent Representative Gene Therapy Clinical Trials for Cystic Fibrosis

Gene Repair: Past, Present, and Future 393

394

Mueller and Flotte

Ca2þ chelators EGTA (ethylene glycol tetraacetic acid) or EDTA (ethylene diamine tetraacetic acid) or to formulate the vector in a 0.1% a-lysophosphatidylcholine solution (27), these strategies may not be clinically relevant. Experiments using a-lysophosphatidylcholine solution aerosolized to the rabbit airway caused mild pneumonia and fever (27). Furthermore, the concept of epithelial disruption itself raises serious safety concerns for CF patients, as disruption of the epithelial barrier could allow dissemination of bacteria that are already present in the airway of these patients. First generation, E1-deleted Ad vectors also elicited Th1 and Th2 immune responses and caused dose-dependent inflammation and cytotoxicity (28,29). Most of the immunogenicity was attributed to the other viral genes present in the vector. To address this, second generation Ad vectors were modified to delete the E2A, E3, and E4 genes. Clinical trials using second generation Ad vectors expressing the full-length CFTR gene were conducted in six CF patients, where a dependent but transient (30 days) expression of CFTR was observed (30). Similarly in another trial involving eleven CF patients and second generation Ad vectors, CFTR expression was observed at low levels for 42 days (11). Unfortunately, readministration of the vector in the first trial did not achieve the original CFTR expression levels and no expression was observed with the third administration, strongly suggesting an immune response to the vector. In fact, in the latter study, Ad-specific CD8 T cells were recorded in the majority of the subjects (11) (Table 1). Despite these setbacks, significant experimental progress has been made with respect to Ad vector design. The latest generation of Ad vectors is termed “gutless” due to the complete absence of viral genes, and these vectors are essentially helper dependent, capable of packaging a 37 kb genetic payload. This increased packaging capacity can be used to create CFTR vectors under the control of more biologically relevant, epithelial promoters such as the human cytokeratin 18 promoter (31). Others have attempted to reduce the immunogenicity of Ad vectors by coating the capsids with polyethylene glycol (PEG). This “PEGylation” reduces the generation of NAbs and T-cell responses after intratracheal delivery (32). While these newer Ad-CFTR vectors have not been tested to date in human trials, Ad vectors have fallen out of favor for potential CF clinical use and have been superseded by rAAV vectors. However, there is renewed interest for Ad vectors in gene therapy approaches to lung and other cancers. B. rAAV Vectors

Adeno-associated viruses (AAVs) are parvoviruses with a linear 4.7 kb single-stranded DNA genome (33,34). Originally, AAV2 was discovered as a laboratory contaminant of Ad cultures (35,36), and was later found to be a frequent isolate among children experiencing an outbreak of Ad-induced diarrhea (37). AAV replicates only in the presence of Ad, herpes virus, or other helper viruses; these helpers supply a number of early functions required for AAV gene expression and replication (37,38). Subsequently, none of the AAV serotypes have been associated with human disease, despite the fact that 90% of adult humans are seropositive for one or more of the so far discovered serotypes (39). The AAV particle is a nonenveloped icosahedron with a diameter of approximately 25 nm. The AAV genome contains two genes, cap, which encodes the three overlapping coat proteins and rep, which encodes the four regulatory Rep proteins, flanked by two inverted terminal repeats (ITR’s) of 125 bases each (40). Naturally

Gene Repair: Past, Present, and Future

395

occurring variations of the cap gene account for the discovery of many different genomic variants and serotypes of wild-type (wt) AAV in recent years (41,42). In the absence of helper Ad, AAV enters a latent state where Rep inhibits viral gene expression and DNA replication, as well as promotes site-specific chromosomal integration (43). In the presence of helper virus, Rep promotes viral gene expression (44), DNA replication, and rescue from the integrated state (45). In AAV vectors, all viral genes are deleted and only the ITR sequences are retained; rAAV is thus a truly gutted vector (46). Variants in the cap gene and/or AAV serotype provide the flexibility of creating altered tropisms for vector transduction. Thus, it is common practice to transcapsidate (or pseudotype) AAV vector genomes with different AAV capsid serotypes by using different AAV packaging plasmids in which AAV2 rep genes are combined with capsid genes of the desired serotype (47–49). rAAV has had no detectable toxicities across a wide range of preclinical studies and in a limited number of clinical trials, even at the highest deliverable doses. Expression profiling of infected cells with microarray analysis indicates that host cell gene expression is remarkably unperturbed after rAAV infection. While some humoral immune responses to the rAAV capsid have been observed, cell-mediated immune responses to AAV are uncommon in the absence of Ad coinfection (50). The relatively low immune profile and lack of toxicity, as well as studies demonstrating gene transfer in nondividing cells and very efficient transduction of a wide range of terminally differentiated cells including neurons, retinal photoreceptor cells, myofibers, cells, hepatocytes, and bronchial epithelial cells, have placed rAAV at the top of the list for candidates for pulmonary gene therapy (43,51–54,55). The majority of preclinical (56,57) and clinical studies with rAAV were performed using first generation vectors with AAV serotype 2–based genomes and capsids. Because of the limited packaging capacity (*4.7 kb) of rAAV and the 4.44 kb coding sequence of CFTR, plus the mandatory 0.3 kb ITR sequence for packaging, these first generation vectors relied on the endogenous promoter elements within the ITRs to drive CFTR expression. Nonetheless, the preclinical studies have demonstrated both vector DNA transfer and mRNA expression for more than six months without any indication of inflammation, toxicity, or rescue of rAAV by wt AAV or wt Ad (56). These studies supported a series of clinical trials testing the delivery of the vector to the nose, maxillary sinus, isolated bronchus, and finally to the entire lower respiratory tract by aerosol delivery (17,19,58–62). The initial phase I clinical trial involving sequential intranasal and endobronchial instillation of rAAV2-CFTR in adult patients with CF demonstrated safety over a 7-log dose range (17,58). Although dose-dependent gene transfer to the airway epithelial cells was demonstrated in these trials, the longevity of gene transfer observed in animals was not evident in humans. However, subsequent studies suggested that there was a correlation between the presence of vector DNA sequences, mRNA expression, and electrophysiologic correction of cAMP-activated chloride flux in primary cells obtained during this trial (18). Clinical studies eventually progressed through phase IIb and were followed by phase II multicenter double-blinded, placebo-controlled trials focusing on repeated aerosol administration of rAAV-CFTR (20). However, significant limitations were noted due to the inconsistent ability to directly demonstrate expression in vivo, the lack of vector genome persistence, the absence of detectable improvement in pulmonary function as measured by forced expiratory volume in one second (FEV1), and finally the

396

Mueller and Flotte

lack of efficacy of repeated dosing in the face of rising NAbs. While there was some indication of positive biological effects and DNA transfer, they were short in duration (30–60 days), and clinical studies with this particular vector were concluded after phase IIb studies, with over 100 subjects treated without a single vector-related significant adverse effect (Table 1). These clinical studies elucidated some of the limitations associated with rAAV vectors. These limitations were, in fact, very similar to those of Ad vectors, including paucity of the AAV2 receptors (heparan sulfate proteoglycan, aV-b5 integrins, and fibroblast growth factor receptor) on the apical surface of the airway epithelium. This inefficient delivery was likely compounded by the weak ITR promoter activity driving the CFTR gene and the development of neutralizing Abs that could effectively limit readministration of rAAV. Second generation rAAV vectors have tried to address these limitations. Use of the strong and constitutive CMV enhancer chicken b-actin hybrid promoter (CBA) may increase CFTR expression, but created a vector-packaging capacity conundrum. As previously mentioned, if the full-length CFTR is to be packaged in AAV there is little room offered for a promoter. To circumvent this, functional CFTR “mini genes” based on alternative mRNA splicing were defined with removal of the first 117 or 264 amino acids of CFTR (63). These mini-CFTRs were functional because only a small portion of the first transmembrane domain (TMD1) is crucial for CFTR stability and function as a chloride channel (64). One of the latest versions of the CFTR minigene termed “AAV-CBAD264CFTR” has been successfully delivered to CF cell lines where it corrected Cl
fluxes; furthermore, intratracheal delivery of this construct to Cftr
/
mice was shown to ameliorate the pathology and inflammation associated with pulmonary exposure to Pseudomonas-agarose beads (63). This vector construct has also been successfully used to partially correct a CFTR-dependent hyper-IgE phenotype modeled in CF mice (8). Preclinical studies after aerosol administration in rhesus monkeys demonstrated safe and efficient delivery to the lung (105 copies of CFTR/mg of DNA), with no signs of inflammation as compared with untreated controls (65). Recently this cassette has been modified to put back a small leader sequence composed of the first 26 amino acids of TMD1, which further enhances the cell membrane stability of the channel. The second generation rAAV vectors also capitalize on the divergent tropisms of newly isolated AAV serotypes (42,66). This allowed investigators to pseudotype rAAV vectors with capsids, such as those from AAV1, AAV5, and AAV6 that would bind receptors on the apical surface of the airway epithelium more efficiently (67–71). One promising candidate was rAAV5, which showed upwards of 10-fold increased efficiency of gene delivery in the mouse lung (72). Further studies in differentiated airway epithelia demonstrated disparate results between human airway epithelia and those observed in a variety of lower nonhuman primates and rodents (71,73). In particular, rAAV5-based vectors again performed very well in mice and in airway cultures from mouse and lower primate species; in contrast, rAAV1-based vectors performed significantly better in human airway cultures. The findings from the in vivo chimpanzee comparison are consistent with those obtained from human airway cell cultures and strongly suggest that rAAV1 has significant advantages, both in terms of overall higher efficiency and lower immunogenicity (data not published). Thus, it seems very likely that the next CF patient trial with AAV will use AAV1 as the indicated serotype to achieve more productive airway delivery.

Gene Repair: Past, Present, and Future

397

One fundamental issue that is not addressed by the latest vectors is the question of persistence of transgene expression. Persistence may inversely correlate with Nab responses since the less frequent the administration, the less robust the memory immune response will be. Persistence of rAAV genomes in transduced cells is primarily episomal, and the site-specific integration observed with wt AAV2 does not occur in the absence of Rep protein (74,75). For the purpose of treating CF, this is problematic since the natural turnover rate (2–3 months) of airway epithelia is up to four times faster in the CF lung. This more rapid cell division would eventually dilute out the therapeutic episomes. There are several promising avenues to overcome this issue. These include limiting the activity of DNA-dependent protein kinase (DNA-PKcs) that convert linear AAV genomes to circular forms, thereby inhibiting genome integration (76–78), and by including Rep in rAAV vectors to promote site-specific integration during transduction (65,79,80). These strategies to promote AAV genome integration, combined with recent data suggesting that rAAV1 and rAAV5 can transduce airway stem/progenitor cells (81), support the hypothesis that lifelong correction of the airway epithelium may be achievable. Recent technical advancements in packaging rAAV vectors that allow up to 8.9 kb of DNA to be packaged into rAAV1 and rAAV5 capsids (albeit at lower titers) (82) may enable future clinical trials to test vectors including the full-length CFTR gene along with a constitutive promoter and the site-specific integration system. Safe and sitespecific integration of full-length CFTR may help circumvent some of the complications associated with readministration, and may offer long-term therapeutic benefits to patients from a single vector administration. C. Lentiviral Vectors

A number of lentiviruses have been derivatized for development of gene transfer vectors for CF, including HIV. These vectors are potentially attractive because they have the capacity and ability to integrate into dividing and nondividing cells. Unfortunately, this virus has low tropism for the apical surface of the airway epithelium (83). However, pseudotyping of lentiviral vectors has been used to enhance gene transfer into the airway cells. One example is the creation of a hybrid vector with Ebola enveloped glycoprotein that increased the efficiency of transduction via the apical surface of the epithelium (84). Promising preclinical data with CFTR vectors have been achieved with cell culture, rodent, and nonhuman primates. Clinical studies have not yet been performed. Although a promising viral vector delivery system, these viral vectors are plagued by their high rate of random integration in the host genome that has led to two patients developing T-cell leukemia in human gene therapy trials for severe combined immune deficiency (SCID) (85). D. Nonviral Vectors

Historically, nonviral vectors including cationic liposomes (lipoplexes) or cationic polymers (polyplexes) have resulted in less efficient airway epithelial gene expression when compared with viral vectors. Transgene expression is generally transient using these systems. Furthermore, while in theory these vehicles should avoid adaptive immune responses, innate immune responses have turned out to be a major hindrance. Recent advances in these vectors and a more comprehensive understanding of the innate responses, have led to animal and clinical studies with promising results using both cationic liposomes and polymers.

398

Mueller and Flotte E.

Cationic Liposomes

Cationic liposome delivery systems are composed of cationic lipids that are usually mixed with cholesterol and dioleoylphosphatidyl-ethanolamine (DOPE). The liposomes bind to plasmid DNA via electrostatic interactions, and the resulting complexes are positively charged particles of 100 to 500 nm in diameter that can fuse with cell membranes and enter cells. The DNA/lipid complexes are then resistant to nuclease degradation and, unlike viral vectors, have no limit to the size of DNA that can be delivered. This allows tissue-specific promoters and locus control regions to be delivered along with the gene of interest, making the gene expression of the therapeutic protein more biologically accurate. Cationic liposomes have demonstrated both in vitro and in vivo efficacy. Formulation GL-67 (Genzyme) had 100-fold greater efficiency over other liposomes in the mouse lung (86) (Table 1), but had in vivo toxicity associated with pulmonary infiltration of neutrophils and to a lesser extent macrophages and lymphocytes, as well as elevated lung levels of the proinflammatory cytokines IL-6, TNF-a, and IFN-g in BALB/C mice (87). In human studies, delivery of GL-67 cationic liposomes containing the CFTR gene by a nasal perfusion to CF patients resulted in partial correction of nasal potential differences (for discussion of this technique, see chap. 8). However, CFTR expression could not be directly verified by the detection of CFTR mRNA in these studies, and subjects in this study developed fever and increased levels of IL-6 (88). These side effects were attributed to innate inflammatory responses orchestrated by TLR 9 in response to the recognition of bacterially derived unmethylated CpG repeats in the plasmid DNA. The immune response to GL-67 was further characterized in another study by Ruiz et al. in which he performed a dose escalation with aerosolized delivery. Subjects who had GL-67 liposome/DNA complexes delivered by aerosol also had fever and increased serum levels of IL-6 as soon as one hour after gene administration, perhaps due to a synergistic response to plasmid DNA complexed with GL-67 (23). Strategies that have been employed to reduce inflammatory stimulation by these vectors include the reduction of nonessential CpG sequences or the use of chloroquine as an inhibitor of the CpG signaling pathway (89,90). Alternatively, methylation of the CpG motifs, while successful at reducing inflammation, was associated with a severe reduction in transgene expression (91). F.

Cationic Polymers

Cationic polymers, such as poly-L-lysine (polyK), polyethyleneimine (PEI), and polyamidoamine dedrimers have also been examined as nonviral vectors for CF gene therapy. In a fashion similar to cationic liposomes, these polymers are able to condense DNA into small nuclease-resistant particles. Because of their net positive charge, the polymers can bind to cells via electrostatic interactions with the negatively charged membrane. In addition, PEI’s endosomal release is facilitated because their branched amines act as proton sinks that cause endosomes to swell and burst (92). In mice, PEI vectors preferentially localize to the lung after intravenous delivery. Transfection efficiency was 1% to 5% and restricted to the distal and branched airways close to the alveoli, including pneumocytes and endothelial cells but few epithelial cells (93). In

Gene Repair: Past, Present, and Future

399

contrast, epithelial cells were primarily transduced after aerosol delivery to the mice lungs (94). Unfortunately, high molecular weight PEI complexes are not biodegradable and PEI’s transduction efficiency has been tied to endosomal rupture, which causes toxicity both in vitro and in vivo (95,96). For these and additional reasons, cationic polymer delivery has recently focused more on polymers of L-amino acids, such as lysine (polyK). These polymers can be conjugated with targeting peptides for cell-specific and enhanced uptake. Although manufacturing large quantities of peptides for large animals may be prohibitively costly, this approach has been tested in mice. Specifically, the human CFTR gene was delivered to mouse lungs using polyK conjugated with a ligand to the serpin-enzyme complex receptor (SecR). SecR is found on hepatocytes, macrophages, and the apical surface of airway epithelia where it usually binds and promotes internalization of protease inhibitors once they have bound to and inactivated their ligands. While vector expression was transient (*12 days), there was a partial correction in chloride secretion (97). Although immune responses to polyK were not observed, there was an antibody response to the SecR ligand, once again hindering the possibility of readministration. Similar to the strategy used to create “stealth” (or PEGylated) Ad vectors, PEG has been used to modify the side chains of polyK. This allowed the polyK complexes to remain stable in physiological (normal) saline instead of the usual 1 M NaCl solution, and diminished the CpG-mediated immune responses; this contributed to a lack of in vivo toxicity (98). Delivery of PEGylated polyK CFTR complexes to the nasal airways of 12 CF patients in 3 escalating doses led to nasal potential difference correction in 8 of the 12 patients for up to six days. No adverse events were associated with this treatment (24) (Table 1).

III.

Conclusions

The data reviewed in this chapter highlight the significant physical and immunological hurdles that have been encountered in the CF gene therapy field. Major barriers for effective viral gene therapy include viral pathogenicity and CTL clearance in the case of Ad vectors. Repeated administrations of viral vectors, which are crucial for a disease such as CF are currently being hindered by NAbs in both Ad and AAV delivery methods. Nonviral delivery systems have to surmount CpG-associated inflammation, cell toxicity, and low gene transfer efficiency. Importantly, the lessons learned from clinical trials have to be adapted to novel ideas from the bench to further evolve currently available gene delivery systems. In this aspect, newer versions of AAV vectors should incorporate strategies or elements that help overcome these hurdles, such as facilitating site-specific integration. This would not only help bring lifelong therapy within a realistic grasp, but could also be directly applied to cell-based therapy approaches for CF. Recent data also suggest that CF gene therapy must consider the correction of alternative nonepithelial cell types. While CFTR gene therapy has naturally focused on the correction of airway epithelia, recent studies have suggested that the CFTR defect may affect the ability of immune cells in the lung to clear pathogens (99). Also, intratracheal delivery of AAV5-CB-D264CFTR and CFTR correction in the lung was associated with a correction of aberrant cytokine secretion from splenocytes in Cftr-

400

Mueller and Flotte

deficient mice (6). Thus, it is conceivable that the CFTR defect may also be playing an intrinsic role in the integrity, effectiveness, and homeostatic balance of the immune system. Nonepithelial CF gene therapy is a relatively untested hypothetical target for CFTR gene correction that may potentially offer new possibilities for cell-based therapies, and may compliment the new generation of gene therapy vectors currently in the clinical pipeline.

References 1. Finkbeiner WE, Shen BQ, Widdicombe JH. Chloride secretion and function of serous and mucous cells of human airway glands. Am J Physiol 1994; 267(2 pt 1):L206–L210. 2. Johnson LG, Olsen JC, Sarkadi B, et al. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 1992; 2(1):21–25. 3. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med 1996; 154(5):1229–1256. 4. Mall M, Grubb BR, Harkema JR, et al. Increased airway epithelial Naþ absorption produces cystic fibrosis-like lung disease in mice. Nat Med 2004; 10(5):487–493. 5. Johnson LG, Boyles SE, Wilson J, et al. Normalization of raised sodium absorption and raised calcium-mediated chloride secretion by adenovirus-mediated expression of cystic fibrosis transmembrane conductance regulator in primary human cystic fibrosis airway epithelial cells. J Clin Invest 1995; 95(3):1377–1382. 6. Mueller C, Torrez D, Braag S, et al. Partial correction of the CFTR-dependent ABPA mouse model with recombinant adeno-associated virus gene transfer of truncated CFTR gene. J Gene Med 2008; 10(1):51–60. 7. Machen TE. Innate immune response in CF airway epithelia: hyperinflammatory? Am J Physiol Cell Physiol 2006; 291(2):C218–C230. 8. Muller C, Braag SA, Herlihy JD, et al. Enhanced IgE allergic response to Aspergillus fumigatus in CFTR-/- mice. Lab Invest 2006; 86(2):130–140. 9. Di A, Brown ME, Deriy LV, et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol 2006; 8(9):933–944. 10. Bruscia EM, Zhang PX, Ferreira E, et al. Macrophages directly contribute to the exaggerated inflammatory response in CFTR-/- mice. Am J Respir Cell Mol Biol 2009; 40(3):295–304. 11. Zuckerman JB, Robinson CB, McCoy KS, et al. A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum Gene Ther 1999; 10(18):2973–2985. 12. Joseph PM, O’Sullivan BP, Lapey A, et al. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications. Hum Gene Ther 2001; 12(11):1369–1382. 13. Perricone MA, Morris JE, Pavelka K, et al. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium. Hum Gene Ther 2001; 12(11):1383–1394. 14. Harvey BG, Maroni J, O’Donoghue KA, et al. Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther 2002; 13(1):15–63. 15. Aitken ML, Moss RB, Waltz DA, et al. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther 2001; 12(15):1907–1916. 16. Wagner JA, Nepomuceno IB, Messner AH, et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther 2002; 13(11):1349–1359.

Gene Repair: Past, Present, and Future

401

17. Flotte TR, Zeitlin PL, Reynolds TC, et al. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther 2003; 14(11): 1079–1088. 18. Flotte TR, Schwiebert EM, Zeitlin PL, et al. Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy. Hum Gene Ther 2005; 16(8):921–928. 19. Moss RB, Rodman D, Spencer LT, et al. Repeated adeno-associated virus serotype 2 aerosolmediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004; 125(2): 509–521. 20. Moss RB, Milla C, Colombo J, et al. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther 2007; 18(8):726–732. 21. Noone PG, Hohneker KW, Zhou Z, et al. Safety and biological efficacy of a lipid-CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis. Mol Ther 2000; 1(1):105–114. 22. Hyde SC, Southern KW, Gileadi U, et al. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther 2000; 7(13):1156–1165. 23. Ruiz FE, Clancy JP, Perricone MA, et al. A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis. Hum Gene Ther 2001; 12(7): 751–761. 24. Konstan MW, Davis PB, Wagener JS, et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther 2004; 15(12): 1255–1269. 25. Grubb BR, Pickles RJ, Ye H, et al. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature 1994; 371(6500):802–806. 26. Harvey BG, Leopold PL, Hackett NR, et al. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest 1999; 104(9):1245–1255. 27. Koehler DR, Frndova H, Leung K, et al. Aerosol delivery of an enhanced helper-dependent adenovirus formulation to rabbit lung using an intratracheal catheter. J Gene Med 2005; 7(11):1409–1420. 28. Yang Q, Chen F, Ross J, et al. Inhibition of cellular and SV40 DNA replication by the adenoassociated virus Rep proteins. Virology 1995; 207(1):246–250. 29. Brody SL, Metzger M, Danel C, et al. Acute responses of non-human primates to airway delivery of an adenovirus vector containing the human cystic fibrosis transmembrane conductance regulator cDNA. Hum Gene Ther 1994; 5(7):821–836. 30. Crystal RG, McElvaney NG, Rosenfeld MA, et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994; 8(1):42–51. 31. Toietta G, Koehler DR, Finegold MJ, et al. Reduced inflammation and improved airway expression using Helper-Dependent adenoviral vectors with a k18 promoter. Mol Ther 2003; 7(5):649–658. 32. Croyle MA, Chirmule N, Zhang Y, et al. “Stealth” adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol 2001; 75(10):4792–4801. 33. Carter BJ, Khoury G, Denhardt DT. Physical map and strand polarity of specific fragments of adenovirus-associated virus DNA produced by endonuclease R-EcoRI. J Virol 1975; 16(3): 559–568.

402

Mueller and Flotte

34. Hermonat PL, Labow MA, Wright R, et al. Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants. J Virol 1984; 51(2):329–339. 35. Atchison RW, Casto BC, Hammon WM. Electron microscopy of adenovirus-associated virus (AAV) in cell cultures. Virology 1966; 29(2):353–357. 36. Hoggan MD, Blacklow NR, Rowe WP. Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc Natl Acad Sci U S A 1966; 55(6):1467–1474. 37. Blacklow NR, Hoggan MD, Kapikian AZ, et al. Epidemiology of adenovirus-associated virus infection in a nursery population. Am J Epidemiol 1968; 88(3):368–378. 38. Blacklow NR, Hoggan MD, Rowe WP. Serologic evidence for human infection with adenovirus-associated viruses. J Natl Cancer Inst 1968; 40(2):319–327. 39. Afione SA, Conrad CK, Flotte TR. Gene therapy vectors as drug delivery systems. Clin Pharmacokinet 1995; 28(3):181–189. 40. Trempe JP, Carter BJ. Alternate mRNA splicing is required for synthesis of adeno-associated virus VP1 capsid protein. J Virol 1988; 62(9):3356–3363. 41. Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther 2005; 5(3):285–297. 42. Gao G, Vandenberghe LH, Alvira MR, et al. Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol 2004; 78(12):6381–6388. 43. Kearns WG, Afione SA, Fulmer SB, et al. Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line. Gene Ther 1996; 3(9):748–755. 44. Shi Y, Seto E, Chang LS, et al. Transcriptional repression by YY1, a human GLI-Kruppelrelated protein, and relief of repression by adenovirus E1A protein. Cell 1991; 67(2): 377–388. 45. Im DS, Muzyczka N. The AAV origin binding protein Rep68 is an ATP-dependent sitespecific endonuclease with DNA helicase activity. Cell 1990; 61(3):447–457. 46. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72(3):2224–2232. 47. Grimm D. Production methods for gene transfer vectors based on adeno-associated virus serotypes. Methods 2002; 28(2):146–157. 48. Merten OW, Geny-Fiamma C, Douar AM. Current issues in adeno-associated viral vector production. Gene Ther 2005; 12(suppl 1):S51–S61. 49. Le Bec C, Douar AM. Gene therapy progress and prospects—vectorology: design and production of expression cassettes in AAV vectors. Gene Ther 2006; 13(10):805–813. 50. Hernandez YJ, Wang J, Kearns WG, et al. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model [in process citation]. J Virol 1999; 73(10):8549–8558. 51. Flotte TR, Afione SA, Conrad C, et al. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci U S A 1993; 90(22):10613–10617. 52. Clark KR, Sferra TJ, Johnson PR. Recombinant adeno-associated viral vectors mediate longterm transgene expression in muscle. Hum Gene Ther 1997; 8(6):659–669. 53. Flannery JG, Zolotukhin S, Vaquero MI, et al. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci U S A 1997; 94(13):6916–6921. 54. Kessler PD, Podsakoff GM, Chen X, et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci U S A 1996; 93(24):14082–14087.

Gene Repair: Past, Present, and Future

403

55. Snyder RO, Miao CH, Patijn GA, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16(3):270–276. 56. Afione SA, Conrad CK, Kearns WG, et al. In vivo model of adeno-associated virus vector persistence and rescue. J Virol 1996; 70(5):3235–3241. 57. Conrad CK, Allen SS, Afione SA, et al. Safety of single-dose administration of an adenoassociated virus (AAV)-CFTR vector in the primate lung. Gene Ther 1996; 3(8):658–668. 58. Flotte T, Carter B, Conrad C, et al. A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther 1996; 7(9):1145–1159. 59. Wagner JA, Messner AH, Moran ML, et al. Safety and biological efficacy of an adenoassociated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope 1999; 109(2 pt 1):266–274. 60. Wagner JA, Reynolds T, Moran ML, et al. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus [letter]. Lancet 1998; 351(9117):1702–1703. 61. Flotte TR, Carter BJ. Adeno-associated virus vectors for gene therapy of cystic fibrosis. Methods Enzymol 1998; 292:717–732. 62. Wagner JA, Messner AH, Moran ML, et al. Safety and biological efficacy of an adenoassociated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope 1999; 109(2 pt 1):266–274. 63. Sirninger J, Muller C, Braag S, et al. Functional characterization of a recombinant adenoassociated virus 5-pseudotyped cystic fibrosis transmembrane conductance regulator vector. Hum Gene Ther 2004; 15:832–841. 64. Carroll TP, Morales MM, Fulmer SB, et al. Alternate translation initiation codons can create functional forms of cystic fibrosis transmembrane conductance regulator. J Biol Chem 1995; 270(20):11941–11946. 65. Fischer AC, Smith CI, Cebotaru L, et al. Expression of a truncated cystic fibrosis transmembrane conductance regulator with an AAV5-pseudotyped vector in primates. Mol Ther 2007; 15(4):756–763. 66. Gao GP, Alvira MR, Wang L, et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 2002; 99(18):11854–11859. 67. Flotte T, Agarwal A, Wang J, et al. Efficient ex vivo transduction of pancreatic islet cells with recombinant adeno-associated virus vectors. Diabetes 2001; 50(3):515–520. 68. Chao H, Liu Y, Rabinowitz J, et al. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2000; 2(6):619–623. 69. Zabner J, Seiler M, Walters R, et al. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 2000; 74(8):3852–3858. 70. Davidson BL, Stein CS, Heth JA, et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A 2000; 97(7):3428–3432. 71. Liu X, Luo M, Trygg C, et al. Biological differences in rAAV transduction of airway epithelia in humans and in old world non-human primates. Mol Ther 2007; 15(12): 2114–2123. 72. Auricchio A, O’Connor E, Weiner D, et al. Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. J Clin Invest 2002; 110(4):499–504. 73. Liu X, Yan Z, Luo M, et al. Species-specific differences in mouse and human airway epithelial biology of recombinant adeno-associated virus transduction. Am J Respir Cell Mol Biol 2006; 34(1):56–64. 74. Steigerwald R, Rabe C, Schmitz V, et al. Requirements for adeno-associated virus-derived non-viral vectors to achieve stable and site-specific integration of plasmid DNA in liver carcinoma cells. Digestion 2003; 68(1):13–23.

404

Mueller and Flotte

75. Nakai H, Montini E, Fuess S, et al. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet 2003; 34(3):297–302. 76. Song S, Laipis PJ, Berns KI, et al. Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle. Proc Natl Acad Sci U S A 2001; 98(7):4084– 4088. 77. Song S, Lu Y, Choi YK, et al. DNA-dependent PK inhibits adeno-associated virus DNA integration. Proc Natl Acad Sci U S A 2004; 101(7):2112–2116. 78. Dyall J, Szabo P, Berns KI. Adeno-associated virus (AAV) site-specific integration: formation of AAV-AAVS1 junctions in an in vitro system. Proc Natl Acad Sci U S A 1999; 96(22):12849–12854. 79. Recchia A, Parks RJ, Lamartina S, et al. Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc Natl Acad Sci U S A 1999; 96(6): 2615–2620. 80. Johnston KM, Jacoby D, Pechan PA, et al. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum Gene Ther 1997; 8(3):359–370. 81. Liu X, Luo M, Guo C, et al. Analysis of adeno-associated virus progenitor cell transduction in mouse lung. Mol Ther 2009; 17(2):285–293. 82. Allocca M, Doria M, Petrillo M, et al. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J Clin Invest 2008; 118(5):1955–1964. 83. Johnson LG. Retroviral approaches to gene therapy of cystic fibrosis. Ann N Y Acad Sci 2001; 953:43–52. 84. Kobinger GP, Weiner DJ, Yu QC, et al. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol 2001; 19(3):225–230. 85. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348 (3):255–256. 86. Lee ER, Marshall J, Siegel CS, et al. Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung. Hum Gene Ther 1996; 7(14): 1701–1717. 87. Scheule RK, St George JA, Bagley RG, et al. Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. Hum Gene Ther 1997; 8(6):689–707. 88. Smith SN, Middleton PG, Chadwick S, et al. The in vivo effects of milrinone on the airways of cystic fibrosis mice and human subjects. Am J Respir Cell Mol Biol 1999; 20(1): 129–134. 89. Yew NS, Zhao H, Wu IH, et al. Reduced inflammatory response to plasmid DNA vectors by elimination and inhibition of immunostimulatory CpG motifs. Mol Ther 2000; 1(3): 255–262. 90. Ji Y, Zhao Y, Sheng Y. [Preclinical study of preimplantation genetic diagnosis in animal]. Zhonghua Fu Chan Ke Za Zhi 2000; 35(8):462–464. 91. Yew NS, Wang KX, Przybylska M, et al. Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid: pDNA complexes. Hum Gene Ther 1999; 10(2):223–234. 92. Boussif O, Lezoualc’h F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A 1995; 92(16):7297–7301. 93. Costello LC, Liu Y, Zou J, et al. The pyruvate dehydrogenase E1 alpha gene is testosterone and prolactin regulated in prostate epithelial cells. Endocr Res 2000; 26(1):23–39. 94. Gautam A, Densmore CL, Golunski E, et al. Transgene expression in mouse airway epithelium by aerosol gene therapy with PEI-DNA complexes. Mol Ther 2001; 3(4):551–556.

Gene Repair: Past, Present, and Future

405

95. Gebhart CL, Kabanov AV. Evaluation of polyplexes as gene transfer agents. J Control Release 2001; 73(2–3):401–416. 96. Chollet P, Favrot MC, Hurbin A, et al. Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. J Gene Med 2002; 4(1):84–91. 97. Ziady AG, Kelley TJ, Milliken E, et al. Functional evidence of CFTR gene transfer in nasal epithelium of cystic fibrosis mice in vivo following luminal application of DNA complexes targeted to the serpin-enzyme complex receptor. Mol Ther 2002; 5(4):413–419. 98. Ziady AG, Davis PB, Konstan MW. Non-viral gene transfer therapy for cystic fibrosis. Expert Opin Biol Ther 2003; 3(3):449–458. 99. Swanson J. CFTR: helping to acidify macrophage lysosomes. Nat Cell Biol 2006; 8(9): 908–909.

25 Restoration of CFTR Function with Small-Molecule Modulators WYNTON HOOVER and JOHN P. CLANCY University of Alabama at Birmingham and Children’s Hospital of Alabama, Birmingham, Alabama, U.S.A.

I.

Introduction—Cystic Fibrosis Therapeutic Strategies That Target Disease Symptoms and Disease Causes Current therapies for CF address the symptoms of the disease, and their systematic use has lead to steady and remarkable improvements in patient longevity. The rationale for all approved therapies is rooted in reducing disease symptoms, despite differences in how and when they are applied (1). For example, mucus obstruction and airway plugging is addressed by airway clearance methodologies, such as daily chest physiotherapy, nebulization of rhDNase (Dornase alfa, to reduce sputum viscosity), and more recently the addition of nebulized hypertonic saline (to hydrate mucus) as part of daily treatment regimens (2). Bacterial infections are treated with pathogen-directed antibiotics, and the choice of delivery route and antibiotic class is based on the infectious agent and the nature of the infection. Intravenous antibiotics directed toward Pseudomonas aeruginosa during pulmonary exacerbations helps restore lung function. Alternatively, cycled aerosolized tobramycin in patients with chronic P. aeruginosa infection suppresses bacterial growth and stabilizes lung function (2). New symptom-based therapies under development will continue to allow CF healthcare providers and patients to choose from diverse and effective treatment options for many years to come. An exciting and novel strategy to treat CF is to target the underlying cause of the disease, providing sufficient expression and activity of the cystic fibrosis transmembrane conductance regulator (CFTR) to CF-affected cells to reduce or reverse their diseaserelated phenotype. This can theoretically be accomplished by three general strategies, including (i) replacement of the disease-causing gene with a normal CFTR gene [i.e., gene transfer or gene therapy (3,4), see also chap. 24], (ii) use of small molecules to overcome the underlying cellular mechanism(s) responsible for manifestation of specific CF-causing mutations (5–15), and (iii) progenitor cell-based regeneration of the airway epithelium [i.e., stem cells (16–18)]. Small-molecule therapy is the focus of this chapter and has drawn directly from large amounts of in vitro data characterizing common and uncommon CFTR mutations. It has also benefited from powerful drug discovery technologies such as high throughput screening (HTS) of combinatorial drug libraries to identify lead compounds for further development (5,6,13,19–23). These screening programs have been coupled with elegant in vitro and in vivo model systems to test candidate compounds, including the isolation

406

Restoration of CFTR Function with Small-Molecule Modulators

407

and culture of primary human airway tissues from CF patients that faithfully recapitulate disease features (24) and the development/use of transgenic mouse models with CF disease-causing mutations (14,25–27). CF is particularly well suited for this restorative approach since the underlying genetic defect produces a recessive loss of Cl
channel activity rather than a dominant defect that disrupts normal CFTR function. Therefore, small differences in CFTR activity are sufficient to produce significant and meaningful differences in disease manifestations. As an example, comparisons of clinical outcomes between CF patients with and without pancreatic sufficiency suggest that retained pancreatic function predicts a significantly milder clinical course compared with patients with exocrine pancreatic dysfunction (28–31). Additionally, patients with “CFTR-opathies” such as congenital bilateral absence of the vas deferens, recurrent pancreatitis, pancreaticsufficient CF (caused by “mild mutations” with residual function), and pancreaticinsufficient CF (caused by “severe mutations”) demonstrate a hierarchy that relates CFTR function to organ manifestations across these different disease entities (29–32). Parallel in vitro and in vivo studies suggest that the amount of total CFTR activity necessary to convert a severe phenotype to a mild phenotype may be as little as 5% to 15% (32–35). Thus, agents that only achieve partial restoration of CFTR function may be quite clinically beneficial, particularly in the context of minimal background CFTR activity (i.e., patients with CF caused by two severe mutations).

II.

Classes of Cystic Fibrosis–Causing Mutations: Different Problems Need Different Strategies As is the case for most genetic diseases, the clinical manifestations of CF result from a number of mutations within the source gene. The absolute number of potential mutations is nearly limitless, but thankfully the mutations can often be grouped together in terms of basic causative mechanisms. While these specific groupings can appear arbitrary, the members within a mutation class share important defective features and often lend themselves to common strategies for functional restoration. Figure 1 provides a summary of the six known mutation classes in CF. These include class I (defects in biosynthesis), class II (defective protein processing), class III (regulatory defects), class IV (reduced Cl
channel conductance), class V (reduced levels of CFTR transcripts), and class VI (increased cell membrane turnover). It is apparent from this segregation that distinctly different approaches are needed to address the fundamental problems responsible for the mutations included within different classes. However, it has also become clear that many mutations are not necessarily restricted to a single class (i.e., they may manifest defects across one or more mutation classes). Furthermore, strategies that are under development for members of one mutational class may be logically applied to mutations within a separate class. Thus, the mutational class system, while helpful for general purposes of categorization, has become “muddy” and is not fully descriptive of mutation manifestations. III.

Suppression of Premature Termination Codons: Translational Readthrough Produced by Small Molecules Base pair substitutions, insertions, or deletions that create premature termination codons (PTCs) are commonly found across most genetic disorders and have been identified in

408

Hoover and Clancy

Figure 1 Mutation classes in CF—summary of cellular mechanisms underlying different CF-

associated mutations. The figure summarizes the different classes of CFTR mutations in relation to different cellular compartments and processes (far left). The cell to the left demonstrates defects that produce severe CFTR dysfunction, including class I mutations that lead to biosynthetic defects in CFTR expression [such as nonsense (i.e., G542X, R553X, R1162X, or W1282X CFTR) and frameshift mutations], class II mutations that lead to defective protein folding and maturation (including the common DF508 CFTR mutation, which is normally targeted to the proteosome for degradation), and class III mutations that disrupt normal regulation of CFTR (including G551D, G551S, and G1349D CFTR, all of which affect ATP binding and hydrolysis and subsequent CFTR Cl
channel gating). The cell to the right summarizes CFTR mutation classes that typically do not produce a severe reduction in CFTR activity, including class IV mutations that reduce single channel conductance (such as R117H, R334W, R347P, and R347H CFTR), class V mutations that depress the transcript levels of CFTR (such as 3849 þ 10 kb C ? T CFTR, wtCFTR in cis with 5T CFTR, promoter, and intron mutations that reduce transcript splicing efficiency), and class VI mutations that alter the normal membrane endosomal recycling of CFTR. These class designations are not mutually exclusive for many of the described CFTR mutations. For example, DF508 CFTR (which is typically considered a class II mutation) also demonstrates altered channel gating (class III) and reduced stability at the cell surface (class VI) when localized to the plasma membrane. The legend at the top of the figure identifies the different aspects of CFTR transcription, translation, and protein maturation. Abbreviations: TGN, trans-Golgi network, ER, endoplasmic reticulum, NMD, nonsense-mediated decay; CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator. Source: Adapted from Ref. 36.

Restoration of CFTR Function with Small-Molecule Modulators

409

over 1800 separate medical conditions (37–39). PTCs halt translation by ribosomes, resulting in the production of abnormally truncated proteins that are generally dysfunctional. In addition, genes with PTC mutations are often associated with low levels of mRNA transcripts. These mRNAs often are more rapidly degraded through a process called nonsense-mediated decay (NMD), resulting in further loss of protein activity (40). Our increased understanding of ribosomal function and the regulatory features of translation as well as the identification of small molecule interactions between the ribosome and mRNA have helped to identify agents that “suppress” PTCs. These small molecules allow the ribosomal translation machinery to occasionally “read through” a PTC resulting in translation of a measurable amount of full-length and functional protein product (39). From this basic understanding, novel CF treatment strategies to restore protein synthesis and function through PTC suppression have emerged. Aminoglycosides were the first agents demonstrated to suppress PTCs that were responsible for disease-causing mutations. Aminoglycosides possess antimicrobial activity against many gram-negative bacteria, select gram-positive bacteria, and nontuberculous mycobacteria by interfering with ribosomal translation (41). There are two major classes of aminoglycosides, discriminated by 4,5- and 4,6-disubstituted 2-deoxystreptamine residues connected to an amino sugar backbone, respectively (42). The largest group includes the 4,6-disubstituted 2-deoxystreptamine derivatives, gentamicin, tobramycin, and amikacin. These aminoglycosides interfere with normal translation via binding to the decoding site within an internal loop of the bacterial 16S rRNA (43). This reduces discrimination between cognate and near cognate tRNA-mRNA complexes, consequently reducing translational fidelity (44,45). The end result is the accumulation of dysfunctional and/or truncated bacterial proteins, which is ultimately bacteriocidal. Mammalian and bacterial ribosomes have fundamental differences in their nucleotide sequences within the segment of the small ribosomal subunit to which the aminoglycosides bind; this confers selective activity of aminoglycosides for their bacterial target (46). Despite these differences, aminoglycosides also have the capacity to bind the human 18S rRNA subunit, albeit with lower affinity. This loose interaction can reduce discrimination of near cognate tRNAs by the ribosome (47–49). While this interaction is less stable than that in bacteria, it is sufficient to occasionally disrupt the normal proofreading function of the ribosome and allow insertion of a near cognate aminoacyltRNA into the growing polypeptide chain at a PTC (39). The result is suppression of the PTC and production of a full-length protein. The first studies capitalizing on PTC suppression to restore function to a diseasecausing mutation in mammalian cells was reported by Howard and Bedwell (15,39,50). They examined the ability of geneticin (G418) to suppress PTCs in cells transiently expressing cDNAs containing the four most common disease-causing PTC or “X” mutations (G542X, R553X, R1162X, and W1282X) in the CFTR gene; these data for W1282X were later confirmed in the immortalized IB3-1 bronchiolar cell line isolated from a W1282X compound heterozygous CF patient. Additionally, gentamicin, a commonly used aminoglycoside in clinical care, was found to allow readthrough of X mutations in CFTR and lead to full-length, functional protein production. Two mouse models possessing PTCs in disease-causing genes, including the mdx mouse (a model of muscular dystrophy) and the transgenic G542X-hCFTR mouse (a model of cystic fibrosis) have been examined in preclinical in vivo studies. Suppression

410

Hoover and Clancy

of the PTC within the dystrophin gene of the mdx mouse with systemically administered gentamicin lead to increased expression of full-length dystrophin protein, improved muscle strength, and resistance to stress-induced injury (12). Similarly, gentamicin increased full-length CFTR expression and function in the gut of G542X-hCFTR mice (14). These mice, which express the human G542X CFTR cDNA under regulatory control of the intestine-specific FABP promoter on a Cftr knockout background, also had a trend toward improved survival with gentamicin treatment. Later reports confirmed these effects with clinically relevant doses of both gentamicin and amikacin in this mouse model and other model systems, with amikacin demonstrating somewhat greater efficacy (26,51). Recently reported studies in the CF and mdx mouse models have described effective translational readthrough and protein rescue with the novel stop codon suppressive agent PTC124. PTC124 was developed by PTC Therapeutics through an HTS program, and is a 1,2,4-oxadiazole benzoic acid derivative. PTC124 interacts with mammalian ribosomes in a fashion distinct from that described for aminoglycosides and has no reported antimicrobial activity (19). Systemic dosing studies demonstrated that PTC124 rescued dystrophin localization to the cell membrane of skeletal and cardiac myotubules in the mdx mouse (19). In the G542X-hCFTR mouse, enteral and intraperitoneal administration led to detectable full-length CFTR at the apical cell membrane of gut glandular cells by immunohistochemical staining, and improved CFTR activity to approximately 20% to 30% of that seen in wild-type (wt) mice (14,27). These findings suggest that significant clinical benefits of this strategy may be recognized with partial restoration of protein function, thus potentially attenuating the most severe clinical manifestations of CF (32). Translational studies and clinical trials of PTC suppressors have tested both proof of principle and explored efficacy. Many, but not all of these studies have demonstrated biologic activity in humans, which has raised important questions regarding factors that influence individual responses. Wilschanski and colleagues in Israel initially reported that topical gentamicin applied to the nasal mucosa of CF patients with PTCs (most of whom possessed W1282X CFTR, which is highly prevalent in Ashkenazi Jews) improved CFTR activity and membrane localization as assayed by the nasal potential difference (NPD) (see chap. 8) (52). These effects were confirmed in a follow-up study, and were not seen in CF patients homozygous for the DF508 CFTR mutation (11). Improvements in CFTR activity were not seen universally across treated patients, and subsequent studies demonstrated that responders had measurably higher CFTR transcript levels relative to nonresponding study subjects (53). Sermet and colleagues confirmed these data in CF subjects (8 out of 9 subjects were homozygous for the Y122X mutation) using systemic gentamicin, demonstrating improvements in NPD measurements (and reduction in sweat chloride values). Their work also provided a hierarchy for response based on the specific PTC possessed by study subjects (54). A larger multicenter trial of topical (nasal) gentamicin and tobramycin across a more genetically diverse CF population (with several different PTCs in CFTR represented) did not, however, demonstrate improvements in the NPD (55). A number of potential reasons for these discrepant results have been postulated, such as variable activity of gentamicin to suppress different PTCs in CFTR, variability of the NPD outcome measure when used in multicenter trials, and potentially different NMD rates across the study populations. In contrast, a recent open label clinical trial of oral PTC124

Restoration of CFTR Function with Small-Molecule Modulators

411

in CF patients possessing a number of different PTCs reported improvements in CFTR activity while on study drug (56). A summary of CF clinical trials investigating suppression of PTCs is provided in Table 1. Despite these inconsistencies in biologic efficacy across clinical studies, suppression of PTCs is emerging as an exciting strategy to treat CF and a number of different genetic disorders. This approach is built on a growing foundation of work examining basic mechanisms of PTC suppression and exploring suppressive activities of aminoglycosides and novel agents in the laboratory and the clinic. These studies have helped to define important additional questions, including what factors underlie variable results across different studies. Also highlighted is the need to establish and/or refine standardized CFTR biomarkers that are sensitive and specific for translational readthrough, including CFTR activity (NPD, sweat Cl
) and expression (quantification of CFTR transcripts and detection of mature, full-length protein). This will ensure that multicenter studies will provide fully interpretable data when there is a paucity of patients possessing these mutations (58).

Restoring Function to DF508 CFTR: Correction, Activation, and Stabilization Deletion of phenylalanine from position 508 of CFTR (DF508 CFTR) is the most common mutation that causes cystic fibrosis (1,36, 59–61). DF508 CFTR is found in approximately 70% of CF-causing chromosomes and at least one copy is found in nearly 90% of CF patients. Because of its severe dysfunction and high prevalence, it is the most logical target for restorative strategies. During the normal maturation of CFTR, the nascent protein goes through a series of folding and glycosylation steps as it traverses the cell’s protein production machinery and traffics to the apical epithelial membrane (59). Immature CFTR has core glycosylation, which is demonstrated biochemically as an approximately 140 to 150 kDa protein (“A band” CFTR). Later steps in maturation lead to N-glycosylation of distinct amino acids in extracellular loop 4 producing “B band” and finally fully mature “C band” CFTR (with molecular weights of *165 and 180 kDa, respectively). In contrast, DF508 CFTR is a temperature-sensitive mutation (62); at 378C, DF508 CFTR accumulates in the immature B band form and produces minimal (if any) C band CFTR and is degraded by the 26S proteosome (59,63,64). Reductions of the growth temperature lead to the appearance of fully mature C band DF508 CFTR. Chemical agents that allow DF508 CFTR to mature to the C band form are termed DF508 CFTR correctors. This refers to the belief that they correct the folding and trafficking defect inherent to the mutant protein and lead to increased amounts of mature DF508 CFTR at the cell membrane. These “corrective” agents may act directly on DF508 CFTR to normalize folding, on protein binding partners to encourage correct folding or ignore incorrect folding, or potentiate effects that block DF508 CFTR degradation. It is also possible that these agents could have effects on other aspects of CFTR biology and metabolism (such as plasma membrane stability, recycling, etc.). In the absence of structural information regarding CFTR, initial corrective strategies were nonspecific and included correction by growth in low-temperature or smallmolecule osmolytes such as glycerol (62,65). With more recent data suggesting that DF508 is found on an external surface of the nucleotide-binding domain (NBD)-1, and is IV.

412

Hoover and Clancy

Table 1 CF Clinical Trials of PTC Suppression

Reference Trial design 52

Open label

Study subjects CF

Results l

l

11 with PTC l

11

57

PlaceboCF: l controlled l and blinded

Open label

l l

l

Improvements in CFTR activity by NPD (Cl
and Naþ transport) and immunofluorescence while on topical nasal gentamicin

l

NPD effects specific for PTC group

l

Majority of patients with W1282X

l

Improvements in CFTR activity by NPD (Cl
transport) while on topical nasal gentamicin

l

NPD effects specific for PTC group

l

Ex vivo gentamicin dose/response effects (improved CFTR trafficking and function) in primary nasal airway cells from PTC patients 3 different PTC mutations represented

19 with PTC 5 DF508/DF508

CF: 5 with PTC 5 without PTC 5 non-CF

l

54

Open label

CF: l

l

9 with PTC l

55

56

Double crossover, double blinded

CF:

Open label, dose ascending

CF:

l l

Hierarchy of treatment effect across mutations shown

l

No improvements seen in CFTR activity by NPD during treatment with either gentamicin or tobramycin 6 different PTC mutations represented across 5 study sites

11 with PTC 18 without PTC

l

l

23 with PTC (part I) 21 with PTC (from part I, included in II)

Improvements in CFTR activity by NPD (Cl
transport) and sweat Cl
while receiving gentamicin All subjects with Y122X

l

l

l

Improvements in CFTR activity by NPD while on topical nasal gentamicin Majority of patients with W1282X

l l l

Improvements in CFTR activity by NPD (Cl
transport) during treatment No clear dose/response No effect on sweat Cl
3 PTC mutations represented

Abbreviations: CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; NPD, nasal potential difference; PTC, premature termination codons.

Restoration of CFTR Function with Small-Molecule Modulators

413

believed to interrupt normal interactions between the cytoplasmic loops of membrane spanning domains with the NBD motifs, corrector development strategies based on detailed structural information are becoming possible (59,66,67). This approach is attractive as it targets the underlying defects in DF508 CFTR, and is perhaps less likely to have off-target effects. The first clinical study to demonstrate evidence of DF508 CFTR correction was published by Rubenstein and Zeitlin (68). In their study, they applied basic laboratory observations made about butyrate compounds to correct DF508 CFTR (69) developing and executing a proof of principle trial of an approved oral butyrate compound (4phenylbutyrate or 4-PBA) in DF508 CFTR homozygous CF patients. Their results indicated that CF patients treated with 4-PBA had detectable improvements in CFTR activity by the NPD relative to placebo-treated controls. While the study was not designed to address clinical outcome measures beyond safety, it provided important proof of concept information and also provided support for the concept that small molecules could overcome CFTR defects and that an in vivo biomarker of CFTR activity (NPD) was capable of detecting biologic activity of DF508 CFTR corrective agents. A separate multicenter study of a different putative DF508 CFTR-activating compound (8-cyclopentyl-1,3-dipropylxanthine or CPX) was published by McCarty and colleagues (70,71). This study was also derived from investigator-initiated, laboratorybased observations (72–76). While the study did not detect biologic effects of CPX, it did provide important information about the challenges and complexities of using CFTR biomarkers in multicenter clinical trials. Another approach to identifying agents that promote increased levels of DF508 CFTR at the cell membrane is to apply therapies developed for non-CF uses to CF building off described drug effects that may overlap with the cellular pathology characteristic of cells that express DF508 CFTR. Bortezomib (Velcade1) is a known proteosome inhibitor developed for the treatment of multiple myeloma and other cancers. In vitro studies have suggested that this may be a means to increase the cell membrane levels of DF508 CFTR by inhibiting its degradation and altering its interactions with binding partners in the protein-folding pathway (77). Other approved pharmacologic agents developed for non-CF clinical uses that correct DF508 CFTR activity include sildenafil [a phosphodiesterase (PDE)5 inhibitor] and miglustat (Zavesca or Nbutyldeoxynojirimycin, a treatment for Gaucher’s disease) (78–83). This “low-hanging fruit” approach is attractive as the agents have well-described dosing ranges and toxicity profiles in humans. CF-specific clinical trials of these approved agents require assessment of pharmacokinetics (due to the frequently altered drug absorption and metabolism seen in CF patients) and careful consideration of CFTR biomarkers to detect biologic effects. Finally, certain nutritional supplements may have DF508 CFTR corrective activity. One recent example of this is curcumin, a spice that binds to SERCA pumps (sarcoplasmic/endoplasmic reticulum calcium) in the ER and lowers intra-ER calcium levels. Since calcium is a common and necessary cofactor for a number of chaperone proteins within the ER that regulate protein maturation, Egan and colleagues examined whether curcumin had effects on DF508 CFTR maturation and activity in cell lines and in transgenic DF508 CFTR mice (84). Their results indicated that curcumin rescued DF508 CFTR activity in vitro and in vivo, with evidence of improved survival of mice possessing the DF508 CFTR mutation with curcumin treatment. While subsequent

414

Hoover and Clancy

studies have demonstrated that curcumin is capable of activating cell membrane CFTR, other laboratories were not able to replicate the corrective effects of curcumin in CF mice, perhaps due to differences in the mouse models used or other unidentified factors (85–89). Nevertheless, the positive results lead to dose ranging and proof-of-concept clinical trials of curcumin in DF508 homozygous CF patients. Preliminary reports suggested that there may be some detectable bioactivity based on secondary NPD analysis. These findings were difficult to rectify, however, due to minimally detectable levels of curcumin in the CF patients and the variability of NPD responses (90). Whether these inconsistencies could represent the effect of curcumin metabolites or other curcumin isoforms found in the curcumin preparations is currently unknown, and poses a barrier when bringing nutritional supplements to CF clinical trials. Further preclinical studies are likely necessary to address these questions before additional clinical trials will be conducted in CF patients. Programs designed to identify novel small-molecule “correctors” of DF508 CFTR were initiated nearly 10 years ago. These programs used sensitive and specific fluorescent readouts in living cultured cells to allow HTS of large compound libraries. Primary hits were typically confirmed in vitro, and a process of compound optimization followed. This work has lead to the identification of a number of novel CFTR-active compounds including putative CFTR correctors, potentiators (discussed in later sections of this chapter), and blockers (5,10,20,21,24,91). While the primary defect in DF508 CFTR is due to misfolding and mistrafficking, additional defects have been described in DF508 CFTR following its localization to the cell membrane including defective channel gating. DF508 CFTR’s open probability has been reported to be less than 0.10 by Hwang and colleagues, compared with nearly 0.50 for wtCFTR following activation by ATP and protein kinase A (92,93). This low singlechannel open probability remains present after low-temperature correction (89,94). These single-channel defects manifest as reduced Cl
conductance across DF508 CFTR-expressing airway cell monolayers following low-temperature correction (95). Full DF508 CFTR activation typically requires stimulation with a cAMP-independent CFTR activator in vitro (such as the flavonoid genistein, 50 mM), and suggests that the vast majority of DF508 CFTR activity may not be detectable by standard CFTRactivating maneuvers. These results have relevance, as they suggest that current CFTR biomarkers (NPD) used in clinical trials of DF508 CFTR correctors may be insensitive to detect DF508 CFTR at the cell membrane (58,96,97). DF508 CFTR also has a reduced cell membrane half-life relative to wtCFTR (98). This may result from accelerated endocytosis and shuttling of DF508 CFTR to the endosomal compartment rather than reduced recycling back to the cell membrane. Interestingly, a report by Varga demonstrated that a chemical corrector of DF508 CFTR improved the cell membrane stability of DF508 CFTR after correction by low temperature (99). These results suggest that corrective agents may be able to improve DF508 CFTR function beyond its well-described maturation defect. The results of studies examining correction of DF508 CFTR, its activity at the cell membrane, and the mutant proteins’ membrane stability after correction collectively provide strong support to explore treatment strategies that address the DF508 CFTR defects in maturation, activation, and stabilization. While the amount of CFTR activity that is necessary to improve clinical parameters in CF patients may be relatively low, it

Restoration of CFTR Function with Small-Molecule Modulators

415

seems unlikely that DF508 CFTR correctors alone will achieve non-CF functional levels. Thus, maximizing the activity of corrected DF508 CFTR will likely be necessary for full clinical benefit. Whether this can be accomplished by single agents or will require combinational therapies is unknown.

V. Potentiation of Mutant CFTR at the Cell Membrane: Primary and Supplemental Strategic Targets The final class of defects in mutant CFTR activity can broadly be described as defects in CFTR when the protein is present at the cell membrane. There are several different potential mechanisms that could account for this phenotype, including defects in CFTR regulation (e.g., G551D, G551S, and G1349D CFTR), defects in CFTR conductance (e. g., R117H, R334W, R347P, and R347H CFTR), defects in CFTR splicing and/or promoter regulation that lead to reduced amounts of CFTR mRNA transcripts (e.g., 3849 + 10 kb C ? T CFTR, wtCFTR in cis with 5T) (see chap. 1), and mutations that reduce the stability or half-life of CFTR at the cell membrane. As the number of CF patients who carry mutations that fall into each of these different classes is limited, it is not feasible to develop independent strategies that are specific for each mutation described. Thus, most approaches to “potentiate” the activity of mutant CFTR at the cell membrane have considered these defects collectively, in addition to secondary defects in CFTR activity that may become manifest following treatment of an underlying primary defect (e.g., the resultant CFTR molecules that are produced following suppression of PTCs, or the activity of DF508 CFTR following correction of its maturation defect). Whether potentiating strategies can be applied across the described surface localizing CFTR mutations is unknown and should be considered in the process of drug development and testing. Two classes of molecules were initially shown to potentiate the activity of mutant CFTR at the cell membrane. First, high concentrations of xanthine-based PDE inhibitors (e.g., IBMX) increased the chloride conductance of G551D CFTR and temperaturecorrected DF508 CFTR (100,101). The concentrations necessary for this potentiating effect (>1 mM) were not feasible for clinical investigation, and this effect on surfacelocalized mutant CFTR is not clearly related to its PDE inhibitory effect. A series of studies by Drumm and colleagues subsequently reported that milrinone, a nonxanthinebased PDE3 inhibitor was capable of activating DF508 CFTR in human airway cells and in transgenic CF mice (102–104). A follow-up NPD-based study of topical milrinone in human subjects demonstrated that it was sufficient to activate wtCFTR-dependent chloride conductance in non-CF subjects, but it had no detectable effect on chloride conductance in CF subjects possessing the G551D CFTR or two copies of the DF508 CFTR mutation (105). The second type of agent capable of potentiating CFTR activity includes flavonoids, a class of molecules that are commonly found in a variety of fruits and vegetables. Several members of this class can activate CFTR, with genistein demonstrating the most consistent activating effects on wt and mutant CFTRs (including G551D CFTR and DF508 CFTR at the cell membrane). The mechanism of activation appears to be independent of cAMP and R domain phosphorylation, and may involve direct interactions with the NBDs (92,93). NPD studies of topical flavonoids in non-CF and CF patients have been reported by Illek and colleagues, in which genistein (and another

416

Hoover and Clancy

flavonoid—quercetin) were shown to activate wt and G551D CFTR-dependent Cl
transport when applied topically to the nasal mucosa (106). As expected, this agent was unable to activate Cl
transport in CF subjects homozygous for the DF508 CFTR mutation. In parallel to HTS programs designed to identify agents that correct DF508 CFTR processing, screening programs have identified novel compounds that potentiate wt and/ or mutant CFTR activity at the cell membrane (6,23). The mechanisms of action for many of these compounds are not fully described, but some, like genistein, appear to act independently of CFTR phosphorylation. The most logical initial target for examining potentiating compounds in human subjects is G551D CFTR; the second most common mutation that causes CF. The G551D mutation severely disrupts gating of the CFTR chloride channel. The processing and membrane stability of G551D CFTR, however, is normal, and thus it represents an available target for testing CFTR potentiating compounds. One agent under development by Vertex Pharmaceuticals (Cambridge, Massachusetts, U.S.), VX-770, has entered dose ranging and safety clinical trials in CF patients. These studies are forced to enroll a limited number of study subjects due to the relatively low number of CF patients that possess the mutation (estimated at less than 5% of the CF population). A phase IIA study of oral VX-770 in CF patients possessing at least one copy of the G551D CFTR mutation suggested that there were dosedependent improvements in CFTR activity (as assessed by sweat chloride and NPD) during two and four weeks of treatment. These improvements were sufficient to fall outside of the CF range for a number of the study subjects. The improvements in CFTR biomarker measures were accompanied by improvements in lung function (FEV1) and trending improvements in patient-reported outcomes (PROs), and together provide strong proof of principle to support the development of new therapeutics that target mutant CFTR (www.clinicaltrials.gov—NCT00457821) (107). The number of CF patients who might benefit from potentiator monotherapy is unknown but may be quite sizeable, with estimates as high as 30% of CF patients. These potential patients would include those with well-described, surface-localizing CFTR mutations that fall into classes III to VI (which cumulatively include *15–20% of CF patients). In addition, investigators have provided evidence that activity of DF508 CFTR can be detected by NPD and/or by ex vivo intestinal current measurements in rectal biopsy tissue from a subgroup of CF patients who are homozygous for the DF508 CFTR mutation (108–110). Standardization of CFTR biomarkers (such as sweat chloride and NPD performance) and the development of new sensitive biomarkers (such as protein biochemistry and functional assessment of rectal biopsy tissue) are warranted as these drugs-in-development progress from patients with clear targets (e.g., patients possessing G551D CFTR) to patient populations that may have variable or low amounts of mutant CFTR at the cell membrane (e.g., subsets of patients who are homozygous for the DF508 CFTR mutation, or CF patients possessing rare, poorly characterized CFTR mutations predicted to have mutant CFTR protein at the cell membrane). It is also easy to envision that future studies will combine potentiators of CFTR with agents that address other primary defects in CFTR (e.g., combinations with drugs that suppress PTCs and/or drugs that correct mutant CFTR processing). The potential complexity of studying these patients and interpreting CFTR biomarker readouts is clear, as variable and unpredictable responsiveness appears likely. These upcoming challenges provide further support to efforts directed at executing standardized clinical

Restoration of CFTR Function with Small-Molecule Modulators

417

research methodology across study institutions. Standardization of these methodologies will be crucial to ensure that appropriate CF subpopulations gain rapid access to these exciting agents, and to allow clear interpretation of studies that combine agents directed at primary and secondary CFTR defects.

VI.

Conclusions

As our understanding of the mechanisms underlying how CF-associated mutations produce disease increases, we are entering a time in which treatment strategies that address the underlying cause of CF are on the horizon. Restoration of CFTR function through the use of drugs designed to overcome mutational barriers has entered clinical trials, and several of the trials have provided important results that demonstrate that CFTR is a logical and feasible target for drug development. These advances are the direct result of a firm understanding of CFTR pathology and provide CF patients and healthcare providers real hope for fundamental changes in how CF is treated and what we can expect from our interventions.

References 1. Rowe SM, Clancy JP. Advances in cystic fibrosis therapies. Curr Opin Pediatr 2006; 18(6):604–613. 2. Flume PA, O’Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176(10):957–969. 3. Griesenbach U, Geddes DM, Alton EW. Gene therapy progress and prospects: cystic fibrosis. Gene Ther 2006; 13(14):1061–1067. 4. Ziady AG, Davis PB. Current prospects for gene therapy of cystic fibrosis. Curr Opin Pharmacol 2006; 6(5):515–521. 5. Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective DeltaF508CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005; 115(9): 2564–2571. 6. Yang H, Shelat AA, Guy RK, et al. Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. J Biol Chem 2003; 278(37): 35079–35085. 7. Norez C, Antigny F, Noel S, et al. A CF respiratory epithelial cell chronically treated by miglustat acquires a non-CF like phenotype. Am J Respir Cell Mol Biol 2009; 41(2): 217–225. 8. Robert R, Carlile GW, Pavel C, et al. Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol Pharmacol 2008; 73(2):478–489. 9. Wang Y, Bartlett MC, Loo TW, et al. Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones. Mol Pharmacol 2006; 70(1):297–302. 10. Yu GJ, Yoo CL, Yang B, et al. Potent s-cis-locked bithiazole correctors of DeltaF508 cystic fibrosis transmembrane conductance regulator cellular processing for cystic fibrosis therapy. J Med Chem 2008; 51(19):6044–6054. 11. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003; 349(15):1433–1441. 12. Barton-Davis ER, Cordier L, Shoturma DI, et al. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999; 104(4):375–381.

418

Hoover and Clancy

13. Hirawat S, Welch EM, Elfring GL, et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 2007; 47(4):430–444. 14. Du M, Jones JR, Lanier J, et al. Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene. J Mol Med 2002; 80(9): 595–604. 15. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996; 2(4):467–469. 16. Weiss DJ. Stem cells and cell therapies for cystic fibrosis and other lung diseases. Pulm Pharmacol Ther 2008; 21(4):588–594. 17. Conese M, Rejman J. Stem cells and cystic fibrosis. J Cyst Fibros 2006; 5(3):141–143. 18. Weiss DJ, Berberich MA, Borok Z, et al. Adult stem cells, lung biology, and lung disease. NHLBI/Cystic Fibrosis Foundation Workshop. Proc Am Thorac Soc 2006; 3(3):193–207. 19. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447(7140):87–91. 20. Galietta LJ, Springsteel MF, Eda M, et al. Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. J Biol Chem 2001; 276(23):19723–19728. 21. Galietta LV, Jayaraman S, Verkman AS. Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists. Am J Physiol Cell Physiol 2001; 281(5): C1734–C1742. 22. Gill S, Gill R, Lee SS, et al. Flux assays in high throughput screening of ion channels in drug discovery. Assay Drug Dev Technol 2003; 1(5):709–717. 23. Ma T, Vetrivel L, Yang H, et al. High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening. J Biol Chem 2002; 277(40):37235–37241. 24. Van Goor F, Straley KS, Cao D, et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006; 290(6):L1117–L1130. 25. Du M, Keeling KM, Fan L, et al. Poly-L-aspartic acid enhances and prolongs gentamicinmediated suppression of the CFTR-G542X mutation in a cystic fibrosis mouse model. J Biol Chem 2009; 284(11):6885–6892. 26. Du M, Keeling KM, Fan L, et al. Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model. J Mol Med 2006; 84(7):573–582. 27. Du M, Liu X, Welch EM, et al. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci U S A 2008; 105(6):2064–2069. 28. Kerem E, Kerem B. Genotype-phenotype correlations in cystic fibrosis. Pediatr Pulmonol 1996; 22(6):387–395. 29. Goubeau C, Wilschanski M, Skalicka V, et al. Phenotypic characterization of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis. Thorax 2009; 64(8):683–691. 30. Wilschanski M. Patterns of gastrointestinal disease associated with mutations of CFTR. Curr Gastroenterol Rep 2008; 10(3):316–323. 31. Cohn JA, Noone PG, Jowell PS. Idiopathic pancreatitis related to CFTR: complex inheritance and identification of a modifier gene. J Investig Med 2002; 50(5):247S–255S. 32. Wilschanski M, Dupuis A, Ellis L, et al. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med 2006; 174(7):787–794.

Restoration of CFTR Function with Small-Molecule Modulators

419

33. Ramalho AS, Beck S, Meyer M, et al. Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis. Am J Respir Cell Mol Biol 2002; 27(5):619–627. 34. Johnson LG, Olsen JC, Sarkadi B, et al. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 1992; 2(1):21–25. 35. Jaron R, Yaakov Y, Rivlin J, et al. Nasal potential difference in non-classic cystic fibrosislong term follow up. Pediatr Pulmonol 2008; 43(6):545–549. 36. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352(19):1992–2001. 37. Kellermayer R. Translational readthrough induction of pathogenic nonsense mutations. Eur J Med Genet 2006; 49(6):445–450. 38. Krawczak M, Ball EV, Fenton I, et al. Human gene mutation database-a biomedical information and research resource. Hum Mutat 2000; 15(1):45–51. 39. Linde L, Kerem B. Introducing sense into nonsense in treatments of human genetic diseases. Trends Genet 2008; 24(11):552–563. 40. Khajavi M, Inoue K, Lupski JR. Nonsense-mediated mRNA decay modulates clinical outcome of genetic disease. Eur J Hum Genet 2006; 14(10):1074–1081. 41. Hermann T. Aminoglycoside antibiotics: old drugs and new therapeutic approaches. Cell Mol Life Sci 2007; 64(14):1841–1852. 42. Hermann T. Drugs targeting the ribosome. Curr Opin Struct Biol 2005; 15(3):355–366. 43. Moazed D, Noller HF. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature 1987; 327(6121):389–394. 44. Ogle JM, Ramakrishnan V. Structural insights into translational fidelity. Annu Rev Biochem 2005; 74:129–177. 45. Shandrick S, Zhao Q, Han Q, et al. Monitoring molecular recognition of the ribosomal decoding site. Angew Chem Int Ed Engl 2004; 43(24):3177–3182. 46. Francois B, Russell RJ, Murray JB, et al. Crystal structures of complexes between aminoglycosides and decoding A site oligonucleotides: role of the number of rings and positive charges in the specific binding leading to miscoding. Nucleic Acids Res 2005; 33(17): 5677–5690. 47. Kondo J, Francois B, Urzhumtsev A, et al. Crystal structure of the Homo sapiens cytoplasmic ribosomal decoding site complexed with apramycin. Angew Chem Int Ed Engl 2006; 45(20):3310–3314. 48. Kondo J, Urzhumtsev A, Westhof E. Two conformational states in the crystal structure of the Homo sapiens cytoplasmic ribosomal decoding A site. Nucleic Acids Res 2006; 34(2):676–685. 49. Hermann T, Tereshko V, Skripkin E, et al. Apramycin recognition by the human ribosomal decoding site. Blood Cells Mol Dis 2007; 38(3):193–198. 50. Bedwell DM, Kaenjak A, Benos DJ, et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 1997; 3(11):1280–1284. 51. Keeling KM, Bedwell DM. Clinically relevant aminoglycosides can suppress diseaseassociated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J Mol Med 2002; 80(6):367–376. 52. Wilschanski M, Famini C, Blau H, et al. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 2000; 161(3 pt 1):860–865. 53. Linde L, Boelz S, Nissim-Rafinia M, et al. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest 2007; 117(3):683–692. 54. Sermet-Gaudelus I, Renouil M, Fajac A, et al. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med 2007; 5:5.

420

Hoover and Clancy

55. Clancy JP, Rowe SM, Bebok Z, et al. No detectable improvements in CFTR by nasal aminoglycosides in CF patients with stop mutations. Am J Respir Cell Mol Biol 2007; 37(1):57–66. 56. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008; 372(9640):719–727. 57. Clancy JP, Bebok Z, Ruiz F, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001; 163(7): 1683–1692. 58. Rowe SM, Accurso F, Clancy JP. Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc Am Thorac Soc 2007; 4(4):387–398. 59. Riordan JR. CFTR function and prospects for therapy. Annu Rev Biochem 2008; 77: 701–726. 60. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245(4922):1066–1073. Erratum in: Science 1989; 245(4925):1437. 61. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245(4922):1073–1080. 62. Denning GM, Anderson MP, Amara JF, et al. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992; 358(6389): 761–764. 63. Ward CL, Kopito RR. Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. J Biol Chem 1994; 269(41):25710–25718. 64. Ward CL, Omura S, Kopito RR. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 1995; 83(1):121–127. 65. Sato S, Ward CL, Krouse ME, et al. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem 1996; 271(2):635–638. 66. Awayn NH, Rosenberg MF, Kamis AB, et al. Crystallographic and single-particle analyses of native and nucleotide-bound forms of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Biochem Soc Trans 2005; 33(pt 5):996–999. 67. Rosenberg MF, Kamis AB, Aleksandrov LA, et al. Purification and crystallization of the cystic fibrosis transmembrane conductance regulator (CFTR). J Biol Chem 2004; 279(37):39051–39057. 68. Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998; 157(2):484–490. 69. Rubenstein RC, Egan ME, Zeitlin PL. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 1997; 100(10):2457–2465. 70. McCarty NA, Standaert TA, Teresi M, et al. A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis. Pediatr Pulmonol 2002; 33(2):90–98. 71. Ahrens RC, Standaert TA, Launspach J, et al. Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis. Pediatr Pulmonol 2002; 33(2):142–150. 72. Arispe N, Ma J, Jacobson KA, et al. Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX). J Biol Chem 1998; 273(10):5727–5734. 73. Cohen BE, Lee G, Jacobson KA, et al. 8-cyclopentyl-1,3-dipropylxanthine and other xanthines differentially bind to the wild-type and delta F508 first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator. Biochemistry 1997; 36(21):6455–6461.

Restoration of CFTR Function with Small-Molecule Modulators

421

74. Guay-Broder C, Jacobson KA, Barnoy S, et al. A1 receptor antagonist 8-cyclopentyl-1,3dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator delta F508 mutation. Biochemistry 1995; 34(28):9079–9087. 75. Casavola V, Turner RJ, Guay-Broder C, et al. CPX, a selective A1-adenosine-receptor antagonist, regulates intracellular pH in cystic fibrosis cells. Am J Physiol 1995; 269(1 pt 1):C226–C233. 76. Eidelman O, Guay-Broder C, van Galen PJ, et al. A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells. Proc Natl Acad Sci U S A 1992; 89(12): 5562–5566. 77. Vij N, Fang S, Zeitlin PL. Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications. J Biol Chem 2006; 281(25):17369–17378. 78. Lubamba B, Lecourt H, Lebacq J, et al. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med 2008; 177(5): 506–515. 79. Antoniu SA. PDE5 inhibitors for cystic fibrosis: can they also enhance chloride transport? Evaluation of: Lubamba B, Lecourt H, Lebacq J, et al. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med 2008; 177(5):506–515. Expert Opin Investig Drugs 2008; 17(6):965–968. 80. Dormer RL, Harris CM, Clark Z, et al. Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax 2005; 60(1): 55–59. 81. Lubamba B, Lebacq J, Lebecque P, et al. Airway delivery of low dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice. Am J Respir Crit Care Med 2009; 179(11):1022–1028. 82. Noel S, Wilke M, Bot AG, et al. Parallel improvement of sodium and chloride transport defects by miglustat (n-butyldeoxynojyrimicin) in cystic fibrosis epithelial cells. J Pharmacol Exp Ther 2008; 325(3):1016–1023. 83. Norez C, Noel S, Wilke M, et al. Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Lett 2006; 580(8):2081–2086. 84. Egan ME, Pearson M, Weiner SA, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004; 304(5670):600–602. 85. Song Y, Sonawane ND, Salinas D, et al. Evidence against the rescue of defective DeltaF508-CFTR cellular processing by curcumin in cell culture and mouse models. J Biol Chem 2004; 279(39):40629–40633. 86. Dragomir A, Bjorstad J, Hjelte L, et al. Curcumin does not stimulate cAMP-mediated chloride transport in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun 2004; 322(2):447–451. 87. Berger AL, Randak CO, Ostedgaard LS, et al. Curcumin stimulates cystic fibrosis transmembrane conductance regulator Cl
channel activity. J Biol Chem 2005; 280(7): 5221–5226. 88. Loo TW, Bartlett MC, Clarke DM. Thapsigargin or curcumin does not promote maturation of processing mutants of the ABC transporters, CFTR, and P-glycoprotein. Biochem Biophys Res Commun 2004; 325(2):580–585. 89. Wang W, Bernard K, Li G, et al. Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains. J Biol Chem 2007; 282(7):4533–4544. 90. Goss CH, Genatossio A, Rowbotham R, et al. A phase I safety and dose finding study of orally adminstered curcuminoids in adult subjects with cystic fibrosis who are homozygous

422

91.

92.

93. 94. 95.

96. 97.

98.

99.

100. 101.

102.

103.

104.

105. 106.

107.

108.

Hoover and Clancy for delta F508 cystic fibrosis transmembrane conductance regulator. Pediatr Pulmonol 2006; 293(suppl 29):A247. Caci E, Folli C, Zegarra-Moran O, et al. CFTR activation in human bronchial epithelial cells by novel benzoflavone and benzimidazolone compounds. Am J Physiol Lung Cell Mol Physiol 2003; 285(1):L180–L188. Wang F, Zeltwanger S, Yang IC, et al. Actions of genistein on cystic fibrosis transmembrane conductance regulator channel gating. Evidence for two binding sites with opposite effects. J Gen Physiol 1998; 111(3):477–490. Hwang TC, Wang F, Yang IC, et al. Genistein potentiates wild-type and delta F508-CFTR channel activity. Am J Physiol 1997; 273(3 pt 1):C988–C998. Wang W, Li G, Clancy JP, et al. Activating cystic fibrosis transmembrane conductance regulator channels with pore blocker analogs. J Biol Chem 2005; 280(25):23622–23630. Bebok Z, Collawn J, Wakefield J, et al. Failure of cAMP agonists to activate rescued {Delta}F508 CFTR in CFBE41o- airway epithelial monolayers. J Physiol 2005; 569(pt 2):601–615. Schuler D, Sermet-Gaudelus I, Wilschanski M, et al. Basic protocol for transepithelial nasal potential difference measurements. J Cyst Fibros 2004; 3(suppl 2):151–155. Knowles MR, Paradiso AM, Boucher RC. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1995; 6(4):445–455. Swiatecka-Urban A, Brown A, Moreau-Marquis S, et al. The short apical membrane halflife of rescued uF508-CFTR results from accelerated endocytosis uF508-CFTR in polarized human airway epithelial cells. J Biol Chem 2005; 280(44):36762–36772. Varga K, Goldstein RF, Jurkuvenaite A, et al. Enhanced cell-surface stability of rescued DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones. Biochem J 2008; 410(3):555–564. Yang Y, Devor DC, Engelhardt JF, et al. Molecular basis of defective anion transport in L cells expressing recombinant forms of CFTR. Hum Mol Genet 1993; 2(8):1253–1261. Al-Nakkash L, Hwang TC. Activation of wild-type and deltaF508-CFTR by phosphodiesterase inhibitors through cAMP-dependent and -independent mechanisms. Pflugers Arch 1999; 437(4):553–561. Kelley TJ, Al-Nakkash L, Cotton CU, et al. Activation of endogenous DF508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition. J Clin Invest 1996; 98(2):513–520. Kelley TJ, al-Nakkash L, Drumm ML. CFTR-mediated chloride permeability is regulated by type III phosphodiesterases in airway epithelial cells. Am J Respir Cell Mol Biol 1995; 13(6):657–664. Kelley TJ, Thomas K, Milgram LJ, et al. In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant DF508 in murine nasal epithelium. Proc Natl Acad Sci U S A 1997; 94(6):2604–2608. Smith SN, Middleton PG, Chadwick S, et al. The in vivo effects of milrinone on the airways of cystic fibrosis mice and human subjects. Am J Respir Cell Mol Biol 1999; 20(1):129–134. Illek B, Zhang L, Lewis NC, et al. Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. Am J Physiol 1999; 277(4 pt 1): C833–C839. Accurso FJ, Rose SM, Durie PR, et al. Interim results of phase 2A study of VX-770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatr Pulmonol 2008; 295(31):A267. Bronsveld I, Mekus F, Bijman J, et al. Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings. J Clin Invest 2001; 108(11):1705–1715.

Restoration of CFTR Function with Small-Molecule Modulators

423

109. Bronsveld I, Mekus F, Bijman J, et al. Residual chloride secretion in intestinal tissue of deltaF508 homozygous twins and siblings with cystic fibrosis. The European CF Twin and Sibling Study Consortium. Gastroenterology 2000; 119(1):32–40. 110. Leal T, Fajac I, Wallace HL, et al. Airway ion transport impacts on disease presentation and severity in cystic fibrosis. Clin Biochem 2008; 41(10–11):764–772.

26 Quality Improvement in Cystic Fibrosis Care MICHAEL S. SCHECHTER Emory University and Children’s Healthcare of Atlanta, Atlanta, Georgia, U.S.A.

I.

Introduction

Quality improvement (QI) efforts and the evolution of expectations regarding cystic fibrosis (CF) care that has occurred in the last decade are best understood in the context of the overall health care delivery system. Wide variations in the processes and outcomes of care among patients being treated for the same health care problems in different locations and health care settings was first noted by Wennberg and Gittelsohn in the mid-1970s (1). This phenomenon was initially of interest to health economists, who focused on the magnitude of variations in health care expenditures across delivery sites, but it soon became clear that this variation in practice led to differences in patient outcomes. While some variation in an activity as complex as medical practice is inevitable, there is a challenge and opportunity to identify the variations that produce better outcomes. From this standpoint, failure to learn from the variation would be a far more serious indictment of the profession than the variation itself (2). The Institute for Health Care Improvement (IHI) was founded in 1991 on the premise that the theory and methods used to manage quality in industry might hold the same promise for health care. In 1999, the Institute of Medicine (IOM) published To Err is Human (3), which contended that tens of thousands of patients die each year from medical errors. This was followed in 2001 by the landmark IOM monograph entitled Crossing the Quality Chasm, which identified problems in the system of health care delivery rather than deficiencies in individual physicians’ practice as the major impediment to attaining quality health care for all Americans. The IOM noted that “[we have] a health care system that frequently falls short in its ability to translate knowledge into practice” and concluded famously that “between the health care we have and the care we could have lies not just a gap, but a chasm (4).”

II.

The Pivotal Role of the Cystic Fibrosis Foundation

Most of the medical care for people with CF in the United States is provided by centers accredited by the Cystic Fibrosis Foundation (CFF), and the evolution of thinking about CF outcomes and care has occurred largely due to the CFFs efforts. A commitment to high-quality care was an important component of the aims of the CFF at its founding in the mid-1950s, leading to the creation of the care center network (5). Currently, there are over 115 CF care centers and 50 affiliate programs in the United States. CFF accreditation requires an on-site evaluation to ensure the presence of a multidisciplinary

424

Quality Improvement in Cystic Fibrosis Care

425

provider team, as well as adequacy of microbiologic testing techniques, sweat chloride testing, and other care practices. As survival into adulthood has become commonplace, the CFFs advocacy for the creation of adult CF care centers to complement existing pediatric centers has resulted in the establishment of more than 90 approved adult care programs. The CFF has produced a number of clinical care guidelines since 1990 (6–9). In the last few years, a more formal and uniform process has developed, with expert panels working in association with consultants at the Johns Hopkins Evidence-Based Practice Center to produce evidence-based guidelines for chronic respiratory and nutritional management (10–12). The development of these recent guidelines includes a systematic review of the literature that synthesizes data to draw conclusions and make recommendations in a way that minimizes bias (13). However, given the limited evidence base in CF care, practice guidelines often must rely on a synthesis of a formal review of the literature with clinical expertise and experience. The CFF also supports the dissemination of knowledge regarding state-of-the-art care by organizing the annual North American CF (NACF) conference, which brings together health care providers and researchers from all disciplines to an annual assembly with strong international participation. The multidisciplinary “networking” facilitated by the NACF meeting leads to the rapid spread of innovative ideas for care; past examples include the adoption of high-fat diets in the 1970s, and of more aggressive treatment of Pseudomonas airway infection in the 1990s. These novel approaches, initially advocated by a small minority, were then rapidly adopted by the mainstream of CF care centers, as word of anecdotal successes spread among colleagues.

III.

The Role of Patient Registries

A national registry containing demographic and clinical data on patients attending accredited CF care centers in the United States was begun by Dr Warren Warwick in the mid-1960s, and was taken over by the CFF in the 1970s; its content and use have evolved over the years. The registry was initially used to generate basic descriptive data regarding the CF population, such as average age of diagnosis, survival, and airway microbiology, and in the 1990s, it began to be used increasingly for analyses by epidemiologists seeking to identify risk factors and generate hypotheses regarding disease pathogenesis. In its earliest form, the registry was used to show improvements in mortality rate among centers that had evolved a comprehensive, multidisciplinary treatment program for CF care, facilitating the spread of this approach (5), but until recently, comparisons of outcomes between care centers were de-emphasized. A second CF patient registry, the Epidemiologic Study of Cystic Fibrosis (ESCF) was begun in the mid-1990s by Genentech, Inc., as a phase IV postmarketing study of dornase alfa (Pulmozyme1). ESCF collected similar clinical data as the CFF registry from over 10,000 subjects at selected CF treatment sites in the United States and Canada (14) but also collected therapeutic data not included in the CFF registry. The “modern era” of QI in CF began in 1999 when CFF national registry reports began to show that disease outcomes such as pulmonary function and nutritional status varied considerably by care center. At about the same time, personalized reports from the ESCF that were distributed directly to CF clinicians showed how their own specific practices compared with others nationally. This approach to personalized reporting was

426

Schechter

Figure 1 Representative displays from the CFF registry report to center directors showing care processes and outcomes at CF centers. (A) Percent of children meeting recommended outpatient monitoring (four clinic visits, two assessments of pulmonary function, and one sputum culture). The upper part of the figure shows each center represented by an individual column; the average for all centers is shown by the column at the far right-hand side; the column representing the center receiving the report is shown in a contrasting color in the original. The lower part shows the five-year trend for average percentage for the entire care center network; the performance of the 10 best centers for that particular measure; the performance of the individual center receiving the report. (B) A similar display representing average FEV1 for patients ¼ 18 years of age. Abbreviations: CFF, Cystic Fibrosis Foundation; FEV1, forced expiratory volume in one second.

then adopted and refined by the CFF, which developed annual center-specific reports showing individual center performance measures within the distribution of care practices and outcomes of all accredited CF centers (Fig. 1 shows examples). In 2003, the registry moved to an Internet Web-based portal, PortCF, allowing encounter-based patient data entry and transforming the registry into an invaluable resource and tool for QI activities. CF care teams can now print out summary data about individual patients to assist in clinic visits and can also access and download overall center outcomes. Port CF also provides additional data support to care teams by providing a readily available repository of current care guidelines and educational materials.

IV.

Partnerships to Improve CF Care

Patient quality of life and survival have increased dramatically in the 70 years since CF was first described, changing the face of the disease in a relatively short period of time

Quality Improvement in Cystic Fibrosis Care

427

Figure 2 The changes in median predicted age of death (using life table analysis) for the CF

population since the disease was first described.

(Fig. 2). Nevertheless, CF registry data suggests that care practices are inconsistent and outcomes quite variable among care centers, providing considerable opportunities for improvement. In the mid-1990s, regional consortia began to form with the assistance of the CFF and pharmaceutical industry partners, with the goal of comparing practices and outcomes among different care center within the same geographical regions of the United States (15). In 2002, the CFF introduced a large-scale initiative, titled “Accelerating the Rate of Improvement in CF Care,” which sought to develop a more sophisticated methodology for improving quality of care by improving the function of the health care delivery system for CF patients (16). A strategic plan set out plans to identify and disseminate “best practices,” teach QI techniques, develop leadership within the CF community, seek participation by patients and families, and provide data support and tools to care center teams, and included articulation of “seven worthy goals” (Table 1) (17). The CFF has attempted to establish an infrastructure to promote the development and spread of QI methods within the CF community and to train centers in their application. Partnerships were developed with several national QI organizations, including the IHI and its pediatric spin-off organization, the National Initiative for Children’s Health Care Quality (NICHQ); The Institute for Health Care Delivery Research, an affiliate of Intermountain Health Care; and the Center for the Evaluative Clinical Sciences at Dartmouth Medical School.

V. Teaching the Essentials of Quality Improvement At traditional continuing medical education (CME) activities, didactic sessions are provided to a passive audience of physicians with the expectation that they will use the new knowledge they receive to improve their practice. Studies of the effectiveness of such efforts suggest that they rarely achieve their intended goal (18). Multifaceted, health care systems–oriented approaches to change the process of care delivery at multiple levels, adapted to local practice settings, appear to be more effective at improving outcomes than passive approaches (19,20). Thus, a series of “Learning and Leadership” collaborative projects was initiated by the CFF, involving face to face meetings as well as teleconferences with multidisciplinary care teams from around the country, to teach the requisite systems-oriented methods and skills. These collaboratives have used a variety of

428

Schechter

Table 1 Seven Worthy Goals of the CFF

1.

Patients and families are full partners with the CF care team in managing this chronic disease. Information and communication will be given in an open and trusting environment so that every patient/family will be able to be involved in care at the level they desire. Care will be respectful of individual patient preferences, needs, and values.

2.

Children and adolescents will have normal growth and nutrition. Adults’ nutrition will be maintained as near normal as possible. All patients will receive appropriate therapies for maintaining lung function and reducing acute episodes of infection. Pulmonary exacerbations will be detected early and treated aggressively to return patients to previous levels of lung function. Clinicians and patients will be well-informed partners in reducing acquisition of respiratory pathogens, particularly Pseudomonas aeruginosa and Burkholderia cepacia. Patients will be screened and managed aggressively for complications of CF, particularly, CF-related diabetes. Severely affected patients will be well supported by their CF team in facing decisions about transplantation and end-of-life care. Patients will have access to appropriate therapies, treatments, and supports regardless of race, age, education, or ability to pay.

3. 4. 5. 6. 7.

Abbreviation: CFF, Cystic Fibrosis Foundation.

approaches, including the IHI/NICHQ model of targeted interventions based on prescribed change packages and centralized measurement and the Dartmouth microsystems method emphasizing professional formation, meeting skills, cause-and-effect diagrams, and flowcharts (15). More recent collaboratives have attempted innovative approaches based upon a synthesis of these methods and more selective teaching of relevant systems-based approaches in the specific CF environment by CF clinicians trained in QI methodology. At this point, the most efficient and reliably effective approach still needs to be identified, but there are certain theoretical and methodological principles of QI (21) that provide the underpinnings of any approach. These are discussed in the next section.

VI.

Basic Tenets of Quality Improvement

A. An Appreciation of the Need to Optimize the System in Which Health Care Is Delivered

The archetype of traditional medicine, the individual physician who by force of intellect and will establishes the correct diagnosis and prescribes the appropriate therapy to cure a patient, is anachronistic and likely ill-suited to the contemporary realities of health care provision for patients with chronic disease. CF care providers depend on the functioning of a complex system in which multiple caregivers must communicate and integrate a complex set of longitudinal data and then prescribe therapy on the basis of the appropriate use of these and other data. Knowledgeable physicians and staff are necessary for this care process, but not sufficient. To ensure the consistent delivery of appropriate care and minimize errors, it is essential to develop a supportive system that makes the correct decisions and actions the default. Much of the variation in practices and outcomes across different CF Care Centers is likely due to variation in the different systems’ ability to provide this support in a consistent manner (4).

Quality Improvement in Cystic Fibrosis Care

429

Figure 3 Wagner’s chronic care model envisions provider teams and patients interacting in an

environment where community resources and policies exist alongside and foster a health care delivery system that provides self-management support, an efficient delivery system design, decision support for providers, and a clinical information system that allows tracking of health care data on the individual patient and also on the aggregate population served by the provider team.

The Chronic Care Model

To optimize the care of patients with chronic disease, like CF, it is useful to conceptualize and work toward instituting an idealized system of health care delivery that is composed of several interdependent components inside and outside the practice setting. Furthermore, care should be considered within a long-term continuum, and not as isolated and independent events. Wagner’s chronic illness care model provides a useful framework for such care (20), and considers the impact of the following components (Fig. 3)a: 1.

2.

a

Community resources: National and regional social policies that impact access to health care resources play an important role affecting care (22), as do organizations such as the CFF. At a local level, medical community organizations and primary care providers can often supply needed services to patients, providing important resources that CF center providers should understand and be able to access. Medical center health delivery system: CF centers are most likely to be successful when they operate within organizations with a permeating culture that promotes safe, high-quality care (23). There should be an open and systematic approach to reducing errors, with incentives to acknowledge and reward high-quality care. Care should be coordinated within and across organizations.

A more detailed explication of this model may be found at http://www.improvingchroniccare.org

430

Schechter 3.

The “microsystem”, consisting of several components at the interface between patients and the health care–delivery system: l Patient and family self-management Patients and families have a right to be informed and empowered as partners in care. When they assume that role, they become an enormous resource for assessment, goal setting, and treatment planning (24). Also, patient and family input can facilitate the configuration of an optimal and accessible delivery system (25). l Delivery system design Delivery system design includes the structure and function of the clinic, from the telephone to the reception area to the examination room. Team members should have clearly defined roles and responsibilities, and ensure that clinic flow is optimized, patient visits are planned to accomplish specific goals, and appropriate follow-up is ensured (26). l Decision support Decision support promotes the application of well-thought-out and, when available, evidence-based care through the use of guidelines, algorithms, and other clinical tools. This can help to ensure that reliance on rote memory is minimized and intended care is actually prescribed. These resources should be available immediately and easily to providers during clinic visits (26). l Clinical information systems For individual patient care, the system should provide ready access to data relevant to care decisions (laboratory, imaging, etc.), provide timely reminders regarding routine interval care, and facilitate sharing of data to coordinate care. The system should also facilitate identification of relevant subpopulations for proactive care and allow providers to monitor overall performance of the practice team. It is the lack of the latter data that limits provider understanding of the true effectiveness of their care (27).

B. Strategies to Improve Health Care Systems

An effective organizational change strategy is an essential component of improvement work. Attempts at making immediate, dramatic changes often fail in their planning stage because they get bogged down in endless preparatory meetings or self-destruct during implementation because of the number of unanticipated problems encountered. In contrast, the Model for Improvement, developed by Associates in Process Improvement, is an example of a more effective approach (28) (Fig. 4). To start, the team should set specific, measurable aims that will allow it to objectively monitor the effectiveness of the planned improvement process, and then identify changes that are likely to lead to the desired improvement. Implementation is accomplished by the repeated use of “plan/do/study/act (PDSA) cycles” to test theories and to identify and evaluate effective methods that accomplish meaningful improvements in care. The essential key to this approach is the use of small changes that are easily accomplished, followed by the analysis of data to evaluate the impact of the intervention.

Quality Improvement in Cystic Fibrosis Care

431

Figure 4 The Model for Improvement (14) provides one example of an approach for accomplishing change that has been used in CF improvement collaboratives. See text for further details, as well as http://www.ihi.org/IHI/Topics/Improvement/ImprovementMethods/HowToImprove/ testingchanges.htm.

C. Quality of Care Can and Must Be Measured

Quality of care has been defined by the IOM as “the degree to which health care services for individuals and populations increase the likelihood of desired health outcomes and are consistent with current professional knowledge” (29). Quality measure can be used to quantify any of the following (30): l

Structure measures address “sufficiency of resources and proper system design,” including organizational characteristics. Structure data describe the capability of organizations or professionals rather than care provided or results achieved.

432

Schechter l

l

l

l

Process measures assess how well specific services are provided by a system to those patients who should receive them. The assumption is that the processes required to achieve optimal outcomes are known and measurable. Process measures are more immediately modifiable than outcome measures, and their measurement can identify specific areas of care that may yield improvement. Process goals should be clearly articulated, sensitive to change, quickly implementable, readily measurable, and valid, effective approaches to care (31–33) Access measures assess the patient’s attainment of timely and appropriate health care. Barriers to access may include inability to pay for health care, difficulty traveling to health care facilities, and difficulties contacting or communicating with health care providers. Patient experience measures aggregate reports of patients about their observations of and participation in health care. These measures provide the patient perspective on quality of care. Outcome measures describe how the care delivered affects the patient’s health, health status, and function (e.g., functional status, quality of life, and mortality). Intermediate outcome measures are linked to endpoint outcomes, such as disability or death [e.g., forced expiratory volume in one second (FEV1), body mass index (BMI), hospitalization, HgbA1c].

Data collection and analysis are essential to recognize where opportunities for improvement exist, and to garner feedback on what changes truly result in improvement. Once an organization decides to implement specific actions for improvement, it needs to track the consistency with which those actions are taken must be tracked. Improved performance on structure, process, and access measures can be considered as a preliminary step to improvement in the patient experience and outcome measures that are the true goal of the work. Feedback must be provided promptly and on a regular basis, and data should be reported in a way that can be easily understood and used by members of the care team, as well as interested outsiders. D. Collaboration, Comparison, and Data Transparency

Data comparisons are an important motivator of change, but for these comparisons to be effective, clinicians need to accept that the data are truly representative and that the comparisons are valid. The validity of registry data is threatened if patient inclusion is biased or if measurements are unreliable (especially in a nonrandom way) (34). Comparisons of processes and outcomes across CF centers, which seem to reveal great variation, are clearly misleading if, for example, disease severity differs among care centers. The challenges of case-mix adjustment are great and are a subject of controversy and intense study by health services researchers (35,36). O’Connor et al. (37) used variables reported in the CFF registry to evaluate intrinsic (primarily demographic) predictors of mortality, and proposed a case-mix adjustment of center performance using these characteristics (gender, nonwhite race, Hispanic ethnicity, symptomatic presentation, cystic fibrosis transmembrane conductance regulator (CFTR) genotype, age at diagnosis, and median household income by zip code); this has been presented in CF registry reports, and suggests that center variation is minimally affected by case mix.

Quality Improvement in Cystic Fibrosis Care

433

While this adjustment does not take into consideration several characteristics that might impact on center outcomes, such as state/regional influences on health due to differences in community and social services support (38,39) or referral patterns, particularly for transplant centers, the adjustment has allowed a cautious acceptance of the validity of center-to-center comparisons. Data sharing (transparency) is an important component of improvement collaboratives. Scientific researchers are familiar with the synergy derived from investigative collaboration, and this strategy is equally effective for the development and spread of innovations for improvement in the delivery of health services. Any health care team that is actively striving to improve its outcomes will devise novel and potentially effective ideas for how to accomplish this. Collaboration among centers that are trying to accomplish similar goals is therefore an important and effective strategy to accelerate change. For many physicians, the sharing of performance data with other providers is an uncomfortable jump from the secretive environment within which the health care team has traditionally operated with regards to care outcomes. Public reporting represents an even greater challenge. The previously mentioned IOM report, “Crossing the Quality Chasm,” challenged health care providers to “make information available to patients and their families that allows them to make informed decisions when selecting a health plan, hospital, or clinical practice” (4). Current experience suggests that most health care consumers make limited use of this information because they do not understand or trust it, and it seems to make a small, although increasing, impact on their decision making. Overall, there is some evidence that the publication of performance data has been associated with an improvement in health outcomes (40,41). In 2006, the CFF began to publish center-specific data from all the accredited CF centers and affiliates on lung function and nutritional status in children and adults, screening for cystic fibrosis–related diabetes (CFRD), and adherence to clinical guidelines care (i.e., outpatient visits, pulmonary function tests, and sputum culture in children and adults). The anecdotal experience among CF patients and providers seems to match that of the general population—the public reporting of data has been noted and used by health care systems, and has been a spur to QI activities, but has had little impact on patient choice of care center (15).

VII.

Searching for Best Practice—Clinical Practice Guidelines and Benchmarking When strong scientific evidence suggests that a specific approach works best, then the goal is to ensure that all appropriate patients receive it. As noted earlier, the CFF has sponsored the development of clinical guidelines to establish an evidence-based foundation for CF clinical care. However, while randomized clinical trials represent the gold standard approach to determining best practice, it is not feasible to perform adequately powered clinical trials to test every possible nuance regarding CF treatment. An alternative method, made possible by using the CFF registry data to compare center activities and outcomes, is to ascertain and spread care practices used at centers that exhibit highlevel performance on specific disease outcomes. The term “benchmarking” refers to the identification of practices that are used at sites that attain superior outcomes. Benchmarking originated as a business tool but has

434

Schechter

recently become recognized as a means to identify and spread effective strategies for health care delivery (42), and has obvious applications in CF, given the limitations in the evidence base. The CFF has sponsored both a pediatric and adult program benchmarking team to visit centers of different size and geographic location identified as having either exceptional nutritional care or exceptional pulmonary care consistently over the previous five years. Program performance was case-mix adjusted as noted earlier, and adult program performance was adjusted for patient status at age 21 to control for pediatric program performance. While some centers had both pulmonary and nutritional outcomes in the top quintiles, more tended to excel in one area and not the other. A multidisciplinary core team of CF experts with training and knowledge of systems-oriented approaches to care then partnered with volunteer teams from CF care centers to visit high performing centers with the goal of learning novel and successful methods to improve care. Benchmarking visits included structured dialogue and discussion regarding approaches to care, their rationale, and their apparent consequences. These visits also included examinations of center-specific registry reports of process and outcome measures. The discussions set a framework for observations in clinic. Team members were paired by discipline to observe and discuss specific approaches and activities in the outpatient clinic, and hospital tours focused on the processes of inpatient care. When possible, visitors attended host team meetings to observe the planning of care and interactions among team members. As a follow-up, the visiting teams presented an evaluation of differences in methods and developed a plan to assimilate new approaches into their practice. Several themes that were noted both at the pediatric and adult program visits included (43,44): 1.

2.

3.

High-functioning teams that provide consistent care. Team members communicate and cooperate with each other and meet regularly. It was typical to find directive center leadership, a strong and autonomous nurse coordinator, and experienced and knowledgeable telephone and clinic support staff. The team members are all aware of clearly defined criteria for diagnosis and treatment, responsibilities are clear, and decisions are communicated clearly to patients who are engaged and understand their care (see point 4 below) High expectations for outcomes among providers and families. For example, high-nutrition centers assume and expect patients to be at or above the 50th percentile for BMI. High-pulmonary centers expect no or minimal symptoms, and little to no loss of pulmonary function. Patients and families are trained to expect the same. Early and aggressive management, with little reliance on “rescues.” At high-nutrition centers, small declines in weight/BMI percentile prompt attention and action, and patients of concern are followed up at more frequent intervals. There is typically close involvement of engaged subspecialists (endocrinology and gastroenterology) who actively seek out complications before they are obvious. Successful pulmonary centers maintain a low threshold for antibiotic use, quickly treat new respiratory symptoms with oral antibiotics, and start IV antibiotics when oral antibiotics

Quality Improvement in Cystic Fibrosis Care

4.

435

do not produce prompt improvement. They tend to favor hospitalization over outpatient IV antibiotic therapy. The need for airway clearance augmentation is emphasized from an early age. Patients/families are engaged, empowered and proactive, and well informed on disease management and its rationale. They know when to contact the center, whom to speak with, and what to expect when they call or when they come for a visit. Their expectations provide additional assurance that they will receive the right treatment.

These apparent themes suggest potentially fruitful approaches to improving outcomes, but the benchmarking method is primarily useful for generating hypotheses. Where possible, these observations should be validated using quantitative techniques such as clinical trials, structured questionnaires, or other methods for comparing treatment approaches across the entire care center network.

VIII.

The Impact of QI on CF Outcomes

The overall impact of QI on CF outcomes is difficult to quantify because it is not possible to distinguish changes in outcomes that have occurred specifically due to the influence of formal QI interventions from those that would have occurred without them or as a result of the introduction of new therapies and interventions (detailed in other chapters). Care at all centers has been impacted by QI thinking, to a greater or lesser degree, so there is no “untreated” comparison group. This is typical of the difficulties involved in measuring the impact of QI initiatives, so analytic approaches to measuring the impact of QI usually compare trends before and after the introduction of the

Figure 5 Average FEV1 of patients aged 18 to 19 years in the CFF registry, 1990 to 2006 with

95% confidence intervals. The slope of improvement over time was 0.52% predicted/yr from 1990 to 2000; the slope from 2000 to 2006 was 1.93% predicted/yr. Abbreviations: CFF, Cystic Fibrosis Foundation; FEV1, forced expiratory volume in one second. Source: CFF registry data courtesy of Hebe Quinton.

436

Schechter

Figure 6 Average BMI of patients aged 18 to 19 years in the CFF registry, 1990 to 2006 with 95% confidence intervals. The slope of improvement over time was 0.86 kg/m2/yr from 1990 to 2000; the slope from 2000 to 2006 was 1.70 kg/m2/yr. Abbreviation: BMI, body mass index; CFF, Cystic Fibrosis Foundation. Source: CFF registry data courtesy of Hebe Quinton.

interventions of interest to evaluate whether an improvement is discernable. Conventional statistical methodologies can be used, but it is often more appropriate to use statistical control methods that were pioneered in the manufacturing industry to distinguish normal variation from “special” variation resulting from the introduction of a new influence (45). Even so, if a number of secular influences develop or are implemented simultaneously, it is not possible to distinguish which has the greatest impact on outcomes of interest. Unfortunately, there are no publications detailing rigorous evaluations of the impact of QI on CF outcomes. Nevertheless, the trends in CF outcomes seem to indicate a significant acceleration in improvement since 2000, coincident with the initiation of the CFF QI program. As noted, a number of new CF therapies became available during this time as well, likely leading to an additive or synergistic effect as the appropriate and consistent use of these new therapies has been an emphasis of QI programs of many centers. Figures 5 and 6 show the mean FEV1 and BMI of patients 18 to 19 years of age between the years 1990 and 2006, derived from the CFF patient registry. These data suggest that the slope of increase in both of these measures has increased greatly between 2000 and 2006 compared with the years 1990 to 2000.

IX.

Summary

To date 84 CF centers, caring for over 17,000 patients, have been trained in a systemsoriented approach to QI, and data from these centers suggest the success of this initiative. CF QI projects have utilized the IHI/NICHQ model of a series of targeted interventions based on prescribed change packages and centralized measurement and the microsystems approach emphasizing professional formation, meeting skills,

Quality Improvement in Cystic Fibrosis Care

437

cause-and-effect diagrams, and flowcharts (15). More recent collaboratives have attempted innovative approaches on the basis of synthesis of these methods and more selective teaching of relevant systems-based approaches in the specific CF environment. At this point, the most efficient and reliably effective approach still needs to be identified. Key tasks for the future are to narrow and shift the center of the “bell curve” (46) of center performance for the nation and the world as a whole, and to find the most efficient way to do so. With the abundance of new therapies currently entering the therapeutic pipeline, it is critically important to prepare the CF community and care centers for their optimal use and to close the “chasm between the health care we have and the care we could have” (4).

References 1. Wennberg J, Gittelsohn. Small area variations in health care delivery. Science 1973; 182(117):1102–1108. 2. Blumenthal D. Quality of health care. Part 4: the origins of the quality-of-care debate. N Engl J Med 1996; 335(15):1146–1149. 3. Kohn L, Corrigan J, Donaldson M, eds. To Err is Human: Building a Safer Health System. Institute of Medicine Report on Medical Errors. Washington, DC: National Academy Press, 1999. 4. Institute of Medicine Committee on Quality Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press, 2001. 5. Doershuk CF. Growth of the foundation’s medical program. In: Doershuk CF, ed. Cystic Fibrosis in the 20th Century. Cleveland, OH: AM Publishing, Ltd, 2001:218–238. 6. Cystic Fibrosis Foundation Center Committee and Guidelines Subcommittee. Cystic Fibrosis Foundation guidelines for patient services, evaluation, and monitoring in cystic fibrosis centers. Am J Dis Child 1990; 144(12):1311–1312. 7. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002; 35(3):246–259. 8. Yankaskas JR, Marshall BC, Sufian B, et al. Cystic fibrosis adult care: consensus conference report. Chest 2004; 125(1 suppl):1S–39S. 9. Aris RM, Merkel PA, Bachrach LK, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005; 90(3):1888–1896. 10. Flume PA, O’Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176(10): 957–969. 11. Flume PA, Robinson KA, O’sullivan BP, et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care 2009; 54(4):522–537. 12. Stallings VA, Stark LJ, Robinson KA, et al. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc 2008; 108(5):832–839. 13. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med 1997; 126(5):376–380. 14. Morgan WJ, Butler SM, Johnson CA, et al. Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol 1999; 28(4):231–241. 15. Quinton HB, O’Connor GT. Current issues in quality improvement in cystic fibrosis. Clin Chest Med 2007; 28(2):459–472. 16. Quality of Care and Outcomes Research in CVD and Stroke Working Groups. Measuring and improving quality of care: a report from the American Heart Association/American College

438

17.

18.

19. 20. 21. 22. 23.

24.

25. 26. 27. 28. 29. 30.

31. 32. 33. 34. 35.

36.

Schechter of Cardiology First Scientific Forum on Assessment of Healthcare Quality in Cardiovascular Disease and Stroke. Circulation 2000; 101(12):1483–1493. Cystic Fibrosis Foundation. Accelerating the Rate of Improvement in CF Care. Available at: https://www.portcf.org/Resources/Quality%20Initiative/QI%20Plan%20%26%207%20Worthy%20Goals%20%28June%202005%29.pdf. Accessed December 16, 2009. Davis D, O’Brien MA, Freemantle N, et al. Impact of formal continuing medical education: do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes? JAMA 1999; 282(9):867–874. Margolis PA, Lannon CM, Stuart JM, et al. Practice based education to improve delivery systems for prevention in primary care: randomised trial. BMJ 2004; 328(7436):388. Wagner EH, Glasgow RE, Davis C, et al. Quality improvement in chronic illness care: a collaborative approach. Jt Comm J Qual Improv 2001; 27(2):63–80. Deming WE. Out of Crisis. Cambridge, MA: MIT Center for Advanced Engineering Study, 1986. Marmot M. Social determinants of health: from observation to policy. Med J Aust 2000; 172(8):379–382. O’Connor PJ, Sperl-Hillen JM, Pronk NP, et al. Primary care clinic-based chronic disease care: features of successful programs. Disease Management & Health Outcomes 2001; 9(12):691–698. Effing T, Monninkhof EM, van der Valk PD, et al. Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007; (4): CD002990. Dunst CJ, Trivette CM, Hamby DW. Meta-analysis of family-centered help giving practices research. Ment Retard Dev Disabil Res Rev 2007; 13(4):370–378. Wasson JH, Godfrey MM, Nelson EC, et al. Microsystems in health care: part 4. Planning patient-centered care. Jt Comm J Qual Saf 2003; 29(5):227–237. Nelson EC, Batalden PB, Homa K, et al. Microsystems in health care: part 2. Creating a rich information environment. Jt Comm J Qual Saf 2003; 29(1):5–15. Langley G, Nolan K, Nolan T, et al. The Improvement Guide: A Practical Approach to Enhancing Organizational Performance. San Francisco: Jossey-Bass, 1996. Institute of Medicine. Medicare: A Strategy for Quality Assurance. Washington, DC: National Academy Press, 1990. National Quality Measures Clearinghouse. Using measures. In: Agency for Healthcare Research and Quality, 2009. Available at: http://www.qualitymeasures.ahrq.gov/resources/ measure_use.aspx. Accessed December 16, 2009. Lohr KN. Rating the strength of scientific evidence: relevance for quality improvement programs. Int J Qual Health Care 2004; 16(1):9–18. Nelson EC, Splaine ME, Godfrey MM, et al. Using data to improve medical practice by measuring processes and outcomes of care. Jt Comm J Qual Improv 2000; 26(12):667–685. Nelson EC, Splaine ME, Plume SK, et al. Good measurement for good improvement work. Qual Manag Health Care 2004; 13(1):1–16. Schechter MS. Patient registry analyses: seize the data, but caveat lector. J Pediatr 2008; 153(6):733–735. Ash AS, Shwartz M, Pekoz EA. Comparing outcomes across providers. In: Iezzoni LI, ed. Risk Adjustment for Measuring Healthcare Outcomes. 3rd ed. Chicago: Health Administration Press, 2003:297–333. Krumholz HM, Brindis RG, Brush JE, et al. Standards for statistical models used for public reporting of health outcomes: an American heart association scientific statement from the quality of care and outcomes research interdisciplinary writing group: cosponsored by the council on epidemiology and prevention and the stroke council. Endorsed by the American College of Cardiology Foundation. Circulation 2006; 113(3):456–462.

Quality Improvement in Cystic Fibrosis Care

439

37. O’Connor GT, Quinton HB, Kahn R, et al. Case-mix adjustment for evaluation of mortality in cystic fibrosis. Pediatr Pulmonol 2002; 33(2):99–105. 38. Goldhagen J, Remo R, Bryant T III, et al. The health status of southern children: a neglected regional disparity. Pediatrics 2005; 116(6):e746–e753. 39. Guagliardo MF, Ronzio CR. Is region of country a useful variable for child health studies? Pediatrics 2005; 116(6):1542–1545. 40. Fung CH, Lim YW, Mattke S, et al. Systematic review: the evidence that publishing patient care performance data improves quality of care. Ann Intern Med 2008; 148(2):111–123. 41. Marshall MN, Shekelle PG, Leatherman S, et al. The public release of performance data: what do we expect to gain? A review of the evidence. JAMA 2000; 283(14):1866–1874. 42. Nelson EC, Batalden PB, Huber TP, et al. Microsystems in health care: part 1. Learning from high-performing front-line clinical units. Jt Comm J Qual Improv 2002; 28(9):472–493. 43. Schechter MS, Leonard A, Nash J, et al. Benchmarking: signature themes. Pediatr Pulmonol 2006; (suppl 29):122–123. 44. Swarup AL, Sabadosa KA, Quinton HB, et al. Insights from the adult CF benchmarking questionnaire. Pediatr Pulmonol 2008; (suppl 31):409. 45. Ogrinc G, Mooney SE, Estrada C, et al. The SQUIRE (Standards for QUality Improvement Reporting Excellence) guidelines for quality improvement reporting: explanation and elaboration. Qual Saf Health Care 2008; 17(suppl 1):i13–i32. 46. Gawande A. The Bell Curve. The New Yorker 2004:82–91.

27 Cystic Fibrosis and Infection Control SUSAN RETTIG The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A.

SUSAN COFFIN University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A.

I.

Introduction

Infection prevention and control practices for cystic fibrosis (CF) patients are unique to this patient population; more expansive than transmission-based precautions; and pose challenges for hospital staff, families, and patients. In 2003, the consensus document, “Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission,” was published (1). Experts in the field of CF and infection prevention and control developed these evidenced-based recommendations that are aimed at reducing the transmission of infectious organisms to and between CF patients. These guidelines give detailed recommendations about interrupting transmission of pathogenic organisms to CF patients from other patients, contaminated equipment, or the hospital environment. These recommendations address risks associated with multiple environments and stress compliance with existing infection control guidelines from the Centers for Disease Control and Prevention (CDC) and Hospital Infection Control Practices Advisory Committee (HICPAC) as essential to prevention of cross-transmission of potential pathogens between patients, and form the basis for much of this chapter.

II.

Rationale for Infection Control Practices

Most individuals with CF harbor transmissible pathogens in their respiratory secretions. These organisms can infect other patients with CF through direct patient-to-patient contact via the contaminated hands of health care workers (HCWs) or through indirect contact with the contaminated environment or respiratory equipment. Molecular epidemiological studies have provided evidence of cross-infection of potentially harmful pathogens and suggest that the mechanisms of transmission can be varied. LiPuma demonstrated that Burkholderia cepacia complex (Bcc) could be transmitted between CF patients and that with strict adherence to infection control practices, including careful adherence to standard and transmission-based precautions, new acquisition decreased (2). In a prospective surveillance study, however, Jones noted that close attention to infection control measures in the absence of patient segregation did not prevent cross-infection of Pseudomonas aeruginosa (3). Finally, Speert studied the transmission of P. aeruginosa among CF patients in Vancouver CF clinics and was unable to find evidence of patient-to-patient spread without close social contact such as 440

Cystic Fibrosis and Infection Control

441

that which occurs with siblings (4). These observations support the use of at least modified infection control measures even if a CF patient is not known to be colonized with a multidrug-resistant organism, because patients may harbor resistant organisms before they are detected by laboratory methods. (5).

III.

General Principles for Health Care Settings

Multiple existing evidence-based infection prevention and control guidelines, used for the care of all hospitalized, ambulatory, and home care patients, are also applicable to CF patients. Compliance with hand hygiene remains the mainstay of infection prevention and control in most health care settings because most health care acquired infections are transmitted via the hands of HCWs. The Guideline for Hand Hygiene in Healthcare Settings discusses the appropriate use of hand hygiene products, for example, alcohol hand rub, soap and water, skin care, fingernail specifics, and monitoring compliance with hand hygiene (6). In addition to hand hygiene, standard precautions also apply to all patients regardless of their known or suspected infection status. Recommendations for standard precautions (as well as transmission-based precautions) are found in Guidelines for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings (7). Besides hand hygiene, standard precautions include the use of personal protective equipment, for example, gloves, gowns, mask, and eye shields if contact with blood or body substances is anticipated. Other HICPAC guidelines that are critical to the safe care of CF patients include the Guideline for Disinfection and Sterilization, which details steps needed to adequately reprocess respiratory equipment (8); the Guideline for Environmental Infection Control in Health Care Facilities (9); the Guideline for Healthcare Acquired Pneumonia (10); Management of Multidrug-Resistant Organisms in Healthcare, which applies to many CF patients (11); and Guideline for Infection Control in Healthcare Personnel (12). These evidence-based recommendations deserve careful review and consideration by HCWs in the field of infection prevention and control, infectious diseases, pulmonary, pharmacy, environmental services, occupational health, respiratory therapy, and central processing. Transmission-based precautions are used in addition to standard precautions when additional measures are needed to prevent the transmission of potentially infectious organisms among patients and staff. Table 1 lists the types of transmission-based precautions used with epidemiologically important pathogens (13). These measures include the use of personal protective equipment specific to the route of transmission of a particular pathogen as well as the segregation of patients from each other. Common indications for transmissionbased precautions for hospitalized CF patients include the prior detection of resistant organisms [e.g., methicillin resistant Staphylococcus aureus (MRSA), Bcc, P. aeruginosa] in their respiratory secretions or acute infection with a respiratory virus (e.g., influenza, respiratory syncytial virus, adenovirus). Because transmission of CF pathogens can occur via the droplet and/or contact route, specific strategies are designed to interrupt these mechanisms of transmission (5). To interrupt contact transmission (usually by a HCW’s hands), gloves and a gown are recommended. Transmission of organisms spreads by coughing, sneezing, or talking and is interrupted by the use of a tight-fitting surgical mask. An alternative strategy to limit transmission is the practice of some form of segregation with all CF patients, that is, keeping a spatial distance of 3 ft between patients. This is sometimes referred to as “the 3-foot rule” and is based on the observation that large, respiratory droplets that can transmit organisms typically settle due to gravity within 3 ft of the source.

442

Rettig and Coffin

Table 1 Transmission-Based Precautions to Prevent the Spread of Epidemiologically Important Pathogens in CF Patients

Type of precaution

Potential pathogen

Standard

Applicable to all CF patients including those infected with: NTM Pseudomonas aeruginosa (not multidrug resistant) Staphylococcus aureus (not MRSA) Multidrug-resistant organisms MRSA Burkholderia cepacia complex Multidrug-resistant P. aeruginosa Stenotrophomonas maltophilia Respiratory syncytial virus Parainfluenza virus Influenza virus Adenovirus Mycobacterium tuberculosis No data supporting the use of positive-pressure ventilation and 12 air exchanges for CF patients with lung transplantation; may consider in the setting of suspected transmission of Aspergillus spp. within transplant centers

Contact

Droplet viruses Airborne Protective environment

Abbreviations: CF, cystic fibrosis; NTM, non-tuberculous mycobacterium; MRSA, multidrug-resistant Staphylococcus aureus. Source: Adapted from Ref. 13.

Reprocessing of medical equipment with a special emphasis on respiratory equipment is another important component of a CF infection control plan. Equipment labeled as single patient use, such as spacers or spirometry mouthpieces, is not to be shared among patients. While it is prudent to follow manufacturers’ guidelines for reprocessing respiratory therapy and pulmonary function testing equipment, the respiratory therapy department’s cleaning and disinfection policies should be written in consultation with the central processing and infection control department to ensure patient safety. Because contaminated nebulizers can be a source of bacterial infection of the lower airways (14), nebulizers used in the hospital for a CF patient should be cleaned, disinfected, and rinsed after each use as per the CF Foundation’s guidelines (1). Usually respiratory therapists or nurses administer aerosolized medications to CF patients in a hospital setting; if there is insufficient time for appropriate reprocessing between patient use, then nebulizers must be discarded.

IV.

Surveillance for CF Pathogens

Respiratory tract culture should be performed on CF patients at least quarterly, during exacerbations, with a change in clinical stays, when hospitalized, and when epidemiologically indicated (1). Target pathogens should include Bcc, MRSA, and all P. aeruginosa, and CF centers should decide which organisms should be deemed important enough to calculate prevalence and incidence rates. The CF and infection control teams should work together on surveillance activities and share data on incidence and prevalence of select organisms.

Cystic Fibrosis and Infection Control

443

V. Infection Control Recommendations for Inpatient Settings A. Room Placement

Strict adherence to standard and transmission-based precautions, thorough medical equipment disinfection, and environmental cleaning may not be sufficient to prevent cross-transmission of potential pathogens between CF patients. CF sputum cultures processed by the microbiology laboratory do not always yield all of the potential pathogens an individual is harboring. As described above, molecular analysis had documented transmission of organisms, such as P. aeruginosa or Bcc, prior to recognition that the index patient is colonized. Thus, to prevent inadvertent transmission, some form of segregation of CF patients is warranted in most clinical settings. CF patients colonized or infected with Bcc, MRSA, vancomycin resistant enterococcus, or a multidrug-resistant gram-negative rod should be placed in a private room and contact precautions should be followed. While it is preferable to admit all CF patients to a private room, it may not be possible; if multibed rooms must be used for CF patients, then they should not share a room with another CF patient (1). Some CF centers have chosen to segregate patients with Bcc from those without evidence of colonization or infection by placing them in a different unit. Other hospitals have developed policies that limit nursing and respiratory staff to only care for one CF patient per shift to minimize indirect contact transmission. It is important to recognize that these practices would be unnecessary if all staff adhered to standard and transmission-based precautions, with meticulous attention to hand hygiene. Siblings with CF sometimes require hospitalization at the same time. Individual CF centers have developed their own strategies to care for families with more than one CF patient. Some CF centers allow siblings to reside in the same room, while others permit room sharing only if the siblings are documented to have similar colonization patterns. Finally, some CF centers make a distinction on the basis of whether the patients share a room at home. If siblings share a hospital room, some centers recommend that the privacy curtain be drawn to interrupt possible droplet transmission during respiratory therapy treatments and chest physiotherapy, although there are no well-designed studies to support this practice. B. Activity Outside the Patient’s Room

CF patients on transmission-based precautions should only be allowed to travel outside of their room for essential tests, procedures, and therapies. The hospital policy for patients colonized with multidrug-resistant organisms should be applied to all CF patients and provide guidance for CF clinicians and infection preventionists. Some patients require specific therapeutic programs that can easily be performed in the patient’s room; however, other patients may require therapies that will provide more benefit to the patient if administered in a specialized setting, such as the physical therapy gym. All CF patients, if developmentally able, should be instructed to perform hand hygiene, preferably with soap and water followed by alcohol hand rub, before exiting their room. Mask use by CF patients when outside of their rooms remains an unresolved issue (1). However, if a center opts for mask use, this practice should be consistently applied and all patients able to do so should be required to wear a mask when outside of their rooms. Caregivers may perceive this practice as beneficial to protecting their child

444

Rettig and Coffin

from cross-transmission of CF pathogens and common respiratory viruses and inconsistencies in practice contribute to feelings of confusion and anger among patients and families. Each CF center will have to decide how best to segregate hospitalized CF patients to prevent cross-transmission of CF pathogens. Many academic children’s hospitals with a CF center have an inpatient unit at least partially dedicated to CF patients. These units may include a playroom, teen room, classroom, family lounge, and shared kitchen. Many hospitals also have off-unit family resource rooms, gift shops, and eatery establishments. Some hospitals even have outside playgrounds. A CF center’s infection control policy should include specific guidelines concerning patient travel to locations outside the patient’s room that are not deemed essential for their care. Additionally, it is important for the CF multidisciplinary team, infection prevention and control, child life, teachers, and other providers to agree and adhere to these recommendations. Inconsistent application of such policies is likely to generate confusion. Some CF centers may take a very conservative approach and not allow any CF inpatient’s travel to sites not deemed essential for their care. Others may allow visits to common areas provided only one CF patient is present at any given time. Staff supervision should be available if a CF center decides, preferably on the basis of low-prevalence rates, to allow more than one CF patient in a common area at a time. Areas frequented by CF patients should be cleaned on a regular basis and whenever contamination with respiratory secretions has occurred. C. Respiratory Therapy

Respiratory therapy usually involves the administration of aerosolized medications via a nebulizer followed by chest physiotherapy. These procedures should always be performed in the patient’s room. The staff who performs these procedures should adhere to standard precautions, especially since these procedures may cause the patient to cough. Thus, staffs will most likely need to don masks, gowns, gloves, and possibly eyewear when administering respiratory therapy, given the probability of cough and direct contact with respiratory secretions. Resistant organisms transmitted from respiratory secretions will usually not induce illness in an immunocompetent host. HCWs, however, can acquire transient colonization of their nares or hands, or contamination of their clothing, and could then transmit these organisms to another CF or immunocompromised patient. However, staff may have difficulty wearing a mask the whole time they are performing chest physiotherapy, so education of staff and patients is important to support this practice. In addition, patients should be reminded to practice respiratory etiquette as outlined by the CDC’s Guidelines for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings (7). These practices include coughing into tissues or elbow, disposing of tissues properly, and performing hand hygiene. Nebulizers should be cleaned and disinfected in-between patient use and should only be used for a single patient. These devices can easily become contaminated with respiratory secretions. If not adequately cleaned after every use, the bacterial organisms contaminating the nebulizer equipment can then be aerosolized during subsequent use (13). A multistep process is needed for adequate disinfection. Cleaning is accomplished with a hospital-approved detergent and is performed as soon as possible after the

Cystic Fibrosis and Infection Control

445

completion of an aerosolized treatment. This step must be performed before disinfection and removes visible debris and reduces bioburden, which is necessary to allow for adequate disinfection. Disinfection can be achieved through either a three- to fiveminute soak of 70% alcohol or 1:50 dilution of sodium hypochlorite. Disinfection is followed by a sterile water rinse, air-dry equipment, and stored in a manner to reduce contamination. At some CF centers there are respiratory therapists dedicated to CF patients and these patients are admitted to an assigned unit. CF patients may need to be admitted to the intensive care unit, or possibly be housed on other units when the hospital is filled to capacity. If a CF center decides to reprocess nebulizers in-between patient use, then a clear, concise, and easy-to-locate policy should be available to all staff charged with this task.

VI.

Ambulatory Settings

A. Clinic Logistics

The CF Foundation guidelines stress the importance of keeping CF patients apart from each other as a way to prevent cross-transmission with possible pathogens. This poses a challenge for staff when a multidisciplinary team needs to see multiple CF patients during a single clinic session. Experienced providers should know approximately how much time a new and follow-up appointment will take and schedule accordingly. The ideal action would be to place patients in an exam room upon arrival to the clinic. Even when this cannot be accomplished, clinic staff responsible for patient flow through the clinic should be attuned to what is happening in the waiting room. Frontline staff should also be aware of which patients on the schedule have a documented history of multidrugresistant organisms in their sputum. These patients may travel to other areas of the hospital for studies; it is prudent to relay this information to the receiving departments so that appropriate precautions can be followed. CF centers with small waiting rooms may need to implement creative strategies to keep CF patients segregated. One suggestion is to ask families to wait in large common areas of the hospital and contact them by pager or cellular phone when an exam room is available. B. Waiting Room Practices

Alcohol hand rubs should be readily available in CF clinic waiting rooms for use by patients and families. Ideally, all ambulatory settings would have hand hygiene products accessible to patients and caregivers, either in the form of alcohol hand rub or disposable hand cleansing towelettes. Patients must be educated to maintain at least 3 ft of separation if interacting with other CF patients and to always avoid physical contact. Some CF centers that have included masks as precautions in their infection control policy make them available to patients upon arrival to clinic. This strategy is not evidence-based but is used in an attempt to interrupt droplet transmission between CF patients within the clinic setting. This strategy is now possible even with very young CF patients because of the availability of pediatric size masks. Many a time, non-CF patients share the waiting room with CF families, and they may have unfounded fears regarding mask use. Hospital staff not attending to CF patients should be able to articulate to families the reasons for mask use (while maintaining patient privacy) and assure families that this group of patients does not pose an infection risk to a non-CF child. CF parents and patients should also be provided with education in regards to

446

Rettig and Coffin

expected waiting room behaviors. These instructions should be reinforced on a regular basis, through either newsletters or parent education nights. Toys, computers, books, and magazines should not be allowed in waiting rooms since they cannot be cleaned between use by patients. C. Precautions for Patients with Multidrug-Resistant Organisms

Patients known to be colonized with multidrug-resistant organisms may need to be managed with transmission-based precautions based on the organism and isolated from other patients. The CF Foundation guidelines recommend using contact and standard precautions if patients are coughing and are infected with Bcc, MRSA, multidrugresistant P. aeruginosa, or other epidemiologically important pathogens (1). CF centers need to consider and incorporate into their CF infection control policy the most efficient way to adhere to this recommendation. Some centers have found it easier to manage all patients known to be colonized with significant pathogens with standard and contact precautions. At a minimum, patients with a history of Bcc in their respiratory secretions should always be segregated from other CF patients, even those already colonized with Bcc; studies have demonstrated that a patient becomes ill after acquisition of a new genomovar of Bcc (15).

VII.

Environmental Infection Control

A. General Sterilization and Disinfection Measures

Staff assigned with the task of reprocessing medical devices should adhere to existing published guidelines for sterilization and disinfection and maintain annual certification of this practice (8). Cleaning and disinfection of nebulizers after use in a hospital setting has been discussed above. Nebulizers are never shared between patients although other devices can be safely reprocessed and used on multiple patients (e.g., dental instruments, endoscopes, and surgical instruments). Respiratory therapy equipment that comes into contact with mucus membranes requires high-level disinfection after every use. Some hospitals allow the respiratory therapy department to reprocess these items while others have all reprocessing performed by the central processing department. Regardless of who performs this important component of infection prevention or where it is performed, written policies should be in place and adhered to at all times. When hospitalized, routine cleaning and disinfection of the patient’s surrounding environment, for example, bathrooms, sinks, or bedrails should occur on a daily basis, which is the usual standard for all hospitalized patients. Room cleaning upon discharge should include all items not cleaned on a daily basis, for example, monitors and blood pressure cuffs. Privacy curtains may need to be changed if visibly soiled. Other areas that a CF patient visits (e.g., playroom, classroom, etc.) should be cleaned afterwards, especially if contamination with respiratory secretions has occurred. B. Pulmonary Function Testing Equipment

Special attention should be given to any environment or equipment that can easily become contaminated with respiratory secretions, such as the pulmonary function testing area. Pulmonary function testing frequently induces coughing, therefore the equipment and surrounding furniture is likely to become contaminated. Respiratory therapists

Cystic Fibrosis and Infection Control

447

should be instructed to clean and disinfect the environment and outside surfaces of the equipment upon completion of testing of every CF patient, regardless of their colonization status. Disinfection should include the use of the hospital-approved low-level disinfectant, which is usually a quaternary ammonium compound. Disposable disinfectant towelettes are available for ease of cleaning and to decrease staff exposure to aerosolized chemicals. Only disposable mouthpieces with filters should be used on pulmonary function testing equipment. C. Disinfection in an Ambulatory Care Setting

High-touch surfaces, such as sinks, door knobs, and exam tables in an ambulatory CF setting need to be cleaned more frequently than in other outpatient practice settings. Viable P.aeruginosa has been recovered from environmental surfaces contaminated more than a week earlier by the respiratory secretions from a colonized CF patient (16). Even though paper on the exam table is changed between patients, the surface of examination tables should be cleaned in between use in case there has been contamination with respiratory secretions. The ideal would be to have a dedicated housekeeper on site during CF clinic. When this is not practical, clinic staff needs to perform routine cleaning and disinfection tasks. The hospital’s CF infection control policy should detail housekeeping chores and frequency of performance.

VIII.

Infection Control in Non–Health Care Settings

A. Multipatient Families

Households with more than one family member with CF face difficult challenges in regards to infection control because contact density (i.e., multiple family members colonized with pathogenic organisms) contributes to cross-transmission. However, it is impracticable to ask siblings to maintain a 3-foot rule and avoid physical contact. Therefore, education should be concentrated on not sharing respiratory equipment, performing chest physiotherapy with only one child in the room, and practicing scrupulous hand hygiene and respiratory etiquette. B. Care of Respiratory Therapy Equipment in the Home

Cleaning and disinfection of nebulizers is essential for infection prevention in the home, but current practices in the home vary (17). Review of actual practices in the household setting has revealed that many patients do not clean and disinfect nebulizers and the devices are also overused (14). Manual cleaning with soap (e.g., dish detergent) and hot water should precede disinfection and be performed soon after completion of therapy. If there are time constraints, the device should be soaked in soap and water until adequate cleaning can be accomplished. Disinfection methods are outlined in Table 2 and will be dependent on manufacturer’s recommendations (13). Acetic acid (vinegar) is no longer recommended for nebulizer disinfection. If nebulizers are chemically disinfected they must be rinsed with sterile or filtered water rinse. Distilled water should not be used because it may contain organisms that are pathogenic to CF patients. This additional rinsing step may make other disinfection options (e.g., boiling in water, dishwasher, or microwave) more feasible for some families. Nebulizer care should be discussed and reviewed with families and patients during clinic visits and hospitalizations. CF centers should promote published guidelines and assist families in deciding which disinfection

448

Rettig and Coffin

Table 2 Effective Methods to Disinfect Respiratory Equipment at Home

Disinfection method

Recommended duration a

Immerse in one of the following: 1:50 dilution of 5.25–6.15% sodium hypochlorite (household bleach) 70–90% ethyl or isopropyl alcohol 3% hydrogen peroxide

3 min 5 min 30 min

or Boil in water

5 min

or Use a standard-cycle dishwasher (>1588F or 708C)

30 min

or Use a home microwave (2.45 GHz)

5 min

Must be permissible by the manufacturer. a These preparations lose activity with time, but the optimal storage time is unknown. For example, chlorine preparations have a 50% reduction in activity after 30 days. Source: Adapted from Ref. 13.

method is most feasible for them. Nebulizers and associated equipment should be changed regularly as recommended by the specific manufacturer. C. Schools

Children with CF may attend the same school as non-CF children, but it is preferable that they not be in the same classroom or activity simultaneously. If that is unavoidable, they should adhere to the 3-foot spatial distance rule at all times. D. Camps

Current infection control guidelines recommend that all CF camps and overnight activities be discontinued (1). This difficult and unpopular decision was based on studies that demonstrated that summer camp attendance was a risk factor for Bcc acquisition. Subsequent analyses have suggested that acquisition may also have been influenced by the prevalence of Bcc at the camp, the extent of camper contact, the duration of camp attendance, and broad environmental contamination (18). European studies of crosstransmission at camps have produced conflicting data on whether cross-transmission occurs, and some CF centers in Europe have been reluctant to disband camps for all patients (19). Although prohibiting camp with peers also living with CF may seem like a draconian measure, CF-specific infection control measures (e.g., 3-foot rule, respiratory etiquette, and frequent disinfection) could not be adhered to in a camp setting. E.

Patient Gatherings

Patient support groups and education events are common within communities where individuals share the same disease entity. They offer psychosocial support, networking opportunities, and a chance to increase knowledge related to a particular disease.

Cystic Fibrosis and Infection Control

449

Although the potential benefits of patient gatherings are obvious, the CF Foundation infection control guidelines recommend excluding individuals with Bcc from these events due to the significant risk of transmission of the organism (1). Audiovisual and computer technology advances may provide a means for these individuals to feel connected to the larger group. Each CF center will have to decide whether or not to sponsor or encourage events where CF patients will gather. At this point, many young teenagers have grown up with the 2003 CF Foundation infection guidelines and are more easily able to adhere to the 3-foot rule, hand hygiene, and respiratory etiquette.

IX.

Psychosocial Issues Related to Infection Control

Because cross-transmission can occur between CF patients in health care settings even when staff adheres to evidence-based infection control guidelines, patient segregation has become a recognized component of CF-specific guidelines. This strategy is unique to the CF patient population, extends beyond the health care setting, and will persist throughout life. Segregation during hospitalization may cause patients to feel lonely or bored and acceptance may depend on maturity and previous experiences (20). Staff, such as child life specialists, teachers, nursing, and social work can facilitate and coordinate alternative activities for hospitalized CF patients confined to their room. Internet and chat rooms may help patients feel more connected to others but caution should be exercised since these are also sources of misinformation (21). Parents and patients provided with education about segregation and updated on a regular basis are more likely to be supportive of this measure (22). Allow parents and patients to verbalize their fears and concerns regarding crossinfection and segregation while at the same time acknowledging that the benefits of segregation outweigh the risk of cross-infection and clarify at each hospital admission expectations for isolation requirements (20).

References 1. Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-topatient transmission. Infect Control Hosp Epidemiol 2003; 24:S6–S52. 2. LiPuma J. Update on the Burkholderia cepacia complex. Curr Opin Pulm Med 2005; 11: 528–533. 3. Jones A, Dodd M, Govan J, et al. Prospective surveillance for Pseudomonas aeruginosa cross-infection at a cystic fibrosis center. Am J Respir Crit Care Med 2005; 171:257–260. 4. Speert D, Campbell M, Henry D, et al. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada. Am J Respir Crit Care Med 2002; 166:988–993. 5. Gibson R, Burns J, Ramsey W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Crit Care Med 2003; 168:918–951. 6. Boyce J, Pittet D. Guidelines for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/ APIC/IDSA Hand Hygiene Task Force. MMWR Recomm Rep 2002; 51:1–45. 7. Siegel J, Rhinehart E, Jackson M, et al. Guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control and Hosp Epidemiol 2007; 35:S65–S164. 8. Rutala W, Weber D, and the Healthcare Infection Control Practices Advisory Committee. Guidelines for disinfection and sterilization in healthcare facilities. Centers for Disease Control and Prevention, Atlanta, 2008.

450

Rettig and Coffin

9. Sehulster L, Chinn R. Guidelines for environmental infection control in healthcare facilities: recommendations of the CDC and Healthcare Infection Control Practices Advisory Committee. Centers for Disease Control and Prevention, Atlanta, 2003. 10. Tablan O, Anderson L, Besser R, et al. Guidelines for prevention of healthcare associated pneumonia: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004; 53(RR03):1–36. 11. Siegel J, Rhinehart E, Jackson M, et al. Guidelines for the management of multi-drug resistant organisms in healthcare settings, 2006. Am J Infect Control and Hosp Epidemiol 2007; 35:S165-S193. 12. Bolyard E, Tablan O, Williams W, et al. Guideline for infection control in healthcare personnel. Infect Control Hosp Epidemiol 1998; 19:407–463. 13. Saiman L, Siegel J. Infection control in cystic fibrosis. Clin Microbiol Rev 2004; 17:57–71. 14. Lester M, Flume P, Gray S, et al. Nebulizer use and maintenance by cystic fibrosis patients. Respir Care 2004; 49:1504–1508. 15. Jones M, Webb A. Recent advances in cross-infection in cystic fibrosis: B. cepacia complex, P. aeruginosa, MRSA, and Pandoraea. J R Soc Med 2003; 43:66–72. 16. Bush A. Decision facing the CF clinician at first isolation of P. aeruginosa. Paediatr Respir Rev 2002; 3:82–88. 17. Reychler G, Aarab K, Van Ossel C, et al. In vitro evaluation of efficacy of 5 methods of disinfection on mouthpieces and facemasks contaminated by strains of CF patients. J Cyst Fibros 2005; 4:183–187. 18. Mychalak-Walsh N, Casano A, Managan L, et al. Risk factors for B. cepacia colonization and infection among patients with cystic fibrosis. J Pediatr 2002; 141:512–517. 19. Brimicombe R, Dijkshoorn L, van der Reijden T, et al. Transmission of P. aeruginosa in children with cystic fibrosis attending summer camps in the Netherlands. J Cyst Fibros 2008; 7:30–36. 20. Russo K, Donnelly M, Reid A. Segregation—the perspectives of young patients and their parents. J Cyst Fibros 2006; 5:93–99. 21. Duff A. Psychological consequences of segregation resulting from chronic B. cepacia infection in adults with cystic fibrosis. Thorax 2002; 57:756–758. 22. Griffiths A, Armstrong D, Carzino R, et al. Cystic fibrosis patients and families support cross-infection measures. Eur Respir J 2004; 24:449–452.

28 Transition to Adult Care SHERSTIN G. TRUITT and JAMES R. YANKASKAS University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A.

I.

Introduction

Investments in cystic fibrosis (CF) research and care have produced marked improvements in available treatments, the quality of life, and survival. These changes have progressively increased the number of adults with CF, and have challenged the CF community to deal with the medical and social issues related to maturation and adulthood. Perceptive caregivers at Dartmouth College, the University of Pittsburgh, the University of North Carolina, and other institutions recognized these needs and started the first adult CF programs in the early 1980s. Issues associated with transition from pediatric to adult health care were identified and addressed on the basis of local needs and resources. Transition tasks and strategies have been addressed in symposia, workshops, short courses, and consultation clinics at every North American CF Conference since 1987. A 1997 meeting of CF center directors defined four adult CF program models, and mandated that all CF centers with more than 40 adults have an accredited adult CF program by 2000. The CF Foundation has fostered this mandate through administrative funding for adult care, workshops, mentoring programs, research and clinical fellowships, and support for faculty development through the Program for Adult Care Excellence (PACE) grants. This chapter summarizes the current goals, knowledge, and methods for planning effective transition by discussing its timing, challenges, and current models of execution. The progress in these important tasks provides a sound basis for ongoing improvement. CF provides a model for health care transition in diseases that were once limited to childhood, but now include large numbers of patients who have significant or normal adult life spans.

II.

Timing of Transition

A well-planned transition should be purposeful and expected by the patient. The process must begin early in life and be fostered during adolescence by asking patients to accept increasing responsibility in disease management as they mature. Interview time without parents (1,2), speaking directly to a patient instead of parents, and asking the teenagers’ opinion regarding treatment plans help young people gain understanding and knowledge of adult medical expectations. There should be some flexibility regarding the actual date of transition, but suggesting a target transfer age at least a year in advance gives both patients and staff more concrete timelines (3) and the opportunity to ask questions while adjusting to the idea of working with new providers.

451

452

Truitt and Yankaskas

Occasionally, transition is not a mutually agreed-upon process by the patient and caregivers, but instead occurs as a result of patient behavior or limitations associated with licensing guidelines. Medical noncompliance, pregnancy, criminal activity, and suicide attempts can usher in rapid change that can be perceived as a punishment (2,4). Patients may have to move to an adult team because some hospitals cannot admit patients over age 21 years, some pediatric nurse practitioners are not permitted to treat individuals over the age of 25, and many consulting physicians are not comfortable caring for young adults (4).

III.

Challenges of Transition

Adolescence is a time to develop more mature relationships, become more confident in social roles, achieve emotional independence from parents, and gain responsibility in preparation for future employment and economic independence. Young adulthood is the period in which children leave home, adapt to living with a roommate or spouse, engage socially, obtain employment, manage a home, and participate in civic responsibilities (5) (Table 1). It is our responsibility to help patients achieve these milestones so they can successfully engage in society and more responsibly manage their health needs. This is a daunting task as not only must these teenagers manage the social pressures of adolescence but also must incorporate regular management of aerosol therapies, take multiple daily medications, and find time for frequent doctor appointments. Therefore, several governing bodies have recommended that adolescent care be paid special attention and given more focus. For example, in United Kingdom, the House of Commons Select Committee on Health, fifth report concluded in 1997 that “the transfer of young people, particularly those with special health needs, from child to adult services requires specific attention” (2,7). In the United States, “the Maternal and Child Health Bureau identified transition as 1 of 6 core outcomes that, when achieved, will indicate successful progress toward the goal of a community-based system of services for children with special health care needs” (8,9). Pediatric patients are often relatively healthy, but as they become older their disease status also progresses, creating a perception that adulthood heralds illness. These fears are perpetuated as teens notice older patients having more difficulties. The adverse effects of poor nutrition and airway colonization with Pseudomonas may increase in tandem with transition time. Patients may notice increased frequency of pulmonary exacerbations, have more difficulty with sinusitis and nasal polyps, be diagnosed with CF-related diabetes (about 5%), suffer from distal intestinal Table 1 Tasks of Late Adolescence (18 to 21 Years)

Shows physical, cognitive, emotional, social, and moral competency Supports a healthy lifestyle Create supportive relationships with others Positively interacts with society at large Displays self-confidence Effectively manages life stressors Demonstrates independent decision making Source: Adapted from Ref. 6.

Transition to Adult Care

453

Table 2 Early Adult CF Complications

Increased number of exacerbations Worsening sinusitis CF-related diabetes DIOS, Liver disease Bone loss Hypertrophic osteoarthropathy Abbreviations: CF, cystic fibrosis; DIOS, distal intestinal obstruction syndrome.

obstruction syndrome and/or liver disease, be diagnosed with osteopenia or osteoporosis, and/or first experience joint pain due to hypertrophic osteoarthropathy (1,10) (Table 2). Adulthood is thus often viewed as leading to health complications, the need for lung transplantation, and ultimately death (2,10). An adult team must understand that these new disease manifestations may be perceived as poor adult care (2). The movement of care from pediatrics to adult medicine is thus an important and multifaceted change extending far beyond the transfer of medical records. Practitioners must be prepared to deal with delays in development, disease progression, and family anxiety in the context of typical adolescent experiences such as social adjustments, sexuality, new behaviors, and economic changes. For example, CF patients are often delayed in their tasks of adolescence due to vigilant parental involvement in diet, school activities, social venues, and health care. Parents may be reluctant to concede care to their children, concerned that it will not be done adequately. Thus, despite being older teenagers, some patients lack significant life planning experience, leaving them less able and less confident in management skills than their peers (5). In the midst of some of these health changes, patients find themselves being treated from a different stylistic perspective. There tends to be a stronger family focus in pediatrics with staff being more available for support. Adult medicine expects more independent relationships and visits are disease and treatment plan focused (4). Patients perceive these differences as a lack of personal interest, and parents often feel alienated from their children’s care (10). As disease worsens, new practitioners may give advice that seems to contradict the pediatric team, leading to mistrust and potential conflict until a new rapport is developed (3). Patients and families are also concerned that an adult provider will not offer the same quality of care as their pediatrician (Table 3). Despite the increasing number of accredited adult CF centers, many patients must still be transitioned to general pulmonologists who often lack specific training regarding the various manifestations and course of CF (1). Adolescents worry that their new physician will not be as accessible as their pediatrician (4,9). They would prefer to be treated by someone familiar with their unique patient experience and not in a clinic, potentially exposing them to new pathogens (10). Thus, there is little motivation to leave the pediatric relationships behind (2,9). Aside from establishing interpersonal relationships, an essential part of any medical care transition is the timely and complete communication of medical records. Checklists from the receiving center help referring practices understand what information is helpful. For example, summaries from pediatric subspecialists, including physicians, nurse coordinators, social workers, nutritionists, and physical therapists, give

454

Truitt and Yankaskas

Table 3 Transition Concerns

Patient concerns

l l l l

Pediatrician concerns

l l

Caregiver concerns

l l

Adequate provider accessibility Exposure to new pathogens Working with strangers Need for lung transplantation Adult provider competence Paucity of adult programs Dependability of their child Alienation from their child’s care

adult providers a better understanding of a patient’s previous course and interaction with the health care system (2). Specific culture results including Pseudomonas and Burkholderia spp., presence of MRSA or atypical mycobacteria, and the antibiotic sensitivities are paramount. Records of weight and pulmonary function, in addition to dates of recent courses of IV or oral antibiotics, are very helpful. The ordering of ageappropriate screening tests prior to transfer (such as a DEXA scan, an oral glucose tolerance test, and a liver ultrasound) help the accepting provider better prepare for CFassociated morbidities, in addition to decreasing patient perceptions that the new physician is primarily focused on tests (10).

IV.

Development of Transition

Centers depend on family member support to achieve the goals of transition, and the process ideally begins prior to adolescence (4). Parents must lay the groundwork for independence and allow their children to perform tasks of daily living, assist with their medical self-care, and take increasing responsibility in asking for more urgent medical attention (4,9). During medical visits, teens should be asked about current activities, plans for higher education and employment as well as health care topics. Interest in CF patients’ futures is vital as many children are acutely aware of having never been asked about their future and understand this as limiting their attainable dreams (1). Social topics, such as drug and alcohol use and sexuality, must be addressed. Although difficult to discuss especially with limited interview time, they are exceptionally important in adolescent development and have clear impact on overall health status. The need for this education is clear as demonstrated in a recent study that reported only 57% of CF males had learned about infertility by age 20 years (11) Furthermore, surveys from teenagers demonstrate a desire to have physicians involved with their contraception decisions, fertility issues, and to address relationship difficulties (9,10). Given that many CF patients do not visit a primary care provider (PCP) regularly and adolescence spans both pediatric and adult care, each team must be comfortable raising these topics. In the midst of developing new social roles, teenagers must also learn the mechanics of interacting with their health care system. These include transportation to medical visits, obtaining medications, and understanding insurance coverage. Social work intervention and education is paramount to uncovering what needs are present at emancipation and informing patients of services for which they qualify. For example, at age 18, children are often dropped from their parents’ coverage unless they have

Transition to Adult Care

455

enrolled in continuing education (1,4). Also, state funding from Title V Children with Special Health Care Needs programs typically ends at 21 years. Some patients, however lose their Title V coverage at age 18 as the Supplemental Security Income qualifications become more strict (4). Medicaid patients receive less coverage and fewer services once they turn 21 years (4) or may lose coverage altogether should they choose to marry.

V. Models of Transition Pediatricians and internists often differ in their philosophy of care. The gap between these models of medical practice must be bridged if patients are successful in gaining independence and parents are comfortable supporting this. Over the past several years, models have been suggested to meet this need: the transition clinic, the adolescent clinic, the primary care clinic, or the lack of transfer. The transition clinic is one in which patients are cared for by both pediatric and adult physicians. This allows for patients to be seen over several visits by either an adult or pediatric provider, or to continue seeing their pediatric pulmonologist with visits from an adult physician (1,5). Patients are able to develop a relationship with their future provider and become more accustomed to the style of questions asked by adult physicians. Personal involvement in the adolescent’s care plan familiarizes the adult team with the unique experiences of each case. The adolescent clinic is a separate clinic designed for teenagers. Younger patients are not treated during that time and the staff focuses on adolescent health concerns as well as the general needs of patients with chronic disease (5,12). The provider is a specialist in adolescent medicine. As such, he or she is trained to expect more independent thought from the patients and to fill the paucity of guidance regarding substance use and sexuality. The primary care model uses a PCP as the coordinator of general care and leaves the subspecialist to provide focused expertise (9,12). As general practitioners are often more focused on family needs, their exams may ensure that many needs are identified and addressed. Unfortunately, many PCPs do not have the most current medical knowledge regarding CF care or the ancillary resources to address the specific social needs discussed above. Some providers continue to advocate for patients to remain with their pediatrician throughout adulthood (5). This is not an optimal choice as there are a multitude of social and medical issues that extend beyond the expertise of pediatricians, especially as CF patients are living past their fourth decade. The multitude of CF comorbid conditions underscores the need for a comprehensive care clinic. In some areas of the United States a highly qualified adult provider is not available. Patients who are near death may not accrue sufficient benefits from adult care to justify reducing their interactions with a skilled pediatrician. Thus, in a few circumstances, transition to adult care may not be the better choice.

VI.

Summary

The movement of patients from pediatric to adult medicine is both exciting and anxiety provoking. Providing educational materials, personally introducing the new provider, printing cards with team contact numbers, sending news bulletins, having updated Web

456

Truitt and Yankaskas

sites, offering support groups, and providing tours of adult facilities often abate many concerns (1,2,10). The multitude and variety of issues involved is great and many challenges remain. Many CF patients receive their primary care from subspecialists who are not trained in developmental tasks and whose clinics are not equipped to address adolescent-specific issues. Institutions that lack formalized transition programs can allow important needs to be overlooked. Medical insurance and adequate financial reimbursement for comprehensive care are essential (9). Many models have been proposed to address these topics. Whichever one is chosen, however, must be well defined. A distinct plan with rigorous attention to detail yields clear expectations for patients and families while guiding health care teams through the multitude of concerns needing to be addressed. Obviously, this is a complicated maneuver, but, if done well, helps launch CF patients into a lifetime of exemplary comprehensive and self-care.

References 1. Landau LI. Cystic fibrosis: transition from paediatric to adult physician’s care. Thorax 1995; 50(10):1031–1032. 2. Viner R. Barriers and good practice in transition from paediatric to adult care. J R Soc Med 2001; 94(suppl 40):2–4. 3. Por J, Golberg B, Lennox V, et al. Transition of care: health care professionals’ view. J Nurs Manag 2004; 12(5):354–361. 4. Reiss JG, Gibson RW, Walker LR. Health care transition: youth, family, and provider perspectives. Pediatrics 2005; 115(1):112–120. 5. Bryon M, Madge S. Transition from paediatric to adult care: psychological principles. J R Soc Med 2001; 94(suppl 40):5–7. 6. Hagan JF, Shaw SJ, Dunca PM, eds. Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents. 3rd ed. Elk Grove Village, IL: American Academy of Pediatrics, 2008. 7. House of Commons Select Committee on Health. Fifth Report: Hospital Services for Children and Young People. London: HMSO, 1997. 8. Maternal Child Health Bureau. Achieving Success for All: Children and Youth with Special Health Care Needs. A 10-Year Action Plan to Accompany Healthy People 2010. Washington, DC: Maternal and Child Health Bureau, 2001. 9. Scal P. Transition for youth with chronic conditions: primary care physicians’ approaches. Pediatrics 2002; 110(6 pt 2):1315–1321. 10. Webb AK, Jones AW, Dodd ME. Transition from paediatric to adult care: problems that arise in the adult cystic fibrosis clinic. J R Soc Med 2001; 94(suppl 40):8–11. 11. Fair A, Griffiths K, Osman LM. Attitudes to fertility issues among adults with cystic fibrosis in Scotland. The Collaborative Group of Scottish Adult CF Centres. Thorax 2000; 55(8): 672–677. 12. Callahan ST, Winitzer RF, Keenan P. Transition from pediatric to adult-oriented health care: a challenge for patients with chronic disease. Curr Opin Pediatr 2001; 13(4):310–316.

29 Reproduction, Sexuality, and Fertility LISA K. TUCHMAN Children’s National Medical Center, Division of Adolescent and Young Adult Medicine, Children’s Research Institute, Center for Clinical and Community Research, Washington, D.C., U.S.A.

IOANNA K. GISONE The Children’s Hospital of Philadelphia, Craig-Dalsimer Division of Adolescent Medicine, Philadelphia, Pennsylvania, U.S.A.

I.

Introduction

In 2007, more than 45% of people with cystic fibrosis (CF) were over age 18 and expectations are that individuals born after 2000 will survive into their fifth decade; thus CF-related reproductive health has become increasingly relevant for patients and families. Adolescents and young adults with CF have similar age of onset of sexual interest and activity as their healthy adolescent peers (1,2) and are in need of disease-specific sexual and reproductive health information that goes beyond what a primary pediatrician or gynecologist can be expected to provide. There are no formal guidelines about timing and content of discussions for CF providers although there have been several published recommendations in the academic literature (2–4). Adolescents and young adults with CF are more likely to be the initiators of reproductive health discussions than their health care providers (5). However, 87% of adolescents with CF report having never discussed sexual or reproductive health with their CF provider (6). Nonetheless, the majority identified their CF provider and parents as the preferred source of reproductive health information (6–8). This chapter addresses CF-specific reproductive pathophysiology, adolescence, gender-specific issues, reproductive health, pregnancy, fertility assistance, and behavioral aspects of sexuality and living with CF.

II.

Reproductive Pathophysiology

A. Structural Abnormalities

Almost all men with CF (99%) have congenital bilateral absence of the vas deferens (CBAVD). The prevalence of CABVD is 1% to 2% among infertile males without CF (9) with 80% positive for CFTR mutations (10). Thus, it seems that a normal amount of functioning CFTR protein is needed for embryologic development of the vas deferens. Although the exact mechanism is unknown, the detection of CFTR mRNA in the human fetal reproductive tract suggests that CFTR protein acts in the development of the reproductive tissues in men (11). In contrast, women with CF typically have structurally normal reproductive tracts. There is an increased prevalence of CFTR mutations among non-CF women with congenital absence of the uterus and vagina (CAUV), but given the

457

458

Tuchman and Gisone

low prevalence of CAUV among women with CF, it is unlikely that the mechanism of agenesis is the same for both genders. B. Puberty

Delayed puberty and menarche are common, even in healthy, well-nourished female adolescents with CF (12). While the mechanism is not well understood, it is known that multiple sites within the female reproductive tract are affected by mutations in CFTR. The hypothalamic pituitary axis controls the onset and rate of puberty. Gonadotropin-releasing hormone (GnRH) is secreted from the hypothalamus inducing luteinizing hormone (LH) and follicle stimulating hormone (FSH) production and release from the anterior pituitary gland. Fluctuations in LH and FSH are critical to ovulation by stimulating development of a primary ovarian follicle and causing the primary follicle to be released (ovulation). Expression of CFTR in the rat brain and the human hypothalamus has been documented (13–15). Thus, it has been speculated that altered CFTR expression in the hypothalamus results in abnormal secretion of GnRH that in turn leads to dysregulatory neuroendocrine secretion of hormones and thereby delays sexual maturation (12). Much of the female reproductive tract is lined by epithelial cells and is therefore also affected by mutations in CFTR (16). In addition to known ovulatory disturbances and tenacious cervical mucous in CF, there are changes in uterine bicarbonate secretion (12,17,18). An alternative theory to explain delayed puberty in females with CF is increased energy consumption [resting energy expenditure (REE)]. When compared with males with CF and control females, females with CF have higher REE (19). However, a recent study showed that raised REE appears to be independent of menarchal status (pre- or post-menarche), and independent of phase of menstrual cycle based on date of last menstrual period (LMP) (20). Additionally, in healthy populations, it is well established by using ultrasensitive recombinant cell assays for estrogen that prepubertal girls have 8-fold higher estrogen levels than prepubertal boys (21). In non-CF children, this may contribute to girls’ greater rate of skeletal maturation, earlier onset of puberty, and earlier cessation of growth when compared with boys. This prepubertal increase in estrogen also provides a potential explanation for why females with CF aged 2 to 20 years have had significantly poorer survival than male patients (22), given concerns about estrogen’s effect on net worsening of airway surface dehydration and decreased mucocilliary clearance (23). Data examining the longitudinal relationship between timing of menarche with disease symptoms and progression are sparse.

III.

Adolescence

Adolescents with CF must navigate through a dynamic physical, biological, social, and psychological transition while managing chronic illness and effects of CF on social and reproductive development and function. Many CF teens have problems with body image and are keenly aware of how they may look different than their peers. Accurate CF sexual and reproductive health information should be routinely offered so that parents and individuals with CF can anticipate how CF may affect physical, emotional, and interpersonal development. Much like their healthy peers, an ongoing age appropriate dialogue regarding reproductive health is critical in minimizing

Reproduction, Sexuality, and Fertility

459

anxiety about how CF affects reproductive function and opens the door for continued discussions as concerns or issues arise. It is recommended that all females aged 13 to 15 years have their first gynecological or adolescent medicine visit for preventive healthcare services, including ageappropriate education and guidance (24). It is important to recognize that routine reproductive and sexual health screenings may not address the CF-specific reproductive health needs. The development of adolescent sexuality is an important complex phenomenon whose success significantly contributes to adaptation into adulthood. Adolescents with CF can expect normal sexual function and to have the same risk as healthy peers to be exposed to sexually transmitted infections (STIs). Although the prevalence of bacterial STIs in the CF population is unknown, it is likely to be very low given the frequent use of antibiotics. Viral STI prevalence (human papillomavirus, genital herpes) in CF populations is also unknown, but can be assumed to be similar to the general population of sexually active individuals. All people with CF should be advised they need to use condoms or barrier protections to reduce the risk of genital STI transmission. It has been well established that rates of cervical dysplasia are increased in immune-suppressed patients (25,26). Therefore, women with CF, particularly lung transplant patients, should get yearly cervical cancer screening. A. Risk Taking

Some risk-taking behavior is normal during adolescence and teens with CF are no different, although consequences can be great. While reported rates of risky behaviors (tobacco use, sexual intercourse) are lower among teens with CF than healthy peers, still 20% of teens with CF report smoking and 28% report sexual intercourse (27). Similarly, many youth with chronic health conditions experiment with adherence-related risk taking. A positive approach to maintaining health is generally more effective than focusing on negative behaviors. Thus, we recommend an open dialogue and nonjudgmental approach to guiding teens and young adults with CF toward healthy behaviors. B. Sources of Information

A recent study revealed that little disease-specific reproductive health information is required for pediatric pulmonology board certification despite the growing adolescent and young adult population with CF (28). Perhaps this stems from insufficient scientific evidence or unclear expectations about whose responsibility it is to provide CF-related reproductive health. Although adolescents may initially acquire sexual and reproductive health information from their parents, the Internet and/or other health care providers, pediatric, and adult pulmonologists along with their CF teams can greatly influence their patients’ reproductive decision-making. CF providers have the opportunity to address myths or concerns regarding inaccurate information seen on the Internet, especially given concerns regarding adherence to AMA guidelines (29) of CF informational Web sites (30). Understanding the role of reproductive health in CF disease as well as informing safer reproductive health care for the growing adolescent and adult CF population should be a priority area of future research. Guidelines for CF providers caring for teens and young adults are included in Figure 1 along with essential CF-specific reproductive health resources in Figure 2.

460

l

l

l

Tuchman and Gisone

A positive approach to maintaining health is generally more effective than focusing on negative behaviors. Thus, we recommend an open dialogue and nonjudgmental approach. Ask about and document hormonal contraception use, menstrual history, pubertal development, and encourage routine gynecologic care. Keep in mind:

 Men with CF should be n

informed that they are not impotent, but likely unable to conceive without fertility medical intervention during early adolescence, n offered semen analysis during adolescence, n advised to use condoms to prevent STI transmission, n offered hope regarding the potential for fatherhood.  Women with CF should be n informed that they are fertile, n offered contraceptive choices during adolescence, n advised to use condoms to prevent STI transmission, n monitored for vaginal yeast infections and incontinence, n screened for diabetes during and after pregnancy.

Figure 1 Tips for CF providers caring for teens and young adults.

1. 2. 3. 4.

Sawyer S, Roseby C. “What They Don’t Tell You: A Young Person’s Guide to Sexual and Reproductive Health Issues in Cystic Fibrosis”. Melbourne: Centre for Adolescents Health, 2001. ISBN 1740560043 “Sexuality and Cystic Fibrosis: Information for Adolescents” available in PORT CF and at: http://www.cysticfibrosis.ca/pdf/AdolescentSexuality2008E.pdf “Sexuality and Cystic Fibrosis: Information for Adults” available in PORT CF and at: http://www.cysticfibrosis.ca/pdf/SexualityAdultE.pdf “Guidelines for the management of pregnancy in women with CF” (53)

Figure 2 Essential Reproductive Health Resources for Adolescents and Young Adults with CF.

IV.

Women

A. Estrogen and CFTR

In women without CF, estrogen is known to increase the water content of cervical mucous; these changes are not observed in women with CF (31). One recent study reported that during phases of the menstrual cycle with increased estrogen levels, women experience decreased calcium-mediated chloride secretion, resulting in a net worsening of airway surface dehydration and decreased mucocilliary clearance (23). It is not known how these epithelial changes relate to clinical status, but it raises both concerns about exogenous estrogen administration and suggesting hormone-based therapeutic possibilities, highlighting the historical gender differences in CF pulmonary disease.

Reproduction, Sexuality, and Fertility

461

B. Menses

Empirically, patients with CF report worsening of respiratory symptoms prior to and during menstruation. There is one small study published investigating lung function changes in relation to the menstrual cycle in twelve females with CF (32). Participants kept daily records during three menstrual cycles that included lung function, sputum quality, and need for IV antibiotics. Airway symptoms were compared at three time points: (i) ovulation: with high estrogen, low progesterone; (ii) luteal phase: high progesterone, low estrogen; and (iii) menses: low progesterone, low estrogen. Pulmonary function was significantly higher with increased forced expiratory volume in one second (FEV1) during the luteal phase compared to ovulatory and menstruation (p < 0.01) possibly due progesterone’s role in inducing smooth muscle relaxation affecting airway smooth muscle. It is unclear whether these differences in lung function and symptoms represent a worsening of pulmonary function because of elevated levels of estrogen during the follicular phase, an improvement because of elevated progesterone levels in the luteal phase, or some other process not yet elucidated. Another study reported higher nasal potential difference (NPD) during the luteal than follicular phase suggesting ion transport is altered by female hormones in vivo (33). Further supporting female sex hormone involvement in mediating pulmonary function is that cyclical changes in symptoms and lung function have only been observed in females with CF, not males (34). C. Models in Other Diseases (Asthma)

There is a well-described subset of female asthmatics, ranging from 33% to 52% reported prevalence, with worsening of asthmatic symptoms during the perimenstrual phase of the menstrual cycle (35–37). Almost half of women admitted to the hospital for an asthma exacerbation in one study were identified as perimenstrual (38). Numerous studies suggest that the use of combination estrogen and progesterone hormonal contraceptive methods reduce endogenous hormonal fluctuation and thereby significantly improve premenstrual asthma and reduce steroid dependence (39–41). Investigators speculate that the role of estrogen and progesterone in premenstrual asthma is related to reduced contractility and increasing relaxation of bronchial smooth muscle (42–44). Further, estrogen withdrawal is known to increase bronchial contractility (45). D. Prostaglandins, Menses, and CF

The sequential stimulation of the endometrium by estrogen (follicular phase) followed by progesterone (luteal phase) results in a large increase in endometrial stores of arachidonic acid, a precursor to prostaglandin production. During menstruation the arachidonic acid is converted to prostaglandin F2-alpha (PGF2), prostaglandin E2 (PGE2), and leukotrienes, which play a major role in inducing uterine contractions during menses. In CF, pulmonary exacerbations are characterized by increased oxidative stress and sputum concentrations of bioactive lipid mediators, including prostaglandins (46). A recent Cochrane meta-analysis concluded that high-dose ibuprofen can slow the progression of lung disease in people with CF, especially in children, suggesting that strategies to modulate lung inflammation can be beneficial for individuals with CF (47). Whether prostaglandins produced monthly during menses affects short- or long-term lung function via increased acute or cumulative inflammation is unclear.

462

Tuchman and Gisone E.

Fertility

The main hypothesized mechanism for decreased fertility among CF women is tenacious cervical mucous that is impermeable to sperm. Malnutrition, inflammation, and other described ovulatory disturbances may play a role (48). F.

Sexual and Reproductive Health Issues

Vulvovaginal candidiasis, stress incontinence, and vaginal dryness are common complaints of women with CF. Gynecology or adolescent medicine referral is appropriate to address these concerns. Recommending aerosol therapy prior to intercourse can reduce coughing and fatigue that may impact intimacy. G. Contraception

Women with CF absolutely need contraception to prevent pregnancy. The same options that exist for non-CF women are appropriate for women with CF. No clinical studies have addressed whether progestin-only methods [progestin only pills, depot medroxy progesterone acetate (intramuscular contraceptive injection), progestin-impregnated intrauterine device (IUD)] adversely affect bone health in CF, but can be assumed to have the same effects as in non-CF women. Pills, patch, and ring (combined estrogen and progesterone hormonal methods) are appropriate but it is unknown how exogenous estrogen may affect ion transport as reported in vivo. Among women with CF, prevalence of contraceptive use is estimated to be around 60% (49), although contraceptive information is not recorded in the CFF registry. Issues such as malabsorption of oral contraceptive pills (50), risk of venous thrombosis, liver dysfunction affecting metabolism of exogenous hormones, pulmonary hypertension (51), and possibility of decreased effectiveness of oral contraceptives with certain medications must be taken into consideration. Condom or barrier protection use should always be encouraged, both for back-up contraception and to reduce risk of STI transmission. H. Pregnancy

Empirically, women with CF report that pregnancy is the time they feel the best, both emotionally and physically. The number of pregnancies and live births reported has increased yearly in the CFF Registry. Encouragingly, the 10-year-survival rate of women with CF who have conceived and delivered children (while controlling for disease severity) was higher than those who never had children (52). Pregnancy and motherhood is a realistic possibility for many women with CF. It should be noted that pregnancy is contraindicated if a woman has preexisting pulmonary hypertension or cor pulmonale (53). There are also concerns of fetal hypoxia and growth retardation in women with severely impaired lung function that requires oxygen supplementation (53). Health optimization is critical prior to conception, although women with CF can expect to choose pregnancy and carry out a term delivery safely, mostly likely without negative long-term health consequences. Importantly, increased medical care around conception, pregnancy, and delivery is essential, especially CF-related diabetes screening and treatment (54,55). Breast-feeding is possible, but needs to be carefully weighed with nutritional demands and crossover of medications into breast milk.

Reproduction, Sexuality, and Fertility

463

V. Men A. Fertility

Although obstructive azoospermia is the primary mechanism of infertility in men, reduced spermatogenesis, sperm and semen volume, as well as low semen pH have all been described and may contribute to reduced fertility (56). B. Sexual and Reproductive Health Issues

Both genders may experience coughing and fatigue impacting intimacy. These symptoms may be reduced by aerosol therapy prior to intercourse. It should be emphasized that while men with CF are unable to conceive naturally, they are not impotent. Men with CF have normal sexual function including arousal and ejaculation. Testosterone levels in men with CF are commonly lower than healthy controls and may impact libido, mood, bone health, and muscular function. Therefore, endocrine referral and routine testosterone level monitoring with intramuscular repletion is appropriate. While it remains unclear whether testosterone repletion affects respiratory muscle function and pulmonary outcomes (57), it likely improves mood and quality of life of men with CF. C. Semen Analysis

Males with CF may be unaware of their fertility status and many report not been offered sperm analysis despite wanting fertility testing (2,3,8). Discussions with CF males should ensure that impotence is not confused with infertility and include specific information regarding the percentage of infertile men with CF, the likelihood of normal spermatogenesis, abnormalities in semen parameters (4,58), and the option of sperm aspiration and intracytoplasmic sperm injection (ICSI) along with genetic counseling to help achieve pregnancy. To make informed decisions about their sexual and reproductive health, all men should be offered semen analysis to assess for fertility (46). Males with CF report preferring to receive information about fertility at an earlier age (14.4 years) than when their provider-patient discussions actually occurred (16.4 years) (59,60). Revisiting semen analysis throughout puberty and young adulthood is appropriate, as relevance is variable depending on maturity and developmental stage.

VI.

Assisted Reproductive Technologies

Advancements in reproductive technologies make conception and pregnancy easier and more successful for couples where one or both partners have CF. While almost all men with CF have abnormalities in semen parameters, biologic paternity can be achieved through surgical techniques that allow for the procurement of viable sperm via microsurgical epididymal sperm aspiration (MESA), percutaneous epididymal or testicular sperm aspiration (PESA, TESA) in combination with ICSI and in vitro fertilization (IVF). Men with CF and their female partners may also choose IVF via donor sperm. Women with CF, while usually fertile, can use intrauterine insemination of washed sperm (61) or IVF to help achieve pregnancy. If ovulation induction is considered, risks such as ovarian hyperstimulation and increased risk of ovarian torsion must be considered.

464

Tuchman and Gisone

VII.

Parenting with CF

With increased life expectancy comes a greater desire for parenthood in women and men with CF (53). The newborn period is often an exhausting and emotional time in which parents with CF will require close medical monitoring and support. Balancing the care of a newborn with the demands of their own self-care can be overwhelming and requires a dedicated partner and family support.

VIII.

Genetic Screening

The probability of conceiving a child with CF is based on the carrier rate in the population and whether one or both partners have CF. A complete review of prenatal genetic-testing options coupled with prenatal counseling early on in planned conception should be offered. Pan-ethnic CF screening has been recommended by the American College of Medical Genetics and the American College of Obstetricians and Gynecologists for all couples interested in parenthood and should include ethnic-specific mutations that may be present within the diverse population of the United States (62). The National Institutes of Health strongly recommends genetic testing for couples when the male partner (or sperm donor) is positive for a CF mutation and has either CF or obstructive azoospermia, and the couple is taking steps to use assisted reproductive technologies (63). However, genetic screens do not yet detect all CF carriers given that there are more than 1400 different CF gene mutations. Therefore, even with a negative genetic screen, there is still a slight possibility that a partner may be a CF carrier. Currently, screening practices vary between cities, states, and countries, and routine screening of both partners may be unavailable or cost prohibitive depending on insurance status. Offering the option of preimplantation genetic diagnosis to allow women with CF and/or their partners to make reproductive choices prior to conception should be considered.

References 1. Sawyer SM, Bowes G, Phelan PD. Reproductive health in young women with CF. J Adolesc Health 1995; 17(1):46–50. 2. Sawyer SM, Tully MA, Dovey M, et al. Reproductive health in males with CF. Paediatr Pulmonol 1998; 25(4):226–230. 3. Hull SC, Kass NE. Adults with cystic fibrosis and (in)fetility: how has the health care system responded? J Androl 2000; 21(6):809–813. 4. Lyon A, Bilton D. Fertility issues in cystic fibrosis. Pediatr Respir Rev 2002; 3(3):236–240. 5. Fair A, Griffiths K, Osman LM. Attitudes to fertility among adults with cystic fibrosis in Scotland. Thorax 2000; 55(8):672–677. 6. Nixon GM, Glazner JA, Martin JM, et al. Female sexual health care in cystic fibrosis. Arch Dis Child 2003; 88(3):265–266. 7. Hames A, Beesley J, Nelson R. Cystic fibrosis: what do patients know, and what else would they like to know? Respir Med 1991; 85(5):389–392. 8. Nolan T, Desmond K, Herlich R, et al. Knowledge of cystic fibrosis in patients and their parents. Pediatrics 1986; 77(2):229–235. 9. Blau H, Freud E, Mussaffi H. Urogenital abnormalities in male children with cystic fibrosis. Arch Dis Child 2004; 87(2):135–138. 10. Clustres M, Guittard C, Bozon D, et al. Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of bilateral vas deferens in France. Hum Mutat 2000; 16(2):143–156.

Reproduction, Sexuality, and Fertility

465

11. Tizzano EF, Chitayat D, Buchwald M. Cell specific localization of CFTR mRNA shows developmentally regulated expression in human fetal tissue. Hum Mol Genet 1993; 2(3): 219–224. 12. Johannesson M, Landgren BM, Csemiczky G, et al. Female patients with cystic fibrosis suffer from reproductive endocrinological disorders despite good clinical status. Hum Reprod 1998; 13(3):2092–2097. 13. Mulberg AE, Resta LP, Wiedner EB, et al. Expression and localization of the cystic fibrosis transmembrane conductance regulator mRNA and its protein in rat brain. J Clin Invest 1995; 96(1):210–242. 14. Johannesson M, Bogdanovic N, Nordqvist AC, et al. Cystic fibrosis mRNA expression in rat brain: cerebral cortex and medial preoptic area. Neuroreport 1997; 8(2):535–539. 15. Mulberg AE, Weyler RT, Altschuler SM, et al. Cystic fibrosis transmembrane conductance regulator expression in human hypothalamus. Neuroreport 1998; 9(1):141–144. 16. Edenborough FP. Women with cystic fibrosis and their potential for reproduction. Thorax 2001; 56(8):649–655. 17. Chan HC, Shi QX, Zhou CX, et al. Critical role of CFTR in uterine bicarbonate secretion and the fertilizing capacity of sperm. Mol Cell Endocrinol 2006; 250(1-2):106–113. 18. Kopito LE, Kosasky HJ, Schwachman H. Water and electrolytes in cervical mucous from patients with cystic fibrosis. Fertil Steril 1973; 24(7):512–516. 19. Stallings VA, Tomezsko JL, Schall JI, et al. Adolescent development and energy expenditure in females with cystic fibrosis. Clin Nutr 2005; 24(5):737–745. 20. Barclay A, Allen JR, Blyler E, et al. Resting energy expenditure in females with cystic fibrosis: is it affected by puberty? Eur J Clin Nutr 2007; 61(10):1207–1212. 21. Klein KO, Baron J, Colli MJ, et al. Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay. J Clin Invest 1994; 94(6):2475–2480. 22. Kulich M, Rosenfeld M, Goss C, et al. Improved survival among young patients with cystic fibrosis. J Peds 2003; 142(6):631–636. 23. Coakley RD, Sun H, Clunes LA, et al. 17B-Estradiol inhibits Ca2+ dependent homeostasis of airway surface liquid volume in human cystic fibrosis airway epithelia. J Clin Invest 2008; 118(12):4025–4035. 24. Delisi K, Gold MA. The initial adolescent preventive care visit. Clin Obstet Gynecol 2008; 51(2):190–204. 25. Paternoster DM, Cester M, Resente C, et al. Human papilloma virus infection and cervical intraepithelial neoplasia in transplanted patients. Transplant Proc 2008; 40(6):1877–1880. 26. Malouf MA, Hopkins PM, Singleton L, et al. Sexual health issues after lung transplantation: importance of cervical screening. J Heart Lung Transplant 2004; 23(7):894–897. 27. Britto MT, Garrett JM, Dugliss MA, et al. Risky behavior in teens with cystic fibrosis or sickle cell disease: a multicenter study. Pediatrics 1998; 101(2):250–256. 28. Tuchman LK, Peter NG, Schwarz DF. What pediatric subspecialists need to know about reproductive health: a review of the American Board of Pediatrics content outlines for subspecialty certifying exams. Int J Sex Health 2008; 20(4):262–269. 29. Winker MA, Flanagin A, Chi-Lum B, et al. Guidelines for medical and health information sites on the Internet. JAMA 2000; 283(12):1600–1606. 30. Anselmo MA, Lash KM, Steib ES, et al. Cystic Fibrosis on the Internet: a survey of site adherence to AMA guidelines. Pediatrics 2004; 114(1):100–103. 31. Kopito LE, Kosasky HJ, Schwachman H. Water and electrolytes in cervical mucous from patients with cystic fibrosis. Fertil Steril 1973; 24:512–516. 32. Johannesson M, Ludviksdottir D, Janson C. Lung function changes in relation to menstrual cycle in females with cystic fibrosis. Respir Med 2000; 94(11):1043–1046. 33. Sweezy NB, Smith D, Corey M, et al. Amiloride-insensitive nasal potential difference varies with the menstrual cycle in cystic fibrosis. Pediatr Pulmonol 2007; 42(6):519–524.

466

Tuchman and Gisone

34. Wilschanski M, Dupuis A, Ellis L, et al. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med 2006; 174(7):787–794. 35. Eliasson O, Scherzer HH, DeGraff AC Jr. Morbidity in asthma in relation to the menstrual cycle. J Allergy Clin Immunol 1986; 77(1 pt 1):87–94. 36. Gibbs CJ, Coutts II, Lock R, et al. Premenstrual exacerbation of asthma. Thorax 1984; 39(11):833–836. 37. Chandler MH, Schuldeisz S, Phillips BA, et al. Premenstrual asthma: the effect of estrogen on symptoms, pulmonary function, and b2-receptors. Pharmacotherapy 1999; 19(2):374–382. 38. Skobeloff EM, Spivey WH, Silverman R, et al. The effect of the menstrual cycle on asthma presentations in the emergency department. Arch Intern Med 1996; 156 (16):1837–1840. 39. Myers JB, Sherman CB. Should supplemental estrogens be used as steroid sparing agents in asthmatic women. Chest 1994; 106(1):318–319. 40. Beynon HL, Garbett ND, Barnes PJ. Severe premenstrual exacerbation of asthma: effect of intramuscular progesterone. Lancet 1988; 2(8607):70–72. 41. Tan KS, McFarlane LC, Lipworth BJ. Modulation of airway reactivity and peak flow variability in asthmatics receiving the oral contraceptive pill. Am J Respir Crit Care Med 1997; 155(4):1273–1277. 42. Abdul-Karim RW, Marhsall LD, Nesbitt RE Jr. Influence of estradiol-17b on the acetylcholine content of the lung in the rabbit neonate. Am J Obstet Gynecol 1970; 107(4):641–644. 43. Perusquı´a M, Herna´ndez R, Montan˜o LM, et al. Inhibitory effect of sex steroids on guinea pig airway smooth muscle contractions. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1997; 118(1):5–10. 44. Foster PS, Goldie RG, Paterson JW. Effect of steroids on b-adrenocepter-mediated relaxation of pig bronchus. Br J Pharmacol 1983; 78(2):441–445. 45. Skobeloff EM. Estrogen withdrawal alters bronchial muscle response in a rabbit asthmatic model. Ann Emerg Med 1995; 25(10):128–129. 46. Reid DW, Misso N, Aggarwal S, et al. Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis. Respirology 2007; 12(1):63–69. 47. Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst Rev 2007; (4); doi: 10.1002/14651858.CD001505.pub2. 48. Galli-Tsinopoulou A, Moudiou T, Mamopoulos A, et al. Multifollicular ovaries in female adolescents with cystic fibrosis. Fertil Steril 2006; 85(5):1484–1487. 49. Plant BJ, Goss CH, Tonelli MR, et al. Contraceptive practices in women with cystic fibrosis. J Cyst Fibrosis 2008; 7(5):412–414. 50. Willett MJ, Ellis AG. Reproductive health in women with cystic fibrosis. Hosp Med 1999; 60(12):863–867. 51. Roberts S, Green P. The sexual health of adolescents with cystic fibrosis. J R Soc Med 2005; 98(suppl 45):7–16. 52. Goss CH, Rubenfeld GD, Otto K, et al. The effect of pregnancy on survival in women with cystic fibrosis. Chest 2003; 124(4):1460–1468. 53. Edenborough FP, Borgo G, knoop C, et al. Guidelines for the management of pregnancy in women with cystic fibrosis. J Cyst Fibros 2008; 7:S2–S32. 54. McMullen AH, Pasta DJ, Frederick PD, et al. Impact of pregnancy on women with cystic fibrosis. Chest 2006; 129(3):706–711. 55. Hardin DS, Rice J, Cohen RC, et al. The metabolic effects of pregnancy in cystic fibrosis. Obstet Gynecol 2005; 106(2):367–375. 56. Sueblinvong V, Whittaker LA. Fertility and pregnancy: common concerns of the aging cystic fibrosis population. Clin Chest Med 2007; 28(2):433–443.

Reproduction, Sexuality, and Fertility

467

57. Barry PJ, Waterhouse DF, Reilly CM, et al. Androgens, exercise capacity, and muscle function in cystic fibrosis. Chest 2008; 134(6):1258–1264. 58. Lewis-Jones DI, Gazvani MR, Mountford R. Cystic fibrosis in infertility: screening before assisted reproduction: opinion. Hum Reprod 2000; 15(11):2415–2417. 59. Sawyer SM, Farrant B, Cerritelli B, et al. A survey of sexual and reproductive health in men with cystic fibrosis: new challenges for adolescent and adult services. Thorax 2005; 60(4):326–330. 60. Sawyer SM, Tully MA, Colin AA. Reproductive and sexual health in males with cystic fibrosis: a case for health professional education and training. J Adolesc Health 2001; 28(1):36–40. 61. Kredentser JV, Pokrant C, McCoshen JA. Intrauterine insemination for infertility due to cystic fibrosis. Feril Steril 1986; 45(3):425–426. 62. Sugarman EA, Rohlfs EM, Silverman LM, et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. Genet Med 2004; 6(5):392–399. 63. Sokol RZ. Infertility in men with cystic fibrosis. Curr Opin Pulm Med 2001; 7(6):421–426.

30 A Biopsychosocial Model of Cystic Fibrosis: Social and Emotional Functioning, Adherence, and Quality of Life DAVID BARKER and ALEXANDRA L. QUITTNER University of Miami, Coral Gables, Florida, U.S.A.

I.

Introduction

Over the last two decades, advances in the diagnosis and treatment of cystic fibrosis (CF) have led to significant improvements in health outcomes and life expectancy. Median life expectancy in the United States is now 36.7 years (1) and the majority of pediatric patients diagnosed today are expected to live into adulthood. These improvements in life expectancy have shifted the focus of CF research and clinical care toward the complex interplay among behavioral, psychosocial, and health outcomes. This change in focus is epitomized by the growing prominence of patient-reported outcomes (PROs), such as health-related quality of life (HRQOL), and new efforts to address behavioral and emotional challenges, such as adherence and depression (2). This chapter introduces a developmental biopsychosocial model that highlights the bidirectional influences of age-related development on disease management and progression, and presents current research on these influences.

II.

A Developmental, Biopsychosocial Model of CF

Across the lifespan, physical, social, and emotional development occurs in the context of multiple interacting systems. Children are members of families, schools, communities, and cultures. All of these systems interact dynamically with each other to influence development (3) (Fig. 1). The presence of CF affects these systems in important ways: it increases family stress, changes family functioning and peer relations, and introduces new systems to the family (4) (health care providers, hospitals, etc.). CF also directly affects children’s physical development (i.e., delayed puberty, short stature) as well as their goals and plans for the future. These systems, in turn, affect the course of the illness and its management (5). The dynamic interplay of these systems often creates transition periods marked by rapid change (6). The most notable and predictable transition periods for patients and families with CF are (i) time of diagnosis, (ii) entrance into school, (iii) development of autonomy during adolescence, and (iv) transition into adult roles. Each transition is typically marked by major changes in one or more social, family, or medical contexts/ systems, requiring the others to adjust. For example, as children enter school, parents must coordinate CF treatments with school personnel, and children must decide how

468

Social and Emotional Functioning, Adherence, and Quality of Life

469

Figure 1 Systems and contexts that influence patient health. This figure depicts the most salient

systems and contexts that influence patient’s health. The white boxes represent systems and the gray boxes represent contexts. Overlapping boxes illustrate how patients and families manage CF in a number of contexts. Abbreviation: CF, cystic fibrosis.

much to disclose their illness to peers. Attending school and developing peer relationships are new contexts that influence how patients and families manage CF (7). Eventually, families adjust to these changes and settle into more predictable patterns of interactions and behaviors. These new patterns, however, may be very different from those preceding the transition. For example, a child who was adherent to his or her treatment regimen prior to entering school may be less adherent following this transition because school activities and homework compete with the time needed to do treatments. Conversely, parents may benefit from the structure school provides (e.g., returning to work) and adherence may improve because of reduced family stress (8). Identifying these transitions is important because even minimal interventions at these critical points may have large and lasting effects for patients and families. For example, children with CF may have difficulty getting enough snacks during the day at school. Facilitating collaboration between parents and schools to provide these snacks may improve the child’s nutritional status and prevent a decrease in weight gain and growth (9). Thus, transitions present critical opportunities for intervention. In the remainder of this chapter, we will briefly review the literature on social and emotional functioning, adherence, and quality of life. First, the impact of CF on each of these outcomes will be discussed, followed by research on their interrelationships during major developmental periods (infancy, middle childhood, adolescence, and young adulthood).

III.

Social and Emotional Functioning, Adherence, and Quality of Life in CF

A. Social and Family Functioning

Because it is present at birth, CF fundamentally changes many aspects of social functioning both within and outside the family. Following diagnosis, families must not only learn about a new and often frightening illness, but also rapidly shift their roles to accommodate caregiving. This leads to significant changes in parenting roles and plans for the future (8,10–12). The advent of newborn screening, which has now been

470

Barker and Quittner

implemented in a majority of states, is likely to improve long-term health outcomes, but has also been shown to contribute to parental distress (13). The illness continues to influence family functioning throughout development. A focus on diet, ingestion of enzymes, and several hours of treatment each day often generate difficulties with mealtimes, behavior problems related to adherence, and sleep disruptions during childhood (14–16). During adolescence, conflict between parents and teens escalates, primarily in relation to adherence, increasing the challenge of balancing the adolescent’s need for independence with adequate parental supervision (17,18). CF also affects social functioning outside of the family. The complex and timeconsuming treatment regimen, frequent hospitalizations, and infection control policies have changed how patients with CF interact with their peers (19,20). This is particularly true for adolescents, who may choose not to disclose their diagnosis. They may forgo social events to do their treatments or may skip treatments to hide their illness from friends (21,22). Moreover, infection control guidelines prohibit all face-to-face contact with other individuals who have CF, which limits the unique type of support these peers provide given their shared experiences (23,24). In other chronic conditions (e.g., pediatric cancer, diabetes, asthma, sickle cell disease) patients can meet in groups to discuss illness-related issues or attend illness-specific camps, which are generally believed to improve emotional well-being and disease management (25). Technology-based innovations, such as online social networks and web-enabled cell phones, may provide opportunities for safe social interactions among peers with CF (26,27). B. Emotional Functioning

Chronic illnesses, such as CF, increase the amount of individual and family distress, often leading to elevated symptoms of depression and anxiety. In CF, rates of depression using standardized screening measures have ranged from 11% to 29% in children and adolescents, 29% to 64% in caregivers, and 29% to 46% in adults (2,28,29). Higher rates of anxiety have also been found (30,31). With the exception of two studies (32,33), evidence of increased symptomatology is highly consistent (2) and has been linked to poorer health outcomes and quality of life (28). An international epidemiological study is currently underway to provide population-based estimates of depression and anxiety, and to examine their associations with health outcomes (tides-CF.org) (2). C. Treatment Adherence

Medications and treatments can only benefit patients if they are taken or completed. Estimates of adherence in CF vary by method of measurement, type of treatment, and age. In one of the few studies examining adherence to several treatment components using multiple methods of assessment, Modi and colleagues reported adherence rates for children ranging from 22% to 71% for objective measures and 67% to 100% for selfreport measures (34). This study also found great variability between treatments, a finding that is consistent with the larger literature on adherence. In general, adherence tends to be better for simple treatments that do not require lifestyle changes (pill taking) than for complex, time-intensive treatments (airway clearance, dietary recommendations, daily inhaled medications, etc.) (35–37). Adherence rates also vary by the patient’s developmental stage; they tend to be better in younger children but drop significantly during adolescence (38).

Social and Emotional Functioning, Adherence, and Quality of Life

471

Measuring adherence in CF is difficult because it is multicomponent and complex (e.g., dietary changes, inhaled medications, airway clearance, etc.). Although adherence behaviors cannot be observed in a practical sense, several indirect measures of adherence are available (39). The simplest, least expensive methods are standardized selfreport questionnaires or interviews to ask patients directly about their adherence behaviors. This method can be adapted to all aspects of the treatment regimen (diet, enzyme and vitamin usage, and airway clearance); however, it has been shown to be highly influenced by the patients’ desire to appear adherent, and thus, is biased toward inflation of these behaviors (39). Daily diaries help to reduce this social desirability bias by asking about daily activities over the past 24 hours in an unobtrusive manner, with few prompts about treatment behaviors. The Daily Phone Diary (DPD) (40) has been used extensively in CF and was judged “well established” in a recent review of evidence-based adherence measures (39). It has now been adapted for asthma, HIV-AIDS, diabetes, and traumatic brain injury. The DPD provides rich information about the social context surrounding treatment regimens (e.g., extent of parental supervision); however, it requires a trained telephone interviewer (34,39,40). Electronic monitors (electronic bottle caps, aerosol counters, etc.) provide a detailed and accurate measure of the date and time of treatment behaviors, but are restricted to treatments that can be monitored electronically (oral medications, nebulized medications, etc.) and are costly to purchase. Finally, pharmacy refill data provide accurate information about whether the patient fills a prescription, but only indirectly indicates whether the medication was taken (41,42). Given the strengths and weaknesses of these various measures, the use of multiple methods is recommended (39). However, there is currently little guidance on how to combine these different measures into a reliable and valid index of adherence (43). D. Patient-Reported Outcomes

Over the past 20 years, tremendous progress has been made in defining and measuring PROs with growing recognition of their importance in health outcomes research and clinical care (44). A PRO has been defined as any measure of a patient’s health status, elicited directly from the patient, that assesses how the patient “feels or functions with respect to his or her health condition” (45). This may include observable events, behaviors, or feelings (e.g., ability to run and exercise, lack of appetite, etc.) or unobservable outcomes known only to the patient (e.g., perceptions of pain, increased chest congestion, feeling sad, etc.). PROs range from single-item symptom ratings to complex, multidimensional HRQOL measures that can be used to evaluate new pharmaceutical, behavioral, and surgical interventions and aid in clinical decision making (44,46–48). PROs used to evaluate interventions must meet rigorous psychometric criteria, including a welldefined conceptual framework and strong evidence of reliability and validity (49,50). If these criteria are met, the Food and Drug Administration (FDA) now accepts PROs as primary or secondary outcomes in drug registration trials (45,51). Although generic measures of HRQOL have been used in CF (52), a substantial body of literature now suggests that disease-specific measures are more sensitive to change and provide information that is more relevant for clinical interventions (50). Efforts to develop reliable and valid PROs for CF have been very successful, resulting in

472

Barker and Quittner

Figure 2 CFQ-R respiratory scale. Abbreviation: CFQ-R, Cystic Fibrosis Questionnaire–Revised.

three disease-specific instruments and a growing base of empirical and clinical evidence (53). Currently, the Cystic Fibrosis Questionnaire–Revised (CFQ-R) (Fig. 2) (54) is the most widely used PRO for CF and has been deemed well established in reviews of evidence-based measures (53,55). The CFQ-R has three developmental versions: one for children aged 6 to 13, a parent report measure for the same ages, and a version for adolescents and adults aged 14 and older (56). A pictorial, preschool version is now being validated for young children with CF, aged three to six, and their parents (53). Evidence of reliability for the CFQ-R is strong, and several studies have demonstrated that it is sensitive to lung functioning (construct validity) and responsive to clinically relevant changes (responsivity). To date, scores on the CFQ-R have been associated with significant improvements in lung function in patients treated for pulmonary exacerbations (57), with independent ratings of pain (55), and with adults who have elevated symptoms of depression (28). Scores on this PRO have successfully differentiated patients by age (e.g., older patients reporting worse HRQOL), disease severity (normal, mild, moderate, and severe lung disease), gender, and socioeconomic and minority status (58). Further, the minimal clinically important difference (MCID) score was recently established using both anchor- and distribution-based methods (59). A 4-point change (out of 100) or greater on the CFQ-R respiratory scale indicates a clinically significant shift in patients’ symptoms. The CFQ-R has been used as a primary and secondary end point in several phase 2 and phase 3 clinical trials (51,60,61) and has been translated into 30 languages, facilitating its use in international studies. Next steps

Social and Emotional Functioning, Adherence, and Quality of Life

473

include publication of normative data on CFQ-R scores across ages and levels of disease severity to facilitate their use during routine practice to improve the quality of care.

IV.

Relationships Among Outcomes

The biopsychosocial model presented in this chapter suggests that social and emotional functioning, adherence, health outcomes, and quality of life interact dynamically across the life span. Many of the links between these developmental systems are empirically based. The following discussion organizes these research findings by developmental period. A. Early Childhood

Diagnosis of CF typically occurs within the first year of life. As mentioned previously, this creates a period of rapid change and adjustment for families, with high levels of parenting stress and depression commonly reported (2,11). Performing daily treatments is time consuming and requires a parent to be present throughout, which can interfere with parents’ social functioning and work roles (8). Ensuring that children receive the recommended number of pancreatic enzymes and fat-soluble vitamins can also be difficult if children have not learned to swallow pills (62). Programs have been developed to teach young children to swallow pills, which may increase adherence and promote weight gain and growth (63). Managing the disease increases parental distress and is associated with symptoms of depression, poor sleep quality, and marital strain in both mothers and fathers of young children with CF (11,64–66). The consequences of parental depression on children’s development are well established in the general literature and include increased risk for emotional, social, and behavioral difficulties later in life (67). Less is known, however, about how parental stress and depression affect health outcomes in CF. These links have only recently been examined. In a prospective study, Quittner and colleagues identified maternal depression as an important predictor of poor enzyme adherence in children aged 1 to 12 and, furthermore, demonstrated short-term causal effects on weight gain and growth (68). Another study found significant associations among parental stress and depression, child eating and sleeping difficulties, and poor adherence to nebulized medications during the preschool years (14). These studies suggest that annual screening of depression in caregivers and adequate support during early childhood could improve children’s health outcomes. B. Middle Childhood

Middle childhood is often more stable than other developmental periods because children and families have acquired a fair amount of knowledge about CF, are more comfortable in their relationships with CF team members, and have developed daily treatment routines. The major transition during this period is entry into school. Schools present a new system parents must negotiate, including coordinating extra snacks, highcalorie lunches, enzyme administration, and academic progress despite absences from school (7). Families may need to get up earlier to fit in treatments before school, and treatments after school must also be accommodated. Similar to early childhood, emotional and family functioning influence adherence during middle childhood. A recent study demonstrated a link between parent-child

474

Barker and Quittner

relationships and adherence, showing that higher quality relationships were associated with better adherence. This study also demonstrated that more depressive symptoms in children were related to worse adherence. Finally, there is emerging evidence that parents may experience “burnout” in their caregiving role near the end of childhood and in the beginning of adolescence. Interestingly, two studies have now shown that better adherence to airway clearance is associated with more depression in caregivers, which may reflect this phenomena of burnout. These findings highlight the importance of monitoring children and parents’ psychological distress and providing additional support to parent caregivers (29,69). Older school-age children may begin to resist doing their treatments. In one of the few studies to assess barriers to adherence, Modi and colleagues found that the most common barriers were behavior problems/treatment refusal and forgetting to do treatments (62). Identifying these barriers is essential to understanding how families manage CF; unfortunately, barriers are rarely systematically evaluated in studies or in clinical practice. More research is needed to understand the interrelationships among social, emotional, and health outcomes during this period. Interventions during late childhood may prevent the considerable challenges that await families during adolescence. C. Adolescence

Adolescence is a period of intense physical and pubertal development, characterized by rapid emotional and social changes and a drive toward autonomy. This developmental period is challenging for healthy teens and their parents, but presents unique difficulties for teens with CF in the areas of adherence, sexual maturation, and development of peer and romantic relationships. Adolescents are also at risk in terms of health outcomes, not only because of decreased adherence (38) but also because of increased pulmonary exacerbations, more frequent hospitalizations, and substantial declines in lung function. Poor adherence has been linked to time spent with peers outside of the home and away from parental monitoring, increased conflict with parents about responsibilities for medical care, and a heightened desire to be similar to healthy peers (17,18,70,71). Similar to healthy adolescents, teens with CF spend more time in social activities outside of the home, making it more difficult to schedule their treatments. They may also be reluctant to disclose their illness to peers, which may lead to worse adherence (72). Parental supervision has recently been identified as playing a key role in adherence, even among older adolescents. Using daily phone diaries, Modi and colleagues found that simply the presence of a parent in the room increased the likelihood that a treatment would be completed (18). The benefit of parental supervision, however, may be dependent on the quality of the parent-teen relationship (71). Family conflict has been identified as a consistent predictor of poor adherence during adolescence. Parents and teens struggle to find a balance between greater autonomy for the adolescent and assurance that daily treatments will be completed as prescribed (17,71,73). The optimal strategy is to provide adolescents with increasing responsibility for disease management, predicated on their ability to organize their time and perform these tasks. If parents transfer responsibility for disease management too quickly, the adolescent may become overwhelmed and nonadherent. If parents are reluctant to transfer responsibility, teens will not learn the necessary skills to independently manage their disease. They may also rebel against

Social and Emotional Functioning, Adherence, and Quality of Life

475

parental controls, resulting in worse adherence (71,73). Family-based interventions addressing these challenges have been successful in adolescents with CF and other chronic illnesses (17,74). Little is known about how peers and close friends influence adherence. In general, social support has been found to increase adherence across ages and illnesses (75). In CF, only two studies have examined social support during adolescence and, unfortunately, neither measured adherence (21,76). These studies did, however, describe the types of support provided by families and friends. Consistent with the broader literature on social support, friends tended to provide more emotional support and a sense of belonging, while family members provided more tangible assistance with treatments. These studies also found that families and friends were both sources of positive (appropriate reminders) and negative (drawing attention to the illness, nagging, etc.) behaviors. Greatz and colleagues linked negative behaviors to more emotional distress in these youth. To move this area of research forward, a disease-specific measure of social support is needed (76).

D. Adulthood

As patients make a transition from adolescence to adulthood, there are unique challenges that influence their disease management and quality of life. Adults continue to extend their social networks beyond their family and leave home to begin college, a job, or a long-term relationship. It can be difficult for adults with CF to achieve autonomy because of increasing symptoms, lengthy treatment times, and the need for health insurance (77,78). Finding a job can also be challenging because of the need for sick leave, which often requires disclosure (79–81). As patients with CF live longer, healthier lives, they participate in a broader array of activities. A recent survey of 865 adults with CF found that most were in a committed relationship, involved in higher education, employed, and lived away from home (82). However, finding the correct balance between treatments and daily activities is a significant challenge (78,83). Importantly, families continue to provide significant treatment-related support during adulthood (84). Adulthood also brings a transition from pediatric to adult care. This transition is important because adult teams focus on broader lifestyle questions, such as fertility, drug and alcohol use, independent self-care, transplantation, and end-of-life issues (85,86). A smooth transition likely depends on the transfer of responsibility from parents to patients during adolescence and an appropriate transition plan that focuses on self-care responsibility (87–90). The knowledge and skills required to manage this complex disease should be taught beginning in early childhood. Similar to younger patients, symptoms of depression and anxiety are related to adherence and HRQOL in adults. Higher rates of depression have been linked to poorer adherence, worse pulmonary functioning, and lower quality-of-life scores (28). In contrast, higher levels of anxiety have been associated with better treatment adherence (91). Patients who are concerned about their health and well-being may both report slightly higher levels of anxiety and be more conscientious about their treatments. Too much anxiety, however, may interfere with broader functioning. This “paradoxical” effect of anxiety is a promising area for future research.

476

Barker and Quittner

V. Conclusion Because CF is present at birth, it affects many aspects of social, emotional, and behavioral development, which in turn influence health outcomes and quality of life. There is growing evidence that these developmental processes are interrelated and importantly connected to health. A developmental, biopsychosocial model provides a unifying framework for both cutting-edge research and new interventions to improve clinical care. The model presented in this chapter emphasizes the importance of considering relationships among multiple systems (family, peers, school, health care team) as well as identifying key periods of transition that require heightened monitoring and targeted interventions. Several recommendations follow from this review. First, we recommend yearly depression and anxiety screening for both caregivers and patients. Screening for caregivers should begin shortly following diagnosis, and screening for patients at age seven (the youngest age covered by validated screening measures). There are a number of well-validated, brief, readily available measures for this purpose (2,92). This will necessitate the development of referral sources for caregivers and patients who may need both pharmacological and cognitive behavioral interventions (2). Second, because adherence is central to long-term health outcomes, we recommend that evidence-based interventions which improve adherence be integrated into routine clinical care. A number of interventions have been developed to help patients and families improve disease management, with several promising translational studies in process. For example, the iCARE (I Change Adherence and Raise Expectations) study identifies key barriers to adherence and engages teens, parents, and health care providers in brief problem-solving sessions (93). In addition, a randomized trial is underway to evaluate the effectiveness of a web-enabled cell phone (CFFONE) for improving adherence and providing safe peer support (27). Third, we suggest that well-validated PROs be included at annual visits to assess patient functioning across a variety of domains (e.g., social and emotional functioning, treatment burden, etc.), and that patients’ respiratory symptoms be assessed using standardized PRO-based instruments during routine clinic visits. This would provide clinicians with reliable information about symptom change, aiding in early identification of pulmonary exacerbations. Patients’ increased life expectancy and involvement in typical adult activities represent powerful evidence of improved clinical care in CF. Building on this success will require continued innovation and consideration of social and emotional functioning and promotion of adherence in clinical science and clinical care. Such efforts will ultimately lead to improvements in patients’ health and quality of life.

References 1. Cystic Fibrosis Foundation. Patient Registry 2006 Annual Report, Bethesda, MD, 2008. 2. Quittner AL, Barker DH, Snell C, et al. Prevalence and impact of depression in cystic fibrosis. Curr Opin Pulm Med 2008; 14:582–588. 3. Bronfenbrenner U. Making human beings human: bioecological perspectives on human development. Thousand Oaks, California: Sage Publications, 2004. 4. Quittner AL, DiGirolamo AM. Family adaptation to childhood disability and illness. In: Ammerman RT, Campo JV, eds. Handbook of Pediatric Psychology and Psychiatry. Boston, Massachusetts: Allyn & Bacon, 1998:70–102.

Social and Emotional Functioning, Adherence, and Quality of Life

477

5. Martin LR, Williams SL, Haskard KB, et al. The challenge of patient adherence. Ther Clin Risk Manag 2005; 1:189–199. 6. Lerner RM, Theokas C, Bobek DL. Concepts and theories of human development: historical and contemporary dimensions. In: Bornstein MH, Lamb ME, eds. Developmental Science: An Advanced Textbook. 5th ed. Mahwah, New Jersey: Lawrence Erlbaum Associates, 2005:3–44. 7. Quittner AL, Modi AC, Roux AL. Psychosocial challenges and clinical interventions for children and adolescents with cystic fibrosis: a developmental approach. In: Brown RT, ed. Handbook of Pediatric Psychology in School Settings. Mahwah, New Jersey: Lawrence Erlbaum Associates, 2004:333–361. 8. Quittner AL, Opipari LC, Espelage DL, et al. Role strain in couples with and without a child with a chronic illness: associations with marital satisfaction, intimacy, and daily mood. Health Psychol 1998; 17:112–124. 9. Stark LJ, Quittner AL, Powers SW, et al. A randomized clinical trial of behavioral and nutritional education to improve calorie intake and weight in children with cystic fibrosis. Arch Pediatr Adolesc Med 2009; 163:915–921. 10. Go¨tz I, Go¨tz M. Cystic fibrosis: psychological issues. Paediatr Respir Rev 2000; 1:121–127. 11. Quittner AL, Opipari LC, Regoli MJ, et al. The impact of caregiving and role strain on family life: comparisons between mothers of children with cystic fibrosis and matched controls. Rehabil Psychol 1992; 37:289–304. 12. Williams B, Mukhopadhyay S, Dowell J, et al. From child to adult: an exploration of shifting family roles and responsibilities in managing physiotherapy for cystic fibrosis. Soc Sci Med 2007; 65:2135–2146. 13. Tluczek A, Koscik R, Farrell PM, et al. Psychosocial risk associated with newborn screening for cystic fibrosis: parents’ experience while awaiting the sweat-test appointment. Pediatrics 2005; 115:1692–1703. 14. Ward C, Massie J, Glazner J, et al. Problem behaviours and parenting in preschool children with cystic fibrosis. Arch Dis Child 2009; 94(5):341–347. 15. Janicke DM, Mitchell MJ, Stark LJ. Family functioning in school-age children with cystic fibrosis: an observational assessment of family interactions in the mealtime environment. J Pediatr Psychol 2005; 30:179–186. 16. Mitchell MJ, Powers SW, Byars KC, et al. Family functioning in young children with cystic fibrosis: observations of interactions at mealtime. J Dev Behav Pediatr 2004; 25:335–346. 17. DeLambo KE, Ievers-Landis CE, Drotar D, et al. Association of observed family relationship quality and problem-solving skills with treatment adherence in older children and adolescents with cystic fibrosis. J Pediatr Psychol 2004; 29:343–353. 18. Modi AC, Marciel KK, Slater SK, et al. The influence of parental supervision on medical adherence in adolescents with cystic fibrosis: developmental shifts from pre to late adolescence. Child Health Care 2008; 37:78–92. 19. Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-topatient transmission. Infect Control Hosp Epidemiol 2003; 24:S6–S52. 20. Quittner AL, Barker DH, Marciel KK, et al. Cystic fibrosis: a model for drug discovery and patient care. In: Roberts MC, Steele RG, eds. Handbook of Pediatric Psychology. New York: The Guilford Press, 2009: 271–286. 21. Graetz BW, Shute RH, Sawyer MG. An Australian study of adolescents with cystic fibrosis: perceived supportive and nonsupportive behaviors from families and friends and psychological adjustment. J Adolesc Health 2000; 26:64–69. 22. Modi A, Quittner AL, Boyle MP. Disclosure of chronic disease in adults with cystic fibrosis: the adult data for understanding lifestyle and transitions (ADULT) survey. Pediatr Pulmonol 2008; S31:445.

478

Barker and Quittner

23. Kyngas H. Support network of adolescents with chronic disease: adolescents’ perspective. Nurs Health Sci 2004; 6:287–293. 24. DiGirolamo AM, Quittner AL, Ackerman V, et al. Identification and assessment of ongoing stressors in adolescents with a chronic illness: an application of the behavior-analytic model. J Clin Child Adolesc Psychol 1997; 26:53–66. 25. Plante WA, Lobato D, Engel R. Review of group interventions for pediatric chronic conditions. J Pediatr Psychol 2001; 26:435–453. 26. Johnson KB, Ravert RD, Everton A. Hopkins teen central: assessment of an internet-based support system for children with cystic fibrosis. Pediatrics 2001; 107:E24. 27. Marciel KK, Saiman L, Quittell L, et al. Cell phone intervention to improve adherence: cystic fibrosis care team, patient, and parent perspectives. Pediatr Pulmonol (in press). 28. Riekert KA, Bartlett SJ, Boyle MP, et al. The association between depression, lung function, and health-related quality of life among adults with cystic fibrosis. Chest 2007; 132:231–237. 29. Smith BA, Modi AC, Quittner AL, et al. Co-morbidity of depression and cystic fibrosis in children and adolescents: associations with adherence to medical treatment cystic fibrosis. Pediatr Pulmonol (in press). 30. Goldbeck L, Besier T, Hinz A, et al.; and the TIDES study group. Prevalence of anxiety and depression in German patients with cystic fibrosis. Chest (under review). 31. Bregnballe V, Thastum M, Schiøtz PO. Psychosocial problems in children with cystic fibrosis. Acta Paediatr 2007; 96:58–61. 32. Havermans T, Colpaert K, Dupont LJ. Quality of life in patients with cystic fibrosis: association with anxiety and depression. J Cyst Fibros 2008; 7:581–584. 33. Anderson DL, Flume PA, Hardy KK. Psychological functioning of adults with cystic fibrosis. Chest 2001; 119:1079–1084. 34. Modi AC, Lim CS, Yu N, et al. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 2006; 5:177–185. 35. DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42:200–209. 36. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA 2002; 288:2880–2883. 37. Arias Llorente RP, Bouson˜o Garcı´a C, Dı´az Martı´n JJ. Treatment compliance in children and adults with cystic fibrosis. J Cyst Fibros 2008; 7:359–367. 38. Zindani GN, Streetman DD, Streetman DS, et al. Adherence to treatment in children and adolescent patients with cystic fibrosis. J Adolesc Health 2006; 38:13–7. 39. Quittner AL, Modi AC, Lemanek KL, et al. Evidence-based assessment of adherence to medical treatments in pediatric psychology. J Pediatr Psychol 2008; 33:916–936. 40. Quittner AL, Opipari LC. Differential treatment of siblings: interview and diary analyses comparing two family contexts. Child Dev 1994; 65:800–814. 41. Riekert KA, Mogayzel PJ, Bilderback A, et al. Medication adherence among children, adolescents and adults with CF. Pediatr Pulmonol 2007; S28:405. 42. Briesacher B, Andrade S, Fouayz IH, et al. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008; 28:437–443. 43. Barker DH, Monaco B, Quittner AL. Challenges in measuring adherence: relationships between self-report, diary, and electronic measures in adolescents with cystic fibrosis. In: National Conference on Child Health Psychology, April 2008, Miami, Florida. 44. Quittner AL, Davis MA, Modi AC. Health-related quality of life in pediatric populations. In: Roberts MC, ed. Handbook of Pediatric Psychology. 3rd ed. New York, New York: Guilford Publications, 2003:696–709. 45. Food and Drug Administration. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. In: U.S. Department of Health and Human Services Food and Drug Administration, ed. 2006. Health Qual Life Outcomes 2006; 4:79.

Social and Emotional Functioning, Adherence, and Quality of Life

479

46. Revivki DA, Erickson PA, Sloan JA, et al. Interpreting and reporting results based on patient reported outcomes. Value Health 2007; 10:S116–S124. 47. Detmar SB, Muller MJ, Schornagel JH, et al. Health-related quality of life assessments and patient-physician communication: a randomised controlled trial. JAMA 2002; 288. 48. Feeny D. Preference-based measures: utility and quality-adjusted life years. In: Fayers P, Hays R, eds. Assessing Quality of Life in Clinical Trials. Oxford: Oxford University Press, 2005:405–430. 49. Eiser C, Morse R. Quality-of-life measures in chronic diseases of childhood. Health Technol Assess 2001; 5:1–157. 50. Goss CH, Quittner AL. Patient-reported outcomes in cystic fibrosis. Proc Am Thorac Soc 2007; 4:378–386. 51. Retsch-Bogart G, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009; 135:1223–1232. 52. Quittner AL. Measurement of quality of life in cystic fibrosis. Curr Opin Pulm Med 1998; 4:326–331. 53. Quittner AL, Modi AC, Cruz I. Systematic review of health-related quality of life measures for children with respiratory conditions. Pediatric Respir Rev 2008; 9:220–232. 54. Quittner AL, Buu A, Messer MA, et al. Development and validation of the cystic fibrosis questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 2005; 128:2347–2354. 55. Palermo TM, Long AC, Lewandowski AS, et al. Evidence-based assessment of health-related quality of life and functional impairment in pediatric psychology. J Pediatr Psychol 2008; 33:983–996. 56. Modi AC, Quittner AL. Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis. J Pediatr Psychol 2003; 28:535–546. 57. Dobbin CJ, Bartlett D, Melehan K, et al. The effect of infective exacerbations on sleep and neurobehavioral function in cystic fibrosis. Am J Respir Crit Care Med 2005; 172:99–104. 58. Quittner AL, Schechter MS, Rasouliyan L, et al. Impact of socioeconomic status, race, and ethnicity on quality of life in patients with cystic fibrosis. Chest (in press). 59. Quittner AL, Modi AC, Wainwright C, et al. Determination of the minimal clinically important difference (MCID) score for the cystic fibrosis questionnaire-revised (CFQ-R) respiratory symptoms scale in two populations of patients with cf and chronic pseudomonas aeruginosa airway infection. Chest 2009; 135:1610–1618. 60. McCoy KS, Quittner AL, Oermann C, et al. Inhaled aztreonam lysine for chronic airway pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178:921–928. 61. Dupont LJ, Minic P, Fustik S, et al. A randomized placebo-controlled study of nebulized liposomal amikacin (ARIKACETM) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. Pediatr Pulmonol 2008; S31:301. 62. Modi AC, Quittner AL. Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? J Pediatr Psychol 2006; 31:846–858. 63. Marciel KK, Cruz I, Barker DH, et al. Effectiveness of a pill swallowing program for young children with cystic fibrosis. Pediatr Pulmonol 2008; S31:458. 64. Glasscoe C, Lancaster GA, Smyth RL, et al. Parental depression following the early diagnosis of cystic fibrosis: a matched, prospective study. J Pediatr 2007; 150:185–191. 65. Yilmaz O, Sogut A, Gulle S, et al. Sleep quality and depression-anxiety in mothers of children with two chronic respiratory diseases: asthma and cystic fibrosis. J Cyst Fibros 2008; 7:495–500. 66. Meltzer LJ, Mindell JA. Impact of a child’s chronic illness on maternal sleep and daytime functioning. Arch Intern Med 2006; 166:1749–1755. 67. Halligan SL, Murray L, Martins C, et al. Maternal depression and psychiatric outcomes in adolescent offspring: a 13-year longitudinal study. J Affect Disord 2007; 97:145–154.

480

Barker and Quittner

68. Quittner AL, Barker DH, Geller D, et al. Effects of maternal depression on electronically monitored enzyme adherence and changes in weight for children with CF. J Cyst Fibros 2007; 6:77. 69. Snell C, Barker DH, Marciel KK, et al. Paradoxical relationships between parental depression and pulmonary functioning in cystic fibrosis: the role of treatment burden and daily mood. Pediatr Pulmonol 2008; S31:454. 70. Badlan K. Young people living with cystic fibrosis: an insight into their subjective experience. Health Soc Care Community 2006; 14:264–270. 71. Smith BA, Wood BL. Psychological factors affecting disease activity in children and adolescents with cystic fibrosis: medical adherence as a mediator. Curr Opin Pediatr 2007; 19:553–558. 72. D’Auria JP, Christian BJ, Richardson LF. Through the looking glass: children’s perceptions of growing up with cystic fibrosis. Can J Nurs Res 1997; 4:99–112. 73. Fiese BH, Everhart RS. Medical adherence and childhood chronic illness: family daily management skills and emotional climate as emerging contributors. Curr Opin Pediatr 2006; 18:551–557. 74. Wysocki T, Harris MA, Buckloh LM, et al. Effects of behavioral family systems therapy for diabetes on adolescents’ family relationships, treatment adherence, and metabolic control. J Pediatr Psychol 2006; 31:928–938. 75. DiMatteo MR. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol 2004; 23:207–218. 76. Barker DH, Cohen LM, Driscoll KA, et al. It takes a village: what family, friends and teachers do to facilitate disease management in adolescents with cystic fibrosis. Pediatr Pulmonol 2008; S31:452. 77. Palmer ML, Boisen LS. Cystic fibrosis and the transition to adulthood. Soc Work Health Care 2002; 36:45–58. 78. Pfeffer PE, Pfeffer JM, Hodson ME. The psychosocial and psychiatric side of cystic fibrosis in adolescents and adults. J Cyst Fibros 2003; 2:61–68. 79. Hogg M, Braithwaite M, Bailey M, et al. Work disability in adults with cystic fibrosis and its relationship to quality of life. J Cyst Fibros 2007; 6:223–227. 80. Burker EJ, Sedway J, Carone S. Psychological and educational factors: better predictors of work status than FEV1 in adults with cystic fibrosis. Pediatr Pulmonol 2004; 38:413–418. 81. Berge JM, Patterson JM, Goetz D, et al. Gender differences in young adults’ perceptions of living with cystic fibrosis during the transition to adulthood: a qualitative investigation. Fam Syst Health 2007; 25:190–203. 82. Quittner AL, Modi AC, Boyle MP. The role of independence in daily functioning for adults with cystic fibrosis: results from the adult data for understanding lifestyle and transitions (ADULT) survey. Pediatr Pulmonol 2008; S31:445. 83. Myers LB, Horn SA. Adherence to chest physiotherapy in adults with cystic fibrosis. Journal of Health Psychol 2006; 11:915–926. 84. McGuffie K, Sellers DE, Sawicki GS, et al. Self-reported involvement of family members in the care of adults with CF. J Cyst Fibros 2008; 7:95–101. 85. Chapman E, Landy A, Lyon A, et al. End of life care for adult cystic fibrosis patients: facilitating a good enough death. J Cyst Fibros 2005; 4:249–257. 86. Brumfield K, Lansbury G. Experiences of adolescents with cystic fibrosis during their transition from paediatric to adult health care: a qualitative study of young Australian adults. Disabil Rehabil 2004; 26:223–234. 87. Parker HW. Transition and transfer of patients who have cystic fibrosis to adult care. Clin Chest Med 2007; 28:423–432. 88. Patton SR, Graham JL, Varlotta L, et al. Measuring self-care independence in children with cystic fibrosis: the self-care independence scale (SCIS). Pediatr Pulmonol 2003; 36:123–130.

Social and Emotional Functioning, Adherence, and Quality of Life

481

89. Blum RW. Transition to adult health care: setting the stage. J Adolesc Health 1995; 17:3–5. 90. Schidlow DV. Transition in cystic fibrosis: much ado about nothing? a pediatrician’s view. Pediatr Pulmonol 2002; 33:325–326. 91. White T, Miller J, Smith GL, et al. Adherence and psychopathology in children and adolescents with cystic fibrosis. Eur Child Adolesc Psychiatry 2008; 18:96–104. 92. Cruz I, Marciel KK, Quittner AL, et al. Anxiety and depression in CF. Semin Respir Crit Care Med 2009; 30:569–578. 93. Quittner AL. Controlled trial of two adherence promotion interventions for cystic fibrosis. In: Health Economics & Outcomes Group, Novartis Pharmaceuticals, 2008.

31 Palliative and End-of-Life Care in Cystic Fibrosis WALTER M. ROBINSON Vanderbilt Children’s Hospital, Center for Biomedical Ethics and Society, Vanderbilt University, Nashville, Tennessee, U.S.A.

JEFFREY C. KLICK University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A.

I.

Introduction

Throughout its history, cystic fibrosis (CF) has been identified in the public imagination as a fatal disease. Readers with even a passing familiarity with CF will recognize this as an outdated characterization: in the 21st century, CF is a manageable chronic illness, still with a limited life span, but with an increasingly healthy childhood population and an enlarging cohort of adults (1). Given the changing epidemiology of those living with CF, our goal in this chapter is twofold: first, to describe state-of-the-art palliative care throughout the lifespan of the child and adult with CF, and second, to describe highquality CF end-of-life care, which for the purposes of this chapter is defined as care for the family and patient during the last two months of life and bereavement care following the death of the patient. Because of confusion about the nature of palliative care, we begin with some definitions. In practice, “palliative care” is used to describe a clinical practice, a conceptual approach to care, and a specific set of interventions all aimed to enhance quality of life in the face of a life-threatening condition. Palliative care is often pursued in conjunction with interventions of curative intent and includes any intervention that focuses on reducing the severity of illness, slowing the progression of disease, improving quality of life, and ensuring that families are able to remain functional and intact (2). Hospice or “end-of-life” care is a subset of palliative care and refers to the end stages of care more focused on supportive care than life-sustaining therapies. Hospice services can be utilized simultaneously with measures of life-sustaining intent; a do-notresuscitate (DNR) order is not required as a condition of enrollment, and patients may disenroll from hospice and return to hospice care at a later date. Hospice agencies are valuable resources, providing 24-hour availability for in-home management of distressing symptoms; psychosocial, spiritual, and decision-making support for the patient and family; and ongoing interventions for grief and bereavement care for the family. Quality palliative care begins with effective symptom assessment. Recent studies in adults (3) and children (4) suggest that the symptom range in CF is quite broad, even in those with relatively mild disease. In addition, the most distressing symptoms may be less directly related to the pathophysiology of CF than to the difficulty of managing life with a chronic, unrelenting illness (5). Psychosocial symptoms such as anxiety and 482

Palliative and End-of-Life Care in Cystic Fibrosis

483

depression (6,7), as well as functional symptoms such as sleep disturbance and fatigue (8) are more common in CF than previously recognized. Some symptoms related to CF are emerging only currently as clinicians perform more systematic assessments; one recent example is urinary incontinence in women related to coughing (9). There have been few studies regarding the treatment of pain and suffering symptoms specific to the CF population. This lack of evidenced-based literature, however, should not limit the treatment of suffering in these children and adults. Instead, the guiding principle for treating any symptom in a child or adult with CF should be a trial of the medication or therapy, including multiple routes of administration, while assessing for efficacy and side effects. If the treatment proves effective for that patient, it should be continued. If it is ineffective or with too great a side-effect profile, a different treatment should be tried until success is achieved.

II.

Assessment and Management of Symptoms

There are four principles in assessing pain and suffering. First, the patient’s self-report is the gold standard of reporting. If the patient is unable to report—due to age, severity of illness, or cognitive impairment—the next of kin or care provider becomes the most reliable reporter. Second, assessment of pain and suffering must take into account the developmental understanding of the patient. Most adults are able to relate pain and suffering to experiences in the past (e.g., “the pain is now a 2/10 but was a 6/10 prior to receiving the morphine you prescribed”). Most young children, usually under seven years of age, only report pain in the moment with no historical context. Third, pain and suffering can change from minute to minute requiring frequent reassessment of symptoms and efficacy of therapy. The most efficient times to reassess symptoms are at any times the patient is at increased risk for pain, including after procedures, when medications are wearing off, and at the peak effect of initiated therapy if an appropriate dose is insufficient to relieve symptoms. Finally, physiological pain is often accompanied by nonorganic factors that can intensify suffering. Pain is not just physiological but also has spiritual, psychological, and social components (10). These aspects of pain are often unrecognized. CF psychosocial team members or a palliative care specialist can help recognize sources of distress and provide management options in these situations. A. Assessment and Management of CF-Related Pain

Headache, abdominal pain, and chest pain are commonly reported by children and adults with CF, even those with mild disease (11,12). Headaches should be characterized by location, frequency, quality of pain, and intensity. Headaches associated with sinus disease in CF may not express the typical localizing symptoms, and surveillance for the presence of polyps and sinus disease should be part of routine care (13,14). Morning headaches may indicate sleeping gas exchange abnormalities that can be diagnosed by means of careful history and/or a sleep study and treated by means of nocturnal oxygen or noninvasive ventilation. The most common causes of chest pain include frequent coughing episodes leading to musculoskeletal spasm and rib fractures, especially in those with existing osteoporosis (15); vertebral compression fractures (16); and musculoskeletal complications of increasing thoracic volume due to obstructive lung disease (17,18). Careful evaluation by physical therapists can lead to a diagnosis treatable by exercise or postural

484

Robinson and Klick

improvements (19,20). Pharmacological intervention using the pain ladder approach outlined below is also appropriate. Abdominal pain can be described as dull, aching, or cramping. Patients may also describe the burning pain associated with gastroesophageal reflux. Bowel distention and urgency can be associated with ineffective functioning of pancreatic replacement enzymes. Cramping and dull or aching pain can be associated with constipation and distal intestinal obstruction syndrome (DIOS) (21). If pain is acute and increasing, it may suggest appendicitis (22).

B. Opioid Use for Acute and Chronic Pain in CF

Mild pain is often effectively managed with nonopioid medications, such as acetaminophen or ibuprofen. If these medications prove ineffective, opioids become the foundation of good pain control. While there are many different formulations of opioids, it is an effective practice to utilize and gain comfort in a single type. Once comfortable with that medication, the practitioner can then better understand the benefits of other opioids, such as fentanyl for its rapid onset and metabolism or methadone for its very long duration of action. For this chapter, we will propose utilizing morphine as an effective initial opioid to base care decisions. Aside from the predictable though manageable side effects of opioid use (23), there are two specific issues that should be considered in using opioids in CF. The first is the increased risk of constipation. In all CF patients, even in those without a history of constipation or DIOS, lactulose should be started once opioids have been used for more than two days. Monitoring of bowel movement frequency and increased vigilance for constipation is appropriate, given the relative ease of preventing constipation compared to relieving it once it has occurred. The second issue regards the concern that opioids will cause respiratory depression and/or tolerance. Pain can cause alterations in breathing patterns that, when relieved, give the mistaken perception of decreased respiratory drive. Respiratory depression is very rare when opioids are dosed appropriately. It is preceded by sleepiness, decreased consciousness, decreased respiratory rate, and, finally, apnea. Once identified, this side effect is best managed by providing respiratory support, decreasing the dose, and waiting for resolution. An opioid antagonist such as naloxone should only be used in the rare case when all the symptoms of respiratory depression are present, especially since it can cause life-threatening withdrawal if used in the setting of chronic opioid therapy. Occasionally, dose-related side effects limit the use of opioids. In these circumstances, improved pain control with fewer side effects may be accomplished by switching to a different opioid (24). Patients exposed to an opioid for a long period of time can develop tolerance, requiring a higher dose to accomplish the same pain effect. When transitioned to another opioid, they may have incomplete cross-tolerance to the new opioid, meaning they may require a relatively lower dose of the new opioid. Because of this incomplete cross-tolerance, the new opioid dose should be decreased by 30% to 60% from a direct conversion. When initiating pain management, the clinician must consider which medication to use, the goals of therapy, the proper initial dose and route of administration, and a plan to manage breakthrough pain (pain that “breaks through” scheduled doses of an analgesic requiring rescue doses of the analgesic). Table 1 describes a thorough

Palliative and End-of-Life Care in Cystic Fibrosis

485

Table 1 Acute and Chronic Pain-Management Algorithm

Ladder

Degree of pain

Step 1

Mild

Step 2

Moderate

Frequency and route

Trigger to advance to next step

Start a nonopioid analgesic (NSAID or acetaminophen)

If no effective benefit or worsening or persistent symptoms advance to step 2

Rescue therapy Morphine oral immediate release preparation Children: 0.2–0.5 mg/kg/dose q 3–4 hr prn Adults: 5–30 mg every 3–4 hr prn Moderate- Sustained therapy: oral persistent Morphine sustained release preparation Children/adults: total daily dose divided b.i.d. Rescue therapy: oral Morphine immediate release preparation Children: 0.2–0.5 mg/kg every 3–4 hr prn Adults: 5–30 mg every 3–4 hr prn

If patient has frequent utilization of rescue medication should advance to step 3 to introduce more sustained and rescue therapy

Step 4

Severe

If the patient is receiving opioid therapy at presentation, an equivalent or greater dose should be continued If patient has frequent utilization of rescue medications should advance to step 5 to introduce more sustained and rescue therapy

Step 5

SevereConsider PCA: morphine persistent Opioid exposed Basal rate: daily morphine dose/24 hr Demand dose: 50–100% of the hourly dose Lockout interval: 5–10 min Opioid naive Children: Basal infusion: 0–0.02 mg/kg/hr Demand dose: 0.015–0.02 mg/kg/dose Lockout interval: 5–10 min Adult: Basal rate: 5–35 mg/hr or 0.07–0.5 mg/kg/hr Demand dose: 0.5–2.5 mg Lockout interval: 5–10 min

Step 3

Rescue therapy: IV, SQ Morphine: Children < 6 mos: 0.05–0.1 mg/kg every 3–4 hr Children > 6 mos: 0.1–0.2 mg/kg every 3–4 hr Adult: 2.5–10 mg every 2–6 hr

If the patient is receiving opioid therapy at presentation, an equivalent or greater dose should be continued If no effective benefit, frequent use of rescue doses, or worsening or persistent symptoms advance to step 4

If the patient is receiving opioid therapy at presentation, an equivalent or greater dose should be continued Sustained therapy dosing best determined using either the acute severe pain-management pathway or by determining amount required in 24 hr in step 4. If no effective benefit, frequent use of rescue doses, or worsening or persistent symptoms continue escalation of dosage until the patient is free of pain

Abbreviations: NSAID, nonsteroidal anti-inflammatory drug; b.i.d., twice a day; IV, intravenous; SQ, subcutaneous; PCA, patient controlled analgesia.

486

Robinson and Klick

pain-management approach adapted from the World Health Organization’s recommendation for the treatment of pain (25). The goal of any pain therapy should be declared prior to initiating therapy. Simply improving pain and suffering scores is not sufficient. Goals should include a dramatic decrease in pain (e.g., decrease pain to zero to three level on numerical scales) and improvement in function (e.g., help the patient walk or tolerate airway clearance modalities). Medications designed to enhance the pharmacological effect of the opioids should then be targeted at the specific type of pain (e.g., gabapentin for neuropathic pain or lorazepam for pain associated with significant anxiety). C. Assessment and Management of Cough

Cough is a part of life with CF. Coughing as a means of deliberate airway clearance should be encouraged, and discussion of airway clearance techniques should take into account the patient’s desire to manage coughing episodes so as to avoid interrupting daily activities (26). Coughing in excess of routine airway clearance, however, can be disturbing and disruptive. A search for the etiology of the troubling cough beyond treatment of pulmonary exacerbations, including investigation of allergies, asthma, or gastroesophageal reflux (27) is essential. Chronic cough may also lead to other symptoms, such as urinary incontinence (9,28). While the use of cough suppressants is discouraged for its negative effect on airway clearance, the rare patient with debilitating cough may temporarily need such medications, particularly at night. Spasmodic and prolonged cough can be a feature of end-stage CF. In this type of cough, a short, sharp inspiration is followed by a prolonged forced exhalation with ineffective airway clearance. These prolonged periods of exhalation can lead to severe headache, syncope, and seizures, as well as dramatic changes in thoracic blood flow with cardiac repercussions (29). In some cases thinning of secretions with inhaled alfa dornase or hypertonic saline may improve the symptoms, but in others the cough may worsen; a monitored trial of efficacy of the therapy is appropriate (30). Utilizing opioids to dull the need to cough is appropriate when the cough is ineffective and distressing to the patient. The management of cough is similar to that for dyspnea (Table 2). D. Assessment and Management of Dyspnea

Dyspnea is a complex physical and psychological symptom (31). In CF, dyspnea can result from a host of interacting factors, including upper airway obstruction, sinus disease, gastroesophageal reflux, chest wall mechanical abnormalities, asthma, allergic responses, allergic bronchopulmonary aspergillosis, gas exchange abnormalities, reduced cardiac function, and physical deconditioning. Initially, symptoms of dyspnea are likely to be related to the level of exertion (32), and many patients will respond by restricting their activity, so that dyspnea may be pronounced when it is finally reported to the clinician. Pulmonary function tests and blood gas analysis are appropriate, but may have no correlation with the degree of experienced dyspnea. In this setting, the patient should simply rate his or her breathlessness on a numerical scale, similar to a pain scale. Management of chronic dyspnea is a complex medical and psychosocial process. For mild dyspnea, nonpharmacological treatments should be tried (33). Assistance with activities of daily living can reduce the time spent feeling breathless per day. Alterations

Nonpharmacological modalities

Consider changes in airway clearance techniques or timing. Initiate support with ADLs

Escalate support with ADLs After examination, consider initiating nocturnal supplemental oxygen and or NIV

Consider initiating nocturnal NIV Initiate fan blowing on the patient’s face (activates trigeminal sensory pathways)

Escalate support with ADLs Consider escalating NIV Continue fan on patient’s face

Degree of dyspnea

Mild

Moderate

Moderate-persistent

Severe

Table 2 Management Algorithm for Dyspnea

Pulmonary rehabilitation or respiratory muscle conditioning If no effect, advance to moderate pathway

Bronchodilators, if evidence of reversible obstruction Additional mucolytic therapy, with consideration of change in frequency of administration Rescue therapy: oral Morphine immediate release preparation Children: 0.2–0.5 mg/kg every 3–4 hr prn Adults: 5–30 mg every 3–4 hr prn Sustained therapy: oral Morphine sustained release preparation Children/adults: total daily dose divided b.i.d. to t.i.d. Rescue therapy: oral Morphine immediate release preparation Children: 0.2–0.5 mg/kg every 3–4 hr prn Adults: 5–30 mg every 3–4 hr prn. Consider adding lorazepam (see dosing below) Escalate rescue therapy: IV, SQ Morphine < 6 mos: 0.05–0.1 mg/kg every 3–4 hr > 6 mos: 0.1–0.2 mg/kg every 3–4 hr Adult: 2.5–10 mg every 2–6 hr (Continued)

If the patient is receiving opioid therapy at presentation, an equivalent or greater dose should be continued

If the patient is receiving opioid therapy at presentation, an equivalent or greater dose should be continued If minimal or insufficient relief, advance to severe pathway

If using multiple doses per day, consider chronic level of therapy If minimal or insufficient relief, advance to severe pathway

Additional therapy

Medication modalities

Palliative and End-of-Life Care in Cystic Fibrosis 487

Escalate support with ADLs Consider escalating NIV Continue fan blowing on the patients face

Severe-persistent

Additional therapy If the patient is receiving opioid therapy at presentation, an equivalent or greater dose should be continued If patient is alert, consider PCA

Medication modalities Initiate PCA or infusion with rescues Opioid exposed: morphine Basal infusion: daily dose divided per hour Rescue dose: 50–100% of the hourly dose Lockout interval: 5–10 min Opioid naive: morphine Children: Basal infusion: 0–0.02 mg/kg/hr Rescue dose: 0.015–0.02 mg/kg/dose Lockout interval: 5–10 min Adult: Basal infusion: 5–35 mg/hr Rescue dose: 0.5–2.5 mg Lockout interval: 5–10 min

Abbreviations: ADL, activities of daily living; NIV, noninvasive ventilation; b.i.d., twice a day; t.i.d., three times a day.

Nonpharmacological modalities

Degree of dyspnea

Table 2 Management Algorithm for Dyspnea (Continued )

488 Robinson and Klick

Palliative and End-of-Life Care in Cystic Fibrosis

489

in airway clearance therapies may be appropriate, especially if the use of these therapies results in prolonged coughing episodes, exhaustion, and more dyspnea. Treatment should also always include assessment of exercise capacity, as improvement of conditioning can improve breathlessness (34). As respiratory function worsens, intermittent use of opioids or benzodiazepines can allow the patient to manage his or her daily activities. Although the use of inhaled opioids has been suggested (35,36), direct studies on their effects have yet to be persuasive (37) while oral and intravenous opioids can substantially reduce the sensation of dyspnea. Appropriate dosing of these agents will not cause respiratory depression (38). As symptoms of dyspnea progress, many patients will experience an added sense of anxiety. In these patients, benzodiazepines can be an effective adjuvant to opioid therapy. Near the end of life in CF, dyspnea is likely to be the most distressing symptom (39). At the end stage, even substantially somnolent patients may be struggling for breath. In this situation, the patient’s subjective sensation or the best assessment of the patient made by caring and compassionate observers should continue to drive the use of opioids to relieve breathlessness. This state of rapidly changing symptoms requires clear and ongoing discussion regarding close and careful monitoring as well as a planned response to any changes in suffering (38). Specific treatment options, including an algorithm for managing the evolution of symptoms for dyspnea is included in Table 2. E.

Assessment and Management of Life-Ending Hemoptysis

Massive hemoptysis with exsanguination is extremely distressing to the patient as well as to those at the bedside (40). (Management of less severe and chronic hemoptysis is discussed in chap. 16, as are the various treatment strategies for non-life-threatening hemoptysis.) A history of substantial hemoptysis (more than 240 cc in 24 hours or recurrent bleeding of more than 100 cc/day over several days) is associated with a high likelihood of recurrence (41). Unfortunately, sedation is the only way to reduce the substantial distress of a patient experiencing end-stage hemoptysis, though the use of dark towels or other dark-colored material to reduce the appearance of bright red blood is effective in reducing the anxiety of both the patient and those in attendance. Effective relief of the distress of life-ending hemoptysis in an outpatient setting is extremely difficult (42) and prediction of the timing of life-ending hemoptysis is virtually impossible. Forthright discussions with the patient and family regarding the possibility of life-ending hemoptysis are essential. F.

Assessment and Management of Constipation/Obstipation

Management of chronic constipation, including bowel regimens, are discussed in chapter 17. In the sicker CF patient, constipation can be exacerbated by medications, decreased fluid intake, slowed intestinal motility, and decreased physical activity. The use of opioids to manage pain and dyspnea near the end of life will increase the risk of constipation or obstipation. In general, stool management therapies should be a part of the regimen for all CF patients on opioids, as well as those patients at risk for dehydration or a history of DIOS. Table 3 suggests an approach to prevention and management of constipation.

490

Robinson and Klick

Table 3 Suggested Algorithm for the Management of Constipation

Step

Assessment and treatment options

Step 1: Prevention

Prophylactic lactulose, adequate enzyme intake with/or without enzyme enhancers, and monitoring of stool output and early contact with clinician Assessment, with physical examination and abdominal X rays. Consider osmotic enema and/or oral electrolyte regimen Evaluate obstruction/impaction and consider surgical referral

Step 2: Escalation and treatment

Step 3: Treatment failure

G. Assessment and Management of Anorexia

An adequate diet with sufficient caloric intake is an essential aspect of management of CF. Yet there are several specific issues that make eating onerous or even painful for patients. For example, chronic sinus disease can reduce the aroma, taste, and attractiveness of food. Remodeling of the thoracic cage can exert downward pressure on the stomach, so that even a moderately full stomach triggers respiratory discomfort. Gastroesophageal reflux disease can make eating uncomfortable, as can cramping associated with ineffective enzyme use. CF-related diabetes can limit or restrict food choices. Economic concerns may limit the patient’s choices of a variety of enticing meals. Finally, fatigue, loneliness, and depression can make the preparing of meals less attractive so that patients will default to more easily prepared but less nutritionally appropriate meals. A comprehensive approach to the assessment of eating strategies will focus not only on caloric intake but also on eating as an element within other activities of daily life. For children, behavioral interventions have shown improvements in caloric intake (43), and similar results can be achieved with comprehensive assessment and intervention in adults (44). H. Assessment and Management of Anxiety and Depression

Recent studies have suggested a higher incidence of depression among CF patients than previously suspected, and ongoing national studies may reveal the appropriateness of depression screening as a routine part of CF care (6). As with other aspects of quality of life, simple and short screening tools are available for depression. Treatment of depression in CF can involve multiple strategies, many of which will not be unique to CF. Optimal use of psychosocial clinicians coupled with referral outside the standard care team, when appropriate, is essential. Acute and chronic anxiety occurs commonly in children and adults with lifethreatening illnesses and can complicate the management of other symptoms. Recent reports suggest that anxiety and worrying are perceived as some of the most distressing symptoms in adults with CF (5). Simple screening tools are available and can be easily integrated into routine care (45). As patients may be anxious about disease progression, simple reassurance and good communication can be helpful. Treating pain, fatigue, dyspnea, cough, and nausea, as well as providing physical aids and nursing help with activities of daily life can facilitate participation in the care plan and reduce anxiety. In persistent or severe cases, medications may be used including oral or intravenous benzodiazepines.

Palliative and End-of-Life Care in Cystic Fibrosis I.

491

Prognostication in CF

Short- and long-term prognostication in CF remains an art (46,47). There is evidence that FEV1 less than 24% and BMI less than 18 are associated with death before discharge from the ICU (48). Children with CF admitted to the ICU for respiratory reasons do relatively well (49), but sicker adults in the ICU do worse than healthier adults (50,51). The need for mechanical ventilation in children prior to lung transplantation is associated with decreased survival (52), but that is not necessarily the case in adults (53). There are also some commonsense indications of an increased likelihood of death in an individual patient within six months: failure of a pulmonary exacerbation to respond to aggressive culture-based antibiotic therapy, weight loss unresponsive to maximum nutritional intervention, substantial (>240 cc/24 hr) hemoptysis unresponsive to embolization therapy, recurrent serious pneumothorax, and increasing daytime arterial PaCO2 levels unresponsive to therapy. Yet their absence is no guarantee of survival; regardless of the severity of existing pulmonary disease, death may be triggered by an acute event such as viral pneumonia or acquisition of a particularly resistant organism. The inability to clearly predict the end stage means that restorative and palliative care should remain intimately intertwined in CF (54). Yet specific palliative care interventions, including therapies directed at managing symptoms, are often not discussed until the patient is in dire straits, thus missing opportunities to improve quality of life and allow for advanced care planning. Much of the cultural anxiety with palliative care (e.g., “giving up” on a patient or “withdrawing therapy”) is exacerbated when such care is first mentioned only when the patient is extremely ill, especially when reasoned discussion of symptom assessment and management could have occurred earlier (55). J.

Lung Transplantation and End-of-Life Care

Lung transplantation (discussed in detail in chap. 23) influences end-of-life care for all patients with CF, even for those who do not pursue transplant. Patients awaiting transplant are more likely to die in the ICU, receive assisted ventilation, remain intubated on the last day of life, and have discussion about terminal care delayed so that they are unable to participate (56,57). While the provision of more aggressive care to those awaiting a transplant is appropriate, some argue that clinicians are opting for aggressive care without considering the realistic odds of survival to transplantation (57). More importantly, by providing an uncertain rescue from respiratory failure near the end of life, lung transplantation has altered the expected trajectory of life with CF, and complicated decisionmaking, advance care planning, symptom management, and end-of-life care for patients, families, and clinicians. K. Advanced Care Planning

Most adults with CF have considered—and discussed with family members—the type of care they would want to have if they became unable to decide for themselves (58). However, only one-third of them have in fact discussed advanced care planning with any member of the CF clinical team, suggesting that many clinicians are reluctant to discuss advanced care planning with CF adults. In minor children, advanced care planning should involve the parents and the child in a developmentally appropriate way. In teenagers, clinicians must not overlook the preferences of the adolescent regarding end-of-life care (59). As only the very rare

492

Robinson and Klick

adolescent has given no thought to the life-limiting nature of the disease (60), they should be allowed to participate in decision-making, allowing a transition from assent to autonomy, and maintaining the patient’s own body image and vision of independence as much as possible. Long-term relationships with the CF care team can facilitate multiple avenues of communication (61). Existing advanced care planning documents are generally based on an oncology model that may not fit CF, given the different trajectory of disease and the less toxic therapies utilized. In the attempt to improve advanced care planning, some CF centers have developed CF-specific living wills or have adapted programs such as Five Wishes (62) for use in CF. L.

Do Not Attempt Resuscitation and Do Not Intubate

Many clinicians see do not attempt resuscitation (DNaR) and do not intubate (DNI) orders as having practical use in advanced planning in CF. Many patients do not have a DNaR order in their chart until the last day or so of life (57,63). In practice, DNaR and DNI orders do not suggest a certain set of comfort care measures. Instead, these orders should be one part of a more comprehensive discussion of the goals of care. M. Psychosocial Support for Children and Adults with CF

Despite improvement in survival, some children and most adults with CF will die earlier than their unaffected peers. The possibility of death during childhood will come as a shock to most parents and feelings of grief and anger are to be expected. The presence of psychosocial clinicians on the CF care team is especially useful in helping patients and families navigate the stressors of a chronic disease and the potential for end-of-life issues. The cultural association of CF with premature mortality is a common theme in the public descriptions of CF in books (64), movies (65), or on the Internet (66). Adolescents and young adults may well have developed certain fantasies or beliefs about their lifespan that can have a direct influence on their planning for the future, adherence to the daily regimen, and quality of life. Time should be taken to discuss out-of-date or inaccurate representations of CF and provide more useful resources. Children with chronic life-threatening illnesses often know that they may die despite never being told directly (67). They will have concerns about impending death and separation from loved ones. Adolescents usually struggle to maintain independence in the face of increasingly severe disease (68). They may also grieve the loss of function, the lack of interaction with their family and peers, and changes in body image, and may decrease communication with the care team in an attempt to minimize the intrusive effects of medical care (69). Adults with CF will have had years to develop coping strategies for the challenges brought by life with a complex chronic illness (70). Most patients will continue to utilize these coping strategies as they face the acceleration of their disease, some inviting their parents back into their support networks (71,72). Each child and adult with CF will approach death differently, some pursuing aggressive lifesustaining measures, others focusing more on quality of life. Expecting each patient to pass through a standard series of prescribed stages is unrealistic. Most patients will want to pursue some mixture of restorative and palliative approaches tailored to their specific clinical and psychosocial circumstances.

Palliative and End-of-Life Care in Cystic Fibrosis

493

N. Grief and Bereavement

Immediately following the death of a loved one, clinicians can best support the family by simply being present. The clinician should remain in the background but be available to the family. Conversations should focus on the sadness of the loss rather than the medical details of the illness. Grief is often experienced during actual, anticipated, or perceived loss, including the time of diagnosis, loss of function, hospitalizations, or any event the patient or family sees tied to the disease. Siblings, especially those with CF, experience grief, although they may be overlooked in this setting (73). Experienced social workers, child-life therapists, and psychologists can be helpful in educating the families about how to provide appropriate support to siblings. In general, families do not “get over” the death of a child or adult, instead they incorporate memories of the deceased family member into their lives. Helping the family find meaning in the life and death of the child or adult is an important act in the resolution of grief. Expressions of sorrow and support in the form of cards or letters from the care team can be a great comfort to the family, as can participation in funerals and memorials. After the death of a patient, many clinicians experience a sense of loss, sadness, and even failure. Clinicians should be aware of their reactions to the death of a patient and should be open to discussion of the death with colleagues. Appropriate recognition and management of grief maintains balance and longevity in clinical practice and allows the clinician to support patients and families in the future. O. Palliative Care Specialists

As the death of patients with CF becomes less common, specialty and primary care providers can lose familiarity with comprehensive palliative and end-of-life care of the CF patient and family. This expertise can be found in pediatric and adult palliative care teams. Consultation with these teams is strongly suggested. Early consultation can allow the palliative care team to help the patient, family, and the CF team navigate the difficult decisions that are unfortunately still part of life with CF.

References 1. O’Sullivan B, Freedman S. Cystic fibrosis. Lancet 2009; 373:1891–1904. 2. American Academy of Pediatrics, Committee on Bioethics and Committee on Hospital Care. Palliative care for children. Pediatrics 2000; 106:351–357. 3. Sawicki GS, Sellers DE, Robinson WM. Self-reported physical and psychological symptom burden in adults with cystic fibrosis. J Pain Symptom Manage 2008; 35:372–380. 4. Stenekes S, Hughes A, Gregoire M, et al. Frequency and self-management of pain, dyspnea, and cough in cystic fibrosis. J Pain Symptom Manage 2009; 38(6):837–848. 5. Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros 2009; 8:91–96. 6. Quittner AL, Barker DH, Snell C, et al. Prevalence and impact of depression in cystic fibrosis. Curr Opin Pulm Med 2008; 14:582–588. 7. Elgudin L, Kishan S, Howe D. Depression in children and adolescents with cystic fibrosis: case studies. Int J Psychiatry Med 2004; 34:391–397. 8. Yue HJ, Conrad D, Dimsdale JE. Sleep disruption in cystic fibrosis. Med Hypotheses 2008; 71:886–888. 9. Vella M, Cartwright R, Cardozo L, et al. Prevalence of incontinence and incontinencespecific quality of life impairment in women with cystic fibrosis. Neurourol Urodyn 2009; 28(8):986–989.

494

Robinson and Klick

10. Saunders C. The challenge of terminal care. In: Symington T, Carter RL, eds. Scientific Foundations of Oncology. London: Heineman, 1976:673–679. 11. Festini F, Ballarin S, Codamo T, et al. Prevalence of pain in adults with cystic fibrosis. J Cyst Fibros 2004; 3:51–57. 12. Koh JL, Harrison D, Palermo TM, et al. Assessment of acute and chronic pain symptoms in children with cystic fibrosis. Pediatr Pulmonol 2005; 40:330–335. 13. Shwachman H, Kulczycki LL, Mueller HL, et al. Nasal polyposis in patients with cystic fibrosis. Pediatrics 1962; 30:389–401. 14. Yung B, Noormohamed FH, Kemp M, et al. Cystic fibrosis-related diabetes: the role of peripheral insulin resistance and b-cell dysfunction. Diabet Med 2002; 19:221–226. 15. Jones AM, Dodd ME, Webb AK, et al. Acute rib fracture pain in CF. Thorax 2001; 56:819. 16. Yen D, Hedden D. Multiple vertebral compression fractures in a patient treated with corticosteroids for cystic fibrosis. Can J Surg 2002; 45:383–384. 17. Koch AK, Bromme S, Wollschlager B, et al. Musculoskeletal manifestations and rheumatic symptoms in patients with cystic fibrosis (CF) no observations of CF-specific arthropathy. J Rheumatol 2008; 35:1882–1891. 18. Ross J, Gamble J, Schultz A, et al. Back pain and spinal deformity in cystic fibrosis. Am J Dis Child 1987; 141:1313–1316. 19. Lee A, Holdsworth M, Holland A, et al. The immediate effect of musculoskeletal physiotherapy techniques and massage on pain and ease of breathing in adults with cystic fibrosis. J Cyst Fibros 2009; 8:79–81. 20. Tattersall R, Walshaw MJ. Posture and cystic fibrosis. J R Soc Med 2003; 96(suppl 43):18–22. 21. Dray X, Bienvenu T, Desmazes-Dufeu N, et al. Distal intestinal obstruction syndrome in adults with cystic fibrosis. Clin Gastroenterol Hepatol 2004; 2:498–503. 22. Shields MD, Levison H, Reisman JJ, et al. Appendicitis in cystic fibrosis. Arch Dis Child 1991; 66:307–310. 23. Friedrichsdorf S, Kang T. The management of pain in children with life-limiting illnesses. Pediatr Clin North Am 2007; 54:645–672. 24. Portnoy R. Opiod tolerance and responsiveness. In: Gebbhart G, Jensen T, eds. Progress in Pain Management and Research. Seattle: IASP Press, 1994:615–619. 25. McGrath PA. Development of the World Health Organization guidelines on cancer pain relief and palliative care in children. J Pain Symptom Manage 1996; 12:87–92. 26. Lowton K. Only when I cough? Adults’ disclosure of cystic fibrosis. Qual Health Res 2004; 14:167–186. 27. Fathi H, Moon T, Donaldson J, et al. Cough in adult cystic fibrosis: diagnosis and response to fundoplication. Cough 2009; 5:1. 28. Browne WJ, Wood CJ, Desai M, et al. Urinary incontinence in 9-16 year olds with cystic fibrosis compared to other respiratory conditions and a normal group. J Cyst Fibros 2009; 8:50–57. 29. Rao DS, Infeld MD, Stern RC, et al. Cough-induced hemiplegic migraine with impaired consciousness in cystic fibrosis. Pediatr Pulmonol 2006; 41:171–176. 30. Davis CL. ABC of palliative care. breathlessness, cough, and other respiratory problems. BMJ 1997; 315:931–934. 31. Gilman SA, Banzett RB. Physiologic changes and clinical correlates of advanced dyspnea. Curr Opin Support Palliat Care 2009; 3:93–97. 32. Sachs S, Weinberg RL. Pulmonary rehabilitation for dyspnea in the palliative-care setting. Curr Opin Support Palliat Care 2009; 3:112–119. 33. Buckholz GT, von Gunten CF. Nonpharmacological management of dyspnea. Curr Opin Support Palliat Care 2009; 3:98–102. 34. Reid WD, Geddes EL, O’Brien K, et al. Effects of inspiratory muscle training in cystic fibrosis: a systematic review. Clin Rehabil 2008; 22:1003–1013.

Palliative and End-of-Life Care in Cystic Fibrosis

495

35. Cohen SP, Dawson TC. Nebulized morphine as a treatment for dyspnea in a child with cystic fibrosis. Pediatrics 2002; 110:e38. 36. Graff GR, Stark JM, Grueber R. Nebulized fentanyl for palliation of dyspnea in a cystic fibrosis patient. Respiration 2004; 71:646–649. 37. Brown SJ, Eichner SF, Jones JR. Nebulized morphine for relief of dyspnea due to chronic lung disease. Ann Pharmacother 2005; 39:1088–1092. 38. Currow DC, Ward AM, Abernethy AP. Advances in the pharmacological management of breathlessness. Curr Opin Support Palliat Care 2009; 3:103–106. 39. Robinson W. Palliative care in cystic fibrosis. J Palliat Med 2000; 3:187–192. 40. Holsclaw DS, Grand RJ, Shwachman H. Massive hemoptysis in cystic fibrosis. J Pediatr 1970; 76:829–838. 41. Flume PA, Strange C, Ye X, et al. Pneumothorax in cystic fibrosis. Chest 2005; 128:720–728. 42. Savage R. Prone position as a life-saving measure for acute pulmonary haemorrhage in a young adult with cystic fibrosis. Anaesth Intensive Care 2002; 30:223–225. 43. Nasr SZ. An 8-week behavioral intervention can improve weight gain in children with cystic fibrosis. J Pediatr 2006; 148:700–701. 44. Watson H, Bilton D, Truby H. A randomized controlled trial of a new behavioral home-based nutrition education program, “eat well with CF,” in adults with cystic fibrosis. J Am Diet Assoc 2008; 108:847–852. 45. Riekert KA, Bartlett SJ, Boyle MP, et al. The association between depression, lung function, and health-related quality of life among adults with cystic fibrosis. Chest 2007; 132:231–237. 46. Konstan MW, Wagener JS, VanDevanter DR. Characterizing aggressiveness and predicting future progression of CF lung disease. J Cyst Fibros 2009; 8(suppl 1):S15–S19. 47. Liou TG, Adler FR, Fitzsimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001; 153:345–352. 48. Vedam H, Moriarty C, Torzillo PJ, et al. Improved outcomes of patients with cystic fibrosis admitted to the intensive care unit. J Cyst Fibros 2004; 3:8–14. 49. Berlinski A, Fan LL, Kozinetz CA, et al. Invasive mechanical ventilation for acute respiratory failure in children with cystic fibrosis: outcome analysis and case-control study. Pediatr Pulmonol 2002; 34:297–303. 50. Slieker MG, van Gestel JP, Heijerman HG, et al. Outcome of assisted ventilation for acute respiratory failure in cystic fibrosis. Intensive Care Med 2006; 32:754–758. 51. Kremer TM, Zwerdling RG, Michelson PH, et al. Intensive care management of the patient with cystic fibrosis. J Intensive Care Med 2008; 23:159–177. 52. Elizur A, Sweet SC, Huddleston CB, et al. Pre-transplant mechanical ventilation increases short-term morbidity and mortality in pediatric patients with cystic fibrosis. J Heart Lung Transplant 2007; 26:127–131. 53. Bartz RR, Love RB, Leverson GE, et al. Pre-transplant mechanical ventilation and outcome in patients with cystic fibrosis. J Heart Lung Transplant 2003; 22:433–438. 54. Bourke S, Doe S, Gascoigne A, et al. An integrated model of provision of palliative care to patients with cystic fibrosis. Palliat Med 2009; 23(6):512–517. 55. Docherty S, Miles M, Brandon D. Searching for “the dying point:” providers’ experiences with palliative care in pediatric acute care. Pediatr Nurs 2007; 33:335–341. 56. Dellon EP, Leigh MW, Yankaskas JR, et al. Effects of lung transplantation on inpatient end of life care in cystic fibrosis. J Cyst Fibros 2007; 6:396–402. 57. Ford D, Flume PA. Impact of lung transplantation on site of death in cystic fibrosis. J Cyst Fibros 2007; 6:391–395. 58. Sawicki GS, Dill EJ, Asher D, et al. Advance care planning in adults with cystic fibrosis. J Palliat Med 2008; 11:1135–1141. 59. Edwards J. A model of palliative care for the adolescent with cancer. Int J Palliat Nurs 2001; 7:485–488.

496

Robinson and Klick

60. Birnkrant DJ, Hen J Jr., Stern RC. The adolescent with cystic fibrosis. Adolesc Med 1994; 5:249–258. 61. Freyer D, Kuperberg A, Sterken D, et al. Multidisciplinary care of the dying adolescent. Child Adolesc Psychiatr Clin North Am 2006; 15:693–715. 62. McCollum AT, Schwartz AH. Social work and the mourning parent. Soc Work 1972; 17: 25–36. 63. Robinson WM, Ravilly S, Berde C, et al. End-of-life care in cystic fibrosis. Pediatrics 1997; 100:205–209. 64. Merullo R. A Little Love Story. New York, NY: Vintage Books, 2005. 65. Parisse V, Stebbings P. Jack and Jill vs the World. 2008. 66. Anselmo MA, Lash KM, Stieb ES, et al. Cystic fibrosis on the Internet: a survey of site adherence to AMA guidelines. Pediatrics 2004; 114:100–103. 67. Waechter EH. Children’s awareness of fatal illness. Am J Nurs 1971; 7:1168–1172. 68. Segal TY. Adolescence: what the cystic fibrosis team needs to know. J R Soc Med 2008; 101(suppl 1):S15–S27. 69. Smith BA, Wood BL. Psychological factors affecting disease activity in children and adolescents with cystic fibrosis: medical adherence as a mediator. Curr Opin Pediatr 2007; 19:553–558. 70. Pinkerton P, Trauer T, Duncan F, et al. Cystic fibrosis in adult life: a study of coping patterns. Lancet 1985; 2:761–763. 71. Abbott J, Dodd M, Gee L, et al. Ways of coping with cystic fibrosis: implications for treatment adherence. Disabil Rehabil 2001; 23:315–324. 72. McGuffie K, Sellers DE, Sawicki GS, et al. Self-reported involvement of family members in the care of adults with CF. J Cyst Fibros 2008; 7:95–101. 73. Fanos J. Sibling Loss. Mahwah, NJ: Lawrence Erlbaum, 1996.

Index

AAP. See American Academy of Pediatrics (AAP) AAV2, 394 AAV-CBA-D264CFTR, 396 ABC. See ATP-binding cassette (ABC) ABPA. See Allergic bronchopulmonary aspergillosis (ABPA) Acapella1, 244 ACBT. See Active cycle of breathing technique (ACBT) Access measure. See Quality measure ACE. See Angiotensin converting enzyme (ACE) Acetaminophen, 484 Acetic acid (vinegar), nebulizer and, 447 Achromobacter xylosoxidans, 44 Acid-fast bacilli (AFB), 37 ACR. See Acute cellular rejection (ACR) Acrodermatitis enteropathica, 322 CFNDD and, 356 ACT. See Airway clearance therapy (ACT) Active cycle of breathing technique (ACBT), 242 Acute cellular rejection (ACR), 379–380 AD. See Autogenic drainage (AD) Ad. See Adenovirus (Ad) ADA. See American Diabetes Association (ADA) Adenovirus (Ad), 381, 392 rAd vectors, for CF gene therapy, 392–394 Adolescence asthma in, 202 pulmonary presentations and, differential diagnosis of, 204 tasks of late, 452, 453

Adolescents, with CF, 458–460, 474–475 adherence rates in, 470 aerosol therapy, regular management of, 452 CFQ-R PRO for, 472 clinic, 455 depression rate in, 470 discussion on social topics with, 454 family conflict, 474–475 governing bodies for, 452 parental supervision, 474 peer relationship, 474, 475 reproductive health information for, sources of, 459–460 risk-taking behaviors in, 459 Adults GI imaging and, 191, 193 hemoptysis in, 206 pneumothorax in, 204–205 pulmonary presentations and, differential diagnosis of, 204 respiratory infections in, 203 Adults, with CF, 475 CFQ-R PRO for, 472 complications in, 452–453 depression rate in, 470 psychosocial support for, 492 Advanced care planning, 491–492 Aerosol therapy, 444–445 AFB. See Acid-fast bacilli (AFB) Age factors in pulmonary exacerbations, 254–255 Air trapping, 185–186 computerized analysis of, 187 Airway clearance in coughing, 486

497

498 [Airway clearance] depression associated with, 474 in dyspnea, 489 need for, 434 treatment adherence and, 470–471 Airway clearance therapy (ACT), 239 cough and, 240, 241 huff and, 240, 241 physiology of, 240–241 techniques ACBT, 242 AD, 243 exercise, 245 HFCC, 244–245 IPV, 245 OscPEP, 243–244 PD&P, 241–242 PEP, 243 selection of, 245–246 Airway conductance (GAW), 163–164 Airway disease, 198 upper, 202 Airway modifiers refinement of, 85 Airway obstruction, measurements of airway resistance (RAW), 163–164 forced oscillometry, 164 gas washout, 164–166 spirometry, 161–163 Airway opening pressure (Pinit), 154 Airway reactivity. See Airway responsiveness Airway resistance (RAW). See Airway obstruction Airway responsiveness BHR, 169–170 bronchodilator responsiveness, 169 Airway surface liquid (ASL), 17, 24, 60, 237 in cystic fibrosis, 29–31 Airway surface liquid hydration therapy, 237 hypertonic saline, 238–239 Alcohol hand rub. See Hand hygiene Alkalinization, 285, 286 Allergens and pulmonary exacerbation, 251, 252

Index Allergic bronchopulmonary aspergillosis (ABPA), 45, 205, 255 classical, 209 defined, 208 diagnosis of, 209, 210 management of, 210–211 pathophysiology, 209 prevalence of, 208–209 prognosis, 211 screening, 210 stages of, 211 a-1 antitrypsin deficiency, 291 a1-antitrypsin (SERPINA1), 86 a-Fetoprotein, 295 a-linolenic acid (ALA), 317 a-Tocopherol, 321 Alveolar pressure (Palv), 154 Ambulatory settings clinic logistics, 445 precautions for patients with multidrugresistant organisms, 446 waiting room practices, 445–446 American Academy of Pediatrics (AAP), 364 American College of Medical Genetics, 464 American College of Obstetricians and Gynecologists, 464 American Diabetes Association (ADA), 341 American Thoracic Society and European Respiratory Society (ATS/ERS), 148 American Thoracic Society (ATS), 161 Amiloride-dependent sodium absorption, 111 Aminoglycosides, 212 Anesthesia, 213–214 Angiotensin converting enzyme (ACE), 291 Anorexia, assessment and management of, 490 Antenatal pulmonary presentations, 201 Antibiotic allergy, 212 Antibiotic choices, 258 Antibiotic resistance in microorganisms, 251, 258 Antibiotic susceptibility, 251, 256, 257, 258 Antibiotic therapy, 251, 252, 254, 257, 258, 259, 260 nephrotoxicity of, 257, 258 ototoxicity of, 257, 258

Index Anticholinergic agents pulmonary health in CF and, maintenance of, 231 Anti-inflammatory therapy implication for, 69–71 Antimicrobial susceptibility testing, 256–257 Antisaccharomyces cerevisiae antibody (ASCA), 275 Anxiety, 470 assessment and management of, 490 Aquagenic wrinkling of the palms (AWP), 357 chloride content in sweat and, 357 etiology of, 357 Aquaporin, 286, 287 Arachidonic acid, 461 metabolism, 63–64 Arterial oxygen, pulmonary hypertension and, 361 ASCA. See Antisaccharomyces cerevisiae antibody (ASCA) ASL. See Airway surface liquid (ASL) Aspergillus, 381 Aspergillus fumigatus, 205, 208, 209, 210 Asthma in adolescence, 202 in adults, 203 in childhood, 202 cough variant, 202 female with CF and, 461 ATP-binding cassette (ABC), 1 ATS. See American Thoracic Society (ATS) ATS/ERS. See American Thoracic Society and European Respiratory Society (ATS/ERS) Autogenic drainage (AD), 242, 243 versus PD&P, 243 AWP. See Aquagenic wrinkling of the palms (AWP)

Back-extrapolated volume (VBE), 149 calculation of, 150 Bacterial cultures, 256–257 BAL. See Bronchoalveolar lavage (BAL)

499 BALF. See Bronchoalveolar lavage fluid (BALF) BC. See Breathing control (BC) Behavioral Pediatrics Feeding Assessment Scale, 317 “benchmarking” in cystic fibrosis care, 433–434 Benzodiazepines, 489 Bereavement and grief, 493 b-Adrenergic stimulation in sweat duct, 16 b-Agonists pulmonary health in CF and, maintenance of, 231 b-cells, pancreatic, 341 b-Lactam antibiotics, 152, 257 efficacy of, 252 BHR. See Bronchial hyperreactivity (BHR) Bicarbonate ion, 285, 286, 287, 288 Bilateral lung transplantation. See Lung transplantation Bile acids for CFALD, 299 Bile formation, 285–287 alternate pathways of, 286–287 CFTR and, 285–287 Bile secretory unit, 285 cholangiocytes, 285, 286, 288, 299 hepatocytes, 285, 286, 292 Biliary manifestations of CFALD cholelithiasis, 294 microgallbladder, 294 Biliary secretion, 286, 299 Biofilms, 251–252, 258 susceptibility testing, 258 Biomarkers of pulmonary exacerbation, 257 Bishop–Koop ileostomy, 270 Bisphosphonates and BMD, 335–336 BMC. See Bone mineral content (BMC) BMI. See Body mass index (BMI) BO. See Bronchiolitis obliterans (BO) Body mass index (BMI), 329, 330, 349 CFRD and, 349–350 and cystic fibrosis in children, 316–317 in females, 316, 317 in males, 316, 317

500 Bone densitometry, 329 mass, 329, 330, 332, 336 mineralization, 328, 330 resorption, 331, 333, 335 Bone diseases biochemical markers of, 333 alkaline phosphatase as, 333 calcium deposition as, 333 osteocalcin as, 333 clinical manifestations of, 328–330 BMD and, 328–330 fractures and, 330 diagnosis of, 328, 333. See also Dual energy X-ray absorptiometry (DXA) histopathology of, 333 management of, 333–337 bisphosphonates in, 335–336 growth hormone (GH) therapy in, 336 vitamin supplementation, 333–335. See also Vitamin D therapy pathophysiology of, 330–332 calcium and, 331 CFTR protein and, 332 glucocorticoids and, 331–332 infection and, 331 LBM and, 332 malnutrition and, 330 vitamin D and, 330 vitamin K and, 331 Bone mineral content (BMC), 328, 329, 332, 336 measurement of, 328, 329. See also Dual energy X-ray absorptiometry (DXA) Bone mineral density (BMD), 328–330, 331, 332, 335, 336 age factors in, 329–330 body mass index (BMI) and, 329, 330 fractures and, 329 measurement of, 328, 329 z scores and, 329, 330 Bortezomib (Velcade1), 413 BOS. See Bronchiolitis obliterans syndrome (BOS) Boyle’s law, 163, 167 Breathing control (BC) cycle of, 242

Index Bronchial hyperreactivity (BHR), 169–170 Bronchiectasis, 57, 202 Bronchiolitis obliterans (BO), 381–382 Bronchiolitis obliterans syndrome (BOS), 381 Bronchoalveolar lavage (BAL), 58, 141, 183, 256 Bronchoalveolar lavage fluid (BALF), 198 Bronchodilator responsiveness, 169 Bronchoscopy, 198, 256 Burkholderia, 379 Burkholderia cepacia, 37, 40, 66, 200, 203, 206, 256, 377, 378–379

Calcidiol, 319 Calcitriol, 319 Calcium absorption, 330, 331 and bone diseases, 331, 336 Calcium bilirubinate, 294 Calmodulin kinase, 286 Calorie intake in cystic fibrosis, 314 cAMP, 286, 288, 299 Camps. See Non-health care settings, infection control in Candidate genes vs. genome-wide association studies, 84–85 Capacitant element (Xc), 151 CAR. See Coxsackievirus adenovirus receptor (CAR) Carbon monoxide (CO), 168–169 Cardiac complications, cystic fibrosis (CF) and, 361–362 cor pulmonale and, 361–362 pulmonary hypertension and, 361–362 Cardiopulmonary exercise testing (CPET), 170 Caregivers, depression rate in, 470. See also Parents “catch-up growth” of brain, 360 Cationic liposome delivery systems CF gene therapy and, 398 Cationic polymers for CF gene therapy, 398–399 Cationic trypsinogen (PRSS1), 270

Index CBAVD. See Congenital bilateral absence of the vas deferens (CBAVD) CDC. See Centers for Disease Control and Prevention (CDC) Celiac disease, 275 Centers for Disease Control and Prevention (CDC), 440 Cervical dysplasia, 459 CEV. See Cumulative expired volume (CEV) CF. See Cystic fibrosis (CF) CFA. See Coefficient of fat absorption (CFA) CFALD. See Cystic fibrosis–associated liver disease (CFALD) CFF. See Cystic Fibrosis Foundation (CFF) CFFONE, 476 CF Foundation Hepatobiliary Disease Consensus Guidelines, 295 CF gene genetic variation in, 79–80 CF gene therapy AAVs vectors for, 394–397 barriers to, 391–392 cationic liposomes for, 398 cationic polymers for, 398–399 gene replacement and, 391 lentiviral vectors for, 397 nonviral vectors for, 397 rAd vectors for, 392–394 target cells for, 390–391 CFNDD. See Cystic fibrosis nutrient deficiency dermatitis (CFNDD) CFQ-R. See Cystic Fibrosis Questionnaire– Revised (CFQ-R) CF-Quality of Life and Transitional Dyspnea Index scores, 375 CFRD. See Cystic fibrosis-related diabetes (CFRD) CFTR. See Cystic fibrosis transmembrane conductance regulator (CFTR); Cystic fibrosis transmembrane conductance regulator (CFTR) gene CFTR gene. See Cystic fibrosis transmembrane conductance regulator (CFTR) gene CFTR-opathies, 407

501 CGMS. See Continuous glucose monitoring system (CGMS) Chest physiotherapy, 214 radiography, 182–183 Chest X ray (CXR), 204 Childhood asthma in, 202 hemoptysis in, 206 pneumothorax in, 204 pulmonary presentations and, differential diagnosis of, 204 Children with CF, 315–317, 473–474 adherence rates for, 470 BMI in, 316–317 CFQ-R PRO for, 472 depression rate in, 470 early, 473 eating behavior in, 317 growth in, 315–317 lung function in, assessment of, 148–157 interrupter technique. See Interrupter technique specific airways resistance. See Specific airways resistance (sRaw) spirometry, modified. See Spirometry, modified tidal breathing, 156–157 medical interventions for, 317 MI and, 191 middle, 473–474 nutrition assessment of, 315–317 psychosocial support for, 492 spirometric findings in, 150 supplements for, 317, 322 weight-for-length stature in, 316, 317 Chloride channels, 285, 286, 287 Choke point (CP), 240 Cholangiocyte membrane, 285, 286, 288, 299 permeability, 285 receptor binding, 286, 287 transport, 285, 286, 287, 288, 291 Cholangiocytes, 285, 286, 288, 299 Cholecystectomy, 294 Cholera toxin (CT), 3

502 Choline deficiency in cystic fibrosis, 318–319 Chronic care model clinical information systems, 429 community resources, 428 decision support, 429 delivery system design, 429 medical center health delivery system, 428 patient and family self-management, 429 Cilia in cystic fibrosis, 31–32 Cisapride, 276 CL. See Lung compliance (CL) Clinic adolescent, 455 logistics, 445 primary care, 455 transition, 455 Clinical information systems. See Chronic care model Clostridium difficile, 274–275 CL-VI. See Collagen type VI (CL-VI) CME. See Continuing medical education (CME) CMV. See Cytomegalovirus (CMV) CNV. See Copy number variants (CNV) CO. See Carbon monoxide (CO) Cochrane Collaborative report, 231 Coefficient of fat absorption (CFA), 117, 315 Coherence function (g2), 153 Collagen type VI (CL-VI), 296 Community resources. See Chronic care model Compliance (Crs), 128 Computed tomography (CT), 141, 183 acquisition technique, 188 clinical utility, 183, 185–186 radiation-induced cancer, risk of, 189 research potential, 187 of sinuses, 190 surrogate endpoints, 187–188 Condoms, CF patients and, 459, 462 Congenital absence of the uterus and vagina (CAUV), 457–458 Congenital bilateral absence of the vas deferens (CBAVD), 7, 92, 457

Index Constipation, 277 assessment and management of, 489–490 opioids, side effects of, 484 Continuing medical education (CME), 426 Continuous glucose monitoring system (CGMS), 347–348 Contraception, 462 Copy number variants (CNV), 79 Corticosteroids used in lung transplantation, 378 Corticosteroid therapy pulmonary health in CF and, maintenance of, 232 Cough airway clearance with, 240, 241 assessment and management of, 486 variant asthma, 202 Coxsackievirus adenovirus receptor (CAR), 392 CP. See Choke point (CP) CPET. See Cardiopulmonary exercise testing (CPET) CPX. See 8-cyclopentyl-1,3dipropylxanthine (CPX) Crossing the Quality Chasm, 423 Crs. See Compliance (Crs) CT. See Cholera toxin (CT); Computed tomography (CT) CTL. See Cytotoxic T lymphocyte (CTL) CAUV. See Congenital absence of the uterus and vagina (CAUV) Cumulative expired volume (CEV), 164 Cutaneous complications, cystic fibrosis (CF) and, 356–358 aquagenic wrinkling of the palms (AWP) and, 357 categories of, 356 cystic fibrosis nutrient deficiency dermatitis (CFNDD), 356–357 CXR. See Chest X ray (CXR) 8-Cyclopentyl-1,3-dipropylxanthine (CPX), 413 Cystic fibrosis–associated liver disease (CFALD), 285 diagnosis of, 294–296 biochemical analysis in, 295. See also Serum liver enzymes

Index [Cystic fibrosis–associated liver disease (CFALD)] biomarkers in, 294–296 liver biopsy in, 296 physical examination in, 294 ultrasonography in, 296 genetic aspects of, 290 genetic liver disease and, 291 immune response and, 291 meconium ileus and, 290 sex factors in, 290 manifestations of, 285 biliary, 285. See also Biliary manifestations of CFALD liver, 285. See also Liver manifestations of CFALD pathophysiology of, 288–290 abnormal CFTR protein and, 289 abnormalities in bile secretion and, 289 abnormalities in mucin secretion and, 289 activation of stellate cell and, 288–290 bile acid toxicology and, 289 hepatic infections and, 290 prevalence of, 291–292 treatment of, 296–299. See also Future therapeutics for CFALD diet in, 297 liver transplantation, 299 nutrition therapy in, 296–297 pancreatic enzyme replacement therapy, 297 ursodeoxycholic acid, 297–298 vitamin supplementation in, 297 Cystic fibrosis (CF), 1 ACT for. See Airway clearance therapy (ACT) in adolescents, 474–475 in adults, 475 airway surface liquid hydration therapy for, 237 hypertonic saline, 238–239 mannitol, 239 airway surface liquid in, 29–31 bacterial STIs in, 459 in children. See Children with CF cilia in, 31–32

503 [Cystic fibrosis (CF)] classic and emerging pathogens in, 37 diagnosis of, 90–94 diagnostic algorithm for, 93–94 emotional functioning in, 470 gastrointestinal complications of Clostridium difficile infection, 274–275 DIOS, 271 dysmotility, 276–277 FC, 277 GER, 271–274 HP infection, 275 intussusception, 276 malabsorption, 266–267 malignancy, 277–278 MI, 270 pancreas, 267–269 pancreatitis, 269–270 rectal prolapse, 276 SBBO, 274 gastrointestinal (GI) imaging in neonate and young child, 191 older children and adults, 191, 193 prenatal, 190–191 incidence of, 1–3 infant lung function in, measures of, 141 mucolytic therapy for goals of, 236 NAC, 236 mutation classes in, 407, 408 nutritional aspects of, 308–322 dietary intake and, 314, 317, 319 nutritional supplements, 312, 313, 317, 320, 321 undernutrition, 317 vitamin A and, 320–321 vitamin D and, 319–320 vitamin E and, 321 zinc in, 322 and pancreatic insufficiency. See Cystic fibrosis related pancreatic insufficiency parenting with, 464, 473 pathogens in, 40–48 peer relationships in school and, 469 pneumothorax in. See Pneumothorax

504 [Cystic fibrosis (CF)] practice guidelines and benefits and limitations of, 228 PROs in, 471–473 pulmonary complications of ABPA. See Allergic bronchopulmonary aspergillosis (ABPA) antibiotic allergy and desensitization, 212 hemoptysis. See Hemoptysis lobar collapse, 211–212 pneumothorax. See Pneumothorax pulmonary exacerbations and, 252 pulmonary health in anticholinergic agents, 231 approaches to maintenance of, 224–227 b-agonists, 231 CFTR and, 233 corticosteroid therapy, 232 exercise and, 231 goals of treatment to maintain, 224, 225 ibuprofen therapy, 232 ion channel therapies, 232–233 macrolides, 232 mucociliary clearance and, 231 therapies for maintenance of, 231–233 signs and symptoms of, 91 sinus Imaging in, 190 sleep quality, cystic fibrosis and, 362–365 social and family functioning in, 469–470 systems, affected, 468–469 time frame of appearance of, 92 treatment adherence in, 470–471 viral STI in, 459 young children with lung function assessment in, 148–157 Cystic fibrosis (CF), complications in cardiac, 361–362 lung diseases and, 361–362 cutaneous, 356–358 allergic response of drugs and, 357 CFTR mutation and, 357 nutritional deficiencies and, 356–357 vasculitis and, 357 metabolic, 358 alkalosis and, 358 neurologic, 358–361 neurologic symptoms and, 360–361

Index [Cystic fibrosis (CF), complications in neurologic] nutritional deficiencies in, 359–360 therapeutics in, 360 sleep, 362–365 disruption, 362–364 gas exchange abnormalities and, 364–365 lung diseases and, 363 oxyhemoglobin saturation and, 364, 365 Cystic fibrosis (CF) care improvement, partnerships for, 425–426 Cystic fibrosis (CF) outcomes impact of QI on, 434–435 Cystic fibrosis (CF) pulmonary disease dornase alfa, 228 infection in preventive and maintenance treatment of, 228–231 pathophysiologic cascade of, 226 practice guidelines and benefits and limitations of, 228 principals of maintenance therapy for, 224–227 stages of, 225, 226 thoracic imaging in chest radiography, 182–183 CT. See Computed tomography (CT) MRI, 189–190 nuclear medicine, 189–190 Cystic fibrosis (CF) symptoms, assessment and management of anorexia, 490 anxiety and depression, 490 constipation/obstipation, 489–490 cough, 486 dyspnea, 486–489 hemoptysis, 489 pain, 483–484 opioid use for, 484–486 Cystic Fibrosis Foundation (CFF), 186, 256, 260, 315 benchmarking and, 432–433 clinical practice guidelines by, 432–434 collaboration, comparison, data transparency and, 431–432 goals of, 426 pivotal role of, 423–424

Index Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group, 296, 298 Cystic Fibrosis Foundation Patient Registry Annual Report, 348 Cystic fibrosis lung, inflammation in characteristics of, 57–59 disordered intracellular signaling as, 64–67 dysregulated arachidonic acid metabolism, 63–64 inflammatory mediators in, 60–63 overview, 57 pathologic consequences of neutrophil, 67–69 role of airway epithelia in, 59–60 Cystic fibrosis nutrient deficiency dermatitis (CFNDD), 356–357 acrodermatitis enteropathica and, 356 nutritional therapy for, 357 sweat test in, 357 Cystic Fibrosis Questionnaire–Revised (CFQ-R), 472 Cystic fibrosis-related diabetes (CFRD), 78, 341–352, 378, 490 diagnosis for, 342–343 hormone secretion and, 344–345 insulin, 344 pathophysiology of, 343–344 b-cell destruction and, 343–344 immunohistochemical studies for, 343–344 prevalence of, 348–349 gender difference in, 349 pulmonary function in, 350 screening for, 345–348 casual blood glucose testing in, 347 continuous glucose monitoring system (CGMS) in, 346–347 HbA1c in, 346 oral glucose tolerance tests (OGTTs) in, 346–347 symptoms of, 345 T1DM and, 342 T2DM and, 342 treatment of, 350–352 insulin therapy in, 350–351 nutritional therapy in, 352

505 Cystic fibrosis related pancreatic insufficiency fat malabsorption and, 314, 319, 321, 322 treatment of, 315 pancreatic enzyme replacement therapy (PERT), 315 Cystic fibrosis transmembrane conductance regulator (CFTR), 190, 199, 224, 267–268, 269–270, 285–289, 291, 332, 333, 342, 356, 390 abnormal, 266 in bile formation, 285–287 in development of reproductive tissues, 457 in female patients, 460 in liver physiology, 285–287 mutation of, 286, 289, 290, 291 pulmonary health in CF and, maintenance of, 233 in rat brain, 458 Cystic fibrosis transmembrane conductance regulator (CFTR) gene, 1, 11, 78, 103, 391 clinical assessment of, 116–118 diagnosis of, 106–107 diagnostic challenges, 107–110 in adulthood, 107–108 diagnostic tests ion channel measurements, 110–114 discovery of, 390 diseases of, 104–106 functions of, 104–106 genetic variation in, 79–80 genotype/phenotype correlation, 6–7 genotyping, 114–116 heterozygote carriers of, 8 ion transport, abnormal conditions, 15–19 ion transport, normal conditions, 12–15 mutations and bone diseases, 332 classes of, 3–6 classification of, 105 nomenclature for, 103–104 overview, 103 recomendation of, 118 Cytomegalovirus (CMV), 381 Cytotoxic T lymphocyte (CTL), 392

506 Daily Phone Diary (DPD), 471 Data sharing (transparency), improvement collaboratives and, 432 Decision support. See Chronic care model Dehydration, 212, 214 7-Dehydrocholesterol, 319 Delayed gastric emptying (DGE), 276 Delayed puberty and bone diseases, 332 Delivery system design. See Chronic care model Denufosol tetrasodium, 33, 232–233 Depression assessment and management of, 490 in parents, 473 rate, in CF, 470 Dermatologic complications in cystic fibrosis. See Cutaneous complications, cystic fibrosis (CF) and Developmental, biopsychosocial model of, 468–469 DGE. See Delayed gastric emptying (DGE) Diabetes and bone diseases, 332 Diabetes mellitus, classification of, 341 Diagnostic algorithm CF based on newborn screening, 94 European Union Diagnostic Working Group, 93 Diet and CFALD, 297 fat intake, 297 protein intake, 297 Dietary intake in cystic fibrosis, 314 Dietary Reference Intake (DRI), 319 Diffusion limitation to carbon monoxide (DLCO), 168–169 1,25-Dihydroxyvitamin D [1,25(OH)2D], 319. See also Calcitriol Dioleoylphosphatidyl-ethanolamine (DOPE), 398 DIOS. See Distal intestinal obstruction syndrome (DIOS) Disinfection in ambulatory care setting. See Environmental infection control measures and general sterilization. See Environmental infection control of nebulizers, 444–445

Index Disordered intracellular signaling cause of excessive inflammation, 64–67 Distal intestinal obstruction syndrome (DIOS), 86, 190, 191, 214, 266, 484 Dizygous twins, 80 DLCO. See Diffusion limitation to carbon monoxide (DLCO) DNA-dependent protein kinase (DNA-PKcs), 397 DNA-PKcs. See DNA-dependent protein kinase (DNA-PKcs) DNaR. See Do not attempt resuscitation (DNaR) DNI. See Do not intubate (DNI) Do not attempt resuscitation (DNaR), 492 Do not intubate (DNI), 492 DOPE. See Dioleoylphosphatidylethanolamine (DOPE) Dornase alfa, 228 treatment of CF with, 237 DPD. See Daily Phone Diary (DPD) DRI. See Dietary Reference Intake (DRI) Drug synergism, 257 Dual energy X-ray absorptiometry (DXA), 328, 329, 333, 335 in bone diseases, 328, 333 Duodenogastric bile reflux, 272 Duty cycle, 172 DXA. See Dual energy X-ray absorptiometry (DXA) Dysmotility, 274, 276–277 Dyspnea, assessment and management of, 486–489

ECG. See Electrocardiography (ECG) EFA. See Essential fatty acids (EFA) EFAD. See EFA deficiency (EFAD) EFA deficiency (EFAD) in cystic fibrosis, 318 EGG. See Electrogastrography (EGG) EIB. See Exercise-induced bronchospasm (EIB) Electrocardiography (ECG), 361 Electrogastrography (EGG), 276 Electronic monitors, 471 Emotional functioning, in CF, 470

Index Endobronchial bacteria, 251–252 Endobronchial pathogens, 251–252 End-of-life care defined, 482 lung transplantation and, 491 Endoplasmic reticulum (ER), 344 End-stage liver disease, 285 End-tidal carbon dioxide (ETCO2) measurements, 373 Energy intake in cystic fibrosis, 314, 317 eNO. See NO in exhaled breath (eNO) Enteral nutrition in cystic fibrosis, 317 Environmental infection control disinfection in ambulatory care setting, 447 general sterilization and disinfection measures, 446 pulmonary function testing equipment, 446–447 Enzymatic digestion, 314 Epidemiologic Study of Cystic Fibrosis (ESCF), 424 Epidemiology of Pulmonary Exacerbations, 254–255 Epithelial cells, 60 Epithelial sodium channel (ENaC), 18, 201 Epstein–Barr virus, 381 ER. See Endoplasmic reticulum (ER) ERS. See European Respiratory Society (ERS) ERV. See Expiratory reserve volume (ERV) Erythematous papules, 356 ESCF. See Epidemiologic Study of Cystic Fibrosis (ESCF) Escherichia coli, 3 Esophagitis, 272–273 Essential fatty acids (EFA), 292, 314, 317–318 Estrogen, in CF patients, 458, 460 ETCO2. See End-tidal carbon dioxide (ETCO2) European Respiratory Society (ERS), 161 Evidence-based management of pulmonary exacerbations, 257–260

507 Exercise for airway clearance, 245 and bone health, 332, 336 pulmonary health in CF and, maintenance of, 231 respiratory system and, 170–171 Exercise-induced bronchospasm (EIB), 170 Expiratory reserve volume (ERV), 167 Extracellular matrix proteins, 296 collagen type VI (CL-VI), 296 hyaluronic acid (HA), 296 procollagen III polypeptide (PIIIP), 296 prolyl hydroxylase (PH), 296 Extracellular polysaccharide matrix, 251 Eye shields. See Standard precautions

False-positive or false-negative sweat test conditions associated with, 96 Fat intake in cystic fibrosis, 314 malabsorption, 314, 319, 321, 322. See also Steatorrhea in stool, 314 Fatty acids defficiency of, 63–64 FC. See Fibrosing colonopathy (FC) DF508 CFTR restoring function to, 411, 413–415 FDA. See Food and Drug Administration (FDA) FDG-PET. See Fluorodeoxyglucose positronemission tomography (FDG-PET) FEF. See Forced expiratory flow (FEF) Females, with CF asthma, 461 estrogen and CFTR, 460 fertility, 462 menses, 458, 461 pregnancy, 462 prostaglandins, 461 sexual and reproductive health issues, 462 survival of, 458 Fentanyl, 484 Fertility in females with CF, 462 in males with CF, 463

508 Fibrocystic disease, 12 Fibrosing colonopathy (FC), 267, 277 Fingernail specifics. See Hand hygiene “First-generation” vectors, 392 Fluorodeoxyglucose positron-emission tomography (FDG-PET), 189 Flutter, 244 fMLP. See N-formyl-methionylleucyl-phenylalanine (fMLP) FO. See Forced oscillometry (FO) Follicle stimulating hormone (FSH), 458 Food and Drug Administration (FDA), 252, 471 Forced oscillometry (FO), 151–154, 164 quality control criteria for, 153 Forced vital capacity (FVC), 129, 149, 162, 256, 376 N-formyl-methionyl-leucyl-phenylalanine (fMLP), 62 Fractures and cystic fibrosis, 330 FRC. See Functional residual capacity (FRC) Frequency dependence, of resistance, 152 FSH. See Follicle stimulating hormone (FSH) Functional residual capacity (FRC), 124, 129, 132, 161, 240 Future therapeutics for CFALD, 299–300 alternative secretory pathways and, 299–300 bile acids as, 299 hepatic stellate cells in, 299–300 FVC. See Forced vital capacity (FVC)

Gabapentin, 486 g2. See Coherence function (g2) g-Glutamyltransferase, 295 g-Tocopherol, 321 Gas dilution, for PFT, 129, 130–131 helium, 168 nitrogen washout, 168 Gastric acid, 266 Gastric inhibitory polypeptide (GIP), 344–345 Gastroesophageal reflux disease (GERD), 271

Index Gastroesophageal reflux (GER), 191, 202, 266, 271–274, 381 hiatal hernias and, 272 Gastrointestinal complications Clostridium difficile infection, 274–275 DIOS, 271 dysmotility, 276–277 FC, 277 GER, 271–274 HP infection, 275 intussusception, 276 malabsorption, 266–267 malignancy, 277–278 MI, 270 pancreas, 267–269 pancreatitis, 269–270 rectal prolapse, 276 SBBO, 274 Gastrointestinal (GI) imaging neonate and young child, 191 older children and adults, 191, 193 prenatal, 190–191 Gastrostomy, 297 GAW. See Airway conductance (GAW) G551D CFTR, 415–416 Gene replacement and CF gene therapy, 391 Gene therapy. See CF gene therapy Genetic carriers, 291 Geneticin (G418) PTCs suppression and, 409 Genetic polymorphisms, 291 Genetic screening, 464 Gene transfer agent (GTA), 390 GER. See Gastroesophageal reflux (GER) GERD. See Gastroesophageal reflux disease (GERD) GI imaging. See Gastrointestinal (GI) imaging GIP. See Gastric inhibitory polypeptide (GIP) GL. See Lung conductance (GL) GL-67 (Genzyme), 398 Gloves. See Standard precautions GLP-1. See Glucagon-like peptide-1 (GLP-1) Glucagon-like peptide-1 (GLP-1), 344–345 Glycogenolysis, 341

Index GM-CSF. See Granulocyte macrophage colony-stimulating factor (GM-CSF) GnRH, Gonadotropin–releasing hormone (GnRH) Gonadotropin-releasing hormone (GnRH), 458 Gowns. See Standard precautions Granulocyte macrophage colonystimulating factor (GM-CSF), 60 Grief and bereavement, 493 Growth hormone (GH) therapy in bone diseases, 335 GTA. See Gene transfer agent (GTA) Guideline for Disinfection and Sterilization, 441 Guideline for Environmental Infection Control in Health Care Facilities, 441 Guideline for Hand Hygiene in Healthcare Settings, 441 Guideline for Healthcare Acquired Pneumonia, 441 Guideline for Infection Control in Healthcare Personnel, 441 Guidelines for Isolation Precautions, 441, 444 Guidelines for reprocessing respiratory therapy and pulmonary function testing equipment, 442 “Gutless,” 394 G542X-hCFTR mouse model, 409–410

Haemophilus influenzae, 40, 41, 59, 204 Hand hygiene alcohol hand rub, 441, 443, 445–446 fingernail specifics, 441 HCWs and, 441 skin care, 441 soap and water, 441, 443 Hardy–Weinberg proportions, 82 HbA1c. See Hemoglobin A1c (HbA1c) HCW. See Health care worker (HCW) He. See Helium (He) Health care system optimizing, need to, 427–429 quality of care and, 430–431 strategies to improve, 429–430

509 Health care workers (HCW), 440 Health-related quality of life (HRQOL), 468 Helicobacter pylori (HP), 275 Helium (He) dilution, 168 Hemochromatosis, 291 CFALD and, 291 genetic aspects of, 291 Hemoglobin A1c (HbA1c), 346 Hemoptysis adults, prevalence in, 206 assessment and management of, 489 children, prevalence in, 206 diagnosis of, 206 management of, 207 pathophysiology, 206 prognosis, 207 spirometry and, 207 Hepatobiliary disease, 290 Hepatocytes, 285 Herring–Breuer reflex, 128 HFCC. See High-frequency chest compression (HFCC) HFCWO. See High-frequency chest wall oscillation (HFCWO) HFO. See High-frequency oscillation (HFO) Hiatal hernias and GER, 272 HICPAC. See Hospital Infection Control Practices Advisory Committee (HICPAC) High-frequency chest compression (HFCC), 244–245 High-frequency chest wall oscillation (HFCWO), 244–245 High-frequency oscillation (HFO), 243–244 High-mobility group box 1 (HMGB1), 62 High pressure positive expiratory pressure (HiPEP), 243 High-resolution computed tomography (HRCT), 164, 198 advantage of, 188 High throughput screening (HTS), 406 HiPEP. See High pressure positive expiratory pressure (HiPEP) HLA. See Human leukocyte antigen (HLA)

510 HMGB1. See High-mobility group box 1 (HMGB1) Homeostasis, 251 Hormone replacement therapy, 336 Hormones estrogen, 458 FSH, 458 GnRH, 458 LH, 458 prostaglandins, 461 Hospice. See End-of-life care Hospital Infection Control Practices Advisory Committee (HICPAC), 440 House of Commons Select Committee on Health, 452 HP. See Helicobacter pylori (HP) HRCT. See High-resolution computed tomography (HRCT) HRQOL. See Health-related quality of life (HRQOL) HTS. See High throughput screening (HTS) Huff airway clearance with, 240, 241 Human leukocyte antigen (HLA), 290 25-Hydroxy vitamin D (25-OHD), 319, 320, 331, 333. See also Calcidiol Hypercapnia, 372 Hyperinflation, 168 Hypertonic saline, 231 mucociliary clearance and, 238–239 Hypogonadism and bone diseases, 332 Hypoxemia, 372

IBD. See Inflammatory bowel disease (IBD) Ibuprofen, 484 oral administration of, 59 Ibuprofen therapy pulmonary health in CF and, maintenance of, 232 %IBW. See Percent ideal body weight (%IBW) %IBW and cystic fibrosis, 315, 316 ICAM-1. See Intercellular adhesion molecule 1 (ICAM-1)

Index iCARE. See I Change Adherence and Raise Expectations study (iCARE) I Change Adherence and Raise Expectations study (iCARE), 476 ICM. See Ion channel measurements (ICM) ICS. See Inhaled corticosteroids (ICS) ICSI. See Intracytoplasmic sperm injection (ICSI) ICU. See Intensive care unit (ICU) IFRD1. See Interferon-related developmental regulator 1 (IFRD1) IGT. See Impaired glucose tolerance (IGT) IHI. See Institute for Health Care Improvement (IHI) Immunoreactive trypsinogen (IRT), 98 Immunosuppressive therapy lung transplantation and, 379 Impaired glucose tolerance (IGT), 343 Inertive element (Xi), 151 Infants CF in, pulmonary manifestations of, 124–125 clinical management of, role of PFT in, 142 lung function in CF, measures of, 141 lung function testing in, 123–143 with MI, 270 PFT in. See Pulmonary function testing (PFT) pulmonary presentations and, differential diagnosis of, 203 respiratory infections in, 201–202 respiratory mechanics in, 124 studying, challenges of, 123–124 Infection inflammation vs., 198–199 lung transplantation and, 380–381 Infection control, 260 environmental, 446–447 in non–health care settings, 447–449 practices, rationale for, 441–442 psychosocial issues related to, 449 recommendations for inpatient settings activity outside the patient’s room, 443–444 respiratory therapy, 444–445 room placement, 443

Index Inflammation role of airway epithelia in, 59–60 vs. infection, 198–199 Inflammatory bowel disease (IBD), 275 Inhaled corticosteroids (ICS), 70, 232 Institute for Health Care Improvement (IHI), 423 Institute of Medicine (IOM), 423 Insulin-dependent diabetes mellitus. See Type 1 diabetes mellitus (T1DM) Insulin pump, 351 Insulin resistance cystic fibrosis and, 345 defined, 341 Insulin secretion, 341 Intensive care unit (ICU), 214–215 Intercellular adhesion molecule 1 (ICAM-1), 62 Interferon-related developmental regulator 1 (IFRD1), 199 Interleukin (IL)-8, 59 International Pediatric Lung Transplant Consortium, 379 International Society of Heart and Lung Transplantation (ISHLT), 378 Interrupter technique, 154–155 gas mixing, 155 Intestinal cells, 314 Intestinal obstructions (MI), 86 Intestine ion transport, 16–17 Intracytoplasmic sperm injection (ICSI), 463 Intrapulmonary percussive ventilation (IPV), 245 Intravenous antibiotics, 254, 257– 260 anti-Pseudomonas antibiotics, 258 Intussusception, 276 Inverted terminal repeats (ITR’s) sequences, 394–395 IOM. See Institute of Medicine (IOM) Ion channel measurements (ICM), 104, 110–114 Ion channel therapies pulmonary health in CF and, maintenance of, 232–233

511 Ion exchange, 285, 287 Ion transport in abnormal CFTR gene, 15–19 in gene, 12 in intestine, 16–17 in liver, 17 in lungs, 17–19 in normal CFTR gene, 12–15 overview, 11 in pancreas, 16 physiology in vitro, 18 in reproductive tract, 17 roll of, 11–12 in sweat gland, 15–16 IPV. See Intrapulmonary percussive ventilation (IPV) IRT. See Immunoreactive trypsinogen (IRT) ISHLT. See International Society of Heart and Lung Transplantation (ISHLT) ITR’s sequences. See Inverted terminal repeats (ITR’s) sequences

KEAP1. See Kelch-like ECH-associated protein 1 (KEAP1) Kelch-like ECH-associated protein 1 (KEAP1), 67 Kyphosis and cystic fibrosis, 330

Lactulose, 484 LAS. See Lung Allocation Score (LAS) Last menstrual period (LMP), 458 Lateral chest radiograph, 182, 184 LBM and bone diseases, 329, 330, 332 LCI. See Lung clearance index (LCI) Lean body mass (LBM), 329, 330, 332, 336 “Learning and leadership” collaborative projects, 426–427 Lentiviral vectors for CF gene therapy, 397 LES. See Lower esophageal sphincter (LES) Leukotriene (LT), 60, 198 LH. See Luteinizing hormone (LH)

512 Life expectancy lung transplantation and, 382 median, in United States, 468 Lipase, 314, 315 Lipoplexes, 397 Lipopolysaccharide (LPS), 61 Liposomes, cationic for CF gene therapy, 398 Lipoxin A4 (LXA4), 64 Liver ion transport, 17 Liver biopsy, 296 complications of, 296 Liver manifestations of CFALD focal biliary cirrhosis, 292–293 hepatic steatosis, 292 multilobular cirrhosis, 292, 293 LMP. See Last menstrual period (LMP) Lobar collapse, 211–212 Lobectomy, 207 Logistic regression models, 254 Lorazepam, 486 Lower esophageal sphincter (LES), 272 “low-hanging fruit” approach, 413 LPS. See Lipopolysaccharide (LPS) LT. See Leukotriene (LT) Lungs air travel and, 212–213 altitude and, 212–213 anesthesia. See Anesthesia ICU. See Intensive care unit (ICU) ion transport, 17–19 Lung Allocation Score (LAS), 377 Lung clearance index (LCI), 129, 130, 155, 164 Lung compliance (CL), 142 Lung conductance (GL), 142 Lung disease pathophysiology of airway disease, early, 198 inflammation vs. infection, 198–199 pulmonary clinical presentations antenatal, 201 overview, 200–201

Index Lung function assessment of, in young children, 148–157 interrupter technique. See Interrupter technique specific airways resistance. See Specific airways resistance (sRaw) spirometry, modified. See Spirometry, modified tidal breathing, 156–157 assessment of, in older children, 161 during menstrual cycles, 461 Lung function testing, infants obstacles during, 123, 124 PFT, techniques for infant. See Pulmonary function testing (PFT) Lung transplantation in CF population, 382–383 complications acute cellular rejection (ACR), 379–380 bronchiolitis obliterans (BO), 381–382 early, 380 infection, 380–381 late, 380 contraindications to, 377–379 end-of-life care and, 491 immunosuppressive therapy, 379 life expectancy, 382 listing, 379 timing of referral for, 376–377 transplant surgery, 379 Lung volumes fractional, 166 measurement of static, 166 gas dilution, 168 plethysmography, 167–168 Luteinizing hormone (LH), 458 LXA4. See Lipoxin A4 (LXA4)

Macroduct, 95 Macrolides pulmonary health in CF and, maintenance of, 232 Magnetic resonance imaging (MRI) nuclear medicine and, 189–190 Malabsorption, 266–267

Index Males, with CF fertility, 463 semen analysis, 463 sexual and reproductive health issues, 463 Malignancy, 277–278 Malnutrition and bone diseases, 330 Management of Multidrug-Resistant Organisms in Healthcare, 441 Mannitol, 239 Mannose-binding lectin-2 (MBL2), 83 Mask. See Standard precautions Maternal and Child Health Bureau, 452 Matrix metalloproteinase (MMP), 62 Maximal expiratory pressure (MEP), 171 Maximal inspiratory pressure (MIP), 171 MBL2. See Mannose-binding lectin-2 (MBL2) MBW. See Multiple-breath washout (MBW) MCID. See Minimal clinically important difference (MCID) MDR. See Multiple drug resistance protein (MDR) mdx mouse model, 409–410 Meconium ileus (MI), 78, 190, 266, 270 infants with, 270 neonate and, 191 young children with CF and, 191 Medical center health delivery system. See Chronic care model Medical equipment reprocessing of, 442 for single patient, 442 nebulizers and, 442, 444 spacers and, 442 spirometry mouthpieces and, 442 Membrane permeability, 285 Menses, 458, 461 MEP. See Maximal expiratory pressure (MEP) MESA. See Microsurgical epididymal sperm aspiration (MESA) Metabolic alkalosis, cystic fibrosis and, 358 chloride loss in, 358 treatment of, 358 Metabolic complications, cystic fibrosis (CF) and, 358

513 Methacholine, 169 Methadone, 484 Methicillin resistant Staphylococcus aureus (MRSA), 43–44, 258, 441 MI. See Intestinal obstructions (MI); Meconium ileus (MI) Microbiology, CF detection and identification of pathogens, 36–39 overview, 36 pathogens in, 40–48 Achromobacter xylosoxidans, 44 Burkholderia spp., 42–43 communities of, 46–48 culture independent techniques, 46–48 Haemophilus influenzae, 41 molds, 45–46 MRSA, 43–44 nontuberculous mycobacteria, 44–45 Pseudomonas aeruginosa, 41–42 Staphylococcus aureus, 40–41 Stenotrophomonas maltophilia, 44 yeasts, 45–46 susceptibility testing, 39 synergy testing, 39–40 Microsurgical epididymal sperm aspiration (MESA), 463 Microvascular complications in CFRD, 350 Miglustat, 413 Minimal clinically important difference (MCID), 472 MIP. See Maximal inspiratory pressure (MIP) MMP. See Matrix metalloproteinase (MMP) Model for improvement, 429–430 Modifier genes assessing the validity of, 83 of CF pulmonary disease, 83–84 identifying disease, 81–82 modify CF, 80–81 of non-airway phenotypes, 85–86 refinement of airway, 85 variation of clinical characteristics, 78–79 sources of, 79 Monofrequency signals, 151 Morphine, 484

514 Mortality in CFRD, 349 Mosaic attenuation, 185–186 MOT. See Multiple occlusion technique (MOT) Mouth pressure (Pmo), 154 MRI. See Magnetic resonance imaging (MRI) MRSA. See Methicillin resistant Staphylococcus aureus (MRSA) MUC5AC, 25 MUC5B, 25 Mucins, 24 Mucociliary clearance, 28–29 airway surface liquid hydration therapy for, 237–239 hypertonic saline, 238–239 overview, 24 pulmonary health in CF and, maintenance of, 231 Mucolytic therapy dornase alfa, 237 goals of, 236 NAC, 236 Mucus layer, 24–26 overview, 24 Mucus plugging, 125 Multidisciplinary care team and, frequent monitoring by, 227 Multidrug-resistant organisms, precautions for patients with, 447 Multifrequency signals, 151 Multipatient families. See Non-health care settings Multiple-breath washout (MBW), 125, 129, 130–131, 133, 155 Multiple drug resistance protein (MDR), 1 Multiple occlusion technique (MOT), 128 Mutant CFTR potentiation of, at cell membrane, 415–417 Mutation classes, in CF, 407, 408 Mycobacteria, 209 Mycobacteria abscessus, 37

NAbs. See Neutralizing antibodies (NAbs) NAC. See N-acetylcysteine (NAC) N-acetylcysteine (NAC), 236

Index Naloxone, 484 Nasal intermittent positive pressure ventilation (NIPPV), 205 Nasal potential difference (NPD), 94, 109, 461 Nasal resistance, infants, 124 National Initiative for Children’s Health Care Quality (NICHQ), 426 National Institutes of Health, 464 NBD. See Nucleotide-binding domains (NBD) NBD-1. See Nucleotide-binding domain (NBD)-1 NBS babies. See New born screening (NBS) babies Nebulizers. See Medical equipment Neonate MI and, 191 Neurologic complications in, cystic fibrosis (CF), 358–361 pancreatic enzyme therapy and, 360 vitamin A deficiency and, 359 vitamin K deficiency and, 359 Neutralizing antibodies (NAbs), 392 Newborn screening, 97–99, 317 New born screening (NBS) babies, 198, 200 NGT. See Normal glucose tolerance (NGT) NICHQ. See National Initiative for Children’s Health Care Quality (NICHQ) NIPPV. See Nasal intermittent positive pressure ventilation (NIPPV) Nitrogen, washout, 168 NIV. See Non-invasive bilevel ventilation (NIV); Non-invasive ventilation (NIV) NMD. See Nonsense-mediated decay (NMD) NO in exhaled breath (eNO), 66 Non–health care settings, infection control in camps, 448 multipatient families, 447 patient gatherings, 448–449 respiratory therapy equipment in home, care of, 447–448 schools, 448

Index

515

Non-insulin-dependent diabetes mellitus. See Type 2 diabetes mellitus (T2DM) Noninvasive bilevel ventilation (NIV), noctural, 365 Noninvasive positive pressure ventilation, 259 Noninvasive ventilation (NIV), 215 for chronic respiratory failure, 375–376 Nonsense-mediated decay (NMD), 409 Nonsteroidal anti-inflammatory drugs (NSAID), 70, 296 Nontuberculous mycobacteria (NTM), 37, 44–45, 203 Nonviral vectors for CF gene therapy, 397 Normal glucose tolerance (NGT), 343 North American CF (NACF) conference, 424 North American Epidemiologic Study of Cystic Fibrosis, 227 NPD. See Nasal potential difference (NPD) Nrf2. See Nuclear factor E2–related factor 2 (Nrf2) NSAID. See Nonsteroidal antiinflammatory drugs (NSAID) NTM. See Nontuberculous mycobacteria (NTM) Nuclear factor E2–related factor 2 (Nrf2), 64 Nuclear medicine MRI and, 189–190 Nucleotide-binding domain (NBD), 1, 411, 413 Nutritional care in cyctic fibrosis, 315, 317 Nutritional management in cystic fibrosis, 315, 318 Nutritional supplements in cystic fibrosis, 312, 313, 317, 320, 321 Nutrition recommendations for cystic fibrosis, 308, 314, 315 energy intake, 314, 317 fat intake, 314 Nutrition screening in cystic fibrosis, 315

[Occlusion techniques, for PFT] Herring–Breuer reflex, 128 MOT, 128 SOT, 128 OGTT. See Oral glucose tolerance tests (OGTT) 1,25(OH)2D. See 1,25-dihydroxyvitamin D [1,25(OH)2D] 25-OHD. See 25-hydroxy vitamin D (25-OHD) Opiates, 214 Opioids fentanyl, 484 methadone, 484 morphine, 484 naloxone, 484 side effects of, 484 Opsonophagocytosis, 69 Oral glucose tolerance tests (OGTT), 342, 346–347 Oral hypoglycemics in CFRD, 351 Oropharyngeal swabs, 256 Oscillating positive expiratory pressure (OscPEP), 243–244, 245 OscPEP. See Oscillating positive expiratory pressure (OscPEP) Osteoblasts, 331, 332, 333 Osteoclasts, 332, 335 Osteoid, 328 Osteopenia, 328, 329, 332 t score and, 328 Osteoporosis, 328, 329, 332, 336 risk factors for, 378 t score and, 328 Outcome measure. See Quality measures Oxygen therapy for cor pulmonale, 361 for pulmonary hypertension, 361 Oxyhemoglobin desaturation elevated respiratory rate and, 365 respiratory symptoms and, 364–365 Oxyhemoglobin saturation and sleep quality, 364, 365

Obstipation, assessment and management of, 489–490 Occlusion techniques, for PFT

PA. See Pseudomonas aeruginosa (PA) PACE. See Program for Adult Care Excellence (PACE)

516 PA chest radiograph. See Posterior-anterior (PA) chest radiograph Pain, CF related, 483–486 Palliative care defined, 482 specialists, 493 Palv. See Alveolar pressure (Palv) Pamidronate and bone diseases, 335–336 Pancreas ion transport, 16 Pancreatic elastase, 268–269 Pancreatic enzyme replacement therapy (PERT), 267, 268–269, 297, 315, 317, 319, 322 FC and, 277 Pancreatic enzymes, 314–315 in digestion, 314 Pancreatic insufficiency (PI), 79, 175, 266, 267–269, 289, 360 Pancreatic sufficient (PS), 266, 267–269 Pancreatic transplantation, 269 Pancreatitis, 269–270 Pandoraea apista, 44 Panton–Valentine leukocidin (PVL), 44 Parathyroid hormone (PTH) on bone, 332, 335–336 Parenting, with CF, 464 Parents depression in, 473 Pathogens, surveillance for, 442 Pathogens transmission by coughing, 441 HCW’s hands and, 441–442 interruption of contact, 441 mechanisms of, 441, 442 by nebulizers, 442 segregation to limit, 441 by sneezing, 441 by spirometry mouthpieces, 442 by talking, 441 Patient and family self-management. See Chronic care model Patient experience measure. See Quality measures Patient gatherings. See Non-health care settings Patient registries, role of, 424–425

Index Patient-reported outcomes (PRO), 252, 416, 468 CFQ-R, 472 defined, 471 FDA and, 471 HRQOL measures and, 471 Patients activity outside the room of, 443–444 infection prevention and control guidelines for, 441–442 room placement, 443 segregation, 441. See also Infection control 4-PBA. See 4-phenylbutyrate (4-PBA) PCD. See Primary ciliary dyskinesia (PCD) PCL. See Periciliary layer (PCL) PCP. See Pneumocystis pneumonia (PCP); Primary care provider (PCP) PDE 5 inhibitor. See Phosphodiesterase (PDE) 5 inhibitor Pdif. See Slower pressure change (Pdif) PD&P. See Postural drainage and percussion (PD&P) PEG. See Polyethylene glycol (PEG) PEGylation, 394 PEI. See Polyethyleneimine (PEI) Pel. See Plateau (elastic recoil pressure) PEP. See Positive expiratory pressure (PEP) Percent ideal body weight (%IBW), 315, 316 Percutaneous epididymal sperm aspiration (PESA), 463 Periciliary layer (PCL), 24, 26–28 Peroxisome proliferator-activated receptors (PPAR), 64, 318 PERT. See Pancreatic enzyme replacement therapy (PERT) PESA. See Percutaneous epididymal sperm aspiration (PESA) PFT. See Pulmonary function testing (PFT) PGP. See Proline-glycine-proline (PGP) PH. See Prolyl hydroxylase (PH) 4-Phenylbutyrate (4-PBA), 413 Phosphodiesterase (PDE) 5 inhibitor, 413 Phosphorylation of CFTR, 15 PI. See Pancreatic insufficiency (PI) Picosiemens (pS), 13

Index PIIIP. See Procollagen III polypeptide (PIIIP) Pilocarpine iontophoresis, 94 Pilogel, 95 Pinit. See Airway opening pressure (Pinit) Piperacillin, 212 PKA. See Protein kinase A (PKA) “plan/do/study/act (PDSA) cycles,” 429 Planktonic bacteria in pulmonary exacerbations, 252 Plateau (elastic recoil pressure), 154 Plethysmography, 125, 128, 167–168 Pmo. See Mouth pressure (Pmo) Pneumocystis jirovecii, 203 prophylaxis, 381 Pneumocystis pneumonia (PCP), 203 Pneumothorax, 213 adults, prevalence in, 204–205 children, prevalence in, 204 diagnosis of, 205 management of, 205 pathophysiology, 205 prognosis, 205 Pollutants and pulmonary exacerbation, 251, 255 Polyamidoamine for CF gene therapy, 398 Polyethylene glycol (PEG), 271, 394 Polyethyleneimine (PEI) for CF gene therapy, 398–399 polyK. See Poly-L-lysine (polyK) poly-L-lysine (polyK) for CF gene therapy, 398–399 Polypeptide chain, 12 Polyplexes, 397 Polysomnography, 363, 364 Polyunsaturated fatty acid (PUFA), 317, 318, 319, 321 Portal hypertension, 291, 293, 296, 297, 298, 299 Port CF, 425 Positive expiratory pressure (PEP), 243, 245 oscillating. See Oscillating positive expiratory pressure (OscPEP) Posterior-anterior (PA) chest radiograph, 182, 184 Postural drainage and percussion (PD&P), 241–242 AD versus, 243

517 PPAR. See Peroxisome proliferator– activated receptor (PPAR) Pregnancy, CF patients and, 462 Premature termination codons (PTCs) suppression of, 407, 409–411 CF clinical trials, 412 Prenatal GI imaging in CF, 190–191 Preschool children modified spirometry and, 148–151 Preschool PFT techniques, 157 Pressure-time tracing, 154 Preventing Transmission of Infectious Agents in Health Care Settings, 441 Primary care clinic, 455 Primary care provider (PCP), 454, 455 Primary ciliary dyskinesia (PCD), 28, 201, 203 Primary sclerosing cholangitis (PSC) CFALD and, 291 PRO. See Patient-reported outcomes (PRO) Process measures. See Quality measures Procollagen III polypeptide (PIIIP), 296 Productive-sounding cough, 201 Prognostication, in CF, 491 Program for Adult Care Excellence (PACE) grants, 451 Proline-glycine-proline (PGP), 62 Prolyl hydroxylase (PH), 296 Prostaglandins in CF patients, 461 menses and, 461 Protease-anti-protease imbalance, 68–69 Protein. See also Hormones CFTR, 457 Protein kinase A (PKA), 1 Protein kinase C (PKC), 1 PRSS1. See Cationic trypsinogen (PRSS1) PS. See Pancreatic sufficient (PS) pS. See Picosiemens (pS) Pseudomonas aeruginosa (PA), 31, 36, 41–42, 59, 90, 108, 200, 206, 208, 251, 252, 255, 256, 257, 378–379, 441 airway infection, 424 detection of, 256 prevention of, 229 PTC124, 410

518 PTCs. See Premature termination codons (PTCs) PTH. See Parathyroid hormone (PTH) Puberty, in CF patients, 458 PUFA. See Polyunsaturated fatty acid (PUFA) PUFA abnormalities in cystic fibrosis, 317–319 docasahexaenoic acid (DHA) deficiency, 318 linoleic acid (LA) deficiency, 318 Pulmonary clinical presentations. See Pulmonary presentations Pulmonary exacerbations age factors in, 254–255 definition of, 252–254 diagnosis of antimicrobial susceptibility testing in, 256–257 biomarkers in, 257 chest tomography (CT), 257 pulmonary function in, 256 epidemiology of, 254–255 infection control of, 260 management of, 257–260 mortality in, 254 outcome in, 252, 255, 257–259 pathophysiology of, 251–252 allergens and, 251–252 irritants and, 251–252 pollutants and, 251–252, 255 viral respiratory infections and, 251–252, 255 prevention of, 260 inhaled corticosteroids in, 260 risk factors of, 254, 255 symptoms of. See Symptoms of pulmonary exacerbations treatment of, 257–260 aminoglycoside, 257, 258 anti-inflammatory agents in, 259 b-lactam in, 252, 257 clinical trials in, 252, 256, 258, 259, 260 cost effectiveness in, 259 efficacy of, 152, 257, 258, 259 hospital care versus home medical care in, 259 intravenous antibiotics in, 254, 257– 260 tobramycin in, 257, 258, 260

Index Pulmonary function, 256, 258, 259. See also Forced vital capacity (FVC) CFRD and, 350 Pulmonary function testing equipment. See Environmental infection control Pulmonary Function testing (PFT), 123, 148, 161 application of, 172–173 future directions, 142–143 preschool, 157 research studies employing infant interventional, 141–142 observational, 131–133, 141 pulmonary disease, measures of, 141 summary of, 134–140 role of, in clinical management of infants, 142 standards for performing, 173 techniques for infant, 124 devices, preparation of, 125 forced expiratory flow, 128–129 gas dilution, 129, 130–131 occlusion techniques. See Occlusion techniques, for PFT plethysmography, 125, 128 RVRTC, 128–129, 130 summary of, 126–127 Pulmonary hypertension, oxygen therapy for, 361 Pulmonary manifestations of, in Infants, 124–125 Pulmonary presentations adulthood, 203 antenatal, 201 childhood and adolescence, 202 differential diagnosis of adulthood, 204 childhood and adolescence, 204 infants, 203 infants, 201–202 overview, 200–201 Purinergic (P2) receptors, 286, 287 PVL. See Panton–Valentine leukocidin (PVL) P2Y receptors, 71

QI. See Quality improvement (QI) Quality improvement (QI), 423

Index [Quality improvement (QI)] basic tenets of, 427–432 chronic care model and, 428–429 model for improvement and, 429–430 essentials of, teaching, 426–427 impact of, 434–435 Quality measures access, 431 outcome, 431 patient experience, 431 process, 431 structure, 430 Quality of life, 251 Quorum sensing, 251

rAAV. See Recombinant adeno-associated virus (rAAV) rAAV2-CFTR, 395 rAd. See Recombinant adenovirus (rAd) Radiation-induced cancer risk of, CT and, 189 Radioallergosorbent test (RAST), 208 RAEs. See Retinol activity equivalents (RAEs) Raised volume rapid thoracoabdominal compression (RVRTC) technique, 128–129, 130, 132, 198 Randomized controlled trial (RCT), 205 RANTES. See Regulated on activation normal T cell expressed and secreted (RANTES) Rapid eye movement (REM), 362–363, 364 RAST. See Radioallergosorbent test (RAST) Rat, CFTR in, 458 RAW. See Airway obstruction RC Cornet1, 244 RCT. See Randomized controlled trial (RCT) R-domain of CFTR, 15 Receptor binding, 286, 287 Recombinant adeno-associated virus (rAAV), 390 AAV2, 394 vectors, for CF gene therapy, 394–397

519 Recombinant adenovirus (rAd) vectors, for CF gene therapy, 392–394 Recombinant human deoxyribonuclease I (rhDNase), 33 Recombinant human deoxyribonuclease (rhDNase), 188 Rectal prolapse, 276 REE. See Resting energy expenditure (REE) Regulated on activation normal T cell expressed and secreted (RANTES), 60 REM. See Rapid eye movement (REM) Rep proteins, 394, 396, 397 Reproductive pathophysiology, in CF patients puberty, 458 structural abnormalities, 457–458 Reproductive technologies, 463 Reproductive tract ion transport, 17 REs. See Retinyl esters (REs) Residual volume (RV), 129, 161 Resistance (Rrs), 128 frequency dependence, 152 Respiratory depression, 484 Respiratory failure, in CF lung transplantation for. See Lung transplantation noninvasive ventilation (NIV) for, 375–376 pathophysiology, 372 increased respiratory load, effects of, 373–374 respiratory pump function, alterations in, 374–375 Respiratory inductance plethysmography (RIP), 156 Respiratory muscle strength measurement of MIP/MEP, 171 TTI, 171–172 Respiratory pump functional alterations in, 374–375 Respiratory syncytial virus (RSV), 201 Respiratory system exercise and, 170–171

520 Respiratory therapy, 444–445 equipment in home, care of. See Non-health care settings Respiratory tract irritants and pulmonary exacerbation, 251 specimens, 38 Resting energy expenditure (REE), 458 Resuscitation, 207 Retinoids, 320 Retinol activity equivalents (RAEs), 320 Retinyl esters (REs), 320 rhDNase. See Recombinant human deoxyribonuclease I (rhDNase); Recombinant human deoxyribonuclease (rhDNase) RIP. See Respiratory inductance plethysmography (RIP) Risk factors for pulmonary exacerbations, 254, 255 Room placement for infection control, 443 Rrs. See Resistance (Rrs) RSV. See Respiratory syncytial virus (RSV) RV. See Residual volume (RV) RVRTC technique. See Raised volume rapid thoracoabdominal compression (RVRTC) technique

Salt hyper-absorption hypotheses, 19 SBBO. See Small bowel bacterial overgrowth (SBBO) SCC. See Staphylococcal chromosomal cassette (SCC) Scedosporium apiospermum, 208 Schools. See also Non-health care settings activities and homework, 469 collaboration between parents and, 469, 473 peer relationships in, 469 SCID. See Severe combined immune deficiency (SCID) SCV. See Small colony variants (SCV) SecR. See Serpin-enzyme complex receptor (SecR) Secretin, 286, 287, 299 in bile formation, 286, 287

Index Secretory leukocyte protease inhibitor (SLPI), 69 Sedation, 124 Semen analysis, 463 Serine protease inhibitor Kazal 1 (SPINK1), 270 Serpin-enzyme complex receptor (SecR), 399 Serum liver enzymes, 295 alanine aminotransferase, 295 alkaline phosphatase, 295 aspartate aminotransferase, 295 bilirubin, 295 in diagnosis of CFALD, 295 Serum trypsinogen, 117 Severe, Persistent, Unusual, Recurrent infections (SPUR), 200 Severe combined immune deficiency (SCID), 397 Sexual and reproductive health issues in females with CF, 462 in males with CF, 463 Sexually transmitted infections (STI), 459 Sexual maturation and bone diseases, 332 sGaw. See Specific airway conductance (sGaw) Shwachman–Diamond syndrome, 117 Shwachman’s syndrome, 203 Signal transducers and activators of transcription (STAT), 64 Sildenafil, 413 Single-breath occlusion technique (SOT), 128 Single-nucleotide polymorphisms (SNP), 79 Single-photon emission computed tomography (SPECT), 189 Sinuses CT imaging of, 190 Sirolimus, 382 Six-minute walk test, 170 Skin care. See Hand hygiene Sleep complications, cystic fibrosis (CF) and, 362–365 in children, 363–364 hypercapnia and, 364–365 hypoxemia and, 362, 364, 365 obstructive sleep apnea and, 364

Index Slight recurrent chest infections, 359 Slower pressure change (Pdif), 154 SLPI. See Secretory leukocyte protease inhibitor (SLPI) Small bowel bacterial overgrowth (SBBO), 266, 274 Small colony variants (SCV), 40 Small-molecule therapy, 406 DF508 CFTR, restoring function to, 411, 413–415 mutation classes in CF, 407, 408 potentiation of mutant CFTR at cell membrane, 415–417 suppression of PTCs, 407, 409–411 SMIP. See Sustained maximal inspiratory pressure (SMIP) SNP. See Single-nucleotide polymorphisms (SNP) Soap and water. See Hand hygiene Social and family functioning, in CF, 469–470 Socioeconomic factors and pulmonary exacerbations, 255 Sodium channel blockers, 33 SOT. See Single-breath occlusion technique (SOT) SP. See Surfactant protein (SP) Spacers. See Medical equipment Specific airway conductance (sGaw), 131 Specific airways resistance (sRaw), 128, 155–156 SPECT. See Single-photon emission computed tomography (SPECT) SPINK1. See Serine protease inhibitor Kazal 1 (SPINK1) Spirometry, 148–151, 161–163, 204, 256, 257, 258, 259 forced oscillometry, 151–154 hemoptysis and, 207 modified, 148–151 mouthpieces. See Medical equipment quality control criteria used for, 149 SPUR. See Severe, Persistent, Unusual, Recurrent infections (SPUR)

521 sRaw. See Specific airways resistance (sRaw) Standard precautions eye shields, 441, 444 gloves, 441, 444 gowns, 441, 444 mask, 441, 443, 444 Staphylococcal chromosomal cassette (SCC), 43–44 Staphylococcus aureus, 36, 40–41, 90, 108, 200, 207, 229 STAT. See Signal transducers and activators of transcription (STAT) Steatorrhea, 314 Stenotrophomonas maltophilia, 44, 174, 208 Sterilization and disinfection measures. See Environmental infection control STI. See Sexually transmitted infections (STI) Stool fats, 314 Streptococcus milleri, 46 Stress, 468. See also Depression Structural abnormalities in reproductive tracts of CF patients, 457–458 Structure measures. See Quality measures Surfactant protein (SP), 201 Surrogate endpoints, 187–188 Susceptibility testing, role of in CF, 39 Sustained maximal inspiratory pressure (SMIP), 172 Sweat chloride test, 94, 110 variability of, 112 Sweat gland ion transport, 15–16 Sweat testing, 94–97 in young infants, 95 Symptom-based therapies, 406–407 Symptoms of pulmonary exacerbations cough, 252–254 exercise intolerance, 252–254 hemoptysis, 252–254 reduced appetite, 252–254 sputum production, 252–254 weight loss, 252–254 Synergy testing, role of, 39–40

522 TAA. See Thoracoabdominal asynchrony (TAA) Tacrolimus, 382 Target cells for CF gene therapy, 390–391 Tauroursodeoxycholic acid (TUDCA), 299 T cells, 62 T1DM. See Type 1 diabetes mellitus (T1DM) T2DM. See Type 2 diabetes mellitus (T2DM) TEE. See Thoracic expansion exercises (TEE) Tension-time index of the respiratory muscles (TTmus), 374 Tension time index (TTI), 171–172 Terminal restriction length polymorphism (T-RFLP), 46 TESA. See Testicular epididymal sperm aspiration (TESA) Testicular epididymal sperm aspiration (TESA), 463 TGFb1. See Transforming growth factor b1 (TGFb1) TGV. See Thoracic gas volume (TGV) TH-17 cells, 62 “The 3-foot rule,” 441 Thoracic expansion exercises (TEE), 242 Thoracic gas volume (TGV), 125 Thoracoabdominal asynchrony (TAA), 156 Tidal breathing, 156–157 Time constant of the respiratory system (Trs), 128 Time to peak expiratory flow over total expiratory time (Tpef/Te), 156 TIPS. See Transjugular portosystemic shunts (TIPS) TIS. See Tobramycin inhalation solution (TIS) TLC. See Total lung capacity (TLC) TLRs. See Toll-like receptors (TLRs) Tobramycin, 39 Tobramycin inhalation solution (TIS), 230 To Err is Human, 423 Toll-like receptors (TLRs), 392 Total lung capacity (TLC), 124, 161

Index Tpef/Te. See Time to peak expiratory flow over total expiratory time (Tpef/Te) Transforming growth factor b1 (TGFb1), 83 Transition challenges of, 452–454 clinic, 455 concerns, 453–454 development of, 454–455 House of Commons Select Committee on Health, 452 Maternal and Child Health Bureau, 452 models of, 455 North American CF Conference and, 451 periods, for patients and families, 468 periods for patients and families with, 468 timing of, 451–452 Transjugular portosystemic shunts (TIPS), 298 Transmission-based precautions, 441 Transmission of cystic fibrosis, 260 nosocomial transmission, 260 Transplant surgery lung transplantation and, 379 Treatment adherence barriers to, 474 in children, 470 daily diaries, 471 DPD, 471 interviews, 471 questionnaires, 471 T-RFLP. See Terminal restriction length polymorphism (T-RFLP) Trs. See Time constant of the respiratory system (Trs) t scores, 328, 329 TTI. See Tension time index (TTI) TTmus. See Tension-time index of the respiratory muscles (TTmus) TUDCA. See Tauroursodeoxycholic acid (TUDCA) Type 1 diabetes mellitus (T1DM), 341–342 b-cell destruction and, 341, 342 Type 2 diabetes mellitus (T2DM), 341, 342 insulin resistance and, 341, 342

Index UDCA. See Ursodeoxycholic acid (UDCA) Undernutrition and cystic fibrosis, 317 United States Cystic Fibrosis Foundation (USCFF), 106–107, 203, 206 Urinary incontinence coughing, related to, 483, 486 Ursodeoxycholic acid (UDCA), 289 USCFF. See United States Cystic Fibrosis Foundation (USCFF)

Variation, modifier genes sources of, 79 VBE. See Back-extrapolated volume (VBE) Vibrio cholera, 3 Vinegar (acetic acid), nebulizer and, 447 Viral colds, 201 Vitamin A supplementation, 321 Vitamin D and bone diseases, 330–331 Vitamin D supplements, 319–320 cholecalciferol (D3), 319–320 ergocalciferol (D2), 319–320 Vitamin D therapy, 333–335 Vitamin E deficiency in cystic fibrosis, 321 Vitamin K supplementation, 335 VX-770, 416

523 Waiting room practices, 445–446 Wasting, defined, 378 WBP. See Whole-body plethysmograph (WBP) Weight monitoring in cystic fibrosis, 316 Wheeze, 201–202 Whole-body plethysmograph (WBP), 155–156 Wilson disease, 291 CFALD and, 291 Wisconsin Cystic Fibrosis Neonatal Screening Project, 359 Wisconsin system, 182–183 wtCFTR, 414 W1282X CFTR, 409, 410

Xc. See Capacitant element (Xc) Xi. See Inertive element (Xi)

Zinc deficiency in cystic fibrosis, 322. See also Acrodermatitis enteropathica

Cystic Fibrosis About the book The median age of survival for those with cystic fibrosis has risen considerably in recent years. This text thoroughly examines the developments and breakthroughs which have led to this improvement in life expectancy. With a focus on the latest discoveries in the diagnosis and treatment of the disease, this book provides a comprehensive overview of the past, current and forthcoming advancements in cystic fibrosis research and clinical care. Key features of Cystic Fibrosis include: • Opening chapters that discuss the molecular basis of the disease from gene abnormalities to modifiers of disease • An examination of standard and novel diagnostic methods and techniques, such as sweat testing, gene studies, lung function testing across the age spectrum, and imaging studies • A focus on pulmonary manifestations and recently introduced therapies • A discussion of clinical treatment of the many extra-pulmonary manifestations of cystic fibrosis, such as nutrition, bone health, and cystic fibrosis related diabetes • A look at emerging developments in treatment like gene repair and pharmacologic therapies • Concluding chapters which address the significance of healthcare systems and psychological factors About the editors JULIAN L. ALLEN is chief of the Division of Pulmonary Medicine and Cystic Fibrosis Center at The Children’s Hospital of Philadelphia. He received his M.D. from the Columbia University College of Physicians and Surgeons. Dr. Allen is a Professor of Pediatrics at the University of Pennsylvania School of Medicine, and is the recipient of the Robert Gerard Morse Endowed Chair in Pulmonary Medicine. Dr. Allen’s research interests include developmental pulmonary physiology, and the pulmonary complications of sickle cell disease and cystic fibrosis. HOWARD B. PANITCH is the Clinical Director of the Division of Pulmonary Medicine at The Children’s Hospital of Philadelphia. He received his M.D. from the University of Pittsburgh School of Medicine. Dr. Panitch is also the director of the Pulmonary Medicine Fellowship Program and the medical director for the Technology Dependence Center. A Professor of Pediatrics at the University of Pennsylvania School of Medicine, Dr. Panitch received the Dean’s Award for excellence in Clinical Teaching in 2002 and a Master Clinician Award from the Department of Pediatrics in 2008. Among Dr. Panitch’s many research interests are the implications and barriers of transitioning technology dependent children to adult care. RONALD C. RUBENSTEIN is the Director of the Cystic Fibrosis Center at The Children’s Hospital of Philadelphia and the University of Pennsylvania. Dr. Rubenstein, who received his M.D. and Ph.D.in Pharmacology from the University of Texas Southwestern Medical School and Graduate School of the Biomedical Sciences, is an Associate Professor of Pediatrics at the University of Pennsylvania School of Medicine. Dr. Rubenstein’s laboratory and translational research program focuses on pharmacologic repair of mutant CFTR function in cystic fibrosis. Dr. Rubenstein serves as Chair of the Clinical Research Committee of the Cystic Fibrosis Foundation. He was named Faculty Teacher of the Year at The Children’s Hospital of Philadelphia in 2006.

Telephone House, 69-77 Paul Street, London EC2A 4LQ, UK 52 Vanderbilt Avenue, New York, NY 10017, USA

www.informahealthcare.com

H100008